

AUSTRALIAN NSP SURVEY NATIONAL DATA REPORT 1995 - 2010

Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees

Never Stand Still

Faculty of Medicine

The Kirby Institute

South Australia
Queensland
New South Wales
Northern Territory

1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010

Australian Capital Territory
Victoria
Western Australia
Tasmania



May 2011

The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health and Ageing.

The Kirby Institute is affiliated with the Faculty of Medicine, The University of New South Wales.

©The Kirby Institute
for infection and immunity in society

ISSN 1448-5915

This publication is available at: <http://www.kirby.unsw.edu.au>

The Kirby Institute
for infection and immunity in society
University of New South Wales
Sydney NSW 2052
Australia

Telephone: 02 9385 0900 Facsimile: 02 9385 0920
International prefix: 612 Email: recpt@kirby.unsw.edu.au

AUSTRALIAN NSP SURVEY

Prevalence of HIV, HCV and injecting and sexual behaviour
among Needle and Syringe Program attendees

NATIONAL DATA REPORT

1995 - 2010

Report prepared by Jenny Iversen, Libby Topp and Lisa Maher

The Kirby Institute
for infection and immunity in society
The University of New South Wales

May 2011

The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, The University of New South Wales.

ACKNOWLEDGEMENTS

We would like to acknowledge the many people who have assisted in the development and conduct of the Australian Needle and Syringe Program Survey (ANSPS) since its inception. We would particularly like to acknowledge the 34,874 occasions that Needle and Syringe Program (NSP) clients have participated in this project, as well as the ongoing support and assistance provided by both staff and management at the participating NSP sites. Special thanks are also due to the laboratory staff at St Vincent's Centre for Applied Research (AMR) and NSW State Reference Laboratory for HIV at St Vincent's Hospital, in particular Mr Philip Cunningham, Ms Celine Yan, Ms Sharon Trevor and the many others who have been involved in serological testing over the past sixteen years. Ms Brenda Currie also made a significant contribution to the preparation of this report by transcribing data from hard copies of previously published reports. Mr Greg Smith and Ms Melissa Lennon at Educational Assessment Australia have scanned and validated completed surveys since 2006.

We would also like to acknowledge the project chief investigators and the original steering committee responsible for developing the survey methodology. In particular we appreciate the dedication and vision of Dr Alex Wodak and Professor John Kaldor as founding members of the project, and the late Dr Margaret MacDonald who was responsible for the development and conduct of the ANSPS until 2003.

The project currently receives support and input from the following members of the ANSPS National Advisory Group: Ms Tracey Dobie (Australian Capital Territory); Ms Rose Mason (New South Wales); Mr Shayne Kilford (Northern Territory); Mr Robert Kemp/Mr Gregory Perry (Queensland); Mr Stephen Lymb (South Australia); Ms Francine Smith (Tasmania); Mr Roland Jauering (Victoria); Ms Jude Bevan (Western Australia); Ms Fiona Poeder (Australian Injecting and Illicit Drug Users League); Mr John Ryan (Anex); Professor John Kaldor, Professor Lisa Maher, Associate Professor Tony Butler, Dr Libby Topp and Ms Jenny Iversen (Kirby Institute) . We are particularly grateful to Dr Alex Wodak (Drug & Alcohol Services, St Vincent's Hospital) for chairing the group.

Ethical approvals were obtained from Institutional Ethics Committees associated with the investigators and participating NSP sites. The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, The University of New South Wales.

TABLE OF CONTENTS

Summary: Key points	5
1. Australian NSP Survey	7
2. Australian Capital Territory	50
3. New South Wales	73
4. Northern Territory	110
5. Queensland	133
6. South Australia	169
7. Tasmania	194
8. Victoria	217
9. Western Australia	242
10. References	267
11. List of tables	269
Appendix 1: Participating NSP services	270
Appendix 2: Methodological notes.....	273

SUMMARY: KEY POINTS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor blood borne viral infections and associated risk behaviour among people who inject drugs.
- The ANSPS has been conducted annually since 1995 and NSP attendees have participated on 34,874 occasions.
- In 2010, 53 of the 85 primary NSP services in Australia participated in the ANSPS.

Demographic characteristics

- The median age of participants was relatively stable at between 27 and 29 years during the first half of the survey period, but increased in subsequent years. Median age increased from a low of 27 years in 1997 to 37 years in 2010, with a concurrent decline in the proportion of respondents aged younger than 25 years, from 36% in 1997 to 8% in 2010.
- The proportion of new injectors (those who initiated injecting less than three years prior to survey participation) increased from 13% to 19% in the 1990s, but declined throughout the following decade and was 5% in 2010. Median time since first injection more than doubled from a low of seven years in 1998 to 16 years in 2010. The median age at first injection remained unchanged, at 18 years, throughout all survey years.
- The proportion of respondents from an Indigenous background increased over the survey period, from 5% in 1995 to 11% in 2010.

HIV and HCV antibody prevalence

- HIV antibody prevalence remained low at 2.1% or less in all of the past sixteen years, with prevalence of 1.0% observed in 2010.
- HIV prevalence was highest among participants reporting male homosexual identity, who comprised between 2% and 5% of annual survey samples, with prevalence in this group ranging from 14% to 39%.
- HCV antibody prevalence was high, with approximately one in two survey participants testing HCV antibody positive in all survey years. HCV antibody prevalence was highest in 1995 at 63%, while prevalence of approximately 50% was observed between 1996 and 1999 and in 2009 and 2010.
- HCV antibody prevalence was highest among participants aged 35 years or older and those who first initiated injecting more than 10 years prior to survey participation.
- HCV antibody prevalence was also high among daily injectors, participants with a history of imprisonment, participants from an Indigenous background and participants who reported receptive sharing of syringes in the month prior to survey participation.
- HCV antibody prevalence was lower among participants who reported injecting methamphetamine most recently, compared to those who last injected heroin. Conversely, HIV antibody prevalence was higher among participants who reported methamphetamine as the drug last injected, compared to those who last injected heroin.

Injecting behaviour

- While there were shifts in the patterns of drugs injected as reported by ANSPS participants over the past 16 years, reports of heroin and methamphetamine as the drugs last injected remained prominent in all survey years.
- Heroin was the most commonly reported drug last injected throughout the 1990s, reported by more than half of ANSPS respondents during this period. However, since 2001, prevalence declined to approximately one third of respondents.
- Methamphetamine was reported as the drug last injected by around one quarter of survey respondents in all survey years, with the exception of the period between 2001 and 2006 when prevalence increased to approximately one third of participants.
- The proportion of participants who reported last injecting pharmaceutical opioids remained stable at 3% to 4% during the 1990s. However, prevalence has increased recently, with 16% of participants in 2010 reporting last injecting this class of drug.
- Prevalence of public injecting in the month preceding survey participation varied from a high of 57% in 2000, to 42% in 2010.
- Prevalence of reuse and receptive sharing of syringes and ancillary injecting equipment has declined significantly since collection of these data began in 1997, 1995 and 1999 respectively. Prevalence of re-use of syringes declined from 31% in 1997 to 22% in 2010, prevalence of receptive sharing of syringes declined from 29% in 1995 to 11% in 2010, and receptive sharing of ancillary injecting equipment declined from 45% in 1999 to 26% in 2010.

1. AUSTRALIAN NSP SURVEY

Introduction

The Australian Needle and Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C (HCV) antibodies and monitors sexual and injecting behaviour among people who inject drugs in Australia. Conducted annually since 1995, NSP services from all states and territories participate in the ANSPS. This report presents results for all survey years over the period 1995 to 2010.


Design and methodology

The ANSPS is an ongoing annual cross-sectional survey consisting of a brief self administered questionnaire and provision of a capillary blood sample. The survey was conducted over a one to two week period in October in all years with the exception of 1995 and 1996 when the survey was conducted in March and June respectively. A steering committee was established prior to the commencement of the ANSPS and the project is currently overseen by a national advisory group comprising representatives from all jurisdictions, relevant peak bodies and other organisations associated with the survey. Ethical approvals for the survey were obtained from institutional ethics committees associated with the investigators and participating NSP sites.

Sample selection

Twenty needle and syringe program (NSP) services were selected to participate in the 1995 ANSPS. Selection was based on the number of client occasions of service per week, willingness to participate and representation across all jurisdictions. A number of additional NSP services were recruited to participate in subsequent years, with the majority of these participating consistently since commencement.

Figure 1.1 Survey respondents by site participation and survey year



Close to half (44%) of the total number of ANSPS participants were recruited from sites that participated in all sixteen survey years (13 sites), a further third (36%) were recruited from sites that participated in ten or more survey years (18 sites), and the remaining 20% of respondents were recruited from sites that participated in less than ten survey years (Figure 1.1). In 2010, 53 of the 85 primary NSP services that operate in Australia participated in the ANSPS. Sample sizes ranged from 1072 (in 1995) to 2697 (in 2009). A list of participating NSP services by survey year is at Appendix 1.

During the survey period, NSP staff invite all NSP attendees to participate in the ANSPS. Verbal, rather than written, consent is obtained; and participation is anonymous and voluntary. Financial reimbursement is not provided, although some services provide non-monetary incentives to participants such as on-site food and drinks, food or movie vouchers, or injecting-related items that are not freely available from the NSP. Sites are reimbursed for expenses associated with conducting the survey.

Records of the age and gender of both ANSPS participants and non-participants are kept. These are used to calculate annual response rates, which have ranged from 38% to 60% over the past 16 years. Response rate data has also been used to assess the representativeness of ANSPS participants. In 2006, data on the drug most recently injected was collected from non-respondents in addition to age and gender. Subsequent analysis demonstrated the generalisability of ANSPS results and concluded that inferences derived from ANSPS results can be reasonably applied to the broader population of public sector NSP clients (Topp et al., 2008a).

Data Collection and Analysis

ANSPS participants complete a brief self-administered questionnaire and provide a capillary blood sample. In each of the past sixteen years the questionnaire has collected data on demographic characteristics, injecting and sexual behaviours, and history of BBV testing, imprisonment and drug treatment. The survey instrument has undergone minor modification over time (see methodological notes at Appendix 2 for details); however, survey questions have remained the same over the 15 year period wherever possible. The survey is designed to be self-completed, although assistance is available where necessary (White, Day & Maher, 2007).

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using Genetic Systems HIV-1 ELISA tests. Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France).

A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 2 EIA, Biorad, France) was used to test for HCV antibody. A modified cut-off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut-off ratio was greater than or equal to one on initial and subsequent testing.


Demographic characteristics

Two thirds of the survey participants were male in all survey years and less than one percent identified as transgender (Table 1.1). The majority of participants identified as heterosexual (range 76% to 83%), with smaller proportions identifying as bisexual (9% to 12%) or homosexual (3% to 7%). Females comprised a greater proportion of bisexual participants (66%), while males comprised a greater proportion of participants identifying as homosexual (58%).

The proportion of participants reporting an Indigenous background increased from 5% in 1995 to 11% in 2010 (χ^2 trend $p < 0.001$). An equivalent increase occurred among participants at the 13 NSP sites that participated in all survey years, where the proportion of participants from an Indigenous background increased from 5% in 1995 to 10% in 2010 (χ^2 trend $p < 0.001$), suggesting that the increasing trend is not attributable to site variation. The majority of participants in all survey years reported being born in Australia (70% to 88%) and that their parents spoke English at home (67% to 95%, data available from 1999). The proportion of participants that reported their parents spoke a language other than English at home and those born in Asia declined from 2004, however this is largely attributable to the withdrawal of a NSP site that specifically targeted this group.

The proportion of young people (those aged younger than 25 years) and new injectors (who initiated injecting less than three years preceding survey participation) increased between 1995 and 1998, but declined in subsequent years (Figure 1.2). There was a concomitant increase in the median age of participants, from 27 years in 1997 to 37 years in 2010. In 1995 less than 10% of ANSPS participants were aged 40 years or older, whereas this group comprised 40% of participants in 2010. Median age at first injection remained stable at 18 years across all survey years.


Figure 1.2 Proportion of new and young injectors by year



Injecting behaviour

During the 1990s, heroin was the most commonly reported drug last injected; reported by more than half of participants in all years between 1996 and 2000 (Figure 1.3). In 2001, coinciding with the well documented changes to the heroin market in Australia (Maher et al., 2007; Degenhardt, Day, Gilmour, & Hall, 2006; Topp, Day, & Degenhardt, 2003), there was a sudden and dramatic decline in the proportion of respondents who reported heroin as the drug last injected. From 2001, heroin was reported as the drug last injected by approximately one third of respondents. A further one third reported methamphetamine as the drug last injected over the same period, although this declined to around one quarter of participants in more recent years. The remaining one third of participants reported last injecting a range of other drugs.


Figure 1.3 Heroin, methamphetamine and all other drugs last injected by year



Reports of methadone as the drug last injected varied between 19% of participants in 1995 and 3% in 1999 and 2000. Since 2004 between 7% and 10% of participants reported last injecting methadone, while approximately 5% reported last injecting buprenorphine (Figure 1.4). Reports of pharmaceutical opioids (including morphine and oxycodone) as the drug last injected were common in Tasmania and the Northern Territory in all survey years, however reports have increased significantly in other jurisdictions since 2000 (χ^2 trend $p < 0.001$). In 2010, 16% of survey respondents reported last injecting pharmaceutical opioids, making pharmaceutical opioids the third most common drug class last injected after heroin and methamphetamine (Figure 1.4).


Reports of anabolic steroids as the drug last injected remained low and stable at 1% to 2% of respondents in all survey years (Table 1.2). Reports of cocaine (or cocaine together with another drug) as the drug last injected were also consistently low at 1% to 3%, with the exception of 2001 when 7% of survey participants reported last injecting cocaine.

Figure 1.4 Methadone, buprenorphine and pharmaceutical opioids last injected by year




Reported prevalence of reuse and receptive sharing of syringes and ancillary injecting equipment has declined significantly since collection of these data began in 1997, 1995 and 1999 respectively (Figure 1.5, Table 1.4). Prevalence of re-use of syringes declined from 31% in 1997 to 22% in 2010 (χ^2 trend $p < 0.001$), while prevalence of receptive sharing of needles and syringes halved from 30% in 1995 to approximately 15% in all years since 2000 (χ^2 trend $p < 0.001$). Receptive sharing of ancillary injecting equipment declined from 45% in 1999 to 26% in 2005 (χ^2 trend $p < 0.001$) with spoons and water identified as the two most commonly shared ancillary equipment items in all survey years.

Figure 1.5 Re-use and receptive sharing of syringes and ancillary equipment by year



The proportion of respondents who reported injecting in at least one public location (street, car, public toilet, beach, park or squat) in the month preceding the survey increased during the late 1990s and then declined in subsequent years (Table 1.3). Rates of public injection are have been stable since 2003 with between 42% and 46% of respondents reporting this behaviour in all years since 2003 (Figure 1.6).

Figure 1.6 Prevalence of public injection by year




Sexual behaviour

Around half of ANSPS respondents report having a regular sex partner (data collected in this format since 2005, Table 1.5). Of these, the majority (69% to 74%) did not use condoms with their regular sex partner. Around 15% of respondents reported sex with a other partners in the month preceding survey participation. Rates of condom use were higher among those reporting sex with non-regular partners, with between two thirds and three quarters of respondents reporting condom use on some or every occasion. Between 5% and 10% of participants reported sex work in the month prior to survey participation in all survey years, with rates of condom use among this group at between 83% and 96%.

BBV testing, drug treatment and prison history


ANSPS participants reported high rates of HIV and HCV testing in all years. The proportion of respondents who reported never having had an HIV test remained relatively stable at between 9% and 13% (Table 1.6), while the proportion never undertaking HCV testing declined from 20% in 1995 to 8% in 2010. However, rates of recent (in the last 12 months) testing declined significantly over the survey period, from 69% in 1995 to 48% in 2010 for HIV testing and from 68% in 1997 to 53% in 2010 for HCV testing (χ^2 trend $p < 0.001$ for both variables; Figure 1.7).

Figure 1.7 Proportion reporting HIV and HCV test in the last 12 months by year



Around half of participants reported a history of imprisonment in all years since data collection of these data began in 2002 (Figure 1.8). Between 9% and 18% of participants reported incarceration in the 12 months preceding the survey in all years. Of those recently incarcerated, between one third and one half reported injecting in prison.

Figure 1.8 Prison history and proportion injecting in prison in last 12 months by year



High rates of previous and/or current engagement in drug treatment (the majority comprising opioid replacement therapy, residential drug treatment and counselling) were observed among participants in all survey years (range 64% to 80%). The proportion of participants who reported current methadone maintenance treatment remained relatively stable at between a quarter and a third of participants in most survey years (Table 1.7). The proportion who reported other current opioid substitution therapy (including buprenorphine and buprenorphine-naloxone combination) increased from 2% in 2000 to 15% in 2010. (χ^2 trend $p < 0.001$), reflecting the increased availability of these treatments.

HIV antibody prevalence

HIV antibody prevalence was low at 2.1% or less in all survey years (Figure 1.9). HIV prevalence was highest among participants reporting male homosexual identity, who comprised between 2% and 5% of annual survey samples, with prevalence among that sub population ranging from 14% to 39% (Figure 1.10, Table 1.10). Male homosexual identity is the strongest independent correlate of HIV antibody-positive serostatus among ANSPS participants (Topp et al., 2011).

Figure 1.9 HIV antibody prevalence by year






Figure 1.10 HIV antibody prevalence by sexual identity and gender and year



HCV antibody prevalence


Notwithstanding some variation over the 16 year period, HCV antibody prevalence was high among ANSPS participants in all survey years (Figure 1.11, Table 1.22). Prevalence was highest at 60% or more in 1995 and between 2004 and 2007, while rates of around 50% were observed between 1996 and 1999 and in 2009 and 2010. A similar pattern of HCV antibody prevalence was observed among participants recruited from the 13 NSP sites that participated in all survey years, indicating that site variation was not responsible for fluctuations in prevalence.

Figure 1.11 HCV antibody prevalence by year




HCV antibody prevalence was higher among participants with longer injection histories (Figure 1.12, Table 1.25) and among older participants (Table 1.24). HCV antibody prevalence was also higher among daily injectors compared to those injecting less frequently (Table 1.27) and participants with a history of imprisonment compared to those with no prison history (Table 1.29).

Figure 1.12 HCV antibody prevalence and time since first injection by year



HCV antibody prevalence varied according to the drug injected most recently (Figure 1.13, Table 1.26). Prevalence was highest among respondents who reported last injecting heroin (range 53% to 74%), although prevalence was also high at more than 50% among respondents who reported last injecting an opioid (including methadone, buprenorphine and pharmaceutical opioids). HCV antibody prevalence was lower among respondents who reported last injecting methamphetamine (range 19% to 51%), while the subpopulation of participants who reported last injecting performance and image enhancing drugs (PIED) had markedly lower rates of HCV antibody prevalence (Day et al., 2008).

Figure 1.13 HCV antibody prevalence and selected drug last injected by year



HCV antibody prevalence was higher among women when compared to men in most survey years, with significant differences observed among participants with shorter injection histories (Iversen et al., 2010, Table 1.25). Respondents who reported receptive sharing of syringes in the month preceding survey participation were significantly more likely to test HCV antibody positive than those who did not report receptive sharing of syringes in most survey years ($p=0.002$ in 2010, Table 1.28).

Table 1.1 Number (percentage) of respondents by demographic characteristic and year

NATIONAL	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Number of sites	20	19	23	33	33	36	37	44	47	46	48	42	51	53	51	53
N° surveyed	N=1072	N=1497	N=1978	N=2665	N=2503	N=2694	N=2454	N=2445	N=2495	N=2035	N=1800	N=1961	N=1912	N=2270	N=2697	N=2396
Response rate	41%	54%	60%	42%	45%	50%	46%	42%	45%	50%	44%	38%	39%	39%	45%	39%
Gender (%)																
Male	703 (66)	1003 (67)	1297 (66)	1719 (65)	1616 (65)	1760 (65)	1616 (66)	1618 (66)	1650 (66)	1360 (67)	1149 (64)	1265 (65)	1241 (65)	1456 (64)	1756 (65)	1611 (67)
Female	353 (33)	477 (32)	674 (34)	935 (35)	875 (35)	918 (34)	814 (33)	806 (33)	819 (33)	659 (32)	642 (36)	683 (35)	660 (35)	803 (35)	924 (34)	771 (32)
Transgender	3 (<1)	1 (<1)	6 (<1)	6 (<1)	9 (<1)	10 (<1)	17 (<1)	14 (<1)	16 (<1)	7 (<1)	8 (<1)	10 (<1)	9 (<1)	6 (<1)	9 (<1)	8 (<1)
Not reported	13 (1)	16 (1)	1 (<1)	5 (<1)	3 (<1)	6 (<1)	7 (<1)	7 (<1)	10 (<1)	9 (<1)	1 (<1)	3 (<1)	2 (<1)	5 (<1)	8 (<1)	6 (<1)
Sexual identity (%)																
Heterosexual	848 (79)	1168 (78)	1564 (79)	2158 (81)	1890 (76)	2069 (77)	1893 (77)	1858 (76)	1908 (77)	1669 (82)	1464 (81)	1611 (82)	1570 (82)	1843 (81)	2236 (83)	1987 (83)
Bisexual	126 (12)	164 (11)	223 (11)	244 (9)	312 (12)	291 (11)	234 (10)	260 (11)	243 (10)	173 (9)	150 (8)	176 (9)	177 (9)	219 (10)	236 (9)	195 (8)
Homosexual	69 (6)	111 (7)	118 (6)	159 (6)	132 (5)	169 (6)	136 (5)	101 (4)	134 (5)	84 (4)	99 (6)	109 (6)	116 (6)	115 (5)	89 (3)	88 (4)
Not reported	29 (3)	54 (4)	73 (4)	104 (4)	169 (7)	165 (6)	191 (8)	226 (9)	210 (8)	109 (5)	87 (5)	65 (3)	49 (3)	93 (4)	136 (5)	126 (5)
Age and time since first injection (years)																
<i>Median age</i>	29	28	27	28	28	28	29	30	31	32	34	34	35	36	36	37
<i>Age range</i>	14-54	13-59	15-58	14-63	14-69	14-61	14-62	14-63	15-64	16-65	15-66	13-68	14-69	16-70	15-66	15-73
<i>Age group (%)</i>																
< 25 years	323 (30)	515 (24)	719 (36)	950 (36)	815 (33)	847 (31)	688 (28)	615 (25)	512 (21)	389 (19)	259 (14)	237 (12)	183 (10)	208 (9)	285 (11)	203 (8)
25+ years	741 (69)	977 (65)	1258 (64)	1713 (64)	1682 (67)	1842 (68)	1761 (72)	1826 (75)	1978 (79)	1637 (80)	1536 (85)	1717 (88)	1726 (90)	2056 (91)	2411 (89)	2191 (91)
Not reported	8 (<1)	5 (<1)	1 (<1)	2 (<1)	6 (<1)	5 (<1)	5 (<1)	5 (<1)	5 (<1)	9 (<1)	5 (<1)	7 (<1)	3 (<1)	6 (<1)	1 (<1)	2 (<1)
<i>Median age 1st IDU</i>	18	18	18	18	18	18	18	18	18	18	18	18	18	18	18	18
<i>Age range</i>	10-48	10-48	10-50	10-47	10-55	10-54	10-53	10-56	10-50	10-56	10-55	10-52	10-56	10-60	10-58	10-63
<i>N° not reported</i>	20	49	42	52	64	72	76	72	82	53	67	71	51	46	67	51
<i>Median years IDU</i>	10	8	8	7	8	8	9	10	11	11	13	14	15	15	15	16
<i>Range</i>	<1-33	<1-37	<1-37	<1-40	<1-36	<1-41	<1-44	<1-43	<1-45	<1-46	<1-46	<1-45	<1-49	<1-48	<1-46	<1-60
<i>Time since first injection</i>																
<3 years	143 (13)	248 (17)	348 (18)	501 (19)	407 (16)	351 (13)	300 (12)	240 (10)	206 (8)	154 (7)	161 (9)	108 (6)	102 (5)	113 (5)	162 (6)	131 (5)
3+ years	906 (85)	1199 (80)	1587 (80)	2111 (79)	2030 (81)	2268 (84)	2075 (85)	2133 (87)	2204 (88)	1827 (90)	1559 (87)	1779 (91)	1759 (92)	2110 (93)	2468 (92)	2213 (92)
Not reported	23 (2)	50 (3)	43 (2)	53 (2)	66 (3)	75 (3)	79 (3)	73 (3)	85 (4)	54 (3)	80 (4)	74 (4)	51 (3)	47 (2)	67 (2)	52 (2)

Table 1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

NATIONAL	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=1072	N=1497	N=1978	N=2665	N=2503	N=2694	N=2454	N=2445	N=2495	N=2035	N=1800	N=1961	N=1912	N=2270	N=2697	N=2396
Aboriginal and Torres Strait Islander origin (%)																
No	987 (92)	1333 (89)	1844 (93)	2442 (92)	2237 (90)	2391 (88)	2196 (89)	2183 (89)	2221 (89)	1813 (89)	1563 (87)	1695 (86)	1663 (87)	1934 (85)	2296 (85)	2071 (86)
Yes	52 (5)	66 (4)	101 (5)	167 (6)	182 (7)	233 (9)	188 (8)	183 (8)	203 (8)	165 (8)	185 (10)	203 (10)	203 (11)	250 (11)	323 (12)	275 (11)
Not reported	33 (3)	98 (7)	33 (2)	56 (2)	84 (3)	70 (3)	70 (3)	79 (3)	71 (3)	57 (3)	51 (3)	63 (3)	46 (2)	86 (4)	78 (3)	50 (2)
Region/country of birth (%)																
Australia	--	--	--	--	2201 (88)	1891 (70)	1824 (74)	1955 (80)	2026 (81)	1613 (79)	1551 (86)	1668 (85)	1649 (86)	1918 (84)	2333 (87)	2088 (87)
Other Oceania	--	--	--	--	--	105 (4)	95 (4)	73 (3)	93 (4)	63 (3)	54 (3)	62 (3)	46 (2)	83 (4)	85 (3)	76 (3)
Asia	--	--	--	--	29 (1)	86 (3)	89 (4)	112 (5)	145 (6)	145 (7)	14 (1)	17 (<1)	22 (1)	32 (1)	25 (1)	29 (1)
UK & Ireland	--	--	--	--	--	116 (4)	102 (4)	118 (5)	114 (4)	91 (5)	95 (5)	105 (5)	85 (4)	125 (6)	120 (4)	94 (4)
Other	--	--	--	--	161 (6)	91 (4)	93 (4)	101 (4)	91 (4)	83 (4)	72 (4)	73 (4)	72 (4)	68 (3)	89 (3)	69 (3)
Not reported	--	--	--	--	112 (5)	405 (15)	251 (10)	86 (3)	26 (1)	40 (2)	14 (1)	36 (2)	38 (2)	44 (2)	45 (2)	40 (2)
Main language spoken at home by parents (%)																
English	--	--	--	--	2196 (88)	2306 (85)	2059 (84)	2044 (84)	2111 (84)	1354 (67)	1543 (85)	1735 (88)	1778 (93)	2128 (94)	2548 (94)	2275 (95)
Non-English	--	--	--	--	161 (6)	259 (10)	271 (11)	290 (12)	267 (11)	228 (11)	266 (15)	121 (6)	102 (5)	109 (5)	113 (4)	90 (4)
Not reported	--	--	--	--	146 (6)	129 (5)	124 (5)	111 (4)	117 (5)	453 (22)	0 (0)	105 (5)	32 (2)	33 (1)	36 (1)	31 (1)
Imprisonment last year (%)																
No	897 (84)	1261 (84)	1684 (85)	2193 (83)	2070 (83)	2142 (80)	1947 (80)	1992 (81)	2047 (82)	1631 (80)	1477 (82)	1622 (83)	1569 (82)	1812 (80)	2238 (83)	1762 (74)
Yes	159 (15)	181 (12)	285 (14)	439 (16)	397 (16)	486 (18)	424 (17)	407 (17)	406 (16)	373 (18)	252 (14)	247 (13)	254 (13)	287 (13)	339 (13)	226 (9)
Not reported	16 (1)	55 (4)	9 (1)	33 (1)	36 (1)	66 (2)	83 (3)	46 (2)	42 (2)	31 (2)	71 (4)	92 (5)	89 (5)	171 (8)	120 (4)	408 (17)
Injected in prison last year (%)																
N° in prison	N=159	N=181	N=285	N=439	N=397	N=486	N=424	N=407	N=406	N=373	N=252	N=247	N=254	N=287	N=339	N=226
Injected in prison	55 (35)	74 (41)	109 (38)	182 (41)	166 (42)	202 (42)	156 (37)	149 (37)	134 (33)	198 (53)	87 (35)	90 (36)	95 (37)	96 (33)	113 (33)	69 (31)
Frequency of injection last month (%)																
Not last month	80 (7)	103 (7)	139 (7)	150 (6)	174 (7)	171 (6)	223 (9)	225 (9)	226 (9)	145 (7)	160 (9)	182 (9)	155 (8)	230 (10)	270 (10)	259 (11)
Less than weekly	195 (18)	292 (19)	494 (25)	349 (13)	369 (15)	340 (13)	447 (18)	393 (16)	470 (19)	348 (17)	297 (17)	368 (19)	337 (18)	343 (15)	418 (15)	423 (18)
Weekly not daily	352 (33)	490 (33)	311 (16)	632 (24)	55 (22)	599 (22)	607 (25)	581 (24)	610 (24)	530 (26)	458 (25)	476 (24)	484 (25)	576 (25)	618 (23)	563 (24)
Daily or more	438 (41)	601 (40)	1023 (51)	1529 (57)	1388 (55)	1547 (58)	1135 (46)	1221 (50)	1149 (46)	982 (48)	879 (49)	919 (47)	900 (47)	1099 (48)	1361 (50)	1119 (47)
Not reported	7 (1)	11 (1)	11 (1)	5 (<1)	22 (1)	37 (1)	42 (2)	26 (1)	40 (2)	30 (2)	6 (<1)	16 (<1)	36 (2)	22 (1)	30 (1)	32 (1)

Table 1.2 Number (percentage) of respondents by drug last injected and year

NATIONAL N° surveyed	1995 N=1072	1996 N=1497	1997 N=1978	1998 N=2665	1999 N=2503	2000 N=2694	2001 N=2454	2002 N=2445	2003 N=2495	2004 N=2035	2005 N=1800	2006 N=1961	2007 N=1912	2008 N=2270	2009 N=2697	2010 N=2396
Drug last injected (%)																
Anabolic steroids	11 (1)	30 (2)	34 (2)	30 (1)	40 (2)	43 (2)	31 (1)	47 (2)	52 (2)	25 (1)	29 (1)	36 (2)	20 (1)	35 (2)	43 (2)	57 (2)
Cocaine	18 (2)	33 (2)	37 (2)	65 (2)	60 (2)	32 (1)	164 (7)	29 (1)	26 (1)	52 (2)	53 (3)	44 (2)	33 (2)	53 (2)	66 (2)	31 (1)
Heroin	470 (44)	796 (53)	1090 (55)	1369 (51)	1333 (53)	1517 (56)	745 (30)	881 (36)	902 (36)	738 (36)	618 (34)	510 (26)	593 (31)	781 (34)	917 (34)	808 (34)
Methadone	204 (19)	169 (11)	211 (11)	220 (8)	84 (3)	94 (3)	127 (5)	165 (7)	154 (6)	135 (7)	166 (9)	180 (9)	187 (10)	192 (8)	232 (9)	177 (7)
Methamphetamine	233 (22)	278 (18)	367 (18)	570 (21)	647 (26)	582 (22)	914(37)	809 (33)	831 (33)	665 (33)	573 (32)	737 (38)	574 (30)	645 (28)	657 (24)	628 (26)
Pharm. opioids	29 (3)	41 (3)	77 (4)	116 (4)	95 (4)	97 (4)	151 (6)	180 (7)	213 (9)	164 (8)	158 (9)	263 (12)	268 (14)	345 (15)	426 (16)	382 (16)
Buprenorphine	--	--	--	--	--	--	--	25 (1)	14 (<1)	42 (2)	56 (3)	101 (5)	99 (5)	104 (5)	134 (5)	100 (4)
More than one	92 (9)	129 (9)	135 (7)	266 (10)	199 (8)	274 (10)	258(11)	246 (10)	178 (7)	136 (7)	40 (2)	36 (2)	53 (3)	53 (2)	86 (3)	118 (5)
Other	9 (1)	16 (1)	16 (1)	14 (1)	12 (<1)	14 (<1)	26 (1)	30 (1)	78 (3)	27 (2)	39 (2)	32 (2)	51 (3)	21 (1)	69 (3)	83 (3)
Not reported	6 (1)	5 (<1)	11 (1)	15 (1)	33 (1)	40 (1)	38 (2)	33 (1)	47 (2)	51 (2)	68 (4)	49 (3)	34 (2)	41 (2)	67 (2)	12 (<1)

Table 1.3 Number (percentage) of respondents by places injected in the last month and year

NATIONAL N° injected last month	1995 N=985	1996 N=1383	1997 N=1828	1998 N=2510	1999 N=2307	2000 N=2486	2001 N=2189	2002 N=2194	2003 N=2229	2004 N=1860	2005 N=1634	2006 N=1763	2007 N=1721	2008 N=2018	2009 N=2397	2010 N=2109
Places injected in the last month (%) [more than one could be selected]																
<i>Private places</i>																
Own home	--	--	1593 (84)	2103 (84)	1873 (81)	2030 (82)	1751 (80)	1770 (81)	1838 (82)	1508 (81)	1319 (81)	1498 (90)	1488 (89)	1780 (89)	2065 (87)	1738 (82)
Friend's home	--	--	903 (49)	1184 (47)	1032 (45)	1161 (47)	1003 (46)	918 (42)	916 (41)	756 (41)	618 (38)	703 (42)	714 (43)	825 (41)	973 (41)	821 (39)
Dealer's home	--	--	336 (18)	483 (19)	447 (19)	509 (20)	442 (20)	400 (18)	375 (17)	319 (17)	233 (14)	279 (17)	278 (17)	362 (22)	385 (16)	335 (16)
Commercial injecting room	--	--	118 (6)	134 (5)	75 (3)	74 (3)	67 (3)	60 (3)	75 (3)	36 (2)	47 (3)	43 (3)	47 (3)	50 (3)	58 (2)	37 (2)
<i>Public places</i>																
Street, park, beach	--	--	543 (30)	744 (30)	712 (31)	843 (34)	578 (26)	576 (26)	548 (25)	431 (23)	351 (21)	352 (21)	385 (23)	441 (22)	534 (22)	416 (20)
Car	--	--	--	836 (33)	910 (39)	1016(41)	762 (35)	767 (35)	701 (31)	586 (32)	487 (30)	548 (33)	561 (33)	606 (30)	724 (30)	588 (28)
Public toilet	--	--	536 (29)	649 (26)	683 (30)	795 (32)	545 (25)	560 (26)	525 (24)	413 (22)	344 (21)	363 (22)	389 (23)	451 (23)	544 (23)	467 (22)
Squat	--	--	--	--	184 (8)	260 (10)	190 (9)	176 (8)	162 (7)	117 (6)	74 (5)	104 (6)	102 (6)	120 (6)	150 (6)	113 (5)
Public injecting in last month (%)																
Any public	--	--	814 (45)	1228 (49)	1258 (55)	1426 (57)	1068 (49)	1117 (51)	1027 (46)	826 (44)	698 (43)	761 (43)	799 (46)	886 (44)	1079 (45)	887 (42)
All private	--	--	942 (52)	1173 (47)	909 (39)	922 (37)	1120 (51)	1003 (46)	1122 (50)	918 (49)	796 (49)	922 (52)	881 (51)	1104 (55)	1298 (54)	1069 (51)
Not reported	--	--	72 (4)	109 (4)	140 (6)	138 (6)	1 (<1)	84 (4)	80 (4)	118 (6)	128 (8)	80 (5)	41 (2)	28 (1)	20 (<1)	153 (7)

Table 1.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

NATIONAL	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=985	N=1383	N=1828	N=2510	N=2307	N=2486	N=2189	N=2194	N=2229	N=1860	N=1634	N=1763	N=1721	N=2018	N=2397	N=2109
Use of sterile needles and syringes last month (%)																
All injections	--	--	1215 (66)	1628 (65)	1530 (66)	1688 (67)	1568 (72)	1591 (72)	1671 (75)	1328 (71)	1184 (72)	1262 (72)	1234 (72)	1429 (71)	1783 (74)	1477 (70)
Most of the time	--	--	494 (27)	640 (26)	600 (26)	610 (24)	492 (22)	466 (21)	447 (20)	411 (22)	371 (23)	371 (21)	374 (22)	475 (24)	503 (21)	398 (19)
Half of the time	--	--	38 (2)	86 (3)	75 (3)	71 (3)	41 (2)	57 (3)	43 (2)	39 (2)	36 (2)	47 (3)	41 (2)	48 (2)	39 (2)	38 (2)
Some of the time	--	--	21 (1)	84 (3)	27 (1)	38 (2)	30 (1)	28 (1)	32 (1)	36 (2)	18 (1)	24 (1)	25 (1)	28 (1)	35 (1)	28 (1)
Not last month	--	--	11 (1)	7 (<1)	8 (<1)	13 (1)	9 (<1)	17 (1)	7 (<1)	11 (1)	4 (0)	17 (<1)	3 (<1)	13 (<1)	8 (<1)	8 (<1)
Not reported	--	--	49 (3)	65 (3)	67 (3)	66 (3)	49 (2)	35 (2)	29 (1)	35 (2)	21 (1)	42 (2)	44 (3)	25 (1)	29 (1)	160 (8)
Re-used someone else's used needle & syringe last month (%)																
None	677 (69)	1001 (72)	1485 (81)	2010 (80)	1734 (75)	1986 (80)	1777 (81)	1767 (80)	1848 (83)	1473 (79)	1345 (83)	1432 (81)	1381 (80)	1640 (81)	1963 (82)	1595 (76)
Once	101 (10)	155 (11)	76 (4)	151 (6)	165 (7)	155 (6)	123 (6)	112 (5)	121 (5)	113 (6)	60 (4)	88 (5)	104 (6)	108 (5)	124 (5)	87 (4)
Twice	101 (10)	116 (8)	72 (4)	126 (5)	107 (5)	113 (5)	77 (3)	102 (5)	73 (3)	92 (5)	57 (4)	64 (4)	53 (3)	101 (5)	93 (4)	70 (3)
3-5 times	71 (7)	64 (5)	70 (4)	98 (4)	94 (4)	88 (4)	69 (3)	74 (3)	77 (3)	83 (5)	55 (3)	62 (4)	70 (4)	70 (3)	86 (4)	58 (3)
> 5 times	34 (3)	44 (3)	42 (2)	62 (2)	75 (3)	55 (2)	60 (3)	56 (3)	49 (2)	45 (2)	37 (2)	47 (3)	36 (2)	55 (3)	73 (3)	47 (2)
Not reported	1 (<1)	3 (<1)	83 (5)	63 (3)	132 (6)	89 (3)	85 (4)	83 (4)	61 (3)	54 (3)	73 (4)	70 (4)	77 (4)	44 (2)	58 (2)	252 (12)
Number of people needle & syringe was re-used after last month (%)																
None	677 (69)	1001 (72)	1485 (81)	2010 (80)	1734 (75)	1986 (80)	1777 (81)	1767 (80)	1793 (80)	1473 (79)	1277 (78)	1432 (81)	1381 (80)	1640 (81)	1963 (82)	1595 (76)
One	187 (19)	242 (18)	255 (14)	354 (14)	360 (16)	315 (13)	190 (9)	209 (10)	216 (10)	168 (9)	147 (9)	129 (7)	125 (7)	169 (8)	185 (8)	127 (6)
Two	87 (9)	121 (9)	32 (2)	54 (2)	46 (2)	34 (1)	28 (1)	32 (2)	28 (1)	31 (2)	13 (1)	19 (1)	22 (1)	19 (<1)	26 (1)	21 (1)
Three to five	12 (1)	6 (<1)	8 (<1)	14 (1)	31 (1)	30 (1)	20 (1)	18 (<1)	17 (<1)	14 (1)	13 (1)	8 (<1)	14 (<1)	17 (<1)	15 (<1)	25 (1)
More than five	12 (1)	10 (1)	7 (<1)	10 (<1)	32 (1)	24 (1)	20 (1)	18 (<1)	12 (<1)	9 (1)	10 (1)	11 (<1)	8 (<1)	7 (<1)	10 (<1)	19 (1)
Don't know	9 (1)	2 (<1)	0 (0)	5 (<1)	21 (1)	14 (1)	31 (1)	38 (2)	47 (2)	44 (2)	67 (4)	46 (3)	43 (3)	71 (4)	58 (2)	41 (2)
Not reported	1 (<1)	1 (<1)	41 (2)	63 (3)	83 (4)	83 (3)	123 (6)	112 (5)	116 (5)	121 (6)	107 (7)	118 (7)	128 (7)	95 (5)	140 (6)	281 (13)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]																
Regular sex partner	--	--	175 (10)	255 (10)	271 (12)	226 (9)	177 (8)	157 (7)	165 (7)	122 (7)	137 (8)	104 (6)	119 (7)	136 (7)	151 (6)	177 (8)
Casual sex partner	--	--	12 (1)	24 (1)	24 (1)	26 (1)	25 (1)	20 (1)	26 (1)	17 (1)	6 (<1)	14 (<1)	12 (<1)	12 (<1)	4 (<1)	16 (<1)
Close friend	--	--	72 (4)	135 (5)	155 (7)	124 (5)	93 (4)	99 (5)	93 (4)	81 (4)	66 (4)	57 (3)	64 (4)	84 (4)	86 (4)	105 (5)
Acquaintance	--	--	24 (1)	42 (2)	52 (2)	54 (2)	49 (2)	34 (2)	44 (2)	36 (2)	31 (2)	26 (1)	23 (1)	29 (1)	32 (1)	38 (2)
Other	--	--	1 (<1)	4 (<1)	33 (1)	24 (1)	14 (1)	20 (1)	9 (<1)	16 (1)	13 (1)	10 (<1)	16 (1)	21 (1)	29 (1)	38 (2)

Table 1.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

NATIONAL	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=985	N=1383	N=1828	N=2510	N=2307	N=2486	N=2189	N=2194	N=2229	N=1860	N=1634	N=1763	N=1721	N=2018	N=2397	N=2109
Equipment used after someone else last month (%) [more than one could be selected]																
Spoon	--	--	--	--	926 (40)	821 (33)	626 (29)	594 (27)	628 (28)	507 (27)	365 (22)	351 (20)	379 (24)	436 (24)	541 (25)	446 (21)
Water	--	--	--	--	651 (28)	550 (22)	457 (21)	479 (21)	460 (21)	400 (22)	293 (18)	255 (15)	274 (17)	314 (17)	358 (16)	316 (15)
Filter	--	--	--	--	525 (23)	455 (18)	348 (16)	393 (18)	368 (17)	299 (16)	201 (12)	173 (10)	208 (13)	219 (12)	273 (12)	212 (10)
Drug mix	--	--	--	--	425 (18)	341 (14)	303 (14)	344 (16)	292 (13)	224 (12)	193 (12)	140 (8)	136 (9)	155 (8)	202 (9)	177 (8)
Tourniquet	--	--	--	--	381 (17)	313 (13)	295 (13)	293 (13)	255 (11)	216 (12)	192 (12)	166 (10)	168 (11)	195 (11)	196 (9)	--
None	--	--	--	--	--	--	--	--	--	--	--	1064 (62)	1024 (65)	1181 (64)	1409 (64)	1319 (63)
Injected by someone after that person injected themselves or others last month (%)																
No	--	--	--	--	1808 (78)	1964 (79)	1689 (77)	1736 (79)	1842 (83)	1538 (83)	1321 (81)	1451 (82)	1402 (81)	1673 (83)	1958 (82)	1639 (78)
Yes	--	--	--	--	376 (17)	409 (17)	410 (19)	379 (17)	320 (14)	258 (14)	217 (13)	240 (14)	235 (14)	281 (14)	387 (16)	242 (11)
Not reported	--	--	--	--	123 (5)	110 (4)	90 (4)	79 (4)	67 (3)	64 (3)	96 (6)	72 (4)	84 (5)	64 (3)	52 (2)	228 (11)

Table 1.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

NATIONAL	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=1072	N=1497	N=1978	N=2665	N=2503	N=2694	N=2454	N=2445	N=2495	N=2035	N=1800	N=1961	N=1912	N=2270	N=2697	N=2396
Sex with a regular partner last month (%)																
No	--	--	--	--	--	--	--	--	--	--	800 (44)	831 (42)	813 (43)	1015 (45)	1215 (45)	1082 (45)
Yes	--	--	--	--	--	--	--	--	--	--	966 (54)	1074 (55)	1026 (54)	1190 (52)	1382 (51)	1210 (51)
Not reported	--	--	--	--	--	--	--	--	--	--	34 (2)	56 (3)	73 (4)	65 (3)	100 (4)	104 (4)
Condom used with regular partner last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=966	N=1074	N=1026	N=1190	N=1382	N=1210
Sometimes	--	--	--	--	--	--	--	--	--	--	686 (71)	750 (70)	756 (74)	828 (70)	999 (72)	840 (69)
Every time	--	--	--	--	--	--	--	--	--	--	133 (14)	150 (14)	131 (13)	144 (12)	179 (13)	154 (13)
Not reported	--	--	--	--	--	--	--	--	--	--	103 (11)	96 (9)	103 (10)	154 (13)	135 (10)	145 (12)
Sex with other partner(s) last month (%)																
No	--	--	--	--	--	--	--	--	--	--	44 (5)	78 (7)	36 (4)	64 (5)	69 (5)	71 (6)
Yes	--	--	--	--	--	--	--	--	--	--	1461 (81)	1569 (80)	1562 (82)	1838 (81)	2186 (81)	1923 (80)
Not reported	--	--	--	--	--	--	--	--	--	--	296 (16)	296 (15)	279 (15)	345 (15)	378 (14)	327 (14)
Sex with other partner(s) last month (%)																
Not reported	--	--	--	--	--	--	--	--	--	--	43 (2)	96 (5)	71 (4)	87 (4)	133 (5)	146 (6)

Table 1.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

NATIONAL	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=1072	N=1497	N=1978	N=2665	N=2503	N=2694	N=2454	N=2445	N=2495	N=2035	N=1800	N=1961	N=1912	N=2270	N=2697	N=2396
Condom used with other partner(s) last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=296	N=296	N=279	N=345	N=378	N=327
Sometimes	--	--	--	--	--	--	--	--	--	--	74 (25)	77 (26)	91 (33)	85 (25)	129 (34)	116 (35)
Every time	--	--	--	--	--	--	--	--	--	--	76 (26)	74 (25)	69 (25)	101 (29)	96 (25)	72 (22)
Not reported	--	--	--	--	--	--	--	--	--	--	135 (46)	127 (43)	105 (38)	143 (41)	148 (39)	124 (38)
	--	--	--	--	--	--	--	--	--	--	11 (4)	18 (6)	14 (5)	16 (5)	5 (1)	15 (5)
Sex last month (%)																
No	260 (24)	397 (27)	680 (34)	831 (31)	783 (31)	898 (33)	714 (29)	682 (28)	531 (21)	618 (30)	--	--	--	--	--	--
Yes	762 (71)	1070 (71)	1289 (65)	1807 (68)	1687 (68)	1763 (66)	1696 (69)	1706 (70)	1916 (77)	1368 (67)	--	--	--	--	--	--
Not reported	50 (5)	30 (2)	9 (1)	27 (1)	33 (1)	33 (1)	44 (2)	57 (2)	48 (2)	49 (3)	--	--	--	--	--	--
Condom use at last sex (%)																
No	602 (56)	689 (46)	1251 (64)	1691 (63)	1548 (62)	1638 (61)	1561 (64)	1577 (65)	1677 (67)	1382 (68)	--	--	--	--	--	--
Yes	281 (26)	351 (23)	699 (35)	904 (34)	879 (35)	964 (36)	797 (32)	813 (33)	756 (30)	601 (29)	--	--	--	--	--	--
Not reported	189 (18)	457 (31)	28 (1)	70 (3)	76 (3)	92 (3)	96 (4)	55 (2)	62 (3)	52 (3)	--	--	--	--	--	--
Condom use with regular sex partner(s) last month (%)																
No	--	629 (66)	782 (66)	965 (65)	971 (68)	970 (66)	747 (65)	721 (64)	758 (66)	626 (68)	--	--	--	--	--	--
Sometimes	--	115 (12)	160 (14)	193 (13)	164 (11)	164 (11)	174 (15)	144 (13)	136 (12)	114 (12)	--	--	--	--	--	--
Always	--	209 (22)	243 (20)	320 (22)	301 (21)	338 (23)	235 (20)	266 (24)	259 (22)	183 (20)	--	--	--	--	--	--
Condom use with new sex partner(s) last month (%)																
No	--	130 (33)	175 (32)	141 (33)	238 (39)	192 (32)	380 (42)	356 (42)	338 (45)	300 (46)	--	--	--	--	--	--
Sometimes	--	42 (11)	68 (13)	65 (15)	74 (12)	80 (14)	153 (17)	128 (15)	117 (15)	107 (17)	--	--	--	--	--	--
Always	--	219 (56)	294 (55)	220 (52)	295 (49)	317 (54)	369 (41)	361 (43)	304 (40)	239 (37)	--	--	--	--	--	--
Condom use with casual sex partner(s) last month (%)																
No	--	--	--	188 (31)	260 (36)	257 (34)	323 (42)	321 (41)	317 (45)	260 (45)	--	--	--	--	--	--
Sometimes	--	--	--	104 (17)	110 (15)	113 (15)	141 (18)	142 (18)	107 (15)	106 (19)	--	--	--	--	--	--
Always	--	--	--	314 (52)	353 (49)	392 (51)	305 (40)	314 (40)	274 (39)	208 (36)	--	--	--	--	--	--
Sex work last month (%)																
No	979 (91)	1321 (88)	1781 (90)	2435 (92)	2216 (89)	2356 (87)	2130 (87)	2171 (89)	2230 (89)	1808 (89)	1653 (92)	1736 (89)	1721 (90)	1991 (88)	2458 (91)	2092 (87)
Yes	54 (5)	104 (7)	155 (8)	167 (6)	221 (9)	258 (10)	224 (9)	201 (8)	183 (7)	172 (8)	108 (6)	125 (6)	115 (6)	139 (6)	130 (5)	128 (5)
Not reported	39 (4)	72 (5)	42 (2)	63 (2)	64 (2)	78 (3)	100 (4)	73 (3)	82 (3)	55 (3)	39 (2)	100 (5)	76 (4)	140 (6)	109 (4)	176 (7)
Condom used at last sex work (%)																
Yes	46 (96)	90 (89)	119 (89)	138 (91)	185 (92)	204 (95)	161 (90)	153 (89)	148 (89)	149 (90)	204 (95)	101 (86)	92 (87)	105 (83)	106 (84)	95 (78)

Table 1.6 Number (percentage) of respondents by previous testing for HIV, HBV, HCV infection, HBV vaccination and HCV treatment by year

NATIONAL	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	
N° surveyed	N=1072	N=1497	N=1978	N=2665	N=2503	N=2694	N=2454	N=2445	N=2495	N=2035	N=1800	N=1961	N=1912	N=2270	N=2697	N=2396	
Previous HIV test (%)																	
Yes, last year	737 (69)	1029 (69)	1358 (68)	1740 (65)	1590 (64)	1770 (66)	1509 (61)	1596 (65)	1562 (63)	1223 (60)	1035 (58)	1117 (57)	1077 (56)	1124 (50)	1360 (50)	1141 (48)	
> 1 year ago	225 (21)	288 (19)	389 (20)	561 (21)	555 (22)	573 (21)	604 (25)	549 (23)	651 (26)	560 (28)	564 (31)	618 (32)	617 (32)	818 (36)	922 (34)	819 (34)	
Never tested	97 (9)	176 (12)	219 (11)	347 (13)	329 (13)	325 (12)	304 (12)	274 (11)	256 (10)	214 (10)	191 (11)	187 (10)	187 (10)	215 (9)	310 (11)	282 (12)	
Not reported	13 (1)	4 (<1)	12(1)	17(1)	29(1)	26(1)	37(2)	26(1)	26(1)	38(2)	10(1)	39(2)	31(2)	113 (5)	105 (4)	154 (6)	
Self report HBV infection (%)																	
No	729 (68)	1072 (72)	1352 (68)	1784 (67)	1808 (72)	1925 (72)	1720 (70)	1692 (69)	1778 (71)	1407 (69)	1255 (70)	1368 (70)	1314 (69)	--	--	--	--
Yes	318 (30)	405 (27)	394 (20)	493 (19)	428 (17)	456 (17)	411 (17)	430 (18)	451 (18)	370 (18)	316 (18)	336 (17)	362 (19)	--	--	--	--
Don't know	--	--	226 (11)	353 (13)	220 (9)	270 (10)	275 (11)	279 (11)	238 (10)	206 (10)	207 (12)	207 (11)	197 (10)	--	--	--	--
Not reported	25 (2)	20 (1)	6 (1)	35 (1)	45 (2)	38 (1)	48 (2)	44 (2)	28 (1)	52 (3)	22 (1)	50 (3)	39 (2)	--	--	--	--
Self report HBV vaccination (%)																	
No	601 (56)	784 (52)	914 (46)	1075 (40)	1001 (40)	959 (36)	848 (35)	849 (35)	872 (35)	722 (35)	595 (33)	598 (30)	599 (31)	--	--	--	--
Yes	433 (40)	669 (45)	778 (39)	1136 (43)	1211 (49)	1395 (52)	1214 (49)	1289 (52)	1336 (54)	1057 (52)	950 (53)	1076 (57)	1072 (56)	--	--	--	--
Don't know	--	--	273 (14)	387 (15)	232 (9)	272 (10)	251 (10)	245 (10)	226 (9)	192 (9)	224 (12)	226 (12)	194 (10)	--	--	--	--
Not reported	38 (4)	44 (3)	13 (1)	67 (2)	59 (2)	64 (2)	141 (6)	62 (3)	61 (2)	64 (3)	31 (2)	61 (3)	47 (2)	--	--	--	--
Previous HCV test (%)																	
Yes, ever ^	825 (77)	1200 (80)	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Yes, last year	--	--	1347 (68)	1730 (65)	1613 (65)	1869 (69)	1601 (65)	1612 (65)	1590 (64)	1287 (63)	1089 (61)	1176 (60)	1147 (60)	1257 (55)	1549 (57)	1280 (53)	
> 1 year ago	--	--	325 (16)	477 (18)	511 (20)	508 (19)	559 (23)	526 (22)	598 (24)	527 (26)	521 (29)	579 (30)	596 (31)	769 (34)	855 (32)	750 (31)	
Never tested	220 (20)	272 (18)	291 (15)	440 (16)	350 (14)	286 (11)	260 (11)	283 (13)	285 (11)	191 (9)	179 (10)	166 (8)	141 (7)	154 (7)	196 (7)	190 (8)	
Not reported	27 (3)	25 (2)	15 (1)	18 (1)	29 (1)	31 (1)	34 (1)	24 (1)	22 (1)	30 (2)	11 (1)	40 (2)	28 (1)	90 (4)	97 (4)	176 (7)	
Any treatment for HCV (%)																	
Interferon/+Ribavirin	--	--	--	--	N=930	N=1105	N=1000	N=1072	N=1110	N=931	N=826	N=894	N=848	N=1203	N=1383	N=1274	
Other	--	--	--	--	25 (3)	46 (4)	38 (4)	44 (4)	46 (4)	51 (5)	39 (5)	50 (6)	43 (5)	107 (9)	126 (9)	136 (11)	
No treatment	--	--	--	--	35 (4)	33 (3)	30 (3)	36 (3)	32 (3)	27 (3)	20 (2)	18 (2)	17 (2)	21 (2)	17 (1)	17 (1)	
Not reported	--	--	--	--	854 (91)	1003 (91)	910 (91)	965 (90)	1006 (91)	824 (89)	759 (92)	791 (88)	747 (88)	1039 (86)	1174 (85)	1072 (84)	
Current treatment for HCV (%)					N=20	N=27	N=21	N=10	N=19	N=21	N=20	N=21	N=15	N=27	N=25	N=32	
Interferon +/- Ribavirin	--	--	--	--	5	7	8	3	7	12	11	11	6	18	21	26	
Other	--	--	--	--	15	20	13	7	12	9	9	10	9	9	4	6	

Table 1.7 Number (percentage) of respondents by treatment for drug use and year

NATIONAL	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=1072	N=1497	N=1978	N=2665	N=2503	N=2694	N=2454	N=2445	N=2495	N=2035	N=1800	N=1961	N=1912	N=2270	N=2697	N=2396
Ever any treatment/therapy for drug use (%)																
No	333 (31)	498 (33)	619 (31)	912 (34)	880 (35)	812 (30)	783 (32)	721 (29)	838 (34)	421 (21)	406 (23)	414 (21)	370 (19)	444 (20)	509 (19)	425 (18)
Yes	734 (68)	990 (66)	1354 (68)	1745 (65)	1606 (64)	1831 (68)	1651 (67)	1700 (70)	1647 (66)	1552 (76)	1374 (76)	1495 (76)	1504 (79)	1785 (79)	2144 (80)	1910 (80)
Not reported	5 (1)	9 (1)	5 (1)	8 (1)	17 (1)	51 (2)	20 (1)	20 (1)	10 (<1)	62 (3)	20 (1)	51 (3)	38 (2)	41 (2)	44 (2)	61 (3)
History of methadone maintenance treatment (%)																
Current	426 (40)	528 (35)	666 (34)	828 (31)	699 (28)	710 (26)	649 (26)	648 (27)	725 (29)	621 (31)	600 (33)	575 (29)	605 (32)	696 (31)	823 (31)	725 (30)
Previous	170 (16)	273 (18)	369 (19)	485 (18)	518 (21)	675 (25)	586 (24)	636 (26)	617 (25)	467 (23)	426 (24)	519 (26)	539 (28)	587 (26)	645 (24)	600 (25)
Never	471 (44)	687 (46)	938 (47)	1344 (50)	1272 (51)	1292 (48)	1192 (49)	1130 (46)	1139 (46)	842 (41)	753 (42)	821 (42)	740 (39)	938 (41)	1167 (43)	946 (39)
Not reported	5 (<1)	9 (1)	5 (<1)	8 (1)	12 (<1)	17 (1)	27 (1)	30 (1)	14 (<1)	105 (5)	21 (1)	46 (2)	28 (1)	49 (2)	62 (2)	125 (5)
History of other pharmacotherapy treatment (%)																
Current	--	--	--	--	--	62 (2)	116 (5)	206 (8)	288 (12)	297 (15)	278 (15)	252 (13)	261 (14)	360 (16)	432 (16)	371 (15)
Previous	--	--	--	--	--	289 (11)	246 (10)	312 (13)	432 (17)	377 (18)	360 (20)	429 (22)	437 (23)	554 (24)	671 (25)	634 (26)
Never	--	--	--	--	--	2084 (77)	2035 (83)	1875 (77)	1731 (69)	1294 (64)	1135 (63)	1230 (63)	1168 (61)	1312 (58)	1551 (58)	1374 (57)
Not reported	--	--	--	--	--	258 (10)	57 (2)	51 (2)	44 (2)	67 (3)	27 (2)	50 (3)	46 (2)	44 (2)	43 (2)	17 (1)

Table 1.8 Number (percentage) of respondents by source of needle and syringe acquisition in the month prior to survey and year

NATIONAL	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=985	N=1383	N=1828	N=2510	N=2307	N=2486	N=2189	N=2194	N=2229	N=1860	N=1634	N=1763	N=1721	N=2018	N=2397	N=2109
Needle/syringe acquisition in the last month (%) [more than one could be selected]																
Needle Syringe Program	--	--	--	--	2173 (87)	2341 (87)	2064 (84)	2055 (84)	2080 (83)	1730 (85)	1559 (87)	1657 (85)	1285 (67)	1879 (83)	1569 (65)	2063 (86)
Pharmacy	--	--	--	--	1418 (57)	1467 (54)	1224 (50)	1181 (48)	1104 (44)	935 (46)	691 (38)	850 (43)	387 (20)	876 (39)	601 (25)	450 (19)
Personal Sources	--	--	--	--	--	--	--	--	--	--	--	--	313 (16)	--	418 (17)	256 (11)
Vending Machine	--	--	--	--	--	--	--	--	--	--	--	--	180 (9)	--	222 (9)	181 (8)
Other sources	--	--	--	--	--	--	--	--	--	--	--	--	64 (3)	--	69 (3)	77 (3)
Onward supply of syringes in last month (%)																
Yes, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	632 (37)	--	808 (34)	827 (39)
No, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	805 (47)	--	1104 (46)	1265 (60)
Not reported	--	--	--	--	--	--	--	--	--	--	--	--	284 (17)	--	485 (20)	17 (1)

HIV ANTIBODY PREVALENCE

Table 1.9 HIV antibody prevalence by gender and year

NATIONAL	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995	655	15 (2.3)	335	5 (1.5)	1004	21 (2.1)
1996	996	20 (2.0)	469	7 (1.5)	1482	27 (1.8)
1997	1187	24 (2.0)	621	4 (0.6)	1814	28 (1.5)
1998	1566	16 (1.0)	853	4 (0.5)	2430	20 (0.8)
1999	1531	26 (1.7)	840	8 (1.0)	2383	34 (1.4)
2000	1639	21 (1.3)	871	0 (0.0)	2525	22 (0.9)
2001	1540	20 (1.3)	778	1 (0.1)	2342	21 (0.9)
2002	1551	25 (1.6)	785	4 (0.5)	2357	31 (1.3)
2003	1600	22 (1.4)	794	2 (0.3)	2418	25 (1.0)
2004	1216	17 (1.4)	595	3 (0.5)	1825	20 (1.1)
2005	1072	15 (1.4)	611	0 (0.0)	1692	15 (0.9)
2006	1223	26 (2.1)	661	2 (0.3)	1897	29 (1.5)
2007	1195	25 (2.1)	639	2 (0.3)	1845	28 (1.5)
2008	1396	29 (2.1)	764	3 (0.4)	2170	33 (1.5)
2009	1725	28 (1.6)	915	2 (0.2)	2657	31 (1.2)
2010	1579	21 (1.3)	759	2 (0.3)	2352	23 (1.0)
χ^2 trend p value		0.861		<0.001		0.323

Table 1.10 HIV antibody prevalence by sexual identity, gender and year

NATIONAL	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
Heterosexual	555	5 (0.9)	239	3 (1.3)	799	9 (1.1)
Bisexual	43	1 (2.3)	69	1 (1.5)	116	2 (1.7)
Homosexual	40	9 (22.5)	22	1 (4.6)	65	10 (15.4)
1996						
Heterosexual	824	4 (0.5)	326	5 (1.5)	1159	9 (0.8)
Bisexual	68	3 (4.4)	91	0 (0.0)	160	3 (1.9)
Homosexual	70	13 (18.6)	39	1 (2.6)	109	14 (12.8)
1997						
Heterosexual	1004	5 (0.5)	418	3 (0.7)	1426	8 (0.6)
Bisexual	77	2 (2.6)	130	1 (0.8)	208	3 (1.4)
Homosexual	54	17 (31.5)	58	0 (0.0)	112	17 (15.2)
1998						
Heterosexual	1339	4 (0.3)	620	2 (0.3)	1963	6 (0.3)
Bisexual	88	2 (2.3)	139	2 (1.4)	228	4 (1.8)
Homosexual	69	10 (14.5)	74	0 (0.0)	144	10 (6.9)
1999						
Heterosexual	1246	10 (0.8)	553	7 (1.3)	1799	17 (0.9)
Bisexual	104	2 (1.9)	187	1 (0.5)	297	3 (1.0)
Homosexual	71	12 (16.9)	52	0 (0.0)	125	12 (9.6)
2000						
Heterosexual	1374	7 (0.5)	558	0 (0.0)	1935	7 (0.4)
Bisexual	77	2 (2.6)	196	0 (0.0)	275	2 (0.7)
Homosexual	84	12 (14.3)	71	0 (0.0)	160	13 (8.1)
2001						
Heterosexual	1268	5 (0.4)	529	1 (0.2)	1808	6 (0.3)
Bisexual	69	2 (2.9)	154	0 (0.0)	225	2 (0.9)
Homosexual	80	13 (16.3)	47	0 (0.0)	129	13 (10.1)
2002						
Heterosexual	1269	7 (0.6)	525	3 (0.6)	1800	10 (0.6)
Bisexual	71	2 (2.8)	171	1 (0.6)	248	4 (1.6)
Homosexual	58	14 (24.1)	32	0 (0.0)	92	15 (16.3)
2003						
Heterosexual	1336	7 (0.5)	513	1 (0.2)	1856	8 (0.4)
Bisexual	60	2 (3.3)	168	1 (0.6)	232	4 (1.7)
Homosexual	73	12 (16.4)	48	0 (0.0)	124	12 (9.7)
2004						
Heterosexual	1058	1 (0.1)	435	2 (0.5)	1496	3 (0.2)
Bisexual	45	1 (2.2)	108	1 (0.9)	155	2 (1.3)
Homosexual	45	13 (28.9)	30	0 (0.0)	75	13 (17.3)
2005						
Heterosexual	939	4 (0.4)	439	0 (0.0)	1379	4 (0.3)
Bisexual	37	0 (0.0)	106	0 (0.0)	144	0 (0.0)
Homosexual	53	11 (20.8)	32	0 (0.0)	90	11 (12.2)
2006						
Heterosexual	1070	3 (0.3)	484	1 (0.2)	1557	4 (0.3)
Bisexual	55	4 (7.3)	110	1 (0.9)	171	6 (3.5)
Homosexual	59	19 (32.2)	46	0 (0.0)	107	19 (17.8)
2007						
Heterosexual	1055	5 (0.5)	458	2 (0.4)	1514	7 (0.5)
Bisexual	47	2 (4.3)	119	0 (0.0)	170	3 (1.8)
Homosexual	69	18 (26.1)	42	0 (0.0)	114	18 (15.8)
2008						
Heterosexual	1228	3 (0.2)	537	1 (0.2)	1767	4 (0.2)
Bisexual	56	3 (5.4)	152	2 (1.3)	209	6 (2.9)
Homosexual	62	23 (37.1)	48	0 (0.0)	112	23 (20.6)
2009						
Heterosexual	1510	7 (0.5)	682	2 (0.3)	2207	9 (0.4)
Bisexual	78	2 (2.5)	146	0 (0.0)	229	3 (1.3)
Homosexual	30	18 (37.5)	37	0 (0.0)	87	18 (20.7)
2010						
Heterosexual	1390	4 (0.3)	558	2 (0.4)	1954	6 (0.3)
Bisexual	61	3 (4.9)	124	0 (0.0)	188	3 (1.6)
Homosexual	48	14 (29.2)	36	0 (0.0)	85	14 (16.5)
2010 p value		<0.001		1.000		<0.001

Table 1.11 HIV antibody prevalence by age group, gender and year

NATIONAL	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
<25 years	167	4 (2.4)	126	1 (0.8)	300	5 (1.7)
25-34 years	303	6 (2.0)	137	3 (2.2)	443	9 (2.0)
35+ years	179	5 (2.8)	71	1 (1.4)	254	7 (2.8)
1996						
<25 years	331	2 (0.6)	176	2 (1.4)	511	4 (0.8)
25-34 years	393	9 (2.3)	203	3 (1.5)	605	12 (2.0)
35+ years	269	9 (3.4)	90	2 (2.2)	361	11 (3.1)
1997						
<25 years	402	1 (0.3)	249	0 (0.0)	652	1 (0.2)
25-34 years	460	12 (2.6)	252	4 (1.6)	715	16 (2.2)
35+ years	324	11 (3.4)	120	0 (0.0)	446	11 (2.5)
1998						
<25 years	524	0 (0.0)	352	1 (0.3)	877	1 (0.1)
25-34 years	626	9 (1.4)	300	2 (0.7)	933	11 (1.2)
35+ years	414	7 (1.7)	201	1 (0.5)	618	8 (1.3)
1999						
<25 years	455	2 (0.4)	315	2 (0.6)	772	4 (0.5)
25-34 years	667	12 (1.8)	331	4 (1.2)	1002	16 (1.6)
35+ years	407	12 (3.0)	193	2 (1.0)	603	14 (2.3)
2000						
<25 years	441	1 (0.2)	346	0 (0.0)	791	1 (0.1)
25-34 years	688	12 (1.7)	333	0 (0.0)	1026	12 (1.2)
35+ years	509	8 (1.6)	192	0 (0.0)	706	9 (1.3)
2001						
<25 years	381	0 (0.0)	265	0 (0.0)	652	0 (0.0)
25-34 years	619	9 (1.4)	307	0 (0.0)	940	9 (1.0)
35+ years	518	11 (2.1)	205	1 (0.5)	746	12 (1.6)
2002						
<25 years	343	0 (0.0)	246	1 (0.4)	592	1 (0.2)
25-34 years	670	15 (2.2)	322	1 (0.3)	998	17 (1.7)
35+ years	535	10 (1.9)	216	2 (0.9)	763	13 (1.7)
2003						
<25 years	310	6 (1.9)	192	0 (0.0)	505	6 (1.2)
25-34 years	640	5 (1.8)	338	1 (0.3)	986	7 (0.7)
35+ years	647	11 (1.7)	262	1 (0.4)	922	12 (1.3)
2004						
<25 years	206	2 (1.0)	136	1 (0.7)	343	3 (0.9)
25-34 years	505	5 (1.0)	219	0 (0.0)	726	5 (0.7)
35+ years	502	9 (1.8)	240	2 (0.8)	748	11 (1.5)
2005						
<25 years	129	1 (0.8)	112	0 (0.0)	241	1 (0.4)
25-34 years	410	3 (0.8)	260	0 (0.0)	671	3 (0.5)
35+ years	538	11 (2.0)	241	0 (0.0)	787	11 (1.4)
2006						
<25 years	120	2 (1.7)	105	0 (0.0)	225	2 (0.9)
25-34 years	492	5 (1.0)	265	1 (0.4)	764	7 (0.9)
35+ years	606	19 (3.1)	289	1 (0.4)	901	20 (2.2)
2007						
<25 years	90	0 (0.0)	84	0 (0.0)	175	0 (0.0)
25-34 years	453	6 (1.3)	236	0 (0.0)	693	6 (0.9)
35+ years	650	19 (2.9)	318	2 (0.6)	974	22 (2.3)
2008						
<25 years	107	0 (0.0)	89	0 (0.0)	196	0 (0.0)
25-34 years	468	7 (1.5)	297	3 (1.0)	767	11 (1.4)
35+ years	816	22 (2.7)	377	0 (0.0)	1201	22 (1.8)
2009						
<25 years	156	1 (0.6)	117	0 (0.0)	275	1 (0.4)
25-34 years	575	7 (1.2)	346	0 (0.0)	925	7 (0.8)
35+ years	984	20 (1.6)	446	1 (0.2)	1441	22 (1.5)
2010						
<25 years	105	1 (1.0)	90	0 (0.0)	197	1 (0.5)
25-34 years	502	3 (0.6)	263	0 (0.0)	766	3 (0.4)
35+ years	971	17 (1.8)	405	2 (0.5)	1387	19 (1.4)
2010 p value		0.163		0.629		0.064

Table 1.12 HIV antibody prevalence by time since first drug injection, gender and year

NATIONAL	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
<3 years	79	1 (1.3)	53	0 (0.0)	134	1 (0.8)
3-10 years	234	5 (2.1)	145	2 (1.4)	384	7 (1.8)
11+ years	327	9 (2.8)	134	3 (2.2)	466	13 (2.8)
1996						
<3 years	170	2 (1.2)	76	2 (2.6)	248	4 (1.6)
3-10 years	397	6 (1.5)	199	3 (1.5)	604	9 (1.5)
11+ years	393	11 (2.8)	183	2 (1.1)	581	13 (2.2)
1997						
<3 years	193	2 (1.0)	126	0 (0.0)	320	2 (0.6)
3-10 years	484	8 (1.6)	275	1 (0.4)	759	9 (1.2)
11+ years	477	13 (2.7)	212	3 (1.4)	694	16 (2.3)
1998						
<3 years	273	2 (0.7)	182	1 (0.6)	457	3 (0.7)
3-10 years	659	3 (0.4)	364	0 (0.0)	1025	3 (0.3)
11+ years	598	11 (1.8)	296	3 (1.0)	899	14 (1.6)
1999						
<3 years	239	2 (0.8)	154	1 (0.6)	393	3 (0.8)
3-10 years	659	7 (1.1)	389	4 (1.0)	1053	11 (1.0)
11+ years	592	16 (2.7)	280	3 (1.1)	875	19 (2.2)
2000						
<3 years	208	4 (1.9)	128	0 (0.0)	336	4 (1.2)
3-10 years	703	6 (0.8)	449	0 (0.0)	1158	6 (0.5)
11+ years	691	11 (1.6)	277	0 (0.0)	972	12 (1.2)
2001						
<3 years	169	3 (1.8)	110	0 (0.0)	282	3 (1.1)
3-10 years	641	8 (1.2)	374	0 (0.0)	1019	8 (0.8)
11+ years	683	8 (1.2)	277	1 (0.4)	972	9 (0.9)
2002						
<3 years	149	2 (1.3)	75	0 (0.0)	227	2 (0.8)
3-10 years	610	5 (0.8)	369	2 (0.5)	986	8 (0.8)
11+ years	751	17 (2.3)	316	2 (0.6)	1075	20 (1.9)
2003						
<3 years	132	2 (1.5)	68	0 (0.0)	201	2 (1.0)
3-10 years	571	10 (1.7)	345	0 (0.0)	923	11 (1.2)
11+ years	842	9 (1.1)	357	2 (0.6)	1211	11 (0.9)
2004						
<3 years	84	2 (2.4)	51	0 (0.0)	135	2 (1.5)
3-10 years	450	5 (1.1)	245	0 (0.0)	698	5 (0.7)
11+ years	656	9 (1.4)	290	3 (1.0)	949	12 (1.3)
2005						
<3 years	54	2 (3.7)	29	0 (0.0)	84	2 (2.4)
3-10 years	197	2 (1.0)	180	0 (0.0)	379	2 (0.5)
11+ years	775	9 (1.2)	372	0 (0.0)	1153	19 (1.6)
2006						
<3 years	59	1 (1.7)	42	0 (0.0)	102	1 (1.0)
3-10 years	308	6 (1.9)	226	1 (0.4)	538	8 (1.5)
11+ years	799	18 (2.3)	378	1 (0.3)	1185	19 (1.6)
2007						
<3 years	61	1 (1.6)	37	0 (0.0)	98	1 (1.0)
3-10 years	277	4 (1.4)	190	0 (0.0)	471	4 (0.8)
11+ years	826	19 (2.4)	394	2 (0.5)	1227	22 (1.8)
2008						
<3 years	67	5 (7.4)	43	0 (0.0)	110	5 (4.6)
3-10 years	308	4 (1.3)	202	0 (0.0)	511	4 (0.8)
11+ years	986	19 (1.9)	508	3 (0.6)	1502	23 (1.5)
2009						
<3 years	90	2 (2.2)	67	0 (0.0)	158	2 (1.3)
3-10 years	317	5 (1.6)	237	0 (0.0)	558	5 (0.9)
11+ years	1279	21 (1.6)	585	1 (0.2)	1875	23 (1.2)
2010						
<3 years	87	2 (2.3)	36	0 (0.0)	124	2 (1.6)
3-10 years	252	2 (0.8)	181	0 (0.0)	434	2 (0.5)
11+ years	1204	17 (1.4)	527	2 (0.4)	1742	19 (1.1)
2010 p value		0.480		1.000		0.336

Table 1.13 HIV antibody prevalence by drug last injected, gender and year

NATIONAL	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
Heroin	295	9 (3.1)	146	2 (1.4)	443	11 (2.5)
Methamphetamine	133	3 (2.2)	72	0 (0.0)	210	3 (1.4)
Other	223	3 (1.4)	117	3 (2.6)	347	7 (2.0)
1996						
Heroin	517	10 (1.9)	263	4 (1.5)	787	14 (1.8)
Methamphetamine	199	6 (3.0)	75	1 (1.3)	277	7 (2.5)
Other	277	4 (1.4)	129	2 (1.6)	413	6 (1.5)
1997						
Heroin	647	15 (2.3)	359	1 (0.3)	1008	16 (1.6)
Methamphetamine	219	4 (1.8)	104	0 (0.0)	325	4 (1.2)
Other	312	5 (1.6)	157	3 (1.9)	471	8 (1.7)
1998						
Heroin	792	6 (0.8)	462	1 (0.2)	1257	7 (0.6)
Methamphetamine	354	3 (0.9)	155	2 (1.3)	510	5 (1.0)
Other	412	7 (1.7)	232	1 (0.4)	649	8 (1.2)
1999						
Heroin	784	6 (0.8)	477	4 (0.8)	1268	10 (0.8)
Methamphetamine	401	13 (3.2)	212	2 (0.9)	614	15 (2.4)
Other	327	7 (2.1)	140	1 (0.7)	468	8 (1.7)
2000						
Heroin	893	9 (1.0)	543	0 (0.0)	1437	9 (0.6)
Methamphetamine	373	7 (1.9)	162	0 (0.0)	538	7 (1.3)
Other	360	4 (1.1)	156	0 (0.0)	521	8 (1.0)
2001						
Heroin	453	4 (0.9)	269	1 (0.4)	725	5 (0.7)
Methamphetamine	591	13 (2.2)	263	0 (0.0)	865	13 (1.5)
Other	478	3 (0.6)	232	0 (0.0)	716	3 (0.4)
2002						
Heroin	552	4 (0.7)	300	2 (0.7)	856	8 (0.9)
Methamphetamine	507	15 (3.0)	260	0 (0.0)	772	15 (1.9)
Other	476	6 (1.3)	213	2 (0.9)	699	8 (1.1)
2003						
Heroin	564	7 (1.2)	311	2 (0.6)	884	10 (1.1)
Methamphetamine	538	11 (2.0)	253	0 (0.0)	797	11 (1.4)
Other	476	4 (0.8)	208	0 (0.0)	691	4 (0.6)
2004						
Heroin	464	4 (0.9)	207	1 (0.5)	676	5 (0.7)
Methamphetamine	360	9 (2.5)	221	1 (0.5)	581	10 (1.7)
Other	364	4 (1.1)	160	1 (0.6)	527	5 (1.0)
2005						
Heroin	353	3 (0.8)	235	0 (0.0)	590	3 (0.5)
Methamphetamine	333	5 (1.5)	196	0 (0.0)	534	5 (0.9)
Other	338	7 (2.1)	168	0 (0.0)	508	7 (1.4)
2006						
Heroin	303	4 (1.3)	187	0 (0.0)	495	4 (0.8)
Methamphetamine	448	17 (3.8)	261	1 (0.4)	713	19 (2.7)
Other	434	5 (1.2)	202	0 (0.0)	640	5 (0.8)
2007						
Heroin	348	4 (1.2)	222	0 (0.0)	574	4 (0.7)
Methamphetamine	348	10 (2.9)	204	1 (0.5)	552	11 (2.0)
Other	475	11 (2.3)	205	1 (0.5)	687	13 (1.9)
2008						
Heroin	494	3 (0.6)	253	1 (0.4)	749	4 (0.5)
Methamphetamine	362	17 (4.7)	238	1 (0.4)	604	19 (3.2)
Other	514	8 (1.6)	261	1 (0.4)	779	9 (1.2)
2009						
Heroin	591	5 (0.9)	311	1 (0.3)	907	6 (0.7)
Methamphetamine	402	15 (3.7)	243	1 (0.4)	649	16 (2.5)
Other	687	8 (1.2)	337	0 (0.0)	1032	9 (0.9)
2010						
Heroin	522	6 (1.2)	272	2 (0.7)	797	8 (1.0)
Methamphetamine	396	10 (2.5)	210	0 (0.0)	612	10 (1.6)
Other	653	5 (0.8)	273	0 (0.0)	931	5 (0.5)
2010 p value		0.063		0.207		0.097

Table 1.14 HIV antibody prevalence by frequency of injection last month, gender and year

NATIONAL	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
Less than daily	337	8 (2.4)	172	3 (1.7)	517	12 (2.3)
Daily or more	263	6 (2.3)	143	2 (1.4)	411	8 (2.0)
Not last month	53	1 (1.9)	19	0 (0.0)	73	1 (1.4)
1996						
Less than daily	511	11 (2.2)	257	3 (1.2)	776	14 (1.8)
Daily or more	409	8 (2.0)	176	4 (2.3)	593	12 (2.0)
Not last month	68	1 (1.5)	33	0 (0.0)	102	1 (1.0)
1997						
Less than daily	505	13 (2.6)	243	3 (1.2)	751	16 (2.1)
Daily or more	586	6 (1.0)	341	0 (0.0)	929	6 (0.7)
Not last month	90	5 (5.6)	34	1 (2.9)	125	6 (4.8)
1998						
Less than daily	619	9 (1.5)	283	2 (0.7)	906	11 (1.2)
Daily or more	859	5 (0.6)	521	2 (0.4)	1384	7 (0.5)
Not last month	86	2 (2.3)	48	0 (0.0)	135	2 (1.5)
1999						
Less than daily	562	8 (1.4)	310	2 (0.7)	875	10 (1.1)
Daily or more	844	13 (1.5)	472	5 (1.1)	1321	18 (1.4)
Not last month	111	5 (4.5)	53	1 (1.9)	165	6 (3.6)
2000						
Less than daily	586	9 (1.5)	286	0 (0.0)	875	10 (1.1)
Daily or more	933	8 (0.9)	525	0 (0.0)	1464	8 (0.6)
Not last month	106	4 (3.8)	52	0 (0.0)	159	4 (2.5)
2001						
Less than daily	681	10 (1.5)	322	1 (0.3)	1010	11 (1.1)
Daily or more	698	8 (1.2)	369	0 (0.0)	1078	8 (0.7)
Not last month	137	2 (1.5)	76	0 (0.0)	215	2 (0.9)
2002						
Less than daily	634	13 (2.1)	292	2 (0.7)	937	17 (1.8)
Daily or more	770	7 (0.9)	410	2 (0.5)	1184	9 (0.8)
Not last month	135	4 (3.0)	73	0 (0.0)	212	4 (1.9)
2003						
Less than daily	717	8 (1.1)	320	0 (0.0)	1048	9 (0.8)
Daily or more	724	13 (1.8)	380	0 (0.0)	1115	13 (1.8)
Not last month	138	0 (0.0)	79	2 (2.5)	217	2 (0.9)
2004						
Less than daily	511	13 (2.5)	271	2 (0.7)	782	15 (1.9)
Daily or more	611	3 (0.5)	274	1 (0.4)	891	4 (0.5)
Not last month	80	0 (0.0)	47	0 (0.0)	129	0 (0.0)
2005						
Less than daily	458	12 (2.6)	240	0 (0.0)	704	12 (1.7)
Daily or more	518	2 (0.4)	310	0 (0.0)	830	2 (0.2)
Not last month	90	1 (1.1)	57	0 (0.0)	148	1 (0.7)
2006						
Less than daily	531	18 (3.4)	283	1 (0.4)	818	19 (2.3)
Daily or more	572	7 (1.2)	308	0 (0.0)	886	8 (0.9)
Not last month	109	1 (0.9)	66	1 (1.5)	178	2 (1.1)
2007						
Less than daily	513	11 (2.1)	276	1 (0.4)	794	13 (1.6)
Daily or more	572	8 (1.4)	292	1 (0.3)	869	9 (1.0)
Not last month	89	5 (5.6)	59	0 (0.0)	149	5 (3.4)
2008						
Less than daily	569	17 (3.0)	309	1 (0.3)	882	18 (2.0)
Daily or more	679	8 (1.2)	363	1 (0.3)	1047	10 (1.0)
Not last month	136	4 (2.9)	83	1 (1.2)	220	5 (2.3)
2009						
Less than daily	645	12 (1.9)	371	2 (0.5)	1023	14 (1.4)
Daily or more	896	12 (1.3)	434	0 (0.0)	1339	13 (1.0)
Not last month	169	4 (2.4)	96	0 (0.0)	266	4 (1.5)
2010						
Less than daily	697	10 (1.4)	351	2 (0.6)	1054	12 (1.1)
Daily or more	706	5 (0.7)	309	0 (0.0)	1019	5 (0.5)
Not last month	155	6 (3.9)	92	0 (0.0)	251	6 (2.4)
2010 p value		0.011		0.616		0.021

Table 1.15 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year

NATIONAL	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
No receptive sharing	429	12 (2.8)	203	4 (2.0)	638	17 (2.7)
Receptive sharing	170	2 (1.2)	112	1 (0.9)	289	3 (1.0)
1996						
No receptive sharing	673	16 (2.4)	304	7 (2.3)	991	23 (2.3)
Receptive sharing	246	3 (1.2)	129	0 (0.0)	377	3 (0.8)
1997						
No receptive sharing	909	17 (1.9)	456	3 (0.7)	1370	20 (1.5)
Receptive sharing	161	2 (1.2)	110	0 (0.0)	271	2 (0.7)
1998						
No receptive sharing	1206	11 (0.9)	616	4 (0.7)	1829	15 (0.8)
Receptive sharing	236	2 (0.9)	165	0 (0.0)	402	2 (0.5)
1999						
No receptive sharing	1065	16 (1.5)	578	6 (1.0)	1650	22 (1.3)
Receptive sharing	289	4 (1.4)	177	1 (0.6)	467	5 (1.1)
2000						
No receptive sharing	1259	17 (1.4)	614	0 (0.0)	1872	18 (1.0)
Receptive sharing	218	0 (0.0)	172	0 (0.0)	391	0 (0.0)
2001						
No receptive sharing	1260	16 (1.3)	633	1 (0.2)	1913	15 (0.9)
Receptive sharing	208	4 (1.9)	103	0 (0.0)	311	4 (1.3)
2002						
No receptive sharing	1134	15 (1.3)	568	3 (0.5)	1717	20 (1.2)
Receptive sharing	234	4 (1.7)	115	1 (0.9)	349	5 (1.4)
2003						
No receptive sharing	1181	18 (1.5)	585	0 (0.0)	1785	19 (1.1)
Receptive sharing	216	3 (1.4)	98	0 (0.0)	317	3 (1.0)
2004						
No receptive sharing	872	13 (1.5)	446	3 (0.7)	1322	16 (1.2)
Receptive sharing	217	2 (0.9)	85	0 (0.0)	304	2 (0.7)
2005						
No receptive sharing	800	13 (1.6)	456	0 (0.0)	1262	13 (1.0)
Receptive sharing	130	1 (0.8)	68	0 (0.0)	200	1 (0.5)
2006						
No receptive sharing	896	20 (2.2)	485	0 (0.0)	1387	20 (1.4)
Receptive sharing	161	4 (2.5)	86	0 (0.0)	249	5 (2.0)
2007						
No receptive sharing	869	15 (1.7)	467	2 (0.4)	1343	18 (1.3)
Receptive sharing	162	4 (2.5)	79	0 (0.0)	244	4 (1.6)
2008						
No receptive sharing	1024	23 (2.3)	544	2 (0.4)	1576	26 (1.7)
Receptive sharing	193	2 (1.0)	118	0 (0.0)	312	2 (0.6)
2009						
No receptive sharing	1268	24 (1.9)	653	2 (0.3)	1936	27 (1.4)
Receptive sharing	238	0 (0.0)	133	0 (0.0)	372	0 (0.0)
2010						
No receptive sharing	1066	14 (1.3)	499	1 (0.2)	1570	15 (1.0)
Receptive sharing	167	1 (0.6)	89	1 (1.1)	257	2 (0.8)
2010 p value		0.708		0.028		1.000

Table 1.16 HIV antibody prevalence by imprisonment last year, gender and year

NATIONAL	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
No imprisonment	533	13 (2.4)	297	5 (1.7)	841	18 (2.2)
Imprisonment	113	2 (1.8)	34	0 (0.0)	150	2 (1.4)
1996						
No imprisonment	821	18 (2.2)	414	6 (1.5)	1250	24 (1.9)
Imprisonment	141	1 (0.7)	38	1 (2.6)	179	2 (1.1)
1997						
No imprisonment	985	23 (2.3)	561	4 (0.7)	1552	27 (1.8)
Imprisonment	198	1 (0.5)	58	0 (0.0)	256	1 (0.4)
1998						
No imprisonment	1245	16 (1.3)	751	3 (0.4)	2002	19 (1.0)
Imprisonment	300	0 (0.0)	97	1 (1.0)	399	1 (0.3)
1999						
No imprisonment	1214	20 (1.7)	747	7 (0.9)	1970	27 (1.4)
Imprisonment	297	4 (1.4)	82	1 (1.2)	380	5 (1.3)
2000						
No imprisonment	1261	16 (1.3)	738	0 (0.0)	2008	16 (0.8)
Imprisonment	337	4 (1.2)	121	0 (0.0)	460	4 (0.9)
2001						
No imprisonment	1189	16 (1.4)	656	1 (0.2)	1864	17 (0.9)
Imprisonment	298	4 (1.3)	101	0 (0.0)	403	4 (1.0)
2002						
No imprisonment	1229	23 (1.9)	682	4 (0.6)	1929	29 (1.5)
Imprisonment	296	2 (0.7)	89	0 (0.0)	386	2 (0.5)
2003						
No imprisonment	1260	16 (1.3)	704	2 (0.3)	1982	19 (1.0)
Imprisonment	314	6 (1.9)	75	0 (0.0)	395	6 (1.5)
2004						
No imprisonment	927	15 (1.6)	522	2 (0.4)	1456	17 (1.2)
Imprisonment	270	2 (0.7)	68	1 (1.5)	340	3 (0.9)
2005						
No imprisonment	845	15 (1.8)	533	0 (0.0)	1386	15 (1.1)
Imprisonment	179	0 (0.0)	59	0 (0.0)	239	0 (0.0)
2006						
No imprisonment	971	25 (2.6)	583	2 (0.3)	1566	28 (1.8)
Imprisonment	181	1 (0.6)	61	0 (0.0)	243	1 (0.4)
2007						
No imprisonment	946	23 (2.4)	560	2 (0.4)	1514	25 (1.7)
Imprisonment	190	2 (1.0)	59	0 (0.0)	249	2 (0.8)
2008						
No imprisonment	1079	26 (2.4)	648	0 (0.0)	1735	27 (1.6)
Imprisonment	208	2 (1.0)	65	2 (3.1)	274	4 (1.5)
2009						
No imprisonment	1402	27 (1.9)	794	2 (0.3)	2213	30 (1.4)
Imprisonment	245	1 (0.4)	88	0 (0.0)	333	1 (0.3)
2010						
No imprisonment	1119	18 (1.6)	605	2 (0.3)	1737	20 (1.1)
Imprisonment	167	1 (0.6)	52	0 (0.0)	219	1 (0.5)
2010 p value		0.497		1.000		0.502

Table 1.17 HIV antibody prevalence by condom use with regular partner in last month, gender and year

NATIONAL	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
No condom use	361	5 (1.4)	198	2 (1.0)	565	7(1.4)
Condom use	172	8 (4.7)	84	2 (2.4)	262	10 (3.8)
1996						
No condom use	437	3 (0.7)	241	3 (1.2)	684	6 (0.9)
Condom use	232	9 (3.9)	113	1 (0.9)	348	10 (2.9)
1997						
No condom use	725	8 (1.1)	426	3 (0.7)	1152	11 (1.0)
Condom use	449	15 (3.3)	186	1 (0.5)	640	16 (2.5)
1998						
No condom use	942	5 (0.5)	583	1 (0.2)	1528	6 (0.4)
Condom use	584	10 (1.7)	249	3 (1.2)	838	13 (1.6)
1999						
No condom use	918	6 (0.7)	545	3 (0.6)	1469	9 (0.6)
Condom use	573	19 (3.3)	264	5 (1.9)	841	24 (2.9)
2000						
No condom use	972	6 (0.6)	556	0 (0.0)	1532	6 (0.4)
Condom use	610	15 (2.5)	290	0 (0.0)	906	15 (1.8)
2001						
No condom use	947	9 (1.0)	547	1 (0.2)	1502	10 (0.7)
Condom use	535	11 (2.1)	203	0 (0.0)	750	11 (1.5)
2002						
No condom use	984	9 (1.0)	531	1 (0.2)	1522	10 (0.7)
Condom use	536	16 (3.0)	237	3 (1.3)	784	21 (2.7)
2003						
No condom use	1048	12 (1.2)	564	2 (0.4)	1628	14 (0.9)
Condom use	513	9 (1.8)	210	0 (0.0)	730	10 (1.4)
2004						
No condom use	805	11 (1.4)	422	2 (0.5)	1235	13 (1.1)
Condom use	385	6 (1.6)	157	1(0.6)	543	7 (1.3)
2005 #						
No condom use	389	1 (0.3)	300	0 (0.0)	690	1 (0.1)
Condom use	177	4 (2.3)	88	0 (0.0)	267	4 (1.5)
2006						
No condom use	533	6 (1.1)	339	1 (0.3)	880	8 (0.9)
Condom use	57	3 (5.3)	35	0 (0.0)	92	3 (3.3)
2007						
No condom use	506	4 (0.8)	344	2 (0.6)	856	7 (0.8)
Condom use	66	1 (1.5)	31	0 (0.0)	98	1 (1.0)
2008						
No condom use	547	4 (0.7)	380	0 (0.0)	930	4 (0.4)
Condom use	93	3 (3.2)	52	1 (1.9)	147	5 (3.4)
2009						
No condom use	671	4 (0.6)	483	1 (0.2)	1162	5 (0.4)
Condom use	91	4 (4.4)	41	0 (0.0)	132	4 (3.0)
2010						
No condom use	506	6 (1.2)	313	0 (0.0)	823	6 (0.7)
Condom use	188	2 (1.1)	102	2 (2.0)	292	4 (1.4)
2010 p value		1.000		0.060		0.299

Question referred to "condom use at last sex" from 1995 to 2004.

Excludes people reporting no sex last month from 2005.

Table 1.18 HIV antibody prevalence by sex work last month, gender and year

NATIONAL	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
No sex work	614	12 (2.0)	293	3 (1.0)	917	16 (1.7)
Sex work	13	3 (23.1)	36	1 (2.8)	52	4 (7.7)
1996						
No sex work	922	17 (1.8)	376	6 (1.6)	1311	23 (1.8)
Sex work	25	1 (4.0)	73	1 (1.4)	99	2 (2.0)
1997						
No sex work	1114	21 (1.9)	518	4 (0.8)	1637	25 (1.5)
Sex work	46	2 (4.4)	94	0 (0.0)	141	2 (1.4)
1998						
No sex work	1486	14 (0.9)	731	2 (0.3)	2223	16 (0.7)
Sex work	43	2 (4.7)	105	2 (1.9)	151	4 (2.7)
1999						
No sex work	1439	22 (1.5)	664	6 (0.9)	2109	28 (1.3)
Sex work	55	2 (3.6)	152	2 (1.3)	211	4 (1.9)
2000						
No sex work	1519	19 (1.3)	677	0 (0.0)	2200	20 (0.9)
Sex work	69	1 (1.5)	174	0 (0.0)	249	1 (0.4)
2001						
No sex work	1419	18 (1.3)	608	1 (0.2)	2039	19 (0.9)
Sex work	61	2 (3.3)	141	0 (0.0)	212	2 (0.9)
2002						
No sex work	1445	24 (1.7)	635	4 (0.6)	2094	29 (1.4)
Sex work	59	2 (1.7)	131	0 (0.0)	194	2 (1.0)
2003						
No sex work	1481	17 (1.2)	666	2 (0.3)	2162	19 (0.9)
Sex work	68	5 (7.4)	103	0 (0.0)	178	6 (3.4)
2004						
No sex work	1123	14 (1.3)	487	2 (0.4)	1615	16 (1.0)
Sex work	64	2 (3.1)	93	1 (1.1)	161	3 (1.9)
2005						
No sex work	1021	14 (1.4)	525	0 (0.0)	1553	14 (0.9)
Sex work	27	1 (3.7)	73	0 (0.0)	102	1 (1.0)
2006						
No sex work	1123	24 (2.1)	548	2 (0.4)	1678	26 (1.6)
Sex work	34	2 (5.9)	81	0 (0.0)	121	3 (2.5)
2007						
No sex work	1108	23 (2.1)	541	2 (0.4)	1656	25 (1.5)
Sex work	34	1 (2.9)	76	0 (0.0)	114	2 (1.8)
2008						
No sex work	1264	27 (2.1)	633	3 (0.5)	1905	30 (1.6)
Sex work	39	2 (5.1)	91	0 (0.0)	131	3 (2.3)
2009						
No sex work	1612	26 (1.6)	790	2 (0.3)	2425	29 (1.2)
Sex work	36	2 (5.6)	90	0 (0.0)	129	2 (1.6)
2010						
No sex work	1427	18 (1.3)	619	2 (0.3)	2057	20 (1.0)
Sex work	42	2 (4.8)	84	0 (0.0)	127	2 (1.6)
2010 p value		0.110		1.000		0.369

Table 1.19 HIV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year

NATIONAL	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
Non-Indigenous	608	13 (2.1)	308	5 (1.6)	927	19 (2.1)
Indigenous	28	2 (7.1)	18	0 (0.0)	47	2 (4.3)
1996						
Non-Indigenous	897	17 (1.9)	418	5 (1.2)	1322	22 (1.7)
Indigenous	40	1 (2.5)	24	2 (8.3)	64	3 (4.7)
1997						
Non-Indigenous	1106	21 (1.9)	579	4 (0.7)	1690	25 (1.5)
Indigenous	59	2 (3.4)	33	0 (0.0)	93	2 (2.2)
1998						
Non-Indigenous	1448	15 (1.0)	776	3 (0.4)	2235	18 (0.8)
Indigenous	85	1 (1.2)	60	1 (1.7)	145	2 (1.4)
1999						
Non-Indigenous	1382	23 (1.7)	739	7 (0.1)	2129	30 (1.4)
Indigenous	100	3 (3.0)	73	1 (1.4)	175	4 (2.3)
2000						
Non-Indigenous	1477	17 (1.2)	753	0 (0.0)	2241	18 (0.8)
Indigenous	127	4 (3.2)	96	0 (0.0)	225	4 (1.8)
2001						
Non-Indigenous	1393	18 (1.3)	691	1 (0.1)	2100	19 (0.9)
Indigenous	102	2 (2.0)	71	0 (0.0)	177	3 (1.1)
2002						
Non-Indigenous	1389	21 (1.5)	697	4 (0.6)	2103	27 (1.3)
Indigenous	108	3 (2.8)	65	0 (0.0)	177	3 (1.7)
2003						
Non-Indigenous	1448	17 (1.2)	687	1 (0.2)	2154	18 (0.8)
Indigenous	106	3 (2.8)	84	1 (1.2)	194	5 (2.6)
2004						
Non-Indigenous	1097	15 (1.4)	522	2 (0.4)	1631	17 (1.0)
Indigenous	87	1 (1.2)	56	1 (1.8)	145	2 (1.4)
2005						
Non-Indigenous	946	15 (1.6)	521	0 (0.0)	1475	15 (1.0)
Indigenous	95	0 (0.0)	74	0 (0.0)	170	0 (0.0)
2006						
Non-Indigenous	1074	24 (2.2)	556	2 (0.4)	1639	27 (1.7)
Indigenous	109	2 (1.8)	89	0 (0.0)	199	2 (1.0)
2007						
Non-Indigenous	1045	21 (2.0)	548	2 (0.4)	1602	23 (1.4)
Indigenous	118	3 (2.5)	80	0 (0.0)	200	4 (2.0)
2008						
Non-Indigenous	1214	26 (2.1)	631	1 (0.2)	1853	28 (1.5)
Indigenous	130	2 (1.5)	105	2 (1.9)	237	4 (1.7)
2009						
Non-Indigenous	1503	26 (1.7)	752	2 (0.3)	2269	28 (1.2)
Indigenous	166	1 (0.6)	145	0 (0.0)	313	2 (0.6)
2010						
Non-Indigenous	1388	19 (1.4)	633	2 (0.3)	2033	21 (1.0)
Indigenous	159	2 (1.3)	112	0 (0.0)	273	2 (0.7)
2010 p value		1.000		1.000		1.000

Table 1.20 HIV antibody prevalence by country of birth, gender and year

NATIONAL	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
Australia	--	--	--	--	--	--
Other	--	--	--	--	--	--
1996						
Australia	--	--	--	--	--	--
Other	--	--	--	--	--	--
1997						
Australia	--	--	--	--	--	--
Other	--	--	--	--	--	--
1998						
Australia	--	--	--	--	--	--
Other	--	--	--	--	--	--
1999						
Australia	1317	24 (1.8)	770	8 (1.0)	2096	32 (1.5)
Other	138	1 (0.7)	41	0 (0.0)	179	1 (0.6)
2000						
Australia	1143	15 (1.3)	633	0 (0.0)	1787	16 (0.9)
Other	496	6 (1.2)	238	0 (0.0)	738	6 (0.8)
2001						
Australia	1152	15 (1.3)	577	1 (0.2)	1742	16 (0.9)
Other	388	5 (1.3)	201	0 (0.0)	600	5 (0.8)
2002						
Australia	1226	24 (2.0)	637	4 (0.6)	1879	1 (0.2)
Other	326	1 (0.3)	148	0 (0.0)	479	30 (1.6)
2003						
Australia	1267	16 (1.3)	670	2 (0.3)	1959	19 (1.0)
Other	314	6 (1.9)	117	0 (0.0)	433	6 (1.4)
2004						
Australia	941	14 (1.5)	498	3 (0.6)	1450	17 (1.2)
Other	252	2 (0.8)	90	0 (0.0)	344	2 (0.6)
2005						
Australia	911	13 (1.4)	541	0 (0.0)	1459	13 (0.9)
Other	154	2 (1.3)	65	0 (0.0)	221	2 (0.9)
2006						
Australia	1026	22 (2.1)	577	2 (0.4)	1611	24 (1.5)
Other	171	4 (2.3)	78	0 (0.0)	252	5 (2.0)
2007						
Australia	1023	22 (2.2)	557	2 (0.4)	1590	25 (1.6)
Other	145	3 (2.1)	75	0 (0.0)	221	3 (1.4)
2008						
Australia	1181	24 (2.0)	650	3 (0.5)	1863	27 (1.5)
Other	194	5 (2.6)	102	0 (0.0)	296	6 (2.0)
2009						
Australia	1480	27 (1.8)	805	2 (0.3)	2298	30 (1.3)
Other	212	1 (0.5)	102	0 (0.0)	318	1 (0.3)
2010						
Australia	1366	19 (1.4)	673	2 (0.3)	2050	21 (1.0)
Other	187	2 (1.1)	78	0 (0.0)	266	2 (0.8)
2010 p value		1.000		1.000		1.000

Table 1.21 HIV antibody prevalence by language spoken at home by parents, gender and year

NATIONAL	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
English speaking	--	--	--	--	--	--
Non-English speaking	--	--	--	--	--	--
1996						
English speaking	--	--	--	--	--	--
Non-English speaking	--	--	--	--	--	--
1997						
English speaking	--	--	--	--	--	--
Non-English speaking	--	--	--	--	--	--
1998						
English speaking	--	--	--	--	--	--
Non-English speaking	--	--	--	--	--	--
1999						
English speaking	1313	23 (1.8)	769	8 (1.0)	2091	31 (1.5)
Non-English speaking	118	0 (0.0)	33	0 (0.0)	151	0 (0.0)
2000						
English speaking	1396	17 (1.2)	755	0 (0.0)	2161	18 (0.8)
Non-English speaking	161	3 (1.9)	82	0 (0.0)	245	3 (1.2)
2001						
English speaking	1261	18 (1.4)	680	1 (0.2)	1959	19 (1.0)
Non-English speaking	180	1 (0.6)	81	0 (0.0)	264	1 (0.4)
2002						
English speaking	1260	23 (1.8)	690	4 (0.6)	1966	29 (1.5)
Non-English speaking	212	1 (0.5)	68	0 (0.0)	284	1 (0.4)
2003						
English speaking	1304	19 (1.5)	721	2 (0.3)	2048	22 (1.1)
Non-English speaking	214	2 (0.9)	47	0 (0.0)	262	2 (0.8)
2004						
English speaking	755	11 (1.5)	454	2 (0.4)	1219	13 (1.1)
Non-English speaking	162	0 (0.0)	43	0 (0.0)	205	0 (0.0)
2005						
English speaking	888	15 (1.7)	546	0 (0.0)	1441	15 (1.0)
Non-English speaking	184	0 (0.0)	65	0 (0.0)	251	0 (0.0)
2006						
English speaking	1063	24 (2.3)	610	2 (0.3)	1683	27 (1.6)
Non-English speaking	84	2 (2.4)	28	0 (0.0)	114	2 (1.8)
2007						
English speaking	1100	24 (2.2)	609	2 (0.3)	1719	27 (1.6)
Non-English speaking	70	1 (1.4)	27	0 (0.0)	98	1 (1.0)
2008						
English speaking	1299	28 (2.2)	728	3 (0.4)	2037	32 (1.6)
Non-English speaking	73	1 (1.4)	28	0 (0.0)	101	1 (1.0)
2009						
English speaking	1628	27 (1.7)	869	2 (0.2)	2513	30 (1.2)
Non-English speaking	72	1 (1.4)	38	0 (0.0)	111	1 (0.9)
2010						
English speaking	1485	21 (1.4)	736	2 (0.3)	2234	23 (1.0)
Non-English speaking	75	0 (0.0)	15	0 (0.0)	90	0 (0.0)
2010 p value		0.621		1.000		1.000

HCV ANTIBODY PREVALENCE

Table 1.22 HCV antibody prevalence by gender and year

NATIONAL	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	639	400 (63)	327	208 (64)	979	618 (63)
1996	977	482 (49)	467	262 (56)	1460	752 (52)
1997	1189	570 (48)	622	344 (55)	1817	917 (50)
1998	1567	735 (47)	855	458 (54)	2433	1199 (49)
1999	1528	756 (49)	840	436 (52)	2379	1198 (50)
2000	1647	865 (53)	874	484 (55)	2536	1357 (54)
2001	1564	882 (56)	788	481 (61)	2376	1378 (58)
2002	1554	845 (56)	784	434 (55)	2359	1324 (56)
2003	1604	914 (57)	794	483 (61)	2422	1412 (58)
2004	1223	715 (58)	599	371 (62)	1836	1093 (60)
2005	1076	657 (61)	609	377 (62)	1694	1040 (61)
2006	1217	736 (60)	656	419 (64)	1886	1162 (62)
2007	1140	695 (61)	605	388 (64)	1756	1091 (62)
2008	1352	852 (63)	737	453 (61)	2099	1311 (62)
2009	1712	840 (49)	912	471 (52)	2641	1318 (50)
2010	1567	838 (53)	756	398 (53)	2337	1244 (53)
χ^2 trend p value		<0.001		0.252		<0.001

Table 1.23 HCV antibody prevalence by sexual identity, gender and year

NATIONAL	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heterosexual	540	348 (64)	234	149 (64)	779	501 (64)
Bisexual	43	23 (53)	66	43 (65)	112	68 (61)
Homosexual	40	20 (50)	22	12 (55)	65	34 (52)
1996						
Heterosexual	808	419 (52)	322	194 (60)	1139	619 (54)
Bisexual	68	35 (51)	93	48 (52)	162	83 (51)
Homosexual	69	29 (42)	39	19 (49)	108	48 (44)
1997						
Heterosexual	1005	494 (49)	419	242 (58)	1428	737 (52)
Bisexual	78	32 (41)	130	64 (49)	209	97 (46)
Homosexual	54	20 (37)	58	24 (41)	112	44 (39)
1998						
Heterosexual	1340	643 (48)	622	351 (56)	1966	996 (51)
Bisexual	88	37 (42)	139	62 (45)	228	99 (43)
Homosexual	69	22 (32)	74	33 (45)	144	56 (39)
1999						
Heterosexual	1243	631 (51)	553	284 (51)	1796	915 (51)
Bisexual	104	43 (41)	187	103 (55)	297	151 (51)
Homosexual	70	24 (34)	52	20 (38)	124	44 (35)
2000						
Heterosexual	1380	749 (54)	561	320 (57)	1944	1070 (55)
Bisexual	79	39 (49)	196	109 (56)	277	149 (54)
Homosexual	84	30 (36)	71	32 (45)	160	65 (41)
2001						
Heterosexual	1284	738 (57)	538	325 (60)	1833	1068 (58)
Bisexual	71	41 (58)	155	97 (63)	230	142 (62)
Homosexual	84	40 (48)	47	31 (66)	133	73 (55)
2002						
Heterosexual	1268	734 (58)	525	291 (55)	1799	1030 (57)
Bisexual	72	39 (54)	171	96 (56)	249	141 (57)
Homosexual	61	23 (38)	32	17 (53)	95	42 (44)
2003						
Heterosexual	1337	772 (58)	513	297 (58)	1857	1074 (58)
Bisexual	60	32 (53)	168	112 (67)	232	146 (63)
Homosexual	76	34 (45)	48	29 (60)	127	64 (50)
2004						
Heterosexual	1065	619 (58)	439	272 (62)	1507	892 (59)
Bisexual	45	28 (62)	108	66 (61)	155	95 (61)
Homosexual	45	25 (56)	30	19 (63)	75	44 (59)
2005						
Heterosexual	943	578 (61)	437	267 (61)	1381	845 (61)
Bisexual	37	20 (54)	106	64 (60)	144	85 (59)
Homosexual	54	31 (57)	32	24 (75)	91	59 (65)
2006						
Heterosexual	1065	669 (63)	481	308 (64)	1549	979 (63)
Bisexual	55	25 (45)	109	76 (70)	170	102 (60)
Homosexual	59	26 (44)	45	23 (51)	106	51 (48)
2007						
Heterosexual	1009	627 (62)	431	278 (65)	1441	906 (63)
Bisexual	45	25 (56)	116	77 (66)	165	105 (64)
Homosexual	63	30 (48)	41	21 (51)	107	53 (50)
2008						
Heterosexual	1192	760 (64)	517	317 (61)	1711	1078 (63)
Bisexual	51	30 (59)	147	93 (63)	199	123 (62)
Homosexual	60	26 (43)	47	29 (62)	109	56 (51)
2009						
Heterosexual	1506	751 (50)	681	335 (49)	2193	1090 (50)
Bisexual	79	36 (44)	146	97 (66)	228	133 (58)
Homosexual	48	13 (27)	37	14 (38)	87	28 (31)
2010						
Heterosexual	1378	755 (55)	556	293 (53)	1940	1052 (54)
Bisexual	60	33 (55)	123	69 (56)	186	104 (56)
Homosexual	49	11 (22)	36	10 (28)	86	21 (24)
2010 p value		<0.001		0.009		<0.001

Table 1.24 HCV antibody prevalence by age group, gender and year

NATIONAL	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
<25 years	163	48 (29)	122	54 (44)	291	106 (36)
25-34 years	296	203 (69)	136	96 (71)	435	302 (69)
35+ years	174	145 (83)	68	58 (85)	246	206 (84)
1996						
<25 years	322	55 (17)	172	53 (31)	498	110 (22)
25-34 years	383	216 (56)	203	145 (71)	594	367 (62)
35+ years	269	231 (86)	92	73 (79)	363	306 (84)
1997						
<25 years	402	68 (17)	249	75 (30)	652	143 (22)
25-34 years	461	229 (50)	252	164 (65)	716	395 (55)
35+ years	325	272 (84)	121	105 (87)	448	378 (84)
1998						
<25 years	524	110 (21)	352	103 (29)	877	213 (24)
25-34 years	627	292 (47)	300	190 (63)	934	486 (52)
35+ years	414	333 (80)	203	165 (81)	620	500 (81)
1999						
<25 years	455	122 (27)	315	102 (32)	772	224 (29)
25-34 years	665	308 (46)	331	184 (56)	1000	495 (50)
35+ years	406	325 (80)	193	149 (77)	601	476 (79)
2000						
<25 years	441	138 (31)	347	157 (45)	792	297 (38)
25-34 years	693	340 (49)	334	196 (59)	1032	538 (52)
35+ years	512	387 (76)	193	131 (68)	710	521 (73)
2001						
<25 years	384	142 (37)	269	129 (48)	659	271 (41)
25-34 years	638	322 (50)	310	188 (61)	953	514 (54)
35+ years	540	417 (77)	208	163 (78)	760	590 (78)
2002						
<25 years	343	145 (42)	246	115 (47)	592	262 (44)
25-34 years	669	350 (52)	321	168 (52)	996	523 (53)
35+ years	538	378 (70)	216	151 (70)	766	537 (70)
2003						
<25 years	310	109 (35)	192	88 (56)	505	199 (39)
25-34 years	641	319 (50)	338	198 (59)	987	520 (53)
35+ years	650	485 (75)	262	196 (75)	925	691 (75)
2004						
<25 years	208	71 (34)	137	68 (50)	346	139 (40)
25-34 years	509	268 (53)	220	117 (53)	731	387 (53)
35+ years	503	374 (74)	242	186 (77)	751	564 (75)
2005						
<25 years	130	37 (28)	112	56 (50)	242	93 (38)
25-34 years	412	219 (53)	259	141 (54)	673	361 (54)
35+ years	538	403 (75)	240	182 (76)	786	590 (75)
2006						
<25 years	118	43 (36)	104	50 (48)	222	93 (42)
25-34 years	492	250 (51)	263	156 (59)	762	409 (54)
35+ years	602	439 (73)	287	211 (74)	895	654 (73)
2007						
<25 years	85	27 (32)	77	37 (48)	163	65 (40)
25-34 years	434	237 (55)	223	132 (59)	661	373 (56)
35+ years	619	429 (69)	304	219 (72)	929	651 (70)
2008						
<25 years	105	31 (30)	89	41 (46)	194	72 (37)
25-34 years	450	249 (55)	291	173 (59)	743	423 (57)
35+ years	792	569 (72)	356	239 (67)	1156	813 (70)
2009						
<25 years	157	32 (20)	117	42 (36)	276	74 (27)
25-34 years	572	246 (43)	348	184 (53)	924	431 (47)
35+ years	983	563 (57)	446	243 (54)	1440	812 (56)
2010						
<25 years	103	17 (17)	90	33 (37)	195	50 (26)
25-34 years	498	228 (46)	262	130 (50)	761	359 (47)
35+ years	965	593 (61)	403	235 (58)	1379	835 (61)
2010 p value		<0.001		<0.001		<0.001

Table 1.25 HCV antibody prevalence by time since first drug injection, gender and year

NATIONAL	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<3 years	77	14 (18)	53	15 (28)	131	29 (22)
3-10 years	229	104 (45)	141	79 (56)	375	188 (50)
11+ years	319	273 (86)	131	113 (86)	455	390 (86)
1996						
<3 years	162	16 (10)	74	12 (16)	238	29 (12)
3-10 years	389	126 (32)	195	89 (46)	591	219 (37)
11+ years	391	320 (82)	187	152 (81)	583	476 (82)
1997						
<3 years	193	23 (12)	126	20 (16)	320	43 (13)
3-10 years	484	139 (29)	275	131 (48)	759	270 (36)
11+ years	479	392 (82)	213	189 (89)	697	584 (84)
1998						
<3 years	273	41 (15)	182	36 (20)	457	77 (17)
3-10 years	660	214 (32)	364	165 (45)	1026	379 (37)
11+ years	598	462 (77)	298	251 (84)	901	717 (80)
1999						
<3 years	238	37 (16)	154	42 (27)	392	79 (20)
3-10 years	658	241 (37)	389	161 (41)	1052	404 (38)
11+ years	591	458 (78)	280	223 (80)	873	683 (78)
2000						
<3 years	208	53 (25)	128	36 (28)	336	89 (26)
3-10 years	705	287 (41)	449	231 (51)	1160	520 (45)
11+ years	697	511 (73)	279	207 (74)	980	721 (74)
2001						
<3 years	171	39 (23)	112	41 (37)	286	80 (28)
3-10 years	649	288 (44)	379	221 (58)	1032	510 (49)
11+ years	695	534 (77)	279	212 (76)	986	757 (77)
2002						
<3 years	149	56 (38)	74	28 (38)	226	85 (38)
3-10 years	611	283 (46)	369	184 (50)	987	471 (48)
11+ years	752	519 (69)	316	211 (67)	1076	738 (69)
2003						
<3 years	132	29 (22)	68	14 (21)	201	43 (21)
3-10 years	574	257 (45)	345	188 (54)	926	448 (48)
11+ years	843	609 (72)	357	271 (76)	1212	889 (73)
2004						
<3 years	84	23 (27)	51	11 (22)	135	34 (25)
3-10 years	453	210 (46)	247	129 (52)	703	340 (48)
11+ years	660	468 (71)	292	225 (77)	955	696 (73)
2005						
<3 years	96	22 (23)	46	22 (48)	144	45 (31)
3-10 years	197	78 (40)	180	83 (46)	379	163 (43)
11+ years	736	529 (72)	353	253 (72)	1094	785 (72)
2006						
<3 years	58	9 (16)	41	9 (22)	100	18 (18)
3-10 years	306	136 (44)	225	121 (54)	535	258 (48)
11+ years	797	558 (70)	375	280 (75)	1180	844 (72)
2007						
<3 years	59	8 (14)	37	11 (30)	96	19 (20)
3-10 years	264	107 (41)	179	97 (54)	447	206 (46)
11+ years	786	558 (71)	372	267 (72)	1165	831 (71)
2008						
<3 years	67	13 (19)	43	17 (40)	110	30 (27)
3-10 years	193	122 (63)	200	98 (49)	494	220 (45)
11+ years	960	699 (73)	485	336 (69)	1453	1040 (72)
2009						
<3 years	90	6 (7)	66	15 (23)	157	21 (13)
3-10 years	314	106 (34)	236	101 (43)	554	209 (38)
11+ years	1269	716 (56)	584	343 (59)	1864	1063 (57)
2010						
<3 years	87	9 (10)	36	9 (25)	124	18 (15)
3-10 years	249	86 (35)	181	77 (43)	431	163 (38)
11+ years	1197	726 (61)	524	306 (58)	1732	1039 (60)
2010 p value		<0.001		<0.001		<0.001

Table 1.26 HCV antibody prevalence by drug last injected, time since first injection and year

NATIONAL	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heroin	39	13 (33)	386	272 (70)	431	288 (67)
Methamphetamine	66	11 (17)	138	61 (44)	206	73 (35)
Other	24	5 (21)	305	244 (80)	339	256 (76)
1996						
Heroin	100	12 (12)	652	395 (61)	775	420 (54)
Methamphetamine	99	9 (9)	169	51 (30)	273	61 (22)
Other	39	8 (21)	351	258 (74)	407	278 (68)
1997						
Heroin	150	31 (21)	845	510 (60)	1008	549 (54)
Methamphetamine	120	8 (7)	199	54 (27)	326	62 (19)
Other	49	4 (8)	407	286 (70)	473	301 (64)
1998						
Heroin	213	51 (24)	1031	603 (58)	1259	665 (53)
Methamphetamine	156	8 (5)	344	90 (26)	510	101 (20)
Other	86	18 (21)	546	398 (73)	650	425 (65)
1999						
Heroin	169	60 (36)	1068	681 (64)	1264	761 (60)
Methamphetamine	167	9 (5)	441	136 (31)	614	146 (24)
Other	55	10 (18)	399	260 (65)	468	280 (60)
2000						
Heroin	168	59 (35)	1256	809 (64)	1440	880 (61)
Methamphetamine	107	11 (10)	420	141 (34)	540	156 (29)
Other	57	18 (32)	453	283 (62)	526	309 (59)
2001						
Heroin	67	29 (43)	652	476 (73)	730	512 (70)
Methamphetamine	149	30 (20)	706	327 (46)	879	364 (41)
Other	69	21 (30)	648	456 (70)	731	489 (67)
2002						
Heroin	54	25 (46)	791	547 (69)	855	575 (67)
Methamphetamine	101	36 (36)	647	272 (42)	772	319 (41)
Other	69	24 (35)	614	386 (63)	700	422 (60)
2003						
Heroin	59	16 (27)	813	586 (72)	885	612 (69)
Methamphetamine	93	18 (19)	690	331 (48)	799	354 (44)
Other	47	9 (19)	622	412 (66)	692	432 (62)
2004						
Heroin	35	12 (34)	639	449 (70)	681	468 (69)
Methamphetamine	62	14 (23)	515	229 (44)	584	248 (42)
Other	31	9 (26)	486	346 (71)	530	362 (68)
2005						
Heroin	30	14 (47)	563	389 (69)	593	403 (68)
Methamphetamine	58	9 (16)	482	241 (50)	540	250 (46)
Other	21	5 (24)	468	342 (73)	509	361 (71)
2006						
Heroin	12	3 (25)	464	349 (75)	493	364 (74)
Methamphetamine	53	4 (8)	635	305 (48)	710	319 (45)
Other	34	10 (29)	576	418 (73)	634	443 (70)
2007						
Heroin	21	6 (29)	517	359 (69)	545	371 (68)
Methamphetamine	52	10 (19)	460	244 (53)	524	265 (51)
Other	22	3 (13)	606	415 (68)	656	435 (66)
2008						
Heroin	22	9 (41)	688	507 (74)	721	524 (73)
Methamphetamine	43	8 (19)	538	256 (48)	587	265 (45)
Other	43	12 (28)	692	473 (68)	756	496 (66)
2009						
Heroin	32	9 (28)	862	512 (59)	902	524 (58)
Methamphetamine	51	4 (8)	585	221 (38)	648	230 (35)
Other	71	8 (11)	929	512 (55)	1030	533 (52)
2010						
Heroin	28	8 (29)	747	476 (64)	792	498 (63)
Methamphetamine	33	3 (9)	567	229 (40)	610	237 (39)
Other	63	7 (11)	839	492 (59)	923	504 (55)
2010 p value		0.086		<0.001		<0.001

Table 1.27 HCV antibody prevalence by frequency of injection, time since first injection and year

NATIONAL	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Less than daily	84	19 (23)	415	286 (69)	507	311 (61)
Daily or more	34	8 (23)	355	258 (73)	399	272 (68)
Not last month	13	2 (15)	56	31 (55)	70	33 (47)
1996						
Less than daily	162	21 (13)	583	359 (62)	762	390 (51)
Daily or more	55	11 (20)	506	319 (63)	590	349 (59)
Not last month	20	1 (5)	75	38 (51)	97	41 (42)
1997						
Less than daily	159	14 (9)	582	295 (51)	752	313 (42)
Daily or more	135	26 (19)	770	498 (65)	931	542 (58)
Not last month	26	3 (12)	93	52 (56)	125	56 (45)
1998						
Less than daily	196	17 (9)	698	356 (51)	906	378 (42)
Daily or more	236	59 (25)	1125	692 (62)	1386	768 (55)
Not last month	24	1 (4)	101	47 (47)	136	50 (37)
1999						
Less than daily	163	23 (14)	692	344 (50)	873	378 (43)
Daily or more	200	54 (27)	1092	662 (61)	1319	736 (56)
Not last month	29	2 (7)	128	74 (58)	165	79 (48)
2000						
Less than daily	121	19 (16)	736	366 (50)	879	397 (45)
Daily or more	184	67 (36)	1262	802 (64)	1472	884 (60)
Not last month	29	2 (7)	126	63 (50)	158	65 (41)
2001						
Less than daily	141	42 (30)	864	496 (57)	1025	544 (53)
Daily or more	109	32 (29)	963	654 (68)	1096	701 (64)
Not last month	34	6 (18)	172	105 (61)	216	115 (53)
2002						
Less than daily	97	34 (35)	821	436 (53)	938	481 (51)
Daily or more	97	40 (41)	1055	674 (64)	1182	725 (61)
Not last month	30	10 (33)	170	89 (52)	231	110 (52)
2003						
Less than daily	99	17 (17)	927	537 (58)	1052	566 (54)
Daily or more	76	22 (29)	1012	692 (68)	1115	734 (66)
Not last month	23	3 (13)	184	98 (53)	217	102 (47)
2004						
Less than daily	55	15 (27)	718	425 (59)	785	447 (57)
Daily or more	67	18 (27)	812	546 (67)	897	578 (64)
Not last month	11	1 (9)	116	59 (51)	131	61 (47)
2005						
Less than daily	47	6 (13)	636	392 (62)	705	410 (58)
Daily or more	26	7 (27)	776	518 (67)	830	546 (66)
Not last month	9	0 (0)	132	84 (64)	149	87 (58)
2006						
Less than daily	51	4 (8)	740	463 (63)	812	476 (59)
Daily or more	39	11 (28)	801	526 (66)	881	566 (64)
Not last month	10	3 (30)	162	106 (65)	178	111 (62)
2007						
Less than daily	54	8 (15)	687	443 (64)	753	463 (62)
Daily or more	36	8 (22)	768	499 (65)	826	525 (63)
Not last month	6	3 (50)	132	75 (57)	147	81 (55)
2008						
Less than daily	52	9 (17)	792	490 (62)	855	505 (59)
Daily or more	36	15 (42)	951	650 (68)	1010	679 (67)
Not last month	17	3 (18)	188	110 (59)	213	116 (54)
2009						
Less than daily	63	6 (10)	940	484 (51)	1018	496 (49)
Daily or more	69	13 (19)	1232	655 (53)	1329	683 (51)
Not last month	24	2 (8)	225	119 (53)	265	123 (46)
2010						
Less than daily	57	4 (7)	978	522 (53)	1047	533 (51)
Daily or more	44	12 (27)	942	556 (59)	1010	578 (57)
Not last month	19	2 (11)	222	112 (50)	252	119 (47)
2010 p value		0.015		0.012		0.002

Table 1.28 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, time since first injection and year

NATIONAL	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
No receptive sharing	88	15 (17)	528	363 (69)	626	386 (62)
Receptive sharing	30	12 (40)	243	182 (75)	279	197 (71)
1996						
No receptive sharing	168	22 (13)	779	452 (58)	974	386 (40)
Receptive sharing	49	6 (12)	312	204 (65)	377	222 (59)
1997						
No receptive sharing	239	31 (13)	1104	630 (57)	1372	679 (49)
Receptive sharing	47	8 (17)	221	144 (65)	272	153 (56)
1998						
No receptive sharing	346	60 (17)	1460	827 (57)	1831	904 (49)
Receptive sharing	75	14 (19)	321	193 (60)	402	211 (52)
1999						
No receptive sharing	271	52 (19)	1346	752 (56)	1646	824 (50)
Receptive sharing	78	22 (28)	378	221 (58)	467	250 (54)
2000						
No receptive sharing	252	63 (25)	1594	906 (57)	1881	988 (53)
Receptive sharing	49	23 (47)	338	224 (66)	394	251 (64)
2001						
No receptive sharing	234	62 (27)	1665	1019 (61)	1939	1098 (57)
Receptive sharing	39	15 (38)	275	190 (69)	317	207 (65)
2002						
No receptive sharing	152	56 (37)	1535	901 (59)	1717	967 (56)
Receptive sharing	37	17 (46)	300	183 (61)	349	207 (59)
2003						
No receptive sharing	148	33 (22)	1604	988 (62)	1789	1042 (58)
Receptive sharing	20	5 (25)	291	214 (74)	317	224 (71)
2004						
No receptive sharing	92	21 (23)	1218	755 (62)	1331	791 (59)
Receptive sharing	26	11 (42)	276	189 (68)	304	202 (66)
2005						
No receptive sharing	94	32 (34)	1111	700 (63)	1265	769 (61)
Receptive sharing	16	7 (44)	173	124 (72)	198	137 (69)
2006						
No receptive sharing	77	13 (17)	1262	791 (63)	1378	824 (60)
Receptive sharing	10	1 (10)	220	156 (71)	248	171 (69)
2007						
No receptive sharing	73	12 (16)	1176	754 (64)	1271	785 (62)
Receptive sharing	13	4 (31)	215	145 (67)	235	156 (66)
2008						
No receptive sharing	71	17 (24)	1428	918 (64)	1529	952 (62)
Receptive sharing	16	8 (50)	278	196 (71)	296	206 (70)
2009						
No receptive sharing	109	11 (10)	1784	922 (52)	1924	948 (49)
Receptive sharing	19	7 (37)	340	194 (57)	369	205 (56)
2010						
No receptive sharing	84	14 (17)	1449	779 (54)	1563	808 (52)
Receptive sharing	7	2 (29)	243	154 (63)	253	157 (62)
2010 p value		0.602		0.005		0.002

Table 1.29 HCV antibody prevalence by imprisonment last year, time since first injection and year

NATIONAL	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
No imprisonment	122	28 (23)	686	460 (67)	821	496 (60)
Imprisonment	8	1 (13)	134	111 (83)	146	114 (78)
1996						
No imprisonment	223	25 (11)	969	547 (56)	1228	592 (48)
Imprisonment	8	2 (25)	161	121 (75)	178	129 (72)
1997						
No imprisonment	307	40 (13)	1212	674 (56)	1555	730 (47)
Imprisonment	11	3 (27)	240	177 (74)	256	184 (72)
1998						
No imprisonment	402	58 (14)	1563	833 (53)	2004	910 (45)
Imprisonment	50	18 (36)	344	250 (73)	400	272 (68)
1999						
No imprisonment	361	64 (18)	1559	811 (52)	1968	900 (46)
Imprisonment	25	13 (52)	344	262 (76)	378	281 (74)
2000						
No imprisonment	293	62 (21)	1681	926 (55)	2016	1004 (50)
Imprisonment	36	25 (69)	416	293 (70)	463	326 (70)
2001						
No imprisonment	253	62 (25)	1584	947 (60)	1892	1030 (54)
Imprisonment	22	12 (55)	380	286 (75)	408	303 (74)
2002						
No imprisonment	185	65 (35)	1687	941 (56)	1932	1029 (53)
Imprisonment	34	18 (53)	345	247 (72)	385	269 (70)
2003						
No imprisonment	174	37 (21)	1743	1050 (60)	1985	1108 (56)
Imprisonment	25	6 (24)	360	261 (73)	396	277 (70)
2004						
No imprisonment	116	29 (25)	1323	774 (59)	1465	815 (56)
Imprisonment	16	5 (31)	317	250 (79)	342	264 (77)
2005						
No imprisonment	124	33 (27)	1205	743 (62)	1386	805 (58)
Imprisonment	13	9 (69)	210	162 (77)	241	187 (78)
2006						
No imprisonment	90	16 (18)	1412	860 (61)	1558	906 (58)
Imprisonment	7	2 (29)	224	176 (79)	240	184 (77)
2007						
No imprisonment	88	16 (18)	1315	816 (62)	1439	855 (59)
Imprisonment	3	2 (67)	226	170 (75)	238	181 (76)
2008						
No imprisonment	96	24 (25)	1555	959 (62)	1680	998 (59)
Imprisonment	7	4 (57)	250	196 (78)	264	204 (77)
2009						
No imprisonment	140	14 (10)	2006	1006 (50)	2200	1038 (47)
Imprisonment	12	6 (50)	311	206 (66)	331	216 (65)
2010						
No imprisonment	110	12 (11)	1580	806 (51)	1730	835 (48)
Imprisonment	2	1 (50)	211	146 (69)	217	149 (69)
2010 p value		0.220		<0.001		<0.001

Table 1.30 HCV antibody prevalence by sex work last month, time since first injection and year

NATIONAL	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
No sex work	120	28 (23)	757	524 (69)	894	562 (63)
Sex work	4	1 (25)	47	35 (74)	51	36 (71)
1996						
No sex work	222	29 (13)	1029	601 (58)	1287	648 (50)
Sex work	5	0 (0)	91	53 (58)	102	58 (57)
1997						
No sex work	302	36 (12)	1299	759 (58)	1639	813 (50)
Sex work	13	5 (38)	127	77 (61)	142	83 (58)
1998						
No sex work	428	69 (16)	1757	976 (55)	2226	1067 (48)
Sex work	19	6 (32)	128	93 (73)	151	100 (66)
1999						
No sex work	358	68 (19)	1700	953 (56)	2105	1046 (50)
Sex work	25	9 (36)	178	103 (58)	211	116 (55)
2000						
No sex work	305	77 (25)	1856	1065 (57)	2211	1163 (53)
Sex work	24	12 (50)	220	146 (66)	249	162 (65)
2001						
No sex work	254	68 (27)	1757	1083 (62)	2067	1176 (57)
Sex work	20	7 (35)	191	143 (75)	216	152 (70)
2002						
No sex work	204	76 (37)	1833	1068 (58)	2096	1170 (56)
Sex work	15	6 (40)	172	108 (63)	194	117 (60)
2003						
No sex work	183	40 (22)	1911	1171 (61)	2165	1236 (57)
Sex work	15	3 (20)	158	120 (76)	179	129 (72)
2004						
No sex work	124	30 (24)	1466	900 (61)	1625	949 (58)
Sex work	7	4 (57)	153	111 (73)	161	116 (72)
2005						
No sex work	140	43 (31)	1345	856 (64)	1555	941 (61)
Sex work	2	2 (100)	93	69 (74)	102	76 (75)
2006						
No sex work	90	17 (19)	1515	964 (64)	1699	1017 (61)
Sex work	5	1 (20)	114	75 (66)	121	77 (64)
2007						
No sex work	82	16 (20)	1452	938 (65)	1573	983 (62)
Sex work	7	2 (29)	98	63 (64)	110	68 (62)
2008						
No sex work	99	26 (26)	1715	1104 (64)	1850	1149 (62)
Sex work	4	3 (75)	117	80 (68)	123	83 (67)
2009						
No sex work	153	19 (12)	2200	1149 (52)	2409	1189 (49)
Sex work	3	2 (67)	120	75 (63)	129	79 (61)
2010						
No sex work	109	13 (12)	1893	1053 (56)	2044	1086 (53)
Sex work	9	4 (44)	115	52 (45)	127	57 (45)
2010 p value		0.024		0.033		0.082

Table 1.31 HCV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year

NATIONAL	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Non-Indigenous	592	369 (62)	300	187 (62)	902	564 (63)
Indigenous	28	18 (64)	18	15 (83)	47	34 (72)
1996						
Non-Indigenous	878	444 (51)	413	235 (57)	1298	684 (53)
Indigenous	40	20 (50)	26	18 (69)	66	38 (58)
1997						
Non-Indigenous	1108	533 (48)	580	316 (54)	1693	851 (50)
Indigenous	59	27 (46)	33	22 (67)	93	50 (54)
1998						
Non-Indigenous	1449	677 (47)	778	410 (53)	2238	1093 (49)
Indigenous	85	37 (44)	60	40 (67)	145	77 (53)
1999						
Non-Indigenous	1380	664 (48)	739	370 (50)	2126	1038 (49)
Indigenous	99	67 (68)	73	51 (70)	174	119 (68)
2000						
Non-Indigenous	1485	782 (53)	755	426 (56)	2251	1213 (54)
Indigenous	127	68 (54)	97	49 (51)	226	118 (52)
2001						
Non-Indigenous	1411	791 (56)	701	427 (61)	2128	1228 (58)
Indigenous	108	68 (63)	71	42 (59)	183	112 (61)
2002						
Non-Indigenous	1391	785 (56)	697	381 (55)	2105	1179 (56)
Indigenous	108	65 (60)	65	42 (65)	177	109 (62)
2003						
Non-Indigenous	1452	820 (56)	687	417 (61)	2158	1248 (58)
Indigenous	106	67 (63)	84	52 (62)	194	122 (63)
2004						
Non-Indigenous	1103	640 (58)	524	320 (61)	1639	966 (59)
Indigenous	88	58 (66)	58	41 (71)	148	100 (68)
2005						
Non-Indigenous	950	576 (61)	521	313 (60)	1479	894 (60)
Indigenous	95	63 (66)	72	56 (78)	168	120 (71)
2006						
Non-Indigenous	1069	639 (60)	553	339 (61)	1631	981 (60)
Indigenous	108	69 (64)	87	68 (78)	196	138 (70)
2007						
Non-Indigenous	998	599 (60)	523	333 (64)	1530	939 (61)
Indigenous	112	80 (71)	73	48 (66)	187	129 (69)
2008						
Non-Indigenous	1177	732 (62)	614	372 (61)	1799	1108 (62)
Indigenous	125	82 (66)	98	67 (68)	225	151 (67)
2009						
Non-Indigenous	1490	721 (48)	749	388 (52)	2253	1115 (49)
Indigenous	166	87 (52)	145	76 (52)	313	163 (52)
2010						
Non-Indigenous	1377	743 (54)	631	343 (54)	2020	1093 (54)
Indigenous	158	77 (49)	111	50 (45)	271	128 (47)
2010 p value		0.238		0.080		0.038

Table 1.32 HCV antibody prevalence by country of birth, gender and year

NATIONAL	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Australia	--	--	--	--	--	--
Other	--	--	--	--	--	--
1996						
Australia	--	--	--	--	--	--
Other	--	--	--	--	--	--
1997						
Australia	--	--	--	--	--	--
Other	--	--	--	--	--	--
1998						
Australia	--	--	--	--	--	--
Other	--	--	--	--	--	--
1999						
Australia	1315	646 (49)	770	403 (52)	2093	1053 (50)
Other	137	72 (53)	41	17 (41)	178	89 (50)
2000						
Australia	1148	596 (52)	636	356 (56)	1795	959 (53)
Other	244	139 (57)	124	75 (60)	369	214 (58)
2001						
Australia	1170	629 (54)	583	348 (60)	1766	984 (56)
Other	247	164 (66)	121	78 (64)	369	243 (66)
2002						
Australia	1226	669 (55)	636	349 (55)	1878	1029 (55)
Other	275	175 (64)	117	67 (57)	397	274 (69)
2003						
Australia	1270	707 (56)	670	402 (60)	1962	1123 (57)
Other	315	196 (62)	117	77 (66)	434	274 (63)
2004						
Australia	946	532 (56)	501	309 (62)	1458	846 (58)
Other	254	167 (66)	91	58 (64)	347	226 (65)
2005						
Australia	914	551 (60)	539	331 (61)	1460	887 (61)
Other	155	101 (65)	65	42 (65)	222	144 (65)
2006						
Australia	1021	613 (60)	573	366 (64)	1602	984 (61)
Other	170	103 (61)	77	47 (61)	250	150 (60)
2007						
Australia	975	592 (61)	526	334 (64)	1511	934 (62)
Other	139	89 (64)	72	49 (68)	212	138 (65)
2008						
Australia	1145	721 (63)	626	378 (60)	1103	1103 (62)
Other	187	117 (63)	100	65 (65)	291	183 (63)
2009						
Australia	1467	728 (50)	802	411 (51)	2282	1144 (50)
Other	212	98 (46)	102	55 (54)	318	155 (49)
2010						
Australia	1357	724 (53)	670	344 (51)	2038	1075 (53)
Other	184	102 (55)	78	48 (62)	263	150 (57)
2010 p value		0.637		0.094		0.212

Table 1.33 HCV antibody prevalence by language spoken at home by parents, gender and year

NATIONAL	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
English speaking	--	--	--	--	--	--
Non-English speaking	--	--	--	--	--	--
1996						
English speaking	--	--	--	--	--	--
Non-English speaking	--	--	--	--	--	--
1997						
English speaking	--	--	--	--	--	--
Non-English speaking	--	--	--	--	--	--
1998						
English speaking	--	--	--	--	--	--
Non-English speaking	--	--	--	--	--	--
1999						
English speaking	1311	644 (49)	769	403 (52)	2088	1051 (50)
Non-English speaking	117	61 (52)	33	15 (45)	150	76 (51)
2000						
English speaking	1404	732 (52)	757	409 (54)	2171	1146 (53)
Non-English speaking	161	102 (63)	82	57 (69)	246	160 (65)
2001						
English speaking	1283	711 (55)	689	413 (60)	1990	1137 (57)
Non-English speaking	181	123 (68)	82	57 (70)	266	180 (68)
2002						
English speaking	1262	702 (56)	689	384 (56)	1967	1098 (56)
Non-English speaking	212	141 (67)	68	37 (54)	284	181 (64)
2003						
English speaking	1307	737 (56)	721	435 (60)	2051	1186 (58)
Non-English speaking	215	133 (62)	47	29 (62)	263	163 (62)
2004						
English speaking	758	431 (57)	456	281 (62)	1224	715 (58)
Non-English speaking	163	109 (67)	44	25 (57)	207	134 (65)
2005						
English speaking	892	546 (61)	544	333 (61)	1443	884 (61)
Non-English speaking	184	111 (60)	65	44 (68)	251	156 (62)
2006						
English speaking	1058	643 (61)	607	391 (64)	1675	1039 (62)
Non-English speaking	83	45 (54)	27	14 (52)	112	60 (54)
2007						
English speaking	1048	642 (61)	576	369 (64)	1634	1018 (62)
Non-English speaking	68	41 (60)	26	17 (65)	95	59 (62)
2008						
English speaking	1262	788 (62)	704	433 (62)	1976	1227 (62)
Non-English speaking	68	51 (75)	26	14 (54)	94	65 (69)
2009						
English speaking	1615	790 (49)	866	449 (52)	2497	1246 (50)
Non-English speaking	72	39 (54)	38	17 (45)	111	56 (50)
2010						
English speaking	1474	788 (53)	734	383 (52)	2221	1178 (53)
Non-English speaking	75	37 (49)	14	8 (57)	89	45 (51)
2010 p value		0.553		0.792		0.666

2. AUSTRALIAN CAPITAL TERRITORY


Recruitment of survey participants in the Australian Capital Territory (ACT) was undertaken by one NSP site in all survey years (the ACT IV League in 1995 and 1996, and the Drug Referral Information Centre/Directions ACT in all years since 1997). Sample sizes have ranged considerably, from 22 (in 2007) to 163 (in 2000). Response rates have also varied considerably, and response rate data is not available for all years (Table 2.1). The relatively small number of participants in some survey years is likely to have contributed to the wide variations in demographic and injecting characteristics observed over time in the ACT.

Demographic Characteristics

The gender distribution of ACT ANSPS samples varied over the period 1995 to 2010, during which between 54% and 82% of participants were male. As in all other jurisdictions, the majority of participants (71% to 88%) identified as heterosexual. Although the proportion of Indigenous participants increased nationally over time, this was not the case in the ACT, where substantial variation occurred from year to year. The majority of ACT survey respondents were born in Australia (79% to 92%) and reported their parents spoke English at home (77% to 98%) across all survey years in which these data were available.

The median age of ACT ANSPS respondents reached a low of 23 years in 1997, but subsequently increased, fluctuating between 30 and 36 years between 2002 and 2010 (Figure 2.1). The proportion of young people (aged younger than 25 years) increased during the late 1990s, and as observed nationally and in other jurisdictions, declined significantly from a high of 59% in 1997 to just 3% in 2010 (χ^2 trend $p < 0.001$). The median age at first injection remained stable at between 16 and 18 years over the period 1995 to 2010.

Figure 2.1 ACT: Median age and proportion of young injectors by year




Injecting behaviour

Across all survey years, heroin and methamphetamine were the drugs ACT participants were most likely to report last injecting. Heroin was clearly the most commonly reported drug last injected throughout the 1990s (Figure 2.2). As occurred elsewhere, and coinciding with well documented changes in heroin availability in Australia (Maher et al., 2007; Degenhardt et al., 2006; Topp et al., 2003), a dramatic and sudden decline in heroin injection was observed in the ACT in 2001. Between 2005 and 2010, the proportion of participants who reported last injecting heroin remained relatively stable at around one third of participants.

A relatively small proportion of respondents reported last injecting methamphetamine during the 1990s, increasing to 40% in 2001, and fluctuating between 20% and 40% until 2010 (Figure 2.2). Prevalence of recent injection of methadone, buprenorphine and pharmaceutical opioids varied over the survey period, due, at least in part, to the small sample sizes observed in some survey years.


Figure 2.2 ACT: Prevalence of heroin and methamphetamine as drug last injected by year



Prevalence of re-use of needles and syringes (including re-use of one’s own needle/syringe) in the month preceding survey participation was relatively stable across the survey period, reported by between a quarter and a third of respondents. Receptive sharing of syringes varied substantially, from 4% in 2005 to 44% in 2007, as did receptive sharing of ancillary injecting equipment which ranged from 31% in 2010 to 66% in 2007. As observed in other jurisdictions, spoons and water were the most common items shared by respondents in the ACT.

Prevalence of public injecting was consistently higher in the ACT than in most other jurisdictions, but declined significantly from 79% in 1997 to 49% in 2010 (χ^2 trend $p=0.001$, Figure 2.3).

Figure 2.3 National and ACT: Prevalence of public injection by year



HIV prevalence

HIV antibodies were rarely detected among ACT ANSPS participants, and no cases were identified between 1999 and 2010 (Table 2.9).

HCV prevalence

HCV antibody prevalence in the ACT fluctuated over the survey period, most likely due to small sample size in some years (Table 2.10). Nevertheless, HCV antibody prevalence was consistently higher in the ACT than observed nationally in all years between 1998 and 2010 (Figure 2.4). Consistent with the national trend, HCV antibody prevalence declined in the ACT in recent years, although the ACT decline began in 2008, whereas the broader national decline was not observed until 2009.

Figure 2.4 National and ACT: HCV antibody prevalence by year




Table 2.1 Number (percentage) of respondents by demographic characteristic and year

ACT	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Number of sites	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
N° surveyed	N=72	N=125	N=87	N=138	N=94	N=163	N=44	N=62	N=60	N=28	N=39	N=52	N=22	N=31	N=63	N=97
Response rate	97%	89%	49%	91%	55%	56%	40%	29%	58%	--	70%	--	--	--	67%	83%
Gender (%)																
Male	47 (65)	69 (55)	59 (68)	87 (63)	51 (54)	120 (74)	34 (77)	41 (66)	41 (68)	23 (82)	30 (77)	31 (60)	12 (55)	22 (71)	39 (62)	72 (74)
Female	24 (34)	55 (44)	28 (32)	51 (37)	43 (46)	43 (26)	10 (23)	21 (34)	19 (32)	5 (18)	9 (23)	20 (39)	10 (45)	9 (29)	24 (38)	25 (26)
Transgender	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)																
Heterosexual	59 (82)	97 (78)	64 (74)	118 (86)	69 (73)	139 (85)	39 (88)	45 (72)	43 (72)	23 (82)	33 (85)	44 (85)	19 (86)	22 (71)	52 (83)	81 (83)
Bisexual	9 (13)	15 (12)	13 (15)	13 (9)	7 (7)	12 (8)	2 (5)	6 (10)	7 (12)	1 (4)	2 (5)	7 (13)	1 (5)	3 (10)	7 (11)	5 (5)
Homosexual	3 (4)	9 (7)	3 (3)	2 (1)	10 (11)	2 (1)	1 (2)	1 (2)	5 (8)	2 (7)	1 (3)	1 (2)	2 (9)	3 (10)	1 (2)	1 (1)
Not reported	1 (1)	4 (3)	7 (8)	5 (4)	8 (9)	10 (6)	2 (5)	10 (16)	5 (8)	2 (7)	3 (8)	0 (0)	0 (0)	3 (10)	3 (5)	10 (10)
Age and time since first injection (years)																
<i>Median age</i>	32	30	23	25	25	27	28	31	33.5	34	36	33	29.5	36	32	35
<i>Age range</i>	17-41	13-49	15-45	16-45	16-46	16-47	19-45	18-54	18-58	17-50	15-57	15-60	17-61	22-56	16-60	19-64
<i>Age group (%)</i>																
< 25 years	13 (18)	33 (26)	51 (59)	64 (46)	43 (46)	65 (40)	14 (32)	14 (23)	10 (17)	5 (18)	6 (15)	7 (13)	5 (23)	3 (10)	15 (23)	3 (3)
25+ years	59 (82)	91 (73)	36 (41)	74 (54)	51 (54)	98 (60)	30 (68)	48 (77)	50 (83)	23 (82)	33 (85)	44 (85)	17 (77)	28 (90)	48 (76)	94 (97)
Not reported	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	18	18	17	17	17	17	17	17	18	18	17	17	16	18	17	18
<i>Age range</i>	13-33	11-33	12-33	12-32	12-34	10-42	11-40	13-39	13-40	14-45	11-28	12-39	12-33	11-40	12-42	10-40
N° not reported	1	5	3	1	2	4	1	2	1	1	9	2	1	0	1	2
<i>Median years IDU</i>	12	10	5	7	6.5	8	11	12	12	14	18	13	11	16	13	17
<i>Range</i>	1-23	<1-34	<1-25	<1-31	<1-28	<1-32	1-30	1-40	<1-44	<1-35	<1-32	<1-45	2-47	2-38	1-36	2-49
<i>Time since first injection</i>																
<3 years	5 (7)	8 (6)	23 (26)	28 (20)	19 (20)	30 (18)	3 (7)	4 (6)	3 (5)	3 (11)	1 (3)	2 (4)	1 (5)	1 (3)	7 (11)	1 (1)
3+ years	66 (92)	112 (90)	61 (70)	109 (79)	73 (78)	129 (79)	40 (91)	56 (90)	56 (93)	24 (86)	38 (97)	48 (92)	20 (91)	30 (97)	55 (87)	94 (97)
Not reported	1 (3)	5 (4)	3 (3)	1 (<1)	2 (2)	4 (2)	1 (2)	2 (3)	1 (2)	1 (3)	0 (0)	2 (4)	1 (5)	0 (0)	1 (2)	2 (2)

Table 2.1 Number (percentage) of respondents by demographic characteristic and year (continued)

ACT	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=72	N=125	N=87	N=138	N=94	N=163	N=44	N=62	N=60	N=28	N=39	N=52	N=22	N=31	N=63	N=97
Aboriginal and Torres Strait Islander origin (%)																
No	65 (90)	110 (88)	83 (95)	123 (89)	76 (81)	140 (87)	39 (89)	53 (85)	56 (93)	23 (82)	31 (79)	49 (94)	21 (95)	25 (81)	56 (89)	79 (81)
Yes	5 (7)	7 (6)	4 (5)	12 (9)	16 (17)	18 (11)	5 (11)	8 (13)	4 (7)	3 (11)	7 (18)	3 (6)	0 (0)	4 (13)	5 (8)	17 (18)
Not reported	2 (3)	8 (6)	0 (0)	3 (2)	2 (2)	4 (2)	0 (0)	1 (2)	0 (0)	2 (7)	1 (3)	0 (0)	1 (5)	2 (6)	2 (3)	1 (1)
Region/country of birth (%)																
Australia	--	--	--	--	84 (89)	139 (85)	37 (84)	52 (84)	52 (87)	26 (92)	32 (82)	43 (83)	18 (82)	25 (81)	50 (79)	89 (92)
Other Oceania	--	--	--	--	--	2 (1)	2 (5)	0 (0)	0 (0)	0 (0)	1 (3)	2 (4)	0 (0)	4 (13)	2 (3)	2 (2)
Asia	--	--	--	--	1 (1)	3 (2)	0 (0)	0 (0)	3 (5)	1 (4)	1 (3)	1 (2)	1 (5)	2 (6)	1 (2)	0 (0)
UK & Ireland	--	--	--	--	--	8 (5)	2 (5)	4 (6)	4 (7)	1 (4)	2 (5)	1 (2)	2 (9)	1 (3)	8 (13)	4 (4)
Other	--	--	--	--	7 (8)	9 (6)	3 (7)	5 (8)	1 (1)	0 (0)	3 (8)	4 (8)	1 (5)	2 (6)	2 (3)	0 (0)
Not reported	--	--	--	--	2 (2)	2 (1)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	1 (3)	0 (0)	2 (2)
Main language spoken at home by parents (%)																
English	--	--	--	--	84 (89)	142 (87)	39 (89)	54 (87)	59 (98)	23 (82)	30 (77)	42 (81)	20 (91)	30 (97)	61 (97)	95 (98)
Non-English	--	--	--	--	8 (9)	17 (10)	3 (7)	5 (8)	1 (2)	0 (0)	9 (23)	7 (13)	2 (9)	1 (3)	2 (3)	2 (2)
Not reported	--	--	--	--	2 (2)	4 (3)	2 (4)	3 (5)	0 (0)	5 (18)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)
Imprisonment last year (%)																
No	64 (89)	107 (85)	71 (82)	110 (80)	76 (81)	139 (85)	29 (66)	56 (90)	49 (82)	22 (79)	33 (85)	44 (85)	19 (86)	26 (84)	51 (81)	67 (69)
Yes	7 (10)	12 (10)	15 (17)	26 (19)	17 (18)	23 (14)	15 (34)	6 (10)	11 (18)	6 (21)	4 (10)	7 (13)	2 (9)	2 (6)	9 (14)	14 (14)
Not reported	1 (1)	6 (5)	1 (1)	2 (1)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (5)	1 (2)	1 (5)	3 (10)	3 (5)	16 (16)
Injected in prison last year (%)																
N° in prison	N=7	N=12	N=15	N=26	N=17	N=23	N=15	N=6	N=11	N=6	N=4	N=7	N=2	N=2	N=9	N=14
Injected in prison	3 (43)	4 (33)	6 (40)	5 (19)	6 (35)	8 (35)	3 (20)	2 (33)	1 (9)	2 (33)	2 (50)	4 (57)	1 (50)	0 (0)	1 (11)	4 (29)
Frequency of injection last month (%)																
Not last month	15 (21)	13 (10)	5 (6)	6 (4)	13 (14)	9 (6)	3 (7)	7 (11)	1 (2)	1 (3)	8 (21)	7 (13)	3 (14)	0 (0)	4 (6)	8 (8)
Less than weekly	19 (26)	25 (20)	21 (24)	14 (10)	19 (20)	25 (15)	10 (23)	9 (15)	11 (18)	8 (29)	4 (10)	13 (25)	1 (5)	3 (10)	10 (16)	15 (15)
Weekly not daily	23 (32)	40 (32)	13 (15)	34 (25)	11 (12)	27 (16)	19 (43)	16 (26)	14 (23)	5 (18)	15 (38)	19 (37)	9 (41)	15 (48)	12 (19)	30 (31)
Daily or more	15 (21)	45 (36)	47 (54)	84 (61)	51 (54)	101 (62)	11 (25)	30 (48)	34 (57)	12 (43)	12 (31)	13 (25)	8 (36)	13 (42)	37 (59)	42 (43)
Not reported	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	2 (7)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	2 (2)

Table 2.2 Number (percentage) of respondents by drug last injected and year

ACT N° surveyed	1995 N=72	1996 N=125	1997 N=87	1998 N=138	1999 N=94	2000 N=163	2001 N=44	2002 N=62	2003 N=60	2004 N=28	2005 N=39	2006 N=52	2007 N=22	2008 N=31	2009 N=63	2010 N=97	
Drug last injected (%)																	
Anabolic steroids	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Cocaine	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	3 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (3)	4 (4)	
Heroin	43 (61)	89 (71)	69 (79)	117 (85)	72 (77)	130 (79)	13 (30)	41 (67)	30 (50)	14 (50)	14 (36)	20 (38)	9 (41)	14 (45)	24 (38)	28 (29)	
Methadone	7 (10)	11 (9)	5 (6)	4 (3)	1 (1)	3 (2)	9 (20)	5 (8)	5 (8)	4 (14)	3 (8)	6 (12)	0 (0)	2 (6)	2 (3)	16 (16)	
Methamphetamine	10 (14)	9 (7)	8 (9)	8 (6)	15 (16)	10 (6)	18 (41)	10 (16)	17 (28)	9 (32)	10 (26)	21 (40)	9 (41)	9 (29)	15 (24)	26 (27)	
Pharm. opioids	3 (4)	0 (0)	0 (0)	2 (1)	0 (0)	3 (2)	1 (2)	0 (0)	0 (0)	0 (0)	2 (5)	1 (2)	1 (5)	2 (6)	6 (10)	3 (3)	
Buprenorphine	--	--	--	--	--	--	--	--	1 (2)	0 (0)	0 (0)	3 (6)	2 (9)	3 (10)	6 (10)	10 (10)	
More than one	5 (7)	15 (12)	4 (5)	7 (5)	5 (5)	13 (8)	2 (5)	6 (9)	2 (3)	0 (0)	2 (5)	0 (0)	1 (5)	0 (0)	2 (3)	7 (7)	
Other	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (3)	1 (4)	0 (0)	1 (2)	0 (0)	0 (0)	4 (6)	3 (3)	
Not reported	1 (1)	1 (1)	1 (1)	0 (0)	0 (0)	1 (1)	1 (2)	0 (0)	0 (0)	0 (0)	8 (20)	0 (0)	0 (0)	1 (3)	2 (3)	0 (0)	

Table 2.3 Number (percentage) of respondents by places injected in the last month and year

ACT N° injected last month	1995 N=57	1996 N=110	1997 N=81	1998 N=132	1999 N=81	2000 N=153	2001 N=40	2002 N=55	2003 N=59	2004 N=25	2005 N=31	2006 N=45	2007 N=18	2008 N=31	2009 N=59	2010 N=87	
Places injected in the last month (%) [More than one could be selected]																	
<i>Private places</i>																	
Own home	--	--	63 (78)	103 (78)	62 (76)	124 (81)	29 (73)	43 (78)	50 (85)	17 (68)	20 (65)	35 (81)	16 (94)	27 (87)	50 (86)	77 (89)	
Friend's home	--	--	59 (73)	87 (66)	40 (49)	80 (52)	18 (45)	37 (67)	37 (63)	13 (52)	11 (35)	20 (47)	11 (65)	11 (35)	30 (52)	45 (52)	
Dealer's home	--	--	36 (44)	40 (30)	17 (21)	45 (29)	10 (25)	21 (38)	14 (24)	7 (28)	6 (19)	14 (33)	8 (47)	5 (16)	13 (22)	24 (28)	
Commercial injecting room	--	--	7 (9)	2 (2)	2 (3)	2 (1)	1 (3)	0 (0)	1 (2)	0 (0)	2 (8)	1 (2)	1 (6)	2 (6)	0 (0)	1 (1)	
<i>Public places</i>																	
Street, park, beach	--	--	40 (49)	64 (48)	43 (53)	65 (42)	15 (38)	28 (51)	27 (46)	6 (24)	9 (29)	11 (26)	8 (47)	12 (39)	16 (28)	19 (22)	
Car	--	--	--	77 (58)	47 (58)	73 (48)	18 (45)	27 (49)	30 (51)	8 (32)	11 (35)	20 (47)	8 (47)	12 (39)	18 (31)	20 (23)	
Public toilet	--	--	55 (68)	76 (58)	49 (60)	78 (51)	19 (48)	25 (45)	31 (53)	12 (48)	11 (35)	16 (37)	9 (53)	2 (6)	17 (29)	32 (37)	
Squat	--	--	--	--	11 (14)	19 (12)	2 (5)	6 (11)	7 (12)	4 (16)	6 (19)	8 (19)	2 (12)	3 (10)	1 (2)	6 (7)	
Public injecting in last month (%)																	
Any public	--	--	64 (79)	101 (77)	64 (79)	109 (71)	29 (73)	39 (71)	42 (71)	17 (65)	16 (59)	27 (60)	11 (61)	20 (64)	30 (51)	40 (46)	
All private	--	--	17 (21)	25 (19)	15 (19)	35 (23)	11 (28)	15 (27)	16 (27)	8 (31)	9 (33)	16 (36)	6 (33)	11 (35)	28 (47)	44 (51)	
Not reported	--	--	0 (0)	6 (5)	2 (2)	9 (6)	0 (0)	1 (2)	1 (2)	1 (4)	2 (7)	2 (4)	1 (6)	0 (0)	1 (2)	3 (3)	

Table 2.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

ACT	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=57	N=110	N=81	N=132	N=81	N=153	N=40	N=55	N=59	N=25	N=31	N=45	N=18	N=31	N=59	N=87
Use of sterile needles and syringes last month (%)																
All injections	--	--	55 (68)	84 (64)	56 (69)	114 (74)	26 (65)	39 (71)	40 (68)	17 (68)	19 (61)	32 (71)	9 (50)	24 (77)	43 (73)	58 (67)
Most of the time	--	--	23 (29)	38 (29)	19 (24)	36 (23)	13 (33)	15 (27)	16 (27)	8 (32)	11 (35)	12 (27)	6 (33)	6 (19)	15 (25)	24 (28)
Half of the time	--	--	2 (2)	3 (2)	2 (2)	1 (1)	1 (3)	1 (2)	1 (2)	0 (0)	0 (0)	1 (2)	1 (6)	1 (3)	1 (2)	0 (0)
Some of the time	--	--	1 (1)	3 (2)	2 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	1 (3)	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)
Not last month	--	--	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Not reported	--	--	0 (0)	4 (3)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)	4 (5)
Re-used someone else's used needle & syringe last month (%)																
None	34 (60)	83 (75)	67 (83)	100 (76)	56 (69)	121 (79)	28 (70)	38 (70)	41 (70)	20 (80)	25 (81)	35 (78)	9 (50)	25 (81)	51 (86)	62 (71)
Once	10 (18)	16 (14)	1 (1)	12 (9)	10 (13)	15 (10)	8 (20)	4 (7)	7 (12)	2 (8)	1 (3)	3 (7)	3 (17)	2 (6)	1 (2)	3 (3)
Twice	3 (5)	6 (5)	4 (5)	8 (6)	5 (6)	5 (3)	2 (5)	4 (7)	4 (7)	1 (4)	0 (0)	0 (0)	1 (6)	2 (6)	1 (2)	7 (8)
3-5 times	6 (10)	1 (1)	7 (9)	6 (4)	9 (11)	4 (3)	0 (0)	2 (4)	2 (3)	1 (4)	0 (0)	3 (7)	2 (11)	1 (3)	4 (7)	3 (3)
> 5 times	4 (7)	4 (4)	0 (0)	2 (2)	0 (0)	7 (4)	1 (3)	3 (5)	3 (5)	0 (0)	0 (0)	3 (7)	2 (11)	1 (3)	1 (2)	2 (2)
Not reported	0 (0)	0 (0)	2 (2)	4 (3)	1 (1)	1 (1)	1 (3)	4 (7)	2 (3)	1 (4)	5 (16)	1 (2)	1 (6)	0 (0)	1 (2)	10 (11)
Number of people needle & syringe was re-used after last month (%)																
None	34 (60)	83 (76)	67 (83)	100 (76)	56 (69)	121 (79)	28 (70)	38 (68)	39 (66)	20 (80)	21 (68)	35 (78)	9 (50)	25 (81)	51 (86)	62 (71)
One	11 (19)	10 (9)	12 (15)	23 (17)	17 (21)	21 (14)	9 (21)	6 (11)	6 (10)	1 (4)	4 (13)	3 (7)	2 (11)	3 (10)	4 (7)	8 (9)
Two	3 (5)	17 (15)	1 (1)	3 (2)	3 (4)	0 (0)	1 (3)	2 (4)	1 (2)	0 (0)	0 (0)	2 (4)	3 (17)	0 (0)	0 (0)	1 (1)
Three to five	1 (2)	0 (0)	1 (1)	2 (1)	1 (1)	3 (2)	0 (0)	0 (0)	2 (3)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	2 (3)	2 (2)
More than five	1 (2)	0 (0)	0 (0)	0 (0)	2 (3)	2 (1)	1 (3)	2 (4)	2 (3)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	2 (3)	1 (1)
Don't know	7 (12)	0 (0)	0 (0)	0 (0)	1 (1)	5 (3)	0 (0)	2 (4)	4 (7)	1 (4)	2 (6)	1 (2)	2 (11)	1 (3)	0 (0)	3 (3)
Not reported	0 (0)	0 (0)	0 (0)	4 (3)	1 (1)	1 (1)	1 (3)	5 (9)	5 (9)	3 (12)	4 (13)	2 (4)	2 (11)	2 (6)	1 (2)	10 (11)
Relationship to people needle & syringe was used after last month (%) [More than one could be selected]																
Regular sex partner	--	--	8 (10)	13 (10)	10 (12)	15 (10)	5 (13)	6 (11)	3 (5)	1 (4)	3 (10)	4 (9)	2 (11)	2 (6)	4 (7)	8 (9)
Casual sex partner	--	--	2 (2)	2 (2)	0 (0)	3 (2)	0 (0)	1 (2)	1 (5)	0 (0)	0 (0)	1 (2)	0 (0)	1 (3)	0 (0)	0 (0)
Close friend	--	--	5 (6)	14 (11)	10 (12)	6 (4)	3 (8)	5 (9)	4 (20)	1 (4)	2 (6)	3 (7)	3 (17)	0 (0)	2 (3)	5 (6)
Acquaintance	--	--	3 (4)	1 (1)	3 (4)	8 (5)	2 (5)	2 (4)	3 (15)	0 (0)	1 (3)	3 (7)	2 (11)	0 (0)	1 (2)	4 (5)
Other	--	--	0 (0)	2 (2)	2 (2)	3 (2)	1 (3)	3 (5)	1 (5)	0 (0)	0 (0)	0 (0)	1 (6)	1 (3)	0 (0)	2 (2)

Table 2.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

ACT	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=57	N=110	N=81	N=132	N=81	N=153	N=40	N=55	N=59	N=25	N=31	N=45	N=18	N=31	N=59	N=87
Equipment used after someone else last month (%) [More than one could be selected]																
Spoon	--	--	--	--	31 (38)	61 (40)	14 (35)	25 (45)	26 (44)	11 (44)	10 (32)	17 (40)	6 (35)	11 (37)	20 (38)	18 (21)
Water	--	--	--	--	20 (25)	31 (20)	4 (10)	15 (27)	14 (24)	7 (28)	9 (29)	12 (28)	9 (53)	8 (27)	14 (26)	16 (18)
Filter	--	--	--	--	22 (27)	35 (23)	3 (8)	15 (27)	15 (25)	7 (28)	5 (16)	7 (16)	4 (24)	6 (20)	4 (8)	8 (9)
Drug mix	--	--	--	--	14 (17)	21 (14)	4 (10)	11 (20)	21 (36)	5 (20)	7 (23)	7 (16)	4 (24)	7 (23)	7 (13)	9 (10)
Tourniquet	--	--	--	--	15 (19)	16 (10)	4 (10)	10 (18)	5 (8)	1 (4)	2 (6)	9 (21)	4 (24)	1 (3)	9 (17)	--
None	--	--	--	--	--	--	--	--	--	--	--	21 (49)	5 (30)	19 (63)	28 (53)	53 (61)
Injected by someone after that person injected themselves or others last month (%)																
No	--	--	--	--	60 (74)	126 (82)	37 (94)	42 (76)	53 (90)	18 (72)	21 (68)	37 (82)	10 (56)	28 (90)	49 (83)	66 (76)
Yes	--	--	--	--	18 (22)	25 (17)	2 (4)	13 (24)	6 (10)	7 (28)	4 (13)	7 (16)	6 (33)	3 (10)	10 (17)	11 (13)
Not reported	--	--	--	--	3 (4)	2 (1)	1 (2)	0 (0)	0 (0)	0 (0)	6 (19)	1 (2)	2 (11)	0 (0)	0 (0)	10 (11)

Table 2.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

ACT	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=72	N=125	N=87	N=138	N=94	N=163	N=44	N=62	N=60	N=28	N=39	N=52	N=22	N=31	N=63	N=97
Sex with a regular partner last month (%)																
No	--	--	--	--	--	--	--	--	--	--	19 (49)	30 (58)	11 (50)	22 (71)	34 (54)	41 (42)
Yes	--	--	--	--	--	--	--	--	--	--	19 (49)	22 (42)	9 (41)	8 (26)	28 (44)	50 (52)
Not reported	--	--	--	--	--	--	--	--	--	--	1 (3)	0 (0)	2 (9)	1 (3)	1 (2)	6 (6)
Condom used with regular partner last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=19	N=22	N=9	N=8	N=28	N=41
Sometimes	--	--	--	--	--	--	--	--	--	--	14 (74)	15 (68)	7 (78)	3 (38)	20 (71)	23 (56)
Every time	--	--	--	--	--	--	--	--	--	--	2 (11)	1 (5)	2 (22)	2 (25)	4 (14)	7 (17)
Not reported	--	--	--	--	--	--	--	--	--	--	1 (5)	5 (23)	0 (0)	2 (25)	3 (11)	9 (22)
Sex with other partner(s) last month (%)																
No	--	--	--	--	--	--	--	--	--	--	2 (40)	40 (77)	14 (64)	26 (84)	59 (94)	82 (85)
Yes	--	--	--	--	--	--	--	--	--	--	3 (60)	10 (19)	7 (32)	3 (10)	2 (3)	6 (6)
Not reported	--	--	--	--	--	--	--	--	--	--	0 (0)	2 (4)	1 (5)	2 (6)	2 (3)	9 (9)

Table 2.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

ACT N° surveyed	1995 N=72	1996 N=125	1997 N=87	1998 N=138	1999 N=94	2000 N=163	2001 N=44	2002 N=62	2003 N=60	2004 N=28	2005 N=39	2006 N=52	2007 N=22	2008 N=31	2009 N=63	2009 N=97
Condom used with other partner(s) last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=5 6 (15)	N=10 4 (40)	N=7 3 (43)	N=3 2 (67)	N=2 1 (50)	N=6 2 (33)
Sometimes	--	--	--	--	--	--	--	--	--	--	3 (8)	1 (10)	2 (29)	1 (33)	0 (0)	2 (33)
Every time	--	--	--	--	--	--	--	--	--	--	1 (3)	4 (40)	2 (29)	0 (0)	1 (50)	1 (17)
Not reported	--	--	--	--	--	--	--	--	--	--	29 (74)	1 (10)	0 (0)	0 (0)	0 (0)	1 (17)
Sex last month (%)																
No	18 (25)	42 (34)	29 (33)	53 (38)	42 (45)	56 (34)	15 (34)	23 (37)	22 (37)	13 (46)	--	--	--	--	--	--
Yes	49 (68)	80 (64)	58 (67)	85 (62)	51 (54)	106 (65)	29 (66)	38 (61)	37 (62)	14 (50)	--	--	--	--	--	--
Not reported	5 (7)	3 (2)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	1 (2)	1 (1)	1 (4)	--	--	--	--	--	--
Condom use at last sex (%)																
No	41 (57)	57 (45)	55 (64)	91 (66)	53 (56)	95 (58)	30 (68)	39 (63)	39 (65)	23 (82)	--	--	--	--	--	--
Yes	15 (21)	22 (18)	30 (34)	41 (30)	38 (41)	66 (41)	13 (30)	22 (35)	20 (33)	5 (18)	--	--	--	--	--	--
Not reported	16 (22)	46 (37)	2 (2)	6 (4)	3 (3)	2 (1)	1 (2)	1 (2)	1 (2)	0 (0)	--	--	--	--	--	--
Condom use with regular sex partner(s) last month (%)																
No	--	50 (67)	36 (70)	42 (60)	33 (81)	58 (63)	16 (67)	10 (44)	14 (67)	5 (72)	--	--	--	--	--	--
Sometimes	--	13 (18)	8 (15)	14 (20)	3 (7)	15 (16)	6 (25)	6 (26)	2 (9)	1 (14)	--	--	--	--	--	--
Always	--	11 (15)	8 (15)	14 (20)	5 (12)	19 (21)	2 (8)	7 (30)	5 (24)	1 (14)	--	--	--	--	--	--
Condom use with new sex partner(s) last month (%)																
No	--	14 (48)	12 (34)	8 (30)	6 (35)	8 (25)	3 (25)	12 (57)	7 (39)	2 (50)	--	--	--	--	--	--
Sometimes	--	1 (3)	5 (14)	4 (15)	2 (12)	5 (16)	5 (42)	3 (14)	4 (22)	1 (25)	--	--	--	--	--	--
Always	--	14 (48)	18 (51)	25 (56)	9 (53)	19 (59)	4 (33)	6 (29)	7 (39)	1 (25)	--	--	--	--	--	--
Condom use with casual sex partner(s) last month (%)																
No	--	--	--	12 (32)	9 (39)	11 (28)	5 (46)	7 (42)	7 (44)	5 (71)	--	--	--	--	--	--
Sometimes	--	--	--	10 (27)	2 (9)	14 (35)	2 (18)	5 (29)	3 (19)	2 (29)	--	--	--	--	--	--
Always	--	--	--	15 (41)	12 (52)	15 (37)	4 (36)	5 (29)	6 (37)	0 (0)	--	--	--	--	--	--
Sex work last month (%)																
No	68 (94)	105 (84)	78 (90)	126 (91)	86 (91)	148 (91)	43 (98)	58 (94)	54 (90)	26 (93)	38 (97)	47 (90)	20 (91)	29 (94)	60 (95)	85 (88)
Yes	2 (3)	10 (8)	7 (8)	8 (6)	7 (7)	11 (7)	1 (2)	3 (5)	4 (7)	2 (7)	1 (3)	3 (6)	1 (5)	2 (6)	0 (0)	2 (2)
Not reported	2 (3)	10 (8)	2 (2)	4 (3)	1 (1)	4 (2)	0 (0)	1 (1)	2 (3)	0 (0)	0 (0)	2 (4)	1 (5)	0 (0)	3 (5)	10 (10)
Condom used at last sex work (%)																
Yes	2 (100)	8 (80)	6 (86)	7 (100)	7 (100)	9 (100)	1 (100)	3 (100)	4 (100)	2 (100)	1 (100)	2 (67)	1 (100)	0 (0)	0 (0)	2 (100)

Table 2.6 Number (percentage) of respondents by previous testing for HIV, HBV, HCV infection, HBV vaccination and HCV treatment by year

ACT	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=72	N=125	N=87	N=138	N=94	N=163	N=44	N=62	N=60	N=28	N=39	N=52	N=22	N=31	N=63	N=97
Previous HIV test (%)																
Yes, last year	43 (58)	73 (58)	60 (69)	92 (67)	55 (59)	101 (62)	24 (54)	41 (65)	34 (57)	19 (68)	20 (51)	39 (75)	13 (59)	8 (26)	30 (48)	50 (52)
> 1 year ago	17 (24)	35 (28)	14 (16)	29 (21)	22 (23)	42 (26)	14 (32)	16 (26)	22 (37)	3 (11)	14 (36)	12 (23)	9 (41)	21 (68)	25 (40)	21 (22)
Never tested	4 (6)	6 (5)	0 (0)	3 (2)	17 (18)	20 (12)	6 (14)	4 (7)	3 (5)	5 (18)	4 (10)	1 (2)	0 (0)	1 (3)	5 (8)	15 (15)
Not reported	9 (12)	11 (9)	13 (15)	14 (10)	0 (0)	0 (0)	0 (0)	1 (2)	1 (1)	1 (3)	1 (3)	0 (0)	0 (0)	1 (3)	3 (5)	11 (11)
Self report HBV infection (%)																
No	50 (70)	84 (67)	53 (61)	98 (71)	70 (75)	119 (73)	33 (75)	36 (58)	32 (53)	18 (64)	25 (64)	36 (70)	16 (73)	--	--	--
Yes	19 (26)	39 (31)	19 (22)	28 (20)	16 (17)	19 (12)	9 (20)	18 (29)	14 (23)	6 (22)	8 (21)	13 (25)	4 (18)	--	--	--
Don't know	--	--	15 (17)	12 (9)	7 (7)	23 (14)	2 (5)	8 (13)	13 (22)	4 (14)	6 (15)	3 (6)	2 (9)	--	--	--
Not reported	3 (4)	2 (2)	0 (0)	0 (0)	1 (1)	2 (1)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	--	--	--
Self report HBV vaccination (%)																
No	39 (54)	58 (46)	29 (33)	50 (36)	33 (35)	61 (37)	17 (39)	20 (32)	13 (22)	9 (32)	14 (36)	14 (27)	2 (9)	--	--	--
Yes	30 (42)	64 (51)	33 (38)	63 (46)	53 (56)	81 (50)	24 (55)	33 (53)	37 (62)	16 (57)	18 (46)	36 (69)	18 (82)	--	--	--
Don't know	--	--	25 (29)	22 (16)	7 (7)	18 (11)	1 (2)	8 (13)	9 (15)	3 (11)	7 (18)	2 (4)	2 (9)	--	--	--
Not reported	3 (4)	3 (2)	0 (0)	3 (2)	1 (1)	3 (2)	2 (5)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	--	--	--
Previous HCV test (%)																
Yes, ever	59 (82)	106 (84)	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Yes, last year	--	--	59 (68)	102 (74)	61 (65)	109 (67)	26 (59)	40 (65)	39 (65)	17 (61)	24 (62)	38 (73)	12 (55)	11 (35)	34 (54)	49 (51)
> 1 year ago	--	--	16 (18)	20 (15)	17 (18)	38 (23)	13 (30)	19 (31)	17 (28)	6 (21)	11 (28)	12 (23)	10 (45)	18 (58)	24 (38)	27 (28)
Never tested	9 (13)	17 (14)	1 (1)	2 (1)	16 (17)	16 (10)	5 (11)	2 (3)	4 (7)	5 (18)	2 (5)	1 (2)	0 (0)	1 (3)	4 (6)	9 (9)
Not reported	4 (5)	2 (2)	11 (13)	14 (10)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	2 (5)	1 (2)	0 (0)	1 (3)	1 (2)	12 (12)
Any treatment for HCV (%)																
Interferon+/or Ribavirin	--	--	--	--	0 (0)	4 (5)	0 (0)	1 (3)	2 (5)	0 (0)	1 (5)	2 (6)	1 (8)	2 (11)	2 (6)	4 (7)
Other	--	--	--	--	1 (2)	1 (1)	0 (0)	2 (5)	1 (3)	0 (0)	17 (81)	0 (0)	0 (0)	1 (6)	0 (0)	1 (2)
No treatment	--	--	--	--	44 (98)	77 (94)	24 (96)	34 (89)	34 (91)	17 (100)	2 (10)	31 (91)	11 (92)	15 (83)	29 (94)	52 (91)
Not reported	--	--	--	--	0 (0)	1 (1)	1 (4)	1 (3)	0 (0)	0 (0)	1 (5)	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)
Current treatment for HCV (%)																
Interferon +/-or Ribavirin	--	--	--	--	0	3	0	0	0	0	1	0	0	0	0	3
Other	--	--	--	--	0	1	0	0	0	0	0	1	0	0	0	0

Table 2.7 Number (percentage) of respondents by treatment for drug use and year

ACT N° surveyed	1995 N=72	1996 N=125	1997 N=87	1998 N=138	1999 N=94	2000 N=163	2001 N=44	2002 N=62	2003 N=60	2004 N=28	2005 N=39	2006 N=52	2007 N=22	2008 N=31	2009 N=63	2010 N=97	
Ever any treatment/therapy for drug use (%)																	
No	13 (18)	20 (16)	20 (23)	33 (24)	24 (26)	29 (18)	4 (9)	11 (18)	10 (17)	5 (18)	13 (33)	7 (13)	5 (23)	3 (10)	10 (16)	11 (11)	
Yes	57 (79)	104 (83)	67 (77)	105 (76)	69 (73)	133 (81)	40 (91)	51 (82)	50 (83)	23 (82)	25 (64)	45 (87)	17 (77)	27 (87)	53 (84)	84 (87)	
Not reported	2 (3)	1 (1)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	1 (3)	0 (0)	2 (2)	
History of methadone maintenance treatment (%)																	
Current	30 (41)	50 (40)	16 (18)	38 (28)	30 (32)	46 (28)	14 (32)	18 (29)	22 (37)	9 (32)	14 (36)	20 (38)	5 (23)	11 (35)	23 (37)	45 (46)	
Previous	15 (21)	34 (27)	19 (22)	32 (23)	18 (19)	52 (32)	14 (32)	26 (42)	17 (28)	6 (21)	9 (23)	11 (21)	9 (41)	10 (32)	18 (29)	16 (16)	
Never	25 (35)	40 (32)	52 (60)	68 (49)	22 (23)	63 (39)	16 (36)	17 (27)	21 (35)	12 (43)	15 (38)	21 (40)	8 (36)	9 (29)	22 (35)	28 (29)	
Not reported	2 (3)	1 (1)	0 (0)	0 (0)	24 (26)	1 (1)	0 (0)	1 (2)	0 (0)	1 (4)	1 (3)	0 (0)	0 (0)	1 (3)	0 (0)	8 (8)	
History of other pharmacotherapy treatment (%)																	
Current	--	--	--	--	--	2 (1)	0 (0)	8 (13)	5 (8)	3 (11)	4 (10)	6 (12)	4 (18)	6 (19)	8 (13)	9 (9)	
Previous	--	--	--	--	--	14 (9)	5 (11)	7 (11)	10 (17)	4 (14)	6 (15)	17 (33)	6 (27)	6 (19)	11 (17)	27 (28)	
Never	--	--	--	--	--	143 (88)	39 (89)	47 (76)	45 (75)	21 (75)	27 (69)	29 (56)	12 (55)	18 (58)	42 (67)	61 (63)	
Not reported	--	--	--	--	--	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (5)	0 (0)	0 (0)	1 (3)	2 (3)	0 (0)	

Table 2.8 Number (percentage) of respondents by source of needle and syringe acquisition in the month prior to survey and year

ACT N° injected last month	1995 N=57	1996 N=110	1997 N=81	1998 N=132	1999 N=81	2000 N=153	2001 N=40	2002 N=55	2003 N=59	2004 N=25	2005 N=31	2006 N=45	2007 N=18	2008 N=31	2009 N=59	2010 N=87	
Needle/syringe acquisition in the last month (%) [More than one could be selected]																	
Needle Syringe Program	--	--	--	--	76 (94)	146 (95)	37 (93)	52 (95)	57 (97)	22 (88)	23 (85)	42 (93)	16 (88)	29 (94)	34 (58)	82 (94)	
Pharmacy	--	--	--	--	43 (53)	71 (46)	18 (45)	26 (47)	30 (51)	15 (60)	14 (52)	25 (56)	9 (50)	20 (65)	30 (51)	21 (24)	
Personal Sources	--	--	--	--	--	--	--	--	--	--	--	--	6 (33)	--	21 (36)	12 (14)	
Vending Machine	--	--	--	--	--	--	--	--	--	--	--	--	7 (39)	--	15 (25)	20 (23)	
Other sources	--	--	--	--	--	--	--	--	--	--	--	--	0 (0)	--	1 (2)	4 (5)	
Onward supply of syringes in last month (%)																	
Yes, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	12 (67)	--	20 (34)	32 (37)	
No, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	4 (22)	--	31 (53)	54 (62)	
Not reported	--	--	--	--	--	--	--	--	--	--	--	--	2 (11)	--	8 (14)	1 (1)	

HIV antibody prevalence

Table 2.9 HIV antibody prevalence by gender and year

ACT	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995	38	2 (5.3)	23	0 (0)	62	2 (3.2)
1996	69	1 (1.5)	55	0 (0)	125	1 (0.8)
1997	53	0 (0)	27	0 (0)	80	0 (0)
1998	87	0 (0)	50	0 (0)	137	0 (0)
1999	50	0 (0)	42	1 (2.4)	92	1 (1.1)
2000	120	0 (0)	42	0 (0)	162	0 (0)
2001	33	0 (0)	8	0 (0)	41	0 (0)
2002	33	0 (0)	21	0 (0)	61	0 (0)
2003	41	0 (0)	19	0 (0)	60	0 (0)
2004	18	0 (0)	5	0 (0)	23	0 (0)
2005	23	0 (0)	7	0 (0)	30	0 (0)
2006	30	0 (0)	18	0 (0)	49	0 (0)
2007	10	0 (0)	8	0 (0)	18	0 (0)
2008	18	0 (0)	8	0 (0)	26	0 (0)
2009	36	0 (0)	22	0 (0)	58	0 (0)
2010	72	0 (0)	25	0 (0)	97	0 (0)
χ^2 trend p value		0.024		0.706		0.036

HCV antibody prevalence

Table 2.10 HCV antibody prevalence by gender and year

ACT	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	32	18 (56)	21	14 (67)	54	33 (61)
1996	69	45 (65)	55	32 (62)	125	80 (64)
1997	53	21 (40)	27	11 (41)	80	32 (40)
1998	87	46 (53)	50	22 (44)	137	68 (50)
1999	48	30 (63)	42	24 (57)	90	54 (60)
2000	120	65 (54)	42	27 (64)	162	92 (57)
2001	33	20 (61)	8	5 (63)	41	25 (61)
2002	40	30 (75)	21	18 (86)	61	48 (79)
2003	41	30 (73)	19	18 (95)	60	48 (80)
2004	18	12 (67)	5	4 (80)	23	16 (70)
2005	24	16 (67)	7	7 (100)	31	23 (74)
2006	29	23 (79)	16	10 (63)	46	33 (72)
2007	10	10 (100)	8	6 (75)	18	16 (89)
2008	18	12 (67)	8	6 (75)	26	18 (69)
2009	36	21 (58)	22	13 (59)	58	34 (59)
2010	70	48 (69)	25	15 (60)	95	63 (66)
χ^2 trend p value		0.002		0.033		<0.001

Table 2.11 HCV antibody prevalence by sexual identity, gender and year

ACT	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Heterosexual	30	17 (57)	15	9 (60)	45	26 (58)
Bisexual	1	1 (100)	5	5 (100)	6	6 (100)
Homosexual	0	0 (0)	1	0 (0)	2	1 (50)
1996						
Heterosexual	59	40 (68)	38	26 (68)	97	66 (68)
Bisexual	4	3 (75)	11	5 (45)	15	8 (53)
Homosexual	4	3 (75)	5	2 (40)	9	5 (56)
1997						
Heterosexual	40	16 (40)	17	8 (47)	57	24 (42)
Bisexual	5	4 (80)	8	3 (38)	13	7 (54)
Homosexual	1	1 (100)	2	0 (0)	3	1 (33)
1998						
Heterosexual	79	43 (54)	38	18 (47)	117	61 (52)
Bisexual	3	2 (67)	10	4 (40)	13	6 (46)
Homosexual	1	1 (100)	1	0 (0)	2	1 (50)
1999						
Heterosexual	43	27 (63)	25	15 (60)	68	42 (62)
Bisexual	0	0 (0)	6	5 (83)	6	5 (83)
Homosexual	1	1 (100)	7	3 (43)	8	4 (50)
2000						
Heterosexual	105	59 (56)	33	20 (60)	138	79 (57)
Bisexual	5	3 (60)	7	6 (86)	12	9 (75)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
2001						
Heterosexual	30	19 (63)	6	4 (67)	36	23 (64)
Bisexual	1	0 (0)	1	0 (0)	2	0 (0)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
2002						
Heterosexual	29	24 (83)	16	14 (88)	45	38 (84)
Bisexual	3	3 (100)	3	3 (100)	6	6 (100)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
2003						
Heterosexual	33	26 (79)	10	9 (90)	43	35 (81)
Bisexual	2	2 (100)	5	5 (100)	7	7 (100)
Homosexual	4	1 (25)	1	1 (100)	5	2 (40)
2004						
Heterosexual	16	11 (69)	3	2 (67)	19	13 (68)
Bisexual	1	0 (0)	1	0 (100)	1	0 (0)
Homosexual	0	0 (0)	1	0 (100)	1	1 (100)
2005						
Heterosexual	20	14 (70)	6	6 (100)	26	20 (77)
Bisexual	1	0 (0)	1	1 (100)	2	1 (50)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
2006						
Heterosexual	28	22 (79)	10	7 (70)	38	29 (76)
Bisexual	0	0	6	3 (50)	7	3 (43)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
2007						
Heterosexual	9	9 (100)	7	5 (71)	16	14 (88)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	1	1 (100)	1	1 (100)	2	2 (100)
2008						
Heterosexual	13	8 (62)	6	4 (67)	19	12 (63)
Bisexual	2	1 (50)	0	0 (0)	2	1 (50)
Homosexual	1	1 (100)	1	1 (100)	2	2 (100)
2009						
Heterosexual	32	19 (59)	18	10 (56)	50	29 (58)
Bisexual	3	1 (33)	2	1 (50)	5	2 (40)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
2010						
Heterosexual	61	44 (72)	18	12 (67)	79	56 (71)
Bisexual	3	2 (67)	2	0 (0)	5	2 (40)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
2010 p value		0.439		0.147		0.078

Table 2.12 HCV antibody prevalence by age group, gender and year

ACT	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	7	4 (57)	4	2 (50)	11	6 (55)
25-34 years	15	8 (53)	12	8 (67)	28	17 (61)
35+ years	10	6 (60)	5	4 (80)	15	10 (67)
1996						
<25 years	16	4 (25)	17	8 (47)	33	12 (36)
25-34 years	28	20 (71)	24	15 (63)	52	35 (67)
35+ years	24	22 (92)	14	11 (79)	39	34 (87)
1997						
<25 years	32	9 (23)	16	4 (25)	48	13 (27)
25-34 years	15	7 (47)	6	3 (50)	21	10 (48)
35+ years	6	5 (83)	5	4 (80)	11	9 (82)
1998						
<25 years	36	6 (17)	27	7 (26)	63	13 (21)
25-34 years	29	20 (69)	14	6 (43)	43	26 (60)
35+ years	22	20 (91)	9	9 (100)	31	29 (94)
1999						
<25 years	22	7 (32)	19	7 (37)	41	14 (34)
25-34 years	16	13 (81)	16	10 (63)	32	23 (72)
35+ years	10	10 (100)	7	7 (100)	17	17 (100)
2000						
<25 years	43	11 (26)	21	12 (57)	64	23 (36)
25-34 years	50	31 (62)	13	9 (69)	63	40 (63)
35+ years	27	23 (85)	8	6 (75)	35	29 (83)
2001						
<25 years	8	1 (13)	4	1 (25)	12	2 (17)
25-34 years	13	8 (62)	2	2 (100)	15	10 (67)
35+ years	12	11 (92)	2	2 (100)	14	13 (93)
2002						
<25 years	5	4 (80)	9	6 (67)	14	10 (71)
25-34 years	18	13 (72)	8	8 (100)	26	21 (81)
35+ years	17	13 (76)	4	4 (100)	21	17 (81)
2003						
<25 years	4	2 (50)	6	5 (83)	10	7 (70)
25-34 years	20	14 (70)	7	7 (100)	27	21 (78)
35+ years	17	14 (82)	6	6 (100)	23	20 (87)
2004						
<25 years	2	1 (50)	3	3 (100)	5	4 (80)
25-34 years	6	3 (50)	1	1 (100)	7	4 (57)
35+ years	10	8 (80)	1	1 (100)	11	8 (73)
2005						
<25 years	5	0 (0)	1	1 (100)	6	1 (17)
25-34 years	5	4 (80)	7	7 (100)	12	11 (92)
35+ years	20	16 (80)	1	1 (100)	21	17 (81)
2006						
<25 years	3	1 (33)	3	1 (33)	6	2 (33)
25-34 years	12	9 (75)	8	5 (63)	21	14 (67)
35+ years	13	12 (92)	5	4 (80)	18	16 (89)
2007						
<25 years	1	1 (100)	4	4 (100)	5	5 (100)
25-34 years	7	7 (100)	2	1 (50)	8	8 (89)
35+ years	2	2 (100)	2	1 (50)	3	3 (75)
2008						
<25 years	1	0 (0)	1	1 (100)	2	1 (50)
25-34 years	4	2 (50)	3	3 (100)	7	5 (71)
35+ years	13	10 (77)	4	2 (50)	17	12 (71)
2009						
<25 years	8	3 (38)	5	4 (80)	13	7 (54)
25-34 years	15	12 (80)	5	3 (60)	20	15 (75)
35+ years	13	6 (46)	12	6 (50)	25	12 (48)
2010						
<25 years	3	2 (67)	0	0 (0)	3	2 (67)
25-34 years	29	19 (66)	10	6 (60)	39	25 (64)
35+ years	38	27 (71)	15	9 (60)	53	36 (68)
2010 p value		0.905		1.000		0.920

Table 2.13 HCV antibody prevalence by time since first injection, gender and year

ACT	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
<3 years	1	1 (100)	3	1 (33)	4	2 (50)
3-10 years	15	7 (47)	6	4 (67)	21	11 (52)
11+ years	16	10 (63)	12	9 (75)	29	20 (69)
1996						
<3 years	0	0 (0)	8	2 (25)	8	2 (25)
3-10 years	32	16 (50)	21	10 (48)	53	26 (49)
11+ years	28	28 (82)	24	20 (83)	59	49 (83)
1997						
<3 years	11	4 (36)	12	1 (8)	23	5 (22)
3-10 years	27	6 (22)	8	4 (50)	35	10 (29)
11+ years	12	9 (75)	7	6 (86)	19	15 (79)
1998						
<3 years	12	1 (8)	16	3 (19)	28	4 (14)
3-10 years	36	10 (28)	19	5 (26)	55	15 (27)
11+ years	38	34 (89)	15	14 (93)	53	48 (91)
1999						
<3 years	11	1 (9)	7	1 (14)	18	2 (11)
3-10 years	19	12 (63)	18	9 (50)	37	21 (57)
11+ years	17	16 (94)	16	13 (81)	33	29 (88)
2000						
<3 years	23	4 (17)	7	3 (43)	30	7 (23)
3-10 years	50	26 (52)	21	13 (62)	71	39 (55)
11+ years	45	34 (76)	12	10 (83)	57	44 (77)
2001						
<3 years	3	1 (33)	0	0 (0)	3	1 (33)
3-10 years	11	4 (36)	6	3 (50)	17	7 (41)
11+ years	18	15 (83)	2	2 (100)	20	17 (85)
2002						
<3 years	2	2 (100)	2	2 (100)	4	4 (100)
3-10 years	13	9 (69)	12	9 (75)	25	18 (72)
11+ years	23	13 (100)	7	7 (100)	30	26 (87)
2003						
<3 years	2	2 (100)	2	2 (100)	4	4 (100)
3-10 years	11	6 (55)	9	8 (89)	20	14 (70)
11+ years	28	22 (79)	8	8 (100)	36	30 (83)
2004						
<3 years	2	1 (50)	1	1 (100)	3	2 (67)
3-10 years	2	1 (50)	3	2 (67)	5	3 (60)
11+ years	14	10 (71)	1	1 (100)	15	11 (73)
2005						
<3 years	8	1 (13)	0	0 (0)	8	1 (13)
3-10 years	0	0 (0)	1	1 (100)	1	1 (100)
11+ years	16	15 (94)	6	6 (100)	22	21 (95)
2006						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3-10 years	10	7 (70)	7	4 (57)	17	11 (65)
11+ years	17	14 (82)	8	6 (75)	26	20 (77)
2007						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3-10 years	3	3 (100)	4	4 (100)	7	7 (100)
11+ years	6	6 (100)	3	1 (33)	9	7 (78)
2008						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3-10 years	4	2 (50)	1	1 (100)	5	3 (60)
11+ years	13	10 (77)	7	5 (71)	20	15 (75)
2009						
<3 years	3	0 (0)	3	2 (67)	6	2 (33)
3-10 years	12	9 (75)	3	2 (67)	15	11 (73)
11+ years	20	11 (55)	16	9 (56)	36	20 (56)
2010						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3-10 years	19	11 (58)	3	0 (0)	22	11 (50)
11+ years	48	35 (73)	22	15 (68)	70	50 (71)
2010 p value		0.140		0.052		0.051

Table 2.14 HCV antibody prevalence by drug last injected, time since first injection and year

ACT	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heroin	2	2 (100)	31	20 (65)	34	23 (68)
Methamphetamine	1	0 (0)	5	4 (80)	6	4 (67)
Other	1	0 (0)	13	6 (46)	14	6 (43)
1996						
Heroin	5	2 (40)	82	54 (66)	89	57 (64)
Methamphetamine	2	0 (0)	7	3 (43)	9	3 (33)
Other	1	0 (0)	23	18 (78)	26	20 (77)
1997						
Heroin	18	4 (22)	43	21 (49)	63	27 (43)
Methamphetamine	2	1 (50)	6	2 (33)	8	3 (38)
Other	3	0 (0)	5	2 (40)	8	2 (25)
1998						
Heroin	23	2 (9)	93	49 (53)	117	52 (44)
Methamphetamine	2	0 (0)	6	5 (83)	8	5 (63)
Other	3	2 (67)	9	9 (100)	12	11 (92)
1999						
Heroin	13	1 (8)	54	42 (78)	68	44 (65)
Methamphetamine	5	1 (20)	10	4 (40)	15	5 (33)
Other	0	0 (0)	6	4 (67)	7	5 (71)
2000						
Heroin	25	7 (28)	102	66 (65)	129	74 (57)
Methamphetamine	3	0 (0)	7	4 (57)	10	4 (40)
Other	2	0 (0)	18	13 (72)	22	14 (64)
2001						
Heroin	1	1 (100)	11	7 (64)	12	8 (67)
Methamphetamine	2	0 (0)	14	7 (50)	16	7 (44)
Other	0	0 (0)	12	10 (83)	12	10 (83)
2002						
Heroin	2	2 (100)	37	28 (76)	40	30 (75)
Methamphetamine	0	0 (0)	10	8 (80)	10	8 (80)
Other	2	2 (100)	8	8 (100)	11	10 (91)
2003						
Heroin	3	3 (100)	27	22 (81)	30	25 (83)
Methamphetamine	0	0 (0)	17	14 (82)	17	14 (82)
Other	0	0 (0)	13	9 (69)	13	9 (69)
2004						
Heroin	0	0 (0)	12	9 (75)	12	9 (75)
Methamphetamine	2	1 (50)	4	2 (50)	6	3 (50)
Other	1	1 (100)	4	3 (75)	5	4 (80)
2005						
Heroin	0	0 (0)	14	14 (100)	14	14 (100)
Methamphetamine	2	0 (0)	8	7 (88)	10	7 (70)
Other	8	1 (13)	7	7 (100)	15	8 (53)
2006						
Heroin	0	0 (0)	16	13 (81)	17	14 (82)
Methamphetamine	1	0 (0)	18	10 (56)	20	11 (55)
Other	0	0 (0)	9	8 (89)	9	8 (9)
2007						
Heroin	0	0 (0)	7	5 (71)	7	5 (71)
Methamphetamine	1	1 (100)	6	6 (100)	8	8 (100)
Other	0	0 (0)	3	3 (100)	3	3 (100)
2008						
Heroin	0	0 (0)	12	10 (83)	12	10 (83)
Methamphetamine	1	0 (0)	7	4 (57)	8	4 (50)
Other	0	0 (0)	6	4 (67)	6	4 (67)
2009						
Heroin	2	2 (100)	22	13 (59)	24	15 (63)
Methamphetamine	0	0 (0)	15	6 (40)	15	6 (40)
Other	4	0 (0)	13	11 (85)	18	12 (67)
2010						
Heroin	0	0 (0)	26	18 (69)	27	19 (70)
Methamphetamine	0	0 (0)	26	13 (50)	26	13 (50)
Other	1	0 (0)	40	30 (75)	42	31 (74)
2010 p value		--		0.105		0.120

Table 2.15 HCV antibody prevalence by frequency of injection, time since first injection and year

ACT	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Less than daily	2	2 (100)	30	21 (70)	32	23 (72)
Daily or more	1	0 (0)	9	6 (67)	11	7 (64)
Not last month	1	0 (0)	10	3 (30)	11	3 (27)
1996						
Less than daily	4	1 (25)	59	39 (66)	65	42 (65)
Daily or more	2	1 (50)	41	27 (66)	45	29 (64)
Not last month	2	0 (0)	11	8 (73)	13	8 (62)
1997						
Less than daily	9	1 (11)	23	13 (57)	32	14 (44)
Daily or more	14	4 (19)	27	9 (33)	42	14 (33)
Not last month	0	0 (0)	4	3 (75)	5	4 (80)
1998						
Less than daily	7	1 (14)	40	27 (68)	47	28 (60)
Daily or more	21	3 (14)	62	30 (48)	84	34 (40)
Not last month	0	0 (0)	6	6 (100)	6	6 (100)
1999						
Less than daily	4	0 (0)	23	20 (87)	27	20 (74)
Daily or more	11	2 (18)	37	22 (59)	50	26 (52)
Not last month	3	0 (0)	10	8 (80)	13	8 (62)
2000						
Less than daily	11	4 (36)	39	24 (62)	52	30 (58)
Daily or more	16	3 (19)	82	54 (66)	100	57 (57)
Not last month	3	0 (0)	6	5 (83)	9	5 (56)
2001						
Less than daily	2	1 (50)	26	17 (65)	28	18 (64)
Daily or more	1	0 (0)	8	5 (63)	9	5 (56)
Not last month	0	0 (0)	3	2 (67)	3	2 (67)
2002						
Less than daily	0	0 (0)	25	19 (76)	25	19 (76)
Daily or more	2	2 (100)	25	21 (84)	29	23 (79)
Not last month	2	2 (100)	5	4 (80)	7	6 (86)
2003						
Less than daily	0	0 (0)	24	16 (67)	25	17 (68)
Daily or more	3	3 (100)	30	26 (87)	34	30 (88)
Not last month	0	0 (0)	1	1 (100)	1	1 (100)
2004						
Less than daily	0	0 (0)	9	6 (67)	9	6 (67)
Daily or more	2	1 (50)	9	6 (67)	11	7 (64)
Not last month	0	0 (0)	1	1 (100)	1	1 (100)
2005						
Less than daily	1	0 (0)	14	13 (93)	15	13 (87)
Daily or more	0	0 (0)	12	12 (100)	12	12 (100)
Not last month	0	0 (0)	2	2 (100)	3	2 (67)
2006						
Less than daily	0	0 (0)	28	22 (79)	30	24 (80)
Daily or more	1	0 (0)	9	4 (44)	10	4 (40)
Not last month	0	0 (0)	6	5 (83)	6	5 (83)
2007						
Less than daily	1	1 (100)	7	6 (86)	8	7 (88)
Daily or more	0	0 (0)	6	5 (83)	7	6 (86)
Not last month	0	0 (0)	2	2 (100)	2	2 (100)
2008						
Less than daily	0	0 (0)	14	10 (71)	14	10 (71)
Daily or more	1	1 (100)	11	8 (73)	12	8 (67)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
2009						
Less than daily	1	0 (0)	19	7 (37)	20	7 (35)
Daily or more	5	2 (40)	28	21 (75)	34	24 (71)
Not last month	0	0 (0)	4	3 (75)	4	3 (75)
2010						
Less than daily	1	0 (0)	47	34 (72)	49	35 (71)
Daily or more	0	0 (0)	35	24 (69)	36	25 (69)
Not last month	0	0 (0)	8	2 (25)	8	2 (25)
2010 p value		--		0.037		0.039

Table 2.16 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, time since first injection and year

ACT	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
No receptive sharing	3	1 (33)	34	20 (59)	37	21 (57)
Receptive sharing	1	1 (100)	15	10 (67)	17	12 (71)
1996						
No receptive sharing	7	2 (29)	86	54 (63)	96	58 (60)
Receptive sharing	1	0 (0)	25	20 (80)	27	21 (78)
1997						
No receptive sharing	18	5 (28)	41	19 (46)	60	25 (42)
Receptive sharing	5	0 (0)	9	3 (33)	14	3 (21)
1998						
No receptive sharing	18	3 (17)	80	48 (60)	99	52 (53)
Receptive sharing	8	1 (13)	20	8 (40)	28	9 (32)
1999						
No receptive sharing	8	1 (13)	43	33 (77)	53	36 (68)
Receptive sharing	6	1 (17)	17	9 (53)	23	10 (43)
2000						
No receptive sharing	22	4 (18)	95	60 (63)	121	66 (55)
Receptive sharing	5	3 (60)	26	18 (69)	31	21 (68)
2001						
No receptive sharing	6	1 (33)	22	17 (77)	25	18 (72)
Receptive sharing	0	0 (0)	12	5 (42)	12	5 (42)
2002						
No receptive sharing	2	2 (100)	35	29 (83)	38	31 (82)
Receptive sharing	2	2 (100)	12	9 (75)	13	9 (69)
2003						
No receptive sharing	2	2 (100)	39	29 (74)	41	31 (76)
Receptive sharing	2	2 (100)	14	12 (86)	16	14 (88)
2004						
No receptive sharing	2	1 (50)	14	10 (71)	16	11 (69)
Receptive sharing	0	0 (0)	3	2 (67)	3	2 (67)
2005						
No receptive sharing	0	0 (0)	18	17 (94)	18	17 (94)
Receptive sharing	0	0 (0)	1	1 (100)	1	1 (100)
2006						
No receptive sharing	0	0 (0)	31	23 (74)	32	24 (75)
Receptive sharing	1	0 (0)	6	3 (50)	7	3 (43)
2007						
No receptive sharing	1	1 (100)	7	5 (71)	8	6 (75)
Receptive sharing	0	0 (0)	5	5 (100)	6	6 (100)
2008						
No receptive sharing	1	0 (0)	20	13 (65)	21	13 (62)
Receptive sharing	0	0 (0)	5	5 (100)	5	5 (100)
2009						
No receptive sharing	5	1 (20)	41	23 (56)	46	24 (52)
Receptive sharing	0	0 (0)	6	5 (83)	7	6 (86)
2010						
No receptive sharing	1	0 (0)	60	39 (65)	62	40 (65)
Receptive sharing	0	0 (0)	13	12 (92)	14	13 (93)
2010 p value		--		0.092		0.052

Table 2.17 HCV antibody prevalence by imprisonment last year, time since first injection and year

ACT	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Not imprisoned	4	2 (50)	43	26 (60)	48	29 (60)
Imprisoned	0	0 (0)	6	4 (67)	6	4 (67)
1996						
Not imprisoned	8	2 (25)	96	65 (68)	107	69 (64)
Imprisoned	0	0 (0)	11	8 (72)	12	9 (75)
1997						
Not imprisoned	22	5 (23)	41	17 (41)	65	24 (37)
Imprisoned	1	0 (0)	12	7 (58)	13	7 (54)
1998						
Not imprisoned	23	4 (17)	86	48 (56)	109	52 (48)
Imprisoned	5	0 (0)	20	15 (75)	26	16 (62)
1999						
Not imprisoned	17	2 (12)	56	40 (71)	74	43 (58)
Imprisoned	1	0 (0)	13	10 (77)	15	11 (73)
2000						
Not imprisoned	29	7 (24)	106	71 (67)	137	79 (58)
Imprisoned	1	0 (0)	21	12 (57)	23	12 (52)
2001						
Not imprisoned	3	1(33)	23	14 (61)	26	15 (58)
Imprisoned	0	0 (0)	14	10 (71)	14	10 (71)
2002						
Not imprisoned	4	4 (100)	49	38 (78)	55	42 (76)
Imprisoned	0	0 (0)	6	6 (100)	6	6 (100)
2003						
Not imprisoned	2	2 (100)	45	35 (78)	49	39 (80)
Imprisoned	1	1 (100)	10	8 (80)	11	9 (82)
2004						
Not imprisoned	2	1 (50)	14	9 (64)	17	10 (63)
Imprisoned	0	0 (0)	5	4 (80)	6	4 (80)
2005						
Not imprisoned	1	1 (100)	24	23 (96)	26	23 (88)
Imprisoned	0	0 (0)	3	3 (100)	3	3 (100)
2006						
Not imprisoned	1	0 (0)	37	26 (70)	39	27 (69)
Imprisoned	0	0 (0)	6	5 (83)	6	5 (83)
2007						
Not imprisoned	1	1 (100)	14	12 (86)	16	14 (88)
Imprisoned	0	0 (0)	1	1 (100)	1	1 (100)
2008						
Not imprisoned	1	0 (0)	20	15 (75)	21	15 (71)
Imprisoned	0	0 (0)	2	1 (50)	2	1 (50)
2009						
Not imprisoned	5	2 (40)	44	27 (61)	49	29 (59)
Imprisoned	1	0 (0)	5	3 (60)	7	4 (57)
2010						
Not imprisoned	1	0 (0)	66	43 (65)	67	43 (64)
Imprisoned	0	0 (0)	12	9 (75)	13	10 (77)
2010 p value		--		0.741		0.526

Table 2.18 HCV antibody prevalence by sex work last month, time since first injection and year

ACT	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
No sex work	3	1 (33)	47	29 (62)	51	31 (61)
Sex work	1	1 (100)	1	1 (100)	2	2 (100)
1996						
No sex work	7	2 (29)	95	63 (66)	105	67 (64)
Sex work	1	0 (0)	9	4 (44)	10	4 (40)
1997						
No sex work	20	5 (25)	49	22 (45)	71	29 (41)
Sex work	2	0 (0)	4	2 (50)	6	2 (33)
1998						
No sex work	26	4 (15)	98	59 (60)	125	64 (51)
Sex work	1	0 (0)	7	3 (43)	8	3 (38)
1999						
No sex work	17	2 (12)	63	45 (71)	82	49 (60)
Sex work	1	0 (0)	6	4 (67)	7	4 (57)
2000						
No sex work	28	6 (21)	114	71 (62)	146	79 (54)
Sex work	1	1 (100)	10	9 (90)	11	10 (91)
2001						
No sex work	3	1 (33)	36	24 (67)	39	25 (64)
Sex work	0	0 (0)	1	0 (0)	1	0 (0)
2002						
No sex work	4	4 (100)	51	40 (78)	57	44 (77)
Sex work	0	0 (0)	3	3 (100)	3	3 (100)
2003						
No sex work	3	3 (100)	50	38 (76)	54	42 (78)
Sex work	0	0 (0)	3	3 (100)	4	4 (100)
2004						
No sex work	1	0 (0)	18	12 (67)	19	12 (63)
Sex work	1	1 (100)	1	1 (100)	2	2 (100)
2005						
No sex work	1	0 (0)	27	26 (96)	29	26 (90)
Sex work	1	0 (0)	1	1 (100)	1	1 (100)
2006						
No sex work	1	0 (0)	39	31 (79)	41	32 (78)
Sex work	0	0 (0)	3	0 (0)	3	0 (0)
2007						
No sex work	1	1 (100)	14	12 (86)	16	14 (88)
Sex work	0	0 (0)	1	1 (100)	1	1 (100)
2008						
No sex work	1	0 (0)	48	30 (63)	24	16 (67)
Sex work	0	0 (0)	3	1 (33)	2	2 (100)
2009						
No sex work	6	2 (33)	48	30 (63)	55	33 (60)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
2010						
No sex work	1	0 (0)	80	53 (66)	83	55 (66)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
2010 p value		--		1.000		1.000

Table 2.19 HCV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year

ACT	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Non-Indigenous	28	16 (57)	18	11 (61)	47	28 (60)
Indigenous	3	2 (67)	2	2 (100)	5	4 (80)
1996						
Non-Indigenous	60	40 (67)	50	32 (64)	110	72 (65)
Indigenous	5	3 (60)	2	1 (50)	7	4 (57)
1997						
Non-Indigenous	50	20 (40)	26	11 (42)	76	31 (41)
Indigenous	3	1 (33)	1	0 (0)	4	1 (25)
1998						
Non-Indigenous	77	44 (57)	45	20 (44)	122	64 (52)
Indigenous	9	1 (11)	3	2 (67)	12	3 (25)
1999						
Non-Indigenous	38	27 (71)	34	17 (50)	72	44 (61)
Indigenous	8	2 (25)	8	7 (88)	16	9 (56)
2000						
Non-Indigenous	102	53 (52)	37	25 (68)	139	78 (56)
Indigenous	13	9 (69)	5	2 (40)	18	11 (61)
2001						
Non-Indigenous	31	19 (61)	7	5 (71)	38	24 (63)
Indigenous	2	1 (50)	1	0 (0)	3	1 (33)
2002						
Non-Indigenous	35	28 (80)	18	16 (89)	53	44 (83)
Indigenous	4	2 (50)	3	2 (67)	7	4 (57)
2003						
Non-Indigenous	38	29 (76)	18	17 (94)	56	46 (82)
Indigenous	3	1 (33)	1	1 (100)	4	2 (50)
2004						
Non-Indigenous	16	10 (63)	3	2 (67)	19	12 (63)
Indigenous	1	1 (100)	2	2 (100)	3	3 (100)
2005						
Non-Indigenous	23	16 (70)	8	8 (100)	31	24 (77)
Indigenous	6	4 (67)	1	1 (100)	7	5 (71)
2006						
Non-Indigenous	27	21 (78)	15	9 (60)	43	30 (70)
Indigenous	2	2 (100)	1	1 (100)	3	3 (100)
2007						
Non-Indigenous	10	10 (100)	7	6 (86)	17	16 (94)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
2008						
Non-Indigenous	13	8 (62)	7	5 (71)	20	13 (65)
Indigenous	4	3 (75)	0	0 (0)	4	3 (75)
2009						
Non-Indigenous	35	21 (60)	17	10 (59)	52	31 (60)
Indigenous	1	0 (0)	3	1 (33)	4	1 (25)
2010						
Non-Indigenous	60	43 (72)	17	12 (71)	77	55 (71)
Indigenous	9	5 (56)	8	3 (38)	17	8 (47)
2010 p value		0.439		0.194		0.085

Table 2.20 HCV antibody prevalence by country of birth, gender and year

ACT	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Australia	37	27 (73)	15	15 (100)	52	42 (81)
Other	4	3 (75)	2	2 (100)	8	6 (75)
2004						
Australia	16	11 (69)	5	4 (80)	21	15 (71)
Other	2	1 (50)	0	0 (0)	2	1 (50)
2005						
Australia	20	14 (70)	6	6 (100)	26	20 (77)
Other	4	2 (50)	1	1 (100)	5	3 (60)
2006						
Australia	27	21 (78)	13	10 (77)	40	31 (78)
Other	1	1 (100)	3	0 (0)	5	2 (40)
2007						
Australia	10	10 (100)	6	5 (83)	16	15 (94)
Other	0	0 (0)	2	1 (50)	2	1 (50)
2008						
Australia	16	11 (69)	6	4 (67)	22	15 (68)
Other	2	1 (50)	1	1 (100)	3	2 (67)
2009						
Australia	27	18 (67)	18	12 (67)	45	30 (67)
Other	9	3 (33)	4	1 (25)	13	4 (31)
2010						
Australia	65	45 (69)	23	15 (65)	88	60 (68)
Other	3	3 (100)	2	0 (0)	5	3 (60)
2010 p value		0.550		0.150		0.656

Table 2.21 HCV antibody prevalence by language spoken at home by parents, gender and year

ACT	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
English speaking	41	30 (73)	18	17 (94)	59	47 (80)
Non-English speaking	0	0 (0)	1	1 (100)	1	1 (100)
2004						
English speaking	15	10 (67)	4	3 (75)	19	13 (68)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
2005						
English speaking	17	13 (76)	7	7 (100)	24	20 (83)
Non-English speaking	7	3 (43)	0	0 (0)	7	3 (43)
2006						
English speaking	23	20 (87)	15	10 (67)	38	30 (79)
Non-English speaking	3	1 (33)	1	0 (0)	5	1 (20)
2007						
English speaking	10	10 (100)	8	6 (75)	18	16 (89)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
2008						
English speaking	18	12 (67)	7	5 (71)	25	17 (68)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
2009						
English speaking	35	21 (60)	21	13 (62)	56	34 (61)
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)
2010						
English speaking	68	46 (68)	25	15 (60)	93	61 (66)
Non-English speaking	2	2 (100)	0	0 (0)	2	2 (100)
2010 p value		1.000		--		0.548


3. NEW SOUTH WALES

Four NSP services in New South Wales (NSW) participated in the ANSPS in 1995, and all four have participated in every year between 1995 and 2010 (Kirketon Road Centre in Kings Cross; Parramatta NSP; Blacktown NSP and St George NSP which is now known as Central Access Service). A further six NSP services (K2 in Kings Cross; Mt Druitt NSP; Nimbin/Lismore NSP; REPIDU Redfern and Canterbury and South Court Primary Care in Nepean) have participated in ten or more survey years. In combination, these 10 NSP services contributed two thirds (N=7,929) of total NSW survey respondents (N=11,837) during the period 1995 to 2010. Representation of regional/rural NSP services increased in recent years, with half of the 22 participating services in 2010 located in regional/rural locations. Appendix 1 provides a detailed breakdown of site participation by state and year. NSW sample sizes ranged from 433 (in 1995) to 1,001 (in 1998). Response rates ranged between 29% (in 2002) and 66% (in 1997).

Demographic Characteristics

As observed nationally and in all other jurisdictions, around two thirds of NSW participants were male in all survey years. The majority of participants (74% to 81%) identified as heterosexual, with approximately 10% (range 8% to 13%) identifying as bisexual and 5% identifying as homosexual (range 4% to 8%). The proportion of Indigenous participants increased in NSW from 6% in 1995 to 14% in 2010 (χ^2 trend $p < 0.001$), with the increase observed in both metropolitan Sydney and rural/regional areas (6% to 13% and 9% to 16% respectively). The majority of NSW respondents were born in Australia and reported their parents spoke English at home across all survey years in which these data were collected (Table 3.1). The proportion of participants born outside Australia and those reporting that their parents spoke a language other than English at home varied over the years, largely due to site variation.

Figure 3.1 NSW: Median age and proportion young injectors by year




The median age of NSW ANSPS respondents was stable at 30-31 years between 1995 and 2002, but increased steadily in subsequent years, to a high of 39 years in 2010 (Figure 3.1). The proportion of young people (aged younger than 25 years) increased during the late 1990s, but declined significantly in later years, from 27% in 2000 to just 8% in 2010 (χ^2 trend $p < 0.001$). The median age at first injection remained stable at 18 years between 1997 and 2010 (Table 3.1).

Injecting behaviour

In NSW, heroin and methamphetamine were the two most commonly reported drugs last injected in all survey years (Figure 3.2). The proportion of participants who reported last injecting heroin increased steadily during the late 1990s to more than half the NSW samples in 1999 and 2000. Coinciding with well documented changes in heroin availability in Australia (Maher et al., 2007; Degenhardt et al., 2006; Topp et al., 2003), a dramatic and sudden decline in heroin injection was observed among NSW ANSPS respondents in 2001. More recently, the proportion of participants who reported last injecting heroin was stable at around one third of NSW samples.

Whereas less than 10% of NSW participants reported that they had last injected methamphetamine during the late 1990s, a steady increase in prevalence of recent methamphetamine injecting was observed between 2000 and 2006. Prevalence was relatively stable at between one quarter and one third of participants between 2007 and 2010.

Figure 3.2 NSW: Prevalence of heroin and methamphetamine as drug last injected by year




The prevalence among NSW participants of recent injection of methadone, cocaine and pharmaceutical opioids varied between 1995 and 2010 (Figure 3.3). In 1995, almost one in two NSW respondents reported last injecting methadone. Prevalence of methadone injecting declined over subsequent years to a low of 6% in 1999. Prevalence of methadone injecting was relatively stable at 12% to 14% between 2005 and 2009, followed by a decline to 9% in 2010.

Nationally, just 1% to 2% of ANSPS participants reported that cocaine was the drug they last injected; however, the vast majority of such reports were from NSW participants. With the exception of the period in 2001 characterised by marked changes in heroin availability, prevalence of cocaine injecting remained relatively low and stable at between 2% and 6% in NSW in all survey years.


As observed nationally and in other jurisdictions, increased reports of pharmaceutical opioid injection emerged in NSW during the 2000s, with the increase in prevalence of this class of drug emerging in NSW three years after the trend was observed nationally and in some other jurisdictions. Between 1995 and 2005 prevalence of recent pharmaceutical opioid injection was low and stable at 3% or less but increased in subsequent years (χ^2 trend $p < 0.001$), with 9% of respondents in 2010 reporting last injecting this class of drug.

Figure 3.3 NSW: Prevalence of methadone, cocaine and pharmaceutical opioids as drug last injected by year




There was a significant reduction in self-reported blood borne viral transmission risk behaviours among NSW respondents over the survey period. The proportion of respondents reporting re-use of needles and syringes (including re-use of one’s own needle/syringe) in the month preceding ANSPS participation declined from around one third to one quarter of participants between 1997 and 2003 (Figure 3.4), remaining relatively stable until 2010 (χ^2 trend $p < 0.001$). Similarly, rates of recent receptive sharing (use of someone else’s used needle/syringe) declined from around one third of participants in 1995 to between 13% and 18% for all years since 1997 (χ^2 trend $p < 0.001$). Rates of receptive sharing of ancillary equipment varied across survey years and by item type. Spoons and water were the ancillary items most commonly shared in NSW, however prevalence of receptive sharing of both items declined significantly, from 42% in 1999 to 17% in 2010 (χ^2 trend $p < 0.001$) and from 27% in 1999 to 12% in 2007 (χ^2 trend $p < 0.001$) respectively (Table 3.4).

Figure 3.4 NSW: Re-use and receptive sharing of syringes by year



There was also some variation, but an overall reduction over the survey period, in the proportion of NSW respondents who reported injecting in a public place in the month prior to survey completion (Figure 3.5). Prevalence of recent public injection increased during the late 1990s to a peak in 2000 of 60% of respondents. Prevalence has since declined by half, with around one in three respondents in 2010 reporting recent public injection (χ^2 trend $p < 0.001$).


Figure 3.5 NSW: Prevalence of public injection by year



HIV prevalence

HIV antibody prevalence in NSW has remained low at 3% or less in all survey years (Figure 3.6). HIV prevalence was highest among participants reporting male homosexual identity, who comprised between 2% and 4% of NSW samples, with prevalence among this sub-population ranging from 7% to 50% (Table 3.9).


Figure 3.6 NSW: HIV antibody prevalence by year



HCV prevalence

In NSW, HCV antibody prevalence was consistently higher than observed nationally, at 60% or more in most survey years (Table 3.10). As occurred nationally and in most other jurisdictions, HCV antibody prevalence declined in 2009 in NSW, with a further decline (to 54%) occurring in NSW in 2010 (Figure 3.7).

Figure 3.7 National and NSW: HCV antibody prevalence by year



HCV prevalence was higher in NSW among older participants (Table 3.24), respondents with a longer injection history (Table 3.25, Figure 3.8) and participants who reported last injecting heroin (Table 3.26).

Figure 3.8 NSW: HCV antibody prevalence and time since first injection by year




Table 3.1 Number (percentage) of respondents by demographic characteristic and year

NEW SOUTH WALES	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Number of sites	4	4	7	11	13	13	14	16	18	18	19	18	21	22	20	22
N° surveyed	N=433	N=499	N=682	N=1001	N=907	N=911	N=691	N=760	N=785	N=646	N=729	N=683	N=701	N=899	N=830	N=680
Response rate	40%	47%	66%	37%	41%	43%	40%	29%	39%	40%	44%	41%	37%	36%	39%	40%
Gender (%)																
Male	267 (62)	324 (65)	414 (61)	597 (60)	575 (63)	570 (63)	430 (62)	485 (64)	543 (69)	436 (67)	464 (64)	434 (64)	450 (64)	582(65)	500 (60)	427 (63)
Female	159 (37)	170 (34)	267 (39)	398 (40)	326 (36)	336 (37)	252 (36)	267 (35)	233 (30)	205 (32)	259 (36)	242 (35)	247 (35)	310 (34)	322 (39)	247 (36)
Transgender	2 (<1)	1 (<1)	11 (<1)	3 (<1)	5 (1)	2 (<1)	5 (1)	6 (1)	4 (<1)	2 (<1)	6 (1)	6 (<1)	3 (<1)	4 (<1)	7 (<1)	5 (1)
Not reported	5 (1)	4 (1)	0 (0)	3 (<1)	1 (<1)	3 (<1)	4 (1)	2 (<1)	5 (<1)	3 (<1)	0 (0)	1 (<1)	1 (<1)	3 (<1)	1 (<1)	1 (<1)
Sexual identity (%)																
Heterosexual	352 (81)	380 (76)	529 (78)	808 (81)	671 (74)	693 (76)	536 (78)	578 (76)	610 (78)	523 (81)	590 (81)	553 (81)	575 (82)	715 (80)	669 (81)	545 (80)
Bisexual	44 (10)	53 (11)	78 (11)	92 (9)	116 (13)	93 (10)	77 (11)	83 (11)	66 (8)	49 (8)	58 (8)	65 (10)	64 (9)	93 (10)	77 (9)	76 (11)
Homosexual	24 (6)	39 (8)	47 (7)	44 (4)	38 (4)	54 (6)	31 (4)	38 (5)	38 (5)	27 (4)	48 (7)	45 (7)	45 (6)	56 (6)	40 (5)	25 (4)
Not reported	13 (3)	27 (5)	28 (4)	57 (6)	82 (9)	71 (8)	47 (7)	61 (8)	71 (9)	47 (7)	33 (5)	20 (3)	17 (2)	35 (4)	44 (5)	34 (5)
Age and time since first injection (years)																
<i>Median age</i>	31	31	31	30	30	30	30	30	32	33	34	36	37	37	38	39
<i>Age range</i>	17-54	15-59	15-58	15-63	16-69	15-61	16-62	16 - 63	15-64	16-65	17-66	15-65	16 - 69	17-70	18-64	18-69
<i>Age group (%)</i>																
< 25 years	84 (19)	96 (19)	154 (23)	283 (28)	223 (25)	247 (27)	168 (24)	169 (22)	163 (21)	106 (16)	89 (12)	61 (9)	59 (8)	81 (9)	66 (8)	54 (8)
25+ years	344 (79)	402 (81)	528 (77)	717 (72)	683 (75)	664 (73)	521 (75)	590 (78)	622 (79)	539 (83)	640 (88)	619 (91)	642 (92)	815 (91)	764 (92)	626 (92)
Not reported	5 (1)	1 (<1)	0 (0)	1 (<1)	1 (<1)	0 (0)	2 (<1)	2 (<1)	0 (0)	1 (<1)	0 (0)	3 (<1)	0 (0)	3 (<1)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	17	17	18	18	18	18	18	18	18	18	18	18	18	18	18	18
<i>Age range</i>	10-40	11-48	10-49	10-46	10-55	10-54	10-52	10-59	10-50	10-50	10-55	10-52	10-56	10-60	10-57	10-63
N° not reported	6	18	20	24	19	23	22	26	21	14	26	3	21	18	17	22
<i>Median years IDU</i>	13	12	11	10	10	9	10	10	11	12	13	15	16	17	17	18
<i>Range</i>	<1-33	<1-34	<1-37	<1-37	<1-35	<1-41	<1-44	<1-43	<1-45	<1-45	<1-46	<1-43	<1-49	<1-48	<1-45	<1-45
<i>Time since first injection</i>																
<3 years	24 (6)	44 (9)	57 (8)	135 (8)	122 (13)	118 (13)	90 (13)	78 (10)	74 (9)	47 (7)	60 (8)	31 (5)	23 (3)	46 (5)	47 (6)	48 (7)
3+ years	400 (92)	435 (87)	603 (88)	841 (84)	753 (83)	760 (83)	573 (83)	654 (86)	690 (88)	585 (91)	642 (88)	625 (92)	657 (94)	835 (93)	766 (92)	610 (90)
Not reported	9 (2)	20 (4)	22 (3)	22 (3)	32 (4)	33 (4)	28 (4)	29 (4)	21 (3)	14 (2)	27 (4)	27 (4)	21 (3)	18 (2)	17 (2)	22 (3)

Table 3.1 Number (percentage) of respondents by demographic characteristic and year (continued)

NEW SOUTH WALES	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=433	N=499	N=682	N=1001	N=907	N=911	N=691	N=760	N=785	N=646	N=729	N=683	N=701	N=899	N=830	N=680
Aboriginal and Torres Strait Islander origin (%)																
No	390 (91)	417 (83)	620 (91)	888 (89)	793 (87)	798 (88)	606 (88)	652 (86)	677 (86)	546 (84)	590 (81)	571 (84)	575 (82)	736 (82)	682 (82)	565 (83)
Yes	28 (6)	34 (7)	46 (7)	80 (8)	80 (9)	93 (10)	63 (9)	76 (10)	91 (12)	81 (13)	115 (16)	87 (13)	105 (15)	131 (15)	122 (15)	96 (14)
Not reported	15 (3)	48 (10)	16 (2)	33 (3)	34 (4)	20 (2)	22 (3)	32 (4)	17 (2)	19 (3)	24 (3)	25 (4)	21 (3)	32 (4)	26 (3)	19 (3)
Region/country of birth (%)																
Australia	--	--	--	--	775 (86)	691 (76)	352 (51)	542 (51)	547 (70)	454 (70)	628 (86)	575 (84)	592 (84)	781 (87)	726 (87)	581 (85)
Other Oceania	--	--	--	--	--	42 (5)	17 (2)	18 (2)	33 (4)	16 (2)	25 (3)	29 (4)	18 (3)	31 (3)	18 (2)	24 (4)
Asia	--	--	--	--	22 (2)	72 (8)	75 (11)	92 (12)	131 (17)	114 (18)	4 (1)	5 (<1)	10 (1)	8 (1)	4 (<1)	10 (1)
UK & Ireland	--	--	--	--	--	34 (3)	17 (2)	26 (4)	27 (3)	17 (3)	31 (4)	35 (5)	26 (4)	38 (4)	37 (4)	23 (3)
Other	--	--	--	--	75 (8)	42 (5)	28 (4)	33 (4)	42 (5)	31 (5)	33 (5)	28 (4)	38 (5)	28 (3)	28 (3)	24 (4)
Not reported	--	--	--	--	35 (4)	30 (3)	202 (30)	50 (7)	5 (1)	14 (2)	8 (1)	11 (2)	17 (2)	13 (1)	17 (2)	18 (3)
Main language spoken at home by parents (%)																
English	--	--	--	--	773 (85)	739 (81)	517 (75)	576 (76)	553 (70)	344 (53)	629 (86)	593 (87)	648 (92)	844 (94)	787 (95)	645 (95)
Non-English	--	--	--	--	87 (10)	137 (15)	156 (22)	159 (21)	197 (25)	143 (22)	100 (14)	60 (9)	37 (5)	40 (4)	33 (4)	23 (3)
Not reported	--	--	--	--	47 (5)	35 (4)	18 (3)	25 (3)	35 (4)	159 (25)	0	30 (4)	16 (2)	15 (2)	10 (1)	12 (2)
Imprisonment last year (%)																
No	335 (77)	384 (77)	543 (80)	746 (74)	721 (79)	671 (74)	520 (75)	582 (77)	599 (76)	493 (76)	568 (78)	556 (81)	566 (81)	687 (76)	684 (82)	492 (72)
Yes	93 (21)	94 (19)	137 (20)	240 (24)	170 (19)	211 (23)	147 (21)	160 (21)	169 (22)	148 (23)	130 (18)	94 (14)	103 (15)	137 (15)	103 (12)	77 (11)
Not reported	5 (1)	21 (4)	2 (<1)	15 (2)	16 (2)	29 (3)	24 (4)	18 (2)	17 (2)	5 (1)	31 (4)	33 (5)	32 (5)	75 (8)	43 (5)	111 (16)
Injected in prison last year (%)																
N° in prison	N=93	N=94	N=137	N=240	N=170	N=211	N=147	N=160	N=169	N=148	N=130	N=94	N=103	N=137	N=103	N=77
Injected in prison	33 (35)	40 (43)	49 (36)	110 (46)	80 (47)	99 (47)	58 (39)	61 (38)	60 (36)	67 (45)	38 (29)	40 (43)	37 (36)	46 (34)	30 (29)	20 (26)
Frequency of injection last month (%)																
Not last month	23 (5)	28 (6)	44 (6)	52 (5)	60 (7)	45 (5)	83 (12)	86 (11)	84 (11)	40 (6)	71 (10)	88 (13)	81 (12)	126 (14)	129 (16)	119 (18)
Less than weekly	71 (16)	83 (17)	169 (25)	90 (9)	115 (13)	85 (9)	107 (15)	108 (14)	160 (20)	118 (18)	121 (17)	131 (19)	136 (19)	146 (16)	150 (18)	128 (19)
Weekly not daily	146	165 (33)	93 (14)	197 (20)	178 (20)	182 (20)	150 (22)	162 (21)	168 (21)	167 (26)	176 (24)	169 (25)	167 (24)	229 (25)	200 (24)	134 (20)
Daily or more	191	219 (44)	369 (54)	660 (66)	548 (60)	585 (64)	336 (49)	393 (53)	359 (46)	312 (48)	357 (49)	285 (42)	298 (43)	392 (44)	337 (41)	284 (42)
Not reported	2 (<1)	4 (1)	7 (1)	2 (<1)	6 (1)	14 (2)	15 (2)	11 (1)	14 (2)	9 (2)	4 (1)	10 (1)	19 (3)	6 (1)	14 (2)	15 (2)

Table 3.2 Number (percentage) of respondents by last drug injected and year

NEW SOUTH WALES N° surveyed	1995 N=433	1996 N=499	1997 N=682	1998 N=1001	1999 N=907	2000 N=911	2001 N=691	2002 N=760	2003 N=785	2004 N=646	2005 N=729	2006 N=683	2007 N=701	2008 N=899	2009 N=830	2010 N=680	
Last drug injected (%)																	
Anabolic steroids	3 (1)	8 (2)	11 (2)	16 (2)	24 (3)	12 (1)	14 (2)	17 (2)	37 (5)	11 (2)	20 (3)	16 (2)	12 (2)	20 (2)	30 (4)	29 (4)	
Cocaine	15 (3)	26 (5)	31 (5)	55 (5)	52 (6)	25 (3)	146 (21)	26 (3)	17 (2)	41 (6)	45 (6)	36 (5)	30 (4)	45 (5)	51 (6)	19 (3)	
Heroin	136 (31)	196 (39)	318 (46)	483 (48)	534 (59)	534 (59)	221 (32)	367 (48)	416 (53)	320 (50)	296 (41)	231 (34)	254 (36)	346 (39)	306 (37)	236 (35)	
Methadone	183 (42)	141 (28)	168 (24)	182 (18)	54 (6)	65 (7)	56 (8)	66 (9)	66 (8)	50 (8)	105 (14)	96 (14)	88 (13)	107 (12)	116 (14)	59 (9)	
Methamphetamine	35 (8)	44 (9)	59 (9)	74 (7)	110 (12)	113 (12)	115 (16)	173 (23)	140 (18)	148 (23)	183 (25)	197 (29)	185 (26)	230 (26)	181 (22)	201 (30)	
Pharm. opioids	3 (1)	8 (2)	1 (<1)	5 (1)	3 (<1)	5 (1)	4 (1)	14 (2)	16 (2)	21 (3)	24 (3)	49 (7)	57 (8)	80 (9)	80 (10)	62 (9)	
Buprenorphine	--	--	--	--	--	--	--	0 (0)	1 (<1)	3 (<1)	2 (<1)	16 (2)	20 (3)	27 (3)	16 (2)	16 (2)	
More than one	56 (13)	72 (14)	85 (12)	174 (17)	120 (13)	138 (15)	110 (16)	82 (11)	47 (6)	33 (5)	11 (2)	9 (<1)	26 (4)	21 (2)	23 (3)	36 (5)	
Other	0 (0)	6 (1)	4 (1)	5 (<1)	4 (<1)	9 (1)	11 (1)	5 (<1)	11 (1)	6 (1)	5 (<1)	4 (<1)	18 (3)	8 (1)	22 (3)	18 (3)	
Not reported	2 (<1)	1 (<1)	5 (1)	7 (1)	8 (1)	11 (1)	14 (2)	10 (1)	14 (2)	7 (1)	25 (3)	20 (3)	11 (2)	15 (2)	21 (3)	4 (<1)	

Table 3.3 Number (percentage) of respondents by places injected in the last month and year

NEW SOUTH WALES N° injected last month	1995 N=408	1996 N=467	1997 N=631	1998 N=947	1999 N=841	2000 N=852	2001 N=593	2002 N=667	2003 N=687	2004 N=597	2005 N=654	2006 N=585	2007 N=601	2008 N=767	2009 N=687	2010 N=548	
Places injected in the last month (%) [more than one could be selected]																	
<i>Private places</i>																	
Own home	--	--	539 (85)	800 (84)	676 (80)	676 (79)	457 (77)	530 (80)	522 (76)	474 (79)	520 (80)	506 (90)	517 (88)	673 (89)	610 (90)	465 (85)	
Friend's home	--	--	257 (41)	363 (38)	331 (39)	352 (41)	243 (41)	236 (36)	239 (35)	201 (34)	228 (35)	219 (39)	226 (39)	316 (42)	244 (36)	205 (37)	
Dealer's home	--	--	85 (13)	157 (17)	141 (17)	141 (17)	81 (14)	85 (13)	85 (12)	68 (11)	100 (15)	84 (15)	101 (17)	120 (16)	94 (14)	73 (13)	
MSIC	--	--	--	--	--	--	64 (11)	73 (11)	30 (4)	43 (7)	42 (6)	59 (11)	62 (11)	64 (8)	60 (9)	38 (7)	
Commercial injecting room	--	--	85 (13)	111 (12)	64 (8)	50 (6)	58 (10)	46 (7)	63 (9)	29 (5)	42 (6)	38 (7)	39 (7)	40 (5)	42 (6)	28 (5)	
<i>Public places</i>																	
Street, park, beach	--	--	177 (28)	305 (32)	296 (35)	346 (41)	191 (32)	195 (29)	177 (26)	129 (22)	160 (24)	126 (22)	143 (24)	165 (22)	130 (19)	82 (15)	
Car	--	--	--	271 (30)	291 (35)	303 (36)	175 (30)	174 (26)	170 (25)	136 (23)	157 (24)	144 (26)	159 (27)	181 (24)	158 (23)	117 (21)	
Public toilet	--	--	158 (25)	241 (25)	265 (32)	307 (36)	177 (30)	171 (26)	137 (20)	110 (18)	134 (20)	110 (20)	137 (23)	163 (22)	126 (19)	86 (16)	
Squat	--	--	--	--	76 (9)	120 (14)	73 (12)	57 (9)	55 (8)	35 (6)	24 (4)	41 (7)	39 (7)	50 (7)	32 (5)	25 (5)	
Public injecting in last month (%)																	
Any public	--	--	237 (38)	465 (49)	471 (56)	512 (60)	310 (52)	325 (49)	309 (45)	218 (36)	265 (41)	235 (40)	268 (46)	308 (40)	249 (36)	176 (32)	
All private	--	--	362 (57)	433 (46)	317 (38)	294 (35)	282 (48)	320 (48)	348 (51)	338 (51)	337 (52)	326 (56)	317 (53)	446 (58)	430 (63)	331 (60)	
Not reported	--	--	32 (5)	49 (5)	53 (6)	46 (5)	1 (<1)	23 (3)	30 (4)	42 (7)	49 (8)	24 (4)	16 (3)	13 (1)	8 (1)	41 (7)	

Table 3.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

NEW SOUTH WALES	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=408	N=467	N=631	N=947	N=841	N=852	N=593	N=667	N=687	N=597	N=654	N=585	N=601	N=767	N=687	N=548
Use of sterile needles and syringes last month (%)																
All injections	--	--	412 (61)	593 (59)	527 (58)	537 (59)	393 (66)	453 (68)	509 (74)	416 (70)	472 (72)	407 (70)	431 (72)	544 (71)	500 (73)	368 (67)
Most of the time	--	--	175 (26)	249 (25)	234 (26)	248 (27)	157 (27)	148 (23)	138 (20)	137 (23)	146 (22)	129 (22)	130 (22)	174 (23)	157 (23)	108 (20)
Half of the time	--	--	16 (2)	26 (3)	36 (4)	31 (3)	16 (3)	22 (3)	13 (2)	10 (2)	15 (2)	12 (2)	17 (3)	22 (3)	10 (1)	14 (3)
Some of the time	--	--	9 (1)	44 (4)	13 (1)	19 (2)	12 (2)	14 (2)	12 (2)	18 (3)	6 (1)	12 (2)	9 (2)	11 (1)	9 (1)	11 (2)
Not last month	--	--	0 (0)	2 (<1)	3 (<1)	6 (1)	2 (<1)	12 (2)	4 (<1)	4 (<1)	1 (<1)	11 (2)	0 (0)	7 (1)	2 (<1)	6 (1)
Not reported	--	--	70 (10)	87 (9)	94 (10)	70 (8)	13 (2)	14 (2)	11 (1)	12 (2)	14 (2)	16 (3)	14 (2)	9 (1)	9 (1)	41 (7)
Re-used someone else's used needle & syringe last month (%)																
None	266 (65)	319 (68)	510 (81)	736 (78)	623 (74)	667 (78)	481 (81)	519 (78)	561 (82)	473 (79)	532 (82)	477 (82)	485 (81)	604 (79)	560 (82)	400 (73)
Once	39 (10)	54 (12)	27 (4)	56 (6)	60 (7)	60 (7)	33 (6)	39 (6)	39 (6)	41 (7)	26 (4)	31 (5)	42 (7)	50 (7)	44 (6)	33 (6)
Twice	52 (13)	52 (11)	24 (3)	54 (6)	38 (5)	37 (5)	12 (2)	30 (5)	23 (3)	28 (5)	24 (4)	20 (3)	19 (3)	42 (5)	33 (5)	19 (3)
3-5 times	29 (7)	22 (5)	16 (3)	49 (5)	28 (3)	43 (5)	26 (4)	20 (3)	29 (4)	27 (4)	26 (4)	17 (3)	17 (3)	26 (3)	18 (3)	16 (3)
> 5 times	22 (5)	18 (4)	16 (3)	20 (2)	27 (3)	16 (2)	19 (3)	17 (3)	14 (2)	10 (2)	16 (2)	14 (2)	6 (1)	22 (3)	17 (2)	15 (3)
Not reported	0 (0)	2 (1)	38 (6)	32 (3)	65 (8)	29 (3)	22 (4)	37 (6)	21 (3)	18 (3)	28 (4)	26 (4)	32 (5)	23 (3)	15 (2)	65 (12)
Number of people needle & syringe was re-used after last month (%)																
None	266 (65)	319 (68)	510 (81)	736 (78)	623 (74)	667 (78)	481 (81)	519 (78)	551 (80)	473 (79)	504 (77)	477 (82)	485 (81)	604 (79)	560 (82)	400 (73)
One	99 (24)	102 (22)	83 (13)	136 (14)	139 (17)	119 (14)	52 (9)	65 (10)	66 (10)	58 (10)	65 (10)	43 (7)	42 (7)	66 (9)	53 (8)	33 (6)
Two	34 (8)	38 (8)	14 (2)	30 (3)	23 (3)	16 (2)	10 (2)	12 (2)	7 (1)	10 (2)	5 (1)	7 (1)	7 (1)	11 (1)	6 (1)	7 (1)
Three to five	3 (1)	0 (0)	2 (<1)	8 (1)	11 (1)	8 (1)	5 (1)	5 (1)	8 (1)	3 (<1)	5 (1)	2 (<1)	5 (<1)	10 (1)	3 (<1)	8 (1)
More than five	5 (1)	6 (1)	4 (1)	4 (1)	10 (1)	9 (1)	8 (1)	8 (1)	5 (<1)	3 (<1)	3 (<1)	2 (<1)	2 (<1)	3 (<1)	2 (<1)	4 (<1)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	4 (<1)	4 (1)	4 (1)	19 (3)	9 (1)	13 (2)	28 (4)	16 (3)	12 (2)	30 (4)	18 (3)	11 (2)
Not reported	1 (1)	2 (1)	18 (3)	32 (3)	31 (4)	29 (3)	33 (5)	35 (5)	41 (6)	37 (6)	44 (7)	38 (7)	48 (8)	43 (6)	45 (7)	85 (16)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]																
Regular sex partner	--	--	60 (10)	88 (9)	101 (12)	81 (10)	45 (8)	53 (8)	50 (7)	43 (7)	60 (9)	30 (5)	36 (6)	56 (7)	39 (6)	53 (10)
Casual sex partner	--	--	4 (1)	10 (1)	12 (1)	6 (1)	8 (1)	4 (1)	7 (1)	4 (1)	3 (<1)	5 (<1)	2 (<1)	7 (1)	3 (<1)	6 (1)
Close friend	--	--	23 (4)	60 (6)	70 (8)	50 (6)	23 (4)	36 (5)	31 (5)	24 (4)	29 (4)	15 (3)	27 (4)	39 (5)	16 (2)	23 (4)
Acquaintance	--	--	7 (1)	25 (3)	16 (2)	19 (2)	12 (2)	11 (2)	13 (2)	16 (3)	10 (2)	12 (2)	12 (2)	12 (2)	13 (2)	11 (2)
Other	--	--	3 (<1)	8 (1)	11 (1)	11 (1)	2 (<1)	8 (1)	6 (1)	6 (1)	4 (1)	4 (<1)	4 (<1)	8 (1)	11 (2)	13 (2)

Table 3.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

NEW SOUTH WALES N° injected last month	1995 N=408	1996 N=467	1997 N=631	1998 N=947	1999 N=841	2000 N=852	2001 N=593	2002 N=667	2003 N=687	2004 N=597	2005 N=654	2006 N=585	2007 N=601	2008 N=767	2009 N=687	2010 N=548	
Equipment used after someone else last month (%)[more than one could be selected]																	
Spoon	--	--	--	--	352 (42)	293 (34)	192 (32)	174 (26)	211 (31)	181 (30)	152 (23)	114 (20)	134 (25)	160 (23)	127 (20)	93 (17)	
Water	--	--	--	--	223 (27)	193 (23)	140 (24)	138 (21)	147 (21)	125 (21)	107 (16)	68 (12)	101 (19)	114 (16)	81 (13)	64 (12)	
Filter	--	--	--	--	172 (20)	147 (17)	98 (17)	102 (15)	121 (18)	89 (15)	66 (10)	36 (6)	62 (11)	78 (11)	52 (8)	36 (7)	
Drug mix	--	--	--	--	120 (14)	110 (13)	79 (13)	95 (14)	87 (13)	59 (10)	67 (10)	45 (8)	45 (8)	50 (7)	52 (8)	29 (5)	
Tourniquet	--	--	--	--	135 (16)	87 (10)	85 (14)	72 (11)	70 (10)	67 (11)	71 (11)	47 (8)	58 (11)	74 (11)	57 (9)	--	
None	--	--	--	--	--	--	--	--	--	--	--	358 (62)	353 (65)	457 (66)	420 (68)	370 (68)	
Injected by someone after that person injected themselves or others last month (%)																	
No	--	--	--	--	676 (80)	666 (78)	444 (75)	511 (77)	574 (84)	502 (84)	528 (81)	497 (85)	494 (82)	631 (82)	592 (86)	432 (79)	
Yes	--	--	--	--	124 (15)	146 (17)	122 (21)	123 (19)	92 (13)	72 (12)	87 (13)	60 (10)	77 (13)	110 (14)	76 (11)	52 (9)	
Not reported	--	--	--	--	41 (5)	40 (5)	27 (4)	29 (4)	21 (3)	23 (4)	41 (6)	28 (5)	30 (5)	26 (3)	19 (3)	64 (12)	

Table 3.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

NEW SOUTH WALES N° surveyed	1995 N=433	1996 N=499	1997 N=682	1998 N=1001	1999 N=907	2000 N=911	2001 N=691	2002 N=760	2003 N=785	2004 N=646	2005 N=729	2006 N=683	2007 N=701	2008 N=899	2009 N=830	2010 N=680	
Sex with a regular partner last month (%)																	
No	--	--	--	--	--	--	--	--	--	--	314 (43)	288 (42)	300 (43)	392 (44)	369 (44)	280 (41)	
Yes	--	--	--	--	--	--	--	--	--	--	397 (54)	376 (55)	375 (54)	481 (54)	439 (53)	370 (54)	
Not reported	--	--	--	--	--	--	--	--	--	--	18 (2)	19 (3)	26 (4)	26 (3)	22 (3)	30 (4)	
Condom used with regular partner last month (%)																	
Never	--	--	--	--	--	--	--	--	--	--	N=397	N=376	N=375	N=481	N=439	N=370	
Sometimes	--	--	--	--	--	--	--	--	--	--	277 (70)	259 (69)	275 (73)	330 (69)	378 (86)	273 (74)	
Every time	--	--	--	--	--	--	--	--	--	--	59 (15)	51 (14)	38 (10)	61 (13)	43 (10)	42 (11)	
Not reported	--	--	--	--	--	--	--	--	--	--	46 (12)	28 (7)	49 (13)	69 (14)	2 (<1)	35 (9)	
Sex with other partner(s) last month (%)																	
No	--	--	--	--	--	--	--	--	--	--	15 (4)	38 (10)	13 (3)	21 (4)	16 (4)	20 (5)	
Yes	--	--	--	--	--	--	--	--	--	--	583 (80)	525 (77)	570 (81)	705 (78)	665 (80)	532 (78)	
Not reported	--	--	--	--	--	--	--	--	--	--	125 (17)	124 (18)	100 (14)	165 (18)	126 (15)	103 (15)	
	--	--	--	--	--	--	--	--	--	--	21 (3)	34 (5)	31 (4)	29 (3)	39 (5)	45 (7)	

Table 3.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

NEW SOUTH WALES	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=433	N=499	N=682	N=1001	N=907	N=911	N=691	N=760	N=785	N=646	N=729	N=683	N=701	N=899	N=830	N=680
Condom used with other partner(s) last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=125	N=124	N=100	N=165	N=126	N=103
Sometimes	--	--	--	--	--	--	--	--	--	--	31 (25)	26 (21)	28 (28)	38 (23)	47 (37)	44 (43)
Every time	--	--	--	--	--	--	--	--	--	--	34 (27)	38 (31)	17 (17)	39 (24)	22 (17)	17 (17)
Not reported	--	--	--	--	--	--	--	--	--	--	56 (45)	53 (43)	47 (47)	79 (48)	55 (44)	39 (38)
											4 (3)	7 (6)	8 (8)	9 (5)	2 (2)	3 (3)
Sex last month (%)																
No	97 (22)	128 (26)	250 (37)	352 (35)	291 (32)	347 (38)	231 (33)	224 (30)	216 (28)	204 (31)	--	--	--	--	--	--
Yes	307 (71)	357 (71)	431 (63)	637 (64)	609 (67)	553 (61)	448 (65)	515 (67)	558 (71)	431 (67)	--	--	--	--	--	--
Not reported	29 (7)	14 (3)	1 (<1)	12 (1)	7 (1)	11 (1)	12 (2)	21 (3)	11 (1)	11 (2)	--	--	--	--	--	--
Condom use at last sex (%)																
No	259 (60)	236 (48)	441 (65)	658 (66)	531 (58)	525 (58)	435 (63)	459 (60)	504 (64)	413 (67)	--	--	--	--	--	--
Yes	107 (25)	107 (21)	225 (33)	315 (31)	344 (38)	350 (38)	235 (34)	279 (37)	261 (33)	220 (34)	--	--	--	--	--	--
Not reported	67 (15)	156 (31)	16 (2)	28 (3)	32 (4)	36 (4)	21 (3)	22 (3)	20 (3)	13 (2)	--	--	--	--	--	--
Condom use with regular sex partner(s) last month (%)																
No	--	233 (73)	257 (64)	357 (66)	333 (64)	296 (64)	189 (62)	209 (59)	225 (62)	177 (68)	--	--	--	--	--	--
Sometimes	--	26 (8)	46 (12)	71 (13)	58 (11)	43 (9)	49 (16)	54 (15)	46 (13)	32 (12)	--	--	--	--	--	--
Always	--	60 (19)	95 (24)	113 (21)	127 (25)	124 (27)	69 (22)	90 (26)	91 (25)	52 (20)	--	--	--	--	--	--
Condom use with new sex partner(s) last month (%)																
No	--	43 (33)	57 (31)	51 (31)	85 (33)	66 (32)	95 (39)	93 (36)	85 (39)	80 (46)	--	--	--	--	--	--
Sometimes	--	14 (11)	23 (12)	26 (16)	37 (14)	23 (11)	46 (19)	36 (14)	34 (16)	29 (17)	--	--	--	--	--	--
Always	--	72 (56)	107 (57)	86 (53)	134 (53)	117 (57)	105 (42)	129 (50)	98 (45)	64 (37)	--	--	--	--	--	--
Condom use with casual sex partner(s) last month (%)																
No	--	--	--	58 (28)	83 (29)	71 (29)	93 (42)	86 (36)	108 (47)	63 (39)	--	--	--	--	--	--
Sometimes	--	--	--	34 (17)	60 (21)	31 (13)	47 (21)	54 (23)	33 (14)	31 (19)	--	--	--	--	--	--
Always	--	--	--	114 (55)	147 (50)	142 (58)	83 (37)	100 (41)	91 (39)	68 (42)	--	--	--	--	--	--
Sex work last month (%)																
No	393 (91)	414 (83)	592 (87)	890 (89)	771 (85)	775 (85)	577 (84)	647 (85)	693 (88)	568 (88)	660 (91)	586 (86)	618 (88)	771 (86)	740 (89)	568 (84)
Yes	27 (6)	52 (10)	74 (11)	84 (8)	110 (12)	105 (12)	85 (12)	85 (11)	62 (8)	65 (10)	52 (7)	59 (9)	50 (7)	78 (9)	57 (7)	51 (8)
Not reported	13 (3)	33 (7)	16 (2)	27 (3)	26 (3)	31 (3)	29 (4)	28 (4)	30 (4)	13 (2)	17 (2)	38 (6)	33 (5)	50 (6)	33 (4)	61 (9)
Condom used at last sex work (%)																
Yes	23 (100)	46 (94)	59 (95)	73 (94)	98 (93)	72 (94)	53 (91)	57 (95)	50 (89)	59 (94)	72 (94)	49 (88)	47 (98)	57 (84)	52 (91)	39 (80)

Table 3.6 Number (percentage) of respondents by previous testing for HIV, HBV, HCV infection, HBV vaccination and HCV treatment by year

NEW SOUTH WALES	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=433	N=499	N=682	N=1001	N=907	N=911	N=691	N=760	N=785	N=646	N=729	N=683	N=701	N=899	N=830	N=680
Previous HIV test (%)																
Yes, last year	319 (74)	398 (80)	536 (79)	797 (80)	604 (67)	618 (68)	437 (63)	491 (65)	501 (64)	411 (64)	436 (60)	409 (60)	392 (56)	443 (49)	423 (51)	337 (50)
> 1 year ago	79 (18)	85 (17)	118 (17)	185 (18)	197 (22)	182 (20)	163 (24)	168 (22)	199 (25)	176 (27)	226 (31)	199 (29)	228 (33)	334 (37)	304 (37)	227 (33)
Never tested	30 (7)	14 (3)	23 (3)	9 (1)	92 (10)	98 (11)	78 (11)	90 (12)	81 (10)	54 (8)	64 (9)	60 (9)	65 (9)	73 (8)	69 (8)	69 (10)
Not reported	5 (1)	2 (<1)	5 (1)	10 (1)	14 (1)	13 (1)	13 (2)	11 (1)	4 (<1)	5 (1)	3 (0)	15 (2)	16 (2)	49 (5)	34 (4)	47 (7)
Self report HBV infection (%)																
No	252 (58)	300 (60)	399 (59)	573 (57)	633 (70)	595 (65)	426 (62)	493 (65)	523 (67)	425 (66)	477 (65)	430 (63)	445 (63)	--	--	--
Yes	176 (41)	194 (39)	192 (28)	253 (25)	193 (21)	201 (22)	153 (22)	161 (21)	187 (24)	148 (23)	151 (21)	150 (22)	162 (23)	--	--	--
Don't know	--	--	88 (13)	154 (15)	65 (7)	101 (11)	98 (14)	94 (12)	74 (9)	61 (9)	89 (12)	88 (13)	76 (11)	--	--	--
Not reported	5 (1)	5 (1)	3 (<1)	21 (2)	16 (2)	14 (2)	14 (2)	12 (2)	1 (<1)	12 (2)	12 (2)	15 (2)	18 (3)	--	--	--
Self report HBV vaccination (%)																
No	240 (55)	263 (53)	303 (44)	392 (39)	390 (43)	350 (38)	239 (35)	287 (38)	321 (41)	253 (39)	230 (32)	246 (36)	235 (34)	--	--	--
Yes	176 (41)	222 (45)	274 (40)	418 (42)	413 (46)	432 (47)	311 (45)	374 (49)	376 (48)	325 (50)	380 (52)	329 (48)	370 (53)	--	--	--
Don't know	--	--	98 (14)	157 (16)	85 (9)	103 (11)	93 (13)	78 (10)	69 (9)	53 (8)	102 (14)	84 (12)	75 (11)	--	--	--
Not reported	17 (4)	14 (3)	7 (1)	34 (3)	19 (2)	26 (3)	48 (7)	22 (3)	19 (2)	15 (2)	17 (2)	24 (4)	21 (3)	--	--	--
Previous HCV test (%)																
Yes, ever	365 (84)	443 (89)	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Yes, last year	--	--	528 (77)	694 (69)	610 (67)	667 (73)	479 (69)	510 (68)	492 (63)	429 (66)	452 (62)	420 (61)	420 (60)	494 (55)	497 (60)	357 (53)
> 1 year ago	--	--	94 (14)	161 (16)	187 (21)	148 (16)	147 (21)	163 (21)	199 (25)	165 (26)	211 (29)	203 (30)	215 (31)	327 (36)	265 (32)	216 (32)
Never tested	59 (14)	48 (10)	55 (8)	139 (14)	97 (11)	83 (9)	55 (8)	79 (10)	90 (11)	45 (7)	64 (9)	47 (7)	52 (7)	45 (5)	39 (5)	59 (9)
Not reported	9 (2)	8 (2)	5 (1)	7 (1)	13 (1)	13 (1)	10 (2)	9 (1)	4 (<1)	7 (1)	2 (0)	13 (2)	14 (2)	33 (4)	29 (3)	48 (7)
Any treatment for HCV (%)																
Interferon+/ Ribavirin	--	--	--	--	10 (3)	24 (5)	11 (3)	16 (4)	16 (4)	16 (5)	19 (5)	17 (5)	12 (3)	53 (10)	50 (10)	47 (13)
Other	--	--	--	--	17 (4)	17 (4)	6 (2)	9 (2)	5 (1)	13 (4)	4 (1)	8 (2)	4 (1)	5 (1)	3 (<1)	5 (1)
No treatment	--	--	--	--	367 (92)	402 (89)	315 (93)	356 (92)	357 (92)	302 (88)	346 (93)	327 (90)	312 (91)	470 (86)	432 (85)	301 (82)
Not reported	--	--	--	--	7 (2)	8 (2)	5 (1)	9 (2)	12 (3)	10 (3)	3 (1)	11 (3)	16 (5)	18 (3)	23 (5)	15 (4)
Current treatment for HCV (%)																
Interferon+/ Ribavirin	--	--	--	--	4	4	3	2	2	3	3	3	2	9	5	11
Other	--	--	--	--	4	9	2	2	4	3	0	4	1	4	1	3

Table 3.7 Number (percentage) of respondents by treatment for drug use and year

NEW SOUTH WALES N° surveyed	1995 N=433	1996 N=499	1997 N=682	1998 N=1001	1999 N=907	2000 N=911	2001 N=691	2002 N=760	2003 N=785	2004 N=646	2005 N=729	2006 N=683	2007 N=701	2008 N=899	2009 N=830	2010 N=680	
Any treatment/therapy for drug use (%)																	
No	45 (10)	77 (15)	111 (16)	200 (20)	238 (26)	211 (23)	165 (24)	189 (25)	208 (27)	80 (12)	123 (17)	97 (14)	106 (15)	128 (14)	112 (13)	111 (16)	
Yes	387 (89)	419 (84)	569 (83)	798 (80)	667 (74)	666 (73)	520 (75)	559 (73)	575 (73)	555 (86)	599 (82)	565 (82)	578 (82)	754 (84)	704 (85)	551 (81)	
Not reported	1 (1)	3 (1)	2 (1)	3 (<1)	2 (<1)	34 (4)	6 (1)	12 (2)	2 (<1)	11 (2)	7 (1)	21 (3)	17 (2)	17 (2)	14 (2)	18 (3)	
History of methadone maintenance treatment (%)																	
Current	300 (69)	279 (56)	382 (56)	500 (50)	369 (40)	304 (33)	294 (43)	266 (35)	331 (42)	285 (44)	320 (44)	298 (44)	286 (41)	379 (42)	396 (48)	279 (41)	
Previous	55 (13)	110 (22)	120 (18)	190 (19)	178 (20)	253 (28)	134 (19)	199 (26)	173 (22)	153 (24)	153 (21)	169 (25)	182 (26)	219 (24)	177 (21)	143 (21)	
Never	77 (18)	107 (21)	178 (26)	308 (31)	359 (40)	347 (38)	256 (37)	280 (37)	279 (35)	198 (31)	250 (34)	201 (29)	218 (31)	281 (31)	236 (28)	218 (32)	
Not reported	1 (<1)	3 (1)	2 (<1)	3 (<1)	1 (<1)	7 (1)	7 (1)	5 (2)	2 (<1)	10 (1)	6 (1)	15 (2)	15 (2)	20 (2)	21 (3)	40 (6)	
History of other pharmacotherapy treatment (%)																	
Current	--	--	--	--	--	8 (1)	31 (4)	29 (4)	83 (11)	70 (11)	76 (10)	62 (9)	63 (9)	133 (15)	109 (13)	81 (12)	
Previous	--	--	--	--	--	79 (9)	50 (7)	82 (11)	145 (18)	141 (22)	160 (22)	147 (22)	159 (23)	188 (21)	206 (25)	165 (24)	
Never	--	--	--	--	--	824 (90)	598 (87)	627 (82)	544 (69)	413 (64)	481 (66)	455 (67)	458 (65)	557 (62)	493 (59)	426 (61)	
Not reported	--	--	--	--	--	0 (0)	12 (2)	22 (3)	13 (2)	22 (3)	12 (2)	19 (3)	21 (3)	21 (2)	22 (3)	8 (1)	

Table 3.8 Number (percentage) of respondents by source of needle and syringe acquisition in the month prior to survey and year

NEW SOUTH WALES N° injected last month	1995 N=408	1996 N=467	1997 N=631	1998 N=947	1999 N=841	2000 N=852	2001 N=593	2002 N=667	2003 N=687	2004 N=597	2005 N=654	2006 N=585	2007 N=601	2008 N=767	2009 N=687	2010 N=548	
Syringe acquisition in the last month (%) [more than one could be selected]																	
Needle Syringe Program	--	--	--	--	781 (93)	783 (92)	544 (92)	604 (91)	586 (85)	530 (89)	602 (92)	539 (92)	435 (72)	687 (90)	474 (69)	491 (90)	
Pharmacy	--	--	--	--	485 (58)	532 (62)	367 (62)	373 (56)	307 (45)	278 (47)	268 (41)	267 (46)	130 (22)	334 (44)	139 (20)	114 (21)	
Personal Sources	--	--	--	--	--	--	--	--	--	--	--	--	82 (14)	--	79 (12)	53 (10)	
Vending Machine	--	--	--	--	--	--	--	--	--	--	--	--	125 (21)	--	129 (19)	82 (15)	
Other sources	--	--	--	--	--	--	--	--	--	--	--	--	28 (5)	--	22 (3)	16 (3)	
Onward supply of syringes in last month (%)																	
Yes, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	202 (34)	--	222 (32)	209 (38)	
No, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	302 (50)	--	333 (48)	332 (61)	
Not reported	--	--	--	--	--	--	--	--	--	--	--	--	97 (16)	--	132 (19)	7 (1)	

HIV antibody prevalence

Table 3.9 HIV antibody prevalence by gender and year

NEW SOUTH WALES	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995	259	6 (2.3)	155	4 (2.6)	420	11 (2.6)
1996	317	8 (2.5)	162	5 (3.1)	484	13 (2.7)
1997	384	6 (1.6)	254	1 (0.4)	639	7 (1.1)
1998	542	5 (0.9)	368	1 (0.3)	916	6 (0.7)
1999	536	8 (1.5)	312	1 (0.3)	854	9 (1.1)
2000	535	11 (2.1)	326	0 (0.0)	866	11 (1.3)
2001	406	6 (1.5)	241	0 (0.0)	656	6 (0.9)
2002	469	13 (2.8)	261	1 (0.4)	738	15 (2.0)
2003	533	12 (2.3)	230	0 (0.0)	772	13 (1.7)
2004	407	6 (1.5)	194	1 (0.5)	606	7 (1.2)
2005	436	6 (1.4)	243	0 (0.0)	685	6 (0.9)
2006	424	12 (2.8)	232	1 (0.4)	663	14 (2.1)
2007	439	12 (2.7)	240	2 (0.8)	683	15 (2.2)
2008	563	15 (2.7)	297	3 (1.0)	867	19 (2.2)
2009	488	12 (2.5)	320	0 (0.0)	816	13 (1.6)
2010	422	8 (1.9)	243	0 (0.0)	671	8 (1.2)
χ^2 trend p value		0.143		0.013		0.460

Table 3.10 HIV antibody prevalence by sexual identity, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
Heterosexual	225	1 (0.4)	113	2 (1.7)	341	4 (1.2)
Bisexual	11	0 (0.0)	31	1 (3.2)	43	1 (2.3)
Homosexual	14	5 (35.7)	9	1 (11.1)	24	6 (25.0)
1996						
Heterosexual	256	0 (0.0)	113	3 (2.7)	371	3 (0.8)
Bisexual	23	2 (8.7)	26	0 (0.0)	49	2 (4.1)
Homosexual	23	6 (26.1)	14	1 (7.1)	37	7 (18.9)
1997						
Heterosexual	319	1 (0.3)	173	1 (0.6)	492	2 (0.4)
Bisexual	30	0 (0.0)	44	0 (0.0)	74	0 (0.0)
Homosexual	17	5 (29.4)	28	0 (0.0)	45	5 (11.1)
1998						
Heterosexual	459	2 (0.4)	274	0 (0.0)	735	2 (0.3)
Bisexual	30	2 (6.7)	60	1 (1.7)	90	3 (3.3)
Homosexual	14	1 (7.1)	23	0 (0.0)	37	1 (2.7)
1999						
Heterosexual	424	3 (0.7)	208	1 (0.5)	632	4 (0.6)
Bisexual	34	0 (0.0)	69	0 (0.0)	107	0 (0.0)
Homosexual	26	5 (19.2)	11	0 (0.0)	37	5 (13.5)
2000						
Heterosexual	451	6 (1.3)	204	0 (0.0)	656	6 (0.9)
Bisexual	18	1 (5.6)	69	0 (0.0)	88	1 (1.1)
Homosexual	22	4 (18.2)	31	0 (0.0)	53	4 (7.6)
2001						
Heterosexual	342	1 (0.3)	168	0 (0.0)	512	1 (0.2)
Bisexual	21	1 (4.8)	49	0 (0.0)	72	1 (1.4)
Homosexual	15	4 (26.7)	14	0 (0.0)	29	4 (13.8)
2002						
Heterosexual	388	3 (0.8)	175	1 (0.6)	566	4 (0.7)
Bisexual	24	1 (4.2)	51	0 (0.0)	79	2 (2.5)
Homosexual	20	8 (40.0)	14	0 (0.0)	34	8 (23.5)
2003						
Heterosexual	460	6 (1.3)	138	0 (0.0)	600	6 (1.0)
Bisexual	16	0 (0.0)	47	0 (0.0)	65	1 (1.5)
Homosexual	17	6 (35.3)	19	0 (0.0)	37	6 (16.2)
2004						
Heterosexual	345	0 (0.0)	141	1 (0.7)	487	1 (0.2)
Bisexual	15	0 (0.0)	33	0 (0.0)	48	0 (0.0)
Homosexual	14	6 (42.9)	11	0 (0.0)	25	6 (24.0)
2005						
Heterosexual	386	1 (0.3)	171	0 (0.0)	557	1 (0.2)
Bisexual	10	0 (0.0)	44	0 (0.0)	55	0 (0.0)
Homosexual	24	5 (20.8)	16	0 (0.0)	44	5 (11.4)
2006						
Heterosexual	366	2 (0.6)	170	1 (0.6)	537	3 (0.6)
Bisexual	23	3 (13.0)	38	0 (0.0)	64	4 (6.3)
Homosexual	27	7 (25.9)	16	0 (0.0)	44	7 (15.9)
2007						
Heterosexual	383	4 (1.0)	174	2 (1.2)	558	6 (1.1)
Bisexual	21	0 (0.0)	42	0 (0.0)	64	1 (1.6)
Homosexual	25	8 (32.0)	19	0 (0.0)	44	8 (18.2)
2008						
Heterosexual	488	2 (0.4)	202	1 (0.5)	691	3 (0.4)
Bisexual	25	0 (0.0)	63	2 (3.2)	89	3 (3.4)
Homosexual	31	13 (41.9)	21	0 (0.0)	54	13 (24.1)
2009						
Heterosexual	424	2 (0.5)	232	0 (0.0)	658	2 (0.3)
Bisexual	21	0 (0.0)	53	0 (0.0)	76	1 (1.3)
Homosexual	22	10 (45.5)	15	0 (0.0)	39	10 (25.6)
2010						
Heterosexual	371	1 (0.3)	166	0 (0.0)	539	1 (0.2)
Bisexual	14	0 (0.0)	58	0 (0.0)	74	0 (0.0)
Homosexual	15	7 (46.7)	8	0 (0.0)	24	7 (29.2)
2010 p value		<0.001		--		<0.001

Table 3.11 HIV antibody prevalence by age group, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
<25 years	37	3 (8.1)	41	1 (2.4)	81	4 (5.0)
25-34 years	130	1 (0.8)	71	2 (2.8)	201	3 (1.5)
35+ years	88	2 (2.3)	42	1 (2.4)	133	4 (3.0)
1996						
<25 years	55	0 (0.0)	36	2 (5.6)	92	2 (2.2)
25-34 years	139	4 (2.9)	90	1 (1.1)	233	5 (2.2)
35+ years	122	4 (3.3)	36	2 (5.6)	158	6 (3.8)
1997						
<25 years	77	0 (0.0)	65	0 (0.0)	142	0 (0.0)
25-34 years	162	4 (2.5)	123	1 (0.8)	285	5 (1.8)
35+ years	145	2 (1.4)	66	0 (0.0)	212	02(0.9)
1998						
<25 years	144	0 (0.0)	118	0 (0.0)	263	0 (0.0)
25-34 years	203	4 (2.0)	147	0 (0.0)	355	4 (1.1)
35+ years	194	1 (0.5)	103	1 (0.3)	297	2 (0.7)
1999						
<25 years	127	0 (0.0)	83	1 (1.2)	210	1 (0.5)
25-34 years	236	5 (2.1)	144	0 (0.0)	382	5 (1.3)
35+ years	173	3 (1.7)	85	0 (0.0)	261	3 (1.2)
2000						
<25 years	127	0 (0.0)	112	0 (0.0)	240	0 (0.0)
25-34 years	218	6 (2.8)	135	0 (0.0)	355	6 (1.7)
35+ years	190	5 (2.6)	79	0 (0.0)	271	5 (1.9)
2001						
<25 years	82	0 (0.0)	73	0 (0.0)	157	0 (0.0)
25-34 years	157	2 (1.3)	95	0 (0.0)	253	2 (0.8)
35+ years	167	4 (2.4)	72	0 (0.0)	244	4 (1.7)
2002						
<25 years	90	0 (0.0)	76	0 (0.0)	167	0 (0.0)
25-34 years	187	8 (4.3)	104	1 (1.0)	293	10 (3.4)
35+ years	191	5 (2.6)	81	0 (0.0)	277	5 (1.8)
2003						
<25 years	111	4 (3.6)	52	0 (0.0)	163	4 (2.5)
25-34 years	199	2 (1.0)	94	0 (0.0)	296	3 (1.0)
35+ years	223	6 (2.7)	84	0 (0.0)	313	6 (1.9)
2004						
<25 years	63	0 (0.0)	36	1 (2.8)	99	1 (1.0)
25-34 years	157	2 (1.3)	72	0 (0.0)	231	2 (0.9)
35+ years	186	4 (2.2)	86	0 (0.0)	275	4 (1.5)
2005						
<25 years	42	1 (2.4)	39	0 (0.0)	81	1 (1.2)
25-34 years	154	2 (1.3)	109	0 (0.0)	264	2 (0.8)
35+ years	239	3 (1.3)	94	0 (0.0)	338	3 (0.9)
2006						
<25 years	34	1 (3.0)	25	0 (0.0)	59	1 (1.7)
25-34 years	136	2 (1.5)	86	1 (1.2)	226	4 (1.8)
35+ years	253	9 (2.6)	119	0 (0.0)	375	9 (2.4)
2007						
<25 years	28	0 (0.0)	28	0 (0.0)	56	0 (0.0)
25-34 years	142	4 (2.8)	74	0 (0.0)	217	4 (1.8)
35+ years	269	8 (3.0)	138	2 (1.5)	410	11 (2.7)
2008						
<25 years	45	0 (0.0)	34	0 (0.0)	79	0 (0.0)
25-34 years	167	4 (2.4)	101	3 (3.0)	270	8 (3.0)
35+ years	348	11 (3.2)	162	0 (0.0)	515	11 (2.1)
2009						
<25 years	26	0 (0.0)	38	0 (0.0)	64	0 (0.0)
25-34 years	135	2 (1.5)	109	0 (0.0)	244	2 (0.8)
35+ years	324	10 (3.1)	173	0 (0.0)	505	11 (2.2)
2010						
<25 years	27	1 (3.7)	25	0 (0.0)	53	1 (1.9)
25-34 years	107	1 (0.9)	85	0 (0.0)	192	1 (0.5)
35+ years	288	6 (2.1)	133	0 (0.0)	426	6 (1.4)
2010 p value		0.438		--		0.421

Table 3.12 HIV antibody prevalence by times since first injection, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
<3 years	9	1 (11.1)	13	0 (0.0)	23	1 (4.4)
3-10 years	76	3 (4.0)	57	2 (3.5)	135	5 (3.7)
11+ years	169	2 (1.2)	83	2 (2.4)	254	5 (2.0)
1996						
<3 years	29	1 (3.5)	14	2 (14.3)	44	3 (6.8)
3-10 years	92	2 (2.2)	59	2 (3.4)	151	4 (2.7)
11+ years	184	5 (2.7)	84	1 (1.2)	272	6 (2.2)
1997						
<3 years	30	2 (6.7)	24	0 (0.0)	54	2 (3.7)
3-10 years	129	3 (2.3)	100	0 (0.0)	229	3 (1.3)
11+ years	211	1 (0.5)	124	1 (0.8)	336	2 (0.6)
1998						
<3 years	71	1 (1.4)	52	0 (0.0)	124	1 (0.8)
3-10 years	187	0 (0.0)	144	0 (0.0)	332	0 (0.0)
11+ years	266	4 (1.5)	167	1 (0.6)	436	5 (1.2)
1999						
<3 years	74	0 (0.0)	43	0 (0.0)	117	0 (0.0)
3-10 years	202	3 (1.5)	127	1 (0.8)	330	4 (1.2)
11+ years	239	5 (2.1)	136	0 (0.0)	378	5 (1.3)
2000						
<3 years	70	1 (1.4)	47	0 (0.0)	116	1 (0.9)
3-10 years	199	4 (2.0)	154	0 (0.0)	353	4 (1.1)
11+ years	245	6 (2.5)	117	0 (0.0)	364	6 (1.7)
2001						
<3 years	55	2 (3.6)	29	0 (0.0)	86	2 (2.3)
3-10 years	139	1 (0.7)	107	0 (0.0)	246	1 (0.4)
11+ years	201	3 (1.5)	101	0 (0.0)	306	3 (1.0)
2002						
<3 years	54	0 (0.0)	20	0 (0.0)	75	0 (0.0)
3-10 years	170	3 (1.8)	120	1 (0.8)	293	5 (1.7)
11+ years	230	9 (3.9)	113	0 (0.0)	346	9 (2.6)
2003						
<3 years	59	2 (3.4)	15	0 (0.0)	74	2 (2.7)
3-10 years	190	6 (3.1)	99	0 (0.0)	291	7 (2.4)
11+ years	270	4 (1.5)	110	0 (0.0)	386	4 (1.0)
2004						
<3 years	26	2 (7.7)	17	0 (0.0)	43	2 (4.7)
3-10 years	150	0 (0.0)	68	0 (0.0)	219	0 (0.0)
11+ years	223	4 (1.8)	107	1 (0.9)	331	5 (1.5)
2005						
<3 years	19	0 (0.0)	10	0 (0.0)	30	0 (0.0)
3-10 years	77	2 (2.6)	67	0 (0.0)	145	2 (1.4)
11+ years	324	2 (0.6)	157	0 (0.0)	485	2 (0.4)
2006						
<3 years	19	1 (5.3)	11	0 (0.0)	30	1 (3.3)
3-10 years	94	3 (3.2)	65	1 (1.5)	163	5 (3.1)
11+ years	292	8 (2.7)	149	0 (0.0)	444	8 (1.8)
2007						
<3 years	11	0 (0.0)	11	0 (0.0)	22	0 (0.0)
3-10 years	92	1 (1.1)	61	0 (0.0)	155	1 (0.6)
11+ years	326	11 (3.4)	158	2 (1.3)	486	14 (2.9)
2008						
<3 years	33	3 (9.1)	15	0 (0.0)	48	3 (6.3)
3-10 years	114	2 (1.8)	64	0 (0.0)	179	2 (3.4)
11+ years	400	10 (2.5)	217	3 (1.4)	622	14 (2.3)
2009						
<3 years	30	2 (6.7)	16	0 (0.0)	46	2 (4.4)
3-10 years	66	2 (3.0)	68	0 (0.0)	135	2 (1.5)
11+ years	382	8 (2.1)	229	0 (0.0)	618	9 (1.5)
2010						
<3 years	30	1 (3.3)	16	0 (0.0)	47	1 (2.1)
3-10 years	59	0 (0.0)	50	0 (0.0)	109	0 (0.0)
11+ years	319	7 (2.2)	170	0 (0.0)	494	7 (1.4)
2010 p value		0.382		--		0.321

Table 3.13 HIV antibody prevalence by drug last injected, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
Heroin	83	2 (2.4)	48	1 (2.1)	131	3 (2.3)
Methamphetamine	22	2 (9.1)	12	0 (0.0)	35	2 (5.7)
Other	153	2 (1.3)	95	3 (3.2)	253	6 (2.4)
1996						
Heroin	129	5 (3.9)	58	3 (5.2)	187	8 (4.3)
Methamphetamine	28	3 (10.7)	15	0 (0.0)	43	3 (7.0)
Other	159	0 (0.0)	88	2 (2.3)	252	2 (0.8)
1997						
Heroin	175	4 (2.3)	118	0 (0.0)	294	4 (1.4)
Methamphetamine	33	1 (3.0)	25	0 (0.0)	58	1 (1.7)
Other	172	1 (0.6)	110	1 (0.9)	282	2 (0.7)
1998						
Heroin	266	3 (1.1)	167	0 (0.0)	435	3 (0.7)
Methamphetamine	36	1 (2.8)	27	0 (0.0)	63	1 (1.6)
Other	236	1 (0.4)	172	1 (0.6)	411	2 (0.5)
1999						
Heroin	311	2 (0.6)	181	1 (0.6)	496	3 (0.6)
Methamphetamine	65	4 (6.2)	38	0 (0.0)	103	4 (3.9)
Other	156	2 (1.3)	90	0 (0.0)	247	2 (0.8)
2000						
Heroin	309	5 (1.6)	195	0 (0.0)	504	5 (1.0)
Methamphetamine	75	3 (4.0)	29	0 (0.0)	105	3 (2.9)
Other	149	3 (2.0)	97	0 (0.0)	247	3 (1.2)
2001						
Heroin	141	1 (0.7)	71	0 (0.0)	212	1 (0.5)
Methamphetamine	64	4 (6.3)	39	0 (0.0)	105	4 (3.8)
Other	195	1 (0.5)	126	0 (0.0)	325	1 (0.3)
2002						
Heroin	227	3 (1.3)	129	1 (0.8)	359	5 (1.4)
Methamphetamine	103	8 (7.8)	60	0 (0.0)	164	8 (4.9)
Other	136	2 (1.5)	68	0 (0.0)	207	2 (1.0)
2003						
Heroin	277	5 (1.8)	126	0 (0.0)	408	6 (1.5)
Methamphetamine	100	4 (4.0)	37	0 (0.0)	138	4 (2.9)
Other	151	3 (2.0)	60	0 (0.0)	213	3 (1.4)
2004						
Heroin	216	2 (0.9)	86	0 (0.0)	304	2 (0.7)
Methamphetamine	82	3 (3.7)	54	1 (1.9)	136	4 (2.9)
Other	106	1 (0.9)	52	0 (0.0)	160	1 (0.6)
2005						
Heroin	183	2 (1.1)	102	0 (0.0)	286	2 (0.7)
Methamphetamine	101	3 (3.0)	65	0 (0.0)	170	3 (1.8)
Other	136	1 (0.7)	70	0 (0.0)	207	1 (0.5)
2006						
Heroin	133	2 (1.5)	88	0 (0.0)	223	2 (0.9)
Methamphetamine	124	8 (6.5)	64	0 (0.0)	192	9 (4.7)
Other	154	2 (1.3)	74	0 (0.0)	228	13 (2.0)
2007						
Heroin	153	4 (2.6)	91	0 (0.0)	246	4 (1.6)
Methamphetamine	109	4 (3.7)	71	1 (1.4)	180	5 (2.8)
Other	168	4 (2.4)	76	1 (1.3)	246	6 (2.4)
2008						
Heroin	218	1 (0.5)	116	1 (0.9)	335	2 (0.6)
Methamphetamine	138	11 (8.0)	75	1 (1.3)	217	13 (6.0)
Other	197	2 (1.0)	101	1 (1.0)	300	3 (1.0)
2009						
Heroin	180	2 (1.1)	119	0 (0.0)	302	2 (0.7)
Methamphetamine	98	7 (7.1)	79	0 (0.0)	178	7 (3.9)
Other	198	3 (1.5)	113	0 (0.0)	315	4 (1.3)
2010						
Heroin	136	1 (0.7)	93	0 (0.0)	231	1 (0.4)
Methamphetamine	121	4 (3.3)	75	0 (0.0)	198	4 (2.0)
Other	163	3 (1.8)	73	0 (0.0)	238	3 (1.3)
2010 p value		0.317		--		0.332

Table 3.14 HIV antibody prevalence by frequency of injection last month, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
Less than daily	136	5 (3.7)	72	2 (2.8)	212	8 (3.8)
Daily or more	108	1 (0.9)	74	2 (2.7)	184	3 (1.6)
Not last month	14	0 (0.0)	9	0 (0.0)	23	0 (0.0)
1996						
Less than daily	162	4 (2.5)	76	2 (2.6)	242	6 (2.5)
Daily or more	136	4 (2.9)	74	3 (4.1)	211	7 (3.3)
Not last month	17	0 (0.0)	10	0 (0.0)	27	0 (0.0)
1997						
Less than daily	161	3 (1.9)	89	1 (1.1)	251	4 (1.6)
Daily or more	194	2 (1.0)	145	0 (0.0)	339	2 (0.6)
Not last month	25	1 (4.0)	17	0 (0.0)	42	1 (2.4)
1998						
Less than daily	163	3 (1.8)	98	1 (1.0)	263	4 (1.5)
Daily or more	350	1 (0.3)	250	0 (0.0)	603	1 (0.2)
Not last month	29	1 (3.5)	19	0 (0.0)	48	1 (2.1)
1999						
Less than daily	171	2 (1.2)	101	0 (0.0)	274	2 (0.7)
Daily or more	322	3 (0.9)	193	1 (0.5)	517	4 (0.8)
Not last month	40	3 (7.5)	16	0 (0.0)	57	3 (5.3)
2000						
Less than daily	162	3 (1.9)	86	0 (0.0)	249	3 (1.2)
Daily or more	336	6 (1.8)	224	0 (0.0)	561	6 (1.1)
Not last month	30	2 (6.7)	13	0 (0.0)	43	2 (4.7)
2001						
Less than daily	145	4 (2.8)	93	0 (0.0)	241	4 (1.7)
Daily or more	202	2 (1.0)	114	0 (0.0)	319	2 (0.6)
Not last month	50	6 (1.5)	31	0 (0.0)	81	0 (0.0)
2002						
Less than daily	175	8 (4.6)	80	0 (0.0)	260	9 (3.5)
Daily or more	245	4 (1.6)	142	1 (0.7)	388	5 (1.3)
Not last month	47	1 (2.1)	33	0 (0.0)	81	1 (1.2)
2003						
Less than daily	232	2 (0.9)	86	0 (0.0)	324	3 (0.9)
Daily or more	234	10 (4.3)	115	0 (0.0)	351	10 (2.9)
Not last month	61	0 (0.0)	22	0 (0.0)	83	0 (0.0)
2004						
Less than daily	167	5 (3.0)	96	0 (0.0)	263	5 (1.9)
Daily or more	212	1 (0.5)	83	1 (1.2)	297	2 (0.7)
Not last month	22	0 (0.0)	14	0 (0.0)	38	0 (0.0)
2005						
Less than daily	183	6 (3.3)	91	0 (0.0)	278	6 (2.2)
Daily or more	207	0 (0.0)	127	0 (0.0)	335	0 (0.0)
Not last month	45	0 (0.0)	22	0 (0.0)	68	0 (0.0)
2006						
Less than daily	196	8 (4.1)	95	0 (0.0)	293	8 (2.7)
Daily or more	172	3 (1.7)	99	0 (0.0)	275	4 (1.5)
Not last month	49	1 (2.0)	36	1 (2.8)	86	2 (2.3)
2007						
Less than daily	186	4 (2.2)	106	1 (0.9)	295	6 (2.0)
Daily or more	196	6 (3.1)	96	1 (1.0)	292	7 (2.4)
Not last month	47	2 (4.3)	32	0 (0.0)	80	2 (2.5)
2008						
Less than daily	244	8 (3.3)	114	1 (0.9)	362	9 (2.5)
Daily or more	239	4 (1.7)	135	1 (0.7)	376	6 (1.6)
Not last month	77	3 (3.9)	45	1 (2.2)	123	4 (3.3)
2009						
Less than daily	194	5 (2.6)	146	0 (0.0)	341	5 (1.5)
Daily or more	207	4 (1.9)	121	0 (0.0)	332	5 (1.5)
Not last month	78	3 (3.9)	48	0 (0.0)	127	3 (2.4)
2010						
Less than daily	180	4 (2.2)	100	0 (0.0)	282	4 (1.4)
Daily or more	172	4 (2.3)	84	0 (0.0)	258	4 (1.6)
Not last month	59	0 (0.0)	56	0 (0.0)	117	0 (0)
2010 p value		0.784		--		0.519

Table 3.15 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
No receptive sharing	159	5 (3.1)	87	3 (3.3)	258	9 (3.9)
Receptive sharing	79	1 (1.3)	55	1 (1.8)	138	2 (1.5)
1996						
No receptive sharing	202	6 (2.9)	91	5 (5.2)	309	11 (3.6)
Receptive sharing	88	2 (2.2)	54	0 (0.0)	144	2 (1.4)
1997						
No receptive sharing	294	4 (1.3)	180	1 (0.6)	480	5 (1.0)
Receptive sharing	52	1 (1.9)	41	0 (0.0)	94	1 (1.1)
1998						
No receptive sharing	390	3 (0.8)	271	1 (0.4)	669	4 (0.6)
Receptive sharing	103	1 (1.0)	61	0 (0.0)	166	1 (0.6)
1999						
No receptive sharing	365	5 (1.4)	213	1 (0.5)	588	6 (1.0)
Receptive sharing	104	0 (0.0)	70	0 (0.0)	174	0 (0.0)
2000						
No receptive sharing	396	9 (2.2)	228	0 (0.0)	635	9 (1.4)
Receptive sharing	82	0 (0.0)	68	0 (0.0)	150	0 (0.0)
2001						
No receptive sharing	285	6 (2.1)	163	0 (0.0)	454	6 (1.3)
Receptive sharing	54	0 (0.0)	32	0 (0.0)	86	0 (0.0)
2002						
No receptive sharing	324	9 (2.8)	181	1 (0.6)	511	11 (2.2)
Receptive sharing	83	3 (3.6)	35	0 (0.0)	118	3 (2.5)
2003						
No receptive sharing	380	11 (2.9)	163	0 (0.0)	550	12 (2.2)
Receptive sharing	72	1 (1.4)	31	0 (0.0)	104	1 (1.0)
2004						
No receptive sharing	290	4 (1.4)	152	1 (0.7)	442	5 (1.1)
Receptive sharing	77	1 (1.3)	23	0 (0.0)	102	1 (1.0)
2005						
No receptive sharing	321	6 (1.9)	176	0 (0.0)	501	6 (1.2)
Receptive sharing	54	0 (0.0)	34	0 (0.0)	89	0 (0.0)
2006						
No receptive sharing	294	9 (3.1)	166	0 (0.0)	464	9 (1.9)
Receptive sharing	56	2 (3.6)	22	0 (0.0)	79	3 (3.8)
2007						
No receptive sharing	306	6 (2.0)	165	2 (1.2)	474	9 (1.9)
Receptive sharing	56	4 (7.1)	26	0 (0.0)	82	4 (4.9)
2008						
No receptive sharing	388	11 (2.8)	190	2 (1.1)	584	14 (2.4)
Receptive sharing	79	1 (1.3)	52	0 (0.0)	131	1 (0.8)
2009						
No receptive sharing	337	9 (2.7)	210	0 (0.0)	554	10 (1.8)
Receptive sharing	56	0 (0.0)	53	0 (0.0)	109	0 (0.0)
2010						
No receptive sharing	259	8 (3.1)	133	0 (0.0)	394	8 (2.0)
Receptive sharing	50	0 (0.0)	32	0 (0.0)	83	0 (0.0)
2010 p value		0.363		--		0.361

Table 3.16 HIV antibody prevalence by imprisonment last year, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
No imprisonment	194	4 (2.1)	130	4 (3.1)	329	9 (2.7)
Imprisonment	63	2 (3.2)	24	0 (0.0)	88	2 (2.3)
1996						
No imprisonment	238	7 (2.9)	130	4 (3.1)	373	11 (3.0)
Imprisonment	67	0 (0.0)	25	1 (4.0)	92	1 (1.1)
1997						
No imprisonment	289	6 (2.1)	219	1 (0.5)	509	7 (1.4)
Imprisonment	94	0 (0.0)	34	0 (0.0)	128	0 (0.0)
1998						
No imprisonment	379	5 (1.3)	297	1 (0.3)	680	6 (0.9)
Imprisonment	155	0 (0.0)	67	0 (0.0)	222	0 (0.0)
1999						
No imprisonment	407	6 (1.5)	265	0 (0.0)	677	6 (0.9)
Imprisonment	120	1 (0.8)	42	1 (2.4)	163	2 (1.2)
2000						
No imprisonment	385	6 (1.6)	251	0 (0.0)	639	6 (0.9)
Imprisonment	133	4 (3.0)	70	0 (0.0)	203	4 (2.0)
2001						
No imprisonment	298	6 (2.0)	190	0 (0.0)	494	6 (1.2)
Imprisonment	95	0 (0.0)	43	0 (0.0)	140	0 (0.0)
2002						
No imprisonment	345	12 (3.5)	214	1 (0.5)	566	14 (2.5)
Imprisonment	116	1 (0.9)	39	0 (0.0)	155	1 (0.7)
2003						
No imprisonment	387	8 (2.1)	196	0 (0.0)	590	9 (1.5)
Imprisonment	135	4 (3.0)	28	0 (0.0)	165	4 (2.4)
2004						
No imprisonment	287	5 (1.7)	167	0 (0.0)	458	5 (1.1)
Imprisonment	117	1 (0.9)	25	1 (4.0)	143	2 (1.4)
2005						
No imprisonment	327	6 (1.8)	201	0 (0.0)	533	6 (1.1)
Imprisonment	90	0 (0.0)	34	0 (0.0)	125	0 (0.0)
2006						
No imprisonment	331	12 (3.6)	200	1 (0.5)	538	14 (2.6)
Imprisonment	66	0 (0.0)	27	0 (0.0)	93	0 (0.0)
2007						
No imprisonment	342	10 (2.9)	205	2 (1.0)	550	12 (2.2)
Imprisonment	76	2 (2.6)	26	0 (0.0)	102	2 (2.0)
2008						
No imprisonment	416	14 (3.4)	240	0 (0.0)	662	15 (2.3)
Imprisonment	98	1 (1.0)	32	2 (6.3)	131	3 (2.3)
2009						
No imprisonment	394	12 (3.1)	273	0 (0.0)	675	13 (1.9)
Imprisonment	70	0 (0.0)	32	0 (0.0)	102	0 (0.0)
2010						
No imprisonment	291	7 (2.4)	190	0 (0.0)	486	7 (1.4)
Imprisonment	54	0 (0.0)	22	0 (0.0)	76	0 (0.0)
2010 p value		0.602		--		0.602

Table 3.17 HIV antibody prevalence by condom use at last sex, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
No condom use	151	3 (2.0)	99	2 (2.0)	252	6 (2.4)
Condom use	70	3 (4.3)	32	1 (3.1)	104	4 (3.9)
1996						
No condom use	148	2 (1.4)	81	3 (3.7)	231	5 (2.2)
Condom use	63	3 (4.8)	40	0 (0.0)	104	3 (2.9)
1997						
No condom use	240	3 (1.3)	176	1 (0.6)	416	4 (1.0)
Condom use	140	2 (1.4)	69	0 (0.0)	210	2 (1.0)
1998						
No condom use	339	2 (0.6)	258	1 (0.4)	598	3 (0.5)
Condom use	189	3 (1.6)	100	0 (0.0)	292	3 (1.0)
1999						
No condom use	295	3 (1.0)	201	1 (0.5)	500	4 (0.8)
Condom use	221	4 (1.8)	100	0 (0.0)	323	4 (1.2)
2000						
No condom use	302	2 (0.7)	195	0 (0.0)	499	2 (0.4)
Condom use	213	9 (4.2)	118	0 (0.0)	334	9 (2.7)
2001						
No condom use	250	5 (2.0)	163	0 (0.0)	417	5 (1.2)
Condom use	143	1 (0.7)	74	0 (0.0)	220	1 (0.5)
2002						
No condom use	281	6 (2.1)	165	1 (0.6)	447	7 (1.6)
Condom use	176	7 (4.0)	90	0 (0.0)	271	8 (3.0)
2003						
No condom use	328	7 (2.1)	163	0 (0.0)	496	7 (1.4)
Condom use	189	5 (2.7)	63	0 (0.0)	256	6 (2.3)
2004						
No condom use	251	4 (1.6)	129	1 (0.8)	385	5 (1.3)
Condom use	148	2 (1.4)	60	0 (0.0)	208	2 (1.0)
2005 #						
No condom use	164	0 (0.0)	113	0 (0.0)	277	0 (0.0)
Condom use	84	2 (2.4)	39	0 (0.0)	125	2 (1.6)
2006						
No condom use	190	2 (1.1)	113	0 (0.0)	306	3 (1.0)
Condom use	15	1 (6.7)	12	0 (0.0)	27	1 (3.7)
2007						
No condom use	181	2 (1.1)	119	2 (1.7)	303	5 (1.7)
Condom use	29	1 (3.5)	19	0 (0.0)	48	1 (2.1)
2008						
No condom use	226	1 (0.4)	150	0 (0.0)	378	1 (0.3)
Condom use	43	1 (2.3)	22	1 (4.6)	67	3 (1.5)
2009						
No condom use	197	1 (0.5)	175	0 (0.0)	374	1 (0.3)
Condom use	31	2 (6.5)	10	0 (0.0)	41	2 (4.9)
2010						
No condom use	163	3 (1.8)	106	0 (0.0)	270	3 (1.1)
Condom use	48	0 (0.0)	27	0 (0.0)	76	0 (0.0)
2010 p value		1.000		--		1.000

Question referred to "condom use at last sex" from 1995 to 2004.

Excludes people reporting no sex last month from 2005.

Table 3.18 HIV antibody prevalence by sex work last month, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
No sex work	243	5 (2.1)	136	2 (1.5)	383	8 (2.1)
Sex work	5	1 (20.0)	18	1 (5.6)	25	2 (8.0)
1996						
No sex work	282	7 (2.5)	118	5 (4.2)	404	12 (3.0)
Sex work	10	0 (0.0)	37	0 (0.0)	47	0 (0.0)
1997						
No sex work	350	4 (1.1)	205	1 (0.5)	556	5 (0.9)
Sex work	26	1 (3.9)	43	0 (0.0)	69	1 (1.5)
1998						
No sex work	503	5 (1.0)	308	1 (0.3)	813	6 (0.7)
Sex work	22	0 (0.0)	54	0 (0.0)	79	0 (0.0)
1999						
No sex work	491	7 (1.4)	231	1 (0.4)	726	8 (1.1)
Sex work	27	1 (3.7)	74	0 (0.0)	103	1 (1.0)
2000						
No sex work	493	10 (2.0)	240	0 (0.0)	736	10 (1.4)
Sex work	23	0 (0.0)	77	0 (0.0)	102	0 (0.0)
2001						
No sex work	371	4 (1.1)	176	0 (0.0)	552	4 (0.7)
Sex work	19	2 (10.5)	56	0 (0.0)	78	2 (2.6)
2002						
No sex work	431	12 (2.8)	193	1 (0.5)	630	13 (2.1)
Sex work	19	1 (5.3)	62	0 (0.0)	82	2 (2.4)
2003						
No sex work	489	9 (1.8)	188	0 (0.0)	683	9 (1.3)
Sex work	22	3 (13.6)	35	0 (0.0)	59	4 (6.8)
2004						
No sex work	376	5 (1.3)	151	1 (0.7)	531	6 (1.1)
Sex work	25	1 (4.0)	37	0 (0.0)	63	1 (1.6)
2005						
No sex work	415	5 (1.2)	202	0 (0.0)	621	5 (0.8)
Sex work	12	1 (8.3)	35	0 (0.0)	49	1 (2.0)
2006						
No sex work	383	10 (2.6)	182	1 (0.6)	568	11 (1.9)
Sex work	18	2 (11.1)	36	0 (0.0)	58	3 (5.0)
2007						
No sex work	407	11 (2.7)	190	2 (1.1)	600	13 (2.2)
Sex work	9	1 (11.1)	40	0 (0.0)	50	2 (4.0)
2008						
No sex work	511	13 (2.5)	229	3 (3.1)	745	16 (2.2)
Sex work	23	2 (8.7)	49	0 (0.0)	73	3 (4.1)
2009						
No sex work	462	10 (2.2)	261	0 (0.0)	726	11 (1.5)
Sex work	7	2 (28.6)	48	0 (0.0)	57	2 (3.5)
2010						
No sex work	374	6 (1.6)	183	0 (0.0)	561	6 (1.1)
Sex work	9	1 (11.1)	41	0 (0.0)	51	1 (2.0)
2010 p value		0.154		--		0.458

Table 3.19 HIV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
Non-Indigenous	236	4 (1.7)	139	4 (2.9)	380	9 (2.4)
Indigenous	16	2 (13.0)	10	0 (0.0)	26	2 (7.7)
1996						
Non-Indigenous	268	6 (2.2)	135	3 (2.2)	406	9 (2.2)
Indigenous	19	1 (5.3)	13	2 (15.0)	32	3 (9.4)
1997						
Non-Indigenous	355	4 (1.1)	225	1 (0.4)	581	5 (0.9)
Indigenous	19	1 (5.3)	24	0 (0.0)	43	1 (2.3)
1998						
Non-Indigenous	484	4 (0.8)	317	1 (0.3)	807	5 (0.6)
Indigenous	35	1 (2.9)	43	0 (0.0)	78	1 (1.3)
1999						
Non-Indigenous	474	6 (1.3)	266	0 (0.0)	74	6 (0.8)
Indigenous	41	2 (4.9)	35	1 (2.9)	78	3 (3.9)
2000						
Non-Indigenous	484	8 (1.7)	271	0 (0.0)	759	8 (1.1)
Indigenous	41	3 (7.3)	49	0 (0.0)	90	3 (3.3)
2001						
Non-Indigenous	366	6 (1.6)	208	0 (0.0)	577	6 (1.0)
Indigenous	28	0 (0.0)	28	0 (0.0)	58	0 (0.0)
2002						
Non-Indigenous	416	12 (2.9)	211	1 (0.5)	634	14 (2.2)
Indigenous	33	1 (3.0)	39	0 (0.0)	73	1 (1.4)
2003						
Non-Indigenous	481	10 (2.1)	184	0 (0.0)	670	10 (1.5)
Indigenous	40	2 (5.0)	42	0 (0.0)	85	3 (3.5)
2004						
Non-Indigenous	353	5 (1.4)	160	0 (0.0)	516	5 (1.0)
Indigenous	42	1 (2.4)	29	1 (3.5)	73	2 (2.7)
2005						
Non-Indigenous	369	6 (1.6)	185	0 (0.0)	559	6 (1.1)
Indigenous	54	0 (0.0)	48	0 (0.0)	103	0 (0.0)
2006						
Non-Indigenous	372	12 (3.2)	176	1 (0.6)	554	14 (2.5)
Indigenous	39	0 (0.0)	47	0 (0.0)	86	0 (0.0)
2007						
Non-Indigenous	366	10 (2.8)	190	2 (1.1)	559	12 (2.2)
Indigenous	56	1 (1.8)	47	0 (0.0)	104	2 (1.9)
2008						
Non-Indigenous	469	13 (2.8)	234	1 (0.4)	709	15 (2.1)
Indigenous	71	1 (1.4)	54	2 (3.7)	126	3 (2.4)
2009						
Non-Indigenous	422	11 (2.6)	245	0 (0.0)	672	11 (1.6)
Indigenous	48	1 (2.1)	70	0 (0.0)	120	2 (1.7)
2010						
Non-Indigenous	357	7 (2.0)	197	0 (0.0)	558	5 (1.3)
Indigenous	52	1 (1.9)	42	0 (0.0)	96	1 (1.0)
2010 p value		1.000		--		1.000

Table 3.20 HIV antibody prevalence by country of birth, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Australia	343	9 (2.6)	183	0 (0.0)	525	10 (1.9)
Other	186	3 (1.6)	46	0 (0.0)	232	3 (1.3)
2004						
Australia	259	6 (2.3)	158	1 (0.6)	420	7 (1.7)
Other	139	0 (0.0)	33	0 (0.0)	173	0 (0.0)
2005						
Australia	368	5 (1.4)	216	0 (0.0)	588	5 (0.9)
Other	64	1 (1.6)	24	0 (0.0)	90	1 (1.1)
2006						
Australia	347	11 (3.2)	208	1 (0.5)	559	12 (2.2)
Other	71	1 (1.4)	22	0 (0.0)	94	2 (2.1)
2007						
Australia	365	11 (3.0)	208	2 (1.0)	576	14 (2.4)
Other	61	1 (1.6)	29	0 (0.0)	91	1 (1.0)
2008						
Australia	485	12 (2.5)	266	3 (1.1)	755	15 (2.0)
Other	62	2 (3.2)	24	0 (0.0)	88	3 (3.4)
2009						
Australia	417	12 (2.9)	292	0 (0.0)	714	13 (1.8)
Other	59	0 (0.0)	25	0 (0.0)	87	0 (0.0)
2010						
Australia	355	7 (2.0)	216	0 (0.0)	575	7 (1.2)
Other	55	1 (1.8)	24	0 (0.0)	80	1 (1.3)
2010 p value		1.000		--		1.000

Table 3.21 HIV antibody prevalence by language spoken at home by parents, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
English speaking	337	10 (3.0)	195	0 (0.0)	541	11 (2.0)
Non-English speaking	167	2 (1.2)	29	0 (0.0)	196	2 (1.0)
2004						
English speaking	183	2 (1.1)	134	1 (0.8)	319	3 (0.9)
Non-English speaking	114	0 (0.0)	24	0 (0.0)	138	0 (0.0)
2005						
English speaking	366	6 (1.6)	218	0 (0.0)	589	6 (1.0)
Non-English speaking	70	0 (0.0)	25	0 (0.0)	96	0 (0.0)
2006						
English speaking	361	11 (3.1)	214	1 (0.5)	581	13 (2.2)
Non-English speaking	42	1 (2.4)	12	0 (0.0)	54	1 (1.9)
2007						
English speaking	403	12 (3.0)	225	2 (0.9)	632	15 (2.4)
Non-English speaking	23	0 (0.0)	14	0 (0.0)	37	0 (0.0)
2008						
English speaking	525	15 (2.9)	284	3 (1.1)	816	19 (2.3)
Non-English speaking	28	0 (0.0)	8	0 (0.0)	36	0 (0.0)
2009						
English speaking	461	12 (2.6)	307	0 (0.0)	776	13 (1.7)
Non-English speaking	21	0 (0.0)	11	0 (0.0)	32	0 (0.0)
2010						
English speaking	398	8 (2.0)	234	0 (0.0)	638	8 (1.3)
Non-English speaking	17	0 (0.0)	6	0 (0.0)	23	0 (0.0)
2010 p value		1.000		--		1.000

HCV antibody prevalence

Table 3.22 HCV antibody prevalence by gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	254	219 (86)	152	124 (82)	412	348 (84)
1996	323	233 (72)	169	117 (69)	497	355 (71)
1997	386	260 (67)	254	176 (69)	641	437 (68)
1998	543	369 (68)	369	265 (72)	918	637 (69)
1999	537	322 (60)	312	198 (63)	854	524 (61)
2000	538	350 (65)	327	225 (69)	870	579 (67)
2001	412	321 (71)	244	183 (75)	655	476 (73)
2002	473	335 (71)	261	181 (69)	741	523 (71)
2003	535	359 (67)	230	161 (70)	774	526 (68)
2004	409	288 (70)	197	141 (72)	611	433 (71)
2005	439	302 (69)	243	168 (69)	688	474 (69)
2006	424	292 (69)	232	173 (75)	663	468 (71)
2007	428	289 (68)	231	169 (73)	663	460 (69)
2008	539	379 (70)	281	208 (74)	827	591 (71)
2009	485	272 (56)	320	193 (60)	813	468 (58)
2010	422	228 (54)	243	135 (56)	671	365 (54)
χ^2 trend p value		<0.001		0.002		<0.001

Table 3.23 HCV antibody prevalence by sexual identity, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Heterosexual	221	191 (86)	112	92 (82)	336	285 (85)
Bisexual	11	11 (100)	29	22 (76)	41	34 (83)
Homosexual	14	10 (71)	9	8 (89)	24	19 (79)
1996						
Heterosexual	261	198 (76)	115	91 (79)	378	291 (77)
Bisexual	23	17 (74)	30	17 (57)	53	34 (64)
Homosexual	24	14 (58)	15	6 (40)	39	20 (51)
1997						
Heterosexual	320	222 (69)	173	120 (69)	493	342 (69)
Bisexual	31	18 (58)	44	30 (68)	75	48 (64)
Homosexual	17	4 (24)	28	17 (61)	45	21 (47)
1998						
Heterosexual	460	317 (69)	275	206 (75)	737	524 (71)
Bisexual	30	18 (60)	60	36 (60)	90	54 (60)
Homosexual	14	6 (43)	23	13 (57)	37	19 (51)
1999						
Heterosexual	424	266 (63)	208	129 (62)	632	395 (63)
Bisexual	34	16 (47)	69	46 (67)	107	66 (62)
Homosexual	26	5 (19)	11	4 (36)	37	9 (24)
2000						
Heterosexual	453	300 (66)	205	149 (73)	659	450 (68)
Bisexual	19	12 (63)	69	48 (70)	89	61 (69)
Homosexual	22	11 (50)	31	17 (55)	53	28 (53)
2001						
Heterosexual	345	240 (70)	171	131 (77)	518	372 (72)
Bisexual	22	17 (77)	49	33 (67)	73	52 (71)
Homosexual	16	7 (44)	14	13 (93)	30	20 (67)
2002						
Heterosexual	389	280 (72)	175	119 (68)	567	401 (71)
Bisexual	25	18 (72)	51	37 (73)	80	59 (74)
Homosexual	22	7 (32)	14	11 (79)	36	18 (50)
2003						
Heterosexual	461	305 (66)	138	90 (65)	601	397 (66)
Bisexual	16	10 (63)	47	36 (77)	65	47 (72)
Homosexual	18	13 (72)	19	15 (79)	38	28 (74)
2004						
Heterosexual	347	242 (70)	144	104 (72)	492	346 (70)
Bisexual	15	8 (53)	33	25 (76)	48	33 (69)
Homosexual	14	10 (71)	11	7 (64)	25	17 (68)
2005						
Heterosexual	389	270 (69)	171	112 (66)	560	382 (68)
Bisexual	11	7 (64)	44	34 (77)	56	42 (75)
Homosexual	24	15 (63)	16	13 (81)	44	31 (70)
2006						
Heterosexual	366	263 (72)	170	130 (76)	537	393 (73)
Bisexual	23	14 (61)	38	27 (71)	64	41 (64)
Homosexual	27	11 (41)	16	9 (56)	44	21 (48)
2007						
Heterosexual	374	264 (71)	166	121 (73)	541	386 (71)
Bisexual	20	11 (55)	41	34 (83)	62	45 (73)
Homosexual	24	8 (33)	19	9 (47)	43	17 (40)
2008						
Heterosexual	468	337 (72)	191	144 (75)	660	481 (73)
Bisexual	24	17 (71)	59	45 (76)	84	62 (74)
Homosexual	29	12 (41)	20	13 (65)	51	26 (51)
2009						
Heterosexual	421	238 (57)	232	134 (58)	655	373 (57)
Bisexual	21	13 (62)	53	41 (77)	76	54 (71)
Homosexual	22	5 (23)	15	7 (47)	39	12 (31)
2010						
Heterosexual	371	209 (56)	166	91 (55)	539	301 (56)
Bisexual	14	8 (57)	58	35 (60)	74	44 (59)
Homosexual	15	2 (13)	8	3 (38)	24	5 (21)
2010 p value		0.003		0.422		0.002

Table 3.24 HCV antibody prevalence by age group, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
<25 years	36	20 (56)	40	28 (70)	79	50 (63)
25-34 years	128	115 (90)	71	61 (86)	199	176 (88)
35+ years	86	80 (93)	40	35 (88)	129	118 (91)
1996						
<25 years	57	25 (44)	38	19 (50)	96	45 (47)
25-34 years	142	106 (75)	93	73 (78)	239	182 (76)
35+ years	123	109 (89)	38	30 (79)	161	139 (86)
1997						
<25 years	77	24 (31)	65	29 (45)	142	53 (37)
25-34 years	163	104 (64)	123	86 (70)	286	190 (66)
35+ years	146	132 (90)	66	61 (92)	213	194 (91)
1998						
<25 years	144	54 (38)	118	63 (53)	263	117 (44)
25-34 years	204	145 (71)	147	110 (75)	356	258 (72)
35+ years	194	170 (88)	104	92 (88)	298	262 (88)
1999						
<25 years	128	52 (41)	83	37 (45)	211	89 (42)
25-34 years	236	129 (55)	144	92 (64)	382	223 (58)
35+ years	173	141 (82)	85	69 (81)	260	212 (82)
2000						
<25 years	127	63 (50)	112	70 (63)	240	133 (55)
25-34 years	220	130 (59)	136	93 (68)	358	225 (63)
35+ years	191	157 (82)	79	62 (78)	272	221 (81)
2001						
<25 years	82	45 (55)	75	51 (68)	159	96 (60)
25-34 years	160	102 (64)	95	65 (68)	256	168 (66)
35+ years	170	140 (82)	73	66 (90)	248	210 (85)
2002						
<25 years	90	53 (59)	76	48 (63)	167	102 (61)
25-34 years	188	127 (68)	104	66 (63)	294	195 (66)
35+ years	193	154 (80)	81	67 (83)	279	225 (81)
2003						
<25 years	111	49 (44)	52	28 (54)	163	77 (47)
25-34 years	200	127 (64)	94	66 (70)	297	194 (65)
35+ years	224	183 (82)	84	67 (80)	314	255 (81)
2004						
<25 years	63	30 (48)	37	21 (57)	100	51 (51)
25-34 years	159	108 (68)	73	47 (64)	234	157 (67)
35+ years	186	149 (80)	87	73 (84)	276	224 (81)
2005						
<25 years	42	13 (31)	39	26 (67)	81	39 (48)
25-34 years	155	96 (62)	109	70 (64)	265	167 (63)
35+ years	241	191 (79)	94	71 (76)	340	265 (75)
2006						
<25 years	34	17 (50)	25	18 (72)	59	35 (59)
25-34 years	136	81 (60)	86	64 (74)	226	146 (65)
35+ years	253	194 (77)	119	89 (75)	375	285 (76)
2007						
<25 years	25	6 (24)	27	16 (59)	52	22 (42)
25-34 years	139	85 (61)	72	51 (71)	212	137 (65)
35+ years	264	198 (75)	132	102 (77)	399	301 (75)
2008						
<25 years	43	15 (35)	34	22 (65)	77	37 (48)
25-34 years	157	99 (63)	98	70 (71)	257	170 (66)
35+ years	336	264 (79)	149	116 (78)	490	383 (78)
2009						
<25 years	26	2 (8)	38	17 (45)	64	19 (30)
25-34 years	135	66 (49)	109	66 (61)	244	132 (54)
35+ years	324	202 (62)	173	109 (63)	505	314 (62)
2010						
<25 years	27	4 (15)	25	16 (64)	53	20 (38)
25-34 years	107	49 (46)	85	39 (46)	192	88 (46)
35+ years	288	175 (61)	133	80 (60)	426	257 (60)
2010 p value		<0.001		0.078		<0.001

Table 3.25 HCV antibody prevalence by time since first injection, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<3 years	9	5 (56)	13	6 (46)	23	11 (48)
3-10 years	73	52 (71)	55	41 (75)	130	95 (73)
11+ years	167	157 (94)	82	76 (93)	251	235 (94)
1996						
<3 years	29	9 (31)	14	3 (21)	44	13 (30)
3-10 years	97	49 (51)	59	42 (71)	156	91 (58)
11+ years	183	170 (93)	90	73 (81)	277	246 (87)
1997						
<3 years	30	6 (20)	24	4 (17)	54	10 (19)
3-10 years	129	60 (47)	100	54 (54)	229	114 (50)
11+ years	213	185 (87)	123	113 (92)	336	299 (90)
1998						
<3 years	71	13 (18)	52	19 (37)	124	32 (26)
3-10 years	188	112 (60)	144	98 (68)	333	210 (63)
11+ years	266	232 (88)	168	144 (86)	436	378 (87)
1999						
<3 years	74	21 (28)	43	16 (37)	117	37 (32)
3-10 years	203	93 (46)	126	65 (52)	330	159 (48)
11+ years	239	195 (82)	134	110 (82)	375	307 (82)
2000						
<3 years	69	26 (38)	47	16 (34)	116	42 (36)
3-10 years	201	112 (56)	154	104 (68)	355	216 (61)
11+ years	248	201 (81)	118	99 (84)	368	302 (82)
2001						
<3 years	55	21 (38)	29	16 (55)	86	37 (43)
3-10 years	140	89 (64)	109	81 (74)	249	170 (68)
11+ years	200	168 (84)	101	83 (82)	305	255 (84)
2002						
<3 years	54	24 (44)	21	11 (52)	76	36 (47)
3-10 years	171	116 (68)	120	79 (66)	294	197 (67)
11+ years	230	187 (81)	111	88 (79)	344	278 (81)
2003						
<3 years	59	17 (29)	15	5 (33)	74	22 (30)
3-10 years	192	119 (62)	99	64 (65)	293	184 (63)
11+ years	269	219 (81)	110	90 (82)	385	312 (81)
2004						
<3 years	26	8 (31)	17	4 (24)	43	12 (28)
3-10 years	151	97 (64)	69	42 (61)	221	140 (63)
11+ years	222	177 (79)	109	93 (86)	331	269 (81)
2005						
<3 years	19	2 (11)	9	4 (44)	29	6 (21)
3-10 years	112	62 (55)	87	53 (61)	200	116 (58)
11+ years	292	228 (78)	136	102 (75)	432	333 (77)
2006						
<3 years	19	2 (11)	11	3 (27)	30	5 (17)
3-10 years	94	49 (52)	65	44 (68)	163	94 (58)
11+ years	292	231 (79)	149	121 (81)	444	354 (80)
2007						
<3 years	11	1 (9)	11	4 (36)	22	5 (23)
3-10 years	88	35 (40)	58	39 (67)	148	75 (51)
11+ years	319	247 (77)	153	119 (78)	474	367 (77)
2008						
<3 years	32	7 (22)	13	6 (46)	45	13 (29)
3-10 years	106	55 (52)	63	40 (63)	170	95 (56)
11+ years	386	309 (80)	203	161 (79)	594	473 (80)
2009						
<3 years	30	1 (3)	16	6 (38)	46	7 (15)
3-10 years	65	20 (31)	68	37 (54)	134	58 (43)
11+ years	380	249 (66)	229	147 (64)	616	398 (65)
2010						
<3 years	30	3 (10)	16	5 (31)	47	8 (17)
3-10 years	59	20 (34)	50	28 (56)	109	48 (44)
11+ years	319	200 (63)	170	100 (59)	494	302 (61)
2010 p value		<0.001		0.114		<0.001

Table 3.26 HCV antibody prevalence by drug last injected, duration of injection, and year

NEW SOUTH WALES	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Heroin	8	3 (38)	120	107 (89)	129	111 (86)
Methamphetamine	9	6 (67)	26	20 (77)	35	26 (74)
Other	6	2 (33)	234	202 (86)	247	210 (85)
1996						
Heroin	18	3 (17)	172	123 (72)	194	130 (67)
Methamphetamine	10	4 (40)	32	22 (69)	44	27 (61)
Other	16	6 (38)	228	191 (84)	257	208 (81)
1997						
Heroin	28	6 (21)	260	188 (72)	294	199 (68)
Methamphetamine	12	2 (17)	45	19 (42)	58	21 (36)
Other	13	2 (15)	258	204 (79)	284	214 (75)
1998						
Heroin	74	18 (24)	354	249 (70)	437	274 (63)
Methamphetamine	12	3 (25)	50	33 (66)	63	37 (59)
Other	38	11 (29)	360	301 (84)	411	320 (78)
1999						
Heroin	72	30 (42)	407	278 (68)	496	320 (65)
Methamphetamine	16	0 (0)	86	33 (38)	103	33 (32)
Other	28	7 (25)	210	153 (73)	247	168 (68)
2000						
Heroin	71	27 (38)	423	311 (74)	506	346 (68)
Methamphetamine	16	1 (6)	84	44 (52)	106	48 (45)
Other	26	13 (50)	213	160 (75)	248	179 (72)
2001						
Heroin	28	14 (50)	180	142 (79)	212	159 (75)
Methamphetamine	16	6 (38)	86	60 (70)	107	70 (65)
Other	42	17 (40)	283	219 (77)	332	241 (73)
2002						
Heroin	37	19 (51)	318	255 (80)	359	275 (77)
Methamphetamine	17	7 (41)	143	85 (59)	166	96 (58)
Other	22	10 (45)	175	134 (77)	207	149 (72)
2003						
Heroin	38	11 (29)	367	277 (76)	408	291 (71)
Methamphetamine	10	6 (60)	127	82 (65)	138	88 (64)
Other	26	5 (19)	179	134 (75)	214	142 (66)
2004						
Heroin	20	7 (35)	284	215 (76)	307	225 (73)
Methamphetamine	12	2 (17)	122	80 (66)	137	84 (61)
Other	11	3 (27)	143	111 (78)	161	120 (75)
2005						
Heroin	10	2 (20)	269	199 (74)	286	207 (72)
Methamphetamine	7	0 (0)	157	93 (59)	171	98 (57)
Other	12	4 (33)	187	146 (78)	209	157 (75)
2006						
Heroin	5	1 (20)	209	164 (78)	223	172 (77)
Methamphetamine	13	1 (8)	175	108 (62)	192	112 (58)
Other	12	3 (25)	207	163 (79)	228	170 (75)
2007						
Heroin	10	2 (20)	229	163 (71)	241	167 (69)
Methamphetamine	6	3 (50)	162	110 (68)	172	116 (67)
Other	5	0 (0)	221	161 (73)	239	169 (71)
2008						
Heroin	10	3 (30)	305	240 (79)	319	245 (77)
Methamphetamine	10	2 (20)	195	123 (63)	209	126 (60)
Other	25	8 (32)	252	195 (77)	286	209 (73)
2009						
Heroin	10	3 (30)	289	187 (65)	301	190 (63)
Methamphetamine	10	3 (30)	164	85 (52)	177	90 (51)
Other	26	7 (15)	283	173 (61)	316	180 (57)
2010						
Heroin	10	3 (30)	214	137 (64)	231	144 (62)
Methamphetamine	11	2 (18)	184	89 (48)	198	93 (47)
Other	26	3 (12)	201	122 (61)	238	126 (53)
2010 p value		0.381		0.005		0.005

Table 3.27 HCV antibody prevalence by frequency of injection, time since first injection and year

NEW SOUTH WALES	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Less than daily	11	6 (55)	194	171 (88)	280	180 (87)
Daily or more	12	5 (42)	163	141 (87)	180	150 (83)
Not last month	23	11 (48)	23	17 (74)	23	17 (74)
1996						
Less than daily	28	8 (29)	211	173 (82)	247	186 (75)
Daily or more	9	4 (44)	198	148 (75)	218	163 (75)
Not last month	6	1 (17)	22	15 (68)	28	16 (57)
1997						
Less than daily	22	2 (9)	226	154 (68)	252	157 (62)
Daily or more	27	7 (26)	298	229 (77)	340	249 (73)
Not last month	5	1 (20)	35	24 (69)	42	25 (60)
1998						
Less than daily	29	4 (14)	228	175 (77)	263	183 (70)
Daily or more	86	27 (31)	505	388 (77)	604	425 (70)
Not last month	9	1 (11)	35	24 (69)	49	27 (55)
1999						
Less than daily	32	6 (19)	234	143 (61)	274	155 (57)
Daily or more	76	30 (39)	425	295 (69)	517	338 (65)
Not last month	9	1 (11)	44	27 (61)	57	30 (53)
2000						
Less than daily	25	6 (24)	215	137 (64)	251	149 (59)
Daily or more	85	35 (41)	466	352 (76)	564	397 (70)
Not last month	5	1 (20)	36	25 (69)	42	26 (62)
2001						
Less than daily	32	16 (50)	209	157 (75)	246	176 (72)
Daily or more	39	16 (41)	277	213 (77)	323	233 (72)
Not last month	15	5 (33)	63	50 (79)	81	57 (70)
2002						
Less than daily	28	11 (39)	225	161 (72)	261	176 (67)
Daily or more	36	20 (56)	343	264 (77)	388	288 (74)
Not last month	11	4 (36)	68	48 (71)	82	55 (67)
2003						
Less than daily	32	10 (31)	284	198 (69)	326	212 (65)
Daily or more	29	10 (34)	319	244 (76)	351	257 (73)
Not last month	10	1 (10)	72	51 (71)	83	52 (63)
2004						
Less than daily	13	3 (23)	248	177 (71)	265	184 (69)
Daily or more	24	9 (38)	268	203 (76)	299	218 (73)
Not last month	4	0 (0)	34	28 (82)	39	28 (72)
2005						
Less than daily	16	3 (19)	255	175 (69)	279	183 (66)
Daily or more	11	3 (27)	313	232 (74)	336	246 (73)
Not last month	2	0 (0)	62	61 (66)	69	43 (62)
2006						
Less than daily	16	0 (0)	269	199 (74)	293	201 (69)
Daily or more	11	3 (27)	251	183 (73)	275	197 (72)
Not last month	3	2 (67)	80	60 (75)	86	62 (72)
2007						
Less than daily	11	2 (18)	272	202 (74)	287	208 (72)
Daily or more	10	3 (30)	265	180 (68)	282	189 (67)
Not last month	1	0 (0)	73	50 (68)	79	52 (66)
2008						
Less than daily	22	2 (9)	318	224 (70)	344	229 (67)
Daily or more	15	8 (53)	332	263 (79)	357	277 (78)
Not last month	7	2 (29)	109	77 (71)	120	80 (67)
2009						
Less than daily	17	3 (18)	321	196 (61)	342	200 (58)
Daily or more	20	2 (10)	305	184 (60)	330	190 (58)
Not last month	8	2 (25)	115	69 (60)	127	71 (56)
2010						
Less than daily	25	2 (8)	253	135 (53)	282	138 (49)
Daily or more	13	4 (31)	235	149 (63)	258	155 (60)
Not last month	7	2 (29)	105	59 (56)	117	64 (55)
2010 p value		0.131		0.073		0.033

Table 3.28 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, time since first injection and year

NEW SOUTH WALES	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
No receptive sharing	15	5 (33)	236	206 (87)	256	216 (84)
Receptive sharing	8	6 (75)	121	106 (88)	132	114 (86)
1996						
No receptive sharing	30	9 (30)	278	216 (76)	317	231 (73)
Receptive sharing	7	3 (43)	131	105 (77)	148	118 (80)
1997						
No receptive sharing	35	6 (17)	430	305 (71)	481	324 (67)
Receptive sharing	11	2 (18)	81	67 (82)	95	70 (74)
1998						
No receptive sharing	87	23 (26)	571	433 (76)	670	467 (69)
Receptive sharing	24	7 (29)	138	114 (82)	166	123 (74)
1999						
No receptive sharing	77	25 (32)	494	323 (66)	587	361 (62)
Receptive sharing	27	9 (33)	140	99 (71)	175	114 (65)
2000						
No receptive sharing	83	29 (35)	538	379 (70)	639	420 (66)
Receptive sharing	25	12 (48)	120	92 (76)	151	108 (72)
2001						
No receptive sharing	60	28 (47)	393	296 (75)	463	330 (71)
Receptive sharing	8	2 (25)	76	59 (77)	86	62 (72)
2002						
No receptive sharing	46	19 (41)	453	340 (75)	510	363 (71)
Receptive sharing	16	11 (69)	98	73 (74)	118	87 (74)
2003						
No receptive sharing	53	17 (32)	487	352 (72)	552	376 (68)
Receptive sharing	5	2 (40)	98	78 (80)	104	80 (77)
2004						
No receptive sharing	27	7 (26)	411	304 (74)	446	318 (71)
Receptive sharing	9	5 (56)	90	64 (71)	102	72 (71)
2005						
No receptive sharing	21	3 (14)	468	327 (70)	504	342 (68)
Receptive sharing	5	2 (40)	80	65 (82)	89	71 (80)
2006						
No receptive sharing	24	3 (13)	429	313 (73)	464	320 (69)
Receptive sharing	2	0 (0)	69	53 (77)	79	61 (77)
2007						
No receptive sharing	14	4 (29)	439	309 (70)	460	320 (70)
Receptive sharing	5	1 (20)	72	53 (74)	79	56 (71)
2008						
No receptive sharing	29	6 (21)	515	379 (74)	558	394 (71)
Receptive sharing	6	4 (67)	114	89 (78)	120	93 (76)
2009						
No receptive sharing	34	3 (9)	510	307 (60)	551	314 (57)
Receptive sharing	3	2 (67)	105	66 (63)	109	68 (62)
2010						
No receptive sharing	30	5 (17)	352	195 (55)	394	203 (52)
Receptive sharing	4	1 (25)	78	52 (67)	83	53 (64)
2010 p value		0.559		0.077		0.052

Table 3.29 HCV antibody prevalence by imprisonment last year, time since first injection and year

NEW SOUTH WALES	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Not imprisoned	20	11 (55)	297	253 (85)	323	269 (83)
Imprisoned	2	0 (0)	82	75 (91)	86	77 (90)
1996						
Not imprisoned	37	8 (22)	334	248 (74)	383	264 (69)
Imprisoned	5	2 (40)	83	67 (81)	93	74 (80)
1997						
Not imprisoned	50	8 (16)	445	317 (71)	511	334 (65)
Imprisoned	4	2 (50)	120	96 (80)	128	102 (80)
1998						
Not imprisoned	97	23 (24)	567	419 (74)	682	455 (67)
Imprisoned	26	9 (35)	192	160 (83)	222	172 (77)
1999						
Not imprisoned	99	27 (27)	556	339 (61)	677	380 (56)
Imprisoned	14	9 (64)	143	124 (87)	163	137 (84)
2000						
Not imprisoned	88	26 (29)	533	366 (69)	641	403 (63)
Imprisoned	25	17 (68)	172	140 (81)	205	164 (80)
2001						
Not imprisoned	68	24 (35)	419	310 (74)	502	341 (68)
Imprisoned	14	10 (71)	126	108 (86)	141	119 (84)
2002						
Not imprisoned	56	21 (38)	494	352 (71)	569	380 (67)
Imprisoned	18	13 (72)	134	114 (85)	155	129 (83)
2003						
Not imprisoned	57	19 (33)	516	366 (71)	591	389 (66)
Imprisoned	17	3 (18)	146	115 (79)	166	121 (73)
2004						
Not imprisoned	31	7 (23)	424	299 (71)	462	310 (67)
Imprisoned	11	5 (45)	127	110 (87)	144	121 (84)
2005						
Not imprisoned	26	15 (34)	490	334 (68)	536	350 (65)
Imprisoned	2	5 (83)	118	97 (82)	126	104 (83)
2006						
Not imprisoned	26	4 (15)	492	347 (71)	538	361 (67)
Imprisoned	3	1 (33)	86	76 (88)	93	80 (86)
2007						
Not imprisoned	20	5 (25)	499	350 (70)	533	363 (68)
Imprisoned	0	0 (0)	95	72 (76)	99	76 (77)
2008						
Not imprisoned	38	10 (26)	582	412 (71)	632	428 (68)
Imprisoned	3	1 (33)	118	100 (85)	125	104 (83)
2009						
Not imprisoned	41	4 (10)	615	360 (59)	673	369 (55)
Imprisoned	3	2 (67)	98	70 (71)	101	72 (71)
2010						
Not imprisoned	41	5 (12)	427	228 (53)	486	238 (49)
Imprisoned	1	0 (0)	74	55 (74)	76	56 (74)
2010 p value		1.000		0.001		<0.001

Table 3.30 HCV antibody prevalence by sex work last month, time since first injection and year

NEW SOUTH WALES	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
No sex work	20	11 (55)	348	302 (87)	375	319 (85)
Sex work	2	0 (0)	23	20 (87)	25	20 (80)
1996						
No sex work	37	11 (30)	365	281 (77)	412	300 (73)
Sex work	3	0 (0)	44	26 (59)	52	30 (58)
1997						
No sex work	49	7 (14)	490	365 (74)	557	383 (69)
Sex work	4	2 (50)	65	39 (60)	70	42 (60)
1998						
No sex work	110	27 (25)	685	518 (76)	815	560 (69)
Sex work	9	4 (44)	69	57 (83)	79	61 (77)
1999						
No sex work	100	31 (31)	606	401 (66)	726	445 (61)
Sex work	13	5 (38)	84	54 (64)	103	62 (60)
2000						
No sex work	102	39 (38)	614	442 (72)	740	495 (67)
Sex work	11	4 (36)	87	64 (74)	102	72 (71)
2001						
No sex work	82	36 (44)	460	354 (77)	558	398 (71)
Sex work	4	1 (25)	75	56 (75)	80	58 (73)
2002						
No sex work	64	32 (50)	550	415 (75)	633	455 (72)
Sex work	8	1 (13)	69	42 (61)	82	45 (55)
2003						
No sex work	65	20 (31)	599	434 (73)	684	460 (67)
Sex work	9	2 (22)	51	41 (80)	60	43 (72)
2004						
No sex work	41	11 (27)	483	354 (73)	536	374 (70)
Sex work	1	1 (100)	61	48 (79)	63	50 (79)
2005						
No sex work	29	6 (21)	571	401 (70)	625	424 (68)
Sex work	0	0 (0)	47	38 (81)	49	40 (82)
2006						
No sex work	26	4 (15)	520	388 (75)	568	404 (71)
Sex work	2	1 (50)	54	37 (69)	58	39 (67)
2007						
No sex work	19	5 (26)	548	393 (72)	581	408 (70)
Sex work	1	0 (0)	45	32 (71)	49	33 (67)
2008						
No sex work	39	10 (26)	659	483 (73)	714	502 (70)
Sex work	3	2 (67)	64	50 (78)	68	52 (76)
2009						
No sex work	45	6 (13)	666	399 (60)	726	410 (56)
Sex work	1	1 (100)	55	40 (73)	57	41 (72)
2010						
No sex work	39	4 (10)	504	293 (58)	561	303 (54)
Sex work	5	3 (60)	45	23 (51)	51	26 (51)
2010 p value		0.023		0.432		0.770

Table 3.31 HCV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Non-Indigenous	231	199 (86)	136	111 (82)	372	314 (84)
Indigenous	16	13 (81)	10	10 (100)	26	23 (88)
1996						
Non-Indigenous	273	204 (75)	139	99 (71)	415	305 (73)
Indigenous	19	11 (58)	15	12 (80)	34	23 (68)
1997						
Non-Indigenous	357	242 (68)	225	156 (69)	583	399 (68)
Indigenous	19	10 (53)	24	17 (71)	43	27 (63)
1998						
Non-Indigenous	485	329 (68)	318	227 (71)	809	559 (69)
Indigenous	35	23 (66)	43	32 (74)	78	55 (71)
1999						
Non-Indigenous	475	274 (58)	266	165 (62)	744	442 (59)
Indigenous	41	33 (80)	35	27 (77)	78	61 (78)
2000						
Non-Indigenous	487	314 (64)	272	192 (71)	763	509 (67)
Indigenous	41	28 (68)	49	30 (61)	90	58 (64)
2001						
Non-Indigenous	369	256 (69)	211	161 (76)	583	418 (72)
Indigenous	31	23 (74)	28	17 (61)	61	42 (69)
2002						
Non-Indigenous	419	294 (70)	211	143 (68)	637	443 (70)
Indigenous	33	28 (85)	39	32 (82)	73	61 (84)
2003						
Non-Indigenous	483	319 (66)	184	129 (70)	672	451 (67)
Indigenous	40	32 (80)	42	28 (67)	85	62 (73)
2004						
Non-Indigenous	354	246 (69)	162	117 (72)	519	366 (71)
Indigenous	43	33 (77)	30	21 (70)	75	55 (73)
2005						
Non-Indigenous	372	258 (69)	185	124 (67)	562	385 (69)
Indigenous	54	38 (70)	48	39 (81)	103	78 (76)
2006						
Non-Indigenous	372	257 (69)	176	125 (71)	554	384 (69)
Indigenous	39	27 (69)	47	42 (89)	86	69 (80)
2007						
Non-Indigenous	358	239 (67)	184	135 (73)	545	376 (69)
Indigenous	54	42 (78)	44	31 (70)	99	73 (74)
2008						
Non-Indigenous	449	314 (70)	225	163 (72)	680	480 (71)
Indigenous	67	50 (75)	48	40 (83)	116	91 (78)
2009						
Non-Indigenous	419	231 (55)	245	152 (62)	669	385 (58)
Indigenous	48	27 (56)	70	37 (53)	120	64 (53)
2010						
Non-Indigenous	357	191 (54)	197	113 (57)	558	305 (55)
Indigenous	52	31 (60)	42	21 (50)	96	53 (55)
2010 p value		0.458		0.397		1.000

Table 3.32 HCV antibody prevalence by country of birth, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2003						
Australia	344	233 (68)	183	127 (69)	536	366 (68)
Other	187	124 (66)	46	33 (72)	233	157 (67)
2004						
Australia	260	174 (67)	160	117 (73)	423	293 (69)
Other	140	105 (75)	34	22 (65)	175	128 (73)
2005						
Australia	371	252 (68)	216	148 (69)	591	403 (68)
Other	64	47 (73)	24	17 (71)	90	65 (72)
2006						
Australia	347	241 (69)	208	155 (75)	559	397 (71)
Other	71	47 (66)	22	16 (73)	94	63 (67)
2007						
Australia	356	237 (67)	200	145 (73)	559	384 (69)
Other	59	45 (76)	28	22 (78)	88	67 (76)
2008						
Australia	464	324 (70)	251	187 (75)	719	514 (71)
Other	59	43 (73)	23	15 (65)	84	58 (69)
2009						
Australia	414	234 (57)	292	171 (59)	711	406 (57)
Other	59	34 (58)	25	20 (80)	87	56 (64)
2010						
Australia	355	195 (55)	216	119 (55)	575	316 (55)
Other	55	28 (51)	24	14 (58)	80	42 (53)
2010 p value		0.663		0.831		0.720

Table 3.33 HCV antibody prevalence by language spoken at home by parents, gender and year

NEW SOUTH WALES	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2003						
English speaking	338	231 (68)	195	136 (70)	542	373 (69)
Non-English speaking	168	107 (64)	29	19 (66)	197	126 (64)
2004						
English speaking	184	121 (66)	135	103 (76)	321	225 (70)
Non-English speaking	115	85 (74)	25	13 (52)	140	98 (70)
2005						
English speaking	369	253 (69)	218	151 (69)	592	407 (69)
Non-English speaking	70	49 (70)	25	17 (68)	96	67 (70)
2006						
English speaking	361	253 (70)	214	159 (74)	581	414 (71)
Non-English speaking	42	25 (60)	12	8 (67)	54	33 (61)
2007						
English speaking	392	266 (68)	216	158 (73)	612	426 (70)
Non-English speaking	23	16 (70)	14	10 (71)	37	26 (70)
2008						
English speaking	503	352 (70)	268	197 (74)	778	553 (71)
Non-English speaking	27	21 (78)	8	7 (88)	35	28 (80)
2009						
English speaking	458	258 (56)	307	183 (60)	773	444 (57)
Non-English speaking	21	10 (48)	11	8 (73)	32	18 (56)
2010						
English speaking	398	220 (55)	234	128 (55)	638	350 (55)
Non-English speaking	17	6 (35)	6	4 (67)	23	10 (43)
2010 p value		0.136		0.693		0.295

4. NORTHERN TERRITORY


Recruitment of survey participants in the Northern Territory (NT) was undertaken in all survey years by the primary NSP services operated by the Northern Territory AIDS & Hepatitis C Council. Darwin NSP Service participated in the ANSPS every year between 1995 to 2010. Alice Springs NSP participated in the ANSPS in 11 of the past 16 years, with Palmerston NSP commencing participation in 2004 (see Appendix 1 for further details). Sample sizes have ranged considerably, from 20 (in 2006) to 102 (in 1997 and 1998). Response rates have also varied considerably, from 16% to 78% (Table 2.1). The relatively small number of participants in some survey years is likely to have contributed to some of the variation in demographic and injecting characteristics observed over time in the NT.

Demographic Characteristics

The majority of survey participants in the NT were male and identified as heterosexual. Despite some variation over the survey period, the proportion of participants from an Indigenous background in the NT increased from 3% in 1995 to 22% in 2010 (χ^2 trend $p=0.001$, Table 4.1). The majority of NT participants were born in Australia (84% to 97%) and reported their parents spoke English at home (74% to 100%) across all years in which these data were available.

The median age of NT participants was higher than observed nationally in most survey years, with a low of 30 years observed in 1996 and a high of 41 years observed in 2010 (Figure 4.1). Young people (aged younger than 25 years) comprised approximately one quarter of the NT samples in the 1990s, and as observed nationally and in other jurisdictions, declined throughout the 2000s, with young people comprising less than 10% of ANSPS participants since 2006 (χ^2 trend $p<0.001$, Table 4.1). The median age at first injection remained relatively stable at between 17 and 20 between 1995 and 2010.


Figure 4.1 NT: Median age and proportion young injectors by year



Injecting behaviour


Pharmaceutical opioids were the class of drug NT participants were most likely to report last injecting in all years between 1997 and 2010. Unlike other jurisdictions there was no increase in the prevalence of recent injection of pharmaceutical opioids over the survey period (χ^2 trend $p=0.234$, Figure 4.2, Table 4.2). Between 11% and 36% of NT participants reported last injecting methamphetamine over the survey period; and although more than one third of NT participants in 1996 reported last injecting heroin, reports of injection of this drug were uncommon throughout the 2000s.

Figure 4.2 NT: Prevalence of heroin, methamphetamine and pharmaceutical opioids as drug last injected by year



No temporal trends were observed in the NT with respect to respondents who reported re-use or receptive sharing of syringes or ancillary injecting equipment. As was the case nationally, rates of receptive sharing of syringes were lower than those reported for ancillary equipment, with spoons and tourniquets the ancillary items NT participants were most likely to report sharing. The proportion of NT respondents who reported injection in a public place in the month preceding survey completion varied over the survey period; prevalence of public injection was lower in the NT than observed nationally in all survey years (Figure 4.3).


Figure 4.3 National and NT: Prevalence of public injection by year



HIV prevalence

HIV antibody prevalence in the NT remained low at 5% or less in all years between 1995 and 2010 (Figure 4.4, Table 4.9). Detailed data on HIV antibody prevalence is not presented in this report due to small cell sizes; however, all HIV antibody positive NT participants were male, and the majority identified as homosexual or bisexual.

Figure 4.4 NT: HIV antibody prevalence by year



HCV prevalence

HCV antibody prevalence in the NT fluctuated over the survey period, and although there was no temporal trend (χ^2 trend $p=0.862$), prevalence declined over the period 2007 to 2009 (Table 4.10, Figure 4.5). The wide variations in HCV antibody prevalence, from 63% in 1995 to 29% in 2006, are most likely attributable to the small sample size in this jurisdiction in some survey years.

Figure 4.5 National and NT: HCV antibody prevalence by year




Table 4.1 Number (percentage) of respondents by demographic characteristic and year

NORTHERN TERRITORY	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Number of sites	2	2	2	2	1	2	2	1	1	2	3	1	3	3	3	3
N° surveyed	N=30	N=19	N=102	N=102	N=93	N=95	N=94	N=47	N=62	N=23	N=29	N=20	N=31	N=75	N=77	N=83
Response rate	42%	17%	70%	58%	55%	65%	57%	42%	78%	16%	39%	--	31%	43%	29%	31%
Gender (%)																
Male	20 (67)	13 (68)	76 (74)	77 (75)	73 (78)	75 (79)	75 (80)	35 (75)	44 (71)	16 (70)	19 (66)	9 (45)	22 (71)	48 (64)	52 (68)	59 (71)
Female	10 (33)	6 (32)	24 (24)	25 (25)	20 (22)	19 (20)	18 (19)	11 (23)	18 (29)	6 (26)	10 (34)	11 (55)	9 (29)	27 (36)	25 (32)	24 (29)
Transgender	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)	1 (1)	1 (2)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)																
Heterosexual	23 (77)	19 (100)	85 (83)	80 (78)	83 (89)	69 (73)	69 (73)	41 (88)	48 (77)	19 (83)	26 (90)	13 (65)	28 (90)	62 (83)	66 (86)	67 (81)
Bisexual	3 (10)	0 (0)	7 (7)	11 (11)	7 (8)	10 (11)	8 (9)	1 (2)	6 (10)	4 (17)	2 (7)	4 (20)	1 (3)	4 (5)	5 (6)	10 (12)
Homosexual	3 (10)	0 (0)	8 (8)	6 (6)	2 (2)	9 (9)	4 (4)	2 (4)	2 (3)	0 (0)	1 (3)	3 (15)	2 (6)	5 (7)	2 (3)	5 (6)
Not reported	1 (3)	0 (0)	2 (2)	5 (5)	1 (1)	7 (7)	13 (14)	3 (6)	6 (10)	0 (0)	0 (0)	0 (0)	0 (0)	4 (5)	4 (5)	1 (1)
Age and time since first injection (years)																
<i>Median age</i>	34	30	30.5	31	33	34	35	37	37	38	35	33	38	39	40	41
<i>Age range</i>	21-48	21-43	16-50	16-56	16-57	18-58	16-52	19-55	20-53	21-50	19-56	24-52	25-59	17-66	22-60	17-63
<i>Age group (%)</i>																
< 25 years	7 (23)	3 (16)	25 (25)	27 (26)	21 (23)	17 (18)	21 (22)	8 (17)	3 (5)	2 (9)	4 (14)	1 (5)	0 (0)	3 (4)	4 (5)	6 (7)
25+ years	23 (77)	16 (84)	77 (75)	75 (74)	72 (77)	78 (82)	73 (78)	39 (83)	58 (93)	21 (91)	25 (86)	19 (95)	31 (100)	72 (96)	73 (95)	77 (93)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	20	18	17	18	18	18	18.5	18	19	18	20	19.5	17	18	18	18
<i>Age range</i>	13-41	11-36	12-41	12-47	10-41	9-45	13-48	12-37	8-40	13-35	11-41	14-30	12-42	13-58	12-42	12-46
N° not reported	2	0	1	1	0	2	4	0	2	0	2	0	1	2	4	0
<i>Median years IDU</i>	8	7	10	10	11	12	11	17	14	19	15	11.5	18	16	18	19
<i>Range</i>	1-28	1-27	<1-30	<1-35	<1-34	<1-35	<1-34	<1-36	1-36	3-32	1-36	5-36	3-36	<1-35	1-37	<1-43
Time since first injection																
<3 years	5 (17)	2 (11)	14 (14)	14 (14)	12 (13)	6 (6)	13 (14)	3 (6)	4 (6)	0 (0)	2 (7)	0 (0)	0 (0)	1 (1)	4 (5)	7 (8)
3+ years	23 (77)	17 (89)	87 (85)	87 (85)	81 (87)	86 (91)	77 (82)	44 (94)	56 (90)	23 (100)	26 (90)	20 (100)	30 (97)	72 (96)	69 (90)	76 (92)
Not reported	2 (7)	0 (0)	1 (1)	1 (1)	0 (0)	3 (3)	4 (4)	0 (0)	2 (3)	0 (0)	1 (3)	0 (0)	1 (3)	2 (3)	4 (5)	0 (0)

Table 4.1 Number (percentage) of respondents by demographic characteristic and year (continued)

NORTHERN TERRITORY	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=30	N=19	N=102	N=102	N=93	N=95	N=94	N=47	N=62	N=23	N=29	N=20	N=31	N=75	N=77	N=83
Aboriginal and Torres Strait Islander origin (%)																
No	27 (90)	18 (95)	92 (90)	89 (87)	83 (89)	87 (92)	81 (86)	44 (94)	54 (87)	21 (92)	27 (93)	17 (85)	30 (97)	61 (81)	65 (84)	64 (77)
Yes	1 (3)	1 (5)	10 (10)	13 (13)	10 (11)	7 (7)	11 (12)	3 (6)	6 (10)	1 (4)	1 (3)	3 (15)	0 (0)	13 (17)	10 (13)	18 (22)
Not reported	2 (7)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	0 (0)	2 (3)	1 (4)	1 (3)	0 (0)	1 (3)	1 (1)	2 (3)	1 (1)
Region/country of birth (%)																
Australia	--	--	--	--	86 (92)	80 (96)	83 (89)	38 (81)	52 (84)	20 (87)	28 (97)	19 (95)	28 (90)	65 (87)	65 (84)	71 (86)
Other Oceania	--	--	--	--	--	1 (1)	5 (5)	1 (2)	3 (5)	0 (0)	0 (0)	1 (5)	1 (3)	2 (3)	2 (3)	3 (4)
Asia	--	--	--	--	0 (0)	2 (2)	1 (1)	0 (0)	1 (1)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	2 (3)	0 (0)
UK & Ireland	--	--	--	--	--	7 (8)	3 (3)	8 (17)	6 (10)	0 (0)	0 (0)	0 (0)	1 (3)	3 (4)	2 (3)	6 (7)
Other	--	--	--	--	7 (8)	2 (2)	1 (1)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	2 (3)	4 (5)	2 (2)
Not reported	--	--	--	--	0 (0)	3 (3)	1 (1)	0 (0)	0 (0)	1 (4)	1 (3)	0 (0)	1 (3)	3 (4)	2 (3)	1 (1)
Main language spoken at home by parents (%)																
English	--	--	--	--	83 (90)	91 (96)	82 (87)	46 (98)	59 (95)	17 (74)	25 (86)	18 (90)	29 (94)	75 (100)	70 (91)	77 (93)
Non-English	--	--	--	--	5 (5)	1 (1)	5 (5)	0 (0)	1 (2)	0 (0)	4 (14)	0 (0)	1 (3)	0 (0)	6 (7)	6 (7)
Not reported	--	--	--	--	5 (5)	3 (3)	7 (8)	1 (2)	2 (3)	6 (26)	0 (0)	2 (10)	1 (3)	0 (0)	1 (1)	0 (0)
Imprisonment last year (%)																
No	29 (97)	16 (84)	92 (90)	90 (88)	84 (90)	81 (85)	72 (77)	41 (87)	56 (90)	17 (74)	26 (90)	19 (95)	29 (94)	69 (92)	72 (94)	65 (78)
Yes	1 (3)	2 (11)	10 (10)	11 (11)	9 (10)	11 (12)	17 (18)	4 (9)	6 (10)	5 (22)	2 (7)	1 (5)	1 (3)	3 (4)	2 (3)	2 (2)
Not reported	0 (0)	1 (5)	0 (0)	1 (1)	0 (0)	3 (3)	5 (5)	2 (4)	0 (0)	1 (4)	1 (3)	0 (0)	1 (3)	3 (4)	3 (4)	16 (19)
Injected in prison last year (%)																
N° in prison	N=1	N=2	N=10	N=11	N=9	N=11	N=17	N=4	N=6	N=5	N=2	N=1	N=1	N=3	N=2	N=2
Injected in prison	0 (0)	1 (50)	4 (40)	5 (45)	1 (11)	5 (45)	2 (12)	2 (50)	2 (33)	3 (60)	1 (50)	0 (0)	1 (100)	0 (0)	1 (50)	1 (50)
Frequency of injection last month (%)																
Not last month	1 (3)	1 (5)	8 (8)	2 (2)	1 (1)	8 (8)	4 (4)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (6)	4 (5)	7 (9)	10 (12)
Less than weekly	7 (23)	6 (32)	24 (24)	12 (12)	10 (11)	14 (15)	7 (7)	6 (13)	4 (7)	4 (18)	5 (17)	5 (25)	3 (10)	8 (11)	13 (17)	13 (16)
Weekly not daily	5 (17)	1 (5)	13 (13)	14 (14)	11 (12)	15 (16)	13 (14)	8 (17)	9 (14)	1 (4)	2 (7)	4 (20)	6 (19)	11 (15)	15 (19)	13 (16)
Daily or more	17 (57)	11 (58)	57 (55)	74 (72)	71 (76)	55 (58)	69 (74)	33 (70)	48 (77)	18 (78)	22 (76)	11 (55)	20 (65)	52 (69)	42 (55)	45 (54)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)

Table 4.2 Number (percentage) of respondents by drug last injected and year

NORTHERN TERRITORY N° surveyed	1995 N=30	1996 N=19	1997 N=102	1998 N=102	1999 N=93	2000 N=95	2001 N=94	2002 N=47	2003 N=62	2004 N=23	2005 N=29	2006 N=20	2007 N=31	2008 N=75	2009 N=77	2010 N=83	
Drug last injected (%)																	
Anabolic steroids	1 (3)	2 (10)	3 (3)	1 (1)	1 (1)	2 (2)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	
Heroin	6 (20)	7 (37)	19 (19)	10 (10)	11 (12)	12 (13)	5 (5)	2 (4)	2 (3)	0 (0)	0 (0)	0 (0)	0 (0)	2 (3)	2 (3)	3 (4)	
Methadone	4 (13)	3 (16)	6 (6)	1 (1)	3 (3)	0 (0)	8 (9)	0 (0)	5 (8)	1 (4)	4 (14)	0 (0)	5 (16)	4 (5)	7 (9)	3 (4)	
Methamphetamine	6 (20)	4 (21)	11 (11)	19 (19)	21 (22)	26 (27)	34 (36)	7 (15)	15 (24)	7 (30)	8 (28)	7 (35)	5 (16)	13 (17)	20 (26)	21 (25)	
Pharm. opioids	10 (34)	3 (16)	59 (57)	71 (69)	56 (61)	43 (46)	40 (43)	37 (79)	33 (53)	13 (57)	14 (48)	12 (60)	16 (52)	47 (63)	38 (49)	50 (60)	
Buprenorphine	--	--	--	--	--	--	--	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	4 (13)	1 (1)	1 (1)	1 (1)	
More than one	3 (10)	0 (0)	3 (3)	0 (0)	0 (0)	9 (9)	6 (6)	0 (0)	3 (5)	2 (9)	0 (0)	1 (5)	0 (0)	2 (3)	1 (1)	0 (0)	
Other	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	2 (3)	0 (0)	1 (3)	0 (0)	0 (0)	4 (5)	2 (3)	4 (5)	
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)	0 (0)	0 (0)	1 (2)	0 (0)	1 (3)	0 (0)	1 (3)	2 (3)	4 (5)	0 (0)	

Table 4.3 Number (percentage) of respondents by places injected in the last month and year

NORTHERN TERRITORY N° injected last month	1995 N=29	1996 N=18	1997 N=94	1998 N=100	1999 N=92	2000 N=84	2001 N=89	2002 N=47	2003 N=61	2004 N=23	2005 N=29	2006 N=17	2007 N=29	2008 N=71	2009 N=70	2010 N=71	
Places injected in the last month (%) [More than one could be selected]																	
<i>Private places</i>																	
Own home	--	--	79 (84)	88 (88)	86 (93)	69 (82)	73 (82)	44 (94)	56 (92)	22 (96)	24 (83)	16 (94)	26 (93)	67 (94)	62 (89)	54 (76)	
Friend's home	--	--	46 (49)	56 (56)	22 (24)	38 (45)	35 (39)	19 (40)	29 (48)	12 (52)	9 (31)	9 (53)	8 (29)	27 (38)	34 (49)	40 (56)	
Dealer's home	--	--	16 (17)	19 (19)	3 (3)	20 (24)	22 (25)	11 (23)	11 (18)	5 (22)	2 (7)	4 (24)	1 (4)	9 (13)	13 (19)	16 (23)	
Commercial injecting room	--	--	0 (0)	0 (0)	1 (1)	3 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	
<i>Public places</i>																	
Street, park, beach	--	--	25 (27)	18 (18)	6 (7)	17 (20)	8 (9)	4 (9)	8 (13)	1 (4)	2 (7)	3 (18)	1 (4)	7 (10)	11 (16)	12 (17)	
Car	--	--	--	29 (29)	19 (21)	27 (32)	17 (19)	17 (15)	12 (20)	4 (17)	3 (10)	4 (24)	3 (11)	8 (11)	18 (26)	14 (20)	
Public toilet	--	--	19 (20)	11 (11)	13 (14)	20 (24)	9 (10)	8 (17)	14 (23)	3 (13)	1 (3)	2 (12)	6 (21)	9 (13)	9 (13)	15 (21)	
Squat	--	--	--	--	2 (2)	9 (11)	4 (4)	4 (9)	3 (5)	1 (4)	2 (7)	0 (0)	0 (0)	1 (1)	3 (4)	3 (4)	
Public injecting in last month (%)																	
Any public	--	--	38 (40)	37 (37)	28 (30)	32 (38)	18 (20)	14 (30)	18 (30)	5 (22)	6 (21)	4 (20)	7 (24)	14 (20)	28 (40)	26 (37)	
All private	--	--	56 (60)	63 (63)	64 (70)	48 (57)	71 (80)	32 (68)	42 (69)	18 (78)	19 (66)	13 (65)	21 (72)	57 (80)	42 (60)	42 (37)	
Not reported	--	--	0 (0)	0 (0)	0 (0)	4 (5)	0 (0)	1 (2)	1 (2)	0 (0)	4 (14)	3 (15)	1 (3)	0 (0)	0 (0)	3 (4)	

Table 4.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

NORTHERN TERRITORY	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=29	N=18	N=94	N=100	N=92	N=84	N=89	N=47	N=61	N=23	N=29	N=17	N=29	N=71	N=70	N=71
Use of sterile needles and syringes last month (%)																
All injections	--	--	62 (66)	78 (78)	82 (89)	64 (77)	67 (75)	41 (87)	53 (86)	21 (92)	26 (90)	15 (75)	26 (90)	61 (86)	59 (84)	57 (80)
Most of the time	--	--	30 (32)	18 (18)	9 (10)	15 (18)	13 (15)	6 (13)	6 (10)	1 (4)	1 (3)	4 (20)	2 (7)	9 (13)	9 (13)	10 (14)
Half of the time	--	--	2 (2)	4 (4)	1 (1)	2 (2)	3 (3)	0 (0)	0 (0)	1 (4)	2 (7)	0 (0)	1 (3)	0 (0)	1 (1)	2 (3)
Some of the time	--	--	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Not last month	--	--	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	--	--	0 (0)	0 (0)	0 (0)	1 (1)	4 (5)	0 (0)	1 (2)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	2 (3)
Re-used someone else's used needle & syringe last month (%)																
None	21 (72)	13 (72)	85 (91)	94 (94)	73 (80)	70 (84)	73 (82)	46 (98)	52 (84)	23 (100)	27 (93)	18 (90)	26 (90)	65 (92)	62 (89)	62 (87)
Once	3 (10)	1 (6)	0 (0)	5 (5)	3 (3)	1 (1)	1 (1)	1 (2)	3 (5)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	5 (7)	1 (1)
Twice	3 (10)	3 (16)	2 (2)	0 (0)	3 (3)	10 (12)	1 (1)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	2 (3)	0 (0)	1 (1)
3-5 times	1 (4)	1 (6)	3 (3)	1 (1)	0 (0)	1 (1)	4 (5)	0 (0)	1 (2)	0 (0)	1 (3)	0 (0)	1 (3)	3 (4)	1 (1)	1 (1)
> 5 times	1 (4)	0 (0)	4 (4)	0 (0)	0 (0)	1 (1)	4 (5)	0 (0)	3 (5)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	13 (14)	1 (1)	6 (6)	0 (0)	1 (2)	0 (0)	1 (3)	1 (5)	2 (7)	0 (0)	1 (1)	6 (8)
Number of people needle & syringe was re-used after last month (%)																
None	21 (72)	13 (72)	85 (91)	94 (94)	73 (80)	70 (84)	73 (82)	46 (98)	52 (85)	23 (100)	27 (93)	18 (90)	26 (90)	65 (92)	62 (89)	62 (87)
One	6 (21)	4 (22)	9 (9)	6 (6)	5 (5)	5 (5)	5 (6)	0 (0)	3 (5)	0 (0)	0 (0)	0 (0)	0 (0)	2 (3)	2 (3)	2 (3)
Two	2 (7)	1 (6)	0 (0)	0 (0)	1 (1)	4 (5)	1 (1)	0 (0)	2 (3)	0 (0)	1 (3)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)
Three to five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (5)	2 (2)	1 (2)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	1 (1)	0 (0)	0 (0)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	2 (3)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	13 (14)	1 (1)	7 (8)	0 (0)	4 (7)	0 (0)	1 (3)	1 (5)	3 (10)	0 (0)	4 (6)	6 (8)
Relationship to people needle & syringe was used after last month (%) [More than one could be selected]																
Regular sex partner	--	--	5 (5)	5 (5)	0 (0)	6 (7)	5 (6)	0 (0)	3 (5)	0 (0)	0 (0)	1 (5)	0 (0)	3 (4)	1 (1)	1 (1)
Casual sex partner	--	--	1 (1)	0 (0)	2 (2)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Close friend	--	--	1 (1)	1 (1)	2 (2)	3 (4)	3 (3)	1 (2)	4 (7)	0 (0)	1 (3)	0 (0)	0 (0)	2 (3)	0 (0)	2 (3)
Acquaintance	--	--	0 (0)	0 (0)	2 (2)	1 (1)	2 (2)	1 (2)	1 (2)	0 (0)	1 (3)	1 (5)	0 (0)	2 (3)	0 (0)	0 (0)
Other	--	--	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)

Table 4.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

NORTHERN TERRITORY N° injected last month	1995 N=29	1996 N=18	1997 N=94	1998 N=100	1999 N=92	2000 N=84	2001 N=89	2002 N=47	2003 N=61	2004 N=23	2005 N=29	2006 N=17	2007 N=29	2008 N=71	2009 N=70	2010 N=71	
Equipment used after someone else last month (%) [More than one could be selected]																	
Spoon	--	--	--	--	4 (4)	29 (35)	21 (24)	7 (15)	16 (26)	7 (30)	8 (28)	3 (16)	4 (17)	18 (26)	12 (18)	19 (27)	
Water	--	--	--	--	11 (12)	11 (13)	11 (12)	0 (0)	6 (10)	2 (9)	4 (14)	0 (0)	1 (4)	5 (7)	4 (6)	4 (6)	
Filter	--	--	--	--	2 (2)	15 (18)	11 (12)	3 (6)	7 (11)	5 (22)	3 (10)	2 (11)	1 (4)	6 (9)	8 (12)	7 (10)	
Drug mix	--	--	--	--	2 (2)	11 (13)	6 (7)	2 (4)	5 (8)	0 (0)	5 (17)	1 (5)	1 (4)	5 (7)	4 (6)	8 (11)	
Tourniquet	--	--	--	--	7 (8)	17 (20)	11 (12)	5 (11)	10 (16)	2 (9)	7 (24)	1 (5)	1 (4)	14 (21)	10 (15)	--	
None	--	--	--	--	--	--	--	--	--	--	--	14 (74)	16 (67)	38 (56)	47 (71)	45 (63)	
Injected by someone after that person injected themselves or others last month (%)																	
No	--	--	--	--	74 (80)	73 (87)	75 (84)	39 (83)	56 (92)	21 (91)	26 (90)	18 (90)	22 (76)	59 (83)	58 (83)	61 (86)	
Yes	--	--	--	--	1 (2)	9 (11)	9 (10)	6 (13)	4 (6)	2 (9)	2 (7)	0 (0)	4 (14)	11 (15)	11 (16)	4 (6)	
Not reported	--	--	--	--	17 (18)	2 (2)	5 (6)	2 (4)	1 (2)	0 (0)	1 (3)	2 (10)	3 (10)	1 (1)	1 (1)	6 (8)	

Table 4.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

NORTHERN TERRITORY N° surveyed	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Sex with a regular partner last month (%)																
No	--	--	--	--	--	--	--	--	--	--	16 (55)	8 (40)	16 (52)	42 (56)	47 (61)	53 (64)
Yes	--	--	--	--	--	--	--	--	--	--	12 (41)	12 (60)	13 (42)	33 (44)	26 (34)	26 (31)
Not reported	--	--	--	--	--	--	--	--	--	--	1 (3)	0 (0)	2 (6)	0 (0)	4 (5)	4 (5)
Condom used with regular partner last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	8 (67)	9 (75)	10 (77)	24 (73)	19 (73)	20 (77)
Sometimes	--	--	--	--	--	--	--	--	--	--	1 (8)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)
Every time	--	--	--	--	--	--	--	--	--	--	1 (8)	1 (8)	3 (23)	8 (24)	3 (12)	4 (15)
Not reported	--	--	--	--	--	--	--	--	--	--	2 (17)	2 (17)	0 (0)	1 (3)	3 (12)	2 (8)
Sex with other partner(s) last month (%)																
No	--	--	--	--	--	--	--	--	--	--	25 (86)	16 (80)	24 (77)	66 (88)	65 (84)	65 (78)
Yes	--	--	--	--	--	--	--	--	--	--	4 (14)	4 (20)	6 (19)	7 (9)	6 (8)	12 (14)
Not reported	--	--	--	--	--	--	--	--	--	--	0 (0)	0 (0)	1 (3)	2 (3)	6 (8)	6 (7)

Table 4.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

NORTHERN TERRITORY N° surveyed	1995 N=30	1996 N=19	1997 N=102	1998 N=102	1999 N=93	2000 N=95	2001 N=94	2002 N=47	2003 N=62	2004 N=23	2005 N=29	2006 N=20	2007 N=31	2008 N=75	2009 N=77	2010 N=83	
Condom used with other partner(s) last month (%)																	
Never	--	--	--	--	--	--	--	--	--	--	3 (75)	1 (25)	2 (33)	2 (29)	2 (33)	5 (42)	
Sometimes	--	--	--	--	--	--	--	--	--	--	0 (0)	1 (25)	0 (0)	3 (43)	1 (17)	2 (17)	
Every time	--	--	--	--	--	--	--	--	--	--	1 (25)	2 (50)	4 (67)	2 (29)	3 (50)	4 (33)	
Not reported	--	--	--	--	--	--	--	--	--	--	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)	
Sex last month (%)																	
No	9 (30)	6 (32)	40 (39)	39 (38)	47 (51)	33 (35)	38 (40)	21 (45)	24 (39)	12 (52)	--	--	--	--	--	--	
Yes	21 (70)	13 (68)	61 (60)	61 (60)	46 (49)	56 (59)	55 (59)	25 (53)	38 (61)	11 (48)	--	--	--	--	--	--	
Not reported	0 (0)	0 (0)	1 (1)	2 (2)	0 (0)	6 (6)	1 (1)	1 (2)	0 (0)	0 (0)	--	--	--	--	--	--	
Condom use at last sex (%)																	
No	18 (60)	6 (32)	64 (63)	59 (58)	64 (69)	52 (55)	46 (49)	32 (68)	39 (63)	16 (70)	--	--	--	--	--	--	
Yes	3 (10)	6 (32)	38 (37)	39 (38)	29 (31)	35 (37)	42 (45)	15 (32)	21 (34)	6 (26)	--	--	--	--	--	--	
Not reported	9 (30)	7 (36)	0 (0)	4 (4)	0 (0)	8 (8)	6 (6)	0 (0)	2 (3)	1 (4)	--	--	--	--	--	--	
Condom use with regular sex partner(s) last month (%)																	
No	--	8 (67)	43 (86)	33 (94)	27 (84)	28 (64)	18 (53)	13 (81)	20 (69)	5 (71)	--	--	--	--	--	--	
Sometimes	--	0 (0)	1 (2)	0 (0)	1 (3)	4 (9)	4 (12)	2 (13)	1 (3)	0 (0)	--	--	--	--	--	--	
Always	--	4 (33)	6 (12)	2 (6)	4 (13)	12 (27)	12 (35)	1 (6)	8 (28)	2 (29)	--	--	--	--	--	--	
Condom use with new sex partner(s) last month (%)																	
No	--	1 (33)	6 (29)	0 (0)	0 (0)	3 (16)	11 (33)	2 (17)	6 (32)	6 (86)	--	--	--	--	--	--	
Sometimes	--	0 (0)	0 (0)	0 (0)	0 (0)	9 (47)	6 (18)	1 (8)	2 (10)	0 (0)	--	--	--	--	--	--	
Always	--	2 (67)	15 (71)	2 (100)	1 (100)	7 (37)	16 (49)	9 (75)	11 (58)	1 (14)	--	--	--	--	--	--	
Condom use with casual sex partner(s) last month (%)																	
No	--	--	--	10 (40)	7 (50)	7 (27)	10 (36)	2 (20)	5 (26)	6 (100)	--	--	--	--	--	--	
Sometimes	--	--	--	3 (12)	1 (7)	7 (27)	3 (11)	0 (0)	2 (11)	0 (0)	--	--	--	--	--	--	
Always	--	--	--	12 (48)	6 (43)	12 (46)	15 (53)	8 (80)	12 (63)	0 (0)	--	--	--	--	--	--	
Sex work last month (%)																	
No	28 (94)	18 (95)	93 (91)	99 (97)	91 (98)	80 (84)	82 (88)	44 (94)	57 (92)	23 (100)	28 (97)	15 (75)	28 (90)	69 (92)	71 (92)	72 (87)	
Yes	1 (3)	1 (5)	4 (4)	3 (3)	2 (2)	9 (10)	6 (6)	3 (6)	3 (5)	0 (0)	0 (0)	4 (20)	1 (3)	4 (5)	3 (4)	5 (6)	
Not reported	1 (3)	0 (0)	5 (5)	0 (0)	0 (0)	6 (6)	6 (6)	0 (0)	2 (3)	0 (0)	1 (3)	1 (5)	2 (6)	2 (3)	3 (4)	6 (7)	
Condom used at last sex work (%)																	
Yes	1 (100)	1 (100)	3 (75)	1 (50)	1 (100)	8 (89)	5 (100)	2 (67)	3 (100)	0 (0)	0 (0)	4 (100)	1 (100)	4 (100)	3 (100)	4 (80)	

Table 4.6 Number (percentage) of respondents by previous testing for HIV, HBV, HCV infection, HBV vaccination and HCV treatment by year

NORTHERN TERRITORY N° surveyed	1995 N=30	1996 N=19	1997 N=102	1998 N=102	1999 N=93	2000 N=95	2001 N=94	2002 N=47	2003 N=62	2004 N=23	2005 N=29	2006 N=20	2007 N=31	2008 N=75	2009 N=77	2010 N=83	
Previous HIV test (%)																	
Yes, last year	17 (57)	11 (58)	45 (44)	52 (51)	61 (66)	44 (46)	55 (58)	27 (57)	33 (53)	13 (57)	15 (52)	15 (75)	16 (52)	36 (48)	32 (42)	38 (46)	
> 1 year ago	8 (27)	5 (26)	40 (39)	39 (38)	26 (28)	29 (31)	26 (28)	12 (26)	21 (34)	7 (30)	12 (41)	4 (20)	12 (39)	25 (33)	33 (43)	28 (34)	
Never tested	3 (10)	3 (16)	17 (17)	11 (11)	6 (6)	20 (21)	10 (11)	7 (15)	7 (11)	3 (13)	2 (7)	0 (0)	2 (6)	9 (12)	9 (12)	12 (14)	
Not reported	2 (6)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	3 (3)	1 (2)	1 (2)	0 (0)	0 (0)	1 (5)	1 (3)	5 (7)	3 (4)	5 (6)	
Self report HBV infection (%)																	
No	23 (77)	18 (95)	77 (75)	79 (77)	76 (81)	62 (65)	68 (72)	30 (64)	39 (63)	18 (78)	24 (83)	16 (80)	16 (52)	--	--	--	
Yes	6 (20)	1 (5)	20 (20)	14 (14)	11 (12)	16 (17)	16 (17)	13 (28)	10 (16)	3 (13)	4 (14)	2 (10)	8 (26)	--	--	--	
Don't know	--	--	5 (5)	9 (9)	6 (7)	16 (17)	10 (11)	4 (9)	11 (18)	2 (9)	1 (3)	2 (10)	6 (19)	--	--	--	
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	2 (3)	0 (0)	0 (0)	0 (0)	1 (3)	--	--	--	
Self report HBV vaccination (%)																	
No	22 (73)	9 (47)	48 (47)	44 (43)	51 (55)	35 (37)	46 (49)	17 (36)	28 (45)	8 (35)	9 (31)	5 (25)	9 (29)	--	--	--	
Yes	8 (27)	9 (47)	42 (41)	37 (36)	35 (38)	39 (41)	30 (32)	24 (51)	19 (31)	10 (43)	18 (62)	12 (60)	15 (48)	--	--	--	
Don't know	--	--	12 (12)	21 (21)	6 (6)	17 (18)	10 (11)	6 (13)	11 (18)	5 (22)	2 (7)	3 (15)	6 (19)	--	--	--	
Not reported	0 (0)	1 (5)	0 (0)	0 (0)	1 (1)	4 (4)	8 (9)	0 (0)	4 (6)	0 (0)	0 (0)	0 (0)	1 (3)	--	--	--	
Previous HCV test (%)																	
Yes, ever	16 (53)	13 (68)	--	--	--	--	--	--	--	--	--	--	--	--	--	--	
Yes, last year	--	--	50 (49)	40 (39)	47 (50)	52 (55)	65 (69)	28 (61)	32 (52)	18 (78)	14 (48)	15 (75)	19 (61)	38 (51)	40 (52)	46 (55)	
> 1 year ago	--	--	37 (36)	47 (46)	35 (38)	19 (20)	20 (21)	13 (28)	18 (29)	5 (22)	14 (48)	5 (25)	10 (32)	27 (36)	32 (42)	23 (28)	
Never tested	14 (47)	6 (32)	15 (15)	15 (15)	11 (12)	22 (23)	7 (8)	5 (11)	11 (18)	0 (0)	1 (3)	0 (0)	1 (3)	5 (7)	3 (40)	8 (10)	
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	2 (2)	1 (2)	1 (1)	0 (0)	0 (0)	0 (0)	1 (3)	5 (7)	2 (3)	6 (7)	
Any treatment for HCV (%)																	
Interferon/+Ribavirin	--	--	--	--	1 (3)	1 (4)	3 (10)	1 (4)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	3 (9)	2 (6)	2 (4)	
Other	--	--	--	--	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)	1 (8)	0 (0)	2 (12)	2 (6)	0 (0)	1 (2)	
No treatment	--	--	--	--	30 (91)	25 (92)	28 (90)	22 (96)	23 (96)	11 (92)	12 (92)	3 (75)	12 (71)	31 (86)	30 (94)	44 (96)	
Not reported	--	--	--	--	2 (6)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (25)	3 (18)	0 (0)	0 (0)	0 (0)	
Current treatment for HCV (%)																	
Interferon/ +Ribavirin	--	--	--	--	0	0	0	0	1	0	0	0	1	1	0	1	
Other	--	--	--	--	0	1	0	0	0	0	0	0	0	1	0	1	

Table 4.7 Number (percentage) of respondents by treatment for drug use and year

NORTHERN TERRITORY N° surveyed	1995 N=30	1996 N=19	1997 N=102	1998 N=102	1999 N=93	2000 N=95	2001 N=94	2002 N=47	2003 N=62	2004 N=23	2005 N=29	2006 N=20	2007 N=31	2008 N=75	2009 N=77	2010 N=83	
Ever any treatment/therapy for drug use (%)																	
No	15 (50)	6 (32)	48 (47)	49 (48)	44 (47)	47 (50)	44 (47)	15 (32)	29 (47)	9 (39)	13 (45)	12 (60)	13 (42)	22 (29)	21 (27)	24 (29)	
Yes	15 (50)	13 (68)	54 (53)	53 (52)	49 (53)	45 (47)	49 (52)	32 (68)	33 (53)	14 (61)	16 (55)	8 (40)	17 (55)	53 (71)	55 (71)	56 (67)	
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	1 (1)	3 (4)	
History of methadone maintenance treatment (%)																	
Current	1 (3)	2 (10)	4 (4)	2 (2)	6 (7)	8 (8)	8 (9)	5 (11)	10 (16)	5 (22)	4 (14)	1 (5)	4 (13)	12 (16)	12 (16)	7 (8)	
Previous	9 (30)	2 (10)	29 (28)	29 (28)	18 (19)	18 (19)	22 (23)	14 (30)	12 (19)	3 (13)	10 (34)	2 (10)	10 (32)	18 (24)	14 (18)	25 (30)	
Never	20 (67)	15 (80)	69 (68)	71 (70)	69 (74)	67 (71)	63 (67)	28 (59)	40 (65)	15 (65)	15 (52)	17 (85)	16 (52)	45 (60)	49 (64)	46 (55)	
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	2 (3)	5 (6)	
History of other pharmacotherapy treatment (%)																	
Current	--	--	--	--	--	0 (0)	2 (2)	2 (4)	6 (10)	4 (17)	2 (7)	0 (0)	0 (0)	15 (20)	5 (6)	11 (13)	
Previous	--	--	--	--	--	5 (5)	6 (6)	9 (19)	8 (13)	4 (17)	6 (21)	4 (20)	7 (23)	20 (27)	17 (22)	17 (20)	
Never	--	--	--	--	--	88 (93)	84 (90)	36 (77)	48 (77)	15 (66)	21 (72)	16 (80)	23 (74)	40 (53)	54 (70)	54 (65)	
Not reported	--	--	--	--	--	2 (2)	2 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	1 (1)	1 (1)	

Table 4.8 Number (percentage) of respondents by source of needle and syringe acquisition in the month prior to survey and year

NSW N° injected last month	1995 N=29	1996 N=18	1997 N=94	1998 N=100	1999 N=92	2000 N=84	2001 N=89	2002 N=47	2003 N=61	2004 N=23	2005 N=29	2006 N=17	2007 N=29	2008 N=71	2009 N=70	2010 N=71	
Needle/syringe acquisition in the last month (%) [More than one could be selected]																	
Needle Syringe Program	--	--	--	--	84 (91)	68 (81)	78 (88)	46 (98)	57 (93)	22 (96)	28 (97)	19 (95)	20 (69)	60 (85)	46 (66)	59 (83)	
Pharmacy	--	--	--	--	36 (39)	26 (31)	34 (38)	14 (30)	19 (31)	5 (22)	5 (17)	6 (30)	0 (0)	16 (23)	7 (10)	9 (13)	
Personal Sources	--	--	--	--	--	--	--	--	--	--	--	--	8 (28)	--	21 (30)	14 (19)	
Other sources	--	--	--	--	--	--	--	--	--	--	--	--	0 (0)	--	0 (0)	4 (6)	
Onward supply of syringes in last month (%)																	
Yes, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	12 (41)	--	21 (30)	209 (38)	
No, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	--	--	39 (56)	332 (61)	
Not reported	--	--	--	--	--	--	--	--	--	--	--	--	5 (17)	--	10 (14)	7 (1)	

HIV ANTIBODY PREVALENCE

Table 4.9 HIV antibody prevalence by gender and year

NORTHERN TERRITORY	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995	20	0 (0.0)	10	0 (0.0)	30	0 (0.0)
1996	13	0 (0.0)	6	0 (0.0)	19	0 (0.0)
1997	76	5 (6.6)	24	0 (0.0)	102	5 (4.9)
1998	65	4 (6.2)	22	0 (0.0)	87	4 (4.6)
1999	64	3 (4.7)	15	0 (0.0)	79	3 (3.8)
2000	70	1 (1.4)	19	0 (0.0)	90	1 (1.1)
2001	60	0 (0.0)	18	0 (0.0)	79	0 (0.0)
2002	35	0 (0.0)	11	0 (0.0)	47	0 (0.0)
2003	43	1 (2.3)	18	0 (0.0)	61	1 (1.6)
2004	11	0 (0.0)	4	0 (0.0)	16	0 (0.0)
2005	15	0 (0.0)	9	0 (0.0)	24	0 (0.0)
2006	9	0 (0.0)	11	0 (0.0)	20	0 (0.0)
2007	20	0 (0.0)	9	0 (0.0)	29	0 (0.0)
2008	46	1 (2.2)	27	0 (0.0)	73	1 (1.4)
2009	51	0 (0.0)	25	0 (0.0)	76	0 (0.0)
2010	55	0 (0.0)	23	0 (0.0)	78	0 (0.0)
χ^2 trend p value		0.008		--		0.005

HCV ANTIBODY PREVALENCE

Table 4.10 HCV antibody prevalence by gender and year

NORTHERN TERRITORY	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995	19	14 (74)	8	3 (38)	27	17 (63)
1996	13	5 (38)	6	2 (33)	19	6 (32)
1997	76	41 (54)	24	10 (42)	102	52 (51)
1998	65	28 (43)	23	7 (30)	88	35 (40)
1999	64	36 (56)	15	3 (20)	79	39 (49)
2000	71	32 (45)	19	6 (32)	91	38 (42)
2001	65	41 (63)	18	8 (44)	84	50 (60)
2002	35	24 (69)	11	5 (45)	47	29 (62)
2003	44	20 (45)	18	9 (50)	62	29 (47)
2004	11	6 (55)	4	3 (75)	16	9 (56)
2005	15	6 (40)	9	6 (67)	23	12 (50)
2006	7	4 (57)	10	1 (10)	17	5 (29)
2007	20	13 (65)	9	5 (56)	29	18 (62)
2008	46	23 (50)	26	15 (58)	72	38 (53)
2009	50	20 (40)	25	9 (36)	75	29 (39)
2010	55	29 (53)	23	8 (35)	78	37 (47)
χ^2 trend p value		0.508		0.292		0.862

Table 4.11 HCV antibody prevalence by sexual identity, gender and year

NORTHERN TERRITORY	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Heterosexual	16	12 (75)	4	1 (25)	20	13 (65)
Bisexual	1	1 (100)	2	2 (100)	3	3 (100)
Homosexual	1	1 (100)	2	0 (0)	3	1 (33)
1996						
Heterosexual	13	5 (38)	6	2 (33)	19	7 (37)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
1997						
Heterosexual	63	37 (59)	20	9 (45)	85	47 (55)
Bisexual	3	0 (0)	4	1 (25)	7	1 (14)
Homosexual	8	3 (38)	0	0 (0)	8	3 (38)
1998						
Heterosexual	50	25 (50)	18	6 (33)	68	31 (46)
Bisexual	5	1 (20)	4	1 (25)	9	2 (22)
Homosexual	5	1 (20)	1	0 (0)	6	1 (17)
1999						
Heterosexual	60	35 (58)	10	1 (10)	70	36 (51)
Bisexual	4	1 (25)	2	1 (50)	6	2 (33)
Homosexual	0	0 (0)	2	0 (0)	2	0 (0)
2000						
Heterosexual	55	28 (51)	11	4 (36)	66	32 (48)
Bisexual	3	1 (33)	6	2 (33)	9	3 (33)
Homosexual	8	2 (25)	1	0 (0)	9	2 (22)
2001						
Heterosexual	51	35 (69)	10	3 (30)	61	38 (62)
Bisexual	1	1 (100)	5	3 (60)	7	5 (71)
Homosexual	4	3 (75)	0	0 (0)	4	3 (75)
2002						
Heterosexual	33	23 (70)	8	2 (25)	41	25 (61)
Bisexual	0	0 (0)	1	1 (100)	1	1 (100)
Homosexual	1	1 (100)	1	1 (100)	2	2 (100)
2003						
Heterosexual	32	15 (47)	16	8 (50)	48	23 (48)
Bisexual	4	3 (75)	2	1 (50)	6	4 (67)
Homosexual	2	0 (0)	0	0 (0)	2	0 (0)
2004						
Heterosexual	11	6 (55)	1	0 (0)	12	6 (50)
Bisexual	0	0 (0)	3	3 (100)	4	3 (75)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
2005						
Heterosexual	14	6 (43)	8	5 (63)	22	11 (50)
Bisexual	0	0 (0)	1	1 (100)	1	1 (100)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
2006						
Heterosexual	6	4 (67)	5	0 (0)	11	4 (36)
Bisexual	0	0 (0)	4	0 (0)	4	0 (0)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
2007						
Heterosexual	18	13 (72)	9	5 (56)	27	18 (67)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
2008						
Heterosexual	40	22 (55)	19	11 (58)	59	33 (56)
Bisexual	1	0 (0)	3	2 (67)	4	2 (50)
Homosexual	2	0 (0)	3	2 (67)	5	2 (40)
2009						
Heterosexual	46	19 (41)	18	7 (39)	64	26 (41)
Bisexual	2	1 (50)	3	1 (33)	5	2 (40)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
2010						
Heterosexual	48	28 (58)	15	7 (47)	63	35 (56)
Bisexual	5	1 (20)	4	1 (25)	9	2 (22)
Homosexual	1	0 (0)	4	0 (0)	5	0 (0)
2010 p value		0.104		0.320		0.007

Table 4.12 HCV antibody prevalence by age group, gender and year

NORTHERN TERRITORY	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	0	0 (0)	5	1 (20)	5	1 (20)
25-34 years	7	4 (57)	1	0 (0)	8	4 (50)
35+ years	12	10 (83)	2	2 (100)	14	12 (86)
1996						
<25 years	1	0 (0)	2	0 (0)	3	0 (0)
25-34 years	6	1 (17)	4	2 (50)	10	3 (30)
35+ years	6	4 (67)	0	0 (0)	6	4 (67)
1997						
<25 years	18	2 (11)	7	1 (14)	25	3 (12)
25-34 years	30	19 (63)	11	4 (36)	43	24 (56)
35+ years	28	20 (71)	6	5 (83)	34	25 (74)
1998						
<25 years	11	0 (0)	13	0 (0)	24	0 (0)
25-34 years	26	8 (31)	4	1 (25)	30	9 (30)
35+ years	28	20 (71)	6	6 (100)	34	26 (76)
1999						
<25 years	9	1 (11)	8	0 (0)	17	1 (6)
25-34 years	24	11 (46)	3	0 (0)	27	11 (41)
35+ years	31	24 (77)	4	3 (75)	35	27 (77)
2000						
<25 years	10	0 (0)	7	2 (29)	17	2 (12)
25-34 years	23	10 (43)	7	3 (43)	30	13 (43)
35+ years	38	22 (58)	5	1 (20)	44	23 (52)
2001						
<25 years	11	4 (36)	5	3 (60)	16	7 (44)
25-34 years	17	8 (47)	6	3 (50)	23	11 (48)
35+ years	37	29 (78)	7	2 (29)	45	32 (71)
2002						
<25 years	3	0 (0)	5	2 (40)	8	2 (25)
25-34 years	10	4 (40)	2	0 (0)	12	4 (33)
35+ years	22	20 (91)	4	3 (75)	27	23 (85)
2003						
<25 years	2	0 (0)	1	1 (100)	3	1 (33)
25-34 years	13	6 (46)	11	5 (45)	24	11 (46)
35+ years	28	13 (46)	6	3 (50)	34	16 (47)
2004						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	4	3 (75)	0	0 (0)	4	3 (75)
35+ years	6	3 (50)	4	3 (75)	11	6 (55)
2005						
<25 years	0	0 (0)	2	2 (100)	2	2 (100)
25-34 years	7	2 (29)	1	0 (0)	8	2 (25)
35+ years	8	4 (50)	6	4 (67)	14	8 (57)
2006						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	5	2 (40)	6	1 (17)	11	3 (27)
35+ years	2	2 (100)	4	0 (0)	6	2 (33)
2007						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	7	3 (43)	3	2 (67)	10	5 (50)
35+ years	13	10 (77)	6	3 (50)	19	13 (68)
2008						
<25 years	1	0 (0)	2	1 (50)	3	1 (33)
25-34 years	13	4 (31)	8	3 (38)	21	7 (33)
35+ years	32	19 (59)	16	11 (69)	48	30 (63)
2009						
<25 years	2	0 (0)	2	1 (50)	4	1 (25)
25-34 years	7	1 (14)	7	2 (29)	14	3 (21)
35+ years	41	19 (46)	16	6 (38)	57	25 (44)
2010						
<25 years	4	1 (25)	2	0 (0)	6	1 (17)
25-34 years	5	0 (0)	7	2 (29)	12	2 (17)
35+ years	46	28 (61)	14	6 (43)	60	34 (57)
2010 p value		0.009		0.543		0.011

Table 4.13 HCV antibody prevalence by time since first injection, gender and year

NORTHERN TERRITORY	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<3 years	2	1 (50)	3	0 (0)	5	1 (20)
3-10 years	4	1 (25)	4	2 (50)	8	3 (38)
11+ years	12	11 (92)	1	1 (100)	13	12 (92)
1996						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3-10 years	4	0 (0)	5	2 (40)	9	2 (22)
11+ years	8	5 (63)	0	0 (0)	8	5 (63)
1997						
<3 years	10	2 (20)	4	1 (25)	14	3 (21)
3-10 years	25	7 (28)	15	5 (33)	40	12 (30)
11+ years	40	32 (80)	5	4 (80)	47	37 (79)
1998						
<3 years	5	0 (0)	8	1 (13)	13	1 (8)
3-10 years	27	7 (26)	9	1 (11)	36	8 (22)
11+ years	32	20 (63)	6	5 (83)	38	25 (66)
1999						
<3 years	5	0 (0)	6	0 (0)	11	0 (0)
3-10 years	21	6 (29)	3	0 (0)	24	6 (25)
11+ years	38	30 (79)	6	3 (50)	44	33 (75)
2000						
<3 years	5	1 (20)	1	1 (100)	6	2 (33)
3-10 years	23	3 (13)	12	3 (25)	35	6 (17)
11+ years	41	28 (68)	6	2 (33)	47	30 (64)
2001						
<3 years	5	1 (20)	7	4 (57)	12	5 (42)
3-10 years	19	7 (37)	6	3 (50)	25	10 (40)
11+ years	38	30 (79)	5	1 (20)	44	32 (73)
2002						
<3 years	1	0 (0)	1	0 (0)	3	0 (0)
3-10 years	5	0 (0)	3	2 (67)	8	2 (25)
11+ years	29	24 (83)	7	3 (43)	36	27 (75)
2003						
<3 years	3	0 (0)	1	0 (0)	4	0 (0)
3-10 years	11	2 (18)	9	4 (44)	20	6 (30)
11+ years	27	17 (63)	8	5 (63)	35	22 (63)
2004						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3-10 years	1	0 (0)	2	1 (50)	4	1 (25)
11+ years	10	6 (60)	2	2 (100)	12	8 (67)
2005						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3-10 years	4	1 (25)	3	2 (67)	7	3 (43)
11+ years	8	5 (63)	5	4 (80)	13	9 (69)
2006						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3-10 years	1	1 (100)	4	0 (0)	5	1 (20)
11+ years	6	3 (50)	6	1 (17)	12	4 (33)
2007						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3-10 years	3	1 (33)	3	2 (67)	6	3 (50)
11+ years	16	11 (69)	6	3 (50)	22	14 (64)
2008						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3-10 years	10	1 (10)	5	4 (80)	15	5 (33)
11+ years	34	22 (65)	20	11 (55)	54	33 (61)
2009						
<3 years	2	0 (0)	2	1 (50)	4	1 (25)
3-10 years	4	1 (25)	5	1 (20)	9	2 (22)
11+ years	42	19 (45)	16	7 (44)	58	26 (45)
2010						
<3 years	4	0 (0)	3	0 (0)	7	0 (0)
3-10 years	7	3 (43)	3	3 (100)	10	6 (60)
11+ years	44	26 (59)	17	5 (29)	61	31 (51)
2010 p value		0.042		0.034		0.020

Table 4.14 HCV antibody prevalence by drug last injected, time since first injection and year

NORTHERN TERRITORY	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Pharm. opioids	2	1 (50)	8	6 (75)	10	7 (70)
Methamphetamine	2	0 (0)	4	2 (50)	6	2 (33)
Other	1	0 (0)	9	7 (78)	11	8 (73)
1996						
Pharm. opioids	0	0 (0)	3	3 (10)	3	3 (100)
Methamphetamine	1	0 (0)	3	0 (0)	4	0 (0)
Other	1	0 (0)	11	4 (36)	12	4 (33)
1997						
Pharm. opioids	5	1 (20)	54	34 (63)	59	35 (59)
Methamphetamine	2	0 (0)	9	2 (22)	11	2 (18)
Other	7	2 (29)	24	13 (54)	32	15 (47)
1998						
Pharm. opioids	6	1 (17)	53	30 (57)	59	31 (53)
Methamphetamine	6	0 (0)	12	1 (8)	19	2 (11)
Other	1	0 (0)	9	2 (22)	10	2 (20)
1999						
Pharm. opioids	4	0 (0)	43	32 (74)	47	32 (68)
Methamphetamine	6	0 (0)	12	2 (17)	18	2 (11)
Other	1	0 (0)	13	5 (38)	14	5 (36)
2000						
Pharm. opioids	1	0 (0)	42	25 (60)	43	25 (58)
Methamphetamine	4	2 (50)	19	2 (11)	23	4 (17)
Other	1	0 (0)	21	9 (43)	22	9 (41)
2001						
Pharm. opioids	3	1 (33)	32	21 (66)	37	24 (65)
Methamphetamine	9	4 (44)	20	9 (45)	30	14 (47)
Other	0	0 (0)	17	12 (71)	17	12 (71)
2002						
Pharm. opioids	1	0 (0)	36	26 (72)	37	26 (70)
Methamphetamine	1	0 (0)	6	2 (33)	7	2 (29)
Other	1	0 (0)	2	1 (50)	3	1 (33)
2003						
Pharm. opioids	0	0 (0)	32	17 (53)	33	17 (52)
Methamphetamine	3	0 (0)	12	3 (25)	15	3 (20)
Other	2	1 (50)	11	7 (64)	13	8 (62)
2004						
Pharm. opioids	0	0 (0)	9	4 (44)	9	4 (44)
Methamphetamine	0	0 (0)	6	4 (67)	6	4 (67)
Other	0	0 (0)	1	1 (100)	1	1 (100)
2005						
Pharm. opioids	1	0 (0)	9	3 (33)	11	3 (27)
Methamphetamine	1	0 (0)	5	3 (60)	6	3 (50)
Other	0	0 (0)	6	6 (100)	6	6 (100)
2006						
Pharm. opioids	0	0 (0)	10	3 (30)	10	3 (30)
Methamphetamine	0	0 (0)	6	1 (17)	6	1 (17)
Other	0	0 (0)	1	1 (100)	1	1 (100)
2007						
Pharm. opioids	0	0 (0)	15	10 (67)	15	10 (67)
Methamphetamine	0	0 (0)	4	1 (25)	5	2 (40)
Other	0	0 (0)	9	6 (67)	9	6 (67)
2008						
Pharm. opioids	0	0 (0)	45	29 (64)	46	29 (63)
Methamphetamine	1	0 (0)	11	2 (18)	12	2 (17)
Other	0	0 (0)	13	7 (54)	13	7 (54)
2009						
Pharm. opioids	2	1 (50)	36	19 (53)	38	20 (53)
Methamphetamine	2	0 (0)	17	3 (18)	19	3 (16)
Other	0	0 (0)	12	4 (33)	14	4 (29)
2010						
Pharm. opioids	2	0 (0)	46	25 (54)	48	25 (52)
Methamphetamine	3	0 (0)	15	7 (47)	18	7 (39)
Other	2	0 (0)	10	5 (50)	12	5 (42)
2010 p value		--		0.866		0.618

Table 4.15 HCV antibody prevalence by frequency of injection, time since first injection and year

NORTHERN TERRITORY	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Less than daily	2	1 (50)	8	3 (38)	11	5 (45)
Daily or more	2	0 (0)	13	12 (92)	15	12 (80)
Not last month	1	0 (0)	0	0 (0)	1	0 (0)
1996						
Less than daily	1	0 (0)	6	1 (17)	7	1 (14)
Daily or more	0	0 (0)	11	6 (55)	11	6 (55)
Not last month	1	0 (0)	0	0 (0)	1	0 (0)
1997						
Less than daily	7	0 (0)	30	11 (37)	37	11 (30)
Daily or more	5	3 (60)	51	35 (69)	57	38 (67)
Not last month	2	0 (0)	6	3 (50)	8	3 (38)
1998						
Less than daily	7	0 (0)	18	2 (11)	25	2 (8)
Daily or more	6	1 (17)	54	31 (57)	61	33 (54)
Not last month	0	0 (0)	2	0 (0)	2	0 (0)
1999						
Less than daily	3	0 (0)	13	4 (31)	16	4 (25)
Daily or more	8	0 (0)	55	35 (64)	63	35 (56)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
2000						
Less than daily	4	2 (50)	22	7 (32)	26	9 (35)
Daily or more	1	0 (0)	54	28 (52)	55	28 (51)
Not last month	1	0 (0)	5	1 (20)	7	1 (14)
2001						
Less than daily	2	2 (100)	14	9 (64)	17	12 (71)
Daily or more	8	3 (38)	53	32 (60)	63	37 (59)
Not last month	2	0 (0)	2	1 (50)	4	1 (25)
2002						
Less than daily	2	0 (0)	12	6 (50)	14	6 (43)
Daily or more	1	0 (0)	32	23 (72)	33	23 (70)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
2003						
Less than daily	2	0 (0)	11	5 (45)	13	5 (38)
Daily or more	2	0 (0)	43	22 (51)	48	23 (48)
Not last month	0	0 (0)	1	1 (100)	1	1 (100)
2004						
Less than daily	0	0 (0)	3	1 (33)	3	1 (33)
Daily or more	0	0 (0)	13	8 (62)	13	8 (62)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
2005						
Less than daily	0	0 (0)	4	3 (75)	5	3 (60)
Daily or more	2	0 (0)	16	9 (56)	19	9 (47)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
2006						
Less than daily	0	0 (0)	8	1 (13)	8	1 (13)
Daily or more	0	0 (0)	9	4 (44)	9	4 (44)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
2007						
Less than daily	0	0 (0)	9	5 (56)	9	5 (56)
Daily or more	0	0 (0)	17	11 (65)	18	12 (67)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
2008						
Less than daily	1	0 (0)	17	7 (41)	18	7 (39)
Daily or more	0	0 (0)	49	30 (61)	51	30 (59)
Not last month	0	0 (0)	3	1 (33)	3	1 (33)
2009						
Less than daily	1	0 (0)	26	14 (54)	28	14 (50)
Daily or more	2	1 (50)	38	14 (37)	41	15 (37)
Not last month	1	0 (0)	3	0 (0)	6	0 (0)
2010						
Less than daily	2	0 (0)	26	15 (58)	28	15 (54)
Daily or more	3	0 (0)	37	18 (49)	40	18 (45)
Not last month	2	0 (0)	6	2 (33)	8	2 (25)
2010 p value		--		0.549		0.377

Table 4.16 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, time since first injection and year

NORTHERN TERRITORY	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
No receptive sharing	2	1 (50)	16	12 (75)	19	14 (74)
Receptive sharing	2	0 (0)	5	3 (60)	7	3 (43)
1996						
No receptive sharing	1	0 (0)	12	6 (50)	13	6 (46)
Receptive sharing	0	0 (0)	5	1 (20)	5	1 (20)
1997						
No receptive sharing	11	2 (18)	73	45 (62)	85	47 (55)
Receptive sharing	1	1 (100)	8	1 (13)	9	2 (22)
1998						
No receptive sharing	11	0 (0)	68	33 (49)	80	34 (43)
Receptive sharing	2	1 (50)	4	0 (0)	6	1 (17)
1999						
No receptive sharing	7	0 (0)	53	33 (62)	60	33 (55)
Receptive sharing	2	0 (0)	4	0 (0)	6	0 (0)
2000						
No receptive sharing	4	1 (25)	63	27 (43)	67	28 (42)
Receptive sharing	1	1 (100)	12	8 (67)	13	9 (69)
2001						
No receptive sharing	7	3 (43)	55	38 (69)	65	44 (68)
Receptive sharing	2	2 (100)	7	3 (43)	9	5 (56)
2002						
No receptive sharing	3	0 (0)	43	28 (65)	46	28 (61)
Receptive sharing	0	0 (0)	1	1 (100)	1	1 (100)
2003						
No receptive sharing	4	0 (0)	45	22 (49)	52	23 (44)
Receptive sharing	0	0 (0)	8	5 (63)	8	5 (63)
2004						
No receptive sharing	0	0 (0)	16	9 (56)	16	9 (56)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
2005						
No receptive sharing	2	0 (0)	18	10 (56)	22	10 (45)
Receptive sharing	0	0 (0)	1	1 (100)	1	1 (100)
2006						
No receptive sharing	0	0 (0)	15	5 (33)	15	5 (33)
Receptive sharing	0	0 (0)	1	0 (0)	1	0 (0)
2007						
No receptive sharing	0	0 (0)	23	14 (61)	24	15 (63)
Receptive sharing	0	0 (0)	1	1 (100)	1	1 (100)
2008						
No receptive sharing	0	0 (0)	61	33 (54)	63	33 (52)
Receptive sharing	1	0 (0)	5	4 (80)	6	4 (67)
2009						
No receptive sharing	3	1 (33)	57	23 (40)	61	24 (39)
Receptive sharing	0	0 (0)	6	4 (67)	7	4 (57)
2010						
No receptive sharing	3	0 (0)	56	30 (54)	59	30 (51)
Receptive sharing	0	0 (0)	3	0 (0)	3	0 (0)
2010 p value		--		0.112		0.238

Table 4.17 HCV antibody prevalence by imprisonment last year, time since first injection and year

NORTHERN TERRITORY	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Not imprisoned	4	0 (0)	21	15 (71)	26	16 (62)
Imprisoned	1	1 (100)	0	0 (0)	1	1 (100)
1996						
Not imprisoned	2	0 (0)	14	6 (43)	16	6 (38)
Imprisoned	0	0 (0)	2	1 (50)	2	1 (50)
1997						
Not imprisoned	14	3 (21)	77	42 (55)	92	45 (49)
Imprisoned	0	0 (0)	10	7 (70)	10	7 (70)
1998						
Not imprisoned	13	1 (8)	64	25 (39)	78	27 (35)
Imprisoned	0	0 (0)	9	7 (78)	9	7 (78)
1999						
Not imprisoned	11	0 (0)	59	33 (56)	70	33 (47)
Imprisoned	0	0 (0)	9	6 (67)	9	6 (67)
2000						
Not imprisoned	6	2 (33)	69	31 (45)	77	33 (43)
Imprisoned	0	0 (0)	11	4 (36)	11	4 (36)
2001						
Not imprisoned	11	4 (36)	54	33 (61)	68	40 (59)
Imprisoned	0	0 (0)	12	8 (67)	12	8 (67)
2002						
Not imprisoned	2	0 (0)	39	24 (62)	41	24 (59)
Imprisoned	0	0 (0)	4	4 (100)	4	4 (100)
2003						
Not imprisoned	4	0 (0)	49	25 (51)	56	26 (46)
Imprisoned	0	0 (0)	6	3 (50)	6	3 (50)
2004						
Not imprisoned	0	0 (0)	12	5 (42)	12	5 (42)
Imprisoned	0	0 (0)	4	4 (100)	4	4 (100)
2005						
Not imprisoned	2	0 (0)	18	10 (56)	22	10 (45)
Imprisoned	0	0 (0)	1	1 (100)	1	1 (100)
2006						
Not imprisoned	0	0 (0)	16	5 (31)	16	5 (31)
Imprisoned	0	0 (0)	1	0 (0)	1	0 (0)
2007						
Not imprisoned	0	0 (0)	27	17 (63)	28	18 (64)
Imprisoned	0	0 (0)	0	0 (0)	0	0 (0)
2008						
Not imprisoned	1	0 (0)	65	35 (54)	66	35 (53)
Imprisoned	0	0 (0)	2	2 (100)	3	2 (67)
2009						
Not imprisoned	4	1 (25)	62	24 (39)	70	25 (36)
Imprisoned	0	0 (0)	2	2 (100)	2	2 (100)
2010						
Not imprisoned	5	0 (0)	57	30 (53)	62	30 (48)
Imprisoned	0	0 (0)	2	0 (0)	2	0 (0)
2010 p value		--		0.237		0.494

Table 4.18 HCV antibody prevalence by sex work last month, time since first injection and year

NORTHERN TERRITORY	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
No sex work	5	1 (20)	19	14 (74)	25	16 (64)
Sex work	0	0 (0)	1	0 (0)	1	0 (0)
1996						
No sex work	2	0 (0)	16	6 (38)	18	6 (33)
Sex work	0	0 (0)	1	1 (100)	1	1 (100)
1997						
No sex work	12	2 (17)	80	47 (59)	93	49 (53)
Sex work	1	0 (0)	3	0 (0)	4	0 (0)
1998						
No sex work	12	1 (8)	72	33 (46)	85	35 (41)
Sex work	1	0 (0)	2	0 (0)	3	0 (0)
1999						
No sex work	10	0 (0)	67	39 (58)	77	39 (51)
Sex work	1	0 (0)	1	0 (0)	2	0 (0)
2000						
No sex work	6	2 (33)	69	31 (45)	76	33 (43)
Sex work	0	0 (0)	8	5 (63)	9	5 (56)
2001						
No sex work	10	4 (40)	61	37 (61)	74	44 (59)
Sex work	1	0 (0)	4	4 (100)	5	4 (80)
2002						
No sex work	2	0 (0)	42	27 (64)	44	27 (61)
Sex work	1	0 (0)	2	2 (100)	3	2 (67)
2003						
No sex work	3	0 (0)	52	27 (52)	57	28 (49)
Sex work	1	0 (0)	2	0 (0)	3	0 (0)
2004						
No sex work	0	0 (0)	16	9 (56)	16	9 (56)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
2005						
No sex work	2	0 (0)	19	11 (58)	23	11 (48)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
2006						
No sex work	0	0 (0)	13	4 (31)	13	4 (31)
Sex work	0	0 (0)	4	1 (25)	4	1 (25)
2007						
No sex work	0	0 (0)	25	17 (68)	26	18 (69)
Sex work	0	0 (0)	1	0 (0)	1	0 (0)
2008						
No sex work	1	0 (0)	65	36 (55)	68	36 (53)
Sex work	0	0 (0)	3	2 (67)	3	2 (67)
2009						
No sex work	4	1 (25)	61	26 (43)	69	27 (39)
Sex work	0	0 (0)	3	0 (0)	3	0 (0)
2010						
No sex work	5	0 (0)	63	35 (56)	68	35 (51)
Sex work	0	0 (0)	5	0 (0)	5	0 (0)
2010 p value		--		0.023		0.055

Table 4.19 HCV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year

NORTHERN TERRITORY	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Non-Indigenous	18	14 (78)	6	2 (33)	24	16 (67)
Indigenous	0	0 (0)	1	0 (0)	1	0 (0)
1996						
Non-Indigenous	12	5 (42)	6	2 (33)	18	7 (39)
Indigenous	1	0 (0)	0	0 (0)	1	0 (0)
1997						
Non-Indigenous	69	36 (52)	22	9 (41)	92	45 (49)
Indigenous	7	5 (71)	2	1 (50)	10	7 (70)
1998						
Non-Indigenous	56	25 (45)	21	6 (29)	77	31 (40)
Indigenous	9	3 (33)	2	1 (50)	11	4 (36)
1999						
Non-Indigenous	57	31 (54)	13	3 (23)	70	34 (49)
Indigenous	7	5 (71)	2	0 (0)	9	5 (56)
2000						
Non-Indigenous	65	28 (43)	17	6 (35)	83	34 (41)
Indigenous	6	4 (67)	1	0 (0)	7	4 (57)
2001						
Non-Indigenous	57	37 (65)	14	6 (43)	72	44 (61)
Indigenous	8	4 (50)	3	1 (33)	11	5 (45)
2002						
Non-Indigenous	32	22 (69)	11	5 (45)	44	27 (61)
Indigenous	3	2 (67)	0	0 (0)	3	2 (67)
2003						
Non-Indigenous	37	18 (49)	17	8 (47)	54	26 (48)
Indigenous	6	1 (17)	0	0 (0)	6	1 (17)
2004						
Non-Indigenous	11	6 (55)	3	2 (67)	15	8 (53)
Indigenous	0	0 (0)	1	1 (100)	1	1 (100)
2005						
Non-Indigenous	14	6 (43)	9	6 (67)	23	12 (52)
Indigenous	1	0 (0)	0	0 (0)	1	0 (0)
2006						
Non-Indigenous	7	4 (57)	7	1 (14)	14	5 (36)
Indigenous	0	0 (0)	3	0 (0)	3	0 (0)
2007						
Non-Indigenous	19	13 (68)	9	5 (56)	28	18 (64)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
2008						
Non-Indigenous	39	21 (54)	20	12 (60)	59	33 (56)
Indigenous	7	2 (29)	6	3 (50)	13	5 (38)
2009						
Non-Indigenous	40	17 (43)	23	9 (39)	63	26 (41)
Indigenous	8	1 (13)	2	0 (0)	10	1 (10)
2010						
Non-Indigenous	43	24 (56)	18	6 (33)	61	30 (49)
Indigenous	12	5 (42)	5	2 (40)	17	7 (41)
2010 p value		0.517		1.000		0.595

Table 4.20 HCV antibody prevalence by country of birth, gender and year

NORTHERN TERRITORY	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Australia	36	17 (47)	16	9 (56)	52	26 (50)
Other	8	3 (38)	2	0 (0)	10	3 (30)
2004						
Australia	10	6 (60)	4	3 (75)	15	9 (60)
Other	1	0 (0)	0	0 (0)	1	0 (0)
2005						
Australia	15	6 (40)	9	6 (67)	15	6 (67)
Other	0	0 (0)	0	0 (0)	0	0 (0)
2006						
Australia	6	3 (50)	10	1 (10)	16	4 (25)
Other	1	1 (100)	0	0 (0)	1	1 (100)
2007						
Australia	17	12 (71)	9	5 (56)	26	17 (65)
Other	2	1 (50)	0	0 (0)	2	1 (50)
2008						
Australia	39	20 (51)	23	13 (57)	62	33 (53)
Other	6	2 (33)	2	1 (50)	8	3 (38)
2009						
Australia	40	14 (35)	23	8 (35)	63	22 (35)
Other	8	4 (50)	2	1 (50)	10	6 (55)
2010						
Australia	46	24 (52)	20	6 (30)	66	30 (45)
Other	8	5 (63)	3	2 (67)	11	7 (64)
2010 p value		0.711		0.269		0.336

Table 4.21 HCV antibody prevalence by language spoken at home by parents, gender and year

NORTHERN TERRITORY	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
English speaking	41	18 (44)	18	9 (50)	59	27 (46)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
2004						
English speaking	6	4 (67)	4	3 (75)	11	7 (64)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
2005						
English speaking	12	6 (50)	9	6 (67)	21	12 (57)
Non-English speaking	3	0 (0)	0	0 (0)	3	0 (0)
2006						
English speaking	6	4 (67)	9	1 (11)	15	5 (33)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
2007						
English speaking	18	12 (67)	9	5 (56)	27	17 (63)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
2008						
English speaking	46	23 (50)	26	15 (58)	72	38 (53)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
2009						
English speaking	44	17 (39)	24	9 (38)	68	26 (38)
Non-English speaking	5	3 (60)	1	0 (0)	6	3 (50)
2010						
English speaking	49	27 (55)	23	8 (35)	72	35 (49)
Non-English speaking	6	2 (33)	0	0 (0)	6	2 (33)
2010 p value		0.406		--		0.678

5. QUEENSLAND


Four NSP services participated in the ANSPS in 1995, three of which participated every year between 1995 and 2010 (Biala, Queensland Injectors Health Network Gold Coast and Brisbane NSP services). Cairns NSP and Kobi House (in Toowoomba) commenced participation in 1996 and participated in all subsequent years. A further three NSP services participated on an annual ongoing basis since their initiation, with Queensland Injectors Health Network Sunshine Coast first participating in 1999, West Moreton Sexual Health Service in 2002 and Townsville ATODS NSP in 2007. Further details of Queensland NSP service participation can be found in Appendix 1. Sample sizes in Queensland ranged from 344 (in 1995) to 834 (in 1999). Response rates ranged between 31% (in 2005) and 74% (in 1997).

Demographic Characteristics

As observed nationally and in other jurisdictions, around two thirds of Queensland participants were male and the majority (74% to 86%) identified as heterosexual in all years from 1995 to 2010. The proportion of Queensland participants from an Indigenous background increased from 3% in 1995 to 11% in 2010 (χ^2 trend $p < 0.001$). The majority of survey respondents were born in Australia (81% to 91%) and reported their parents spoke English at home (77% to 97%) across all survey years where these data were available.

During the period 1995 to 1999, the median age of Queensland participants was stable at approximately 25 years, which was younger than that observed nationally. Median age increased over the period 2000 to 2007 but was relatively stable at 34 or 35 years between 2007 and 2010 (Figure 5.1). The proportion of young people (aged younger than 25 years) declined from a high of 51% in 1996 to 11% in 2010 (χ^2 trend $p < 0.001$). A concurrent decline was observed among new injectors (those who first injected less than 3 years prior to survey participation). Over the period 1995 to 1999, between 20% and 28% of the Queensland samples were new injectors, but the proportion declined to less than 10% in all years between 2003 and 2010 (Table 5.1). The median age at first injection was 18 years except in 1998, when participants reported a median age at first injection of 19 years.

Figure 5.1 QLD: Median age and proportion young injectors by year



Injecting behaviour

In each year between 1995 and 2000, more than 80% of Queensland ANSPS participants reported most recently injecting either heroin or methamphetamine (Figure 5.2). Prevalence of recent injecting of both heroin and methamphetamine declined in subsequent years.


Coinciding with well documented changes in heroin availability in Australia (Maher et al., 2007; Degenhardt et al., 2006; Topp et al., 2003), a dramatic decline in the proportion of Queensland ANSPS participants who reported last injecting heroin occurred in 2001, with prevalence declining from 45% in 2000 to 26% in 2001. Prevalence returned to 43% the following year (2002), but declined to 26% in 2003. Prevalence of heroin injection remained stable at between 22% and 29% in all years between 2003 and 2010 (Figure 5.1, Table 5.2).

One third of Queensland ANSPS participants in 1995 and 1996 reported last injecting methamphetamine, with prevalence increasing in subsequent years to a high of 52% in 2001. A steady decline in prevalence of methamphetamine injecting occurred between 2003 and 2010, to a low of 27% in 2010.

As occurred nationally and in other jurisdictions, prevalence of recent injecting of pharmaceutical opioids increased significantly throughout the 2000s. The proportion of Queensland ANSPS participants who reported last injecting this class of drugs increased from less than 1% in 2003 to 26% in 2010 (χ^2 trend $p < 0.001$).


The proportion of Queensland ANSPS participants who reported last injecting methadone or buprenorphine was less than 10% in all years between 1995 and 2010. Reports of cocaine injection were rare, with prevalence of recent injection of this drug at 1% or less in Queensland over the period 1995 to 2010 (Table 5.2).

Figure 5.2 QLD: Prevalence of heroin, methamphetamine and pharmaceutical opioids as drug last injected by year




The proportion of Queensland participants who reported re-use of needles and syringes (including re-use of one’s own needle/syringe) in the month preceding survey participation remained stable between 1997 and 2010 (range 22% to 27%, χ^2 trend $p=0.227$, Figure 5.3, Table 5.4). In contrast, the proportion of participants who reported receptive sharing of syringes (use of someone else’s used needle/syringe) in the month preceding the survey declined from 28% in 1995 to 8% in 2010 (χ^2 trend $p<0.001$). Rates of receptive sharing of ancillary equipment varied across survey years and by item type. Consistent with results from other jurisdictions, spoons and water were the ancillary items Queensland ANSPS participants were most likely to report sharing in most survey years.

Figure 5.3 QLD: Syringe re-use and receptive sharing in the last month by year



The proportion of Queensland participants who reported injection in a public place in the month prior to survey completion varied between 33% and 52% over the survey period, although no temporal trend was observed (χ^2 trend $p=0.2341$, Figure 5.4, Table 5.3).


Figure 5.4 QLD: Prevalence of public injection by year



HIV prevalence

HIV antibody prevalence in Queensland remained low at 2.4% or less in all survey years (Figure 5.5, Table 5.9). HIV prevalence was highest among participants reporting male homosexual identity, who comprised between 1% and 6% of Queensland samples, with prevalence among that sub population ranging from 13% to 67% (Table 5.10).


Figure 5.5 QLD: HIV antibody prevalence by year



HCV prevalence

In Queensland, HCV antibody prevalence was consistently lower than observed nationally, although the difference narrowed as HCV antibody prevalence increased in Queensland between 1998 and 2007 (χ^2 trend $p < 0.001$, Figure 5.6, Table 5.22). Consistent with the national trend, HCV antibody prevalence declined in Queensland in recent years, although the Queensland decline began in 2008, whereas the broader national decline was not observed until 2009.

Figure 5.6 National & QLD: HCV antibody prevalence by year



As observed nationally and in other jurisdictions, HCV prevalence was higher in Queensland among older participants (Table 5.24) and respondents with a longer injection history (Figure 5.7, Table 5.25).

Figure 5.7 QLD: HCV antibody prevalence and time since first injection by year




Table 5.1 Number (percentage) of respondents by demographic characteristic and year

QUEENSLAND	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Number of sites	4	5	5	6	6	6	6	9	10	7	7	7	7	8	8	8
N° surveyed	N=344	N=513	N=520	N=694	N=834	N=750	N=817	N=715	N=745	N=587	N=291	N=501	N=417	N=508	N=801	N=550
Response rate	56%	69%	74%	50%	51%	57%	50%	48%	50%	58%	31%	33%	34%	35%	54%	34%
Gender (%)																
Male	247 (72)	374 (73)	358 (69)	490 (71)	552 (66)	487 (65)	562 (69)	504 (70)	512 (69)	407 (69)	198 (68)	353 (70)	282 (68)	341 (67)	585 (73)	419 (76)
Female	92 (27)	132 (26)	160 (31)	202 (29)	227 (33)	257 (34)	247 (30)	205 (29)	226 (30)	179 (30)	91 (31)	145 (29)	131 (31)	165 (32)	211 (26)	126 (23)
Transgender	0 (0)	0 (0)	2 (<1)	2 (<1)	4 (<1)	4 (<1)	6 (1)	5 (1)	5 (<1)	1 (<1)	1 (0)	2 (<1)	3 (<1)	1 (<1)	1 (<1)	1 (<1)
Not reported	5 (1)	7 (1)	0 (0)	0 (0)	1 (<1)	2 (<1)	2 (<1)	1 (<1)	2 (<1)	0 (0)	1 (0)	1 (<1)	1 (<1)	1 (<1)	4 (<1)	4 (<1)
Sexual identity (%)																
Heterosexual	264 (77)	395 (77)	419 (81)	561 (81)	621 (74)	573 (76)	626 (76)	529 (74)	577 (77)	492 (84)	236 (81)	411 (82)	350 (84)	436 (86)	868 (86)	457 (83)
Bisexual	42 (12)	65 (13)	55 (10)	67 (10)	106 (13)	80 (11)	71 (9)	71 (10)	70 (9)	46 (8)	23 (8)	37 (7)	32 (8)	40 (8)	63 (8)	39 (7)
Homosexual	27 (8)	38 (7)	26 (5)	50 (7)	51 (6)	45 (6)	48 (6)	36 (5)	42 (6)	27 (4)	19 (7)	39 (8)	25 (6)	21 (4)	10 (1)	28 (5)
Not reported	11 (3)	15 (3)	20 (4)	16 (2)	56 (7)	52 (7)	72 (9)	79 (11)	56 (8)	22 (4)	13 (4)	14 (3)	10 (2)	11 (2)	42 (5)	26 (5)
Age and time since first injection (years)																
<i>Median age</i>	25	24	24	25	26	28	28	29	31	31	32	33	35	34	34	35
<i>Age range</i>	16-49	15-51	16-55	16-57	14-52	15-56	16-57	14-58	15-55	16-61	16-63	13-57	17-60	16-60	15-66	15-73
<i>Age group (%)</i>																
<25 years	165 (48)	263 (51)	269 (52)	308 (44)	339 (41)	266 (35)	242 (30)	199 (28)	170 (23)	117 (20)	43 (15)	75 (15)	49 (12)	68 (13)	117 (15)	61 (11)
25+ years	177 (51)	248 (48)	251 (48)	385 (55)	493 (59)	482 (64)	572 (70)	513 (72)	573 (77)	468 (80)	248 (85)	425 (85)	367 (88)	438 (86)	684 (85)	487 (86)
Not reported	2 (<1)	2 (<1)	0 (0)	1 (<1)	2 (<1)	2 (<1)	3 (<1)	3 (<1)	2 (<1)	2 (<1)	0 (0)	1 (<1)	1 (<1)	2 (<1)	0 (0)	2 (<1)
<i>Median age 1st IDU</i>	18	18	18	19	18	18	18	18	18	18	18	18	18	18	18	18
<i>Age range</i>	10-48	10-47	10-50	12-47	10-47	10-51	10-52	10-56	10-49	10-56	11-50	10-52	11-44	10-57	10-58	10-59
N° not reported	10	17	11	14	26	18	32	24	37	11	9	1	12	7	19	13
<i>Median years IDU</i>	5	4	5	5	6	7	8	9	10	11	13	13	14	14	14	15
<i>Range</i>	0-31	0-28	0-30	0-40	0-36	0-37	<1-38	<1-38	<1-40	<1-37	<1-37	<1-43	<1-38	<1-40	<1-46	<1-60
<i>Time since first injection</i>																
<3 years	78 (23)	131 (26)	144 (28)	168 (24)	170 (20)	99 (13)	104 (13)	84 (12)	65 (9)	45 (8)	18 (6)	39 (8)	32 (8)	29 (6)	58 (7)	40 (7)
3+ years	256 (74)	365 (71)	365 (70)	511 (74)	635 (76)	632 (84)	678 (83)	606 (85)	642 (86)	531 (90)	258 (89)	442 (88)	373 (89)	471 (93)	724 (90)	496 (90)
Not reported	10 (3)	17 (3)	11 (2)	15 (2)	29 (3)	19 (3)	35 (4)	25 (4)	38 (5)	11 (2)	15 (5)	20 (4)	12 (3)	8 (2)	19 (2)	14 (3)

Table 5.1 Number (percentage) of respondents by demographic characteristic and year (continued)

QUEENSLAND	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=344	N=513	N=520	N=694	N=834	N=750	N=817	N=715	N=745	N=587	N=291	N=501	N=417	N=508	N=801	N=550
Aboriginal and Torres Strait Islander origin (%)																
No	322 (94)	465 (91)	489 (94)	662 (95)	755 (91)	669 (90)	735 (90)	636 (89)	669 (90)	541 (92)	273 (94)	438 (87)	375 (90)	459 (90)	675 (84)	479 (87)
Yes	10 (3)	16 (3)	22 (4)	23 (3)	41 (5)	49 (6)	51 (6)	49 (7)	51 (7)	33 (6)	14 (5)	49 (10)	38 (10)	32 (6)	105 (13)	62 (11)
Not reported	12 (3)	32 (6)	9 (2)	9 (1)	38 (4)	32 (4)	31 (4)	30 (4)	25 (3)	13 (2)	4 (1)	14 (3)	4 (<1)	17 (3)	21 (3)	9 (2)
Region/country of birth (%)																
Australia	--	--	--	--	758 (91)	604 (81)	686 (84)	605 (85)	645 (87)	492 (84)	259 (89)	436 (87)	374 (90)	431 (85)	698 (87)	490 (89)
Other Oceania	--	--	--	--	--	41 (5)	48 (6)	32 (4)	37 (5)	31 (5)	11 (4)	21 (4)	15 (4)	25 (5)	40 (5)	20 (4)
Asia	--	--	--	--	1 (<1)	2 (<1)	5 (<1)	3 (<1)	7 (1)	7 (1)	2 (1)	4 (<1)	1 (<1)	5 (1)	5 (<1)	5 (1)
UK & Ireland	--	--	--	--	--	31 (4)	24 (3)	23 (3)	26 (3)	29 (5)	13 (4)	18 (4)	14 (3)	22 (4)	24 (3)	17 (3)
Other	--	--	--	--	29 (3)	23 (3)	22 (3)	25 (4)	17 (2)	16 (3)	5 (2)	12 (2)	10 (2)	14 (3)	21 (3)	15 (3)
Not reported	--	--	--	--	46 (6)	49 (7)	32 (4)	27 (4)	13 (2)	12 (2)	1 (<1)	10 (2)	3 (<1)	11 (2)	13 (2)	3 (<1)
Main language spoken at home by parents (%)																
English	--	--	--	--	758 (91)	678 (91)	715 (87)	628 (88)	692 (93)	453 (77)	259 (89)	465 (93)	395 (95)	489 (96)	768 (96)	535 (97)
Non-English	--	--	--	--	23 (3)	25 (3)	40 (5)	37 (5)	27 (4)	12 (2)	32 (11)	17 (3)	17 (4)	13 (3)	24 (3)	9 (2)
Not reported	--	--	--	--	53 (6)	47 (6)	62 (8)	50 (7)	26 (3)	122 (21)	0 (0)	19 (4)	5 (1)	6 (1)	9 (1)	6 (1)
Imprisonment last year (%)																
No	306 (89)	462 (90)	482 (93)	624 (90)	713 (85)	639 (85)	670 (82)	595 (83)	636 (85)	499 (85)	250 (86)	412 (82)	363 (87)	418 (82)	656 (82)	410 (75)
Yes	31 (9)	37 (7)	36 (7)	63 (9)	107 (13)	98 (13)	115 (14)	109 (15)	96 (13)	83 (14)	34 (12)	67 (13)	43 (10)	56 (11)	111 (14)	51 (9)
Not reported	7 (2)	14 (3)	2 (<1)	7 (1)	14 (2)	13 (2)	32 (4)	11 (2)	13 (2)	5 (1)	7 (2)	22 (4)	11 (3)	34 (7)	34 (4)	89 (16)
Injected in prison last year (%)																
N° in prison	N=31	N=37	N=36	N=63	N=107	N=98	N=115	N=109	N=96	N=83	N=34	N=67	N=43	N=56	N=111	N=51
Injected in prison	7 (23)	16 (43)	23 (64)	26 (41)	43 (40)	39 (40)	41 (36)	43 (39)	30 (31)	55 (66)	14 (41)	27 (40)	22 (51)	20 (36)	51 (46)	25 (49)
Frequency of injection last month (%)																
Not last month	29 (9)	39 (8)	53 (10)	53 (8)	70 (8)	67 (9)	84 (10)	85 (12)	88 (12)	59 (10)	35 (12)	61 (12)	32 (8)	50 (10)	74 (9)	59 (11)
Less than weekly	63 (18)	124 (24)	157 (30)	144 (17)	145 (18)	132 (18)	180 (22)	120 (17)	149 (20)	119 (20)	45 (15)	100 (20)	70 (17)	80 (16)	123 (15)	103 (19)
Weekly not daily	111 (32)	164 (32)	92 (18)	204 (29)	203 (24)	202 (27)	207 (25)	165 (23)	196 (26)	141 (24)	89 (31)	96 (19)	119 (29)	137 (27)	173 (22)	131 (24)
Daily or more	137 (40)	183 (35)	217 (42)	292 (42)	402 (48)	343 (46)	333 (41)	339 (47)	297 (40)	265 (45)	120 (41)	243 (49)	188 (45)	234 (46)	426 (53)	252 (46)
Not reported	4 (1)	3 (1)	1 (<1)	1 (<1)	14 (2)	6 (1)	13 (2)	6 (1)	15 (2)	3 (1)	2 (1)	1 (<1)	8 (2)	7 (1)	5 (<1)	5 (1)

Table 5.2 Number (percentage) of respondents by drug last injected and year

QUEENSLAND N° surveyed	1995 N=344	1996 N=513	1997 N=520	1998 N=694	1999 N=834	2000 N=750	2001 N=817	2002 N=715	2003 N=745	2004 N=587	2005 N=291	2006 N=501	2007 N=417	2008 N=508	2009 N=801	2010 N=550
Drug last injected (%)																
Anabolic steroids	5 (1)	15 (3)	17 (3)	12 (2)	14 (2)	22 (3)	14 (2)	14 (2)	11 (2)	8 (1)	6 (2)	13 (3)	5 (1)	11 (2)	9 (1)	24 (4)
Cocaine	1 (<1)	5 (1)	2 (<1)	2 (<1)	2 (<1)	3 (<1)	2 (<1)	2 (<1)	2 (<1)	5 (1)	1 (<1)	2 (<1)	1 (<1)	2 (<1)	7 (<1)	2 (<1)
Heroin	169 (49)	264 (51)	238 (46)	290 (42)	360 (43)	337 (45)	217 (26)	360 (43)	194 (26)	165 (28)	85 (29)	115 (23)	106 (25)	124 (24)	218 (27)	123 (22)
Methadone	9 (3)	5 (1)	14 (3)	7 (1)	10 (1)	12 (1)	32 (4)	10 (1)	25 (3)	24 (4)	10 (3)	24 (5)	19 (5)	32 (6)	38 (5)	36 (7)
Methamphetamine	126 (37)	173 (34)	212 (41)	318 (46)	361 (43)	283 (38)	422 (52)	361 (43)	345 (46)	256 (44)	116 (40)	197 (39)	145 (35)	171 (34)	232 (29)	149 (27)
Pharm. opioids	4 (1)	15 (3)	5 (1)	13 (2)	13 (2)	18 (2)	50 (6)	13 (2)	83 (11)	67 (11)	43 (14)	94 (19)	96 (23)	120 (24)	177 (22)	141 (26)
Buprenorphine	--	--	--	--	--	--	--	0 (0)	2 (<1)	14 (2)	10 (3)	30 (6)	28 (7)	26 (5)	53 (7)	32 (6)
More than one	23 (7)	31 (6)	27 (5)	47 (7)	53 (6)	61 (8)	66 (8)	53 (7)	47 (6)	35 (6)	8 (3)	4 (<1)	2 (<1)	11 (2)	30 (4)	19 (3)
Other	6 (2)	5 (1)	2 (<1)	4 (<1)	6 (<1)	4 (<1)	6 (1)	6 (<1)	13 (2)	5 (1)	2 (<1)	2 (<1)	6 (1)	6 (1)	20 (2)	22 (4)
Not reported	1 (<1)	0 (0)	3 (<1)	1 (<1)	15 (2)	10 (1)	8 (1)	15 (2)	20 (3)	7 (1)	9 (3)	15 (3)	9 (2)	5 (1)	17 (2)	2 (<1)

Table 5.3 Number (percentage) of respondents by places injected in the last month and year

QUEENSLAND N° injected last month	1995 N=311	1996 N=471	1997 N=466	1998 N=640	1999 N=750	2000 N=677	2001 N=720	2002 N=624	2003 N=642	2004 N=525	2005 N=254	2006 N=439	2007 N=377	2008 N=451	2009 N=722	2010 N=487
Places injected in the last month (%) [more than one could be selected]																
<i>Private places</i>																
Own home	--	--	386 (83)	517 (81)	602 (80)	576 (85)	578 (80)	495 (79)	530 (83)	418 (80)	202 (80)	355 (85)	328 (88)	410 (91)	591 (83)	406 (83)
Friend's home	--	--	241 (52)	315 (49)	371 (49)	337 (50)	336 (47)	292 (47)	271 (42)	211 (40)	97 (38)	165 (40)	159 (43)	172 (38)	309 (43)	155 (32)
Dealer's home	--	--	96 (21)	125 (20)	197 (26)	141 (21)	156 (22)	142 (23)	119 (19)	99 (19)	38 (15)	65 (16)	53 (14)	66 (15)	131 (18)	59 (12)
Commercial injecting room	--	--	11 (2)	7 (1)	6 (1)	8 (1)	6 (1)	11 (2)	3 (<1)	4 (1)	2 (1)	1 (<1)	3 (<1)	13 (3)	7 (1)	4 (1)
<i>Public places</i>																
Street, park, beach	--	--	96 (21)	117 (18)	189 (25)	154 (23)	157 (22)	166 (27)	145 (23)	117 (22)	57 (22)	88 (21)	65 (17)	73 (16)	186 (26)	78 (16)
Car	--	--	--	201 (31)	293 (39)	250 (37)	241 (33)	237 (38)	198 (31)	167 (32)	77 (30)	126 (30)	134 (36)	137 (31)	218 (31)	118 (24)
Public toilet	--	--	91 (20)	107 (17)	186 (25)	163 (24)	164 (23)	166 (27)	158 (25)	117 (22)	66 (26)	94 (23)	73 (20)	71 (16)	184 (26)	86 (18)
Squat	--	--	--	--	42 (6)	34 (5)	56 (8)	51 (8)	45 (7)	31 (6)	25 (10)	35 (8)	17 (5)	2 (<1)	62 (9)	22 (5)
Public injecting in last month (%)																
Any public	--	--	154 (33)	249 (39)	364 (49)	314 (46)	315 (44)	324 (52)	280 (44)	227 (43)	106 (42)	187 (43)	164 (44)	164 (36)	347 (49)	174 (36)
All private	--	--	286 (61)	352 (55)	329 (44)	325 (48)	405 (56)	280 (45)	335 (52)	256 (49)	127 (50)	229 (52)	209 (55)	285 (63)	367 (51)	280 (57)
Not reported	--	--	26 (6)	39 (6)	57 (8)	38 (6)	0 (0)	23 (4)	27 (4)	42 (8)	20 (8)	23 (5)	4 (1)	2 (<1)	8 (1)	33 (7)

Table 5.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

QUEENSLAND	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=311	N=471	N=466	N=640	N=750	N=677	N=720	N=624	N=642	N=525	N=254	N=439	N=377	N=451	N=722	N=487
Use of sterile needles and syringes last month (%)																
All injections	--	--	328 (71)	455 (71)	534 (71)	506 (75)	535 (74)	469 (75)	484 (75)	392 (75)	187 (74)	332 (76)	282 (75)	329 (73)	532 (74)	348 (71)
Most of the time	--	--	103 (22)	127 (20)	170 (23)	134 (20)	154 (21)	130 (21)	129 (20)	104 (20)	55 (22)	85 (19)	71 (19)	107 (24)	151 (21)	91 (19)
Half of the time	--	--	10 (2)	21 (3)	16 (2)	12 (2)	10 (1)	8 (1)	13 (2)	6 (1)	5 (2)	9 (2)	9 (2)	7 (2)	10 (1)	8 (2)
Some of the time	--	--	5 (1)	15 (2)	4 (<1)	5 (1)	2 (<1)	8 (1)	7 (1)	7 (1)	4 (2)	2 (<1)	2 (<1)	2 (<1)	14 (2)	5 (1)
Not last month	--	--	5 (1)	4 (1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)	1 (<1)	5 (1)	1 (0)	1 (<1)	3 (<1)	2 (<1)	5 (<1)	1 (<1)
Not reported	--	--	15 (3)	18 (3)	25 (3)	18 (3)	16 (3)	8 (1)	8 (1)	11 (2)	2 (1)	10 (2)	10 (3)	4 (1)	10 (1)	34 (7)
Re-used someone else's used needle & syringe last month (%)																
None	220 (71)	340 (72)	367 (79)	523 (82)	562 (75)	560 (83)	578 (80)	500 (80)	535 (83)	417 (79)	206 (82)	349 (80)	316 (84)	388 (86)	579 (80)	377 (77)
Once	31 (10)	56 (12)	18 (4)	39 (6)	61 (8)	34 (5)	40 (6)	36 (6)	34 (5)	33 (6)	10 (4)	29 (7)	16 (4)	24 (5)	37 (5)	13 (3)
Twice	30 (9)	39 (8)	21 (5)	22 (3)	35 (5)	30 (4)	31 (4)	31 (5)	25 (4)	19 (4)	9 (4)	18 (4)	12 (3)	14 (3)	23 (5)	9 (2)
3-5 times	24 (8)	26 (6)	20 (4)	22 (3)	36 (4)	16 (2)	22 (3)	25 (4)	20 (3)	25 (5)	11 (4)	16 (4)	16 (4)	7 (2)	32 (4)	11 (2)
> 5 times	5 (1)	9 (2)	14 (3)	17 (3)	25 (4)	12 (2)	20 (3)	18 (3)	9 (2)	12 (2)	8 (3)	9 (2)	9 (2)	13 (3)	31 (4)	10 (2)
Not reported	1 (1)	1 (<1)	16 (3)	17 (3)	25 (3)	24 (4)	29 (4)	12 (2)	19 (3)	19 (4)	8 (3)	18 (4)	8 (2)	5 (1)	20 (3)	67 (14)
Number of people needle & syringe was re-used after last month (%)																
None	220 (71)	340 (72)	367 (79)	523 (82)	562 (75)	560 (83)	578 (80)	500 (80)	514 (80)	417 (79)	196 (77)	349 (80)	316 (84)	388 (86)	579 (80)	377 (77)
One	49 (16)	91 (19)	68 (15)	79 (12)	119 (16)	72 (11)	66 (9)	65 (10)	62 (10)	48 (9)	22 (9)	33 (8)	28 (7)	35 (8)	63 (9)	26 (5)
Two	32 (10)	34 (7)	9 (2)	10 (1)	8 (1)	5 (1)	8 (1)	10 (2)	10 (2)	9 (2)	1 (<1)	3 (<1)	5 (1)	0 (0)	11 (2)	1 (<1)
Three to five	3 (1)	1 (<1)	3 (<1)	3 (<1)	10 (1)	8 (1)	5 (1)	8 (1)	3 (<1)	4 (1)	5 (2)	2 (<1)	2 (<1)	3 (1)	7 (1)	7 (1)
More than five	6 (2)	4 (1)	3 (<1)	4 (1)	13 (2)	5 (1)	5 (1)	5 (1)	2 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)	3 (1)	5 (<1)	3 (<1)
Don't know	0 (0)	0 (0)	1 (<1)	4 (1)	13 (2)	1 (<1)	14 (2)	10 (2)	0 (0)	10 (2)	14 (6)	12 (3)	8 (2)	9 (2)	16 (2)	10 (2)
Not reported	1 (<1)	1 (<1)	15 (3)	17 (3)	25 (3)	24 (3)	44 (6)	26 (4)	32 (25)	36 (7)	15 (6)	38 (9)	17 (5)	13 (3)	41 (6)	63 (13)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]																
Regular sex partner	--	--	51 (11)	65 (10)	91 (12)	62 (9)	64 (9)	47 (8)	47 (6)	34 (6)	21 (8)	29 (7)	26 (7)	26 (6)	52 (7)	29 (6)
Casual sex partner	--	--	2 (<1)	6 (1)	8 (1)	11 (2)	8 (1)	10 (2)	11 (2)	4 (1)	0 (0)	4 (<1)	2 (<1)	1 (<1)	1 (<1)	1 (<1)
Close friend	--	--	18 (4)	28 (4)	43 (6)	32 (5)	34 (5)	28 (4)	29 (5)	20 (4)	8 (3)	12 (3)	13 (3)	13 (3)	43 (6)	17 (3)
Acquaintance	--	--	8 (1)	6 (1)	14 (2)	14 (2)	10 (1)	11 (2)	18 (3)	12 (2)	6 (2)	1 (<1)	0 (0)	7 (2)	8 (1)	7 (1)
Other	--	--	2 (<1)	2 (<1)	10 (1)	11 (2)	6 (1)	5 (1)	0 (0)	1 (<1)	3 (1)	2 (<1)	5 (1)	3 (1)	6 (<1)	6 (1)

Table 5.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

QUEENSLAND	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=311	N=471	N=466	N=640	N=750	N=677	N=720	N=624	N=642	N=525	N=254	N=439	N=377	N=541	N=722	N=487
Equipment used after someone else last month (%) [more than one could be selected]																
Spoon	--	--	--	--	281 (38)	188 (28)	177 (25)	179 (29)	180 (28)	129 (25)	68 (27)	83 (20)	80 (23)	85 (21)	187 (28)	97 (20)
Water	--	--	--	--	220 (30)	134 (20)	143 (20)	151 (24)	145 (23)	109 (21)	45 (18)	67 (16)	50 (15)	61 (15)	132 (20)	74 (15)
Filter	--	--	--	--	165 (22)	111 (16)	98 (14)	125 (20)	117 (18)	76 (14)	38 (15)	51 (12)	53 (15)	48 (12)	100 (15)	56 (12)
Drug mix	--	--	--	--	119 (16)	86 (13)	84 (12)	97 (16)	76 (12)	56 (11)	32 (13)	35 (8)	33 (10)	32 (8)	65 (10)	41 (8)
Tourniquet	--	--	--	--	119 (16)	92 (14)	95 (13)	84 (13)	72 (11)	55 (10)	26 (10)	41 (10)	27 (8)	39 (9)	56 (9)	--
None	--	--	--	--	--	--	--	--	--	--	--	268 (63)	239 (69)	280 (68)	389 (59)	317 (65)
Injected by someone after that person injected themselves or others last month (%)																
No	--	--	--	--	566 (76)	535 (79)	549 (76)	519 (83)	522 (81)	427 (81)	212 (83)	358 (82)	314 (83)	381 (84)	575 (80)	382 (78)
Yes	--	--	--	--	127 (18)	106 (16)	141 (20)	87 (14)	96 (15)	79 (15)	31 (12)	65 (15)	52 (14)	62 (14)	133 (18)	49 (10)
Not reported	--	--	--	--	48 (6)	36 (5)	30 (4)	18 (3)	24 (4)	19 (4)	11 (4)	16 (4)	11 (3)	8 (2)	14 (2)	56 (12)

Table 5.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

QUEENSLAND	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=344	N=513	N=520	N=694	N=834	N=750	N=817	N=715	N=745	N=587	N=291	N=501	N=417	N=508	N=801	N=487
Sex with a regular partner last month (%)																
No	--	--	--	--	--	--	--	--	--	--	135 (46)	200 (40)	178 (43)	228 (45)	358 (45)	241 (44)
Yes	--	--	--	--	--	--	--	--	--	--	154 (53)	284 (57)	224 (54)	261 (51)	414 (52)	284 (52)
Not reported	--	--	--	--	--	--	--	--	--	--	2 (1)	17 (3)	15 (4)	19 (4)	29 (4)	25 (5)
Condom used with regular partner last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=154	N=284	N=224	N=261	N=414	N=284
Sometimes	--	--	--	--	--	--	--	--	--	--	110 (71)	191 (67)	165 (74)	191 (73)	293 (71)	194 (68)
Every time	--	--	--	--	--	--	--	--	--	--	18 (12)	49 (17)	31 (14)	25 (10)	58 (14)	42 (15)
Not reported	--	--	--	--	--	--	--	--	--	--	21 (14)	29 (10)	21 (9)	27 (10)	41 (10)	33 (12)
Sex with other partner(s) last month (%)																
No	--	--	--	--	--	--	--	--	--	--	246 (85)	410 (82)	347 (83)	417 (82)	653 (82)	440 (80)
Yes	--	--	--	--	--	--	--	--	--	--	38 (13)	68 (14)	61 (15)	68 (13)	117 (15)	79 (14)
Not reported	--	--	--	--	--	--	--	--	--	--	7 (2)	23 (5)	9 (2)	23 (5)	31 (4)	31 (6)

Table 5.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

QUEENSLAND N° surveyed	1995 N=344	1996 N=513	1997 N=520	1998 N=694	1999 N=834	2000 N=750	2001 N=817	2002 N=715	2003 N=745	2004 N=587	2005 N=291	2006 N=501	2007 N=417	2008 N=508	2009 N=801	2010 N=550
Condom used with other partner(s) last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=38 9 (24)	N=68 17 (25)	N=61 20 (33)	N=68 21 (31)	N=117 40 (34)	N=79 25 (32)
Sometimes	--	--	--	--	--	--	--	--	--	--	9 (24)	15 (22)	22 (36)	16 (24)	40 (34)	20 (25)
Every time	--	--	--	--	--	--	--	--	--	--	18 (47)	32 (47)	16 (26)	28 (41)	36 (31)	31 (39)
Not reported	--	--	--	--	--	--	--	--	--	--	2 (5)	4 (6)	3 (5)	3 (4)	1 (<1)	3 (4)
Sex last month (%)																
No	81 (23)	131 (25)	175 (34)	191 (27)	232 (28)	207 (28)	214 (26)	194 (27)	195 (26)	161 (27)	--	--	--	--	--	--
Yes	260 (76)	379 (74)	341 (65)	499 (72)	585 (70)	536 (72)	584 (72)	502 (70)	535 (72)	410 (70)	--	--	--	--	--	--
Not reported	3 (1)	3 (1)	4 (1)	4 (1)	17 (2)	5 (1)	19 (2)	19 (3)	15 (2)	16 (3)	--	--	--	--	--	--
Condom use at last sex (%)																
No	181 (53)	227 (44)	319 (61)	411 (59)	516 (62)	481 (64)	503 (62)	459 (65)	499 (67)	407 (69)	--	--	--	--	--	--
Yes	110 (32)	138 (27)	196 (38)	272 (39)	288 (34)	243 (33)	271 (33)	246 (34)	223 (30)	171 (29)	--	--	--	--	--	--
Not reported	53 (15)	148 (29)	5 (1)	11 (2)	30 (4)	26 (3)	43 (5)	10 (1)	23 (3)	9 (2)	--	--	--	--	--	--
Condom use with regular sex partner(s) last month (%)																
No	--	191 (57)	196 (61)	247 (59)	337 (67)	316 (67)	239 (61)	212 (61)	217 (62)	194 (68)	--	--	--	--	--	--
Sometimes	--	57 (17)	56 (17)	56 (13)	68 (14)	57 (12)	61 (16)	41 (12)	54 (15)	34 (12)	--	--	--	--	--	--
Always	--	86 (26)	71 (22)	115 (28)	95 (19)	98 (21)	90 (23)	92 (27)	81 (23)	57 (20)	--	--	--	--	--	--
Condom use with new sex partner(s) last month (%)																
No	--	46 (31)	47 (34)	41 (34)	92 (47)	77 (43)	162 (48)	127 (46)	119 (48)	101 (48)	--	--	--	--	--	--
Sometimes	--	20 (13)	27 (20)	13 (11)	23 (12)	21 (12)	55 (16)	428 (15)	40 (16)	33 (16)	--	--	--	--	--	--
Always	--	84 (56)	63 (46)	67 (55)	81 (41)	80 (45)	124 (36)	109 (39)	88 (36)	74 (36)	--	--	--	--	--	--
Condom use with casual sex partner(s) last month (%)																
No	--	--	--	48 (29)	95 (43)	108 (47)	115 (44)	116 (46)	85 (42)	87 (50)	--	--	--	--	--	--
Sometimes	--	--	--	28 (17)	32 (14)	23 (10)	52 (20)	40 (16)	36 (18)	26 (15)	--	--	--	--	--	--
Always	--	--	--	91 (54)	96 (43)	100 (43)	96 (36)	94 (38)	82 (40)	61 (35)	--	--	--	--	--	--
Sex work last month (%)																
No	323 (93)	485 (94)	484 (93)	660 (95)	755 (91)	682 (91)	724 (89)	658 (92)	681 (91)	535 (91)	275 (95)	458 (91)	387 (93)	455 (90)	740 (92)	489 (89)
Yes	12 (3)	15 (3)	25 (5)	23 (3)	51 (6)	38 (5)	54 (7)	44 (6)	48 (6)	35 (6)	9 (3)	20 (4)	20 (5)	14 (3)	30 (4)	14 (3)
Not reported	9 (3)	13 (2)	11 (2)	11 (2)	28 (3)	29 (4)	39 (4)	8 (3)	16 (2)	17 (3)	7 (2)	23 (5)	10 (2)	39 (8)	31 (4)	47 (9)
Condom used at last sex work (%)																
Yes	10 (83)	12 (80)	16 (76)	18 (90)	38 (88)	32 (94)	41 (89)	36 (83)	36 (86)	31 (94)	32 (94)	17 (85)	11 (65)	12 (86)	18 (69)	10 (83)

Table 5.6 Number (percentage) of respondents by previous testing for HIV, HBV, HCV infection, HBV vaccination and HCV treatment by year

QUEENSLAND	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=344	N=513	N=520	N=694	N=834	N=750	N=817	N=715	N=745	N=587	N=291	N=501	N=417	N=508	N=801	N=550
Previous HIV test (%)																
Yes, last year	197 (57)	331 (66)	327 (64)	436 (63)	517 (62)	490 (65)	496 (61)	476 (67)	466 (62)	364 (62)	179 (62)	297 (59)	239 (57)	258 (51)	410 (51)	239 (43)
> 1 year ago	74 (22)	93 (18)	95 (18)	137 (20)	170 (20)	151 (20)	187 (23)	141 (20)	184 (25)	154 (26)	83 (29)	159 (32)	135 (32)	176 (35)	239 (30)	205 (37)
Never tested	70 (20)	88 (16)	95 (17)	117 (17)	133 (16)	96 (13)	120 (14)	89 (12)	88 (12)	58 (10)	29 (10)	37 (7)	40 (10)	49 (10)	126 (16)	73 (13)
Not reported	3 (1)	1 (<1)	3 (1)	4 (<1)	14 (2)	12 (2)	14 (2)	9 (1)	7 (1)	11 (2)	0 (0)	8 (2)	3 (<1)	25 (5)	26 (3)	33 (6)
Self report HBV infection (%)																
No	259 (75)	415 (81)	383 (74)	480 (69)	624 (75)	569 (76)	595 (73)	515 (72)	546 (73)	432 (74)	217 (75)	365 (73)	294 (71)	--	--	--
Yes	73 (21)	88 (17)	68 (13)	90 (13)	110 (13)	105 (14)	117 (14)	101 (14)	112 (15)	79 (13)	41 (14)	72 (14)	75 (18)	--	--	--
Don't know	--	--	68 (13)	115 (16)	79 (9)	55 (7)	81 (10)	84 (12)	72 (10)	60 (10)	29 (10)	48 (10)	41 (10)	--	--	--
Not reported	12 (3)	10 (2)	1 (1)	9 (1)	21 (3)	18 (2)	24 (3)	15 (2)	15 (2)	16 (3)	4 (1)	16 (3)	7 (2)	--	--	--
Self report HBV vaccination (%)																
No	179 (52)	249 (49)	198 (38)	239 (34)	260 (31)	199 (27)	238 (29)	199 (28)	204 (27)	181 (31)	75 (26)	116 (23)	103 (25)	--	--	--
Yes	155 (45)	251 (49)	244 (47)	341 (49)	470 (56)	464 (62)	451 (55)	417 (58)	452 (61)	328 (56)	183 (63)	317 (63)	268 (64)	--	--	--
Don't know	--	--	74 (14)	96 (14)	79 (9)	64 (9)	73 (9)	76 (11)	68 (9)	54 (9)	30 (10)	51 (10)	36 (9)	--	--	--
Not reported	10 (3)	13 (3)	4 (<1)	18 (3)	25 (3)	23 (3)	55 (7)	23 (3)	21 (3)	24 (4)	3 (1)	17 (3)	10 (2)	--	--	--
Previous HCV test (%)																
Yes, ever	240 (70)	380 (74)	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Yes, last year	--	--	317 (71)	403 (58)	527 (63)	507 (68)	522 (64)	470 (66)	468 (63)	383 (65)	185 (64)	297 (59)	258 (62)	289 (57)	446 (56)	281 (51)
> 1 year ago	--	--	71 (14)	118 (17)	141 (17)	145 (19)	165 (20)	128 (18)	160 (21)	142 (24)	77 (26)	154 (31)	123 (30)	160 (32)	249 (31)	187 (34)
Never tested	95 (28)	126 (25)	127 (24)	166 (24)	153 (18)	87 (12)	112 (14)	109 (15)	105 (14)	54 (9)	28 (10)	38 (8)	32 (8)	36 (7)	85 (11)	44 (8)
Not reported	9 (2)	7 (1)	5 (1)	7 (1)	13 (2)	11 (1)	18 (2)	8 (1)	12 (2)	8 (2)	1 (<1)	12 (2)	4 (1)	23 (5)	21 (9)	38 (7)
Any treatment for HCV (%)																
Interferon/+Ribavirin	--	--	--	--	8 (3)	8 (3)	11 (4)	12 (4)	13 (4)	15 (6)	7 (5)	12 (6)	12 (6)	18 (8)	25 (7)	27 (10)
Other	--	--	--	--	10 (4)	7 (3)	10 (4)	11 (4)	16 (6)	7 (3)	7 (5)	3 (1)	5 (3)	2 (1)	6 (2)	2 (1)
No treatment	--	--	--	--	226 (92)	211 (90)	253 (90)	245 (88)	255 (88)	217 (87)	112 (87)	187 (90)	163 (87)	211 (89)	300 (85)	222 (84)
Not reported	--	--	--	--	2 (1)	7 (3)	7 (2)	7 (3)	7 (2)	9 (4)	3 (2)	5 (2)	8 (4)	7 (3)	20 (6)	12 (5)
Current treatment for HCV (%)																
Interferon/ Interferon+Ribavirin	--	--	--	--	0	1	1	1	4	4	3	3	4	1	6	2
Other	--	--	--	--	6	3	6	0	0	4	3	2	0	0	2	0

Table 5.7 Number (percentage) of respondents by treatment for drug use and year

QUEENSLAND N° surveyed	1995 N=344	1996 N=513	1997 N=520	1998 N=694	1999 N=834	2000 N=750	2001 N=817	2002 N=715	2003 N=745	2004 N=587	2005 N=291	2006 N=501	2007 N=417	2008 N=508	2009 N=801	2010 N=550
Ever any treatment/therapy for drug use (%)																
No	182 (53)	269 (52)	261 (50)	359 (52)	376 (45)	303 (40)	321 (39)	271 (38)	308 (41)	174 (30)	73 (25)	115 (23)	86 (21)	124 (24)	182 (23)	119 (22)
Yes	161 (47)	241 (47)	258 (50)	332 (47)	446 (54)	440 (59)	485 (59)	433 (60)	432 (58)	407 (69)	215 (74)	374 (75)	323 (77)	374 (74)	606 (76)	410 (75)
Not reported	1 (<1)	3 (1)	1 (<1)	3 (1)	12 (1)	7 (1)	11 (1)	11 (2)	5 (1)	6 (1)	3 (1)	12 (2)	8 (2)	10 (2)	13 (2)	21 (4)
History of methadone maintenance treatment (%)																
Current	59 (17)	110 (21)	112 (21)	144 (21)	159 (19)	191 (25)	164 (20)	142 (20)	157 (21)	141 (24)	62 (21)	91 (18)	94 (23)	92 (18)	143 (18)	98 (18)
Previous	53 (15)	63 (12)	76 (15)	79 (11)	173 (21)	153 (20)	177 (22)	143 (20)	165 (22)	120 (21)	87 (30)	140 (28)	132 (32)	129 (25)	189 (24)	133 (24)
Never	231 (67)	337 (66)	331 (64)	468 (67)	502 (60)	403 (54)	461 (56)	418 (58)	417 (56)	318 (54)	137 (47)	253 (51)	189 (45)	272 (54)	453 (57)	292 (53)
Not reported	1 (1)	3 (1)	1 (<1)	3 (1)	0 (0)	3 (<1)	15 (2)	12 (2)	6 (1)	8 (1)	5 (2)	17 (3)	2 (<1)	15 (3)	16 (2)	27 (5)
History of other pharmacotherapy treatment (%)																
Current	--	--	--	--	--	18 (2)	24 (3)	54 (8)	73 (10)	81 (14)	47 (16)	81 (16)	81 (19)	88 (17)	142 (18)	100 (18)
Previous	--	--	--	--	--	81 (11)	74 (9)	86 (12)	108 (14)	93 (16)	61 (21)	110 (22)	87 (21)	120 (24)	180 (22)	126 (23)
Never	--	--	--	--	--	638 (85)	686 (84)	557 (77)	550 (74)	396 (67)	180 (62)	300 (60)	241 (58)	292 (57)	470 (59)	320 (58)
Not reported	--	--	--	--	--	12 (2)	22 (4)	18 (3)	14 (2)	17 (3)	3 (1)	10 (2)	8 (2)	8 (2)	9 (1)	4 (1)

Table 5.8 Number (percentage) of respondents by source of needle and syringe acquisition in the month prior to survey and year

QUEENSLAND N° injected last month	1995 N=311	1996 N=471	1997 N=466	1998 N=640	1999 N=750	2000 N=677	2001 N=720	2002 N=624	2003 N=642	2004 N=525	2005 N=254	2006 N=439	2007 N=377	2008 N=541	2009 N=722	2010 N=487
Needle/syringe acquisition in the last month (%) [more than one could be selected]																
Needle Syringe Program	--	--	--	--	682 (91)	616 (91)	643 (89)	560 (90)	586 (91)	477 (91)	238 (94)	391 (89)	263 (70)	411 (91)	461 (64)	430 (88)
Pharmacy	--	--	--	--	495 (66)	413 (61)	397 (55)	374 (60)	355 (55)	298 (57)	121 (48)	221 (50)	95 (25)	187 (41)	234 (32)	112 (23)
Personal Sources	--	--	--	--	--	--	--	--	--	--	--	--	59 (16)	--	133 (18)	47 (10)
Vending Machine	--	--	--	--	--	--	--	--	--	--	--	--	36 (10)	--	71 (10)	56 (12)
Other sources	--	--	--	--	--	--	--	--	--	--	--	--	13 (3)	--	18 (2)	4 (6)
Onward supply of syringes in last month (%)																
Yes, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	138 (36)	--	251 (35)	202 (41)
No, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	158 (42)	--	336 (47)	284 (58)
Not reported	--	--	--	--	--	--	--	--	--	--	--	--	81 (21)	--	135 (19)	1 (<1)

HIV ANTIBODY PREVALENCE

Table 5.9 HIV antibody prevalence by gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995	225	4 (1.8)	84	1 (1.2)	314	5 (1.6)
1996	374	7 (1.9)	132	1 (0.8)	513	8 (1.6)
1997	327	7 (2.1)	150	2 (1.3)	479	9 (1.9)
1998	472	4 (0.9)	196	1 (0.5)	670	5 (0.8)
1999	531	11 (2.1)	268	2 (0.8)	804	13 (1.6)
2000	464	7 (1.5)	250	0 (0.0)	720	8 (1.1)
2001	550	8 (1.5)	240	0 (0.0)	798	8 (1.0)
2002	479	10 (2.1)	200	2 (1.0)	685	13 (1.9)
2003	505	7 (1.4)	219	0 (0.0)	731	7 (1.0)
2004	379	10 (2.6)	165	1 (0.6)	544	11 (2.0)
2005	188	4 (2.1)	88	0 (0.0)	278	4 (1.4)
2006	350	11 (3.1)	142	1 (0.7)	495	12 (2.4)
2007	279	10 (3.6)	130	0 (0.0)	413	10 (2.4)
2008	335	9 (2.7)	161	0 (0.0)	498	9 (1.8)
2009	581	10 (1.7)	209	0 (0.0)	795	10 (1.3)
2010	407	11 (2.1)	123	0 (0.0)	535	11 (2.1)
χ^2 trend p value		0.037		0.029		0.136

Table 5.10 HIV antibody prevalence by sexual identity, gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
Heterosexual	184	1 (0.5)	59	1 (1.7)	244	2 (0.8)
Bisexual	19	0 (0.0)	17	0 (0.0)	38	0 (0.0)
Homosexual	17	3 (17.7)	6	0 (0.0)	24	3 (12.5)
1996						
Heterosexual	303	0 (0.0)	88	2 (1.1)	395	1 (0.3)
Bisexual	32	1 (3.1)	32	0 (0.0)	65	1 (1.5)
Homosexual	26	6 (23.0)	12	0 (0.0)	38	6 (15.8)
1997						
Heterosexual	278	1 (0.4)	105	1 (1.0)	384	2 (0.5)
Bisexual	18	0 (0.0)	34	1 (2.9)	52	1 (1.9)
Homosexual	16	6 (37.5)	10	0 (0.0)	26	6 (23.1)
1998						
Heterosexual	401	0 (0.0)	142	0 (0.0)	544	0 (0.0)
Bisexual	29	0 (0.0)	35	1 (2.9)	64	1 (1.6)
Homosexual	29	4 (13.8)	17	0 (0.0)	47	4 (8.5)
1999						
Heterosexual	422	4 (1.0)	177	2 (1.1)	599	6 (1.0)
Bisexual	42	0 (0.0)	59	0 (0.0)	103	0 (0.0)
Homosexual	29	5 (17.2)	17	0 (0.0)	48	5 (10.4)
2000						
Heterosexual	378	1 (0.3)	167	0 (0.0)	547	1 (0.2)
Bisexual	26	1 (3.9)	53	0 (0.0)	79	1 (1.3)
Homosexual	26	5 (19.2)	15	0 (0.0)	44	6 (13.6)
2001						
Heterosexual	440	2 (0.5)	167	0 (0.0)	611	2 (0.3)
Bisexual	25	0 (0.0)	44	0 (0.0)	70	0 (0.0)
Homosexual	33	6 (18.2)	13	0 (0.0)	47	6 (12.8)
2002						
Heterosexual	337	3 (0.8)	129	1 (0.8)	507	4 (0.8)
Bisexual	19	1 (5.3)	47	1 (2.1)	68	2 (2.9)
Homosexual	24	6 (25.0)	8	0 (0.0)	34	7 (20.6)
2003						
Heterosexual	414	1 (0.2)	152	0 (0.0)	567	1 (0.2)
Bisexual	17	1 (5.9)	50	0 (0.0)	69	1 (1.5)
Homosexual	32	4 (12.5)	6	0 (0.0)	40	4 (10.0)
2004						
Heterosexual	335	1 (0.3)	121	0 (0.0)	456	1 (0.2)
Bisexual	13	1 (7.7)	30	1 (3.3)	43	2 (4.7)
Homosexual	16	7 (43.8)	8	0 (0.0)	24	7 (29.2)
2005						
Heterosexual	159	1 (0.6)	67	0 (0.0)	227	1 (0.4)
Bisexual	8	0 (0.0)	14	0 (0.0)	22	0 (0.0)
Homosexual	12	3 (25.0)	5	0 (0.0)	17	3 (17.7)
2006						
Heterosexual	303	0 (0.0)	104	0 (0.0)	408	0 (0.0)
Bisexual	11	0 (0.0)	22	1 (4.5)	34	1 (2.9)
Homosexual	26	11 (42.3)	12	0 (0.0)	39	11 (28.2)
2007						
Heterosexual	249	1 (0.4)	98	0 (0.0)	347	1 (0.3)
Bisexual	7	1 (14.3)	22	0 (0.0)	31	1 (3.2)
Homosexual	18	8 (44.4)	6	0 (0.0)	25	8 (32.0)
2008						
Heterosexual	3022	0 (0.0)	127	0 (0.0)	430	0 (0.0)
Bisexual	10	2 (20.0)	27	0 (0.0)	37	2 (5.4)
Homosexual	17	17 (41.0)	4	0 (0.0)	21	7 (33.0)
2009						
Heterosexual	519	1 (0.2)	162	0 (0.0)	682	1 (0.1)
Bisexual	24	2 (8.3)	37	0 (0.0)	62	2 (3.2)
Homosexual	9	6 (67.0)	1	0 (0.0)	10	6 (60.0)
2010						
Heterosexual	345	2 (0.6)	97	0 (0.0)	445	2 (0.5)
Bisexual	21	2 (9.5)	16	0 (0.0)	37	2 (5.4)
Homosexual	21	7 (33)	6	0 (0.0)	27	87(25.9)
2010 p value		<0.001		---		<0.001

Table 5.11 HIV antibody prevalence by age group, gender and year

QUEENSLAND	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
<25 years	99	1 (1.0)	44	0 (0.0)	147	1 (0.7)
25-34 years	86	2 (2.3)	26	1 (3.9)	113	3 (2.7)
35+ years	38	1 (2.6)	13	0 (0.0)	51	1 (2.0)
1996						
<25 years	190	2 (1.1)	70	0 (0.0)	263	2 (0.8)
25-34 years	122	2 (1.6)	37	1 (2.7)	161	3 (1.9)
35+ years	62	3 (4.8)	25	0 (0.0)	87	3 (3.5)
1997						
<25 years	159	1 (0.6)	89	0 (0.0)	249	1 (0.4)
25-34 years	107	3 (2.8)	41	2 (4.9)	149	5 (3.4)
35+ years	61	3 (4.9)	20	0 (0.0)	81	3 (3.7)
1998						
<25 years	201	0 (0.0)	95	0 (0.0)	296	0 (0.0)
25-34 years	186	3 (1.6)	58	1 (1.7)	245	4 (1.6)
35+ years	84	1 (1.2)	43	0 (0.0)	128	1 (0.8)
1999						
<25 years	194	2 (1.0)	123	0 (0.0)	319	2 (0.6)
25-34 years	226	4 (1.8)	87	1 (1.2)	315	5 (1.6)
35+ years	110	5 (4.6)	58	1 (1.7)	168	6 (3.6)
2000						
<25 years	138	1 (0.7)	112	0 (0.0)	252	1 (0.4)
25-34 years	195	4 (2.1)	78	0 (0.0)	275	4 (1.5)
35+ years	130	2 (1.5)	60	0 (0.0)	191	3 (1.6)
2001						
<25 years	145	0 (0.0)	94	0 (0.0)	241	0 (0.0)
25-34 years	226	3 (1.3)	92	0 (0.0)	321	3 (0.9)
35+ years	177	5 (2.8)	54	0 (0.0)	234	5 (2.1)
2002						
<25 years	119	0 (0.0)	69	1 (1.5)	188	1 (0.5)
25-34 years	229	6 (2.6)	73	0 (0.0)	304	6 (2.0)
35+ years	129	4 (3.1)	57	1 (1.8)	190	6 (3.2)
2003						
<25 years	111	2 (1.8)	56	0 (0.0)	169	2 (1.2)
25-34 years	189	1 (0.5)	86	0 (0.0)	277	1 (0.4)
35+ years	202	4 (2.0)	77	0 (0.0)	282	4 (1.4)
2004						
<25 years	68	1 (1.5)	42	0 (0.0)	110	1 (0.9)
25-34 years	162	3 (1.9)	60	0 (0.0)	222	3 (1.4)
35+ years	148	5 (3.4)	63	1 (1.6)	211	6 (2.8)
2005						
<25 years	29	0 (0.0)	14	0 (0.0)	43	0 (0.0)
25-34 years	79	0 (0.0)	37	0 (0.0)	116	0 (0.0)
35+ years	80	4 (5.0)	37	0 (0.0)	119	4 (3.4)
2006						
<25 years	46	1 (2.2)	28	0 (0.0)	74	1 (1.4)
25-34 years	149	2 (1.3)	58	0 (0.0)	209	2 (1.0)
35+ years	154	8 (5.2)	56	1 (1.8)	211	9 (4.3)
2007						
<25 years	34	0 (0.0)	15	0 (0.0)	49	0 (0.0)
25-34 years	107	1 (0.9)	45	0 (0.0)	154	1 (0.7)
35+ years	137	9 (6.6)	70	0 (0.0)	209	9 (4.3)
2008						
<25 years	38	0 (0.0)	26	0 (0.0)	64	0 (0.0)
25-34 years	127	2 (1.6)	60	0 (0.0)	187	2 (1.1)
35+ years	169	7 (4.1)	74	0 (0.0)	245	7 (2.9)
2009						
<25 years	75	0 (0.0)	39	0 (0.0)	116	0 (0.0)
25-34 years	220	3 (1.4)	82	0 (0.0)	304	3 (1.0)
35+ years	283	7 (2.5)	85	0 (0.0)	369	7 (1.9)
2010						
<25 years	44	0 (0.0)	13	0 (0.0)	58	0 (0.0)
25-34 years	155	2 (1.3)	50	0 (0.0)	205	2 (1.0)
35+ years	207	9 (4.4)	59	0 (0.0)	270	9 (3.3)
2010 p value		0.135		--		0.092

Table 5.12 HIV antibody prevalence by time since first injection, gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
<3 years	51	0 (0.0)	20	0 (0.0)	72	0 (0.0)
3-10 years	97	2 (2.1)	39	0 (0.0)	138	2 (1.4)
11+ years	69	2 (2.9)	25	1 (4.0)	95	3 (3.2)
1996						
<3 years	100	1 (1.0)	30	0 (0.0)	131	1 (0.8)
3-10 years	177	3 (1.7)	66	0 (0.0)	247	3 (1.2)
11+ years	84	3 (3.6)	34	1 (2.9)	118	4 (3.4)
1997						
<3 years	88	0 (0.0)	47	0 (0.0)	135	0 (0.0)
3-10 years	148	2 (1.4)	69	0 (0.0)	217	2 (0.9)
11+ years	84	5 (6.0)	32	2 (6.3)	117	7 (6.0)
1998						
<3 years	107	1 (0.9)	55	0 (0.0)	162	1 (0.6)
3-10 years	246	1 (0.4)	88	0 (0.0)	334	1 (0.3)
11+ years	108	2 (1.9)	50	1 (2.0)	160	3 (1.9)
1999						
<3 years	101	2 (2.0)	62	1 (1.6)	163	3 (1.8)
3-10 years	261	3 (1.1)	132	1 (0.8)	397	4 (1.0)
11+ years	152	5 (3.3)	67	0 (0.0)	219	5 (2.3)
2000						
<3 years	59	2 (3.4)	35	0 (0.0)	94	2 (2.1)
3-10 years	216	2 (0.9)	143	0 (0.0)	363	2 (0.6)
11+ years	177	3 (1.7)	68	0 (0.0)	246	4 (1.6)
2001						
<3 years	61	1 (1.6)	38	0 (0.0)	99	1 (1.0)
3-10 years	257	3 (1.2)	120	0 (0.0)	380	3 (0.8)
11+ years	210	3 (1.4)	73	0 (0.0)	286	3 (1.1)
2002						
<3 years	54	2 (3.7)	25	0 (0.0)	79	2 (2.5)
3-10 years	211	2 (0.9)	93	1 (1.1)	306	3 (1.0)
11+ years	201	6 (3.0)	72	1 (1.4)	276	8 (2.9)
2003						
<3 years	38	0 (0.0)	24	0 (0.0)	63	0 (0.0)
3-10 years	195	2 (1.0)	90	0 (0.0)	288	2 (0.7)
11+ years	245	4 (1.6)	96	0 (0.0)	343	4 (1.2)
2004						
<3 years	29	0 (0.0)	13	0 (0.0)	42	0 (0.0)
3-10 years	155	4 (2.6)	73	0 (0.0)	228	4 (1.75)
11+ years	189	5 (2.7)	76	1 (1.3)	265	6 (2.3)
2005						
<3 years	13	1 (7.7)	3	0 (0.0)	16	1 (6.3)
3-10 years	41	0 (0.0)	29	0 (0.0)	70	0 (0.0)
11+ years	124	3 (2.4)	51	0 (0.0)	177	3 (1.7)
2006						
<3 years	25	0 (0.0)	14	0 (0.0)	39	0 (0.0)
3-10 years	88	3 (3.4)	52	0 (0.0)	140	3 (2.1)
11+ years	219	7 (3.2)	74	1 (1.4)	296	8 (2.7)
2007						
<3 years	23	1 (4.4)	9	0 (0.0)	32	1 (3.1)
3-10 years	77	1 (1.3)	34	0 (0.0)	111	1 (0.9)
11+ years	169	7 (4.1)	85	0 (0.0)	258	7 (2.7)
2008						
<3 years	19	1 (5.3)	10	0 (0.0)	29	1 (3.5)
3-10 years	95	1 (1.1)	61	0 (0.0)	156	1 (0.6)
11+ years	215	7 (3.3)	88	0 (0.0)	305	7 (2.3)
2009						
<3 years	36	0 (0.0)	20	0 (0.0)	57	0 (0.0)
3-10 years	128	1 (0.8)	67	0 (0.0)	197	1 (0.5)
11+ years	404	9 (2.2)	116	0 (0.0)	522	9 (1.7)
2010						
<3 years	29	0 (0.0)	7	0 (0.0)	36	0 (0.0)
3-10 years	81	2 (2.5)	28	0 (0.0)	110	2 (1.8)
11+ years	288	9 (3.1)	83	0 (0.0)	375	9 (2.4)
2010 p value		1.000		--		1.000

Table 5.13 HIV antibody prevalence by drug last injected, gender and year

QUEENSLAND	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
Heroin	116	3 (2.6)	45	1 (2.2)	162	4 (2.5)
Methamphetamine	75	1 (1.3)	30	0 (0.0)	108	1 (0.9)
Other	33	0 (0.0)	8	0 (0.0)	43	0 (0.0)
1996						
Heroin	174	2 (1.2)	86	0 (0.0)	264	2 (0.8)
Methamphetamine	133	3 (2.2)	36	1 (2.8)	173	4 (2.3)
Other	65	2 (3.1)	10	0 (0.0)	76	2 (2.6)
1997						
Heroin	144	5 (3.5)	83	0 (0.0)	227	5 (2.2)
Methamphetamine	136	1 (0.7)	53	0 (0.0)	191	1 (0.5)
Other	45	1 (2.2)	14	2 (14.3)	59	3 (5.1)
1998						
Heroin	182	1 (0.6)	98	0 (0.0)	281	1 (0.4)
Methamphetamine	227	2 (0.9)	77	1 (1.3)	304	3 (1.0)
Other	62	1 (1.6)	21	0 (0.0)	84	1 (1.2)
1999						
Heroin	205	1 (0.5)	141	0 (0.0)	349	1 (0.3)
Methamphetamine	237	7 (3.0)	106	2 (1.9)	344	9 (2.6)
Other	79	3 (3.8)	17	0 (0.0)	96	3 (3.1)
2000						
Heroin	187	2 (1.1)	140	0 (0.0)	328	2 (0.6)
Methamphetamine	183	3 (1.6)	85	0 (0.0)	270	3 (1.1)
Other	88	1 (1.1)	22	0 (0.0)	112	2 (1.8)
2001						
Heroin	144	1 (0.7)	68	0 (0.0)	212	1 (0.5)
Methamphetamine	285	5 (1.8)	123	0 (0.0)	413	5 (1.2)
Other	117	2 (1.7)	47	0 (0.0)	166	2 (1.2)
2002						
Heroin	137	0 (0.0)	68	0 (0.0)	206	1 (0.5)
Methamphetamine	217	6 (2.8)	85	0 (0.0)	304	6 (2.0)
Other	122	4 (3.3)	46	2 (4.4)	171	6 (3.5)
2003						
Heroin	122	2 (1.6)	70	0 (0.0)	193	2 (1.0)
Methamphetamine	237	4 (1.7)	95	0 (0.0)	336	4 (1.2)
Other	132	1 (0.8)	48	0 (0.0)	182	1 (0.6)
2004						
Heroin	109	2 (1.8)	45	0 (0.0)	154	2 (1.3)
Methamphetamine	161	6 (3.7)	73	0 (0.0)	234	6 (2.6)
Other	102	2 (2.0)	47	1 (2.1)	149	3 (2.0)
2005						
Heroin	50	0 (0.0)	38	0 (0.0)	79	0 (0.0)
Methamphetamine	74	1 (1.4)	30	0 (0.0)	114	1 (0.8)
Other	59	3 (5.1)	18	0 (0.0)	77	3 (3.9)
2006						
Heroin	71	1 (1.4)	41	0 (0.0)	113	1 (0.9)
Methamphetamine	139	7 (5.0)	56	1 (1.8)	195	8 (4.1)
Other	127	3 (2.4)	43	0 (0.0)	172	3 (1.7)
2007						
Heroin	64	0 (0.0)	41	0 (0.0)	106	0 (0.0)
Methamphetamine	97	4 (4.1)	46	0 (0.0)	143	4 (2.8)
Other	112	6 (5.4)	40	0 (0.0)	155	6 (3.9)
2008						
Heroin	83	1 (1.2)	41	0 (0.0)	124	1 (0.8)
Methamphetamine	107	4 (3.7)	56	0 (0.0)	163	4 (2.5)
Other	142	4 (2.8)	62	0 (0.0)	206	4 (1.9)
2009						
Heroin	158	1 (0.6)	57	0 (0.0)	216	1 (0.5)
Methamphetamine	169	7 (4.1)	60	0 (0.0)	231	7 (3.0)
Other	242	2 (0.8)	84	0 (0.0)	328	2 (0.6)
2010						
Heroin	93	3 (3.2)	30	0 (0.0)	123	3 (2.4)
Methamphetamine	106	6 (5.7)	33	0 (0.0)	142	6 (4.2)
Other	207	2 (1.0)	59	0 (0.0)	268	2 (0.8)
2010 p value		0.031		--		0.039

Table 5.14 HIV antibody prevalence by frequency of injection last month, gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
Less than daily	117	2 (1.7)	41	1 (2.4)	160	3 (1.9)
Daily or more	86	2 (2.3)	39	0 (0.0)	127	2 (1.6)
Not last month	21	0 (0.0)	2	0 (0.0)	24	0 (0.0)
1996						
Less than daily	209	5 (2.4)	76	1 (1.3)	288	6 (2.1)
Daily or more	131	1 (0.8)	48	0 (0.0)	183	1 (0.6)
Not last month	31	1 (3.2)	8	0 (0.0)	39	1 (2.6)
1997						
Less than daily	163	4 (2.5)	67	2 (3.0)	231	6 (2.6)
Daily or more	124	0 (0.0)	76	0 (0.0)	201	0 (0.0)
Not last month	39	3 (7.7)	7	0 (0.0)	46	3 (6.5)
1998						
Less than daily	249	3 (1.2)	88	0 (0.0)	338	3 (0.9)
Daily or more	186	0 (0.0)	94	1 (1.0)	281	1 (0.4)
Not last month	36	1 (2.8)	14	0 (0.0)	50	1 (2.0)
1999						
Less than daily	230	3 (1.3)	104	0 (0.0)	335	3 (0.9)
Daily or more	246	8 (3.3)	139	2 (1.4)	388	10 (2.6)
Not last month	44	0 (0.0)	23	0 (0.0)	67	0 (0.0)
2000						
Less than daily	215	5 (2.3)	102	0 (0.0)	318	6 (1.9)
Daily or more	207	2 (1.0)	120	0 (0.0)	331	2 (0.6)
Not last month	39	0 (0.0)	26	0 (0.0)	65	0 (0.0)
2001						
Less than daily	271	4 (1.5)	107	0 (0.0)	381	4 (1.1)
Daily or more	216	4 (1.9)	105	0 (0.0)	325	4 (1.2)
Not last month	55	0 (0.0)	25	0 (0.0)	80	0 (0.0)
2002						
Less than daily	192	5 (2.6)	77	1 (1.3)	274	7 (2.6)
Daily or more	227	2 (0.9)	98	1 (1.0)	325	3 (0.9)
Not last month	55	3 (5.5)	24	0 (0.0)	80	3 (3.8)
2003						
Less than daily	235	5 (2.1)	99	0 (0.0)	337	5 (1.5)
Daily or more	200	1 (0.5)	89	0 (0.0)	293	1 (0.3)
Not last month	58	0 (0.0)	27	0 (0.0)	85	0 (0.0)
2004						
Less than daily	165	7 (4.2)	76	1 (1.3)	241	8 (3.3)
Daily or more	177	2 (1.1)	69	0 (0.0)	246	2 (0.8)
Not last month	34	0 (0.0)	20	0 (0.0)	54	0 (0.0)
2005						
Less than daily	91	4 (4.4)	33	0 (0.0)	126	4 (3.2)
Daily or more	74	0 (0.0)	40	0 (0.0)	114	0 (0.0)
Not last month	22	0 (0.0)	13	0 (0.0)	35	0 (0.0)
2006						
Less than daily	141	8 (5.7)	51	1 (2.0)	193	9 (4.7)
Daily or more	169	3 (1.8)	71	0 (0.0)	241	3 (1.2)
Not last month	39	0 (0.0)	20	0 (0.0)	60	0 (0.0)
2007						
Less than daily	125	7 (5.6)	59	0 (0.0)	186	7 (3.8)
Daily or more	123	0 (0.0)	62	0 (0.0)	187	0 (0.0)
Not last month	24	2 (8.3)	8	0 (0.0)	32	2 (6.3)
2008						
Less than daily	145	7 (4.8)	69	0 (0.0)	214	7 (3.3)
Daily or more	154	2 (1.3)	73	0 (0.0)	229	2 (0.9)
Not last month	31	0 (0.0)	17	0 (0.0)	48	0 (0.0)
2009						
Less than daily	218	6 (2.8)	76	0 (0.0)	296	6 (2.0)
Daily or more	305	3 (1.0)	112	0 (0.0)	420	3 (0.7)
Not last month	56	1 (1.8)	18	0 (0.0)	74	1 (1.4)
2010						
Less than daily	181	4 (2.2)	58	0 (0.0)	242	4 (1.7)
Daily or more	174	1 (0.6)	57	0 (0.0)	232	1 (0.4)
Not last month	48	6 (12.5)	8	0 (0.0)	57	6 (10.5)
2010 p value		<0.001		--		<0.001

Table 5.15 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year

QUEENSLAND	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
No receptive sharing	149	4 (2.7)	53	1 (1.9)	204	5 (2.5)
Receptive sharing	53	0 (0.0)	27	0 (0.0)	82	0 (0.0)
1996						
No receptive sharing	243	5 (2.1)	92	1 (1.1)	340	6 (1.8)
Receptive sharing	96	1 (1.0)	32	0 (0.0)	130	1 (0.8)
1997						
No receptive sharing	234	4 (1.7)	105	2 (1.9)	341	6 (1.8)
Receptive sharing	40	0 (0.0)	35	0 (0.0)	75	0 (0.0)
1998						
No receptive sharing	356	1 (0.3)	149	1 (0.7)	507	2 (0.4)
Receptive sharing	65	1 (1.5)	30	0 (0.0)	95	1 (1.1)
1999						
No receptive sharing	365	7 (1.9)	177	1 (0.6)	545	8 (1.5)
Receptive sharing	96	4 (4.2)	58	1 (1.7)	155	5 (3.2)
2000						
No receptive sharing	362	7 (1.9)	170	0 (0.0)	536	8 (1.5)
Receptive sharing	46	0 (0.0)	44	0 (0.0)	91	0 (0.0)
2001						
No receptive sharing	391	5 (1.3)	172	0 (0.0)	570	5 (0.9)
Receptive sharing	76	3 (4.0)	33	0 (0.0)	109	3 (2.8)
2002						
No receptive sharing	338	6 (1.8)	140	1 (0.7)	483	8 (1.7)
Receptive sharing	76	1 (1.3)	31	1 (3.2)	107	2 (1.9)
2003						
No receptive sharing	357	5 (1.4)	161	0 (0.0)	524	5 (1.0)
Receptive sharing	61	1 (1.6)	25	0 (0.0)	87	1 (1.2)
2004						
No receptive sharing	277	8 (2.9)	112	1 (0.9)	389	9 (2.3)
Receptive sharing	54	1 (1.9)	28	0 (0.0)	82	1 (1.2)
2005						
No receptive sharing	136	4 (2.9)	57	0 (0.0)	194	4 (2.1)
Receptive sharing	25	0 (0.0)	11	0 (0.0)	37	0 (0.0)
2006						
No receptive sharing	254	9 (3.5)	90	0 (0.0)	345	9 (2.6)
Receptive sharing	44	1 (2.3)	27	0 (0.0)	71	1 (1.4)
2007						
No receptive sharing	207	7 (3.4)	104	0 (0.0)	314	7 (2.2)
Receptive sharing	34	0 (0.0)	16	0 (0.0)	51	0 (0.0)
2008						
No receptive sharing	255	8 (3.1)	123	0 (0.0)	380	8 (2.1)
Receptive sharing	40	1 (2.5)	18	0 (0.0)	58	1 (1.7)
2009						
No receptive sharing	418	9 (2.2)	152	0 (0.0)	574	9 (1.6)
Receptive sharing	94	0 (0.0)	28	0 (0.0)	123	0 (0.0)
2010						
No receptive sharing	279	4 (1.4)	88	0 (0.0)	369	4 (1.1)
Receptive sharing	28	1 (2.6)	13	0 (0.0)	41	1 (2.4)
2010 p value		0.382		--		0.411

Table 5.16 HIV antibody prevalence by imprisonment last year, gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
No imprisonment	198	4 (2.0)	78	1 (1.3)	280	5 (1.8)
Imprisonment	22	0 (0.0)	5	0 (0.0)	28	0 (0.0)
1996						
No imprisonment	333	6 (1.8)	123	1 (0.8)	462	7 (1.5)
Imprisonment	33	1 (3.0)	4	0 (0.0)	37	1 (2.7)
1997						
No imprisonment	303	7 (2.3)	141	2 (1.4)	446	9 (2.0)
Imprisonment	24	0 (0.0)	9	0 (0.0)	33	0 (0.0)
1998						
No imprisonment	417	4 (1.0)	185	1 (0.5)	603	5 (0.8)
Imprisonment	50	0 (0.0)	10	0 (0.0)	61	0 (0.0)
1999						
No imprisonment	436	7 (1.6)	249	2 (0.8)	689	9 (1.3)
Imprisonment	87	3 (3.5)	15	0 (0.0)	102	3 (2.9)
2000						
No imprisonment	382	7 (1.8)	227	0 (0.0)	613	7 (1.1)
Imprisonment	73	0 (0.0)	21	0 (0.0)	95	1 (1.1)
2001						
No imprisonment	437	5 (1.1)	213	0 (0.0)	656	5 (0.8)
Imprisonment	89	3 (3.4)	22	0 (0.0)	113	3 (2.7)
2002						
No imprisonment	388	9 (2.3)	179	2 (1.1)	573	12 (2.1)
Imprisonment	85	1 (1.2)	17	0 (0.0)	102	1 (1.0)
2003						
No imprisonment	417	7 (1.7)	202	0 (0.0)	624	7 (1.1)
Imprisonment	78	0 (0.0)	14	0 (0.0)	94	0 (0.0)
2004						
No imprisonment	311	9 (2.9)	149	1 (0.7)	460	10 (2.2)
Imprisonment	63	1 (1.6)	16	0 (0.0)	79	1 (1.3)
2005						
No imprisonment	155	4 (2.6)	80	0 (0.0)	237	4 (1.7)
Imprisonment	29	0 (0.0)	5	0 (0.0)	34	0 (0.0)
2006						
No imprisonment	273	10 (3.7)	130	1 (0.8)	406	11 (2.7)
Imprisonment	57	1 (1.8)	10	0 (0.0)	67	1 (1.5)
2007						
No imprisonment	238	10 (4.2)	118	0 (0.0)	359	10 (2.8)
Imprisonment	32	0 (0.0)	11	0 (0.0)	43	0 (0.0)
2008						
No imprisonment	276	7 (2.5)	134	0 (0.0)	411	7 (1.7)
Imprisonment	36	1 (2.8)	47	0 (0.0)	53	1 (1.9)
2009						
No imprisonment	465	10 (2.2)	182	0 (0.0)	652	10 (1.5)
Imprisonment	86	0 (0.0)	24	0 (0.0)	110	0 (0.0)
2010						
No imprisonment	302	10 (3.3)	94	0 (0.0)	401	10 (2.5)
Imprisonment	38	0 (0.0)	10	0 (0.0)	48	0 (0.0)
2010 p value		0.610		--		0.609

Table 5.17 HIV antibody prevalence by condom use at last sex, gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
No condom use	115	1 (0.9)	46	0 (0.0)	164	1 (0.6)
Condom use	69	2 (2.9)	29	1 (3.5)	100	3 (3.0)
1996						
No condom use	154	0 (0.0)	70	0 (0.0)	227	0 (0.0)
Condom use	104	5 (4.8)	33	1 (3.0)	138	6 (4.4)
1997						
No condom use	196	3 (1.5)	95	2 (2.1)	291	5 (1.7)
Condom use	128	4 (3.1)	55	0 (0.0)	185	4 (2.2)
1998						
No condom use	263	2 (0.8)	130	0 (0.0)	394	2 (0.5)
Condom use	202	2 (1.0)	63	1 (1.6)	266	3 (1.1)
1999						
No condom use	321	3 (0.9)	175	1 (0.6)	498	4 (0.8)
Condom use	197	8 (4.1)	79	1 (1.3)	278	9 (3.2)
2000						
No condom use	283	3 (1.1)	176	0 (0.0)	461	3 (0.7)
Condom use	165	4 (2.4)	65	0 (0.0)	234	5 (2.1)
2001						
No condom use	326	2 (0.6)	162	0 (0.0)	491	2 (0.4)
Condom use	197	6 (3.1)	68	0 (0.0)	267	6 (2.3)
2002						
No condom use	296	2 (0.7)	142	0 (0.0)	440	2 (0.5)
Condom use	176	8 (4.6)	56	2 (3.6)	236	11 (4.7)
2003						
No condom use	336	5 (1.5)	150	0 (0.0)	490	5 (1.0)
Condom use	156	1 (0.6)	61	0 (0.0)	220	1 (0.5)
2004						
No condom use	253	6 (2.4)	125	0 (0.0)	378	6 (1.6)
Condom use	120	4 (3.3)	39	1 (2.6)	159	5 (3.1)
2005 #						
No condom use	69	1 (1.5)	40	0 (0.0)	110	1 (0.9)
Condom use	32	1 (3.1)	11	0 (0.0)	43	1 (2.3)
2006						
No condom use	156	3 (1.9)	77	1 (1.3)	236	4 (1.7)
Condom use	21	1 (4.8)	8	0 (0.0)	29	1 (3.5)
2007						
No condom use	117	1 (0.9)	75	0 (0.0)	194	1 (0.5)
Condom use	14	0 (0.0)	6	0 (0.0)	21	0 (0.0)
2008						
No condom use	133	2 (1.5)	78	0 (0.0)	212	2 (0.9)
Condom use	15	0 (0.0)	9	0 (0.0)	24	0 (0.0)
2009						
No condom use	224	3 (1.3)	118	0 (0.0)	347	3 (0.9)
Condom use	33	2 (6.1)	22	0 (0.0)	41	2 (4.9)
2010						
No condom use	131	3 (2.3)	56	0 (0.0)	189	3 (1.6)
Condom use	56	2 (3.8)	15	0 (0.0)	71	2 (2.8)
2010 p value		0.637		--		0.616

Excludes people reporting no sex last month. Question referred to "condom use at last sex" from 1995 to 2004.

Table 5.18 HIV antibody prevalence by sex work last month, gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
No sex work	215	3 (1.4)	73	1 (1.4)	293	4 (1.4)
Sex work	5	1 (20.0)	7	0 (0.0)	12	1 (8.3)
1996						
No sex work	356	6 (1.7)	124	1 (0.8)	485	7 (1.4)
Sex work	9	1 (11.1)	6	0 (0.0)	15	1 (6.7)
1997						
No sex work	308	7 (2.3)	138	2 (1.5)	447	9 (2.0)
Sex work	12	0 (0.0)	11	0 (0.0)	24	0 (0.0)
1998						
No sex work	456	4 (0.9)	178	1 (0.6)	636	5 (0.8)
Sex work	7	0 (0.0)	16	0 (0.0)	23	0 (0.0)
1999						
No sex work	499	9 (1.8)	228	2 (0.9)	729	11 (1.5)
Sex work	18	1 (5.6)	29	0 (0.0)	49	1 (2.0)
2000						
No sex work	436	7 (1.6)	214	0 (0.0)	653	8 (1.2)
Sex work	10	0 (0.0)	26	0 (0.0)	38	0 (0.0)
2001						
No sex work	512	8 (1.6)	194	0 (0.0)	709	8 (1.1)
Sex work	14	0 (0.0)	36	0 (0.0)	54	0 (0.0)
2002						
No sex work	452	10 (2.2)	175	2 (1.1)	631	13 (2.1)
Sex work	19	0 (0.0)	21	0 (0.0)	42	0 (0.0)
2003						
No sex work	474	6 (1.3)	191	0 (0.0)	669	6 (0.9)
Sex work	21	1 (4.8)	24	0 (0.0)	48	1 (2.1)
2004						
No sex work	351	9 (2.6)	146	1 (0.7)	497	10 (2.0)
Sex work	14	0 (0.0)	18	0 (0.0)	32	0 (0.0)
2005						
No sex work	177	4 (2.3)	83	0 (0.0)	262	4 (1.5)
Sex work	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
2006						
No sex work	327	11 (3.7)	123	1 (0.8)	452	12 (2.7)
Sex work	6	0 (0.0)	13	0 (0.0)	20	0 (0.0)
2007						
No sex work	263	10 (3.8)	118	0 (0.0)	383	10 (2.6)
Sex work	8	0 (0.0)	10	0 (0.0)	20	0 (0.0)
2008						
No sex work	300	9 (3.0)	144	0 (0.0)	446	9 (2.0)
Sex work	2	0 (0.0)	11	0 (0.0)	13	0 (0.0)
2009						
No sex work	545	10 (1.8)	188	0 (0.0)	737	10 (1.4)
Sex work	13	0 (0.0)	16	0 (0.0)	30	0 (0.0)
2010						
No sex work	370	11 (3.0)	103	0 (0.0)	477	11 (2.3)
Sex work	4	0 (0.0)	9	0 (0.0)	13	0 (0.0)
2010 p value		1.000		--		1.000

Table 5.19 HIV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995						
Non-Indigenous	210	4 (1.9)	80	1 (1.3)	293	5 (1.7)
Indigenous	6	0 (0.0)	2	0 (0.0)	9	0 (0.0)
1996						
Non-Indigenous	343	6 (1.8)	120	1 (0.8)	465	7 (1.5)
Indigenous	10	0 (0.0)	6	0 (0.0)	16	0 (0.0)
1997						
Non-Indigenous	304	7 (2.3)	145	2 (1.4)	451	9 (2.0)
Indigenous	17	0 (0.0)	3	0 (0.0)	20	0 (0.0)
1998						
Non-Indigenous	451	4 (0.9)	189	1 (0.5)	642	5 (0.8)
Indigenous	14	0 (0.0)	6	0 (0.0)	20	0 (0.0)
1999						
Non-Indigenous	487	11 (2.3)	241	2 (0.8)	732	13 (1.8)
Indigenous	22	0 (0.0)	15	0 (0.0)	37	0 (0.0)
2000						
Non-Indigenous	420	6 (1.4)	220	0 (0.0)	643	7 (1.1)
Indigenous	28	1 (3.6)	19	0 (0.0)	49	1 (2.0)
2001						
Non-Indigenous	498	8 (1.6)	217	0 (0.0)	721	8 (1.1)
Indigenous	31	0 (0.0)	16	0 (0.0)	49	0 (0.0)
2002						
Non-Indigenous	421	7 (1.7)	184	2 (1.1)	609	10 (1.6)
Indigenous	37	2 (5.4)	8	0 (0.0)	47	2 (4.3)
2003						
Non-Indigenous	451	5 (1.1)	197	0 (0.0)	654	5 (0.8)
Indigenous	36	0 (0.0)	14	0 (0.0)	51	0 (0.0)
2004						
Non-Indigenous	347	9 (2.6)	156	1 (0.6)	503	10 (2.0)
Indigenous	23	0 (0.0)	5	0 (0.0)	28	0 (0.0)
2005						
Non-Indigenous	176	4 (2.3)	82	0 (0.0)	260	4 (1.5)
Indigenous	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)
2006						
Non-Indigenous	306	9 (2.9)	128	1 (0.8)	434	10 (2.3)
Indigenous	34	2 (5.9)	13	0 (0.0)	48	2 (4.2)
2007						
Non-Indigenous	250	8 (3.2)	119	0 (0.0)	372	8 (2.2)
Indigenous	26	2 (7.7)	10	0 (0.0)	37	2 (5.4)
2008						
Non-Indigenous	316	9 (2.9)	136	0 (0.0)	453	9 (1.9)
Indigenous	7	0 (0.0)	20	0 (0.0)	28	0 (0.0)
2009						
Non-Indigenous	495	10 (2.0)	172	0 (0.0)	672	10 (1.5)
Indigenous	67	0 (0.0)	35	0 (0.0)	102	0 (0.0)
2010						
Non-Indigenous	358	10 (2.8)	103	0 (0.0)	466	10 (2.2)
Indigenous	42	1 (2.4)	19	0 (0.0)	61	1 (1.6)
2010 p value		1.000		--		1.000

Table 5.20 HIV antibody prevalence by country of birth, gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2003						
Australia	435	5 (1.2)	191	0 (0.0)	632	5 (0.8)
Other	59	2 (3.4)	25	0 (0.0)	85	2 (2.4)
2004						
Australia	322	7 (2.2)	138	1 (0.7)	460	8 (1.7)
Other	51	2 (3.9)	23	0 (0.0)	74	2 (2.7)
2005						
Australia	163	3 (1.8)	83	0 (0.0)	248	3 (1.2)
Other	24	1 (4.2)	5	0 (0.0)	29	1 (3.4)
2006						
Australia	302	8 (2.7)	125	1 (0.8)	430	9 (2.1)
Other	39	3 (7.7)	16	0 (0.0)	55	3 (5.5)
2007						
Australia	248	9 (3.6)	118	0 (0.0)	370	9 (2.4)
Other	28	1 (3.6)	12	0 (0.0)	40	1 (2.5)
2008						
Australia	283	8 (2.8)	138	0 (0.0)	422	8 (1.9)
Other	45	1 (2.2)	20	0 (0.0)	65	1 (1.5)
2009						
Australia	504	10 (2.0)	183	0 (0.0)	692	10 (1.5)
Other	65	0 (0.0)	25	0 (0.0)	90	0 (0.0)
2010						
Australia	361	10 (2.8)	110	0 (0.0)	476	10 (2.1)
Other	45	1 (2.2)	12	0 (0.0)	57	1 (1.8)
2010 p value		1.000		--		1.000

Table 5.21 HIV antibody prevalence by language spoken at home by parents, gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2003						
English speaking	468	6 (1.3)	205	0 (0.0)	680	6 (0.9)
Non-English speaking	18	0 (0.0)	7	0 (0.0)	25	0 (0.0)
2004						
English speaking	291	8 (2.8)	133	0 (0.0)	424	8 (1.9)
Non-English speaking	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
2005						
English speaking	166	4 (2.4)	79	0 (0.0)	246	4 (1.6)
Non-English speaking	22	0 (0.0)	9	0 (0.0)	32	0 (0.0)
2006						
English speaking	323	10 (3.1)	134	1 (0.8)	459	11 (2.4)
Non-English speaking	12	1 (8.3)	4	0 (0.0)	17	1 (5.9)
2007						
English speaking	261	9 (3.5)	126	0 (0.0)	391	9 (2.3)
Non-English speaking	13	1 (7.7)	4	0 (0.0)	17	1 (5.9)
2008						
English speaking	321	8 (2.5)	156	0 (0.0)	479	8 (1.7)
Non-English speaking	9	1 (11)	4	0 (0.0)	13	13 (7.7)
2009						
English speaking	558	10 (1.8)	199	0 (0.0)	762	10 (1.3)
Non-English speaking	14	0 (0.0)	10	0 (0.0)	24	0 (0.0)
2010						
English speaking	396	11 (2.8)	120	0 (0.0)	521	11 (2.1)
Non-English speaking	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)
2010 p value		1.000		--		1.000

HCV ANTIBODY PREVALENCE

Table 5.22 HCV antibody prevalence by gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	223	84 (38)	82	37 (45)	309	124 (40)
1996	358	107 (30)	125	54 (43)	489	162 (33)
1997	327	86 (26)	150	51 (34)	479	138 (29)
1998	472	114 (24)	196	76 (39)	670	192 (29)
1999	531	191 (36)	268	115 (43)	804	307 (38)
2000	467	172 (37)	250	110 (44)	723	285 (39)
2001	556	238 (43)	243	121 (50)	807	363 (45)
2002	479	231 (48)	198	93 (47)	683	329 (48)
2003	505	241 (48)	219	123 (56)	731	366 (50)
2004	381	188 (49)	166	94 (57)	547	282 (52)
2005	188	105 (56)	86	40 (47)	276	146 (53)
2006	349	185 (53)	142	88 (62)	494	276 (56)
2007	278	158 (57)	129	85 (66)	411	247 (60)
2008	333	182 (55)	159	91 (57)	494	275 (56)
2009	576	244 (42)	209	94 (45)	790	339 (43)
2010	403	180 (45)	121	58 (48)	529	241 (46)
χ^2 trend p value		<0.001		<0.001		<0.001

Table 5.23 HCV antibody prevalence by sexual identity, gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Heterosexual	182	73 (40)	57	25 (44)	240	99 (41)
Bisexual	19	4 (21)	17	8 (47)	37	13 (35)
Homosexual	17	6 (35)	6	2 (33)	24	8 (33)
1996						
Heterosexual	289	88 (30)	84	36 (43)	377	125 (33)
Bisexual	32	12 (38)	30	12 (40)	63	24 (38)
Homosexual	25	6 (24)	11	7 (64)	36	13 (36)
1997						
Heterosexual	278	74 (27)	105	41 (39)	384	115 (30)
Bisexual	17	3 (18)	34	6 (18)	52	10 (19)
Homosexual	16	6 (38)	10	4 (40)	26	10 (38)
1998						
Heterosexual	401	96 (24)	142	56 (39)	544	153 (28)
Bisexual	29	11 (38)	35	11 (31)	64	22 (34)
Homosexual	29	5 (17)	17	9 (53)	47	15 (32)
1999						
Heterosexual	422	154 (36)	177	79 (45)	599	233 (39)
Bisexual	42	15 (36)	59	25 (42)	103	41 (40)
Homosexual	29	8 (28)	17	7 (41)	48	15 (31)
2000						
Heterosexual	381	146 (38)	167	72 (43)	550	218 (40)
Bisexual	26	11 (42)	53	24 (45)	79	35 (44)
Homosexual	26	6 (23)	15	7 (47)	44	15 (34)
2001						
Heterosexual	445	200 (45)	170	84 (49)	619	285 (46)
Bisexual	25	9 (36)	44	25 (57)	70	35 (50)
Homosexual	34	11 (32)	13	6 (46)	48	18 (38)
2002						
Heterosexual	377	180 (48)	128	66 (52)	506	247 (49)
Bisexual	19	11 (58)	47	20 (43)	68	33 (49)
Homosexual	24	12 (50)	8	3 (38)	34	17 (50)
2003						
Heterosexual	414	202 (49)	152	84 (55)	567	286 (50)
Bisexual	17	4 (24)	50	27 (54)	69	32 (46)
Homosexual	32	15 (47)	6	4 (67)	40	20 (50)
2004						
Heterosexual	337	165 (49)	122	73 (60)	459	238 (52)
Bisexual	13	8 (62)	30	13 (43)	43	21 (49)
Homosexual	16	9 (56)	8	4 (50)	24	13 (54)
2005						
Heterosexual	159	84 (53)	64	32 (50)	224	116 (52)
Bisexual	8	5 (63)	15	4 (27)	23	9 (41)
Homosexual	13	10 (77)	5	3 (60)	18	13 (72)
2006						
Heterosexual	302	165 (55)	104	62 (60)	407	228 (56)
Bisexual	11	4 (36)	22	16 (73)	34	21 (62)
Homosexual	26	12 (46)	12	7 (58)	39	20 (51)
2007						
Heterosexual	248	140 (56)	97	62 (64)	345	202 (59)
Bisexual	7	4 (57)	22	16 (73)	31	22 (71)
Homosexual	18	11 (61)	6	3 (50)	25	15 (60)
2008						
Heterosexual	300	164 (55)	126	67 (53)	427	232 (54)
Bisexual	10	5 (50)	26	18 (69)	36	23 (64)
Homosexual	17	8 (47)	4	3 (75)	21	11 (52)
2009						
Heterosexual	514	222 (43)	162	67 (41)	677	289 (43)
Bisexual	24	7 (29)	37	22 (59)	62	29 (47)
Homosexual	9	3 (33)	1	1 (100)	10	4 (40)
2010						
Heterosexual	340	150 (44)	96	45 (47)	439	197 (45)
Bisexual	21	10 (48)	15	9 (60)	36	19 (53)
Homosexual	22	7 (32)	6	2 (33)	28	9 (32)
2010 p value		0.486		0.490		0.267

Table 5.24 HCV antibody prevalence by age group, gender and year

QUEENSLAND	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	98	16 (16)	43	10 (23)	144	28 (19)
25-34 years	86	41 (48)	26	16 (62)	113	58 (51)
35+ years	37	27 (73)	13	11 (85)	50	38 (76)
1996						
<25 years	184	16 (9)	64	15 (23)	251	32 (13)
25-34 years	113	43 (38)	36	20 (56)	150	63 (42)
35+ years	61	52 (85)	25	20 (80)	86	72 (84)
1997						
<25 years	159	9 (6)	89	16 (18)	249	25 (10)
25-34 years	107	29 (27)	41	18 (44)	149	48 (32)
35+ years	61	48 (79)	20	17 (85)	81	65 (80)
1998						
<25 years	201	14 (7)	95	9 (9)	296	23 (8)
25-34 years	186	41 (22)	58	35 (60)	245	77 (31)
35+ years	84	59 (70)	43	32 (74)	128	92 (72)
1999						
<25 years	194	29 (15)	123	32 (26)	319	61 (19)
25-34 years	226	72 (32)	87	38 (44)	315	111 (35)
35+ years	110	90 (82)	58	45 (78)	168	135 (80)
2000						
<25 years	138	24 (17)	112	28 (25)	252	54 (21)
25-34 years	196	53 (27)	78	44 (56)	276	97 (35)
35+ years	132	95 (72)	60	38 (63)	193	133 (69)
2001						
<25 years	145	33 (23)	94	30 (32)	241	63 (26)
25-34 years	231	77 (33)	94	44 (47)	328	123 (38)
35+ years	178	127 (71)	55	47 (85)	236	176 (75)
2002						
<25 years	119	45 (38)	69	29 (42)	188	74 (39)
25-34 years	228	102 (45)	72	29 (40)	302	132 (44)
35+ years	130	83 (64)	56	35 (63)	190	122 (64)
2003						
<25 years	111	29 (26)	56	15 (27)	169	45 (27)
25-34 years	189	65 (34)	86	51 (59)	277	116 (42)
35+ years	203	147 (72)	77	57 (74)	283	205 (72)
2004						
<25 years	69	17 (25)	42	19 (45)	111	36 (32)
25-34 years	163	59 (36)	60	22 (37)	223	81 (36)
35+ years	148	111 (75)	64	53 (83)	212	164 (77)
2005						
<25 years	29	5 (17)	14	1 (7)	43	6 (14)
25-34 years	80	37 (46)	36	13 (36)	116	50 (43)
35+ years	79	63 (80)	36	26 (72)	117	90 (77)
2006						
<25 years	46	11 (24)	28	12 (43)	74	23 (31)
25-34 years	149	64 (43)	58	27 (47)	209	93 (45)
35+ years	153	109 (71)	56	49 (88)	210	159 (76)
2007						
<25 years	34	9 (26)	14	6 (43)	48	15 (31)
25-34 years	107	55 (51)	45	23 (51)	154	80 (52)
35+ years	136	93 (68)	70	56 (80)	208	151 (73)
2008						
<25 years	38	10 (26)	26	13 (50)	64	23 (36)
25-34 years	125	56 (45)	58	32 (55)	183	88 (48)
35+ years	169	115 (68)	74	46 (62)	245	163 (67)
2009						
<25 years	75	17 (23)	39	15 (38)	116	32 (28)
25-34 years	218	75 (34)	85	39 (46)	305	114 (37)
35+ years	283	152 (54)	85	40 (47)	369	193 (52)
2010						
<25 years	43	7 (16)	13	3 (23)	57	10 (18)
25-34 years	154	55 (36)	50	25 (50)	204	80 (39)
35+ years	205	118 (58)	57	30 (53)	266	151 (57)
2010 p value		<0.001		0.166		<0.001

Table 5.25 HCV antibody prevalence by time since first injection, gender and year

QUEENSLAND	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<3 years	50	4 (8)	20	3 (15)	70	7 (10)
3-10 years	97	29 (30)	38	14 (37)	137	45 (33)
11+ years	68	48 (71)	24	20 (83)	93	69 (74)
1996						
<3 years	95	4 (4)	28	3 (11)	124	7 (6)
3-10 years	169	41 (24)	62	21 (34)	234	63 (27)
11+ years	82	63 (77)	34	30 (88)	116	93 (80)
1997						
<3 years	87	4 (5)	47	3 (6)	135	7 (5)
3-10 years	148	18 (12)	69	22 (32)	217	40 (18)
11+ years	84	62 (74)	32	26 (81)	117	89 (76)
1998						
<3 years	107	4 (4)	55	3 (5)	162	7 (4)
3-10 years	246	40 (16)	88	28 (32)	334	68 (20)
11+ years	108	68 (63)	50	45 (90)	160	115 (72)
1999						
<3 years	101	8 (8)	62	15 (24)	163	23 (14)
3-10 years	260	62 (24)	132	42 (32)	396	105 (27)
11+ years	151	115 (76)	67	55 (82)	218	170 (78)
2000						
<3 years	59	6 (10)	35	6 (17)	94	12 (13)
3-10 years	217	47 (22)	143	56 (39)	364	105 (29)
11+ years	177	115 (65)	68	47 (69)	246	162 (66)
2001						
<3 years	62	5 (8)	39	7 (18)	101	12 (12)
3-10 years	260	78 (30)	120	51 (43)	383	130 (34)
11+ years	211	149 (71)	75	60 (80)	289	211 (73)
2002						
<3 years	54	22 (41)	24	7 (29)	78	29 (37)
3-10 years	211	87 (41)	93	41 (44)	306	129 (42)
11+ years	201	116 (58)	71	41 (58)	275	160 (58)
2003						
<3 years	38	4 (11)	24	4 (17)	63	8 (13)
3-10 years	195	67 (34)	90	37 (41)	288	105 (36)
11+ years	243	161 (66)	95	76 (80)	340	238 (70)
2004						
<3 years	29	10 (34)	13	2 (15)	42	12 (29)
3-10 years	156	51 (33)	74	33 (45)	230	84 (37)
11+ years	189	124 (66)	76	57 (75)	265	181 (68)
2005						
<3 years	13	1 (8)	3	0 (0)	16	1 (6)
3-10 years	58	17 (29)	37	10 (27)	95	27 (28)
11+ years	113	85 (75)	43	29 (67)	157	114 (73)
2006						
<3 years	25	4 (16)	14	4 (29)	39	8 (21)
3-10 years	88	32 (36)	52	32 (62)	140	64 (46)
11+ years	218	140 (64)	74	52 (70)	295	195 (66)
2007						
<3 years	23	4 (17)	9	2 (22)	32	6 (19)
3-10 years	77	30 (39)	33	16 (48)	110	46 (42)
11+ years	168	117 (70)	85	66 (78)	257	187 (73)
2008						
<3 years	19	2 (11)	10	4 (40)	29	6 (21)
3-10 years	94	28 (30)	61	29 (48)	155	57 (37)
11+ years	214	149 (70)	86	58 (67)	302	209 (69)
2009						
<3 years	36	3 (8)	20	3 (15)	57	6 (11)
3-10 years	127	41 (32)	67	27 (40)	196	68 (35)
11+ years	400	196 (49)	116	63 (54)	518	260 (50)
2010						
<3 years	29	2 (7)	7	0 (0)	36	2 (6)
3-10 years	80	25 (31)	28	9 (32)	109	34 (31)
11+ years	285	149 (52)	81	47 (58)	370	199 (54)
2010 p value		<0.001		0.001		<0.001

Table 5.26 HCV antibody prevalence by drug last injected, time since first injection and year

QUEENSLAND	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heroin	19	3 (16)	135	69 (51)	159	74 (47)
Methamphetamine	39	2 (5)	65	25 (38)	106	28 (26)
Other	11	2 (18)	30	20 (67)	43	22 (51)
1996						
Heroin	36	2 (6)	209	112 (54)	253	117 (46)
Methamphetamine	74	4 (5)	91	20 (22)	168	24 (14)
Other	14	1 (7)	50	24 (48)	68	26 (38)
1997						
Heroin	31	3 (10)	194	90 (46)	227	94 (41)
Methamphetamine	88	4 (5)	97	19 (20)	191	23 (12)
Other	16	0 (0)	42	20 (48)	59	21 (36)
1998						
Heroin	34	2 (6)	244	119 (49)	281	123 (44)
Methamphetamine	104	4 (4)	193	37 (19)	304	41 (13)
Other	23	1 (4)	57	27 (47)	84	28 (33)
1999						
Heroin	31	13 (42)	312	177 (57)	349	194 (56)
Methamphetamine	113	7 (6)	226	66 (29)	344	74 (22)
Other	19	3 (16)	71	31 (44)	96	38 (40)
2000						
Heroin	22	6 (27)	305	169 (55)	328	176 (54)
Methamphetamine	52	4 (8)	211	56 (26)	270	61 (23)
Other	19	2 (11)	90	40 (44)	115	44 (38)
2001						
Heroin	15	4 (27)	195	119 (61)	215	126 (59)
Methamphetamine	71	8 (11)	327	123 (38)	417	134 (32)
Other	14	0 (0)	149	99 (66)	168	102 (61)
2002						
Heroin	7	2 (29)	197	111 (56)	206	113 (55)
Methamphetamine	52	21 (40)	238	95 (40)	302	120 (40)
Other	19	6 (32)	145	83 (57)	171	95 (56)
2003						
Heroin	5	1 (20)	185	126 (68)	193	130 (67)
Methamphetamine	44	6 (14)	281	118 (42)	336	128 (38)
Other	13	1 (8)	161	98 (61)	182	104 (57)
2004						
Heroin	3	1 (33)	149	84 (56)	156	89 (57)
Methamphetamine	24	9 (38)	210	84 (40)	235	94 (40)
Other	12	2 (17)	134	97 (72)	149	99 (66)
2005						
Heroin	2	0 (0)	74	42 (57)	78	44 (56)
Methamphetamine	12	1 (8)	99	38 (38)	113	40 (36)
Other	2	0 (0)	74	58 (78)	77	59 (77)
2006						
Heroin	3	1 (33)	104	73 (70)	113	78 (69)
Methamphetamine	22	2 (9)	165	70 (42)	195	73 (37)
Other	13	4 (31)	153	108 (71)	171	115 (67)
2007						
Heroin	4	0 (0)	100	66 (66)	106	67 (63)
Methamphetamine	24	5 (21)	119	63 (53)	143	68 (48)
Other	4	1 (25)	140	99 (71)	153	106 (69)
2008						
Heroin	2	1 (50)	120	82 (68)	123	84 (68)
Methamphetamine	15	2 (13)	146	62 (42)	162	65 (40)
Other	11	3 (27)	187	118 (63)	204	122 (60)
2009						
Heroin	12	3 (25)	202	114 (56)	216	117 (54)
Methamphetamine	22	0 (0)	206	65 (32)	231	65 (28)
Other	11	3 (14)	296	143 (48)	327	151 (46)
2010						
Heroin	5	0 (0)	113	66 (58)	122	70 (57)
Methamphetamine	11	1 (9)	128	46 (36)	142	47 (33)
Other	20	1 (5)	237	121 (51)	263	124 (47)
2010 p value		1.000		0.001		<0.001

Table 5.27 HCV antibody prevalence by frequency of injection, time since first injection and year

QUEENSLAND	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Less than daily	47	6 (13)	109	52 (48)	160	60 (38)
Daily or more	15	1 (7)	105	54 (51)	124	56 (45)
Not last month	8	0 (0)	14	7 (50)	23	7 (30)
1996						
Less than daily	90	5 (6)	183	80 (44)	276	85 (31)
Daily or more	26	2 (8)	140	69 (49)	177	74 (42)
Not last month	8	0 (0)	24	7 (29)	33	8 (24)
1997						
Less than daily	81	3 (4)	145	45 (31)	231	49 (21)
Daily or more	41	2 (5)	157	70 (45)	201	73 (36)
Not last month	13	2 (15)	31	14 (45)	46	16 (35)
1998						
Less than daily	93	3 (3)	240	80 (33)	338	84 (25)
Daily or more	55	4 (7)	222	96 (43)	281	101 (36)
Not last month	13	0 (0)	32	7 (22)	50	7 (14)
1999						
Less than daily	90	7 (8)	239	87 (36)	335	97 (29)
Daily or more	59	15 (25)	321	165 (51)	388	184 (47)
Not last month	14	1 (7)	49	21 (43)	67	23 (34)
2000						
Less than daily	51	5 (10)	261	96 (37)	319	104 (33)
Daily or more	27	6 (22)	300	155 (52)	333	163 (49)
Not last month	16	1 (6)	48	15 (31)	65	16 (25)
2001						
Less than daily	57	9 (16)	317	143 (45)	385	153 (40)
Daily or more	29	2 (7)	289	169 (58)	330	177 (54)
Not last month	14	1 (7)	61	28 (46)	80	30 (38)
2002						
Less than daily	35	13 (37)	231	105 (45)	272	121 (44)
Daily or more	31	11 (35)	286	159 (56)	325	170 (52)
Not last month	10	4 (40)	61	24 (39)	80	36 (45)
2003						
Less than daily	32	3 (9)	298	153 (51)	338	161 (48)
Daily or more	19	3 (16)	263	167 (64)	293	176 (60)
Not last month	12	2 (17)	67	23 (34)	85	26 (31)
2004						
Less than daily	23	8 (35)	216	108 (50)	241	117 (49)
Daily or more	14	3 (21)	232	141 (61)	249	146 (59)
Not last month	5	1 (20)	47	16 (34)	54	18 (33)
2005						
Less than daily	11	1 (9)	111	53 (48)	125	56 (45)
Daily or more	1	0 (0)	111	70 (63)	113	71 (63)
Not last month	4	0 (0)	30	18 (60)	35	19 (54)
2006						
Less than daily	17	1 (6)	169	93 (55)	192	95 (49)
Daily or more	17	6 (35)	212	137 (65)	241	150 (62)
Not last month	5	1 (20)	53	29 (55)	60	31 (52)
2007						
Less than daily	20	3 (15)	163	92 (56)	186	98 (53)
Daily or more	10	2 (20)	170	124 (73)	185	130 (70)
Not last month	2	1 (50)	28	14 (50)	32	15 (47)
2008						
Less than daily	14	4 (29)	199	106 (53)	214	110 (51)
Daily or more	9	2 (22)	213	140 (66)	225	143 (64)
Not last month	6	0 (0)	39	16 (41)	48	18 (38)
2009						
Less than daily	22	1 (5)	268	105 (39)	294	107 (36)
Daily or more	26	5 (19)	383	186 (49)	417	194 (47)
Not last month	9	0 (0)	59	34 (58)	74	35 (47)
2010						
Less than daily	19	0 (0)	216	89 (41)	237	90 (38)
Daily or more	10	2 (20)	212	116 (55)	230	122 (53)
Not last month	5	0 (0)	50	28 (56)	58	28 (48)
2010 p value		0.098		0.011		0.004

Table 5.28 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, time since first injection and year

QUEENSLAND	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
No receptive sharing	52	5 (10)	145	62 (43)	201	69 (34)
Receptive sharing	10	2 (20)	69	44 (64)	82	47 (57)
1996						
No receptive sharing	87	5 (6)	225	97 (43)	323	104 (32)
Receptive sharing	29	2 (7)	97	51 (53)	129	54 (42)
1997						
No receptive sharing	99	5 (5)	235	79 (34)	341	86 (25)
Receptive sharing	18	0 (0)	56	31 (55)	75	31 (41)
1998						
No receptive sharing	125	7 (6)	377	136 (36)	507	143 (28)
Receptive sharing	19	0 (0)	73	33 (45)	95	35 (37)
1999						
No receptive sharing	115	14 (12)	419	191 (46)	545	211 (39)
Receptive sharing	31	8 (26)	121	52 (43)	155	61 (39)
2000						
No receptive sharing	68	9 (13)	457	198 (44)	538	212 (39)
Receptive sharing	8	2 (25)	84	48 (57)	92	50 (54)
2001						
No receptive sharing	70	6 (9)	486	231 (48)	574	243 (42)
Receptive sharing	11	4 (36)	98	64 (65)	112	69 (62)
2002						
No receptive sharing	55	21 (38)	415	208 (50)	479	231 (48)
Receptive sharing	10	3 (30)	92	50 (54)	106	54 (51)
2003						
No receptive sharing	45	6 (13)	463	254 (55)	525	270 (51)
Receptive sharing	3	0 (0)	83	58 (70)	87	59 (68)
2004						
No receptive sharing	30	8 (27)	358	189 (53)	392	199 (51)
Receptive sharing	5	2 (40)	76	50 (66)	82	53 (65)
2005						
No receptive sharing	11	1 (9)	179	96 (54)	194	100 (52)
Receptive sharing	1	0 (0)	34	21 (62)	35	21 (60)
2006						
No receptive sharing	30	7 (23)	303	177 (58)	344	189 (55)
Receptive sharing	3	0 (0)	61	41 (67)	71	44 (62)
2007						
No receptive sharing	27	4 (15)	280	175 (63)	313	184 (59)
Receptive sharing	3	1 (33)	46	37 (80)	50	39 (78)
2008						
No receptive sharing	17	3 (18)	356	209 (59)	376	213 (57)
Receptive sharing	6	3 (50)	52	34 (63)	58	37 (64)
2009						
No receptive sharing	33	1 (3)	529	225 (43)	569	228 (40)
Receptive sharing	13	5 (38)	106	57 (54)	123	63 (51)
2010						
No receptive sharing	25	2 (8)	331	149 (45)	365	156 (43)
Receptive sharing	1	0 (0)	38	24 (63)	40	24 (60)
2010 p value		1.000		0.040		0.044

Table 5.29 HCV antibody prevalence by imprisonment last year, time since first injection and year

QUEENSLAND	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
No imprisonment	66	7 (11)	203	98 (48)	275	107 (39)
Imprisonment	4	0 (0)	22	13 (59)	28	13 (46)
1996						
No imprisonment	119	7 (6)	308	127 (41)	439	138 (31)
Imprisonment	0	0 (0)	34	25 (74)	36	25 (69)
1997						
No imprisonment	132	7 (5)	304	110 (36)	446	119 (27)
Imprisonment	3	0 (0)	30	19 (63)	33	19 (58)
1998						
No imprisonment	155	7 (5)	435	148 (34)	603	157 (26)
Imprisonment	5	0 (0)	55	34 (62)	61	34 (56)
1999						
No imprisonment	157	21 (13)	510	208 (41)	689	237 (34)
Imprisonment	4	1 (25)	96	62 (65)	102	64 (63)
2000						
No imprisonment	90	11 (12)	512	206 (40)	615	219 (36)
Imprisonment	3	1 (33)	88	59 (67)	96	63 (66)
2001						
No imprisonment	94	12 (13)	544	265 (49)	663	283 (43)
Imprisonment	4	0 (0)	107	65 (61)	115	68 (59)
2002						
No imprisonment	68	25 (37)	481	225 (47)	571	260 (46)
Imprisonment	9	4 (44)	91	59 (65)	102	64 (63)
2003						
No imprisonment	58	7 (12)	532	286 (54)	624	304 (49)
Imprisonment	3	1 (33)	86	52 (60)	94	57 (61)
2004						
No imprisonment	40	12 (30)	413	209 (51)	462	226 (49)
Imprisonment	1	0 (0)	79	55 (70)	80	55 (69)
2005						
No imprisonment	15	1 (7)	213	115 (54)	235	119 (51)
Imprisonment	1	0 (0)	32	21 (66)	34	22 (65)
2006						
No imprisonment	34	8 (24)	355	200 (56)	405	214 (53)
Imprisonment	3	0 (0)	62	44 (71)	67	45 (67)
2007						
No imprisonment	31	5 (16)	317	188 (59)	358	199 (56)
Imprisonment	1	1 (100)	39	34 (87)	42	37 (88)
2008						
No imprisonment	26	4 (15)	375	207 (55)	407	213 (52)
Imprisonment	2	2 (100)	50	40 (80)	53	43 (81)
2009						
No imprisonment	48	2 (4)	587	250 (43)	648	254 (39)
Imprisonment	7	4 (57)	99	58 (59)	110	64 (58)
2010						
No imprisonment	35	2 (0)	351	154 (44)	397	160 (40)
Imprisonment	0	0 (0)	47	29 (62)	48	29 (60)
2010 p value		--		0.028		0.009

Table 5.30 HCV antibody prevalence by sex work last month, time since first injection and year

QUEENSLAND	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
No sex work	65	7 (11)	216	105 (49)	290	115 (40)
Sex work	1	0 (0)	10	7 (70)	11	7 (64)
1996						
No sex work	118	7 (6)	331	147 (44)	462	157 (34)
Sex work	1	0 (0)	13	6 (46)	15	7 (47)
1997						
No sex work	131	7 (5)	307	119 (39)	447	128 (29)
Sex work	2	0 (0)	21	9 (43)	24	9 (38)
1998						
No sex work	160	7 (4)	463	163 (35)	636	172 (27)
Sex work	1	0 (0)	21	13 (62)	23	13 (57)
1999						
No sex work	154	20 (13)	553	243 (44)	729	271 (37)
Sex work	5	3 (60)	42	22 (52)	49	26 (53)
2000						
No sex work	90	11 (12)	549	231 (42)	656	247 (38)
Sex work	3	1 (33)	34	22 (65)	38	23 (61)
2001						
No sex work	88	10 (11)	606	299 (49)	717	317 (44)
Sex work	7	0 (0)	44	32 (73)	54	32 (59)
2002						
No sex work	73	26 (36)	535	263 (49)	629	299 (48)
Sex work	4	3 (75)	36	21 (58)	42	25 (60)
2003						
No sex work	60	7 (12)	575	309 (54)	669	328 (49)
Sex work	3	1 (33)	42	29 (67)	48	32 (67)
2004						
No sex work	40	12 (30)	451	237 (53)	499	252 (51)
Sex work	1	0 (0)	31	20 (65)	32	20 (63)
2005						
No sex work	16	1 (6)	226	132 (56)	260	137 (53)
Sex work	0	0 (0)	9	4 (44)	9	4 (44)
2006						
No sex work	37	8 (22)	394	229 (58)	451	246 (55)
Sex work	0	0 (0)	20	14 (70)	20	14 (70)
2007						
No sex work	29	6 (21)	341	211 (62)	381	224 (59)
Sex work	1	0 (0)	18	16 (89)	20	17 (85)
2008						
No sex work	27	5 (19)	408	238 (58)	442	246 (56)
Sex work	1	1 (100)	12	6 (50)	13	7 (54)
2009						
No sex work	55	5 (9)	663	294 (44)	732	302 (41)
Sex work	1	1 (100)	26	19 (73)	30	21 (70)
2010						
No sex work	36	2 (6)	426	200 (47)	472	206 (44)
Sex work	0	0 (0)	12	7 (58)	13	7 (54)
2010 p value		--		0.561		0.574

Table 5.31 HCV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year

QUEENSLAND	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Non-Indigenous	208	79 (38)	79	35 (44)	289	116 (40)
Indigenous	6	0 (0)	2	1 (50)	9	2 (22)
1996						
Non-Indigenous	328	99 (30)	113	48 (42)	443	148 (33)
Indigenous	10	3 (30)	6	3 (50)	16	6 (38)
1997						
Non-Indigenous	304	81 (27)	145	49 (34)	451	131 (29)
Indigenous	17	4 (24)	3	1 (33)	20	5 (25)
1998						
Non-Indigenous	451	110 (24)	189	73 (39)	642	185 (29)
Indigenous	14	2 (14)	6	3 (50)	20	5 (25)
1999						
Non-Indigenous	487	171 (35)	241	97 (40)	732	269 (37)
Indigenous	22	13 (59)	15	13 (87)	37	26 (70)
2000						
Non-Indigenous	423	162 (38)	220	98 (45)	646	261 (40)
Indigenous	28	7 (25)	19	9 (47)	49	17 (35)
2001						
Non-Indigenous	503	212 (42)	220	108 (49)	729	324 (44)
Indigenous	32	19 (59)	16	9 (56)	50	28 (56)
2002						
Non-Indigenous	421	206 (49)	183	85 (46)	608	295 (49)
Indigenous	37	18 (49)	8	3 (38)	47	22 (47)
2003						
Non-Indigenous	452	208 (46)	197	112 (57)	655	321 (49)
Indigenous	36	21 (58)	14	8 (57)	51	30 (59)
2004						
Non-Indigenous	349	173 (50)	156	86 (55)	505	259 (51)
Indigenous	23	11 (48)	6	5 (83)	29	16 (55)
2005						
Non-Indigenous	176	99 (56)	82	38 (46)	260	138 (53)
Indigenous	10	4 (40)	2	2 (100)	12	6 (50)
2006						
Non-Indigenous	305	161 (53)	128	74 (58)	433	235 (54)
Indigenous	34	16 (47)	13	13 (100)	48	30 (63)
2007						
Non-Indigenous	249	142 (57)	118	76 (64)	370	221 (60)
Indigenous	26	14 (54)	10	8 (80)	37	23 (62)
2008						
Non-Indigenous	314	168 (54)	135	72 (53)	450	241 (54)
Indigenous	7	3 (43)	20	16 (80)	28	20 (71)
2009						
Non-Indigenous	490	203 (41)	172	78 (45)	667	282 (42)
Indigenous	67	33 (49)	35	16 (46)	102	49 (48)
2010						
Non-Indigenous	354	159 (45)	101	52 (51)	460	214 (47)
Indigenous	42	17 (40)	19	6 (32)	61	23 (38)
2010 p value		0.625		0.137		0.219

Table 5.32 HCV antibody prevalence by country of birth, gender and year

QUEENSLAND	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Australia	436	206 (47)	191	105 (55)	633	313 (49)
Other	59	29 (49)	25	16 (64)	85	45 (53)
2004						
Australia	324	161 (50)	139	80 (58)	463	241 (52)
Other	51	25 (49)	23	12 (52)	74	37 (50)
2005						
Australia	163	92 (56)	81	38 (47)	246	131 (53)
Other	24	12 (50)	5	2 (40)	29	14 (48)
2006						
Australia	301	160 (53)	125	75 (60)	429	238 (55)
Other	39	19 (49)	16	12 (75)	55	31 (56)
2007						
Australia	247	141 (57)	117	77 (66)	368	222 (60)
Other	28	15 (54)	12	8 (67)	40	23 (58)
2008						
Australia	281	154 (55)	137	75 (55)	419	230 (55)
Other	45	23 (51)	20	14 (70)	65	37 (57)
2009						
Australia	499	215 (43)	183	85 (46)	687	301 (44)
Other	68	24 (35)	26	9 (35)	94	33 (35)
2010						
Australia	358	157 (44)	108	49 (45)	471	209 (44)
Other	44	22 (50)	12	8 (67)	56	30 (54)
2010 p value		0.521		0.225		0.204

Table 5.33 HCV antibody prevalence by language spoken at home by parents, gender and year

QUEENSLAND	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
English speaking	469	228 (49)	205	117 (57)	681	347 (51)
Non-English speaking	18	6 (33)	7	2 (29)	25	8 (32)
2004						
English speaking	292	147 (50)	134	72 (54)	426	219 (51)
Non-English speaking	6	4 (67)	2	1 (50)	8	5 (63)
2005						
English speaking	166	95 (57)	77	34 (44)	244	130 (53)
Non-English speaking	22	10 (45)	9	6 (67)	32	16 (50)
2006						
English speaking	322	169 (52)	134	83 (62)	458	254 (55)
Non-English speaking	12	7 (58)	4	2 (50)	17	10 (59)
2007						
English speaking	260	150 (58)	125	83 (66)	389	237 (61)
Non-English speaking	13	6 (46)	4	2 (50)	17	8 (47)
2008						
English speaking	319	174 (55)	155	89 (57)	476	265 (56)
Non-English speaking	9	5 (56)	4	2 (50)	13	7 (54)
2009						
English speaking	553	231 (42)	199	90 (45)	757	322 (43)
Non-English speaking	15	9 (60)	10	4 (40)	25	13 (52)
2010						
English speaking	392	173 (44)	118	57 (48)	515	233 (45)
Non-English speaking	7	3 (43)	2	0 (0)	9	3 (33)
2010 p value		1.000		0.497		0.523

6. SOUTH AUSTRALIA


Three NSP or Clean Needle Program (CNP) services participated in the ANSPS in 1995, of which, two participated every year between 1995 and 2010 (South Australian Voice for Intravenous Education Shopfront and Norwood CNP services). Of the seven CNP services that participated in the ANSPS in 2010, six participated in 10 or more years. South Australia (SA) is the only state in which an Aboriginal Community Controlled Health Organisation participates in the survey (Nunkuwarnin Yunti). Appendix 1 provides more details of site participation by year. Sample sizes in South Australia ranged from 37 (in 1995) to 355 (in 2003). Response rates ranged between 26% (in 1997) and 70% (in 1999).

Demographic Characteristics

Around two thirds of South Australian participants were male in all years between 1995 and 2010, and the majority of participants (73% to 86%) identified as heterosexual. As occurred nationally and elsewhere, the proportion of Indigenous participants increased in South Australia from 3% in 1995 to 11% in 2010 (χ^2 trend $p < 0.001$). Some of this increase is attributable to the inclusion of participants from Nunkuwarnin Yunti NSP service, although a less significant trend remained when participants from this service were excluded from the analysis (χ^2 trend $p = 0.011$). The majority of South Australian respondents were born in Australia (range 82% to 88%) and reported that their parents spoke English at home (range 80% to 92%) across all survey years in which these data were collected.

The median age of South Australian ANSPS respondents remained stable at 29-31 years between 1995 and 2004, but subsequently increased steadily, to a high of 38 years in 2010 (Figure 6.1). The proportion of young people (aged younger than 25 years) increased between 1995 and 1997, but declined significantly in later years, from a high of 21% in 1997 to just 2% in 2010 (χ^2 trend $p < 0.001$). The median age at first injection remained stable at 18 years between 1995 and 2010 (Table 6.1).

Figure 6.1 SA: Median age and proportion young injectors by year




Injecting behaviour

In each year between 1995 and 2010, South Australian ANSPS participants were most likely to report last injecting either heroin or methamphetamine. The proportion of South Australian participants who reported last injecting heroin was highest, at 70%, in 1995. As occurred nationally, and coinciding with well documented changes in heroin availability in Australia (Maher et al., 2007; Degenhardt et al., 2006; Topp et al., 2003), prevalence of recent heroin injecting declined by half between 2000 (56%) and 2001 (25%) (Figure 6.2, Table 6.2). Prevalence of recent heroin injecting varied between 20% and 40% over the period 2001 to 2010.

Prevalence of recent injection of methamphetamine varied over the period 1995 to 2010, from a low of 21% in 1995 to a high of 52% in 2001, coinciding with the reduced prevalence of heroin injection in that year. In 2009 and 2010, prevalence dropped below 40% for the first time since 2000.

Figure 6.2 SA: Prevalence of heroin and methamphetamine as drug last injected by year




As occurred nationally and in other jurisdictions, the proportion of South Australian participants who reported last injecting pharmaceutical opioids increased significantly in the 2000s, rising from 3% in 2000 to 12% in 2010 (χ^2 trend $p < 0.001$, Figure 6.2, Table 6.2).

The proportion of South Australian ANSPS participants who reported last injecting methadone or buprenorphine remained at less than 10% in all survey years between 1995 and 2010. Reports of recent injection of cocaine and performance and image enhancing drugs were rare, with prevalence of these drugs at 2% or less in South Australia over the period 1995 to 2010 (Table 6.2).

The proportion of South Australian ANSPS respondents who reported re-use of needles and syringes (including re-use of one's own needle/syringe) in the month preceding the survey varied between 15% and 29% over the period 1997 to 2010 (Figure 6.3). Following a decline in


the rate of recent receptive sharing (use of someone else’s used needle/syringe) that occurred between 1995 and 1997, prevalence of recent receptive sharing varied between 9% and 19% in all subsequent years from 1998 to 2010. As observed nationally and in other jurisdictions, spoons and water were the ancillary items South Australian participants were most likely to report sharing (Table 6.4).

Figure 6.3 SA: Re-use and receptive sharing of syringes by year



The proportion of South Australian respondents who reported injecting in a public place in the month prior to survey completion (Figure 6.4) increased during the late 1990s to a peak in 2000 of 58% of respondents. Prevalence subsequently declined to less than 50%, with the majority of public injections occurring in a car in each year between 1999 and 2010.


Figure 6.4 SA: Prevalence of public injection by year



HIV prevalence

HIV antibody prevalence in South Australia remained low at 2.6% or less in all years between 1995 and 2010 (Figure 6.5). Detailed data on HIV antibody prevalence is not presented in this report due to small cell sizes. However unlike most other jurisdictions, the majority (67%) of HIV antibody positive South Australian participants identified as heterosexual.


Figure 6.5 SA: HIV antibody prevalence by year



HCV prevalence

With the exception of the period 1995 to 1997, HCV antibody prevalence was consistently lower in South Australia than observed nationally. Over the period 1995 to 2010, HCV antibody prevalence ranged from a high of 59% (in 1995) to a low of 27% (in 1998). Whereas a decline in HCV antibody prevalence was observed nationally in 2009, antibody prevalence in South Australia declined in 2007 and 2008, with an increase observed in 2009 (Figure 6.6).

Figure 6.6 National and SA: HCV antibody prevalence by year



HCV prevalence was higher in South Australia among older participants (Table 6.13), respondents with a longer injection history (Table 6.12) and participants who reported last injecting heroin (Figure 6.7, Table 6.14).

Figure 6.7 SA: HCV antibody prevalence and time since first injection by year




Table 6.1 Number (percentage) of respondents by demographic characteristic and year

SOUTH AUSTRALIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Number of sites	2	2	2	5	6	8	6	6	6	6	7	6	7	7	7	7
N° surveyed	N=37	N=45	N=59	N=230	N=250	N=312	N=276	N=318	N=355	N=255	N=211	N=200	N=220	N=196	N=248	N=216
Response rate	46%	36%	26%	46%	70%	64%	60%	49%	50%	42%	47%	36%	39%	45%	52%	41%
Gender (%)																
Male	21 (57)	30 (67)	39 (66)	134 (58)	152 (61)	212 (68)	174 (63)	199 (63)	221 (62)	161 (63)	126 (60)	114 (57)	127 (58)	101 (52)	156 (63)	129 (60)
Female	13 (35)	14 (31)	20 (34)	95 (41)	98 (39)	97 (31)	100 (36)	117 (37)	129 (36)	89 (35)	84 (40)	86 (43)	91 (41)	93 (47)	92 (37)	86 (40)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (1)	2 (1)	1 (<1)	4 (1)	3 (1)	1 (0)	0 (0)	2 (1)	1 (1)	0 (0)	1 (<1)
Not reported	3 (8)	1 (2)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	1 (<1)	1 (<1)	2 (1)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Sexual identity (%)																
Heterosexual	27 (73)	36 (80)	47 (80)	178 (78)	187 (75)	231 (75)	208 (76)	240 (76)	265 (75)	203 (80)	166 (79)	160 (80)	175 (80)	146 (74)	204 (82)	185 (86)
Bisexual	6 (16)	1 (2)	4 (7)	17 (7)	33 (13)	40 (13)	28 (10)	41 (13)	45 (13)	34 (13)	27 (13)	17 (9)	23 (10)	29 (15)	23 (9)	11 (5)
Homosexual	1 (3)	5 (11)	3 (5)	28 (12)	17 (7)	17 (7)	26 (9)	11 (3)	25 (7)	8 (3)	9 (4)	10 (5)	15 (7)	13 (7)	13 (5)	12 (6)
Not reported	3 (8)	3 (7)	5 (8)	7 (3)	13 (5)	13 (5)	14 (5)	26 (8)	20 (5)	10 (4)	9 (4)	13 (7)	7 (3)	8 (4)	8 (3)	8 (4)
Age and time since first injection (years)																
<i>Median age</i>	31	30	30	29	30	29	30	30	31	30	33	34	34	36	38	38
<i>Age range</i>	16-45	18-48	16-50	16-53	17-50	14-52	14-53	15-54	16-60	16-56	18-59	16-58	19-58	17-56	16-61	18-62
<i>Age group (%)</i>																
<25 years	7 (19)	10 (22)	15 (25)	73 (32)	68 (27)	96 (31)	75 (27)	72 (23)	58 (16)	65 (26)	30 (14)	27 (14)	25 (11)	19 (10)	25 (10)	18 (8)
25+ years	29 (78)	35 (78)	43 (73)	157 (68)	181 (72)	215 (69)	201 (73)	246 (77)	296 (83)	187 (73)	181 (86)	172 (86)	193 (88)	177 (90)	222 (90)	198 (92)
Not reported	1 (3)	0 (0)	1 (2)	0 (0)	1 (<1)	1 (<1)	0 (0)	0 (0)	1 (<1)	3 (1)	0 (0)	1 (<1)	2 (1)	0 (0)	1 (<1)	0 (0)
<i>Median age 1st IDU</i>	18	18	18	18	18	18	18	18	18	18	18	18	18	18	18	18
<i>Age range</i>	14-33	14-40	12-43	10-43	10-47	11-40	11-53	11-50	11-48	11-52	12-50	10-44	10-47	11-45	12-46	12-44
N° not reported	1	1	2	2	4	2	2	8	10	13	4	1	5	4	5	2
<i>Median years IDU</i>	10	11	7	7	9.5	8	9	11	12	10	13	14	13	15	17	17
<i>Range</i>	<1-23	<1-25	<1-24	<1-33	<1-36	<1-35	<1-31	<1-37	<1-38	<1-71	<1-38	<1-41	<1-41	1-41	<1-44	<1-45
Time since first injection																
<3 years	2 (5)	6 (13)	13 (22)	49 (21)	33 (13)	45 (14)	38 (14)	31 (10)	25 (7)	24 (9)	16 (8)	15 (8)	16 (7)	13 (7)	15 (6)	5 (2)
3+ years	34 (92)	38 (84)	43 (73)	179 (78)	213 (85)	264 (85)	236 (86)	279 (88)	320 (90)	217 (85)	187 (89)	180 (90)	199 (90)	179 (91)	228 (92)	209 (97)
Not reported	1 (3)	1 (2)	3 (5)	2 (<1)	4 (2)	3 (1)	2 (<1)	8 (3)	10 (3)	14 (6)	8 (4)	5 (3)	5 (2)	4 (2)	5 (2)	2 (1)

Table 6.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
SOUTH AUSTRALIA																
N° surveyed	N=37	N=45	N=59	N=230	N=250	N=312	N=276	N=318	N=355	N=255	N=211	N=200	N=220	N=196	N=248	N=216
Aboriginal and Torres Strait Islander origin (%)																
No	34 (92)	42 (93)	56 (95)	209 (91)	237 (95)	267 (85)	246 (89)	295 (92)	317 (89)	228 (90)	186 (88)	176 (88)	202 (92)	158 (81)	206 (83)	185 (86)
Yes	1 (3)	0 (0)	2 (3)	17 (7)	10 (4)	40 (13)	24 (9)	18 (6)	25 (7)	21 (8)	17 (8)	18 (9)	16 (7)	28 (14)	31 (13)	23 (11)
Not reported	2 (5)	3 (7)	1 (2)	4 (2)	3 (1)	5 (2)	6 (2)	5 (2)	13 (4)	6 (2)	8 (4)	6 (3)	2 (1)	10 (5)	11 (4)	8 (4)
Region/country of birth (%)																
Australia	--	--	--	--	215 (86)	--	238 (86)	273 (86)	314 (88)	218 (85)	183 (87)	167 (84)	186 (85)	160 (82)	219 (88)	191 (88)
Other Oceania	--	--	--	--	--	--	4 (1)	2 (<1)	2 (1)	3 (1)	2 (1)	1 (<1)	3 (1)	4 (2)	5 (2)	3 (1)
Asia	--	--	--	--	2 (1)	--	2 (1)	6 (2)	1 (<1)	8 (3)	2 (1)	5 (3)	2 (<1)	5 (3)	1 (<1)	4 (2)
UK & Ireland	--	--	--	--	--	--	20 (7)	25 (8)	20 (6)	13 (5)	16 (8)	18 (9)	18 (8)	17 (9)	17 (7)	11 (5)
Other	--	--	--	--	13 (5)	--	7 (3)	9 (3)	14 (4)	9 (4)	7 (3)	8 (4)	8 (4)	7 (4)	5 (2)	4 (2)
Not reported	--	--	--	--	20 (8)	--	5 (2)	3 (1)	4 (1)	4 (2)	1 (0)	1 (<1)	3 (1)	3 (2)	1 (<1)	3 (1)
Main language spoken at home by parents (%)																
English	--	--	--	--	215 (86)	251 (80)	243 (88)	256 (80)	290 (82)	179 (70)	174 (82)	166 (83)	195 (89)	179 (91)	224 (90)	198 (92)
Non-English	--	--	--	--	10 (4)	35 (11)	18 (7)	40 (13)	22 (6)	24 (10)	37 (18)	19 (10)	23 (10)	12 (6)	19 (8)	16 (7)
Not reported	--	--	--	--	25 (10)	26 (8)	15 (5)	22 (7)	43 (12)	52 (20)	0 (0)	15 (8)	2 (1)	5 (3)	5 (2)	2 (1)
Imprisonment last year (%)																
No	30 (81)	38 (84)	46 (78)	200 (87)	209 (84)	247 (79)	239 (87)	265 (83)	304 (86)	197 (77)	179 (85)	174 (87)	173 (79)	158 (81)	199 (80)	168 (78)
Yes	6 (16)	4 (9)	13 (22)	30 (13)	38 (15)	60 (19)	34 (12)	44 (14)	48 (13)	43 (17)	24 (11)	18 (9)	32 (15)	21 (11)	37 (15)	16 (7)
Not reported	1 (3)	3 (7)	0 (0)	0 (0)	3 (1)	5 (2)	3 (1)	9 (3)	3 (1)	15 (6)	8 (4)	8 (4)	15 (7)	17 (9)	12 (5)	32 (15)
Injected in prison last year (%)																
N° in prison	N=6	N=4	N=13	N=30	N=38	N=60	N=34	N=44	N=48	N=43	N=24	N=18	N=32	N=21	N=37	N=16
Injected in prison	5 (83)	1 (25)	3 (23)	10 (33)	16 (42)	20 (33)	16 (47)	12 (27)	17 (35)	22 (51)	8 (33)	4 (22)	8 (25)	7 (33)	5 (14)	1 (6)
Frequency of injection last month (%)																
Not last month	0 (0)	4 (9)	4 (7)	12 (5)	13 (5)	18 (6)	11 (4)	11 (3)	25 (7)	17 (7)	20 (9)	7 (4)	14 (6)	20 (10)	22 (9)	13 (6)
Less than weekly	6 (16)	6 (13)	13 (22)	39 (16)	38 (15)	39 (12)	56 (20)	58 (18)	60 (17)	34 (13)	42 (20)	37 (19)	40 (18)	30 (15)	38 (15)	42 (19)
Weekly not daily	12 (32)	20 (45)	12 (20)	61 (27)	82 (33)	70 (22)	88 (32)	89 (28)	94 (27)	68 (27)	51 (24)	58 (29)	54 (25)	51 (26)	59 (24)	61 (28)
Daily or more	18 (49)	15 (33)	29 (49)	119 (52)	116 (46)	183 (59)	120 (43)	156 (49)	171 (48)	129 (50)	98 (46)	96 (48)	112 (51)	93 (47)	127 (51)	99 (46)
Not reported	1 (3)	0 (0)	1 (2)	0 (0)	1 (1)	2 (1)	1 (1)	4 (1)	5 (1)	7 (3)	0 (0)	2 (1)	0 (0)	2 (1)	2 (1)	1 (<1)

Table 6.2 Number (percentage) of respondents by drug last injected and year

SOUTH AUSTRALIA N° surveyed	1995 N=37	1996 N=45	1997 N=59	1998 N=230	1999 N=250	2000 N=312	2001 N=276	2002 N=318	2003 N=355	2004 N=255	2005 N=211	2006 N=200	2007 N=220	2008 N=196	2009 N=248	2010 N=216	
Drug last injected (%)																	
Anabolic steroids	0 (0)	0 (0)	1 (2)	0 (0)	1 (<1)	2 (1)	0 (0)	4 (1)	3 (1)	1 (<1)	2 (1)	3 (2)	2 (1)	1 (1)	0 (0)	0 (0)	
Cocaine	0 (0)	2 (4)	1 (2)	8 (3)	4 (2)	4 (1)	9 (3)	1 (<1)	4 (1)	4 (2)	2 (1)	1 (<1)	2 (1)	4 (2)	3 (1)	2 (1)	
Heroin	26 (70)	24 (54)	23 (38)	104 (45)	113 (45)	175 (56)	68 (25)	78 (25)	83 (23)	74 (29)	77 (36)	40 (20)	62 (28)	49 (25)	84 (34)	86 (40)	
Methadone	0 (0)	2 (4)	4 (7)	7 (3)	3 (1)	7 (2)	10 (4)	13 (4)	14 (4)	12 (5)	5 (2)	7 (4)	11 (5)	10 (5)	8 (3)	7 (3)	
Methamphetamine	8 (21)	14 (31)	26 (43)	87 (38)	104 (42)	93 (30)	143 (52)	144 (45)	169 (48)	101 (40)	88 (42)	101 (51)	95 (43)	100 (51)	91 (37)	87 (40)	
Pharm. opioids	1 (3)	2 (4)	1 (2)	5 (2)	10 (4)	10 (3)	20 (7)	27 (8)	33 (9)	18 (7)	17 (8)	24 (12)	24 (11)	20 (10)	34 (14)	26 (12)	
Buprenorphine	--	--	--	--	--	--	--	3 (1)	0 (0)	2 (1)	4 (2)	14 (7)	10 (5)	7 (4)	14 (6)	2 (1)	
More than one	1 (3)	0 (0)	1 (2)	15 (7)	12 (5)	18 (6)	21 (8)	34 (11)	36 (10)	16 (6)	6 (3)	3 (2)	6 (3)	2 (1)	5 (2)	3 (1)	
Other	0 (0)	0 (0)	1 (2)	2 (1)	1 (<1)	0 (0)	0 (0)	1 (<1)	2 (1)	1 (<1)	1 (<1)	2 (1)	6 (3)	0 (0)	3 (1)	3 (1)	
Not reported	1 (3)	1 (2)	1 (2)	2 (1)	2 (1)	3 (1)	5 (2)	13 (4)	8 (2)	24 (9)	7 (3)	5 (2)	2 (1)	3 (2)	6 (2)	0 (0)	

Table 6.3 Number (percentage) of respondents by places injected in the last month and year

SOUTH AUSTRALIA N° injected last month	1995 N=36	1996 N=41	1997 N=54	1998 N=218	1999 N=236	2000 N=292	2001 N=264	2002 N=303	2003 N=325	2004 N=231	2005 N=191	2006 N=191	2007 N=206	2008 N=174	2009 N=224	2010 N=202	
Places injected in the last month (%) [more than one could be selected]																	
<i>Private places</i>																	
Own home	--	--	45 (83)	194 (89)	199 (84)	245 (84)	242 (92)	261 (86)	287 (88)	191 (83)	164 (86)	168 (92)	176 (88)	151 (88)	198 (89)	170 (84)	
Friend's home	--	--	20 (37)	126 (58)	130 (55)	157 (54)	145 (55)	143 (47)	145 (45)	112 (48)	88 (46)	85 (47)	90 (45)	74 (43)	92 (41)	82 (41)	
Dealer's home	--	--	9 (17)	51 (23)	38 (16)	80 (27)	60 (23)	59 (19)	68 (21)	51 (22)	28 (15)	39 (21)	32 (16)	35 (20)	24 (11)	31 (15)	
Commercial injecting room	--	--	1 (2)	6 (3)	1 (1)	4 (1)	1 (1)	2 (1)	1 (<1)	2 (1)	1 (1)	0 (0)	1 (<1)	1 (<1)	0 (0)	1 (<1)	
<i>Public places</i>																	
Street, park, beach	--	--	5 (9)	46 (21)	33 (14)	67 (23)	34 (13)	47 (16)	72 (22)	43 (19)	34 (18)	28 (15)	45 (23)	34 (20)	24 (11)	39 (19)	
Car	--	--	--	28 (13)	111 (47)	143 (49)	101 (38)	120 (40)	123 (38)	89 (39)	87 (46)	63 (35)	84 (42)	66 (38)	70 (31)	83 (41)	
Public toilet	--	--	7 (13)	35 (16)	49 (21)	75 (26)	41 (16)	45 (15)	64 (20)	43 (19)	30 (16)	33 (18)	44 (22)	36 (21)	29 (13)	38 (19)	
Squat	--	--	--	--	6 (3)	11 (4)	4 (2)	8 (3)	10 (3)	9 (4)	4 (2)	3 (2)	10 (5)	5 (3)	3 (1)	6 (3)	
Public injecting in last month (%)																	
Any public	--	--	15 (28)	77 (35)	121 (51)	168 (58)	114 (43)	137 (45)	145 (45)	116 (50)	99 (52)	73 (38)	102 (50)	83 (48)	82 (37)	94 (47)	
All private	--	--	35 (65)	140 (64)	100 (42)	109 (37)	150 (57)	155 (51)	175 (54)	104 (45)	78 (41)	109 (57)	97 (47)	89 (51)	141 (63)	97 (48)	
Not reported	--	--	4 (7)	1 (<1)	15 (6)	15 (5)	0 (0)	11 (4)	5 (2)	11 (5)	13 (7)	9 (5)	7 (4)	2 (1)	1 (<1)	11 (5)	

Table 6.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

SOUTH AUSTRALIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=36	N=41	N=54	N=218	N=236	N=292	N=264	N=303	N=325	N=231	N=191	N=191	N=206	N=174	N=224	N=202
Use of sterile needles and syringes last month (%)																
All injections	--	--	41 (76)	151 (69)	169 (72)	206 (71)	214 (81)	223 (74)	253 (78)	162 (70)	134 (70)	143 (75)	147 (71)	126 (72)	184 (82)	151 (75)
Most of the time	--	--	8 (15)	51 (23)	53 (22)	65 (22)	41 (16)	61 (20)	57 (18)	57 (25)	48 (25)	27 (14)	45 (22)	34 (20)	31 (14)	32 (16)
Half of the time	--	--	1 (2)	7 (3)	4 (2)	7 (2)	3 (1)	9 (3)	7 (2)	6 (3)	6 (3)	10 (5)	4 (2)	6 (3)	4 (2)	4 (2)
Some of the time	--	--	0 (0)	8 (4)	3 (1)	6 (2)	3 (1)	3 (1)	2 (1)	2 (1)	3 (2)	3 (2)	3 (1)	5 (3)	3 (1)	4 (2)
Not last month	--	--	1 (2)	1 (<1)	1 (<1)	0 (0)	2 (1)	1 (<1)	1 (<1)	1 (<1)	0 (0)	2 (1)	0 (0)	1 (1)	0 (0)	0 (0)
Not reported	--	--	3 (5)	0 (0)	6 (3)	8 (3)	1 (<1)	6 (2)	5 (1)	3 (1)	0 (0)	6 (3)	7 (3)	5 (3)	2 (1)	11 (5)
Re-used someone else's used needle & syringe last month (%)																
None	24 (67)	32 (78)	47 (87)	182 (83)	186 (79)	240 (82)	229 (87)	250 (82)	278 (86)	181 (78)	163 (85)	157 (82)	166 (81)	138 (79)	197 (88)	154 (76)
Once	3 (8)	4 (10)	2 (4)	15 (7)	16 (7)	11 (4)	14 (5)	11 (4)	12 (4)	8 (3)	8 (4)	5 (3)	11 (5)	7 (4)	7 (3)	8 (4)
Twice	5 (14)	2 (5)	3 (5)	10 (5)	7 (3)	12 (3)	5 (2)	13 (4)	7 (2)	15 (7)	6 (3)	8 (4)	8 (4)	10 (6)	7 (3)	4 (2)
3-5 times	4 (11)	2 (5)	0 (0)	5 (2)	4 (2)	8 (3)	3 (1)	9 (3)	16 (5)	12 (5)	2 (1)	11 (6)	8 (4)	11 (6)	3 (1)	7 (3)
> 5 times	0 (0)	1 (2)	1 (2)	6 (3)	10 (4)	5 (2)	9 (3)	8 (3)	5 (1)	11 (5)	4 (2)	5 (3)	4 (2)	2 (1)	4 (2)	5 (2)
Not reported	0 (0)	0 (0)	1 (2)	0 (0)	6 (2)	11 (4)	4 (2)	12 (4)	7 (2)	4 (2)	8 (4)	5 (3)	9 (4)	2 (1)	6 (3)	24 (12)
Number of people needle & syringe was re-used after last month (%)																
None	24 (67)	32 (78)	47 (87)	182 (83)	186 (79)	240 (82)	229 (87)	250 (82)	272 (84)	181 (79)	157 (82)	157 (82)	166 (81)	138 (79)	197 (88)	154 (76)
One	7 (19)	6 (15)	5 (9)	34 (16)	33 (14)	31 (11)	18 (7)	25 (8)	30 (9)	21 (9)	12 (6)	12 (6)	10 (5)	17 (10)	11 (5)	7 (3)
Two	4 (11)	2 (5)	1 (2)	2 (1)	4 (2)	2 (1)	0 (0)	3 (1)	3 (1)	3 (1)	1 (1)	5 (3)	5 (2)	3 (2)	3 (1)	3 (1)
Three to five	1 (3)	1 (2)	0 (0)	0 (0)	4 (2)	4 (1)	2 (1)	1 (<1)	0 (0)	3 (1)	1 (1)	0 (0)	3 (1)	0 (0)	0 (0)	3 (1)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	3 (1)	3 (1)	1 (<1)	1 (<1)	0 (0)	2 (1)	3 (2)	0 (0)	1 (<1)	0 (0)	0 (0)	3 (1)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	5 (2)	3 (1)	5 (1)	7 (3)	8 (4)	7 (4)	5 (2)	8 (5)	4 (2)	4 (2)
Not reported	0 (0)	0 (0)	1 (2)	0 (0)	6 (2)	11 (4)	9 (3)	20 (7)	15 (5)	14 (6)	9 (5)	10 (5)	16 (8)	8 (5)	9 (4)	28 (14)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]																
Regular sex partner	--	--	2 (4)	25 (11)	27 (11)	23 (8)	19 (7)	19 (6)	25 (47)	13 (6)	15 (8)	10 (5)	15 (7)	10 (6)	9 (4)	19 (9)
Casual sex partner	--	--	1 (2)	1 (<1)	0 (0)	1 (<1)	2 (1)	2 (1)	2 (4)	3 (1)	1 (<1)	2 (1)	4 (2)	0 (0)	0 (0)	2 (1)
Close friend	--	--	1 (2)	8 (4)	14 (6)	15 (5)	3 (1)	13 (94)	8 (15)	11 (5)	5 (3)	7 (4)	2 (1)	7 (4)	3 (1)	13 (6)
Acquaintance	--	--	0 (0)	4 (2)	5 (2)	5 (2)	6 (2)	0 (0)	4 (8)	6 (3)	3 (2)	4 (2)	1 (<1)	3 (2)	2 (1)	2 (1)
Other	--	--	0 (0)	1 (<1)	2 (1)	1 (<1)	3 (1)	0 (0)	1 (2)	4 (2)	0 (0)	3 (2)	2 (1)	4 (2)	0 (0)	6 (3)

Table 6.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

SOUTH AUSTRALIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=36	N=41	N=54	N=218	N=236	N=292	N=264	N=303	N=325	N=231	N=191	N=191	N=206	N=174	N=224	N=202
Equipment used after someone else last month (%) [more than one could be selected]																
Spoon	--	--	--	--	101 (43)	121 (41)	52 (20)	66 (22)	73 (22)	59 (26)	35 (18)	35 (19)	47 (24)	25 (16)	36 (18)	46 (23)
Water	--	--	--	--	71 (30)	98 (34)	56 (21)	64 (21)	73 (22)	56 (24)	37 (19)	32 (17)	39 (20)	36 (23)	28 (14)	42 (21)
Filter	--	--	--	--	70 (30)	80 (27)	45 (17)	49 (16)	57 (18)	40 (17)	20 (10)	19 (10)	29 (15)	16 (10)	19 (9)	24 (12)
Drug mix	--	--	--	--	56 (24)	60 (21)	19 (19)	53 (17)	67 (21)	36 (16)	24 (13)	14 (8)	15 (8)	9 (6)	20 (10)	16 (8)
Tourniquet	--	--	--	--	51 (22)	49 (17)	33 (13)	43 (14)	50 (15)	38 (16)	30 (16)	16 (9)	30 (15)	17 (11)	14 (7)	--
None	--	--	--	--	--	--	--	--	--	--	--	112 (60)	118 (60)	100 (63)	141 (69)	121 (60)
Injected by someone after that person injected themselves or others last month (%)																
No	--	--	--	--	187 (79)	232 (79)	207 (78)	239 (79)	277 (85)	184 (80)	150 (79)	146 (75)	167 (81)	143 (82)	183 (82)	148 (73)
Yes	--	--	--	--	43 (18)	48 (17)	51 (20)	53 (17)	41 (13)	39 (17)	32 (17)	36 (19)	30 (15)	24 (14)	34 (15)	31 (15)
Not reported	--	--	--	--	6 (3)	12 (4)	6 (2)	11 (4)	7 (2)	8 (3)	9 (5)	9 (5)	9 (4)	7 (4)	7 (3)	23 (11)

Table 6.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

SOUTH AUSTRALIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=37	N=45	N=59	N=230	N=250	N=312	N=276	N=318	N=355	N=255	N=211	N=200	N=220	N=196	N=248	N=216
Sex with a regular partner last month (%)																
No	--	--	--	--	--	--	--	--	--	--	98 (46)	88 (44)	88 (40)	81 (41)	112 (45)	100 (46)
Yes	--	--	--	--	--	--	--	--	--	--	107 (51)	111 (56)	122 (55)	107 (55)	124 (50)	106 (49)
Not reported	--	--	--	--	--	--	--	--	--	--	6 (3)	1 (<1)	10 (5)	8 (4)	12 (5)	10 (5)
Condom used with regular partner last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=107	N=111	N=122	N=107	N=124	N=106
Sometimes	--	--	--	--	--	--	--	--	--	--	82 (77)	81 (73)	97 (80)	78 (73)	80 (64)	71 (67)
Every time	--	--	--	--	--	--	--	--	--	--	15 (14)	14 (13)	17 (14)	17 (16)	23 (19)	13 (12)
Not reported	--	--	--	--	--	--	--	--	--	--	8 (7)	8 (7)	6 (5)	8 (7)	12 (10)	10 (9)
Sex with other partner(s) last month (%)																
No	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Yes	--	--	--	--	--	--	--	--	--	--	172 (82)	164 (82)	171 (78)	153 (78)	205 (83)	170 (79)
Not reported	--	--	--	--	--	--	--	--	--	--	34 (16)	30 (15)	42 (19)	31 (16)	31 (13)	33 (15)
Not reported																
	--	--	--	--	--	--	--	--	--	--	5 (2)	6 (3)	7 (3)	12 (6)	12 (5)	13 (6)

Table 6.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

SOUTH AUSTRALIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=37	N=45	N=59	N=230	N=250	N=312	N=276	N=318	N=355	N=255	N=211	N=200	N=220	N=196	N=248	N=216
Condom used with other partner(s) last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=34	N=30	N=42	N=31	N=31	N=33
Sometimes	--	--	--	--	--	--	--	--	--	--	7 (21)	9 (30)	21 (50)	5 (16)	9 (29)	7 (21)
Every time	--	--	--	--	--	--	--	--	--	--	9 (26)	7 (23)	6 (14)	12 (39)	9 (29)	7 (21)
Not reported	--	--	--	--	--	--	--	--	--	--	17 (50)	12 (40)	14 (33)	14 (45)	13 (42)	16 (48)
											1 (3)	2 (7)	1 (2)	0 (0)	0 (0)	3 (9)
Sex last month (%)																
No	13 (35)	10 (22)	13 (22)	57 (25)	62 (25)	106 (34)	77 (28)	77 (24)	104 (29)	82 (32)	--	--	--	--	--	--
Yes	22 (60)	34 (76)	46 (78)	171 (74)	185 (74)	205 (66)	192 (70)	234 (74)	241 (68)	167 (66)	--	--	--	--	--	--
Not reported	2 (5)	1 (2)	0 (0)	2 (1)	3 (1)	1 (<1)	7 (2)	7 (2)	10 (3)	6 (2)	--	--	--	--	--	--
Condom use at last sex (%)																
No	19 (52)	21 (47)	40 (68)	153 (67)	163 (65)	216 (69)	195 (71)	223 (70)	249 (70)	166 (65)	--	--	--	--	--	--
Yes	9 (24)	11 (24)	18 (30)	70 (30)	83 (33)	95 (30)	72 (26)	82 (26)	97 (27)	69 (27)	--	--	--	--	--	--
Not reported	9 (24)	13 (29)	1 (2)	7 (3)	4 (2)	1 (<1)	9 (3)	13 (4)	9 (3)	20 (8)	--	--	--	--	--	--
Condom use with regular sex partner(s) last month (%)																
No	--	18 (62)	31 (79)	94 (68)	108 (68)	113 (69)	98 (74)	97 (69)	121 (74)	74 (63)	--	--	--	--	--	--
Sometimes	--	3 (10)	3 (8)	17 (12)	14 (9)	18 (11)	19 (14)	14 (10)	11 (7)	20 (17)	--	--	--	--	--	--
Always	--	8 (28)	5 (13)	28 (20)	37 (23)	32 (20)	15 (12)	29 (21)	31 (19)	24 (20)	--	--	--	--	--	--
Condom use with new sex partner(s) last month (%)																
No	--	4 (36)	14 (58)	16 (36)	39 (48)	15 (23)	31 (43)	44 (43)	44 (43)	44 (49)	--	--	--	--	--	--
Sometimes	--	1 (9)	0 (0)	9 (21)	6 (7)	10 (15)	10 (14)	19 (18)	17 (16)	12 (13)	--	--	--	--	--	--
Always	--	6 (55)	10 (42)	19 (43)	37 (45)	40 (62)	31 (43)	40 (39)	42 (41)	34 (38)	--	--	--	--	--	--
Condom use with casual sex partner(s) last month (%)																
No	--	--	--	16 (27)	41 (44)	27 (29)	32 (44)	31 (33)	38 (42)	34 (42)	--	--	--	--	--	--
Sometimes	--	--	--	13 (22)	8 (9)	20 (21)	10 (14)	24 (26)	19 (21)	23 (28)	--	--	--	--	--	--
Always	--	--	--	31 (51)	44 (47)	47 (50)	31 (42)	39 (41)	33 (37)	25 (30)	--	--	--	--	--	--
Sex work last month (%)																
No	31 (84)	42 (93)	57 (96)	209 (91)	223 (89)	282 (90)	242 (88)	286 (90)	318 (90)	221 (87)	195 (92)	182 (91)	194 (88)	170 (87)	229 (92)	184 (85)
Yes	3 (8)	2 (5)	1 (2)	12 (5)	22 (9)	30 (10)	25 (9)	16 (5)	15 (4)	19 (7)	10 (5)	12 (6)	21 (10)	13 (7)	10 (4)	20 (9)
Not reported	3 (8)	1 (2)	1 (2)	9 (4)	5 (2)	0 (0)	9 (3)	16 (5)	22 (6)	15 (6)	6 (3)	6 (3)	5 (2)	13 (7)	9 (4)	12 (6)
Condom used at last sex work (%)																
Yes	3 (100)	2 (100)	1 (100)	8 (80)	17 (89)	24 (96)	15 (75)	13 (81)	15 (100)	17 (94)	24 (96)	8 (80)	13 (72)	11 (85)	9 (90)	13 (68)

Table 6.6 Number (percentage) of respondents by previous testing for HIV, HBV, HCV infection, HBV vaccination and HCV treatment by year

SOUTH AUSTRALIA N° surveyed	1995 N=37	1996 N=45	1997 N=59	1998 N=230	1999 N=250	2000 N=312	2001 N=276	2002 N=318	2003 N=355	2004 N=255	2005 N=211	2006 N=200	2007 N=220	2008 N=196	2009 N=248	2010 N=216	
Previous HIV test (%)																	
Yes, last year	24 (65)	28 (62)	44 (75)	128 (56)	144 (58)	183 (59)	161 (58)	199 (63)	225 (63)	134 (53)	107 (51)	99 (50)	116 (53)	94 (48)	130 (52)	88 (41)	
> 1 year ago	10 (27)	11 (25)	9 (15)	67 (29)	61 (24)	82 (26)	80 (29)	81 (25)	96 (27)	76 (30)	77 (36)	67 (34)	76 (35)	62 (32)	81 (33)	92 (43)	
Never tested	2 (5)	6 (13)	6 (10)	35 (15)	45 (18)	47 (15)	35 (13)	35 (11)	28 (8)	31 (12)	26 (12)	34 (17)	27 (12)	30 (15)	28 (11)	25 (12)	
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	6 (2)	14 (5)	1 (<1)	0 (0)	1 (<1)	10 (5)	9 (4)	11 (5)	
Self report HBV infection (%)																	
No	24 (65)	27 (60)	49 (83)	160 (70)	160 (64)	210 (67)	212 (77)	238 (75)	276 (78)	173 (68)	166 (79)	156 (78)	175 (80)	--	--	--	--
Yes	12 (32)	17 (38)	6 (10)	37 (16)	44 (17)	50 (16)	35 (13)	32 (10)	43 (12)	38 (15)	24 (11)	22 (11)	25 (11)	--	--	--	--
Don't know	--	--	4 (7)	33 (14)	42 (17)	51 (16)	26 (9)	37 (12)	33 (9)	28 (11)	21 (10)	19 (10)	8 (8)	--	--	--	--
Not reported	1 (3)	1 (2)	0 (0)	0 (0)	4 (2)	1 (<1)	3 (1)	11 (3)	3 (1)	16 (6)	0 (0)	3 (2)	2 (1)	--	--	--	--
Self report HBV vaccination (%)																	
No	22 (59)	20 (44)	29 (49)	94 (41)	94 (38)	97 (31)	101 (37)	107 (34)	125 (35)	83 (33)	73 (35)	59 (30)	70 (32)	--	--	--	--
Yes	11 (30)	21 (47)	19 (32)	94 (41)	111 (44)	171 (55)	138 (50)	174 (55)	192 (54)	123 (48)	110 (52)	112 (56)	123 (56)	--	--	--	--
Don't know	--	--	11 (19)	41 (18)	36 (14)	40 (13)	28 (10)	26 (8)	30 (8)	33 (13)	26 (12)	26 (13)	24 (11)	--	--	--	--
Not reported	4 (11)	4 (9)	0 (0)	1 (<1)	9 (4)	4 (1)	9 (3)	11 (3)	8 (2)	16 (6)	2 (1)	3 (2)	3 (1)	--	--	--	--
Previous HCV test (%)																	
Yes, ever	25 (68)	36 (80)	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Yes, last year	--	--	46 (78)	134 (58)	150 (60)	197 (63)	153 (55)	198 (62)	223 (63)	138 (54)	113 (54)	117 (59)	123 (56)	104 (53)	139 (56)	99 (46)	--
> 1 year ago	--	--	6 (10)	50 (22)	54 (21)	72 (23)	87 (32)	78 (25)	93 (26)	75 (30)	70 (33)	51 (26)	73 (33)	57 (29)	67 (27)	73 (34)	--
Never tested	10 (27)	8 (18)	7 (12)	46 (20)	44 (18)	43 (14)	36 (13)	38 (12)	37 (10)	34 (13)	27 (13)	32 (16)	23 (10)	29 (15)	28 (11)	23 (11)	--
Not reported	2 (5)	1 (20)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	4 (1)	2 (1)	8 (3)	1 (<1)	0 (0)	1 (<1)	6 (3)	14 (6)	21 (10)	--
Any treatment for HCV (%)																	
Interferon/+Ribavirin	--	--	--	--	2 (3)	5 (4)	0 (0)	7 (6)	3 (2)	3 (4)	3 (4)	5 (7)	2 (3)	7 (12)	14 (14)	6 (7)	--
Other	--	--	--	--	4 (5)	2 (2)	4 (4)	3 (3)	5 (4)	2 (2)	1 (1)	2 (3)	1 (2)	0 (0)	1 (1)	0 (0)	--
No treatment	--	--	--	--	68 (88)	107 (93)	85 (94)	95 (82)	130 (92)	77 (93)	65 (93)	53 (78)	53 (90)	50 (85)	81 (79)	83 (90)	--
Not reported	--	--	--	--	3 (4)	1 (1)	2 (2)	10 (9)	3 (2)	2 (2)	1 (1)	8 (12)	3 (5)	2 (3)	6 (6)	3 (3)	--
Current treatment for HCV (%)																	
Interferon +/- Ribavirin	--	--	--	--	2	6	0	0	1	1	1	2	2	1	2	2	--
Other	--	--	--	--	0	0	0	0	3	1	1	1	0	0	1	0	--

Table 6.7 Number (percentage) of respondents by treatment for drug use and year

SOUTH AUSTRALIA N° surveyed	1995 N=37	1996 N=45	1997 N=59	1998 N=230	1999 N=250	2000 N=312	2001 N=276	2002 N=318	2003 N=355	2004 N=255	2005 N=211	2006 N=200	2007 N=220	2008 N=196	2009 N=248	2010 N=216
Ever any treatment/therapy for drug use (%)																
No	15 (40)	16 (36)	33 (56)	122 (53)	119 (48)	121 (39)	119 (43)	129 (41)	147 (41)	51 (20)	72 (34)	69 (35)	60 (27)	66 (34)	67 (27)	46 (21)
Yes	21 (57)	29 (64)	26 (44)	108 (47)	131 (52)	190 (61)	157 (57)	189 (59)	206 (58)	162 (64)	136 (64)	127 (64)	158 (72)	123 (63)	176 (71)	163 (75)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	2 (1)	42 (16)	3 (1)	4 (2)	2 (1)	7 (4)	5 (2)	7 (3)
History of methadone maintenance treatment (%)																
Current	5 (14)	17 (38)	14 (24)	42 (18)	57 (23)	66 (21)	59 (21)	71 (22)	72 (20)	47 (18)	45 (21)	25 (13)	51 (23)	39 (20)	61 (25)	57 (26)
Previous	7 (19)	5 (11)	5 (8)	37 (16)	40 (16)	54 (17)	53 (19)	79 (25)	90 (26)	41 (16)	48 (23)	64 (32)	57 (26)	40 (20)	46 (19)	53 (25)
Never	24 (64)	23 (51)	40 (68)	151 (66)	153 (61)	191 (61)	164 (60)	168 (53)	189 (53)	89 (35)	114 (54)	108 (54)	109 (50)	112 (57)	135 (54)	92 (42)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	4 (1)	78 (31)	4 (2)	3 (2)	3 (1)	5 (3)	6 (2)	14 (6)
History of other pharmacotherapy treatment (%)																
Current	--	--	--	--	--	15 (5)	14 (5)	20 (6)	32 (9)	35 (14)	46 (22)	27 (14)	28 (13)	26 (13)	42 (17)	29 (13)
Previous	--	--	--	--	--	26 (8)	25 (9)	33 (10)	55 (15)	39 (15)	32 (15)	38 (19)	46 (21)	33 (17)	60 (24)	62 (29)
Never	--	--	--	--	--	269 (86)	233 (84)	261 (83)	259 (73)	156 (61)	128 (61)	130 (65)	143 (65)	130 (66)	145 (58)	124 (57)
Not reported	--	--	--	--	--	2 (1)	4 (2)	4 (1)	9 (3)	25 (10)	5 (2)	5 (3)	3 (1)	7 (4)	1 (<1)	1 (<1)

Table 6.8 Number (percentage) of respondents by source of needle and syringe acquisition in the month prior to survey and year

SOUTH AUSTRALIA N° injected last month	1995 N=36	1996 N=41	1997 N=54	1998 N=218	1999 N=236	2000 N=292	2001 N=264	2002 N=303	2003 N=325	2004 N=231	2005 N=191	2006 N=191	2007 N=206	2008 N=174	2009 N=224	2010 N=202
Needle/syringe acquisition in the last month (%) [more than one could be selected]																
Needle Syringe Program	--	--	--	--	213 (90)	272 (93)	248 (94)	263 (87)	303 (93)	207 (90)	175 (92)	166 (87)	139 (67)	144 (83)	150 (67)	183 (91)
Pharmacy	--	--	--	--	139 (59)	138 (47)	112 (42)	123 (41)	151 (46)	112 (48)	80 (42)	79 (41)	37 (18)	66 (38)	36 (16)	26 (13)
Personal Sources	--	--	--	--	--	--	--	--	--	--	--	--	49 (24)	--	39 (17)	24 (12)
Other sources	--	--	--	--	--	--	--	--	--	--	--	--	6 (3)	--	9 (4)	5 (2)
Onward supply of syringes in last month (%)																
Yes, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	92 (45)	--	87 (39)	89 (44)
No, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	86 (42)	--	89 (40)	113 (56)
Not reported	--	--	--	--	--	--	--	--	--	--	--	--	28 (14)	--	48 (21)	0 (0)

HIV ANTIBODY PREVALENCE

Table 6.9 HIV antibody prevalence by gender and year

SOUTH AUSTRALIA	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995	19	0 (0.0)	11	0 (0.0)	32	0 (0.0)
1996	30	0 (0.0)	14	0 (0.0)	45	0 (0.0)
1997	25	1 (4.0)	14	0 (0.0)	39	1 (2.6)
1998	96	1 (1.0)	71	1 (1.4)	168	2 (1.2)
1999	142	2 (1.4)	96	4 (4.2)	238	6 (2.5)
2000	200	0 (0.0)	92	0 (0.0)	294	0 (0.0)
2001	173	3 (1.7)	99	1 (1.0)	274	4 (1.5)
2002	194	1 (0.5)	115	1 (0.9)	311	2 (0.6)
2003	190	1 (0.5)	115	1 (0.9)	308	2 (0.7)
2004	145	0 (0.0)	80	1 (1.3)	229	1 (0.4)
2005	122	1 (0.8)	82	0 (0.0)	205	1 (0.5)
2006	112	1 (0.9)	85	0 (0.0)	197	1 (0.5)
2007	120	2 (1.7)	89	0 (0.0)	211	2 (1.0)
2008	96	0 (0.0)	92	0 (0.0)	189	0 (0.0)
2009	155	2 (1.3)	91	1 (1.1)	246	3 (1.2)
2010	129	0 (0.0)	84	1 (1.2)	214	1 (0.5)
χ^2 trend p value		0.621		0.166		0.210

HCV ANTIBODY PREVALENCE

Table 6.10 HCV antibody prevalence by gender and year

SOUTH AUSTRALIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	19	14 (74)	11	4 (36)	32	19 (59)
1996	30	17 (57)	13	6 (46)	44	24 (55)
1997	25	9 (36)	14	8 (57)	39	17 (44)
1998	96	28 (29)	71	17 (24)	168	45 (27)
1999	142	61 (43)	96	37 (39)	238	98 (41)
2000	200	96 (48)	92	42 (46)	294	138 (47)
2001	174	89 (51)	99	51 (52)	275	142 (52)
2002	192	90 (47)	115	43 (37)	309	133 (43)
2003	190	86 (45)	115	53 (46)	308	142 (46)
2004	147	67 (46)	80	39 (49)	231	108 (47)
2005	122	54 (44)	82	40 (49)	205	95 (46)
2006	112	49 (44)	85	35 (41)	197	84 (43)
2007	120	50 (42)	89	31 (35)	211	82 (39)
2008	95	30 (32)	90	24 (27)	186	54 (29)
2009	155	65 (42)	91	36 (40)	246	101 (41)
2010	127	54 (43)	84	38 (45)	212	93 (44)
χ^2 trend p value		0.098		0.714		0.116

Table 6.11 HCV antibody prevalence by sexual identity, gender and year

SOUTH AUSTRALIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Heterosexual	16	13 (81)	8	2 (25)	25	16 (64)
Bisexual	1	0 (0)	2	2 (100)	4	2 (50)
Homosexual	1	0 (0)	0	0 (100)	1	0 (0)
1996						
Heterosexual	23	14 (61)	11	6 (55)	35	21 (60)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	5	2 (40)	0	0 (0)	5	2 (0)
1997						
Heterosexual	19	6 (32)	11	7 (64)	30	13 (43)
Bisexual	2	1 (50)	1	0 (0)	3	1 (33)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
1998						
Heterosexual	80	23 (29)	46	12 (26)	127	35 (28)
Bisexual	6	2 (33)	8	2 (25)	14	4 (29)
Homosexual	9	3 (33)	15	3 (20)	24	6 (25)
1999						
Heterosexual	118	50 (42)	60	22 (37)	178	72 (40)
Bisexual	7	2 (29)	26	11 (42)	33	13 (39)
Homosexual	7	4 (57)	8	2 (25)	15	6 (40)
2000						
Heterosexual	163	82 (50)	52	25 (48)	215	107 (50)
Bisexual	15	6 (40)	23	12 (52)	39	18 (46)
Homosexual	17	5 (29)	14	2 (14)	32	7 (22)
2001						
Heterosexual	147	74 (50)	58	25 (43)	207	101 (49)
Bisexual	8	4 (50)	21	15 (71)	29	19 (66)
Homosexual	14	8 (57)	12	6 (50)	26	14 (54)
2002						
Heterosexual	156	81 (52)	76	27 (36)	232	108 (47)
Bisexual	12	3 (25)	28	12 (43)	40	15 (38)
Homosexual	7	2 (29)	4	1 (25)	11	3 (27)
2003						
Heterosexual	159	74 (47)	72	32 (44)	233	108 (46)
Bisexual	11	6 (55)	26	15 (58)	37	21 (57)
Homosexual	11	3 (36)	9	3 (33)	20	7 (35)
2004						
Heterosexual	133	62 (47)	52	27 (52)	186	90 (48)
Bisexual	7	5 (71)	22	9 (41)	30	15 (50)
Homosexual	4	0 (0)	3	1 (33)	7	1 (14)
2005						
Heterosexual	107	47 (44)	55	28 (51)	162	75 (46)
Bisexual	5	2 (40)	21	10 (48)	26	12 (46)
Homosexual	5	1 (20)	2	1 (50)	8	3 (38)
2006						
Heterosexual	99	47 (47)	59	26 (44)	158	73 (46)
Bisexual	4	0 (0)	13	8 (62)	17	8 (47)
Homosexual	2	1 (50)	8	1 (13)	10	2 (20)
2007						
Heterosexual	103	41 (40)	64	26 (41)	167	67 (40)
Bisexual	5	3 (60)	16	3 (19)	22	7 (32)
Homosexual	8	4 (50)	6	2 (33)	15	6 (40)
2008						
Heterosexual	84	29 (35)	55	17 (31)	139	46 (33)
Bisexual	5	1 (20)	23	4 (17)	28	5 (18)
Homosexual	3	0 (0)	10	3 (30)	13	3 (23)
2009						
Heterosexual	134	59 (44)	68	27 (40)	202	86 (43)
Bisexual	11	3 (27)	12	6 (50)	23	9 (36)
Homosexual	4	0 (0)	9	3 (33)	13	3 (23)
2010						
Heterosexual	113	51 (45)	69	31 (45)	182	82 (45)
Bisexual	1	1 (100)	8	4 (50)	10	6 (60)
Homosexual	7	0 (0)	5	1 (20)	12	1 (8)
2010 p value		0.10		0.661		0.019

Table 6.12 HCV antibody prevalence by age group, gender and year

SOUTH AUSTRALIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
<25 years	5	2 (40)	1	0 (0)	6	2 (33)
25-34 years	9	7 (78)	8	3 (38)	18	11 (61)
35+ years	5	5 (100)	2	1 (50)	8	6 (75)
1996						
<25 years	6	2 (33)	4	0 (0)	10	2 (20)
25-34 years	14	10 (71)	5	3 (60)	20	14 (70)
35+ years	10	6 (60)	4	3 (75)	14	9 (64)
1997						
<25 years	7	2 (29)	1	0 (0)	8	2 (25)
25-34 years	11	3 (27)	8	6 (75)	19	9 (47)
35+ years	6	3 (50)	5	2 (40)	11	5 (45)
1998						
<25 years	30	0 (0)	21	0 (0)	51	0 (0)
25-34 years	38	11 (29)	30	9 (30)	69	20 (29)
35+ years	28	17 (61)	20	8 (40)	48	25 (52)
1999						
<25 years	37	6 (16)	28	3 (11)	65	9 (14)
25-34 years	61	25 (41)	45	23 (51)	106	48 (45)
35+ years	44	30 (68)	22	10 (45)	66	40 (61)
2000						
<25 years	60	13 (22)	31	13 (42)	92	26 (28)
25-34 years	81	41 (51)	41	16 (39)	123	57 (46)
35+ years	59	42 (71)	20	13 (65)	79	55 (70)
2001						
<25 years	52	20 (38)	23	10 (43)	75	30 (40)
25-34 years	70	33 (47)	43	23 (53)	113	56 (50)
35+ years	52	36 (69)	33	18 (55)	87	56 (64)
2002						
<25 years	41	8 (20)	29	3 (10)	70	11 (16)
25-34 years	87	40 (46)	52	20 (38)	139	60 (44)
35+ years	64	42 (66)	34	20 (59)	100	62 (62)
2003						
<25 years	28	7 (25)	25	9 (36)	53	16 (30)
25-34 years	99	41 (41)	53	20 (38)	153	62 (41)
35+ years	63	38 (60)	36	23 (64)	101	63 (62)
2004						
<25 years	33	6 (18)	24	10 (42)	57	16 (28)
25-34 years	64	32 (50)	26	10 (38)	90	42 (47)
35+ years	48	29 (60)	30	19 (63)	80	50 (63)
2005						
<25 years	13	3 (23)	15	5 (33)	28	8 (29)
25-34 years	51	18 (35)	37	13 (35)	88	31 (35)
35+ years	58	33 (57)	30	22 (73)	89	56 (63)
2006						
<25 years	9	0 (0)	17	2 (12)	26	2 (8)
25-34 years	48	18 (38)	34	13 (38)	82	31 (38)
35+ years	54	30 (56)	34	20 (59)	88	50 (57)
2007						
<25 years	7	4 (57)	14	4 (29)	22	9 (41)
25-34 years	45	14 (31)	37	10 (27)	82	24 (29)
35+ years	67	31 (46)	37	17 (46)	105	48 (46)
2008						
<25 years	6	0 (0)	11	2 (18)	17	2 (12)
25-34 years	23	5 (22)	37	7 (19)	60	12 (20)
35+ years	66	25 (38)	42	15 (36)	109	40 (37)
2009						
<25 years	14	1 (7)	10	4 (40)	24	5 (21)
25-34 years	37	13 (35)	30	11 (37)	67	24 (36)
35+ years	104	51 (49)	50	21 (42)	154	72 (47)
2010						
<25 years	8	0 (0)	10	2 (20)	18	2 (11)
25-34 years	30	8 (27)	23	11 (48)	53	19 (36)
35+ years	89	46 (52)	51	25 (49)	141	72 (51)
2010 p value		0.001		0.266		0.002

Table 6.13 HCV antibody prevalence by time since first injection, gender and year

SOUTH AUSTRALIA	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<3 years	1	1 (100)	1	0 (0)	2	1 (50)
3-10 years	9	4 (44)	6	2 (33)	16	7 (44)
11+ years	9	9 (100)	4	2 (50)	14	11 (79)
1996						
<3 years	4	2 (50)	2	0 (0)	6	2 (33)
3-10 years	7	3 (43)	6	1 (17)	14	5 (36)
11+ years	18	12 (67)	5	5 (100)	23	17 (74)
1997						
<3 years	5	1 (20)	3	2 (67)	8	3 (38)
3-10 years	8	2 (25)	6	3 (50)	14	5 (36)
11+ years	10	5 (50)	5	3 (60)	15	8 (53)
1998						
<3 years	18	1 (6)	17	2 (12)	35	3 (9)
3-10 years	39	4 (10)	32	3 (9)	72	7 (10)
11+ years	37	22 (59)	22	12 (55)	59	34 (58)
1999						
<3 years	22	1 (5)	10	2 (20)	32	3 (9)
3-10 years	49	16 (33)	52	13 (25)	101	29 (29)
11+ years	71	44 (62)	32	21 (66)	103	65 (63)
2000						
<3 years	25	5 (20)	18	3 (17)	43	8 (19)
3-10 years	92	32 (35)	38	17 (45)	132	49 (37)
11+ years	82	59 (72)	35	21 (60)	117	80 (68)
2001						
<3 years	21	7 (33)	17	6 (35)	38	13 (34)
3-10 years	72	28 (39)	41	20 (49)	113	48 (42)
11+ years	79	52 (66)	41	25 (61)	122	79 (65)
2002						
<3 years	17	3 (18)	12	3 (25)	30	6 (20)
3-10 years	68	16 (24)	53	10 (19)	121	26 (21)
11+ years	104	70 (67)	47	27 (57)	151	97 (64)
2003						
<3 years	11	1 (9)	11	2 (18)	22	3 (14)
3-10 years	55	14 (25)	49	18 (37)	104	32 (31)
11+ years	120	70 (58)	51	32 (63)	173	104 (60)
2004						
<3 years	13	3 (23)	9	1 (11)	22	4 (18)
3-10 years	54	15 (28)	35	14 (40)	89	29 (33)
11+ years	72	47 (65)	34	22 (65)	108	71 (66)
2005						
<3 years	8	0 (0)	8	1 (13)	16	1 (6)
3-10 years	29	5 (17)	33	10 (30)	63	12 (25)
11+ years	80	47 (59)	41	29 (71)	121	77 (63)
2006						
<3 years	5	1 (20)	9	0 (0)	14	1 (7)
3-10 years	31	4 (13)	31	7 (23)	62	11 (18)
11+ years	72	41 (57)	44	28 (64)	116	69 (59)
2007						
<3 years	8	0 (0)	7	4 (57)	15	4 (27)
3-10 years	27	9 (33)	33	9 (27)	61	18 (30)
11+ years	82	39 (48)	47	17 (36)	130	57 (44)
2008						
<3 years	5	0 (0)	7	1 (14)	12	1 (8)
3-10 years	16	4 (25)	24	3 (13)	40	7 (18)
11+ years	74	26 (35)	57	20 (35)	132	46 (35)
2009						
<3 years	4	0 (0)	10	1 (10)	14	1 (7)
3-10 years	26	4 (15)	20	8 (40)	46	12 (26)
11+ years	122	59 (48)	59	27 (46)	181	86 (48)
2010						
<3 years	3	0 (0)	2	0 (0)	5	0 (0)
3-10 years	18	0 (0)	20	7 (35)	38	7 (18)
11+ years	105	54 (51)	61	31 (51)	167	86 (52)
2010 p value		<0.001		0.242		<0.001

Table 6.14 HCV antibody prevalence by drug last injected, time since first injection and year

SOUTH AUSTRALIA	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heroin	1	1 (100)	22	16 (73)	23	17 (74)
Methamphetamine	1	0 (0)	6	1 (17)	7	1 (14)
Other	0	0 (0)	2	1 (50)	2	1 (50)
1996						
Heroin	2	1 (50)	20	13 (65)	23	15 (65)
Methamphetamine	4	1 (25)	10	4 (40)	14	5 (36)
Other	0	0 (0)	6	5 (83)	6	5 (83)
1997						
Heroin	4	3 (75)	14	9 (64)	19	12 (63)
Methamphetamine	3	0 (0)	9	2 (22)	12	2 (17)
Other	1	0 (0)	5	1 (20)	7	2 (29)
1998						
Heroin	10	3 (30)	60	28 (47)	71	31 (44)
Methamphetamine	21	0 (0)	45	5 (11)	67	6 (9)
Other	4	0 (0)	25	8 (32)	29	8 (28)
1999						
Heroin	7	2 (29)	99	62 (63)	107	65 (61)
Methamphetamine	23	1 (4)	77	15 (19)	100	16 (16)
Other	2	0 (0)	26	17 (65)	29	17 (59)
2000						
Heroin	15	4 (27)	149	88 (59)	165	93 (56)
Methamphetamine	26	3 (12)	62	20 (32)	89	23 (26)
Other	2	1 (50)	36	20 (56)	38	21 (55)
2001						
Heroin	6	3 (50)	62	48 (77)	68	51 (75)
Methamphetamine	28	7 (25)	114	44 (37)	142	51 (36)
Other	4	3 (75)	54	32 (59)	60	37 (62)
2002						
Heroin	1	1 (100)	73	42 (58)	75	44 (59)
Methamphetamine	21	3 (14)	119	41 (34)	142	45 (32)
Other	6	2 (33)	72	38 (53)	79	41 (52)
2003						
Heroin	2	0 (0)	68	44 (65)	75	46 (61)
Methamphetamine	16	1 (6)	128	51 (40)	148	53 (36)
Other	3	2 (67)	74	37 (50)	78	40 (51)
2004						
Heroin	5	3 (60)	59	38 (64)	65	42 (65)
Methamphetamine	13	1 (8)	77	24 (31)	92	26 (28)
Other	2	0 (0)	50	29 (58)	53	30 (57)
2005						
Heroin	3	1 (33)	71	40 (56)	77	42 (55)
Methamphetamine	11	0 (0)	71	26 (37)	84	27 (32)
Other	2	0 (0)	36	22 (61)	38	22 (58)
2006						
Heroin	1	0 (0)	39	23 (59)	40	23 (58)
Methamphetamine	8	0 (0)	89	22 (25)	99	22 (22)
Other	5	1 (20)	46	32 (70)	53	35 (66)
2007						
Heroin	3	2 (67)	57	29 (51)	60	31 (52)
Methamphetamine	9	1 (11)	78	19 (24)	90	23 (26)
Other	3	1 (33)	54	26 (48)	59	27 (46)
2008						
Heroin	3	1 (33)	45	22 (49)	48	23 (48)
Methamphetamine	7	0 (0)	85	12 (14)	92	12 (13)
Other	2	0 (0)	41	19 (46)	43	19 (44)
2009						
Heroin	3	0 (0)	79	40 (51)	83	41 (49)
Methamphetamine	6	1 (17)	83	28 (34)	90	29 (32)
Other	5	0 (0)	61	29 (48)	67	30 (44)
2010						
Heroin	2	0 (0)	83	41 (49)	85	41 (48)
Methamphetamine	3	0 (0)	82	26 (32)	86	26 (30)
Other	0	0 (0)	40	26 (65)	41	26 (63)
2010 p value		--		0.002		0.001

Table 6.15 HCV antibody prevalence by frequency of injection, time since first injection and year

SOUTH AUSTRALIA	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Less than daily	1	0 (0)	14	10 (71)	15	10 (67)
Daily or more	1	1 (100)	16	8 (50)	17	9 (53)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
1996						
Less than daily	5	2 (40)	20	12 (60)	25	14 (56)
Daily or more	1	0 (0)	13	7 (54)	15	8 (53)
Not last month	0	0 (0)	4	3 (75)	4	3 (75)
1997						
Less than daily	4	3 (75)	13	6 (46)	18	10 (56)
Daily or more	3	0 (0)	15	6 (40)	19	6 (32)
Not last month	1	0 (0)	1	1 (100)	2	1 (50)
1998						
Less than daily	24	1 (4)	56	14 (25)	80	15 (19)
Daily or more	9	2 (22)	70	26 (37)	81	29 (36)
Not last month	2	0 (0)	5	1 (20)	7	1 (14)
1999						
Less than daily	20	3 (15)	94	39 (41)	116	43 (37)
Daily or more	10	0 (0)	100	48 (48)	110	48 (44)
Not last month	2	0 (0)	9	7 (78)	11	7 (64)
2000						
Less than daily	15	0 (0)	87	38 (44)	104	39 (38)
Daily or more	26	8 (31)	148	81 (55)	174	89 (51)
Not last month	2	0 (0)	13	9 (69)	15	9 (60)
2001						
Less than daily	24	7 (29)	120	56 (47)	144	63 (44)
Daily or more	14	6 (43)	104	64 (62)	119	71 (60)
Not last month	0	0 (0)	11	7 (64)	11	7 (64)
2002						
Less than daily	15	3 (20)	129	49 (38)	146	53 (36)
Daily or more	10	3 (30)	134	72 (54)	148	78 (53)
Not last month	5	0 (0)	6	1 (17)	11	1 (9)
2003						
Less than daily	13	0 (0)	117	44 (38)	136	45 (33)
Daily or more	8	3 (38)	138	81 (59)	149	87 (58)
Not last month	1	0 (0)	18	9 (50)	20	9 (45)
2004						
Less than daily	7	1 (14)	80	35 (44)	90	37 (41)
Daily or more	13	3 (23)	103	60 (58)	119	66 (55)
Not last month	2	0 (0)	13	5 (38)	16	5 (31)
2005						
Less than daily	9	1 (11)	79	40 (51)	90	42 (47)
Daily or more	3	0 (0)	89	43 (48)	95	44 (46)
Not last month	3	0 (0)	16	9 (56)	19	9 (47)
2006						
Less than daily	9	1 (11)	84	36 (43)	93	37 (40)
Daily or more	3	0 (0)	89	43 (48)	95	45 (47)
Not last month	2	0 (0)	4	1 (25)	7	2 (29)
2007						
Less than daily	10	1 (10)	77	33 (43)	88	35 (40)
Daily or more	4	2 (50)	103	40 (39)	111	44 (40)
Not last month	1	1 (100)	11	2 (18)	12	3 (25)
2008						
Less than daily	6	0 (0)	68	19 (28)	74	19 (26)
Daily or more	4	1 (25)	87	30 (34)	91	31 (34)
Not last month	2	0 (0)	16	4 (25)	19	4 (21)
2009						
Less than daily	6	1 (17)	89	43 (48)	96	44 (46)
Daily or more	5	0 (0)	118	51 (43)	126	53 (42)
Not last month	3	0 (0)	18	3 (17)	22	3 (14)
2010						
Less than daily	3	0 (0)	100	46 (46)	104	46 (44)
Daily or more	1	0 (0)	92	43 (47)	94	43 (46)
Not last month	1	0 (0)	12	4 (33)	13	4 (31)
2010 p value		--		0.763		0.613

Table 6.16 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, time since first injection and year

SOUTH AUSTRALIA	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
No receptive sharing	1	0 (0)	19	12 (63)	20	12 (60)
Receptive sharing	1	1 (100)	11	6 (55)	12	7 (58)
1996						
No receptive sharing	5	2 (40)	27	13 (48)	32	15 (47)
Receptive sharing	1	0 (0)	6	6 (100)	8	7 (88)
1997						
No receptive sharing	6	2 (33)	23	8 (35)	31	11 (35)
Receptive sharing	1	1 (100)	4	3 (75)	5	4 (80)
1998						
No receptive sharing	28	1 (4)	107	34 (32)	137	36 (26)
Receptive sharing	5	2 (40)	19	6 (32)	24	8 (33)
1999						
No receptive sharing	24	2 (8)	150	63 (42)	176	66 (38)
Receptive sharing	4	1 (25)	40	22 (55)	44	23 (52)
2000						
No receptive sharing	37	6 (16)	188	89 (47)	227	96 (42)
Receptive sharing	4	2 (50)	36	23 (64)	40	25 (63)
2001						
No receptive sharing	28	10 (36)	198	101 (51)	227	112 (49)
Receptive sharing	9	3 (33)	23	18 (78)	32	21 (66)
2002						
No receptive sharing	21	5 (24)	218	97 (45)	242	103 (43)
Receptive sharing	2	1 (50)	36	18 (50)	40	21 (53)
2003						
No receptive sharing	15	1 (7)	218	100 (46)	239	103 (43)
Receptive sharing	5	2 (40)	33	21 (64)	39	24 (62)
2004						
No receptive sharing	12	2 (17)	143	70 (49)	161	76 (47)
Receptive sharing	7	2 (29)	37	23 (62)	44	25 (57)
2005						
No receptive sharing	13	2 (15)	139	67 (48)	159	72 (45)
Receptive sharing	2	0 (0)	17	11 (65)	19	11 (58)
2006						
No receptive sharing	10	0 (0)	141	61 (43)	154	63 (41)
Receptive sharing	1	0 (0)	28	14 (50)	29	14 (48)
2007						
No receptive sharing	13	2 (15)	145	61 (42)	161	64 (40)
Receptive sharing	1	1 (100)	27	9 (33)	29	11 (38)
2008						
No receptive sharing	7	0 (0)	125	40 (32)	132	40 (30)
Receptive sharing	3	1 (33)	26	8 (31)	29	9 (31)
2009						
No receptive sharing	10	1 (10)	181	85 (47)	195	88 (45)
Receptive sharing	0	0 (0)	21	7 (33)	21	7 (33)
2010						
No receptive sharing	4	0 (0)	146	66 (45)	151	66 (44)
Receptive sharing	0	0 (0)	24	9 (38)	24	9 (38)
2010 p value		--		0.515		0.660

Table 6.17 HCV antibody prevalence by imprisonment last year, time since first injection and year

SOUTH AUSTRALIA	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
No imprisonment	2	1 (50)	24	14 (58)	26	15 (58)
Imprisonment	0	0 (0)	5	3 (60)	5	3 (60)
1996						
No imprisonment	6	2 (33)	30	17 (57)	37	20 (54)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
1997						
No imprisonment	8	3 (38)	23	10 (43)	32	14 (44)
Imprisonment	0	0 (0)	6	3 (50)	7	3 (43)
1998						
No imprisonment	33	2 (6)	115	37 (32)	150	40 (27)
Imprisonment	2	1 (50)	16	4 (25)	18	5 (28)
1999						
No imprisonment	30	3 (10)	168	72 (43)	199	75 (38)
Imprisonment	2	0 (0)	33	20 (61)	36	21 (58)
2000						
No imprisonment	41	6 (15)	187	97 (52)	230	104 (45)
Imprisonment	2	2 (100)	58	30 (52)	60	32 (53)
2001						
No imprisonment	34	11 (32)	203	105 (52)	238	117 (49)
Imprisonment	2	1 (50)	31	21 (68)	34	23 (68)
2002						
No imprisonment	26	6 (23)	228	101 (44)	260	110 (42)
Imprisonment	2	0 (0)	38	19 (50)	41	20 (49)
2003						
No imprisonment	20	2 (10)	236	110 (47)	263	113 (43)
Imprisonment	2	1 (50)	40	25 (63)	43	27 (63)
2004						
No imprisonment	19	4 (21)	149	68 (46)	176	75 (43)
Imprisonment	2	0 (0)	39	25 (64)	41	25 (61)
2005						
No imprisonment	18	2 (11)	151	72 (48)	174	75 (43)
Imprisonment	1	0 (0)	20	11 (55)	23	13 (57)
2006						
No imprisonment	14	0 (0)	153	67 (44)	171	70 (41)
Imprisonment	0	0 (0)	17	8 (47)	18	9 (50)
2007						
No imprisonment	12	3 (25)	150	51 (34)	165	55 (33)
Imprisonment	1	0 (0)	30	20 (67)	32	21 (66)
2008						
No imprisonment	11	1 (9)	139	42 (30)	151	43 (28)
Imprisonment	0	0 (0)	21	8 (38)	21	8 (38)
2009						
No imprisonment	13	1 (8)	180	72 (40)	197	74 (38)
Imprisonment	1	0 (0)	35	20 (57)	37	21 (57)
2010						
No imprisonment	5	0 (0)	159	62 (39)	166	62 (37)
Imprisonment	0	0 (0)	16	10 (63)	16	10 (63)
2010 p value		--		0.107		0.062

Table 6.18 HCV antibody prevalence by sex work last month, time since first injection and year

SOUTH AUSTRALIA	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
No sex work	2	1 (50)	25	14 (56)	27	15 (56)
Sex work	0	0 (0)	3	2 (67)	3	2 (67)
1996						
No sex work	6	2 (33)	34	20 (59)	41	23 (56)
Sex work	0	0 (0)	2	1 (50)	2	1 (50)
1997						
No sex work	8	3 (38)	27	12 (44)	37	16 (43)
Sex work	0	0 (0)	1	1 (100)	1	1 (100)
1998						
No sex work	29	2 (7)	123	37 (30)	154	40 (26)
Sex work	4	1 (25)	4	3 (75)	8	4 (50)
1999						
No sex work	31	3 (10)	179	84 (47)	212	88 (42)
Sex work	1	0 (0)	20	7 (35)	21	7 (33)
2000						
No sex work	40	6 (15)	224	117 (52)	266	124 (47)
Sex work	3	2 (68)	25	12 (48)	28	14 (50)
2001						
No sex work	30	8 (27)	210	111 (53)	242	121 (50)
Sex work	3	3 (100)	21	14 (67)	24	17 (71)
2002						
No sex work	28	5 (18)	243	112 (46)	277	121 (50)
Sex work	1	1 (100)	15	6 (40)	16	7 (44)
2003						
No sex work	20	3 (15)	246	114 (46)	275	120 (44)
Sex work	0	0 (0)	13	11 (85)	13	11 (85)
2004						
No sex work	18	4 (22)	171	84 (49)	199	92 (46)
Sex work	2	0 (0)	17	11 (65)	19	11 (58)
2005						
No sex work	19	2 (11)	163	84 (52)	189	89 (47)
Sex work	0	0 (0)	9	5 (56)	10	6 (60)
2006						
No sex work	12	1 (8)	163	72 (44)	179	75 (42)
Sex work	2	0 (0)	10	6 (60)	12	6 (50)
2007						
No sex work	12	3 (25)	169	70 (41)	185	75 (41)
Sex work	2	0 (0)	18	4 (22)	21	5 (24)
2008						
No sex work	11	1 (9)	150	48 (32)	162	49 (30)
Sex work	0	0 (0)	13	5 (38)	13	5 (38)
2009						
No sex work	14	1 (7)	208	93 (45)	227	96 (42)
Sex work	0	0 (0)	10	2 (20)	10	2 (20)
2010						
No sex work	5	0 (0)	174	80 (46)	181	80 (44)
Sex work	0	0 (0)	20	5 (25)	20	5 (25)
2010 p value		--		0.096		0.151

Table 6.19 HCV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year

SOUTH AUSTRALIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Non-Indigenous	18	13 (72)	11	4 (36)	31	18 (58)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
1996						
Non-Indigenous	29	18 (62)	12	5 (42)	41	23 (56)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
1997						
Non-Indigenous	23	7 (30)	14	8 (57)	37	15 (41)
Indigenous	1	1 (100)	0	0 (0)	1	1 (100)
1998						
Non-Indigenous	91	26 (29)	66	16 (24)	158	42 (27)
Indigenous	5	2 (40)	2	1 (50)	7	3 (43)
1999						
Non-Indigenous	136	58 (43)	89	35 (39)	225	93 (41)
Indigenous	6	3 (50)	4	0 (0)	10	3 (30)
2000						
Non-Indigenous	171	82 (48)	77	35 (45)	250	117 (47)
Indigenous	27	14 (52)	13	5 (38)	40	19 (48)
2001						
Non-Indigenous	156	81 (52)	87	43 (49)	245	126 (51)
Indigenous	14	6 (43)	10	6 (60)	24	12 (50)
2002						
Non-Indigenous	173	81 (47)	111	43 (39)	286	124 (43)
Indigenous	15	7 (47)	3	0 (0)	18	7 (39)
2003						
Non-Indigenous	170	75 (44)	101	44 (44)	274	122 (45)
Indigenous	12	10 (83)	10	6 (60)	22	16 (73)
2004						
Non-Indigenous	138	61 (44)	65	30 (46)	207	93 (45)
Indigenous	7	5 (71)	12	8 (67)	19	13 (68)
2005						
Non-Indigenous	110	45 (41)	71	34 (48)	182	80 (44)
Indigenous	6	5 (83)	9	5 (56)	15	10 (67)
2006						
Non-Indigenous	99	40 (40)	74	30 (41)	173	70 (41)
Indigenous	8	6 (75)	10	4 (40)	18	10 (56)
2007						
Non-Indigenous	110	43 (39)	82	29 (35)	194	73 (38)
Indigenous	9	6 (67)	6	2 (33)	15	8 (53)
2008						
Non-Indigenous	75	23 (31)	77	23 (30)	153	46 (30)
Indigenous	17	6 (35)	8	0 (0)	25	6 (24)
2009						
Non-Indigenous	128	50 (39)	76	28 (37)	204	78 (38)
Indigenous	20	12 (60)	11	7 (64)	31	19 (61)
2010						
Non-Indigenous	108	46 (43)	72	33 (46)	181	80 (44)
Indigenous	15	5 (33)	8	3 (38)	23	8 (35)
2010 p value		0.584		0.724		0.504

Table 6.20 HCV antibody prevalence by country of birth, gender and year

SOUTH AUSTRALIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2003						
Australia	172	77 (45)	99	45 (45)	274	125 (46)
Other	15	8 (53)	15	7 (47)	30	15 (50)
2004						
Australia	124	56 (45)	72	33 (46)	199	91 (46)
Other	20	9 (45)	9	4 (44)	29	15 (52)
2005						
Australia	103	48 (47)	73	34 (47)	177	83 (47)
Other	19	6 (32)	8	6 (75)	27	12 (44)
2006						
Australia	90	37 (41)	74	29 (39)	164	66 (41)
Other	21	11 (52)	11	6 (55)	32	17 (53)
2007						
Australia	102	41 (40)	73	23 (32)	177	65 (37)
Other	16	9 (56)	15	8 (53)	31	17 (55)
2008						
Australia	79	24 (30)	73	15 (21)	152	39 (26)
Other	13	6 (46)	15	8 (53)	29	14 (48)
2009						
Australia	137	60 (44)	80	29 (36)	217	89 (41)
Other	18	5 (28)	10	6 (60)	28	11 (39)
2010						
Australia	113	45 (40)	74	32 (43)	188	78 (41)
Other	12	9 (75)	9	6 (67)	21	15 (71)
2010 p value		0.030		0.289		0.011

Table 6.21 HCV antibody prevalence by language spoken at home by parents, gender and year

SOUTH AUSTRALIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2003						
English speaking	150	67 (45)	101	43 (43)	253	112 (44)
Non-English speaking	14	9 (64)	5	2 (40)	20	12 (60)
2004						
English speaking	93	46 (49)	66	32 (48)	162	79 (49)
Non-English speaking	17	5 (29)	5	3 (60)	22	8 (36)
2005						
English speaking	94	40 (43)	74	35 (47)	169	76 (45)
Non-English speaking	28	14 (50)	8	5 (63)	36	19 (53)
2006						
English speaking	90	39 (43)	74	33 (45)	164	72 (44)
Non-English speaking	13	5 (38)	6	1 (17)	19	6 (32)
2007						
English speaking	102	40 (39)	85	30 (35)	188	70 (37)
Non-English speaking	17	9 (53)	3	1 (33)	21	11 (52)
2008						
English speaking	87	26 (30)	83	21 (25)	171	47 (27)
Non-English speaking	5	4 (80)	6	2 (33)	11	6 (55)
2009						
English speaking	142	63 (44)	83	33 (40)	225	96 (43)
Non-English speaking	12	2 (17)	6	1 (17)	18	3 (17)
2010						
English speaking	112	46 (41)	81	37 (46)	194	84 (43)
Non-English speaking	13	6 (46)	3	1 (33)	16	7 (44)
2010 p value		0.772		1.000		1.000

7. TASMANIA


In Tasmania, one NSP site (Tasmanian Council on AIDS, Hepatitis & Related Diseases Hobart NSP) participated in the ANSPS in every year between 1995 and 2010. Site participation varied throughout the early to mid 2000s and then stabilised in 2007, with four NSP services participating consistently between 2007 and 2010 (Tasmanian Council on AIDS, Hepatitis & Related Diseases Hobart and Glenorchy NSP services, Clarence Community Health Centre NSP and Salvation Army Launceston NSP). Appendix 1 provides a detailed breakdown of site participation by state and year. Tasmanian sample sizes ranged considerably, from 6 (in 1995) to 168 (in 2007). Response rates also varied markedly, from 7% in 1995 to 85% in 2004. The relatively small number of participants in some survey years is likely to have contributed to the wide variations in demographic and injecting characteristics observed over time in Tasmania.

Demographic Characteristics

The gender composition of Tasmanian ANSPS samples varied over the period 1995 to 2010, during which between 58% and 79% of participants were male (Table 7.1). As in all other jurisdictions, the majority of participants (67% to 91%) identified as heterosexual. Although nationally the proportion of Indigenous participants increased over time, this was not the case in Tasmania, where substantial variation occurred from year to year, ranging from 0% to 17% over the survey period. The majority of Tasmanian survey respondents were born in Australia (84% to 96%) and reported their parents spoke English at home (66% to 99%) across all survey years in which these data were available.

The median age of Tasmanian ANSPS respondents was lowest at 21 years in 1996. Notably, the sample comprised just 18 participants in that year (Table 7.1). The median age of survey participants was relatively stable at between 29 years and 33 years over the period 1999 to 2006, and then increased to 36 years in 2008 (Figure 7.1). As observed nationally and in other jurisdictions, the proportion of young people (aged younger than 25 years) declined significantly over the survey period (χ^2 trend $p < 0.001$, Table 7.1), while the median age at first injection varied between 16 and 19 years.


Figure 7.1 Tasmania: Median age and proportion of new injectors by year



Injecting behaviour

Unlike most other jurisdictions, where heroin and methamphetamine were the two most commonly injected drugs, Tasmanian ANSPS participants most commonly reported last injecting methamphetamine, methadone and pharmaceutical opioids (Figure 7.2, Table 7.2). As occurred nationally, recent injection of methamphetamine was highest in Tasmania in 2006, but declined in 2007 (from 59% to 30%). In 2010 relatively equal proportions of the Tasmanian ANSPS sample reported last injecting methamphetamine (27%), methadone (28%) and pharmaceutical opioids (33%). Recent injection of heroin, cocaine, buprenorphine and performance and image enhancing drugs was rare.


Figure 7.2 Tasmania: Prevalence of methamphetamine, methadone and pharmaceutical opioids as drug last injected by year



The proportion of Tasmanian respondents who reported re-use of syringes, receptive sharing of syringes or receptive sharing of ancillary injecting equipment varied over the period 1995 to any 2010 (Figure 7.3, Table 7.4). Unlike other jurisdictions, no temporal trends were observed for any of these behaviours in Tasmania. Rates of receptive sharing of syringes were lower than those reported for ancillary equipment, with spoons, water and tourniquets the ancillary items Tasmanian participants were most likely to report receptively sharing.

The proportion of Tasmanian respondents who reported injection in a public place in the month preceding survey completion varied over the survey period, however prevalence of public injection was lower in Tasmania than observed nationally in all survey years (Figure 7.3). Whereas prevalence of public injection increased between 1997 and 2000 nationally and in most other jurisdictions, in Tasmania, public injection was lowest over this period at between 15% and 22%. Injection in a car was the most commonly reported place of public injection in Tasmania.

Figure 7.3 National and Tasmania: Prevalence of public injection by year



HIV prevalence

HIV antibodies were rarely detected among Tasmanian ANSPS participants, and no cases were identified between 2002 and 2010 (Table 7.9).

HCV prevalence

HCV antibody prevalence in Tasmania fluctuated substantially over the survey period, most likely due to small sample size in some years (Figure 7.4, Table 7.10). Consistent with the national trend, HCV antibody prevalence declined in Tasmania in 2009, with a further decline (to 45%) observed in 2010.

Figure 7.4 National and Tasmania: HCV antibody prevalence by year




Table 7.1 Number (percentage) of respondents by demographic characteristic and year

TASMANIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Number of sites	1	1	1	2	1	1	1	4	4	4	3	2	4	4	4	4
N° surveyed	N=6	N=18	N=23	N=51	N=25	N=27	N=28	N=151	N=118	N=107	N=137	N=150	N=168	N=57	N=122	N=106
Response rate	7%	11%	34%	29%	29%	30%	27%	58%	32%	85%	--	50%	45%	25%	22%	39%
Gender (%)																
Male	4 (67)	11 (61)	17 (74)	40 (78)	19 (76)	18 (67)	22 (79)	97 (64)	70 (59)	66 (62)	86 (63)	94 (63)	111 (66)	33 (58)	74 (61)	68 (64)
Female	2 (33)	7 (39)	6 (26)	11 (22)	6 (24)	9 (33)	6 (21)	52 (34)	47 (40)	40 (37)	51 (37)	56 (37)	57 (34)	24 (42)	47 (39)	38 (36)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)																
Heterosexual	4 (67)	14 (78)	18 (79)	44 (86)	20 (80)	19 (71)	20 (71)	120 (79)	93 (79)	94 (88)	124 (91)	130 (87)	138 (82)	46 (81)	101 (83)	96 (91)
Bisexual	2 (33)	0 (0)	3 (13)	4 (8)	3 (12)	3 (11)	2 (7)	10 (7)	10 (8)	5 (5)	5 (4)	14 (9)	12 (7)	6 (11)	12 (10)	4 (4)
Homosexual	0 (0)	4 (22)	1 (4)	2 (4)	1 (4)	2 (7)	1 (4)	4 (3)	1 (1)	0 (0)	1 (1)	0 (0)	13 (8)	3 (5)	5 (4)	1 (1)
Not reported	0 (0)	0 (0)	1 (4)	1 (2)	1 (4)	3 (11)	5 (18)	17 (11)	14 (2)	8 (7)	7 (5)	6 (4)	5 (3)	2 (4)	4 (3)	5 (5)
Age and time since first injection (years)																
<i>Median age</i>	29	21	28	26	29	33	28	29	28	32	31	33	34	36	33	35
<i>Age range</i>	20-31	16-43	21-40	16-51	19-49	20-45	19-36	15-55	16-51	17-57	18-53	16-60	15-57	21-58	17-59	20-60
<i>Age group (%)</i>																
< 25 years	1 (16)	12 (67)	5 (22)	22 (43)	6 (24)	7 (26)	8 (29)	53 (35)	37 (31)	13 (12)	23 (17)	21 (14)	26 (10)	3 (5)	13 (11)	7 (7)
25+ years	5 (83)	6 (33)	18 (78)	29 (57)	19 (76)	20 (74)	20 (71)	98 (65)	81 (69)	93 (87)	114 (83)	129 (86)	152 (90)	54 (95)	109 (89)	99 (93)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	16.5	16	17	17	18	19	17.5	17	17	19	19	18	18	18	19	19
<i>Age range</i>	14-18	13-22	13-30	12-31	14-31	13-40	10-25	12-42	10-45	10-46	11-49	11-47	10-44	11-38	11-44	12-42
N° not reported	0	0	0	1	0	0	0	2	1	4	7	0	3	1	5	0
<i>Median years IDU</i>	11.5	5	10	6	8	8	9	9	9	12	11	12	14	16.5	13	14
<i>Range</i>	2-17	<1-24	1-27	<1-23	1-27	<1-26	2-19	<1-31	<1-32	<1-35	<1-34	<1-40	<1-40	1-41	<1-39	<1-42
<i>Time since first injection</i>																
<3 years	1 (17)	4 (22)	3 (13)	12 (24)	2 (8)	2 (7)	1 (4)	13 (9)	10 (8)	8 (7)	7 (5)	9 (6)	10 (6)	1 (2)	9 (7)	4 (4)
3+ years	5 (83)	14 (78)	20 (87)	38 (75)	23 (92)	25 (93)	27 (96)	136 (90)	107 (91)	95 (89)	122 (89)	137 (91)	155 (92)	55 (96)	108 (89)	102 (96)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (1)	1 (1)	4 (4)	8 (6)	4 (3)	3 (2)	1 (2)	5 (4)	0 (0)

Table 7.1 Number (percentage) of respondents by demographic characteristic and year (continued)

TASMANIA N° surveyed	1995 N=6	1996 N=18	1997 N=23	1998 N=51	1999 N=25	2000 N=27	2001 N=28	2002 N=151	2003 N=118	2004 N=107	2005 N=137	2006 N=150	2007 N=168	2008 N=57	2009 N=122	2010 N=106	
Aboriginal and Torres Strait Islander origin (%)																	
No	5 (83)	17 (94)	21 (91)	47 (92)	20 (80)	25 (92)	23 (83)	129 (84)	100 (85)	96 (90)	121 (88)	121 (81)	141 (84)	50 (88)	100 (82)	94 (89)	
Yes	1 (17)	0 (0)	2 (9)	3 (6)	4 (16)	1 (4)	4 (14)	17 (11)	13 (11)	8 (7)	12 (9)	25 (17)	25 (15)	5 (9)	15 (12)	12 (11)	
Not reported	0 (0)	1 (6)	0 (0)	1 (2)	1 (4)	1 (4)	1 (3)	5 (3)	5 (4)	3 (3)	4 (3)	4 (3)	2 (1)	2 (4)	7 (6)	0 (0)	
Region/country of birth (%)																	
Australia	--	--	--	--	24 (96)	24 (89)	23 (83)	137 (91)	111 (94)	95 (89)	126 (92)	138 (92)	159 (95)	48 (84)	111 (91)	98 (92)	
Other Oceania	--	--	--	--	--	0 (0)	1 (4)	2 (1)	1 (<1)	2 (2)	0 (0)	1 (<1)	3 (2)	0 (0)	2 (2)	2 (2)	
Asia	--	--	--	--	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
UK & Ireland	--	--	--	--	--	0 (0)	2 (7)	6 (4)	3 (3)	3 (3)	6 (4)	6 (4)	3 (2)	6 (11)	2 (2)	4 (4)	
Other	--	--	--	--	0 (0)	0 (0)	0 (0)	6 (4)	3 (3)	4 (3)	3 (2)	2 (1)	0 (0)	0 (0)	2 (2)	2 (2)	
Not reported	--	--	--	--	1 (4)	3 (11)	2 (7)	0 (0)	0 (0)	3 (3)	2 (2)	3 (2)	3 (2)	3 (5)	5 (4)	0 (0)	
Main language spoken at home by parents (%)																	
English	--	--	--	--	24 (96)	26 (96)	25 (89)	142 (94)	114 (96)	71 (66)	115 (84)	136 (91)	165 (98)	55 (96)	119 (98)	105 (99)	
Non-English	--	--	--	--	1 (4)	1 (4)	2 (7)	6 (4)	2 (2)	3 (3)	22 (16)	2 (1)	3 (2)	2 (4)	1 (1)	1 (1)	
Not reported	--	--	--	--	0 (0)	0 (0)	1 (4)	3 (2)	2 (2)	33 (31)	0 (0)	12 (8)	0 (0)	0 (0)	2 (2)	0 (0)	
Imprisonment last year (%)																	
No	5 (83)	17 (94)	20 (87)	45 (88)	22 (88)	21 (78)	25 (89)	136 (90)	101 (86)	91 (85)	113 (82)	126 (84)	139 (83)	45 (79)	98 (80)	81 (76)	
Yes	1 (17)	0 (0)	2 (9)	5 (10)	3 (12)	4 (15)	2 (7)	13 (9)	16 (13)	14 (13)	18 (13)	19 (13)	25 (15)	7 (12)	17 (14)	5 (5)	
Not reported	0 (0)	1 (6)	1 (4)	1 (2)	0 (0)	2 (7)	1 (4)	2 (1)	1 (1)	2 (2)	6 (4)	5 (3)	4 (2)	5 (9)	7 (6)	20 (19)	
Injected in prison last year (%)																	
N° in prison	N=1	N=0	N=2	N=5	N=3	N=4	N=2	N=13	N=16	N=14	N=18	N=19	N=25	N=7	N=17	N=5	
Injected in prison	1 (100)	0 (0)	1 (50)	2 (40)	0 (0)	0 (0)	1 (50)	5 (38)	6 (38)	10 (71)	3 (17)	3 (16)	11 (44)	3 (43)	6 (35)	0 (0)	
Frequency of injection last month (%)																	
Not last month	0 (0)	2 (11)	1 (4)	1 (2)	0 (0)	4 (15)	2 (7)	4 (3)	8 (7)	3 (3)	6 (4)	4 (3)	6 (4)	2 (4)	7 (6)	9 (8)	
Less than weekly	1 (17)	5 (28)	5 (22)	4 (8)	5 (20)	2 (7)	4 (15)	20 (13)	20 (17)	20 (19)	31 (23)	31 (21)	48 (29)	8 (14)	18 (15)	21 (20)	
Weekly not daily	1 (17)	7 (39)	8 (35)	24 (47)	7 (28)	6 (22)	11 (39)	55 (36)	45 (38)	38 (35)	46 (34)	41 (27)	55 (33)	23 (40)	47 (39)	45 (42)	
Daily or more	4 (66)	4 (22)	9 (39)	22 (43)	13 (52)	15 (56)	11 (39)	72 (48)	45 (38)	45 (42)	54 (39)	73 (49)	58 (35)	24 (42)	46 (38)	31 (29)	
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (<1)	1 (<1)	0 (0)	4 (3)	0 (0)	

Table 7.2 Number (percentage) of respondents by drug last injected and year

TASMANIA N° surveyed	1995 N=6	1996 N=18	1997 N=23	1998 N=51	1999 N=25	2000 N=27	2001 N=28	2002 N=151	2003 N=118	2004 N=107	2005 N=137	2006 N=150	2007 N=168	2008 N=57	2009 N=122	2010 N=106
Drug last injected (%)																
Anabolic steroids	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	1 (1)	0 (0)	1 (1)	1 (<1)	1 (<1)	0 (0)	0 (0)	1 (<1)	1 (1)
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)
Heroin	2 (33)	1 (6)	0 (0)	5 (10)	0 (0)	3 (11)	0 (0)	4 (3)	1 (1)	0 (0)	2 (1)	3 (2)	3 (2)	4 (7)	4 (3)	1 (1)
Methadone	0 (0)	5 (28)	10 (44)	17 (33)	9 (36)	4 (15)	8 (28)	49 (32)	38 (32)	41 (38)	30 (22)	35 (23)	54 (32)	24 (42)	40 (33)	30 (28)
Methamphetamine	1 (17)	4 (22)	8 (35)	16 (31)	5 (20)	6 (22)	6 (22)	45 (30)	33 (28)	33 (31)	64 (47)	73 (49)	50 (30)	13 (23)	30 (25)	29 (27)
Pharm. opioids	2 (33)	6 (33)	4 (17)	10 (20)	4 (20)	6 (22)	8 (28)	25 (16)	28 (24)	20 (19)	27 (20)	24 (16)	43 (26)	12 (21)	33 (27)	35 (33)
Buprenorphine	--	--	--	--	--	--	--	1 (1)	0 (0)	1 (1)	1 (<1)	0 (0)	1 (<1)	1 (2)	2 (2)	0 (0)
More than one	1 (17)	0 (0)	1 (4)	2 (4)	4 (16)	7 (26)	5 (18)	20 (13)	15 (13)	9 (8)	6 (4)	6 (4)	5 (3)	1 (2)	4 (3)	8 (8)
Other	0 (0)	2 (11)	0 (0)	0 (0)	2 (8)	0 (0)	1 (4)	6 (4)	2 (1)	0 (0)	2 (1)	0 (0)	9 (5)	1 (2)	5 (4)	2 (2)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	4 (3)	5 (3)	3 (2)	1 (2)	3 (2)	0 (0)

Table 7.3 Number (percentage) of respondents by places injected in the last month and year

TASMANIA N° injected last month	1995 N=6	1996 N=16	1997 N=22	1998 N=50	1999 N=25	2000 N=23	2001 N=26	2002 N=147	2003 N=110	2004 N=103	2005 N=131	2006 N=145	2007 N=161	2008 N=55	2009 N=111	2010 N=97
Places injected in the last month (%) [more than one could be selected]																
<i>Private places</i>																
Own home	--	--	20 (91)	44 (88)	24 (96)	19 (83)	22 (85)	128 (87)	103 (94)	87 (85)	115 (88)	121 (86)	147 (91)	50 (94)	102 (93)	78 (80)
Friend's home	--	--	13 (59)	23 (46)	8 (32)	8 (35)	7 (27)	53 (36)	43 (39)	35 (34)	51 (39)	52 (37)	72 (45)	13 (25)	40 (36)	27 (28)
Dealer's home	--	--	6 (27)	14 (28)	3 (12)	5 (22)	3 (12)	18 (12)	15 (14)	7 (7)	11 (8)	11 (8)	17 (11)	6 (11)	5 (5)	6 (6)
Commercial injecting room	--	--	1 (5)	1 (2)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)
<i>Public places</i>																
Street, park, beach	--	--	4 (18)	5 (10)	0 (0)	1 (4)	2 (8)	19 (13)	14 (13)	6 (6)	10 (8)	13 (9)	18 (11)	4 (8)	7 (6)	8 (8)
Car	--	--	--	18 (36)	3 (12)	5 (22)	4 (15)	49 (33)	27 (25)	22 (21)	36 (27)	52 (37)	51 (32)	15 (28)	37 (34)	27 (28)
Public toilet	--	--	6 (27)	9 (18)	3 (12)	1 (4)	2 (8)	29 (20)	17 (15)	14 (14)	18 (14)	19 (13)	24 (15)	9 (17)	13 (12)	11 (11)
Squat	--	--	--	--	0 (0)	1 (4)	0 (0)	4 (3)	2 (2)	1 (1)	0 (0)	1 (<1)	5 (3)	0 (0)	2 (2)	1 (1)
Public injecting in last month (%)																
Any public	--	--	8 (36)	22 (44)	5 (20)	5 (22)	4 (15)	66 (45)	40 (36)	30 (29)	43 (33)	59 (41)	58 (36)	20 (36)	43 (39)	32 (33)
All private	--	--	13 (59)	27 (54)	19 (76)	14 (61)	22 (85)	77 (52)	66 (60)	68 (66)	83 (63)	82 (57)	103 (64)	33 (60)	67 (60)	52 (54)
Not reported	--	--	1 (5)	1 (2)	1 (4)	4 (17)	0 (0)	4 (3)	4 (4)	5 (5)	5 (4)	4 (3)	0 (0)	2 (4)	1 (1)	13 (13)

Table 7.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

TASMANIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=6	N=16	N=22	N=50	N=25	N=23	N=26	N=147	N=110	N=103	N=131	N=145	N=161	N=55	N=111	N=97
Use of sterile needles and syringes last month (%)																
All injections	--	--	14 (64)	37 (74)	21 (84)	20 (87)	18 (69)	118 (80)	90 (82)	88 (85)	112 (86)	114 (79)	131 (81)	40 (73)	93 (84)	75 (77)
Most of the time	--	--	7 (32)	11 (22)	2 (8)	2 (9)	7 (27)	25 (17)	18 (16)	10 (10)	19 (15)	26 (18)	27 (17)	13 (24)	15 (14)	10 (10)
Half of the time	--	--	0 (0)	1 (2)	2 (8)	0 (0)	0 (0)	3 (2)	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	2 (2)	0 (0)
Some of the time	--	--	1 (4)	1 (2)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)	0 (0)	1 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)
Not last month	--	--	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	--	--	0 (0)	0 (0)	0 (0)	1 (4)	1 (4)	0 (0)	1 (1)	4 (4)	0 (0)	3 (2)	2 (1)	2 (4)	1 (1)	12 (12)
Re-used someone else's used needle & syringe last month (%)																
None	5 (83)	11 (69)	19 (86)	42 (84)	23 (92)	19 (83)	23 (88)	130 (88)	102 (92)	86 (83)	121 (92)	127 (88)	132 (82)	44 (80)	94 (85)	82 (85)
Once	0 (0)	2 (12)	0 (0)	2 (4)	0 (0)	1 (4)	2 (8)	2 (1)	2 (2)	4 (4)	3 (2)	4 (3)	8 (5)	2 (4)	1 (1)	1 (1)
Twice	0 (0)	3 (19)	1 (5)	3 (6)	1 (4)	0 (0)	0 (0)	5 (4)	2 (2)	5 (5)	2 (2)	5 (3)	3 (2)	2 (4)	4 (4)	1 (1)
3-5 times	1 (17)	0 (0)	2 (9)	1 (2)	1 (4)	0 (0)	0 (0)	6 (5)	0 (0)	2 (2)	2 (2)	0 (0)	6 (4)	3 (5)	7 (6)	0 (0)
> 5 times	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (1)	2 (2)	1 (1)	0 (0)	2 (1)	2 (1)	2 (4)	2 (2)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (13)	1 (4)	2 (1)	2 (2)	5 (5)	0 (0)	7 (5)	10 (6)	2 (4)	3 (3)	13 (13)
Number of people needle & syringe was re-used after last month (%)																
None	5 (83)	11 (69)	19 (86)	42 (84)	23 (92)	19 (83)	23 (88)	130 (88)	99 (90)	86 (83)	114 (87)	127 (88)	132 (82)	44 (80)	94 (85)	82 (85)
One	0 (0)	2 (12)	3 (14)	5 (10)	2 (8)	0 (0)	1 (4)	10 (7)	4 (4)	5 (5)	7 (5)	5 (3)	6 (4)	3 (5)	3 (3)	2 (2)
Two	1 (17)	3 (19)	0 (0)	1 (2)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Three to five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)	1 (<1)	0 (0)	1 (2)	1 (1)	0 (0)
More than five	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	1 (<1)	0 (0)	1 (1)	0 (0)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	5 (4)	1 (<1)	4 (2)	1 (2)	3 (3)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (13)	2 (8)	2 (8)	5 (4)	8 (8)	4 (3)	11 (8)	18 (11)	6 (11)	9 (8)	13 (13)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]																
Regular sex partner	--	--	2 (9)	4 (8)	1 (4)	0 (0)	1 (4)	9 (6)	5 (5)	5 (5)	5 (4)	5 (3)	7 (4)	4 (7)	4 (4)	5 (5)
Casual sex partner	--	--	0 (0)	1 (2)	0 (0)	0 (0)	1 (4)	1 (1)	1 (1)	0 (0)	0 (0)	1 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)
Close friend	--	--	0 (0)	3 (6)	0 (0)	0 (0)	1 (4)	1 (1)	0 (0)	3 (3)	4 (3)	2 (1)	2 (1)	2 (4)	1 (1)	1 (1)
Acquaintance	--	--	0 (0)	2 (4)	0 (0)	1 (4)	0 (0)	2 (1)	0 (0)	0 (0)	1 (1)	1 (<1)	2 (1)	0 (0)	1 (1)	0 (0)
Other	--	--	1 (5)	0 (0)	1 (4)	3 (13)	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)

Table 7.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

TASMANIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=6	N=16	N=22	N=50	N=25	N=23	N=26	N=147	N=110	N=103	N=131	N=145	N=161	N=55	N=111	N=97
Equipment used after someone else last month (%) [more than one could be selected]																
Spoon	--	--	--	--	4 (16)	2 (9)	6 (23)	17 (12)	13 (12)	6 (6)	9 (7)	11 (8)	16 (11)	4 (9)	6 (6)	9 (9)
Water	--	--	--	--	2 (8)	2 (9)	4 (15)	12 (8)	9 (8)	10 (10)	18 (14)	15 (11)	17 (11)	5 (11)	7 (7)	12 (12)
Filter	--	--	--	--	2 (8)	1 (4)	4 (15)	6 (4)	4 (4)	4 (4)	9 (7)	3 (2)	10 (7)	0 (0)	6 (6)	6 (6)
Drug mix	--	--	--	--	0 (0)	1 (4)	4 (15)	13 (9)	7 (6)	4 (4)	11 (8)	6 (4)	5 (3)	1 (2)	3 (3)	4 (4)
Tourniquet	--	--	--	--	3 (12)	2 (9)	5 (19)	19 (13)	9 (8)	8 (8)	12 (9)	12 (8)	12 (8)	7 (16)	7 (7)	--
None	--	--	--	--	--	--	--	--	--	--	--	98 (69)	112 (75)	36 (82)	86 (84)	67 (69)
Injected by someone after that person injected themselves or others last month (%)																
No	--	--	--	--	20 (80)	16 (70)	19 (73)	117 (80)	91 (83)	86 (83)	110 (84)	111 (77)	130 (81)	47 (85)	83 (75)	76 (78)
Yes	--	--	--	--	5 (20)	4 (17)	6 (23)	21 (16)	16 (14)	11 (11)	14 (11)	27 (19)	21 (13)	4 (7)	27 (24)	8 (8)
Not reported	--	--	--	--	0 (0)	3 (13)	1 (4)	6 (4)	3 (3)	6 (6)	7 (5)	7 (5)	10 (6)	4 (7)	1 (1)	13 (13)

Table 7.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

TASMANIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=6	N=18	N=23	N=51	N=25	N=27	N=28	N=151	N=118	N=107	N=137	N=150	N=168	N=57	N=122	N=106
Sex with a regular partner last month (%)																
No	--	--	--	--	--	--	--	--	--	--	45 (33)	55 (37)	63 (38)	23 (40)	52 (43)	59 (56)
Yes	--	--	--	--	--	--	--	--	--	--	88 (64)	91 (61)	103 (61)	34 (60)	59 (48)	43 (41)
Not reported	--	--	--	--	--	--	--	--	--	--	4 (3)	4 (3)	2 (1)	0 (0)	11 (9)	4 (4)
Condom used with regular partner last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=88	N=91	N=103	N=34	N=59	N=59
Sometimes	--	--	--	--	--	--	--	--	--	--	67 (76)	70 (77)	74 (72)	21 (62)	51 (86)	44 (75)
Every time	--	--	--	--	--	--	--	--	--	--	9 (10)	9 (10)	15 (15)	5 (15)	1 (2)	7 (12)
Not reported	--	--	--	--	--	--	--	--	--	--	3 (3)	8 (9)	9 (9)	7 (21)	4 (7)	6 (10)
Sex with other partner(s) last month (%)																
No	--	--	--	--	--	--	--	--	--	--	113 (82)	132 (88)	145 (86)	48 (84)	86 (70)	94 (89)
Yes	--	--	--	--	--	--	--	--	--	--	21 (15)	9 (6)	16 (10)	7 (12)	19 (16)	7 (7)
Not reported	--	--	--	--	--	--	--	--	--	--	3 (2)	9 (6)	7 (4)	2 (4)	17 (14)	5 (5)

Table 7.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

TASMANIA N° surveyed	1995 N=6	1996 N=18	1997 N=23	1998 N=51	1999 N=25	2000 N=27	2001 N=28	2002 N=151	2003 N=118	2004 N=107	2005 N=137	2006 N=150	2007 N=168	2008 N=55	2009 N=122	2010 N=106	
Condom used with other partner(s) last month (%)																	
Never	--	--	--	--	--	--	--	--	--	--	N=21 7 (33)	N=9 4 (44)	N=16 7 (44)	N=7 2 (29)	N=19 4 (21)	N=7 4 (57)	
Sometimes	--	--	--	--	--	--	--	--	--	--	6 (29)	3 (33)	5 (31)	2 (29)	5 (26)	1 (14)	
Every time	--	--	--	--	--	--	--	--	--	--	7 (33)	2 (22)	3 (19)	3 (43)	9 (47)	2 (29)	
Not reported	--	--	--	--	--	--	--	--	--	--	1 (5)	0 (0)	1 (6)	0 (0)	1 (5)	0 (0)	
Sex last month (%)																	
No	1 (17)	4 (22)	7 (30)	12 (24)	7 (28)	6 (22)	9 (32)	36 (24)	28 (24)	32 (30)	--	--	--	--	--	--	
Yes	5 (83)	14 (78)	16 (70)	39 (76)	18 (72)	20 (74)	19 (68)	113 (75)	90 (76)	70 (65)	--	--	--	--	--	--	
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	2 (1)	0 (0)	5 (5)	--	--	--	--	--	--	
Condom use at last sex (%)																	
No	3 (50)	12 (67)	19 (83)	41 (80)	20 (80)	19 (70)	21 (75)	110 (73)	87 (74)	72 (67)	--	--	--	--	--	--	
Yes	2 (33)	2 (11)	4 (17)	10 (20)	4 (16)	7 (26)	7 (25)	38 (25)	31 (26)	30 (28)	--	--	--	--	--	--	
Not reported	1 (17)	4 (22)	0 (0)	0 (0)	1 (4)	1 (4)	0 (0)	3 (2)	0 (0)	5 (5)	--	--	--	--	--	--	
Condom use with regular sex partner(s) last month (%)																	
No	--	--	--	--	--	--	--	51 (75)	44 (71)	37 (74)	--	--	--	--	--	--	
Sometimes	--	--	--	--	--	--	--	7 (10)	4 (6)	3 (6)	--	--	--	--	--	--	
Always	--	--	--	--	--	--	--	10 (15)	14 (23)	10 (20)	--	--	--	--	--	--	
Condom use with new sex partner(s) last month (%)																	
No	--	--	--	--	--	--	--	24 (59)	32 (65)	14 (52)	--	--	--	--	--	--	
Sometimes	--	--	--	--	--	--	--	5 (13)	4 (8)	3 (11)	--	--	--	--	--	--	
Always	--	--	--	--	--	--	--	11 (28)	13 (27)	10 (37)	--	--	--	--	--	--	
Condom use with casual sex partner(s) last month (%)																	
No	--	--	--	--	--	--	--	20 (47)	25 (66)	17 (68)	--	--	--	--	--	--	
Sometimes	--	--	--	--	--	--	--	7 (17)	3 (8)	1 (4)	--	--	--	--	--	--	
Always	--	--	--	--	--	--	--	15 (36)	10 (26)	7 (28)	--	--	--	--	--	--	
Sex work last month (%)																	
No	6 (100)	18 (100)	22 (96)	51 (100)	23 (92)	26 (96)	27 (96)	140 (93)	113 (96)	93 (87)	129 (94)	134 (89)	157 (93)	54 (95)	107 (88)	101 (95)	
Yes	0 (0)	0 (0)	1 (4)	0 (0)	1 (4)	0 (0)	0 (0)	5 (3)	5 (4)	10 (9)	4 (3)	5 (3)	3 (2)	2 (4)	2 (2)	2 (2)	
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	1 (4)	1 (4)	6 (4)	0 (0)	4 (4)	4 (3)	11 (7)	8 (5)	1 (2)	13 (11)	3 (3)	
Condom used at last sex work (%)																	
Yes	--	--	--	--	--	--	--	--	2 (40)	5 (56)	0 (0)	4 (80)	3 (100)	1 (100)	1 (50)	1 (50)	

Table 7.6 Number (percentage) of respondents by previous testing for HIV, HBV, HCV infection, HBV vaccination and HCV treatment by year

TASMANIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=6	N=18	N=23	N=51	N=25	N=27	N=28	N=151	N=118	N=107	N=137	N=150	N=168	N=57	N=122	N=106
Previous HIV test (%)																
Yes, last year	4 (66)	14 (78)	13 (57)	36 (71)	12 (48)	18 (67)	17 (61)	103 (68)	76 (64)	58 (54)	61 (45)	71 (47)	92 (55)	35 (61)	50 (41)	43 (41)
> 1 year ago	1 (17)	1 (6)	7 (30)	11 (21)	10 (40)	6 (22)	9 (32)	36 (24)	22 (19)	28 (26)	49 (36)	50 (33)	54 (32)	16 (28)	41 (34)	42 (40)
Never tested	0 (0)	0 (0)	1 (4)	3 (6)	3 (12)	2 (7)	2 (7)	12 (8)	20 (17)	18 (17)	25 (18)	25 (17)	22 (13)	5 (9)	18 (15)	15 (14)
Not reported	1 (17)	3 (17)	2 (9)	1 (2)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	3 (3)	2 (1)	4 (3)	0 (0)	1 (2)	13 (11)	6 (6)
Self report HBV infection (%)																
No	6 (100)	16 (89)	15 (65)	43 (84)	20 (80)	20 (74)	22 (78)	119 (78)	98 (83)	80 (75)	104 (76)	122 (81)	130 (77)	--	--	--
Yes	0 (0)	2 (11)	6 (26)	6 (12)	3 (12)	3 (11)	3 (11)	28 (19)	11 (9)	16 (15)	14 (10)	14 (9)	27 (16)	--	--	--
Don't know	--	--	2 (9)	2 (4)	1 (4)	3 (11)	3 (11)	4 (3)	8 (7)	7 (6)	15 (11)	10 (7)	11 (7)	--	--	--
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	1 (4)	0 (0)	0 (0)	1 (1)	4 (4)	4 (3)	4 (3)	0 (0)	--	--	--
Self report HBV vaccination (%)																
No	4 (67)	12 (67)	12 (52)	26 (51)	16 (64)	14 (52)	7 (25)	58 (38)	34 (29)	46 (43)	50 (37)	39 (26)	56 (33)	--	--	--
Yes	1 (17)	6 (33)	8 (35)	18 (35)	7 (28)	12 (44)	19 (68)	78 (52)	73 (62)	53 (50)	70 (51)	86 (57)	99 (59)	--	--	--
Don't know	--	--	3 (13)	7 (14)	1 (4)	0 (0)	1 (4)	13 (9)	11 (9)	6 (6)	13 (9)	21 (14)	11 (7)	--	--	--
Not reported	1 (17)	0 (0)	0 (0)	0 (0)	1 (4)	1 (4)	1 (4)	2 (1)	0 (0)	2 (2)	4 (3)	4 (3)	2 (1)	--	--	--
Previous HCV test (%)																
Yes, ever	5 (83)	14 (78)	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Yes, last year	--	--	15 (65)	34 (66)	15 (60)	17 (63)	14 (50)	98 (65)	82 (69)	65 (61)	70 (51)	81 (54)	99 (59)	37 (65)	71 (58)	56 (53)
> 1 year ago	--	--	6 (26)	8 (16)	6 (24)	7 (26)	8 (29)	37 (24)	22 (19)	23 (21)	43 (31)	44 (29)	53 (32)	17 (30)	37 (30)	36 (34)
Never tested	1 (17)	4 (22)	2 (9)	8 (16)	4 (16)	2 (7)	6 (21)	15 (10)	14 (12)	17 (16)	23 (17)	22 (15)	16 (10)	3 (5)	8 (7)	10 (9)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	1 (4)	0 (0)	1 (1)	0 (0)	2 (2)	1 (1)	3 (2)	0 (0)	1 (2)	6 (5)	4 (4)
Any treatment for HCV (%)																
Interferon/+Ribavirin	--	--	--	--	0 (0)	0 (0)	0 (0)	1 (2)	2 (4)	1 (2)	1 (1)	5 (8)	7 (10)	0 (0)	6 (9)	2 (4)
Other	--	--	--	--	1 (14)	0 (0)	0 (0)	2 (4)	2 (4)	0 (0)	1 (1)	2 (3)	1 (1)	1 (3)	1 (1)	1 (2)
No treatment	--	--	--	--	6 (86)	8 (100)	8 (100)	53 (95)	46 (92)	47 (98)	70 (97)	51 (88)	59 (88)	29 (97)	61 (90)	40 (83)
Not reported	--	--	--	--	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Current treatment for HCV (%)																
Interferon +/ Ribavirin	--	--	--	--	0	0	0	0	0	0	0	0	0	0	0	0
Other	--	--	--	--	0	0	0	0	0	0	0	0	0	0	0	0

Table 7.7 Number (percentage) of respondents by treatment for drug use and year

TASMANIA N° surveyed	1995 N=6	1996 N=18	1997 N=23	1998 N=51	1999 N=25	2000 N=27	2001 N=28	2002 N=151	2003 N=118	2004 N=107	2005 N=137	2006 N=150	2007 N=168	2008 N=57	2009 N=122	2010 N=106	
Ever any treatment/therapy for drug use (%)																	
No	3 (50)	10 (56)	4 (17)	16 (31)	9 (36)	9 (33)	5 (18)	26 (17)	32 (27)	34 (32)	50 (37)	51 (34)	46 (27)	13 (23)	31 (25)	28 (26)	
Yes	3 (50)	8 (44)	19 (83)	35 (69)	16 (64)	17 (73)	23 (82)	125 (83)	86 (73)	73 (68)	85 (62)	95 (63)	120 (71)	43 (75)	88 (72)	77 (73)	
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	4 (3)	2 (1)	1 (2)	3 (2)	1 (1)	
History of methadone maintenance treatment (%)																	
Current	2 (33)	4 (22)	14 (61)	23 (45)	12 (48)	12 (44)	20 (72)	79 (52)	57 (48)	48 (45)	49 (36)	52 (35)	66 (39)	24 (42)	47 (39)	44 (42)	
Previous	1 (17)	2 (11)	3 (13)	7 (14)	3 (12)	3 (11)	2 (7)	26 (17)	29 (25)	15 (14)	19 (14)	24 (16)	41 (24)	12 (21)	24 (20)	19 (18)	
Never	3 (50)	12 (67)	6 (26)	21 (41)	1 (4)	11 (41)	6 (21)	45 (30)	32 (27)	43 (40)	67 (49)	70 (47)	61 (36)	21 (37)	46 (38)	40 (38)	
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	9 (36)	1 (4)	0 (0)	1 (1)	0 (0)	1 (1)	2 (1)	4 (3)	0 (0)	0 (0)	5 (4)	3 (3)	
History of other pharmacotherapy treatment (%)																	
Current	--	--	--	--	--	1 (4)	1 (4)	6 (4)	6 (5)	2 (2)	6 (4)	3 (2)	10 (6)	5 (9)	8 (7)	7 (7)	
Previous	--	--	--	--	--	0 (0)	3 (10)	12 (8)	10 (8)	9 (8)	10 (7)	14 (9)	14 (8)	10 (18)	28 (23)	25 (24)	
Never	--	--	--	--	--	25 (92)	23 (82)	130 (86)	100 (85)	95 (89)	120 (88)	127 (85)	141 (84)	39 (68)	83 (68)	73 (69)	
Not reported	--	--	--	--	--	1 (4)	1 (4)	31 (2)	2 (2)	1 (1)	1 (1)	6 (4)	3 (2)	3 (5)	3 (2)	1 (1)	

Table 7.8 Number (percentage) of respondents by source of needle and syringe acquisition in the month prior to survey and year

TASMANIA N° injected last mth	1995 N=6	1996 N=16	1997 N=22	1998 N=50	1999 N=25	2000 N=23	2001 N=26	2002 N=147	2003 N=110	2004 N=103	2005 N=131	2006 N=145	2007 N=161	2008 N=55	2009 N=111	2010 N=97	
Needle/syringe acquisition in the last month (%) [more than one could be selected]																	
Needle Syringe Program	--	--	--	--	23 (92)	18 (78)	24 (92)	140 (95)	108 (98)	98 (95)	123 (94)	130 (90)	128 (80)	54 (98)	73 (66)	96 (99)	
Pharmacy	--	--	--	--	4 (16)	7 (30)	8 (31)	55 (37)	34 (31)	27 (26)	50 (38)	72 (50)	18 (11)	15 (27)	21 (19)	9 (9)	
Personal Sources	--	--	--	--	--	--	--	--	--	--	--	--	15 (9)	--	15 (14)	3 (3)	
Vending Machine	--	--	--	--	--	--	--	--	--	--	--	--	3 (2)	--	3 (3)	0 (0)	
Other sources	--	--	--	--	--	--	--	--	--	--	--	--	0 (0)	--	1 (1)	0 (0)	
Onward supply of syringes in last month (%)																	
Yes, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	44 (27)	--	31 (28)	33 (34)	
No, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	94 (58)	--	49 (44)	64 (66)	
Not reported	--	--	--	--	--	--	--	--	--	--	--	--	23 (14)	--	31 (28)	0 (0)	

HIV ANTIBODY PREVALENCE

Table 7.9 HIV antibody prevalence by gender and year

TASMANIA	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
1996	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)
1997	16	1 (6.3)	4	0 (0.0)	20	1 (5.0)
1998	35	1 (2.9)	8	0 (0.0)	43	1 (2.3)
1999	18	0 (0.0)	6	0 (0.0)	24	0 (0.0)
2000	17	1 (5.9)	8	0 (0.0)	25	1 (4.0)
2001	21	1 (4.8)	6	0 (0.0)	27	1 (3.7)
2002	96	0 (0.0)	50	0 (0.0)	148	0 (0.0)
2003	70	0 (0.0)	46	0 (0.0)	117	0 (0.0)
2004	65	0 (0.0)	39	0 (0.0)	105	0 (0.0)
2005	86	0 (0.0)	51	0 (0.0)	137	0 (0.0)
2006	94	0 (0.0)	56	0 (0.0)	150	0 (0.0)
2007	110	0 (0.0)	56	0 (0.0)	166	0 (0.0)
2008	33	0 (0.0)	73	0 (0.0)	57	0 (0.0)
2009	73	0 (0.0)	47	0 (0.0)	121	0 (0.0)
2010	68	0 (0.0)	38	0 (0.0)	106	0 (0.0)
χ^2 trend p value		0.002		--		<0.001

HCV ANTIBODY PREVALENCE

Table 7.10 HCV antibody prevalence by gender and year

TASMANIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	2	2 (100)	2	1 (50)	4	3 (75)
1996	10	2 (20)	7	0 (0)	17	2 (12)
1997	16	7 (44)	5	4 (80)	21	11 (52)
1998	35	14 (40)	8	4 (50)	43	18 (42)
1999	18	7 (39)	6	4 (67)	24	11 (46)
2000	17	9 (53)	8	1 (13)	25	10 (40)
2001	22	8 (36)	6	2 (33)	28	10 (36)
2002	96	47 (49)	50	18 (36)	148	66 (45)
2003	70	36 (51)	46	31 (67)	117	67 (57)
2004	66	30 (45)	39	20 (51)	106	50 (47)
2005	86	51 (59)	51	30 (59)	137	81 (59)
2006	93	53 (57)	55	32 (58)	148	85 (57)
2007	91	52 (57)	43	30 (70)	134	82 (61)
2008	32	26 (81)	24	19 (79)	56	45 (90)
2009	73	38 (52)	45	24 (53)	119	63 (53)
2010	68	30 (44)	38	18 (47)	106	48 (45)
χ^2 trend p value		0.021		0.021		<0.001

Table 7.11 HCV antibody prevalence by sexual identity, gender and year

TASMANIA	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heterosexual	1	0 (0)	1	0 (0)	2	1 (50)
Bisexual	1	0 (0)	1	1 (100)	2	2 (100)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
1996						
Heterosexual	8	2 (25)	5	0 (0)	13	2 (15)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	2	0 (0)	2	0 (0)	4	0 (0)
1997						
Heterosexual	13	6 (46)	3	2 (67)	16	8 (50)
Bisexual	2	1 (50)	1	1 (100)	3	2 (67)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
1998						
Heterosexual	30	13 (43)	6	3 (50)	36	16 (44)
Bisexual	2	0 (0)	2	1 (50)	4	1 (25)
Homosexual	2	1 (50)	0	0 (0)	2	1 (50)
1999						
Heterosexual	15	6 (40)	4	2 (50)	19	8 (42)
Bisexual	1	0 (0)	2	2 (100)	3	2 (67)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
2000						
Heterosexual	12	8 (67)	6	1 (17)	18	9 (50)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	2	0 (0)	0	0 (0)	2	0 (0)
2001						
Heterosexual	15	6 (40)	5	2 (40)	20	8 (40)
Bisexual	1	1 (100)	1	0 (0)	2	1 (50)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
2002						
Heterosexual	81	41 (51)	37	13 (35)	119	55 (46)
Bisexual	3	2 (67)	6	3 (50)	9	5 (56)
Homosexual	1	0 (0)	3	1 (33)	4	1 (25)
2003						
Heterosexual	55	30 (55)	37	25 (68)	93	55 (59)
Bisexual	5	3 (60)	4	3 (75)	9	6 (67)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
2004						
Heterosexual	59	28 (47)	34	17 (50)	93	45 (48)
Bisexual	1	1 (100)	4	3 (75)	5	4 (80)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
2005						
Heterosexual	82	48 (59)	42	26 (62)	124	74 (60)
Bisexual	3	2 (67)	2	0 (0)	5	2 (40)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
2006						
Heterosexual	86	51 (59)	43	23 (53)	129	74 (57)
Bisexual	5	2 (40)	8	7 (88)	13	9 (69)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
2007						
Heterosexual	83	46 (55)	28	18 (64)	111	64 (58)
Bisexual	3	2 (67)	9	7 (78)	12	9 (75)
Homosexual	5	4 (80)	4	4 (100)	9	8 (89)
2008						
Heterosexual	31	25 (81)	14	11 (79)	45	36 (80)
Bisexual	0	0 (0)	6	5 (83)	6	5 (83)
Homosexual	1	1 (100)	2	2 (100)	3	3 (100)
2009						
Heterosexual	64	33 (52)	33	18 (55)	98	52 (53)
Bisexual	4	3 (75)	8	5 (63)	12	8 (67)
Homosexual	4	2 (50)	1	0 (0)	5	2 (40)
2010						
Heterosexual	66	28 (42)	30	15 (50)	96	43 (45)
Bisexual	0	0 (0)	4	2 (50)	4	2 (50)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
2010 p value		--		1.000		1.000

Table 7.12 HCV antibody prevalence by age group, gender and year

TASMANIA	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	0	0 (0)	1	1 (100)	1	1 (100)
25-34 years	2	0 (0)	1	0 (0)	3	2 (67)
35+ years	0	0 (0)	0	0 (0)	0	0 (0)
1996						
<25 years	6	1 (17)	5	0 (0)	11	1 (9)
25-34 years	3	0 (0)	2	0 (0)	5	0 (0)
35+ years	1	1 (100)	0	0 (0)	1	1 (100)
1997						
<25 years	2	0 (0)	2	1 (50)	4	1 (25)
25-34 years	11	6 (55)	1	1 (100)	12	7 (58)
35+ years	3	1 (33)	2	2 (100)	5	3 (60)
1998						
<25 years	13	0 (0)	5	2 (40)	18	2 (11)
25-34 years	16	9 (56)	3	2 (67)	19	11 (58)
35+ years	6	5 (83)	0	0 (0)	6	5 (83)
1999						
<25 years	5	0 (0)	1	0 (0)	6	0 (0)
25-34 years	11	6 (55)	3	2 (67)	14	8 (57)
35+ years	2	1 (50)	2	2 (100)	4	3 (75)
2000						
<25 years	3	0 (0)	4	0 (0)	7	0 (0)
25-34 years	5	3 (60)	2	0 (0)	7	3 (43)
35+ years	9	6 (67)	2	1 (50)	11	7 (64)
2001						
<25 years	5	0 (0)	3	2 (67)	8	2 (25)
25-34 years	14	7 (50)	3	0 (0)	17	7 (41)
35+ years	3	1 (33)	0	0 (0)	3	1 (33)
2002						
<25 years	31	11 (35)	21	7 (33)	53	18 (34)
25-34 years	37	20 (54)	23	10 (43)	61	31 (51)
35+ years	28	16 (57)	6	1 (17)	34	17 (50)
2003						
<25 years	20	5 (25)	16	9 (56)	36	14 (39)
25-34 years	35	19 (54)	17	13 (76)	53	32 (60)
35+ years	15	12 (80)	13	9 (69)	28	21 (75)
2004						
<25 years	7	2 (29)	6	2 (33)	13	4 (31)
25-34 years	33	14 (42)	17	9 (53)	50	23 (46)
35+ years	26	14 (54)	16	9 (56)	42	23 (55)
2005						
<25 years	12	6 (50)	11	4 (36)	23	10 (43)
25-34 years	44	25 (57)	24	15 (63)	68	40 (59)
35+ years	30	20 (67)	16	11 (69)	46	31 (67)
2006						
<25 years	8	2 (25)	12	5 (42)	20	7 (35)
25-34 years	41	21 (51)	24	14 (58)	65	35 (54)
35+ years	44	30 (68)	19	13 (68)	63	43 (68)
2007						
<25 years	3	3 (100)	7	3 (43)	10	6 (60)
25-34 years	39	21 (54)	18	14 (78)	57	35 (61)
35+ years	49	28 (57)	18	13 (72)	67	41 (61)
2008						
<25 years	2	2 (100)	1	1 (100)	3	3 (100)
25-34 years	10	8 (80)	14	11 (79)	24	19 (79)
35+ years	20	16 (80)	9	19 (79)	29	23 (79)
2009						
<25 years	9	4 (44)	3	0 (0)	12	4 (33)
25-34 years	29	12 (41)	30	18 (60)	59	30 (51)
35+ years	35	22 (63)	12	6 (50)	48	29 (60)
2010						
<25 years	2	0 (0)	5	2 (40)	7	2 (29)
25-34 years	30	12 (40)	13	7 (54)	43	19 (44)
35+ years	36	18 (50)	20	9 (45)	56	27 (48)
2010 p value		0.442		0.906		0.677

Table 7.13 HCV antibody prevalence by time since first injection, gender and year

TASMANIA	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<3 years	0	0 (0)	1	1 (100)	1	1 (100)
3-10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	2	2 (100)	1	0 (0)	3	2 (67)
1996						
<3 years	2	1 (50)	2	0 (0)	4	1 (25)
3-10 years	5	0 (0)	4	0 (0)	9	0 (0)
11+ years	3	1 (33)	1	0 (0)	4	1 (25)
1997						
<3 years	3	0 (0)	0	0 (0)	3	0 (0)
3-10 years	5	2 (40)	3	2 (67)	8	4 (50)
11+ years	8	5 (63)	2	2 (100)	10	7 (70)
1998						
<3 years	4	0 (0)	3	0 (0)	7	0 (0)
3-10 years	14	2 (14)	4	3 (75)	18	5 (28)
11+ years	16	11 (69)	1	1 (100)	17	12 (71)
1999						
<3 years	2	0 (0)	0	0 (0)	2	0 (0)
3-10 years	8	2 (25)	5	3 (60)	13	5 (38)
11+ years	8	5 (63)	1	1 (100)	9	6 (67)
2000						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3-10 years	8	3 (38)	5	0 (0)	13	3 (23)
11+ years	8	6 (75)	2	1 (50)	10	7 (70)
2001						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3-10 years	10	2 (20)	4	2 (50)	14	4 (29)
11+ years	11	6 (55)	2	0 (0)	13	6 (46)
2002						
<3 years	6	2 (33)	7	4 (57)	13	6 (46)
3-10 years	44	16 (36)	26	8 (31)	71	24 (34)
11+ years	44	27 (61)	17	6 (35)	62	34 (55)
2003						
<3 years	6	1 (17)	4	1 (25)	10	2 (20)
3-10 years	37	15 (41)	24	20 (83)	62	35 (56)
11+ years	26	20 (77)	18	10 (56)	44	30 (68)
2004						
<3 years	4	0 (0)	4	1 (25)	8	1 (13)
3-10 years	21	8 (38)	16	10 (63)	37	18 (49)
11+ years	40	21 (53)	16	9 (56)	56	30 (54)
2005						
<3 years	6	0 (0)	1	0 (0)	7	0 (0)
3-10 years	31	16 (52)	21	9 (43)	52	25 (48)
11+ years	40	31 (78)	28	20 (71)	68	51 (75)
2006						
<3 years	4	1 (25)	4	1 (25)	8	2 (25)
3-10 years	26	13 (50)	27	13 (48)	53	26 (49)
11+ years	60	37 (62)	23	18 (78)	83	55 (66)
2007						
<3 years	5	1 (20)	2	0 (0)	7	1 (14)
3-10 years	20	11 (55)	13	6 (46)	33	17 (52)
11+ years	65	39 (60)	26	22 (85)	91	61 (67)
2008						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3-10 years	5	5 (100)	8	6 (75)	13	11 (85)
11+ years	26	20 (77)	15	12 (80)	41	32 (78)
2009						
<3 years	5	0 (0)	4	1 (25)	9	1 (11)
3-10 years	16	8 (50)	15	6 (40)	31	14 (45)
11+ years	51	29 (57)	22	15 (68)	74	45 (61)
2010						
<3 years	4	0 (0)	0	0 (0)	4	0 (0)
3-10 years	13	5 (38)	12	4 (33)	25	9 (36)
11+ years	51	25 (49)	26	14 (54)	77	39 (51)
2010 p value		0.181		0.307		0.108

Table 7.14 HCV antibody prevalence by drug last injected, time since first injection and year

TASMANIA	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Pharm. opioids	0	0 (0)	1	0 (0)	1	0 (0)
Methamphetamine	1	1 (100)	0	0 (0)	1	1 (100)
Other	0	0 (0)	2	2 (100)	2	2 (100)
1996						
Pharm. opioids	3	1 (33)	3	0 (0)	6	1 (17)
Methamphetamine	1	0 (0)	3	0 (0)	4	0 (0)
Other	0	0 (0)	7	1 (14)	7	1 (14)
1997						
Pharm. opioids	0	0 (0)	4	2 (50)	4	2 (50)
Methamphetamine	2	0 (0)	5	3 (60)	7	3 (43)
Other	1	0 (0)	9	6 (67)	10	6 (60)
1998						
Pharm. opioids	4	0 (0)	5	3 (60)	9	3 (33)
Methamphetamine	2	0 (0)	10	3 (30)	12	3 (25)
Other	0	0 (0)	20	11 (55)	21	12 (57)
1999						
Pharm. opioids	1	0 (0)	4	2 (50)	5	2 (40)
Methamphetamine	1	0 (0)	3	1 (33)	4	1 (25)
Other	0	0 (0)	15	8 (53)	15	8 (53)
2000						
Pharm. opioids	1	0 (0)	5	2 (40)	6	2 (33)
Methamphetamine	0	0 (0)	5	1 (20)	5	1 (20)
Other	1	0 (0)	13	7 (54)	14	7 (50)
2001						
Pharm. opioids	0	0 (0)	8	5 (63)	8	5 (62)
Methamphetamine	1	0 (0)	5	3 (60)	6	3 (50)
Other	0	0 (0)	14	2 (14)	14	2 (14)
2002						
Pharm. opioids	3	2 (67)	21	10 (48)	24	12 (50)
Methamphetamine	5	3 (60)	38	10 (26)	44	14 (32)
Other	5	1 (20)	74	38 (51)	80	40 (50)
2003						
Pharm. opioids	0	0 (0)	27	18 (67)	28	18 (64)
Methamphetamine	7	1 (14)	26	9 (35)	33	10 (30)
Other	3	1 (33)	53	38 (72)	56	39 (70)
2004						
Pharm. opioids	0	0 (0)	20	8 (40)	20	8 (40)
Methamphetamine	4	0 (0)	27	8 (30)	32	8 (25)
Other	3	1 (33)	47	32 (68)	52	34 (65)
2005						
Pharm. opioids	1	0 (0)	24	17 (71)	27	18 (67)
Methamphetamine	6	0 (0)	55	29 (53)	64	30 (47)
Other	0	0 (0)	40	28 (70)	42	29 (69)
2006						
Pharm. opioids	1	1 (100)	21	16 (76)	23	17 (74)
Methamphetamine	6	0 (0)	65	28 (43)	72	28 (39)
Other	1	1 (100)	45	33 (73)	48	36 (75)
2007						
Pharm. opioids	2	1 (50)	33	23 (70)	35	24 (69)
Methamphetamine	4	0 (0)	33	15 (45)	38	16 (42)
Other	1	0 (0)	55	39 (71)	58	41 (71)
2008						
Pharm. opioids	0	0 (0)	12	9 (75)	12	9 (75)
Methamphetamine	0	0 (0)	12	11 (92)	12	11 (92)
Other	1	1 (100)	29	22 (76)	31	24 (77)
2009						
Pharm. opioids	1	0 (0)	30	19 (63)	32	19 (59)
Methamphetamine	7	0 (0)	23	9 (39)	30	9 (30)
Other	1	1 (100)	49	28 (57)	54	32 (59)
2010						
Pharm. opioids	1	0 (0)	34	16 (47)	35	16 (46)
Methamphetamine	2	0 (0)	27	9 (33)	29	9 (31)
Other	1	0 (0)	41	23 (56)	42	23 (55)
2010 p value		--		0.187		0.153

Table 7.15 HCV antibody prevalence by frequency of injection, time since first injection and year

TASMANIA	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Less than daily	1	1 (100)	1	0 (0)	2	1 (50)
Daily or more	0	0 (0)	2	2 (100)	2	2 (100)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
1996						
Less than daily	3	1 (33)	8	1 (13)	11	2 (18)
Daily or more	0	0 (0)	4	0 (0)	4	0 (0)
Not last month	1	0 (0)	1	0 (0)	2	0 (0)
1997						
Less than daily	1	0 (0)	11	5 (45)	12	5 (42)
Daily or more	2	0 (0)	6	5 (83)	8	5 (63)
Not last month	0	0 (0)	1	1 (100)	1	1 (100)
1998						
Less than daily	4	0 (0)	18	8 (44)	22	8 (36)
Daily or more	3	0 (0)	16	9 (56)	20	10 (50)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
1999						
Less than daily	2	0 (0)	10	4 (40)	12	4 (33)
Daily or more	0	0 (0)	12	7 (58)	12	7 (58)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
2000						
Less than daily	2	0 (0)	6	4 (67)	8	4 (50)
Daily or more	0	0 (0)	13	6 (46)	13	6 (46)
Not last month	0	0 (0)	4	0 (0)	4	0 (0)
2001						
Less than daily	1	0 (0)	14	4 (29)	15	4 (27)
Daily or more	0	0 (0)	11	6 (55)	11	6 (55)
Not last month	0	0 (0)	2	0 (0)	2	0 (0)
2002						
Less than daily	7	4 (57)	65	28 (43)	74	34 (46)
Daily or more	5	2 (40)	65	27 (42)	70	29 (41)
Not last month	1	0 (0)	3	3 (100)	4	3 (75)
2003						
Less than daily	7	2 (29)	57	38 (67)	64	40 (63)
Daily or more	3	0 (0)	42	24 (57)	45	24 (53)
Not last month	0	0 (0)	7	3 (43)	8	3 (38)
2004						
Less than daily	5	1 (20)	50	29 (58)	58	31 (53)
Daily or more	3	0 (0)	40	19 (48)	44	19 (43)
Not last month	0	0 (0)	3	0 (0)	3	0 (0)
2005						
Less than daily	5	0 (0)	65	39 (60)	77	42 (55)
Daily or more	2	0 (0)	49	33 (67)	54	35 (65)
Not last month	0	0 (0)	6	4 (67)	6	4 (67)
2006						
Less than daily	4	1 (25)	66	37 (56)	71	39 (55)
Daily or more	4	1 (25)	65	41 (63)	72	43 (60)
Not last month	0	0 (0)	4	2 (50)	4	2 (50)
2007						
Less than daily	3	1 (33)	80	53 (66)	84	55 (65)
Daily or more	3	0 (0)	41	25 (61)	45	26 (58)
Not last month	1	0 (0)	3	0 (0)	5	1 (20)
2008						
Less than daily	0	0 (0)	30	23 (77)	31	24 (77)
Daily or more	1	1 (100)	22	19 (86)	23	20 (87)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
2009						
Less than daily	6	1 (17)	57	34 (60)	65	37 (57)
Daily or more	1	0 (0)	40	23 (58)	44	24 (55)
Not last month	2	0 (0)	5	1 (20)	7	1 (14)
2010						
Less than daily	1	0 (0)	67	30 (45)	68	30 (44)
Daily or more	1	0 (0)	28	16 (57)	29	16 (55)
Not last month	2	0 (0)	7	2 (29)	9	2 (22)
2010 p value		--		0.356		0.220

Table 7.16 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, time since first injection and year

TASMANIA	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
No receptive sharing	1	1 (100)	2	1 (50)	3	2 (67)
Receptive sharing	0	0 (0)	1	1 (100)	1	1 (100)
1996						
No receptive sharing	3	1 (33)	7	1 (14)	10	2 (20)
Receptive sharing	0	0 (0)	5	0 (0)	5	0 (0)
1997						
No receptive sharing	3	0 (0)	14	9 (64)	17	9 (53)
Receptive sharing	0	0 (0)	3	1 (33)	3	1 (33)
1998						
No receptive sharing	6	0 (0)	27	13 (48)	34	14 (41)
Receptive sharing	1	0 (0)	7	4 (57)	8	4 (50)
1999						
No receptive sharing	2	0 (0)	20	11 (55)	22	11 (50)
Receptive sharing	0	0 (0)	2	0 (0)	2	0 (0)
2000						
No receptive sharing	2	0 (0)	15	8 (53)	17	8 (47)
Receptive sharing	0	0 (0)	1	1 (100)	1	1 (100)
2001						
No receptive sharing	0	0 (0)	23	9 (39)	23	9 (39)
Receptive sharing	1	1 (100)	1	0 (0)	2	0 (0)
2002						
No receptive sharing	8	4 (50)	117	54 (46)	127	60 (47)
Receptive sharing	3	2 (67)	12	0 (0)	15	2 (13)
2003						
No receptive sharing	10	2 (20)	91	56 (62)	101	58 (57)
Receptive sharing	0	0 (0)	6	4 (67)	6	4 (67)
2004						
No receptive sharing	7	1 (14)	75	38 (51)	86	40 (47)
Receptive sharing	1	0 (0)	10	6 (60)	11	6 (55)
2005						
No receptive sharing	7	0 (0)	105	67 (64)	121	71 (59)
Receptive sharing	0	0 (0)	6	3 (50)	7	4 (57)
2006						
No receptive sharing	8	2 (25)	113	67 (59)	125	71 (57)
Receptive sharing	0	0 (0)	11	8 (73)	11	8 (73)
2007						
No receptive sharing	5	1 (20)	98	67 (68)	104	69 (66)
Receptive sharing	0	0 (0)	15	6 (40)	16	7 (44)
2008						
No receptive sharing	1	1 (100)	42	34 (81)	43	35 (81)
Receptive sharing	0	0 (0)	8	8 (100)	9	9 (100)
2009						
No receptive sharing	6	1 (17)	82	49 (60)	93	53 (57)
Receptive sharing	1	0 (0)	12	8 (67)	13	8 (62)
2010						
No receptive sharing	1	0 (0)	81	38 (47)	82	38 (46)
Receptive sharing	0	0 (0)	2	2 (100)	2	2 (100)
2010 p value		--		0.229		0.224

Table 7.17 HCV antibody prevalence by imprisonment last year, time since first injection and year

TASMANIA	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
No imprisonment	1	1 (100)	3	2 (67)	4	3 (75)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
1996						
No imprisonment	4	1 (25)	12	1 (8)	16	2 (13)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
1997						
No imprisonment	2	0 (0)	17	11 (65)	19	11 (58)
Imprisonment	0	0 (0)	1	0 (0)	1	0 (0)
1998						
No imprisonment	7	0 (0)	30	15 (50)	37	15 (41)
Imprisonment	0	0 (0)	5	2 (40)	5	2 (40)
1999						
No imprisonment	2	0 (0)	19	10 (53)	21	10 (48)
Imprisonment	0	0 (0)	3	1 (33)	3	1 (33)
2000						
No imprisonment	2	0 (0)	18	7 (39)	20	7 (35)
Imprisonment	0	0 (0)	3	3 (100)	3	3 (100)
2001						
No imprisonment	1	0 (0)	24	7 (29)	25	7 (28)
Imprisonment	0	0 (0)	2	2 (100)	2	2 (100)
2002						
No imprisonment	11	4 (36)	120	53 (44)	133	59 (44)
Imprisonment	1	1 (100)	12	5 (42)	13	6 (46)
2003						
No imprisonment	10	2 (20)	89	53 (60)	100	55 (55)
Imprisonment	0	0 (0)	16	11 (69)	16	11 (69)
2004						
No imprisonment	7	1 (14)	80	39 (49)	90	40 (44)
Imprisonment	1	0 (0)	12	8 (67)	14	9 (64)
2005						
No imprisonment	6	0 (0)	98	60 (61)	113	64 (57)
Imprisonment	0	0 (0)	17	12 (71)	18	13 (72)
2006						
No imprisonment	7	1 (14)	113	62 (55)	124	65 (52)
Imprisonment	1	1 (100)	18	15 (83)	19	16 (84)
2007						
No imprisonment	7	1 (14)	100	60 (60)	110	64 (58)
Imprisonment	0	0 (0)	20	15 (75)	20	15 (75)
2008						
No imprisonment	1	1 (100)	43	33 (77)	44	34 (77)
Imprisonment	0	0 (0)	6	6 (100)	7	7 (100)
2009						
No imprisonment	8	1 (13)	85	48 (56)	96	51 (53)
Imprisonment	0	0 (0)	15	10 (67)	16	10 (63)
2010						
No imprisonment	3	0 (0)	78	29 (37)	81	29 (36)
Imprisonment	0	0 (0)	5	5 (100)	5	5 (100)
2010 p value		--		0.010		0.008

Table 7.18 HCV antibody prevalence by sex work last month, time since first injection and year

TASMANIA	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
No sex work	1	1 (100)	3	2 (67)	4	3 (75)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
1996						
No sex work	4	1 (25)	13	1 (8)	17	2 (12)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
1997						
No sex work	3	0 (0)	17	10 (59)	20	10 (50)
Sex work	0	0 (0)	1	1 (100)	1	1 (100)
1998						
No sex work	7	0 (0)	35	17 (49)	43	18 (42)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
1999						
No sex work	2	0 (0)	20	10 (50)	22	10 (45)
Sex work	0	0 (0)	1	0 (0)	1	0 (0)
2000						
No sex work	2	0 (0)	22	10 (45)	24	10 (42)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
2001						
No sex work	1	0 (0)	26	10 (38)	27	10 (37)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
2002						
No sex work	12	6 (50)	124	57 (46)	138	65 (47)
Sex work	0	0 (0)	4	1 (25)	4	1 (25)
2003						
No sex work	9	2 (22)	102	63 (62)	112	65 (58)
Sex work	1	0 (0)	4	2 (50)	5	2 (40)
2004						
No sex work	8	2 (13)	80	42 (53)	92	44 (48)
Sex work	0	0 (0)	10	4 (40)	10	4 (40)
2005						
No sex work	6	0 (0)	114	71 (62)	129	75 (58)
Sex work	0	0 (0)	3	2 (67)	4	3 (75)
2006						
No sex work	6	2 (33)	123	71 (58)	133	75 (56)
Sex work	1	0 (0)	4	2 (50)	5	2 (40)
2007						
No sex work	7	1 (14)	115	73 (63)	125	77 (62)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
2008						
No sex work	1	1 (100)	51	40 (78)	53	42 (79)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
2009						
No sex work	9	1 (11)	92	54 (59)	104	57 (55)
Sex work	0	0 (0)	1	1 (100)	2	2 (100)
2010						
No sex work	3	0 (0)	98	47 (48)	101	47 (47)
Sex work	0	0 (0)	2	0 (0)	2	0 (0)
2010 p value		--		0.497		0.499

Table 7.19 HCV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year

TASMANIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Non-Indigenous	2	2 (100)	2	1 (50)	4	3 (75)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
1996						
Non-Indigenous	10	2 (20)	6	0 (0)	16	2 (13)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
1997						
Non-Indigenous	15	7 (47)	4	3 (75)	19	10 (53)
Indigenous	1	0 (0)	1	1 (100)	2	1 (50)
1998						
Non-Indigenous	33	13 (39)	7	3 (43)	40	16 (40)
Indigenous	2	1 (50)	0	0 (0)	2	1 (50)
1999						
Non-Indigenous	14	5 (36)	5	3 (60)	19	8 (42)
Indigenous	3	2 (67)	1	1 (100)	4	3 (75)
2000						
Non-Indigenous	17	9 (53)	7	1 (14)	24	10 (42)
Indigenous	0	0 (0)	1	0 (0)	1	0 (0)
2001						
Non-Indigenous	17	5 (29)	6	2 (33)	23	7 (30)
Indigenous	4	2 (50)	0	0 (0)	4	2 (50)
2002						
Non-Indigenous	85	42 (49)	40	18 (45)	126	61 (48)
Indigenous	9	5 (56)	7	0 (0)	17	5 (29)
2003						
Non-Indigenous	60	32 (53)	38	26 (68)	99	58 (59)
Indigenous	7	2 (29)	6	3 (50)	13	5 (38)
2004						
Non-Indigenous	58	27 (47)	36	20 (56)	95	47 (49)
Indigenous	6	3 (50)	2	0 (0)	8	3 (38)
2005						
Non-Indigenous	74	45 (61)	47	26 (55)	121	71 (59)
Indigenous	8	5 (63)	4	4 (100)	12	9 (75)
2006						
Non-Indigenous	73	39 (53)	48	28 (58)	121	67 (55)
Indigenous	17	11 (65)	6	3 (50)	23	14 (61)
2007						
Non-Indigenous	78	44 (56)	35	24 (69)	113	68 (60)
Indigenous	12	8 (67)	7	5 (71)	19	13 (68)
2008						
Non-Indigenous	29	23 (79)	20	16 (80)	49	39 (80)
Indigenous	3	3 (100)	2	1 (50)	5	4 (80)
2009						
Non-Indigenous	61	30 (49)	36	20 (56)	98	51 (52)
Indigenous	9	6 (67)	6	3 (50)	15	9 (60)
2010						
Non-Indigenous	61	27 (44)	33	15 (45)	94	42 (45)
Indigenous	7	3 (43)	5	3 (60)	12	6 (50)
2010 p value		1.000		0.653		0.766

Table 7.20 HCV antibody prevalence by country of birth, gender and year

TASMANIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2003						
Australia	65	31 (48)	44	29 (66)	110	60 (55)
Other	5	5 (100)	2	2 (100)	7	7 (100)
2004						
Australia	59	25 (42)	35	16 (46)	95	41 (43)
Other	5	4 (80)	4	4 (100)	9	8 (89)
2005						
Australia	79	45 (57)	47	27 (57)	126	72 (57)
Other	6	6 (100)	3	2 (67)	9	8 (89)
2006						
Australia	86	47 (55)	50	30 (60)	136	77 (57)
Other	4	3 (75)	4	2 (50)	8	5 (63)
2007						
Australia	86	48 (56)	39	26 (67)	125	74 (59)
Other	5	4 (80)	4	4 (100)	9	8 (89)
2008						
Australia	30	24 (80)	17	13 (76)	47	37 (79)
Other	1	1 (100)	6	5 (83)	7	6 (86)
2009						
Australia	68	36 (53)	40	21 (53)	109	58 (53)
Other	2	1 (50)	4	3 (75)	6	4 (67)
2010						
Australia	65	28 (43)	33	15 (45)	98	43 (44)
Other	3	2 (67)	5	3 (60)	8	5 (63)
2010 p value		0.579		0.653		0.463

Table 7.21 HCV antibody prevalence by language spoken at home by parents, gender and year

TASMANIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2003						
English speaking	66	33 (50)	46	31 (67)	113	64 (57)
Non-English speaking	2	2 (100)	0	0 (0)	2	2 (100)
2004						
English speaking	39	18 (46)	31	15 (48)	71	33 (46)
Non-English speaking	2	1 (50)	1	1 (100)	3	2 (67)
2005						
English speaking	70	40 (57)	45	27 (60)	115	67 (58)
Non-English speaking	16	11 (69)	6	3 (50)	22	14 (64)
2006						
English speaking	81	45 (56)	53	32 (60)	134	77 (57)
Non-English speaking	2	1 (50)	0	0 (0)	2	1 (50)
2007						
English speaking	88	50 (57)	43	30 (70)	131	80 (91)
Non-English speaking	3	2 (67)	0	0 (0)	3	2 (67)
2008						
English speaking	31	25 (81)	22	17 (77)	54	43 (80)
Non-English speaking	0	0 (0)	1	1 (100)	1	1 (100)
2009						
English speaking	70	37 (53)	44	24 (55)	117	63 (54)
Non-English speaking	0	0 (0)	1	0 (0)	1	0 (0)
2010						
English speaking	67	30 (45)	38	18 (47)	105	48 (46)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
2010 p value		1.000		--		1.000

8. VICTORIA


Five Victorian NSP services participated in the ANSPS in 1995, two of which (St Kilda NSP and Melbourne Inner-city Needle Exchange based in Collingwood which is now known as Innerspace) participated in every year between 1995 and 2010, with a third (SHARPS NSP in Frankston) participating in all years except 1999, 2000 and 2001. Two NSP services commenced participation 2007 (North Richmond NSP and Barwon NSP) and have participated every subsequent year to 2010. Appendix 1 provides a detailed breakdown of site participation by state and year. Victorian sample sizes ranged from 120 (in 1995) to 445 (in 2010). Response rates ranged between 20% (in 2006) and 58% (in 2010).

Demographic Characteristics

As observed nationally and in all other jurisdictions, the majority of survey participants in Victoria were male (60% to 70%) and identified as heterosexual (71% to 85%). The proportion of participants from an Indigenous background increased in Victoria from 5% in 1995 to 8% in 2010 (χ^2 trend $p < 0.001$, Table 8.1). The majority of Victorian respondents were born in Australia (79% to 88%) and reported their parents spoke English at home (67% to 93%) across all survey years in which these data were collected.

The median age of Victorian ANSPS respondents ranged between 26 and 29 years between 1995 and 1999, but increased steadily in subsequent years, to a high of 35 years in 2010 (Figure 8.1). As occurred elsewhere, the proportion of young people (aged younger than 25 years) increased during the late 1990s, but declined significantly in later years (χ^2 trend $p < 0.001$), from a high of 42% in 1998 to a low of 6% in 2008. The median age at first injection remained stable at 17 or 18 years across all years between 1995 and 2010 (Table 8.1).

Figure 8.1 Victoria: Median age and proportion young injectors by year




Injecting behaviour

In all survey years, heroin was the drug Victorian ANSPS participants were most likely to report injected most recently. The proportion of participants who reported last injecting heroin was highest in the late 1990s, reaching a peak of 90% of Victorian ANSPS respondents in 1998 (Figure 8.2, Table 8.2). Coinciding with well documented changes in heroin availability in Australia (Maher et al., 2007; Degenhardt et al. 2006; Topp et al., 2003), a dramatic and sudden decline in heroin injection was observed among ANSPS respondents in Victoria in 2001. A further decline was observed nationally and in Victoria in the mid 2000s, with prevalence of heroin injecting declining from 59% in 2004 to 36% in 2006. In 2010, 60% of the Victorian sample reported last injecting heroin.

Methamphetamine was the second most common drug last injected in all survey years. Less than 10% of Victorian participants reported that they had last injected methamphetamine between 1996 and 2000, however prevalence increased in 2001 and remained at between 16% and 35% between 2001 and 2007. Prevalence declined in subsequent years and was 13% in 2009 and 2010.


Figure 8.2 Victoria: Prevalence of heroin and methamphetamine as drug last injected by year



Reports of buprenorphine as the drug last injected were more prevalent in Victoria (range 3% to 11%) than nationally (range 1% to 5%) in all years between 2002 (when reporting of this drug commenced) and 2010 (Table 8.2). Conversely, reports of recent injection of methadone were lower in Victoria (range 0% to 3%) than observed nationally (3% to 19%).


As observed nationally and in other jurisdictions, there was an increase in the proportion of Victorian participants who reported last injecting pharmaceutical opioids over the last decade, from 2% in 2000 to 8% in 2010 (Figure 8.3, χ^2 trend $p < 0.001$). Prevalence of recent injection of this class of drugs was lower in Victoria (range 0% to 8%) than observed nationally (3% to 16%). Recent injection of cocaine or performance and image enhancing drugs was rare in Victoria over the period 1995 to 2010.

Figure 8.3 Victoria: Prevalence of methadone, cocaine and pharmaceutical opioids as drug last injected by year




There was a reduction in the proportion of Victorian ANSPS respondents reporting re-use of needles and syringes (including re-use of one’s own needle/syringe) in the month preceding survey participation between 1997 and 2010 (χ^2 trend $p < 0.001$, Figure 8.4, Table 8.4). However, rates of recent receptive sharing of syringes (use of someone else’s used needle and syringe in the month preceding survey completion) and receptive sharing of ancillary injecting equipment remained stable over the period (χ^2 trend $p = 0.989$ and $p = 0.385$ respectively). As observed nationally, spoons and water were the ancillary items Victorian participants were most likely to report receptively sharing in all survey years (Table 8.4).

Figure 8.4 Victoria: Re-use and receptive sharing of syringes by year



The proportion of Victorian respondents who reported injecting in a public place in the month preceding survey completion increased during the late 1990s, to a peak in 1999 of 79%, which was well above the national prevalence of 55% in that year (Figure 8.5). Prevalence of public injecting was consistently higher in Victoria than observed nationally, but nevertheless declined significantly over the survey period (χ^2 trend $p=0.001$).


Figure 8.5 National and Victoria: Prevalence of public injection by year



HIV prevalence

HIV antibody prevalence in Victoria remained low at 2.1% or less in all years between 1995 and 2010 (Figure 8.6, Table 8.9). Detailed data on HIV antibody prevalence is not presented in this report due to small cell sizes, however the majority (89%) of Victorian HIV antibody positive participants were male, and 57% identified as homosexual or bisexual.


Figure 8.6 Victoria: HIV antibody prevalence by year



HCV prevalence

In Victoria, HCV antibody prevalence was slightly higher than observed nationally in most survey years (Figure 8.7, Table 8.10). As occurred nationally and in most other jurisdictions, HCV antibody prevalence increased significantly over the period 1995 to 2010 (χ^2 trend $p < 0.001$), despite a decline occurring nationally and across Victoria in 2009 (Figure 8.7).

Figure 8.7 National and Victoria: HCV antibody prevalence by year



HCV prevalence was higher in Victoria among older participants (Table 8.12), respondents with a longer injection history (Figure 8.8, Table 8.13) and participants who reported last injecting heroin (Table 3.1).

Figure 8.8 Victoria: HCV antibody prevalence and time since first injection by year




Table 8.1 Number (percentage) of respondents by demographic characteristic and year

VICTORIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Number of sites	5	3	4	4	3	3	4	4	4	5	5	4	6	6	6	5
N° surveyed	N=120	N=195	N=457	N=288	N=214	N=293	N=340	N=265	N=237	N=228	N=194	N=195	N=243	N=308	N=334	N=445
Response rate	25%	45%	44%	35%	26%	43%	39%	23%	25%	42%	44%	20%	33%	36%	--	58%
Gender (%)																
Male	79 (66)	131 (67)	308 (67)	197 (68)	141 (66)	177 (60)	219 (64)	167 (63)	144 (61)	152 (67)	116 (60)	126 (65)	166 (68)	206 (67)	216 (65)	310 (70)
Female	41 (34)	63 (32)	147 (32)	91 (32)	72 (34)	115 (39)	119 (35)	96 (36)	90 (38)	74 (32)	78 (40)	68 (35)	76 (31)	102 (33)	116 (35)	133 (30)
Transgender	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)	2 (<1)	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	2 (<1)	1 (<1)
Not reported	0 (0)	1 (1)	1 (<1)	0 (0)	1 (<1)	1 (<1)	0 (0)	2 (1)	1 (<1)	2 (1)	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	1 (<1)
Sexual identity (%)																
Heterosexual	96 (80)	159 (82)	364 (80)	246 (85)	174 (81)	239 (82)	264 (78)	206 (78)	168 (71)	182 (80)	151 (78)	165 (85)	192 (79)	258 (84)	273 (82)	373 (84)
Bisexual	15 (13)	21 (11)	56 (12)	22 (8)	29 (14)	39 (13)	35 (10)	37 (14)	30 (13)	23 (10)	19 (10)	18 (9)	37 (15)	22 (7)	34 (10)	36 (8)
Homosexual	9 (8)	11 (6)	27 (6)	12 (4)	7 (3)	10 (3)	17 (5)	2 (<1)	14 (6)	12 (5)	12 (6)	4 (2)	8 (3)	7 (2)	8 (2)	8 (2)
Not reported	0 (0)	4 (2)	10 (2)	8 (3)	4 (2)	5 (2)	24 (7)	20 (8)	25 (10)	11 (5)	12 (6)	8 (4)	6 (2)	21 (7)	19 (6)	28 (6)
Age and times since first injection (years)																
<i>Median age</i>	28.5	27	26	26	26	27	28	29	31	30	32	32	33	34	34	35
<i>Age range</i>	17-50	16-53	15-50	14-51	16-47	15-50	16-55	15-54	18-58	16-58	16-53	15-54	14-62	16-65	17-61	18-62
<i>Age group (%)</i>																
<25 years	37 (31)	64 (33)	183 (40)	120 (42)	88 (41)	101 (34)	110 (32)	73 (28)	53 (22)	51 (22)	33 (17)	27 (14)	19 (8)	19 (6)	29 (9)	46 (10)
25+ years	83 (69)	131 (67)	274 (60)	168 (58)	124 (58)	192 (66)	230 (68)	192 (72)	183 (77)	176 (77)	161 (83)	167 (86)	224 (92)	289 (94)	305 (91)	399 (90)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	0 (0)	1 (1)	1 (<1)	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>																
Age range	18	18	18	18	18	18	18	18	18	18	18	18	17	18	18	17
10-40	10-40	11-37	10-45	11-42	11-44	10-40	10-45	10-51	11-48	11-42	11-35	10-41	10-42	10-45	11-51	10-50
N° not reported	0	4	5	3	1	2	8	6	5	5	7	1	6	9	9	9
<i>Median years IDU</i>																
Range	<1-31	<1-37	<1-33	<1-33	<1-27	<1-31	<1-37	<1-37	<1-42	<1-44	<1-37	<1-35	<1-46	<1-40	<1-40	<1-42
<i>Time since first injection</i>																
<3 years	21 (18)	34 (17)	89 (19)	74 (26)	41 (19)	35 (12)	32 (9)	18 (7)	15 (6)	19 (8)	11 (6)	7 (6)	12 (5)	19 (6)	13 (9)	15 (3)
3+ years	99 (83)	157 (81)	363 (79)	211 (73)	171 (80)	256 (87)	300 (88)	241 (91)	216 (91)	204 (90)	172 (89)	174 (89)	225 (93)	280 (91)	312 (93)	421 (95)
Not reported	0 (0)	4 (2)	5 (1)	3 (1)	2 (1)	2 (<1)	8 (2)	6 (2)	6 (3)	5 (2)	11 (6)	14 (7)	6 (2)	9 (3)	9 (3)	9 (2)

Table 8.1 Number (percentage) of respondents by demographic characteristic and year (continued)

VICTORIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=120	N=195	N=457	N=288	N=214	N=293	N=340	N=265	N=237	N=228	N=194	N=195	N=243	N=308	N=334	N=445
Aboriginal and Torres Strait Islander origin (%)																
No	114 (95)	184 (94)	438 (96)	281 (97)	196 (92)	276 (94)	312 (92)	251 (95)	226 (95)	212 (93)	178 (92)	170 (87)	217 (89)	266 (86)	304 (91)	405 (91)
Yes	6 (5)	6 (3)	12 (3)	5 (2)	15 (7)	15 (5)	20 (6)	11 (4)	6 (3)	9 (4)	9 (5)	14 (7)	14 (6)	28 (9)	23 (7)	36 (8)
Not reported	0 (0)	5 (3)	7 (2)	2 (1)	3 (1)	2 (1)	8 (2)	3 (1)	5 (2)	7 (3)	7 (4)	11 (6)	12 (5)	14 (5)	7 (2)	4 (1)
Region/country of birth (%)																
Australia	--	--	--	--	179 (84)	251 (86)	277 (82)	210 (79)	200 (84)	185 (81)	156 (80)	160 (82)	202 (83)	259 (84)	285 (85)	392 (88)
Other Oceania	--	--	--	--	--	12 (4)	11 (3)	15 (6)	11 (5)	5 (2)	9 (5)	4 (2)	5 (2)	5 (2)	8 (2)	9 (2)
Asia	--	--	--	--	3 (1)	4 (1)	5 (1)	5 (2)	2 (1)	9 (4)	3 (2)	2 (1)	7 (3)	10 (3)	7 (2)	7 (2)
UK & Ireland	--	--	--	--	--	17 (6)	17 (5)	17 (6)	14 (6)	11 (5)	11 (6)	15 (8)	12 (5)	20 (6)	12 (4)	13 (3)
Other	--	--	--	--	30 (14)	6 (2)	23 (7)	16 (6)	8 (3)	15 (7)	15 (8)	8 (4)	10 (4)	8 (3)	20 (6)	15 (3)
Not reported	--	--	--	--	2 (1)	3 (1)	7 (2)	2 (1)	2 (1)	3 (1)	0 (0)	6 (3)	7 (3)	6 (2)	2 (<1)	9 (2)
Main language spoken at home by parents (%)																
English	--	--	--	--	179 (84)	252 (86)	287 (84)	231 (87)	217 (92)	154 (67)	158 (81)	171 (88)	221 (91)	270 (88)	303 (91)	412 (93)
Non-English	--	--	--	--	27 (12)	30 (10)	40 (12)	33 (12)	14 (6)	31 (14)	36 (19)	10 (5)	17 (7)	32 (10)	23 (7)	26 (6)
Not reported	--	--	--	--	8 (4)	11 (4)	13 (4)	1 (<1)	6 (2)	43 (19)	0 (0)	14 (7)	5 (2)	6 (2)	8 (2)	7 (2)
Imprisonment last year (%)																
No	103 (86)	169 (89)	391 (86)	245 (85)	170 (79)	228 (78)	259 (76)	204 (77)	192 (81)	185 (81)	162 (84)	161 (83)	195 (80)	241 (78)	285 (85)	319 (72)
Yes	17 (14)	20 (11)	65 (14)	40 (14)	42 (20)	54 (18)	68 (20)	58 (22)	41 (17)	42 (18)	22 (11)	20 (10)	30 (12)	40 (13)	39 (12)	45 (10)
Not reported	0 (0)	0 (0)	1 (<1)	3 (1)	2 (1)	11 (4)	13 (4)	3 (1)	4 (2)	1 (<1)	10 (5)	14 (7)	18 (7)	27 (9)	10 (3)	81 (18)
Injected in prison last year (%)																
N° in prison	N=17	N=20	N=65	N=40	N=42	N=54	N=68	N=58	N=41	N=42	N=22	N=20	N=30	N=40	N=39	N=45
Injected in prison	4 (24)	8 (40)	20 (31)	16 (40)	18 (43)	21 (39)	21 (31)	20 (34)	11 (27)	22 (52)	10 (45)	5 (25)	9 (30)	12 (30)	12 (31)	15 (33)
Frequency of injection last month (%)																
Not last month	11 (9)	6 (3)	23 (5)	8 (3)	12 (6)	13 (4)	27 (8)	17 (6)	16 (6)	13 (6)	12 (6)	10 (5)	11 (5)	21 (7)	21 (6)	30 (7)
Less than weekly	24 (20)	27 (14)	96 (21)	23 (8)	25 (12)	32 (11)	59 (17)	47 (18)	47 (20)	27 (12)	31 (16)	31 (16)	30 (12)	53 (17)	44 (13)	72 (16)
Weekly not daily	41 (34)	68 (34)	75 (16)	64 (22)	42 (20)	60 (20)	79 (23)	57 (22)	52 (22)	68 (30)	41 (21)	47 (24)	53 (22)	61 (20)	69 (21)	101 (23)
Daily or more	44 (37)	93 (48)	262 (57)	193 (67)	134 (63)	186 (64)	168 (50)	141 (53)	120 (51)	118 (52)	110 (57)	106 (54)	143 (59)	167 (54)	196 (59)	235 (53)
Not reported	0 (0)	3 (2)	1 (<1)	0 (0)	1 (<1)	2 (1)	7 (2)	3 (1)	2 (<1)	2 (<1)	0 (0)	1 (<1)	6 (2)	6 (2)	4 (1)	7 (2)

Table 8.2 Number (percentage) of respondents by drug last injected and year

VICTORIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=120	N=195	N=457	N=288	N=214	N=293	N=340	N=265	N=237	N=228	N=194	N=195	N=243	N=308	N=334	N=445
Drug last injected (%)																
Anabolic steroids	1 (1)	1 (1)	2 (<1)	1 (<1)	0 (0)	1 (<1)	2 (1)	6 (2)	0 (0)	4 (2)	0 (0)	1 (<1)	1 (<1)	3 (1)	1 (<1)	1 (<1)
Cocaine	1 (1)	0 (0)	3 (1)	0 (0)	0 (0)	0 (0)	5 (1)	0 (0)	0 (0)	1 (<1)	5 (3)	4 (2)	0 (0)	2 (1)	0 (0)	4 (1)
Heroin	75 (63)	159 (82)	391 (86)	259 (90)	186 (87)	255 (87)	197 (58)	150 (57)	137 (58)	134 (59)	96 (49)	71 (36)	131 (54)	180 (58)	205 (61)	265 (60)
Methadone	1 (1)	2 (1)	2 (<1)	2 (1)	1 (<1)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	3 (2)	3 (2)	6 (2)	8 (3)	9 (3)	13 (3)
Methamphetamine	37 (31)	18 (9)	37 (8)	13 (5)	15 (7)	19 (6)	84 (24)	60 (23)	57 (24)	37 (16)	47 (24)	69 (35)	51 (21)	55 (18)	45 (13)	57 (13)
Pharm. opioids	2 (2)	0 (0)	4 (1)	1 (<1)	2 (1)	5 (2)	9 (3)	6 (2)	8 (3)	7 (3)	7 (4)	10 (5)	8 (3)	22 (7)	21 (6)	34 (8)
Buprenorphine	--	--	--	--	--	--	--	12 (5)	8 (3)	18 (8)	19 (10)	22 (11)	27 (11)	21 (7)	26 (8)	31 (7)
More than one	1 (1)	1 (1)	12 (3)	10 (3)	0 (0)	11 (4)	34 (10)	27 (10)	19 (8)	20 (9)	4 (2)	9 (5)	8 (3)	6 (2)	10 (3)	23 (5)
Other	1 (1)	1 (1)	5 (1)	1 (<1)	2 (1)	0 (0)	3 (3)	2 (1)	7 (3)	1 (<1)	2 (1)	1 (<1)	6 (2)	2 (1)	11 (3)	17 (4)
Not reported	1 (1)	1 (1)	1 (<1)	1 (<1)	8 (4)	2 (1)	6 (2)	1 (<1)	0 (0)	3 (1)	7 (4)	3 (2)	5 (2)	9 (3)	6 (2)	0 (0)

Table 8.3 Number (percentage) of respondents by places injected in the last month and year

VICTORIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=109	N=188	N=433	N=280	N=201	N=278	N=306	N=245	N=219	N=213	N=182	N=184	N=226	N=281	N=309	N=409
Places injected in the last month (%) [more than one could be selected]																
<i>Private places</i>																
Own home	--	--	366 (85)	241 (86)	158 (79)	219 (79)	226 (74)	176 (72)	175 (80)	181 (85)	145 (80)	155 (89)	187 (85)	231 (84)	256 (83)	314 (77)
Friend's home	--	--	239 (55)	136 (49)	91 (46)	119 (43)	144 (47)	96 (39)	96 (44)	104 (49)	77 (42)	80 (46)	100 (46)	112 (41)	117 (38)	188 (46)
Dealer's home	--	--	76 (18)	36 (13)	22 (11)	49 (18)	61 (20)	43 (18)	38 (17)	52 (24)	20 (11)	30 (17)	35 (16)	65 (24)	56 (18)	84 (21)
Commercial injecting room	--	--	8 (2)	6 (2)	1 (1)	4 (1)	1 (<1)	1 (1)	5 (2)	1 (<1)	0 (0)	2 (1)	2 (1)	3 (1)	6 (2)	3 (1)
<i>Public places</i>																
Street, park, beach	--	--	182 (42)	148 (53)	118 (59)	147 (53)	121 (40)	96 (39)	79 (36)	92 (43)	54 (30)	56 (32)	82 (37)	91 (33)	109 (35)	133 (33)
Car	--	--	--	163 (58)	113 (56)	154 (55)	148 (48)	115 (47)	99 (45)	114 (54)	67 (37)	82 (47)	81 (37)	107 (39)	130 (42)	148 (36)
Public toilet	--	--	183 (42)	125 (45)	94 (47)	109 (39)	92 (30)	89 (36)	78 (36)	80 (38)	61 (34)	63 (36)	77 (35)	106 (39)	106 (34)	157 (38)
Squat	--	--	--	--	41 (20)	55 (20)	37 (12)	41 (17)	34 (16)	23 (11)	11 (6)	14 (8)	21 (10)	30 (11)	28 (9)	43 (11)
Public injecting in last month (%)																
Any public	--	--	277 (64)	210 (75)	158 (79)	209 (75)	202 (66)	158 (64)	139 (63)	146 (69)	102 (57)	110 (60)	139 (62)	174 (62)	195 (63)	257 (63)
All private	--	--	148 (34)	65 (23)	37 (18)	56 (20)	104 (34)	71 (29)	72 (33)	57 (27)	62 (35)	65 (35)	80 (35)	100 (36)	113 (37)	126 (31)
Not reported	--	--	8 (2)	5 (2)	6 (3)	13 (5)	0 (0)	17 (7)	8 (4)	10 (5)	15 (8)	9 (5)	7 (3)	7 (2)	1 (<1)	26 (6)

Table 8.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

VICTORIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=109	N=188	N=433	N=280	N=201	N=278	N=306	N=245	N=219	N=213	N=182	N=184	N=226	N=281	N=309	N=409
Use of sterile needles and syringes last month (%)																
All injections	--	276 (64)	151 (54)	107 (53)	189 (68)	231 (75)	179 (73)	164 (75)	141 (66)	131 (72)	117 (64)	150 (66)	186 (66)	224 (72)	289 (71)	
Most of the time	--	135 (31)	104 (37)	79 (39)	66 (24)	57 (19)	50 (20)	45 (20)	57 (27)	47 (26)	48 (26)	64 (28)	76 (27)	69 (22)	76 (19)	
Half of the time	--	7 (2)	14 (5)	6 (3)	9 (3)	2 (1)	7 (3)	4 (2)	8 (4)	3 (2)	8 (4)	3 (1)	7 (2)	7 (2)	5 (1)	
Some of the time	--	4 (1)	6 (2)	3 (1)	3 (1)	6 (2)	0 (0)	4 (2)	2 (1)	0 (0)	5 (3)	2 (1)	6 (2)	5 (2)	6 (1)	
Not last month	--	5 (1)	0 (0)	2 (1)	5 (2)	0 (0)	3 (1)	0 (0)	1 (<1)	1 (1)	2 (1)	0 (0)	0 (0)	0 (0)	0 (0)	
Not reported	--	6 (1)	5 (2)	4 (2)	6 (2)	10 (3)	22 (3)	2 (1)	4 (2)	0 (0)	4 (2)	7 (3)	6 (2)	4 (1)	33 (8)	
Re-used someone else's used needle & syringe last month (%)																
None	87 (80)	146 (78)	353 (82)	227 (81)	156 (78)	226 (81)	257 (84)	193 (79)	179 (82)	163 (77)	147 (81)	142 (77)	172 (76)	226 (80)	252 (82)	307 (75)
Once	12 (11)	18 (9)	24 (6)	16 (6)	14 (7)	20 (7)	13 (4)	14 (6)	17 (8)	15 (7)	5 (3)	8 (4)	14 (6)	11 (4)	16 (5)	20 (5)
Twice	6 (6)	7 (4)	15 (4)	16 (6)	8 (4)	11 (4)	11 (4)	14 (6)	4 (2)	13 (6)	7 (4)	9 (5)	9 (4)	19 (7)	13 (4)	16 (4)
3-5 times	4 (4)	9 (5)	19 (4)	8 (3)	10 (5)	7 (3)	6 (2)	7 (3)	4 (2)	9 (4)	5 (3)	10 (5)	9 (4)	11 (4)	9 (3)	16 (4)
> 5 times	0 (0)	8 (4)	6 (1)	9 (3)	6 (3)	4 (1)	3 (1)	5 (2)	9 (4)	7 (3)	6 (3)	7 (4)	10 (4)	7 (2)	11 (4)	11 (3)
Not reported	0 (0)	0 (0)	6 (1)	4 (1)	5 (2)	10 (4)	16 (5)	10 (4)	6 (2)	6 (3)	12 (7)	8 (4)	12 (5)	7 (2)	8 (3)	39 (10)
Number of people needle & syringe was re-used after last month (%)																
None	87 (80)	146 (78)	353 (82)	227 (81)	156 (78)	226 (81)	257 (84)	193 (79)	172 (79)	163 (76)	139 (76)	142 (77)	172 (76)	226 (80)	252 (82)	307 (75)
One	11 (10)	19 (10)	67 (15)	45 (17)	34 (16)	38 (14)	17 (5)	28 (11)	26 (12)	23 (11)	20 (11)	19 (10)	24 (11)	27 (10)	26 (8)	33 (8)
Two	7 (6)	20 (10)	5 (1)	4 (1)	1 (1)	1 (<1)	3 (1)	2 (1)	2 (<1)	4 (2)	2 (1)	2 (1)	2 (1)	2 (1)	1 (<1)	4 (1)
Three to five	3 (3)	3 (2)	2 (1)	0 (0)	3 (1)	1 (<1)	2 (1)	1 (<1)	1 (<1)	2 (1)	1 (1)	0 (0)	3 (1)	1 (<1)	2 (<1)	4 (1)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	2 (1)	2 (1)	1 (<1)	2 (<1)	2 (1)	0 (0)	3 (2)	2 (1)	0 (0)	1 (<1)	7 (2)
Don't know	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	4 (1)	1 (<1)	6 (3)	2 (1)	5 (3)	5 (3)	8 (4)	13 (5)	7 (2)	8 (2)
Not reported	0 (0)	0 (0)	6 (1)	4 (1)	5 (2)	10 (4)	21 (7)	19 (8)	10 (5)	17 (8)	15 (8)	13 (7)	15 (7)	12 (4)	20 (6)	46 (11)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]																
Regular sex partner	--	42 (10)	35 (13)	24 (12)	25 (9)	20 (7)	20 (7)	16 (7)	19 (9)	16 (8)	18 (10)	16 (9)	21 (9)	19 (7)	24 (8)	41 (10)
Casual sex partner	--	1 (<1)	3 (1)	2 (1)	3 (1)	3 (1)	3 (1)	2 (1)	4 (2)	4 (2)	0 (0)	1 (<1)	2 (1)	0 (0)	0 (0)	4 (1)
Close friend	--	22 (5)	9 (3)	8 (4)	9 (3)	11 (4)	11 (4)	9 (4)	10 (5)	10 (5)	6 (3)	9 (5)	10 (4)	13 (5)	8 (3)	33 (8)
Acquaintance	--	5 (1)	3 (1)	5 (2)	4 (1)	7 (2)	7 (2)	4 (2)	2 (1)	1 (<1)	5 (3)	3 (2)	6 (3)	2 (1)	2 (<1)	8 (2)
Other	--	5 (1)	1 (<1)	4 (2)	3 (1)	1 (<1)	1 (<1)	2 (1)	1 (<1)	2 (1)	2 (1)	1 (<1)	3 (1)	3 (1)	4 (1)	6 (1)

Table 8.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

VICTORIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=109	N=188	N=433	N=280	N=201	N=278	N=306	N=245	N=219	N=213	N=182	N=184	N=226	N=281	N=309	N=409
Equipment used after someone else last month (%) [more than one could be selected]																
Spoon	--	--	--	--	113 (56)	81 (29)	111 (36)	101 (41)	81 (37)	82 (39)	52 (29)	63 (36)	70 (34)	96 (36)	105 (36)	128 (31)
Water	--	--	--	--	79 (39)	50 (18)	59 (19)	77 (31)	44 (20)	63 (30)	42 (23)	34 (19)	43 (21)	56 (21)	55 (19)	76 (19)
Filter	--	--	--	--	70 (35)	36 (13)	53 (17)	74 (30)	31 (14)	55 (26)	35 (19)	32 (18)	36 (17)	45 (17)	49 (17)	52 (13)
Drug mix	--	--	--	--	99 (49)	35 (13)	42 (14)	60 (24)	23 (11)	47 (22)	31 (17)	15 (9)	21 (10)	31 (12)	31 (11)	51 (12)
Tourniquet	--	--	--	--	28 (14)	30 (11)	37 (12)	39 (16)	21 (10)	25 (12)	24 (13)	18 (10)	16 (8)	20 (8)	23 (8)	--
None	--	--	--	--	--	--	--	--	--	--	--	96 (55)	118 (57)	151 (57)	167 (58)	220 (54)
Injected by someone after that person injected themselves or others last month (%)																
No	--	--	--	--	156 (78)	225 (81)	244 (80)	183 (75)	169 (77)	178 (84)	147 (81)	155 (84)	182 (81)	234 (83)	246 (80)	314 (77)
Yes	--	--	--	--	42 (21)	41 (15)	48 (16)	52 (21)	43 (20)	28 (13)	23 (13)	23 (13)	29 (13)	37 (13)	57 (18)	64 (16)
Not reported	--	--	--	--	3 (1)	11 (4)	14 (5)	10 (4)	7 (3)	7 (3)	12 (7)	6 (3)	15 (7)	10 (4)	6 (2)	31 (8)

Table 8.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

VICTORIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=120	N=195	N=457	N=288	N=214	N=293	N=340	N=265	N=237	N=228	N=194	N=195	N=243	N=308	N=334	N=445
Sex with a regular partner last month (%)																
No	--	--	--	--	--	--	--	--	--	--	86 (44)	85 (44)	115 (47)	146 (47)	140 (42)	216 (49)
Yes	--	--	--	--	--	--	--	--	--	--	107 (55)	101 (52)	114 (47)	153 (50)	179 (54)	215 (48)
Not reported	--	--	--	--	--	--	--	--	--	--	1 (1)	9 (5)	14 (6)	9 (3)	15 (4)	14 (3)
Condom used with regular partner last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=107	N=101	N=114	N=153	N=179	N=215
Sometimes	--	--	--	--	--	--	--	--	--	--	69 (64)	68 (67)	82 (72)	101 (66)	126 (70)	138 (64)
Every time	--	--	--	--	--	--	--	--	--	--	21 (20)	17 (17)	20 (18)	22 (14)	23 (13)	31 (14)
Not reported	--	--	--	--	--	--	--	--	--	--	12 (11)	12 (12)	7 (6)	19 (12)	24 (13)	36 (17)
Sex with other partner(s) last month (%)																
No	--	--	--	--	--	--	--	--	--	--	156 (80)	158 (81)	194 (80)	259 (84)	273 (82)	353 (79)
Yes	--	--	--	--	--	--	--	--	--	--	37 (19)	22 (11)	36 (15)	35 (11)	45 (13)	65 (15)
Not reported	--	--	--	--	--	--	--	--	--	--	1 (1)	15 (8)	13 (5)	14 (5)	16 (5)	27 (6)

Table 8.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

VICTORIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=120	N=195	N=457	N=288	N=214	N=293	N=340	N=265	N=237	N=228	N=194	N=195	N=243	N=308	N=334	N=445
Condom used with other partner(s) last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=37	N=22	N=36	N=35	N=45	N=65
Sometimes	--	--	--	--	--	--	--	--	--	--	7 (19)	6 (27)	8 (22)	9 (26)	14 (31)	21 (32)
Every time	--	--	--	--	--	--	--	--	--	--	5 (14)	6 (27)	13 (36)	14 (40)	10 (22)	17 (26)
Not reported	--	--	--	--	--	--	--	--	--	--	23 (62)	8 (36)	14 (39)	10 (29)	20 (44)	23 (35)
	--	--	--	--	--	--	--	--	--	--	2 (5)	2 (9)	1 (3)	2 (6)	1 (2)	4 (6)
Sex last month (%)																
No	31 (26)	45 (23)	150 (33)	84 (29)	76 (36)	100 (34)	85 (25)	74 (28)	61 (26)	63 (28)	--	--	--	--	--	--
Yes	86 (72)	147 (75)	306 (67)	204 (71)	134 (63)	188 (64)	251 (74)	190 (72)	173 (73)	162 (71)	--	--	--	--	--	--
Not reported	3 (3)	3 (2)	1 (<1)	0 (0)	4 (2)	5 (2)	4 (1)	1 (<1)	3 (1)	3 (1)	--	--	--	--	--	--
Condom use at last sex (%)																
No	68 (57)	99 (51)	284 (62)	184 (64)	137 (64)	166 (57)	209 (61)	166 (62)	163 (69)	169 (74)	--	--	--	--	--	--
Yes	27 (23)	45 (23)	171 (37)	94 (33)	71 (33)	115 (39)	119 (35)	95 (36)	72 (30)	57 (25)	--	--	--	--	--	--
Not reported	25 (21)	51 (26)	2 (<1)	10 (3)	6 (3)	12 (4)	12 (4)	4 (2)	2 (1)	2 (1)	--	--	--	--	--	--
Condom use with regular sex partner(s) last month (%)																
No	--	96 (71)	195 (69)	106 (70)	77 (66)	93 (66)	125 (69)	85 (68)	75 (70)	83 (67)	--	--	--	--	--	--
Sometimes	--	12 (9)	37 (13)	20 (13)	16 (14)	16 (11)	25 (14)	13 (10)	15 (14)	19 (15)	--	--	--	--	--	--
Always	--	28 (20)	50 (18)	26 (17)	24 (20)	32 (23)	31 (17)	28 (22)	17 (16)	23 (18)	--	--	--	--	--	--
Condom use with new sex partner(s) last month (%)																
No	--	13 (27)	35 (30)	9 (36)	7 (23)	13 (25)	40 (31)	38 (41)	30 (39)	27 (32)	--	--	--	--	--	--
Sometimes	--	4 (8)	11 (10)	3 (12)	2 (6)	5 (9)	21 (16)	12 (13)	11 (14)	23 (27)	--	--	--	--	--	--
Always	--	31 (65)	69 (60)	13 (52)	22 (71)	35 (66)	68 (53)	42 (46)	35 (46)	34 (41)	--	--	--	--	--	--
Condom use with casual sex partner(s) last month (%)																
No	--	--	--	23 (37)	16 (29)	22 (26)	38 (35)	36 (40)	36 (49)	28 (39)	--	--	--	--	--	--
Sometimes	--	--	--	10 (16)	6 (11)	9 (11)	15 (14)	9 (10)	9 (12)	18 (25)	--	--	--	--	--	--
Always	--	--	--	29 (47)	33 (60)	54 (63)	55 (51)	44 (50)	29 (39)	26 (36)	--	--	--	--	--	--
Sex work last month (%)																
No	104 (87)	163 (84)	419 (92)	264 (92)	188 (88)	237 (81)	283 (83)	223 (84)	199 (84)	210 (88)	168 (87)	169 (67)	218 (90)	266 (86)	308 (92)	393 (88)
Yes	7 (6)	17 (9)	35 (8)	17 (6)	20 (9)	50 (17)	45 (13)	37 (14)	33 (14)	25 (11)	24 (12)	12 (6)	15 (6)	17 (6)	17 (5)	28 (6)
Not reported	9 (8)	15 (8)	3 (1)	7 (2)	5 (3)	6 (2)	12 (4)	5 (2)	5 (2)	2 (1)	2 (1)	14 (7)	10 (4)	25 (8)	9 (3)	24 (5)
Condom used at last sex work (%)																
Yes	6 (100)	16 (94)	26 (90)	14 (88)	17 (94)	47 (98)	40 (95)	33 (89)	27 (82)	22 (88)	47 (98)	10 (83)	12 (86)	11 (73)	15 (88)	21 (78)

Table 8.6 Number (percentage) of respondents by previous testing for HIV, HBV, HCV infection, HBV vaccination and HCV treatment by year

VICTORIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=120	N=195	N=457	N=288	N=214	N=293	N=340	N=265	N=237	N=228	N=194	N=195	N=243	N=308	N=334	N=445
Previous HIV test (%)																
Yes, last year	76 (63)	109 (56)	298 (65)	189 (66)	134 (63)	209 (71)	219 (64)	184 (69)	137 (58)	124 (54)	121 (62)	104 (53)	151 (62)	151 (49)	174 (52)	233 (52)
> 1 year ago	25 (21)	50 (26)	95 (21)	59 (20)	50 (23)	58 (20)	79 (23)	58 (22)	77 (32)	77 (34)	55 (28)	66 (34)	65 (27)	109 (35)	121 (36)	144 (32)
Never tested	15 (13)	33 (17)	4 (1)	1 (<1)	27 (13)	26 (9)	36 (11)	22 (8)	17 (7)	24 (11)	16 (8)	18 (9)	19 (8)	34 (11)	29 (9)	40 (9)
Not reported	4 (3)	3 (2)	60 (13)	39 (14)	3 (1)	0 (0)	6 (2)	1 (1)	6 (3)	3 (1)	2 (1)	7 (4)	8 (3)	14 (5)	10 (3)	28 (6)
Self report HBV infection (%)																
No	92 (77)	147 (75)	344 (75)	239 (83)	166 (78)	235 (80)	246 (72)	176 (67)	168 (71)	155 (68)	122 (63)	122 (63)	159 (65)	--	--	--
Yes	26 (22)	46 (24)	71 (16)	38 (19)	34 (16)	43 (15)	53 (16)	51 (19)	48 (20)	47 (21)	44 (23)	45 (23)	49 (20)	--	--	--
Don't know	--	--	40 (9)	9 (3)	13 (6)	12 (4)	36 (11)	35 (13)	19 (8)	24 (10)	27 (14)	21 (11)	26 (11)	--	--	--
Not reported	2 (2)	2 (1)	2 (<1)	2 (1)	1 (<1)	3 (1)	5 (1)	3 (1)	2 (1)	2 (1)	1 (1)	7 (4)	9 (4)	--	--	--
Self report HBV vaccination (%)																
No	80 (67)	127 (65)	266 (58)	167 (58)	124 (58)	141 (48)	139 (41)	113 (43)	96 (41)	85 (37)	72 (37)	70 (36)	87 (36)	--	--	--
Yes	38 (32)	61 (31)	144 (32)	99 (34)	77 (36)	126 (43)	161 (47)	122 (46)	112 (47)	120 (53)	92 (47)	91 (47)	119 (49)	--	--	--
Don't know	--	--	45 (10)	18 (6)	12 (6)	22 (8)	26 (8)	30 (11)	22 (9)	20 (9)	26 (13)	26 (13)	30 (12)	--	--	--
Not reported	2 (2)	7 (4)	2 (<1)	4 (1)	1 (<1)	4 (1)	14 (4)	0 (0)	7 (3)	3 (1)	4 (2)	8 (4)	7 (3)	--	--	--
Previous HCV test (%)																
Yes, ever	87 (73)	144 (75)	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Yes, last year	--	--	294 (63)	202 (70)	140 (65)	208 (71)	227 (67)	187 (71)	160 (68)	131 (57)	127 (65)	114 (58)	154 (63)	176 (57)	194 (58)	268 (60)
> 1 year ago	--	--	85 (19)	50 (17)	51 (24)	63 (22)	85 (25)	59 (22)	60 (25)	81 (36)	50 (26)	58 (30)	78 (32)	98 (32)	110 (33)	125 (28)
Never tested	29 (24)	46 (24)	76 (16)	36 (13)	22 (10)	19 (6)	24 (7)	19 (7)	15 (6)	13 (6)	15 (8)	15 (8)	6 (2)	20 (6)	14 (4)	24 (5)
Not reported	4 (3)	1 (1)	2 (<1)	0 (0)	0 (0)	3 (1)	4 (1)	0 (0)	2 (1)	3 (1)	2 (1)	8 (4)	5 (2)	14 (5)	16 (5)	28 (6)
Any treatment for HCV (%)																
Interferon/+Ribavirin	--	--	--	--	1 (1)	3 (2)	6 (4)	4 (3)	7 (6)	8 (6)	4 (4)	4 (4)	8 (6)	15 (8)	14 (7)	16 (9)
Other	--	--	--	--	2 (2)	3 (2)	8 (5)	8 (6)	2 (2)	4 (3)	4 (4)	3 (3)	3 (2)	6 (3)	5 (2)	5 (2)
No treatment	--	--	--	--	88 (96)	130 (94)	147 (88)	125 (92)	114 (92)	110 (88)	95 (92)	92 (91)	122 (87)	158 (85)	176 (88)	238 (85)
Not reported	--	--	--	--	1 (1)	3 (2)	6 (4)	0 (0)	1 (<1)	4 (3)	0 (0)	2 (2)	8 (6)	6 (3)	6 (3)	11 (4)
Current treatment for HCV (%)																
Interferon +/- Ribavirin	--	--	--	--	0	0	2	1	0	1	1	2	2	3	2	1
Other	--	--	--	--	1	3	2	1	0	1	4	1	1	2	0	3

Table 8.7 Number (percentage) of respondents by treatment for drug use and year

VICTORIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=120	N=195	N=457	N=288	N=214	N=293	N=340	N=265	N=237	N=228	N=194	N=195	N=243	N=308	N=334	N=445
Ever any treatment/therapy for drug use (%)																
No	47 (39)	56 (29)	129 (28)	76 (26)	44 (20)	44 (15)	72 (21)	41 (15)	57 (24)	29 (13)	22 (11)	22 (11)	23 (9)	34 (11)	29 (9)	36 (8)
Yes	73 (61)	137 (70)	328 (72)	212 (74)	168 (79)	247 (84)	266 (78)	224 (85)	180 (76)	197 (86)	172 (89)	169 (87)	215 (88)	272 (88)	304 (91)	404 (91)
Not reported	0 (0)	2 (1)	0 (0)	0 (0)	2 (1)	2 (1)	2 (1)	0 (0)	0 (0)	2 (1)	0 (0)	4 (2)	5 (2)	2 (1)	1 (<1)	5 (1)
History of methadone maintenance treatment (%)																
Current	18 (15)	46 (24)	104 (23)	44 (15)	40 (19)	55 (19)	53 (16)	45 (17)	49 (21)	58 (25)	56 (29)	58 (30)	78 (32)	100 (32)	88 (26)	140 (31)
Previous	25 (21)	42 (22)	113 (25)	88 (31)	75 (35)	112 (38)	145 (43)	112 (42)	94 (40)	86 (38)	66 (34)	66 (34)	81 (33)	104 (34)	125 (37)	155 (35)
Never	77 (64)	105 (53)	240 (52)	156 (54)	97 (46)	124 (52)	138 (40)	107 (40)	93 (39)	78 (34)	72 (37)	67 (34)	79 (33)	99 (32)	114 (34)	133 (30)
Not reported	0 (0)	2 (1)	0 (0)	0 (0)	1 (<1)	2 (1)	4 (1)	1 (1)	1 (<1)	6 (3)	0 (0)	4 (2)	5 (2)	5 (2)	7 (2)	17 (4)
History of other pharmacotherapy treatment (%)																
Current	--	--	--	--	--	9 (3)	27 (8)	65 (25)	61 (26)	74 (32)	55 (28)	48 (25)	61 (25)	59 (19)	83 (25)	102 (23)
Previous	--	--	--	--	--	48 (16)	53 (16)	60 (23)	67 (28)	56 (25)	55 (28)	65 (33)	84 (35)	125 (41)	128 (38)	169 (38)
Never	--	--	--	--	--	236 (81)	256 (75)	137 (51)	104 (44)	97 (43)	83 (43)	77 (40)	92 (38)	122 (40)	120 (36)	172 (39)
Not reported	--	--	--	--	--	0 (0)	4 (1)	3 (1)	5 (2)	1 (<1)	1 (1)	5 (3)	6 (2)	2 (<1)	3 (1)	2 (<1)

Table 8.8 Number (percentage) of respondents by source of needle and syringe acquisition in the month prior to survey and year

VICTORIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last mth	N=109	N=188	N=433	N=280	N=201	N=278	N=306	N=245	N=219	N=213	N=182	N=184	N=226	N=281	N=309	N=409
Needle/syringe acquisition in the last month (%) [more than one could be selected]																
Needle Syringe Program	--	--	--	--	195 (97)	266 (96)	290 (95)	229 (93)	207 (95)	201 (94)	170 (95)	172 (93)	185 (82)	263 (94)	229 (74)	385 (94)
Pharmacy	--	--	--	--	127 (63)	162 (58)	157 (51)	129 (53)	102 (47)	109 (51)	70 (39)	74 (40)	49 (22)	112 (40)	62 (20)	75 (18)
Personal Sources	--	--	--	--	--	--	--	--	--	--	--	--	51 (23)	--	64 (21)	58 (14)
Other sources	--	--	--	--	--	--	--	--	--	--	--	--	8 (4)	--	13 (4)	13 (3)
Onward supply of syringes in last month (%)																
Yes, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	84 (37)	--	99 (32)	140 (34)
No, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	112 (50)	--	150 (49)	261 (64)
Not reported	--	--	--	--	--	--	--	--	--	--	--	--	30 (13)	--	60 (19)	8 (2)

HIV ANTIBODY PREVALENCE

Table 8.9 HIV antibody prevalence by gender and year

VICTORIA	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
1995	77	1 (1.3)	41	0 (0.0)	118	1 (0.9)
1996	131	3 (2.3)	63	1 (1.6)	195	4 (2.1)
1997	294	4 (1.4)	141	1 (0.7)	436	5 (1.2)
1998	193	0 (0.0)	90	0 (0.0)	283	0 (0.0)
1999	137	2 (1.5)	69	0 (0.0)	207	2 (1.0)
2000	177	1 (0.6)	115	0 (0.0)	293	1 (0.3)
2001	214	2 (0.9)	117	0 (0.0)	333	2 (0.6)
2002	151	1 (0.7)	91	0 (0.0)	244	1 (0.4)
2003	144	1 (0.7)	90	1 (1.1)	237	2 (0.8)
2004	122	1 (0.8)	65	0 (0.0)	189	1 (0.5)
2005	102	1 (1.0)	76	0 (0.0)	178	1 (0.6)
2006	122	1 (0.8)	68	0 (0.0)	191	1 (0.5)
2007	163	0 (0.0)	76	0 (0.0)	240	0 (0.0)
2008	199	2 (1.0)	93	0 (0.0)	292	2 (0.7)
2009	215	3 (1.4)	116	0 (0.0)	333	3 (0.9)
2010	305	2 (0.7)	131	0 (0.0)	438	2 (0.5)
χ^2 trend p value		0.414		0.116		0.206

HCV ANTIBODY PREVALENCE

Table 8.10 HCV antibody prevalence by gender and year

VICTORIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	77	43 (56)	41	20 (49)	118	63 (53)
1996	127	56 (44)	62	35 (56)	190	92 (48)
1997	294	140 (48)	141	81 (57)	436	221 (51)
1998	193	104 (54)	90	48 (53)	283	152 (54)
1999	135	81 (60)	69	40 (58)	205	122 (60)
2000	177	114 (64)	115	68 (59)	293	183 (62)
2001	218	150 (69)	119	87 (73)	339	237 (70)
2002	152	84 (55)	91	57 (63)	245	143 (58)
2003	144	95 (66)	90	59 (66)	237	157 (66)
2004	122	82 (67)	65	48 (74)	189	130 (69)
2005	101	64 (63)	76	55 (72)	177	119 (67)
2006	121	84 (69)	67	50 (75)	189	135 (71)
2007	139	100 (72)	65	48 (74)	205	149 (73)
2008	188	141 (75)	90	58 (64)	278	199 (72)
2009	212	120 (57)	115	60 (52)	329	182 (55)
2010	303	204 (67)	130	72 (55)	435	278 (64)
χ^2 trend p value		<0.001		0.228		<0.001

Table 8.11 HCV antibody prevalence by sexual identity, gender and year

VICTORIA	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heterosexual	64	37 (58)	30	16 (53)	94	53 (56)
Bisexual	8	4 (50)	7	2 (29)	15	6 (40)
Homosexual	5	2 (40)	4	2 (50)	9	4 (44)
1996						
Heterosexual	114	55 (48)	40	21 (53)	154	76 (49)
Bisexual	6	2 (33)	15	12 (80)	21	14 (67)
Homosexual	6	2 (33)	5	3 (60)	11	5 (45)
1997						
Heterosexual	261	127 (49)	86	52 (60)	348	179 (51)
Bisexual	17	5 (29)	37	23 (62)	54	28 (52)
Homosexual	10	6 (60)	15	3 (20)	25	9 (36)
1998						
Heterosexual	176	100 (57)	65	37 (57)	241	137 (57)
Bisexual	9	1 (11)	13	4 (31)	22	5 (23)
Homosexual	3	2 (67)	9	5 (56)	12	7 (58)
1999						
Heterosexual	116	68 (59)	49	27 (55)	165	95 (58)
Bisexual	11	7 (64)	18	11 (61)	29	18 (62)
Homosexual	5	4 (80)	2	2 (100)	7	6 (86)
2000						
Heterosexual	162	102 (63)	77	46 (60)	239	148 (62)
Bisexual	8	5 (63)	31	17 (55)	39	22 (56)
Homosexual	5	5 (100)	4	3 (75)	10	9 (90)
2001						
Heterosexual	180	124 (69)	82	57 (70)	264	181 (69)
Bisexual	10	6 (60)	25	20 (80)	35	26 (74)
Homosexual	11	9 (82)	5	4 (80)	16	13 (81)
2002						
Heterosexual	128	74 (58)	62	36 (58)	191	111 (58)
Bisexual	9	2 (22)	25	17 (68)	34	19 (56)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
2003						
Heterosexual	117	79 (68)	50	30 (60)	168	110 (65)
Bisexual	4	4 (100)	26	19 (73)	30	23 (77)
Homosexual	7	0 (0)	7	5 (71)	14	5 (36)
2004						
Heterosexual	101	67 (66)	48	32 (67)	150	99 (66)
Bisexual	8	6 (75)	11	10 (91)	19	16 (84)
Homosexual	7	4 (57)	4	4 (100)	11	8 (73)
2005						
Heterosexual	84	54 (64)	54	38 (70)	138	92 (67)
Bisexual	6	4 (67)	13	9 (69)	19	13 (68)
Homosexual	6	3 (50)	5	5 (100)	11	8 (73)
2006						
Heterosexual	105	74 (70)	54	38 (70)	160	113 (71)
Bisexual	8	3 (38)	10	9 (90)	18	12 (67)
Homosexual	1	1 (100)	3	3 (100)	4	4 (100)
2007						
Heterosexual	124	91 (73)	37	30 (81)	161	121 (75)
Bisexual	9	5 (56)	24	16 (67)	33	21 (64)
Homosexual	3	2 (67)	2	1 (50)	6	4 (67)
2008						
Heterosexual	165	122 (74)	67	44 (66)	232	166 (72)
Bisexual	5	4 (80)	16	9 (56)	21	13 (62)
Homosexual	4	3 (75)	3	3 (100)	7	6 (86)
2009						
Heterosexual	186	108 (58)	82	40 (49)	270	150 (56)
Bisexual	11	5 (45)	22	14 (64)	33	19 (58)
Homosexual	4	1 (25)	4	2 (50)	8	3 (38)
2010						
Heterosexual	269	183 (68)	97	52 (54)	367	236 (64)
Bisexual	13	10 (77)	21	13 (62)	34	23 (68)
Homosexual	3	2 (67)	4	1 (25)	7	3 (43)
2010 p value		0.893		0.409		0.442

Table 8.12 HCV antibody prevalence by age group, gender and year

VICTORIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
<25 years	16	6 (38)	21	9 (43)	37	15 (41)
25-34 years	42	23 (55)	16	8 (50)	58	31 (53)
35+ years	19	14 (74)	4	3 (75)	23	17 (74)
1996						
<25 years	35	6 (17)	27	7 (26)	62	13 (21)
25-34 years	61	28 (46)	29	25 (86)	91	54 (59)
35+ years	31	26 (84)	6	5 (83)	37	31 (84)
1997						
<25 years	102	21 (21)	68	24 (35)	170	45 (26)
25-34 years	122	60 (49)	58	45 (78)	180	105 (58)
35+ years	70	59 (84)	15	12 (80)	86	71 (83)
1998						
<25 years	68	32 (47)	51	17 (33)	119	49 (41)
25-34 years	92	45 (49)	28	20 (71)	120	65 (54)
35+ years	33	27 (82)	11	11 (100)	44	38 (86)
1999						
<25 years	47	22 (47)	40	20 (50)	87	42 (48)
25-34 years	69	43 (62)	19	12 (63)	88	55 (63)
35+ years	18	15 (83)	10	8 (80)	28	23 (82)
2000						
<25 years	46	23 (50)	55	32 (58)	101	55 (54)
25-34 years	92	61 (66)	47	28 (60)	139	89 (64)
35+ years	39	30 (77)	13	8 (62)	53	39 (74)
2001						
<25 years	61	33 (54)	47	29 (62)	110	62 (56)
25-34 years	103	71 (69)	50	40 (80)	153	111 (73)
35+ years	54	46 (85)	22	18 (82)	76	64 (84)
2002						
<25 years	35	19 (54)	29	19 (66)	65	39 (60)
25-34 years	72	35 (49)	49	28 (57)	122	64 (52)
35+ years	45	30 (67)	13	10 (77)	58	40 (69)
2003						
<25 years	28	16 (57)	24	18 (75)	53	35 (66)
25-34 years	59	34 (58)	47	26 (55)	106	60 (57)
35+ years	57	45 (79)	18	15 (83)	77	62 (81)
2004						
<25 years	23	13 (57)	18	12 (67)	42	25 (60)
25-34 years	60	39 (65)	30	23 (77)	90	62 (69)
35+ years	39	30 (77)	17	13 (76)	56	43 (77)
2005						
<25 years	14	5 (36)	19	13 (68)	33	18 (55)
25-34 years	44	23 (52)	27	16 (59)	71	39 (55)
35+ years	43	36 (84)	31	27 (87)	74	63 (85)
2006						
<25 years	10	7 (70)	15	9 (60)	25	16 (64)
25-34 years	68	41 (60)	29	22 (76)	97	63 (65)
35+ years	42	35 (83)	23	19 (83)	66	55 (83)
2007						
<25 years	9	2 (22)	8	4 (50)	17	6 (35)
25-34 years	72	48 (67)	33	25 (76)	106	74 (70)
35+ years	58	50 (86)	24	19 (79)	82	69 (84)
2008						
<25 years	9	3 (33)	9	1 (11)	18	4 (22)
25-34 years	79	54 (68)	48	32 (67)	127	86 (68)
35+ years	100	84 (84)	33	25 (76)	133	109 (82)
2009						
<25 years	15	2 (13)	14	1 (7)	29	3 (10)
25-34 years	95	49 (52)	49	27 (55)	145	77 (53)
35+ years	102	69 (68)	52	32 (62)	155	102 (66)
2010						
<25 years	14	3 (21)	29	7 (24)	43	10 (23)
25-34 years	112	69 (62)	44	26 (59)	157	96 (61)
35+ years	177	132 (75)	57	39 (68)	235	172 (73)
2010 p value		<0.001		<0.001		<0.001

Table 8.13 HCV antibody prevalence by times since first injection, gender and year

VICTORIA	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<3 years	14	2 (14)	7	2 (29)	21	4 (19)
3-10 years	27	10 (37)	30	15 (50)	57	25 (44)
11+ years	36	31 (86)	4	3 (75)	40	34 (85)
1996						
<3 years	21	2 (10)	11	3 (36)	32	6 (19)
3-10 years	53	18 (34)	29	13 (45)	83	32 (39)
11+ years	49	38 (76)	21	19 (90)	70	57 (81)
1997						
<3 years	47	6 (13)	35	9 (26)	82	15 (18)
3-10 years	134	42 (31)	72	41 (57)	206	83 (40)
11+ years	107	89 (83)	33	30 (91)	141	119 (84)
1998						
<3 years	49	22 (45)	23	6 (26)	72	28 (39)
3-10 years	70	27 (39)	44	20 (45)	114	47 (41)
11+ years	73	55 (75)	21	20 (95)	94	75 (80)
1999						
<3 years	21	6 (29)	20	8 (40)	41	14 (34)
3-10 years	67	40 (60)	36	21 (58)	103	61 (59)
11+ years	46	34 (74)	13	11 (85)	59	45 (76)
2000						
<3 years	19	8 (42)	16	7 (44)	35	15 (43)
3-10 years	91	58 (64)	66	36 (55)	157	94 (60)
11+ years	66	48 (73)	30	24 (77)	97	72 (74)
2001						
<3 years	19	3 (16)	12	6 (50)	32	9 (28)
3-10 years	107	67 (63)	67	51 (76)	175	118 (67)
11+ years	85	74 (87)	36	28 (78)	121	102 (84)
2002						
<3 years	8	2 (25)	6	1 (17)	14	3 (21)
3-10 years	65	29 (45)	48	29 (60)	114	59 (52)
11+ years	74	51 (69)	34	24 (71)	109	76 (70)
2003						
<3 years	10	3 (30)	5	0 (0)	15	3 (20)
3-10 years	53	28 (53)	44	29 (66)	98	58 (59)
11+ years	77	60 (78)	39	29 (74)	118	91 (77)
2004						
<3 years	7	0 (0)	7	2 (29)	14	2 (14)
3-10 years	45	28 (62)	30	22 (73)	76	50 (66)
11+ years	67	51 (76)	28	24 (86)	95	76 (79)
2005						
<3 years	5	1 (20)	5	4 (80)	10	5 (50)
3-10 years	33	18 (55)	34	22 (65)	67	40 (60)
11+ years	58	42 (72)	36	28 (78)	94	70 (74)
2006						
<3 years	4	1 (25)	2	1 (50)	6	2 (33)
3-10 years	33	19 (58)	24	14 (58)	57	33 (58)
11+ years	75	57 (76)	38	32 (84)	114	90 (79)
2007						
<3 years	7	1 (14)	5	1 (20)	12	2 (17)
3-10 years	30	14 (47)	24	19 (79)	55	34 (62)
11+ years	97	81 (84)	35	27 (77)	132	108 (82)
2008						
<3 years	8	2 (25)	9	4 (44)	17	6 (35)
3-10 years	35	19 (54)	21	10 (48)	56	29 (52)
11+ years	139	115 (83)	57	43 (75)	196	158 (81)
2009						
<3 years	6	2 (33)	6	0 (0)	12	2 (17)
3-10 years	44	16 (36)	36	13 (36)	81	30 (37)
11+ years	159	101 (64)	68	43 (63)	227	144 (63)
2010						
<3 years	10	4 (40)	4	2 (50)	14	6 (43)
3-10 years	40	18 (45)	44	15 (34)	84	33 (39)
11+ years	247	177 (71)	81	54 (67)	329	323 (71)
2010 p value		0.001		0.001		<0.001

Table 8.14 HCV antibody prevalence by last drug injected, time since first injection and year

VICTORIA	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Heroin	9	4 (44)	65	50 (77)	74	54 (73)
Methamphetamine	9	0 (0)	27	7 (26)	36	7 (19)
Other	2	0 (0)	5	2 (40)	7	2 (29)
1996						
Heroin	28	6 (21)	123	80 (65)	155	89 (57)
Methamphetamine	3	0 (0)	15	3 (20)	18	3 (17)
Other	1	0 (0)	15	6 (40)	16	6 (38)
1997						
Heroin	66	14 (21)	302	183 (61)	374	200 (53)
Methamphetamine	10	1 (10)	24	6 (25)	34	7 (21)
Other	6	0 (0)	20	12 (60)	27	13 (48)
1998						
Heroin	63	25 (40)	190	113 (59)	255	139 (55)
Methamphetamine	4	0 (0)	8	3 (38)	12	3 (25)
Other	5	3 (60)	10	6 (60)	15	9 (60)
1999						
Heroin	39	14 (36)	137	88 (64)	177	103 (58)
Methamphetamine	1	0 (0)	14	10 (71)	15	10 (67)
Other	1	0 (0)	4	2 (50)	5	2 (40)
2000						
Heroin	30	12 (40)	222	147 (66)	255	161 (63)
Methamphetamine	2	1 (50)	17	9 (53)	19	10 (53)
Other	3	2 (67)	14	9 (64)	17	11 (65)
2001						
Heroin	16	6 (38)	178	140 (79)	197	149 (76)
Methamphetamine	13	3 (23)	69	42 (61)	84	47 (56)
Other	3	0 (0)	48	37 (77)	52	38 (73)
2002						
Heroin	8	2 (25)	131	90 (69)	144	96 (67)
Methamphetamine	3	0 (0)	49	14 (29)	54	15 (28)
Other	3	1 (33)	43	31 (72)	46	32 (70)
2003						
Heroin	7	1 (14)	128	89 (70)	137	92 (67)
Methamphetamine	8	2 (25)	46	29 (63)	57	33 (58)
Other	0	0 (0)	42	31 (74)	43	32 (74)
2004						
Heroin	7	1 (14)	105	80 (76)	113	82 (73)
Methamphetamine	4	0 (0)	23	13 (57)	28	14 (50)
Other	2	1 (50)	43	32 (74)	46	34 (74)
2005						
Heroin	4	3 (75)	83	60 (71)	89	64 (72)
Methamphetamine	2	0 (0)	37	21 (57)	42	23 (55)
Other	3	1 (33)	35	24 (69)	41	28 (68)
2006						
Heroin	2	1 (50)	67	54 (81)	70	55 (79)
Methamphetamine	3	1 (33)	58	37 (64)	66	42 (64)
Other	1	0 (0)	45	31 (69)	50	35 (70)
2007						
Heroin	4	2 (50)	101	78 (77)	106	81 (76)
Methamphetamine	4	0 (0)	36	25 (69)	42	27 (64)
Other	4	0 (0)	46	36 (78)	53	38 (72)
2008						
Heroin	6	3 (50)	151	114 (76)	161	120 (75)
Methamphetamine	7	3 (43)	42	29 (69)	50	32 (64)
Other	4	0 (0)	52	38 (73)	59	40 (68)
2009						
Heroin	4	0 (0)	194	117 (60)	201	119 (59)
Methamphetamine	1	0 (0)	41	18 (44)	45	21 (47)
Other	6	2 (33)	68	36 (53)	77	39 (51)
2010						
Heroin	8	4 (50)	246	169 (69)	257	176 (68)
Methamphetamine	1	0 (0)	52	22 (42)	56	25 (45)
Other	5	2 (40)	115	74 (64)	122	77 (63)
2010 p value		1.000		0.002		0.004

Table 8.15 HCV antibody prevalence by frequency of injection, time since first injection and year

VICTORIA	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Less than daily	16	2 (13)	47	25 (53)	63	27 (43)
Daily or more	2	0 (0)	42	31 (74)	44	31 (70)
Not last month	3	2 (67)	8	3 (38)	11	5 (45)
1996						
Less than daily	18	3 (17)	73	40 (55)	93	44 (47)
Daily or more	13	3 (23)	75	48 (64)	90	53 (59)
Not last month	1	0 (0)	5	1 (20)	6	1 (17)
1997						
Less than daily	34	5 (15)	129	58 (45)	164	64 (39)
Daily or more	43	10 (23)	203	138 (68)	251	151 (60)
Not last month	5	0 (0)	15	6 (40)	21	6 (29)
1998						
Less than daily	22	7 (32)	61	34 (56)	83	41 (49)
Daily or more	50	21 (42)	139	82 (59)	192	105 (55)
Not last month	0	0 (0)	8	6 (75)	8	6 (75)
1999						
Less than daily	11	7 (64)	54	31 (57)	65	38 (58)
Daily or more	29	7 (24)	97	66 (68)	127	74 (58)
Not last month	1	0 (0)	11	9 (82)	12	9 (75)
2000						
Less than daily	10	2 (20)	82	52 (63)	92	54 (59)
Daily or more	23	13 (57)	160	107 (67)	186	122 (66)
Not last month	2	0 (0)	11	6 (55)	13	6 (46)
2001						
Less than daily	18	6 (33)	118	85 (72)	137	92 (67)
Daily or more	10	3 (30)	156	120 (77)	168	125 (74)
Not last month	3	0 (0)	22	15 (68)	27	16 (59)
2002						
Less than daily	4	1 (25)	88	46 (52)	93	48 (52)
Daily or more	9	2 (22)	119	82 (69)	134	88 (66)
Not last month	1	0 (0)	14	6 (43)	15	6 (40)
2003						
Less than daily	9	1 (11)	89	58 (65)	99	60 (61)
Daily or more	6	2 (33)	110	82 (75)	120	88 (73)
Not last month	0	0 (0)	16	9 (56)	16	9 (56)
2004						
Less than daily	5	1 (20)	73	52 (71)	78	53 (68)
Daily or more	9	1 (11)	89	68 (76)	101	72 (71)
Not last month	0	0 (0)	9	5 (56)	9	5 (56)
2005						
Less than daily	4	1 (25)	58	42 (72)	63	44 (70)
Daily or more	5	4 (80)	90	60 (67)	102	69 (68)
Not last month	0	0 (0)	11	7 (64)	11	7 (64)
2006						
Less than daily	3	1 (33)	68	48 (71)	74	52 (70)
Daily or more	3	1 (33)	92	69 (75)	104	77 (74)
Not last month	0	0 (0)	10	6 (60)	10	6 (60)
2007						
Less than daily	4	0 (0)	59	45 (76)	66	48 (73)
Daily or more	7	1 (14)	115	88 (77)	124	91 (73)
Not last month	1	1 (100)	8	4 (50)	10	5 (50)
2008						
Less than daily	8	3 (38)	96	74 (77)	108	79 (73)
Daily or more	5	2 (40)	137	101 (73)	147	107 (73)
Not last month	2	1 (50)	15	10 (67)	17	11 (65)
2009						
Less than daily	5	0 (0)	104	62 (60)	111	64 (58)
Daily or more	7	2 (29)	182	100 (55)	193	104 (54)
Not last month	0	0 (0)	19	9 (47)	21	10 (48)
2010						
Less than daily	2	1 (50)	189	127 (67)	195	132 (68)
Daily or more	11	5 (45)	193	123 (64)	206	129 (63)
Not last month	1	0 (0)	26	13 (50)	29	15 (52)
2010 p value		1.000		0.225		0.204

Table 8.16 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, time since first injection and year

VICTORIA	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
No receptive sharing	12	1 (8)	73	47 (64)	85	48 (56)
Receptive sharing	6	1 (17)	16	9 (56)	22	10 (45)
1996						
No receptive sharing	23	5 (22)	117	68 (58)	143	75 (52)
Receptive sharing	8	1 (13)	31	20 (65)	40	22 (55)
1997						
No receptive sharing	66	11 (17)	270	155 (57)	340	169 (50)
Receptive sharing	11	4 (36)	57	37 (65)	69	41 (59)
1998						
No receptive sharing	60	24 (40)	159	97 (61)	222	123 (55)
Receptive sharing	11	3 (27)	38	18 (47)	49	21 (43)
1999						
No receptive sharing	33	10 (30)	115	71 (62)	149	82 (55)
Receptive sharing	6	3 (50)	32	23 (72)	38	26 (68)
2000						
No receptive sharing	31	14 (45)	192	127 (66)	226	143 (63)
Receptive sharing	2	1 (50)	40	25 (63)	42	26 (62)
2001						
No receptive sharing	24	6 (25)	230	166 (72)	256	174 (68)
Receptive sharing	3	3 (100)	30	27 (90)	33	30 (91)
2002						
No receptive sharing	10	3 (30)	163	104 (64)	179	111 (62)
Receptive sharing	3	0 (0)	34	20 (59)	38	21 (55)
2003						
No receptive sharing	13	3 (23)	163	114 (70)	179	120 (67)
Receptive sharing	2	0 (0)	30	24 (80)	34	26 (76)
2004						
No receptive sharing	11	1 (9)	126	92 (73)	139	95 (68)
Receptive sharing	3	1 (33)	32	26 (81)	36	28 (78)
2005						
No receptive sharing	7	4 (57)	120	84 (70)	133	94 (71)
Receptive sharing	2	1 (50)	18	10 (56)	22	11 (50)
2006						
No receptive sharing	4	1 (25)	127	89 (70)	138	95 (69)
Receptive sharing	2	1 (50)	28	24 (86)	33	28 (85)
2007						
No receptive sharing	8	0 (0)	129	97 (75)	140	100 (71)
Receptive sharing	2	1 (50)	36	28 (78)	39	30 (77)
2008						
No receptive sharing	13	5 (38)	188	140 (74)	209	150 (72)
Receptive sharing	0	0 (0)	40	32 (80)	41	33 (80)
2009						
No receptive sharing	11	2 (18)	234	135 (58)	249	140 (56)
Receptive sharing	1	0 (0)	44	23 (52)	47	24 (51)
2010						
No receptive sharing	11	5 (45)	287	184 (64)	303	193 (64)
Receptive sharing	2	1 (50)	57	37 (65)	59	38 (64)
2010 p value		1.000		1.000		1.000

Table 8.17 HCV antibody prevalence by imprisonment last year, time since first injection and year

VICTORIA	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
No imprisonment	20	4 (20)	81	45 (56)	101	49 (49)
Imprisonment	1	0 (0)	16	14 (88)	17	14 (82)
1996						
No imprisonment	30	6 (20)	131	73 (56)	164	80 (49)
Imprisonment	2	0 (0)	16	13 (81)	20	15 (75)
1997						
No imprisonment	78	14 (18)	291	160 (55)	376	178 (47)
Imprisonment	3	1 (33)	56	42 (75)	59	43 (73)
1998						
No imprisonment	61	20 (33)	176	99 (56)	240	121 (50)
Imprisonment	9	7 (78)	31	22 (71)	40	29 (73)
1999						
No imprisonment	37	11 (30)	126	75 (60)	164	87 (53)
Imprisonment	4	3 (75)	35	30 (86)	39	33 (85)
2000						
No imprisonment	28	9 (32)	197	123 (62)	228	133 (58)
Imprisonment	4	4 (100)	49	37 (76)	54	42 (78)
2001						
No imprisonment	30	8 (27)	220	159 (72)	258	172 (67)
Imprisonment	1	0 (0)	66	53 (80)	68	54 (79)
2002						
No imprisonment	12	3 (25)	175	102 (58)	192	107 (56)
Imprisonment	2	0 (0)	47	32 (68)	51	34 (67)
2003						
No imprisonment	14	3 (21)	175	112 (64)	192	118 (61)
Imprisonment	1	0 (0)	38	35 (92)	41	37 (90)
2004						
No imprisonment	13	2 (15)	141	100 (71)	155	103 (66)
Imprisonment	1	0 (0)	30	25 (83)	33	27 (82)
2005						
No imprisonment	8	3 (38)	134	89 (66)	149	97 (65)
Imprisonment	1	1 (100)	18	16 (89)	20	18 (90)
2006						
No imprisonment	6	2 (33)	142	98 (69)	158	108 (68)
Imprisonment	0	0 (0)	17	14 (82)	18	15 (83)
2007						
No imprisonment	10	1 (10)	149	111 (75)	163	115 (71)
Imprisonment	1	1 (100)	26	20 (77)	28	22 (79)
2008						
No imprisonment	15	6 (40)	198	141 (71)	220	152 (69)
Imprisonment	1	0 (0)	33	27 (82)	35	27 (77)
2009						
No imprisonment	12	2 (17)	261	140 (54)	282	148 (52)
Imprisonment	0	0 (0)	38	28 (74)	38	28 (74)
2010						
No imprisonment	10	3 (30)	299	183 (61)	315	192 (61)
Imprisonment	1	1 (100)	40	27 (68)	42	28 (67)
2010 p value		0.364		0.492		0.505

Table 8.18 HCV antibody prevalence by sex work last month, time since first injection and year

VICTORIA	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
No sex work	19	4 (21)	83	50 (60)	102	54 (53)
Sex work	0	0 (0)	7	3 (43)	7	3 (43)
1996						
No sex work	30	6 (20)	123	69 (56)	158	78 (49)
Sex work	0	0 (0)	17	12 (71)	17	12 (71)
1997						
No sex work	78	12 (15)	315	176 (56)	400	192 (48)
Sex work	4	3 (75)	29	24 (83)	33	27 (82)
1998						
No sex work	70	27 (39)	188	108 (57)	260	136 (52)
Sex work	1	0 (0)	15	10 (67)	17	11 (65)
1999						
No sex work	37	12 (32)	142	93 (65)	180	106 (59)
Sex work	3	1 (33)	17	11 (65)	20	12 (60)
2000						
No sex work	28	11 (39)	205	135 (66)	237	148 (62)
Sex work	6	4 (67)	44	29 (66)	50	33 (66)
2001						
No sex work	27	6 (22)	245	180 (73)	282	193 (68)
Sex work	5	3 (60)	39	32 (82)	45	36 (80)
2002						
No sex work	13	2 (15)	187	108 (58)	206	113 (55)
Sex work	1	1 (100)	33	27 (82)	36	30 (83)
2003						
No sex work	15	3 (20)	182	122 (67)	199	127 (64)
Sex work	0	0 (0)	30	23 (77)	33	26 (79)
2004						
No sex work	13	1 (8)	148	106 (72)	163	109 (67)
Sex work	1	1 (100)	22	19 (86)	24	21 (88)
2005						
No sex work	9	4 (44)	137	89 (65)	154	99 (64)
Sex work	1	1 (100)	22	19 (86)	23	20 (87)
2006						
No sex work	6	2 (33)	146	102 (70)	163	113 (69)
Sex work	0	0 (0)	12	10 (83)	12	10 (83)
2007						
No sex work	9	0 (0)	170	129 (76)	183	133 (73)
Sex work	2	2 (100)	11	8 (73)	13	10 (77)
2008						
No sex work	15	6 (40)	219	164 (75)	241	175 (73)
Sex work	0	0 (0)	14	11 (79)	15	11 (73)
2009						
No sex work	11	2 (18)	284	160 (56)	303	168 (55)
Sex work	1	0 (0)	15	8 (53)	17	8 (47)
2010						
No sex work	11	5 (45)	366	239 (65)	384	250 (65)
Sex work	3	1 (33)	24	12 (50)	28	14 (50)
2010 p value		1.000		0.185		0.152

Table 8.19 HCV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year

VICTORIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Non-Indigenous	74	40 (54)	38	18 (47)	112	58 (52)
Indigenous	3	3 (100)	3	2 (67)	6	5 (83)
1996						
Non-Indigenous	119	56 (47)	60	35 (58)	179	91 (51)
Indigenous	5	3 (60)	1	1 (100)	6	4 (67)
1997						
Non-Indigenous	279	134 (48)	137	77 (56)	417	211 (51)
Indigenous	10	6 (60)	2	2 (100)	12	8 (67)
1998						
Non-Indigenous	187	101 (54)	89	47 (53)	276	148 (54)
Indigenous	5	3 (60)	0	0 (0)	5	3 (60)
1999						
Non-Indigenous	124	71 (57)	63	37 (59)	187	108 (58)
Indigenous	9	8 (89)	5	2 (40)	14	10 (71)
2000						
Non-Indigenous	168	109 (65)	107	65 (61)	276	175 (63)
Indigenous	8	5 (63)	7	2 (29)	15	7 (67)
2001						
Non-Indigenous	198	135 (68)	111	82 (74)	311	217 (70)
Indigenous	13	10 (77)	7	5 (71)	20	15 (75)
2002						
Non-Indigenous	143	79 (55)	86	52 (60)	231	133 (58)
Indigenous	6	3 (50)	5	5 (100)	11	8 (73)
2003						
Non-Indigenous	140	94 (67)	83	55 (66)	226	152 (67)
Indigenous	1	0 (0)	5	4 (80)	6	4 (67)
2004						
Non-Indigenous	117	80 (68)	59	43 (73)	178	123 (69)
Indigenous	3	2 (67)	3	3 (100)	6	5 (83)
2005						
Non-Indigenous	94	58 (62)	71	51 (72)	165	109 (66)
Indigenous	5	4 (80)	4	3 (75)	9	7 (78)
2006						
Non-Indigenous	105	72 (69)	59	45 (76)	165	118 (72)
Indigenous	7	6 (86)	6	4 (67)	13	10 (77)
2007						
Non-Indigenous	123	87 (71)	60	46 (77)	184	134 (73)
Indigenous	9	9 (100)	3	0 (0)	12	9 (75)
2008						
Non-Indigenous	165	121 (73)	77	50 (65)	242	171 (71)
Indigenous	16	14 (88)	10	6 (60)	26	20 (77)
2009						
Non-Indigenous	195	52 (51)	102	52 (51)	299	164 (55)
Indigenous	12	8 (73)	11	8 (73)	23	15 (65)
2010						
Non-Indigenous	281	192 (68)	113	66 (58)	396	260 (66)
Indigenous	18	10 (56)	17	6 (35)	35	16 (46)
2010 p value		0.301		0.115		0.026

Table 8.20 HCV antibody prevalence by country of birth, gender and year

VICTORIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2003						
Australia	122	79 (65)	76	50 (66)	200	131 (66)
Other	20	15 (75)	14	9 (64)	35	25 (71)
2004						
Australia	99	67 (68)	54	39 (72)	155	106 (68)
Other	22	15 (68)	11	9 (82)	33	24 (73)
2005						
Australia	79	46 (58)	64	47 (73)	143	93 (65)
Other	22	18 (82)	12	8 (67)	34	26 (76)
2006						
Australia	96	67 (70)	57	42 (74)	154	110 (71)
Other	20	13 (65)	9	7 (78)	29	20 (69)
2007						
Australia	114	85 (75)	56	40 (71)	171	126 (74)
Other	20	12 (60)	8	7 (88)	28	19 (68)
2008						
Australia	159	120 (75)	76	47 (62)	235	167 (71)
Other	27	19 (70)	14	11 (79)	41	30 (73)
2009						
Australia	180	105 (58)	99	51 (52)	281	158 (56)
Other	31	14 (45)	16	9 (56)	47	23 (49)
2010						
Australia	260	178 (68)	122	65 (53)	383	244 (64)
Other	37	22 (59)	7	6 (86)	44	28 (64)
2010 p value		0.349		0.128		1.000

Table 8.21 HCV antibody prevalence by language spoken at home by parents, gender and year

VICTORIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2003						
English speaking	130	85 (65)	84	53 (63)	217	141 (65)
Non-English speaking	9	7 (78)	5	5 (100)	14	12 (86)
2004						
English speaking	77	53 (69)	53	38 (72)	132	91 (69)
Non-English speaking	19	12 (63)	6	4 (67)	25	16 (64)
2005						
English speaking	80	51 (64)	64	45 (70)	144	96 (67)
Non-English speaking	21	13 (62)	12	10 (83)	33	23 (70)
2006						
English speaking	104	72 (69)	62	45 (73)	167	118 (71)
Non-English speaking	6	3 (50)	3	3 (100)	9	6 (67)
2007						
English speaking	126	92 (73)	60	43 (72)	187	136 (73)
Non-English speaking	10	7 (70)	4	4 (100)	14	11 (79)
2008						
English speaking	162	120 (74)	85	57 (67)	247	177 (72)
Non-English speaking	21	17 (81)	5	1 (20)	26	18 (69)
2009						
English speaking	193	107 (55)	103	54 (52)	298	163 (55)
Non-English speaking	18	12 (67)	10	5 (50)	28	17 (61)
2010						
English speaking	277	188 (68)	126	69 (55)	404	258 (64)
Non-English speaking	23	13 (57)	2	2 (100)	25	15 (60)
2010 p value		0.356		0.502		0.675

9. WESTERN AUSTRALIA


Western Australia Substance Users Association (WASUA) commenced ANSPS participation in 1995, participating in all years between 1995 and 2010. In 1998, the mobile NSP operated by Western Australia AIDS Council commenced participation, and participated in all subsequent years (1998 to 2010). In addition, WASUA's Bunbury-based NSP service participated in the ANSPS between 2001 and 2006, and recommenced participation in 2010. Appendix 1 provides a detailed breakdown of site participation by survey year. Western Australian sample sizes ranged from 30 (in 1995) to 222 (in 2009). Response rates ranged between 28% (in 1997) and 80% (in 2009).

Demographic Characteristics

Across all survey years, between 54% and 71% of Western Australian ANSPS participants were male and the majority of respondents (74% to 85%) identified as heterosexual. Whereas the proportion of Indigenous participants increased nationally over the survey period 1995 to 2010, this was not the case in Western Australia (χ^2 trend $p=0.522$) where Indigenous participants comprised 0% to 9% of the ANSPs samples over the same period. The majority of Western Australian respondents were born in Australia (79% to 88%) and reported their parents spoke English at home (67% to 93%) across all years in which these data were collected.

The median age of Western Australian respondents was stable at 27-28 years between 1995 and 2000, subsequently increasing to a high of 40 years in 2010 (Figure 9.1). The proportion of young people (aged younger than 25 years) ranged from 30% to 41% during the late 1990s, but declined significantly in later years, from 34% in 2000 to just 4% in 2010 (χ^2 trend $p<0.001$). The median age at first injection remained stable at 17-18 years between 1995 and 2010 (Table 9.1).

Figure 9.1 WA: Median age and proportion young injectors by year




Injecting behaviour

Consistent with patterns observed nationally, Western Australian participants were most likely to report last injecting either heroin or methamphetamine in all survey years. The proportion of Western Australian respondents who reported last injecting heroin was highest over the period 1996 to 1999, at around two thirds of Western Australian samples (Figure 9.2, Table 9.2). Prevalence of recent heroin injection declined dramatically in the early 2000s, from 66% in 2000 to just 15% in 2002. This decline occurred around the time of well documented changes in heroin availability in Australia (Maher et al., 2007; Degenhardt et al. 2006; Topp et al., 2003), although the Western Australian decline appeared to commence in 2000, before the decline was reflected nationally. Between 2002 and 2006, 19% to 25% of Western Australian participants reported last injecting heroin, with prevalence increasing to 30% to 33% between 2008 and 2010.

Conversely, the proportion of Western Australian participants who reported last injecting methamphetamine was low during the period 1996 to 2000, at between 13% and 22% (Figure 9.2, Table 9.2). Prevalence subsequently increased to between 34% and 56% of Western Australian samples during the early 2000s. As occurred nationally and elsewhere, prevalence of recent methamphetamine injection declined during the last half of the 2000s, and was 26% in 2010.


Figure 9.2 WA: Prevalence of heroin and methamphetamine as drug last injected by year



As occurred nationally and in other jurisdictions, prevalence of recent injection of pharmaceutical opioids increased significantly throughout the 2000s (χ^2 trend $p < 0.001$). The proportion of Western Australian participants who reported last injecting this class of drugs increased from 5% in 2000 to a high of 21% in 2007 and 2008. Reports of recent injection of cocaine or performance and image enhancing drugs were rare at 1% or less across all years from 1995 to 2010.


There were significant reductions in self-reported blood borne viral transmission risk behaviours among Western Australian respondents over the survey period. The proportion of respondents reporting re-use of needles and syringes (including re-use of one's own needle/syringe) in the month preceding ANSPS participation declined from a high of 55% in 1999 to a low of 26% in 2010 (χ^2 trend $p < 0.001$, Figure 9.3). Similarly, rates of recent receptive sharing (use of someone else's used needle/syringe) declined from a high of 31% in 1995 and 2000 to 14% in 2010 (χ^2 trend $p = 0.008$). Rates of receptive sharing of spoons, water and filters also decreased significantly between 1999 (when collection of these data commenced) and 2010 (χ^2 trend $p \leq 0.001$ for all three of these ancillary items).

Figure 9.3 WA: Re-use and receptive sharing of syringes by year



The proportion of Western Australian participants who reported injection in a public place in the month prior to survey completion varied between 38% and 61% over the survey period with no consistent trend observed over time (χ^2 trend $p = 0.109$). Western Australian rates of public injection were similar to those observed nationally in most survey years (Figure 9.4).


Figure 9.4 National and WA: Prevalence of public injection by year



HIV prevalence

HIV antibody prevalence among Western Australian ANSPS samples remained low at less than 2% in all years between 1996 and 2010 (Figure 9.5). HIV antibody prevalence was higher at 8.1% in 1995. Notably, the Western Australian sample comprised just 30 participants in that year. Just over half (53%) the HIV antibody positive survey participants were males who reported homosexual identity (Table 9.9). Detailed data on HIV antibody prevalence is not presented in this report due to small cell sizes.


Figure 9.5 WA: HIV antibody prevalence by year



HCV prevalence

HCV antibody prevalence in Western Australia fluctuated between 41% and 58% over the survey period, although an overall increase in prevalence was observed between 1995 and 2010 (χ^2 trend $p=0.004$, Figure 9.6, Table 9.10).

Figure 9.6 National and WA: HCV antibody prevalence by year



In most years between 1995 and 2010, HCV antibody prevalence was higher among Western Australian participants who were older (Table 9.12) and who reported a longer injection history (Table 9.13). As observed nationally and in most other jurisdictions, HCV antibody prevalence was higher among respondents who reported last injecting heroin compared to those who reported last injecting methamphetamine (Figure 9.7, Table 9.14).

Figure 9.7 WA: HCV antibody prevalence and drug last injected by year




Table 9.1 Number (percentage) of respondents by demographic characteristic and year

WESTERN AUSTRALIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
Number of sites	1	1	1	2	2	2	3	3	3	3	3	3	2	2	2	3
N° surveyed	N=30	N=83	N=48	N=161	N=86	N=143	N=164	N=127	N=133	N=161	N=170	N=160	N=110	N=196	N=222	N=219
Response rate	29%	51%	28%	40%	43%	68%	57%	73%	--	65%	48%	53%	51%	73%	80%	56%
Gender (%)																
Male	18 (60)	51 (62)	26 (54)	97 (60)	53 (62)	101 (71)	100 (60)	90 (71)	75 (56)	99 (61)	110 (65)	104 (65)	71 (65)	123 (63)	134 (60)	127 (58)
Female	12 (40)	30 (36)	22 (46)	62 (38)	33 (38)	42 (29)	62 (38)	37 (29)	57 (43)	61 (38)	60 (35)	55 (34)	39 (35)	73 (37)	87 (39)	92 (42)
Transgender	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	1 (<1)	0 (0)
Not reported	0 (0)	2 (2)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)																
Heterosexual	23 (77)	68 (82)	38 (79)	123 (77)	65 (76)	105 (74)	131 (80)	99 (78)	104 (78)	133 (83)	138 (81)	135 (84)	93 (85)	158 (81)	185 (83)	183 (84)
Bisexual	5 (17)	9 (11)	7 (15)	18 (11)	11 (13)	14 (10)	11 (7)	11 (9)	9 (7)	11 (7)	14 (8)	14 (9)	8 (7)	22 (11)	15 (7)	14 (6)
Homosexual	2 (6)	5 (6)	3 (6)	15 (9)	6 (7)	15 (10)	8 (5)	7 (6)	7 (5)	8 (5)	8 (5)	7 (4)	7 (6)	7 (4)	10 (5)	8 (4)
Not reported	0 (0)	1 (1)	0 (0)	5 (3)	4 (4)	9 (6)	14 (8)	10 (8)	13 (10)	9 (5)	10 (6)	4 (3)	2 (2)	9 (5)	12 (5)	14 (6)
Age and time since first injection (years)																
<i>Median age</i>	27.5	27.5	27	28	28	28	29	33	34	35	36	35	36.5	35	36	40
<i>Age range</i>	16-43	16-43	20-51	15-54	17-51	16-49	15-55	14-53	16-55	16-60	17-57	16-68	16-55	17-65	15-62	18-63
<i>Age group (%)</i>																
< 25 years	9 (30)	34 (41)	17 (35)	53 (33)	27 (31)	48 (34)	50 (30)	27 (21)	18 (14)	30 (19)	31 (18)	18 (11)	10 (9)	12 (6)	16 (7)	8 (4)
25+ years	21 (70)	48 (58)	31 (65)	108 (67)	59 (69)	93 (65)	114 (70)	100 (79)	115 (86)	130 (81)	139 (82)	142 (89)	100 (91)	183 (93)	206 (93)	211 (96)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	17	18	18	18	18	18	17	18	18	17	18	18	18	18	18	18
<i>Age range</i>	14-34	12-33	12-36	11-44	11-42	12-42	12-43	12-46	12-46	10-40	12-40	12-46	12-49	11-47	11-52	11-50
N° not reported	0	4	0	6	2	12	7	5	6	5	3	0	2	5	7	3
<i>Median years IDU</i>	10.5	7	7	8	8	8	10	11	14	13	15	15	15	15	16	18
<i>Range</i>	<1-23	1-29	2-32	<1-27	<1-28	<1-28	<1-35	<1-35	<1-39	<1-46	<1-37	<1-41	<1-37	<1-42	<1-44	<1-47
<i>Time since first injection</i>																
<3 years	7 (23)	19 (23)	5 (10)	21 (13)	8 (9)	16 (11)	19 (12)	9 (7)	10 (8)	8 (5)	5 (3)	5 (3)	8 (7)	3 (2)	9 (4)	11 (5)
3+ years	23 (77)	59 (71)	43 (90)	133 (83)	76 (88)	112 (78)	138 (84)	113 (89)	117 (88)	148 (92)	161 (95)	153 (96)	100 (91)	188 (96)	206 (93)	205 (94)
Not reported	0 (0)	5 (6)	0 (0)	7 (4)	2 (2)	15 (10)	7 (4)	5 (4)	6 (4)	5 (3)	4 (2)	2 (1)	2 (2)	5 (3)	7 (3)	3 (1)

Table 9.1 Number (percentage) of respondents by demographic characteristic and year (continued)

WESTERN AUSTRALIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=30	N=83	N=48	N=161	N=86	N=143	N=164	N=127	N=133	N=161	N=170	N=160	N=110	N=196	N=222	N=219
Aboriginal and Torres Strait Islander origin (%)																
No	30 (100)	80 (97)	45 (94)	143 (89)	78 (91)	128 (90)	154 (94)	123 (97)	122 (92)	146 (91)	157 (93)	153 (96)	102 (93)	179 (91)	208 (94)	200 (91)
Yes	0 (0)	2 (2)	3 (6)	14 (9)	6 (7)	10 (7)	10 (6)	1 (1)	7 (5)	9 (5)	10 (6)	4 (3)	5 (5)	9 (5)	12 (5)	11 (5)
Not reported	0 (0)	1 (1)	0 (0)	4 (2)	2 (2)	5 (3)	0 (0)	3 (2)	4 (3)	6 (4)	2 (1)	3 (2)	3 (3)	8 (4)	2 (1)	8 (4)
Region/country of birth (%)																
Australia	--	--	--	--	80 (93)	102 (72)	128 (78)	98 (77)	105 (79)	123 (76)	138 (82)	130 (81)	90 (82)	149 (76)	179 (81)	176 (80)
Other Oceania	--	--	--	--	--	7 (5)	7 (4)	3 (2)	6 (4)	6 (4)	6 (4)	3 (2)	1 (1)	16 (8)	8 (4)	13 (6)
Asia	--	--	--	--	0 (0)	3 (2)	1 (1)	6 (5)	0 (0)	5 (3)	2 (1)	0 (0)	1 (1)	2 (1)	5 (2)	3 (1)
UK & Ireland	--	--	--	--	--	19 (13)	17 (10)	9 (7)	14 (11)	17 (11)	16 (9)	12 (8)	9 (8)	18 (9)	18 (8)	16 (7)
Other	--	--	--	--	0 (0)	9 (6)	9 (6)	7 (6)	6 (4)	7 (4)	6 (4)	11 (7)	5 (5)	7 (4)	7 (3)	7 (3)
Not reported	--	--	--	--	6 (7)	3 (2)	2 (1)	4 (3)	2 (2)	3 (2)	2 (1)	4 (3)	4 (4)	4 (2)	5 (2)	4 (2)
Main language spoken at home by parents (%)																
English	--	--	--	--	80 (93)	127 (89)	151 (92)	111 (87)	127 (96)	113 (70)	143 (85)	144 (90)	105 (95)	186 (86)	216 (97)	208 (95)
Non-English	--	--	--	--	0 (0)	13 (9)	7 (4)	10 (8)	3 (2)	15 (9)	26 (15)	6 (4)	2 (2)	10 (5)	5 (2)	7 (3)
Not reported	--	--	--	--	6 (7)	3 (2)	6 (4)	6 (5)	3 (2)	33 (21)	1 (<1)	10 (6)	3 (3)	0 (0)	1 (<1)	4 (2)
Imprisonment last year (%)																
No	25 (83)	68 (82)	39 (81)	133 (83)	75 (87)	116 (81)	133 (81)	113 (89)	110 (83)	127 (79)	146 (86)	130 (81)	85 (77)	168 (86)	193 (87)	160 (73)
Yes	3 (10)	12 (14)	7 (15)	24 (15)	11 (13)	25 (18)	26 (16)	13 (10)	19 (14)	32 (20)	18 (11)	21 (13)	18 (16)	21 (11)	21 (9)	16 (7)
Not reported	2 (7)	3 (4)	2 (4)	4 (2)	0 (0)	2 (1)	5 (3)	1 (1)	4 (3)	2 (1)	6 (4)	9 (6)	7 (6)	7 (4)	8 (4)	43 (20)
Injected in prison last year (%)																
N° in prison	N=3	N=12	N=7	N=24	N=11	N=25	N=26	N=13	N=19	N=32	N=18	N=21	N=18	N=21	N=21	N=16
Injected in prison	2 (67)	4 (33)	3 (43)	8 (33)	2 (18)	10 (40)	14 (54)	4 (31)	7 (37)	17 (53)	11 (61)	7 (33)	6 (33)	8 (38)	7 (33)	3 (19)
Frequency of injection last month (%)																
Not last month	1 (3)	10 (12)	1 (2)	16 (10)	5 (6)	7 (5)	9 (5)	5 (12)	3 (2)	12 (7)	7 (4)	5 (3)	6 (5)	7 (4)	6 (3)	11 (5)
Less than weekly	4 (13)	16 (19)	9 (19)	24 (15)	13 (15)	12 (9)	24 (15)	25 (20)	19 (14)	18 (11)	18 (11)	20 (13)	9 (8)	15 (8)	22 (10)	29 (13)
Weekly not daily	13 (44)	25 (30)	5 (10)	34 (21)	16 (19)	36 (25)	40 (25)	29 (23)	32 (24)	42 (26)	38 (22)	42 (26)	21 (19)	49 (25)	43 (19)	48 (22)
Daily or more	12 (40)	31 (38)	33 (69)	85 (53)	52 (60)	79 (55)	87 (53)	56 (43)	75 (56)	83 (52)	106 (63)	92 (58)	73 (66)	124 (63)	150 (68)	131 (60)
Not reported	0 (0)	1 (1)	0 (0)	2 (1)	0 (0)	9 (6)	4 (2)	2 (2)	4 (3)	6 (4)	1 (<1)	1 (<1)	1 (1)	1 (1)	1 (<1)	0 (0)

Table 9.2 Number (percentage) of respondents by drug last injected and year

WESTERN AUSTRALIA N° surveyed	1995 N=30	1996 N=83	1997 N=48	1998 N=161	1999 N=86	2000 N=143	2001 N=164	2002 N=127	2003 N=133	2004 N=161	2005 N=170	2006 N=160	2007 N=110	2008 N=196	2009 N=222	2010 N=219
Drug last injected (%)																
Anabolic steroids	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	1 (<1)	1 (<1)
Cocaine	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	2 (1)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)
Heroin	13 (43)	56 (68)	32 (67)	101 (62)	57 (66)	71 (49)	24 (15)	25 (19)	39 (29)	31 (19)	48 (28)	30 (19)	28 (25)	62 (32)	74 (33)	66 (30)
Methadone	0 (0)	0 (0)	2 (4)	0 (0)	2 (2)	3 (2)	4 (2)	6 (5)	1 (1)	3 (2)	6 (4)	9 (6)	4 (4)	5 (3)	12 (5)	13 (6)
Methamphetamine	10 (33)	12 (14)	6 (13)	35 (22)	16 (19)	33 (23)	92 (56)	50 (39)	55 (41)	74 (46)	57 (34)	72 (45)	34 (31)	54 (28)	43 (19)	58 (26)
Pharm. opioids	4 (13)	7 (8)	3 (6)	9 (5)	6 (7)	7 (5)	19 (12)	10 (8)	12 (9)	18 (11)	24 (14)	22 (14)	23 (21)	42 (21)	37 (17)	31 (14)
Buprenorphine	--	--	--	--	--	--	--	5 (4)	1 (1)	4 (2)	19 (11)	16 (10)	7 (6)	18 (9)	16 (7)	8 (4)
More than one	2 (7)	4 (5)	2 (4)	11 (7)	5 (6)	16 (11)	14 (9)	15 (12)	9 (7)	21 (13)	4 (2)	4 (3)	5 (5)	10 (5)	11 (5)	22 (10)
Other	1 (3)	4 (5)	3 (6)	1 (1)	0 (0)	1 (1)	5 (3)	10 (8)	11 (8)	0 (0)	5 (3)	1 (<1)	6 (6)	0 (0)	18 (8)	14 (6)
Not reported	0 (0)	0 (0)	0 (0)	3 (2)	0 (0)	10 (7)	4 (2)	4 (3)	4 (3)	8 (5)	7 (4)	1 (<1)	3 (3)	5 (3)	8 (4)	6 (3)

Table 9.3 Number (percentage) of respondents by places injected in the last month and year

WESTERN AUSTRALIA N° injected last month	1995 N=29	1996 N=72	1997 N=47	1998 N=143	1999 N=81	2000 N=127	2001 N=151	2002 N=110	2003 N=126	2004 N=143	2005 N=163	2006 N=154	2007 N=103	2008 N=188	2009 N=215	2010 N=208
Places injected in the last month (%) [more than one could be selected]																
<i>Private places</i>																
Own home	--	--	41 (87)	116 (81)	66 (81)	102 (80)	124 (82)	93 (85)	115 (91)	118 (83)	129 (80)	142 (96)	91 (93)	171 (92)	196 (91)	174 (84)
Friend's home	--	--	28 (60)	78 (55)	39 (48)	70 (55)	75 (50)	42 (38)	56 (44)	68 (48)	57 (35)	73 (49)	48 (49)	100 (54)	107 (50)	79 (38)
Dealer's home	--	--	15 (32)	41 (29)	26 (32)	28 (22)	49 (32)	21 (19)	25 (20)	30 (21)	28 (17)	32 (22)	31 (32)	56 (30)	49 (23)	42 (20)
Commercial injecting room	--	--	5 (11)	1 (1)	0 (0)	2 (2)	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	1 (<1)	0 (0)	2 (1)	1 (<1)	0 (0)
<i>Public places</i>																
Street, park, beach	--	--	14 (30)	41 (29)	27 (33)	46 (36)	50 (33)	21 (19)	26 (21)	37 (26)	25 (15)	27 (18)	23 (23)	55 (30)	51 (24)	45 (22)
Car	--	--	--	49 (34)	33 (41)	61 (48)	58 (38)	38 (35)	42 (33)	46 (32)	49 (30)	57 (39)	41 (42)	80 (43)	75 (35)	61 (29)
Public toilet	--	--	17 (36)	45 (31)	24 (30)	41 (32)	41 (27)	27 (25)	26 (21)	34 (24)	23 (14)	26 (18)	19 (19)	45 (24)	60 (28)	42 (20)
Squat	--	--	--	--	6 (7)	10 (8)	14 (9)	5 (5)	6 (5)	13 (9)	2 (1)	2 (1)	8 (8)	18 (10)	19 (9)	7 (3)
Public injecting in last month (%)																
Any public	--	--	21 (45)	67 (47)	47 (58)	77 (61)	76 (50)	54 (49)	54 (43)	67 (47)	61 (38)	66 (43)	50 (49)	103 (55)	105 (49)	88 (42)
All private	--	--	25 (53)	68 (48)	28 (35)	41 (32)	75 (50)	53 (48)	68 (54)	69 (48)	81 (50)	82 (53)	48 (47)	83 (44)	110 (51)	97 (47)
Not reported	--	--	1 (2)	8 (6)	6 (7)	9 (7)	0 (0)	4 (4)	4 (3)	7 (5)	20 (12)	6 (4)	5 (5)	2 (1)	0 (0)	23 (11)

Table 9.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

WESTERN AUSTRALIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=29	N=72	N=47	N=143	N=81	N=127	N=151	N=110	N=126	N=143	N=163	N=154	N=103	N=188	N=215	N=208
Use of sterile needles and syringes last month (%)																
All injections	--	--	32 (68)	79 (55)	35 (43)	66 (52)	84 (55)	69 (63)	78 (62)	91 (64)	103 (64)	102 (66)	58 (56)	119 (63)	148 (69)	131 (63)
Most of the time	--	--	14 (30)	42 (29)	32 (40)	45 (36)	50 (33)	31 (28)	38 (30)	37 (26)	44 (27)	40 (26)	29 (28)	56 (30)	56 (26)	47 (23)
Half of the time	--	--	0 (0)	10 (7)	8 (10)	8 (6)	6 (4)	7 (6)	5 (4)	8 (5)	5 (3)	6 (4)	6 (6)	5 (3)	4 (2)	5 (2)
Some of the time	--	--	1 (2)	7 (5)	3 (4)	3 (2)	6 (4)	2 (2)	4 (3)	6 (4)	4 (2)	3 (2)	7 (7)	3 (2)	3 (1)	2 (1)
Not last month	--	--	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	1 (<1)	0 (0)	3 (2)	1 (<1)	0 (0)
Not reported	--	--	0 (0)	5 (4)	2 (2)	5 (4)	4 (3)	1 (1)	1 (1)	1 (1)	6 (3)	2 (1)	3 (3)	2 (1)	3 (1)	23 (11)
Re-used someone else's used needle & syringe last month (%)																
None	20 (69)	57 (78)	37 (79)	106 (75)	55 (68)	83 (65)	108 (72)	91 (82)	100 (79)	110 (77)	124 (78)	127 (82)	75 (73)	150 (80)	168 (78)	151 (73)
Once	3 (10)	4 (6)	4 (9)	6 (4)	1 (1)	13 (10)	11 (7)	5 (5)	7 (6)	10 (7)	7 (4)	8 (5)	10 (10)	11 (6)	13 (6)	8 (4)
Twice	2 (7)	4 (6)	2 (4)	13 (9)	10 (13)	8 (6)	15 (10)	5 (5)	7 (6)	11 (8)	9 (6)	4 (3)	1 (1)	10 (5)	12 (6)	13 (6)
3-5 times	2 (7)	3 (4)	3 (6)	6 (4)	6 (7)	9 (7)	8 (5)	4 (4)	5 (4)	7 (5)	8 (5)	5 (3)	11 (11)	8 (4)	12 (6)	4 (2)
> 5 times	2 (7)	4 (6)	1 (2)	6 (4)	7 (9)	10 (8)	4 (3)	3 (3)	4 (3)	4 (3)	3 (2)	6 (4)	3 (3)	8 (4)	6 (3)	4 (2)
Not reported	0 (0)	0 (0)	0 (0)	6 (4)	2 (2)	4 (3)	5 (3)	2 (2)	3 (2)	1 (<1)	9 (5)	4 (3)	3 (3)	1 (1)	4 (2)	28 (13)
Number of people needle & syringe was re-used after last month (%)																
None	20 (69)	57 (79)	37 (79)	106 (75)	55 (68)	83 (65)	108 (72)	91 (82)	97 (77)	110 (77)	119 (73)	127 (82)	75 (73)	150 (80)	168 (78)	151 (73)
One	4 (14)	8 (11)	8 (17)	25 (16)	11 (14)	27 (22)	22 (14)	10 (9)	19 (15)	12 (8)	17 (10)	14 (9)	13 (13)	16 (9)	23 (11)	16 (8)
Two	4 (14)	6 (8)	2 (4)	4 (3)	6 (8)	5 (4)	5 (3)	2 (2)	3 (2)	5 (4)	3 (2)	0 (0)	1 (1)	2 (1)	5 (2)	4 (2)
Three to five	1 (3)	1 (2)	0 (0)	1 (1)	2 (2)	2 (2)	4 (3)	1 (1)	1 (1)	1 (1)	1 (1)	1 (<1)	1 (1)	1 (1)	1 (<1)	1 (<1)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	3 (4)	3 (2)	1 (1)	0 (0)	1 (1)	0 (0)	2 (1)	3 (2)	1 (1)	0 (0)	1 (<1)	1 (<1)
Don't know	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	3 (2)	4 (3)	3 (3)	0 (0)	9 (6)	5 (3)	4 (3)	4 (4)	8 (4)	6 (3)	5 (2)
Not reported	0 (0)	0 (0)	0 (0)	6 (4)	2 (2)	4 (3)	7 (4)	3 (3)	5 (4)	6 (4)	16 (9)	5 (3)	9 (9)	11 (6)	11 (5)	30 (14)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]																
Regular sex partner	--	--	5 (11)	20 (14)	16 (20)	22 (17)	17 (11)	7 (6)	14 (11)	10 (7)	15 (9)	9 (6)	12 (12)	16 (9)	18 (8)	21 (10)
Casual sex partner	--	--	1 (2)	1 (1)	0 (0)	2 (2)	2 (1)	0 (0)	0 (0)	2 (1)	2 (1)	0 (0)	1 (1)	3 (2)	0 (0)	2 (1)
Close friend	--	--	2 (4)	12 (8)	8 (10)	11 (9)	15 (10)	6 (5)	7 (6)	12 (8)	11 (7)	9 (6)	7 (7)	8 (4)	13 (6)	11 (5)
Acquaintance	--	--	1 (2)	1 (2)	7 (9)	4 (3)	9 (6)	3 (3)	3 (2)	1 (1)	4 (2)	1 (<1)	0 (0)	3 (2)	5 (2)	6 (3)
Other	--	--	1 (4)	0 (0)	6 (7)	4 (3)	1 (1)	1 (1)	0 (0)	2 (1)	3 (1)	0 (0)	1 (1)	2 (1)	5 (2)	3 (1)

Table 9.4 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

WESTERN AUSTRALIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° injected last month	N=29	N=72	N=47	N=143	N=81	N=127	N=151	N=110	N=126	N=143	N=163	N=154	N=103	N=188	N=215	N=208
Equipment used after someone else last month (%) [more than one could be selected]																
Spoon	--	--	--	--	39 (48)	46 (36)	53 (35)	25 (23)	28 (22)	32 (22)	31 (19)	25 (16)	22 (22)	37 (23)	48 (24)	36 (17)
Water	--	--	--	--	22 (27)	31 (25)	40 (26)	22 (20)	22 (17)	28 (20)	31 (19)	27 (18)	14 (14)	29 (18)	37 (19)	28 (13)
Filter	--	--	--	--	21 (26)	30 (24)	36 (24)	19 (17)	16 (13)	23 (16)	25 (16)	23 (15)	13 (13)	20 (12)	35 (18)	23 (11)
Drug mix	--	--	--	--	14 (17)	17 (13)	35 (23)	13 (12)	6 (5)	17 (12)	16 (10)	17 (11)	12 (12)	20 (12)	20 (10)	19 (9)
Tourniquet	--	--	--	--	22 (27)	20 (16)	25 (17)	21 (19)	18 (14)	20 (14)	20 (12)	22 (14)	17 (17)	23 (14)	20 (10)	--
None	--	--	--	--	--	--	--	--	--	--	--	97 (63)	63 (64)	100 (61)	131 (66)	126 (61)
Injected by someone after that person injected themselves or others last month (%)																
No	--	--	--	--	62 (77)	90 (71)	114 (76)	86 (78)	100 (79)	122 (85)	126 (78)	129 (84)	83 (81)	150 (80)	172 (80)	160 (77)
Yes	--	--	--	--	17 (21)	31 (25)	31 (20)	20 (19)	22 (17)	20 (14)	24 (15)	22 (14)	16 (16)	30 (16)	39 (18)	23 (11)
Not reported	--	--	--	--	2 (2)	5 (4)	6 (4)	3 (3)	4 (3)	1 (1)	13 (7)	3 (2)	4 (4)	8 (4)	4 (2)	25 (12)

Table 9.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

WESTERN AUSTRALIA	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
N° surveyed	N=30	N=83	N=48	N=161	N=86	N=143	N=164	N=127	N=133	N=161	N=170	N=160	N=110	N=196	N=222	N=219
Sex with a regular partner last month (%)																
No	--	--	--	--	--	--	--	--	--	--	86 (51)	77 (48)	42 (38)	81 (41)	103 (46)	99 (45)
Yes	--	--	--	--	--	--	--	--	--	--	82 (49)	77 (48)	66 (60)	113 (58)	113 (51)	109 (50)
Not reported	--	--	--	--	--	--	--	--	--	--	2 (1)	6 (4)	2 (2)	2 (1)	6 (3)	11 (5)
Condom used with regular partner last month (%)																
Never	--	--	--	--	--	--	--	--	--	--	N=82	N=77	N=66	N=113	N=113	N=109
Sometimes	--	--	--	--	--	--	--	--	--	--	59 (72)	57 (74)	46 (70)	80 (71)	89 (79)	77 (71)
Every time	--	--	--	--	--	--	--	--	--	--	8 (10)	9 (12)	8 (12)	12 (11)	12 (11)	12 (11)
Not reported	--	--	--	--	--	--	--	--	--	--	11 (13)	5 (6)	8 (12)	14 (12)	5 (4)	12 (11)
Sex with other partner(s) last month (%)																
No	--	--	--	--	--	--	--	--	--	--	134 (79)	124 (78)	97 (88)	164 (84)	180 (81)	187 (85)
Yes	--	--	--	--	--	--	--	--	--	--	32 (19)	29 (18)	11 (10)	29 (15)	32 (14)	22 (10)
Not reported	--	--	--	--	--	--	--	--	--	--	4 (2)	7 (4)	2 (2)	3 (2)	10 (5)	10 (5)

Table 9.5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

WESTERN AUSTRALIA N° surveyed	1995 N=30	1996 N=83	1997 N=48	1998 N=161	1999 N=86	2000 N=143	2001 N=164	2002 N=127	2003 N=133	2004 N=161	2005 N=170	2006 N=160	2007 N=110	2008 N=196	2009 N=215	2010 N=219	
Condom used with other partner(s) last month (%)																	
Never	--	--	--	--	--	--	--	--	--	--	N=32 8 (25)	N=29 10 (34)	N=11 2 (18)	N=29 6 (21)	N=32 12 (38)	N=22 8 (36)	
Sometimes	--	--	--	--	--	--	--	--	--	--	10 (31)	3 (10)	4 (36)	14 (48)	9 (28)	6 (27)	
Every time	--	--	--	--	--	--	--	--	--	--	13 (41)	14 (48)	5 (45)	7 (24)	11 (34)	8 (36)	
Not reported	--	--	--	--	--	--	--	--	--	--	1 (3)	2 (7)	0 (0)	2 (7)	0 (0)	0 (0)	
Sex last month (%)																	
No	11 (37)	31 (37)	16 (33)	42 (26)	26 (30)	44 (31)	45 (27)	33 (26)	40 (30)	51 (32)	--	--	--	--	--	--	
Yes	19 (63)	50 (61)	30 (63)	116 (72)	59 (69)	98 (68)	118 (72)	89 (70)	89 (67)	103 (64)	--	--	--	--	--	--	
Not reported	0 (0)	2 (2)	2 (4)	3 (2)	1 (1)	1 (1)	1 (1)	5 (4)	4 (3)	7 (4)	--	--	--	--	--	--	
Condom use at last sex (%)																	
No	13 (43)	31 (37)	29 (61)	94 (58)	64 (74)	84 (59)	122 (75)	89 (70)	97 (73)	116 (72)	--	--	--	--	--	--	
Yes	8 (27)	20 (24)	17 (35)	63 (39)	22 (26)	53 (37)	38 (23)	36 (28)	31 (23)	43 (27)	--	--	--	--	--	--	
Not reported	9 (30)	32 (39)	2 (4)	4 (3)	0 (0)	6 (4)	4 (2)	2 (2)	5 (4)	2 (1)	--	--	--	--	--	--	
Condom use with regular sex partner(s) last month (%)																	
No	--	27 (57)	13 (48)	58 (62)	39 (76)	52 (64)	53 (70)	44 (73)	42 (74)	51 (73)	--	--	--	--	--	--	
Sometimes	--	6 (13)	6 (22)	15 (16)	4 (8)	10 (12)	8 (10)	7 (12)	3 (5)	5 (7)	--	--	--	--	--	--	
Always	--	14 (30)	8 (30)	20 (22)	8 (16)	20 (24)	15 (20)	9 (15)	12 (21)	14 (20)	--	--	--	--	--	--	
Condom use with new sex partner(s) last month (%)																	
No	--	6 (35)	4 (31)	13 (33)	7 (35)	10 (28)	33 (53)	20 (51)	15 (50)	26 (49)	--	--	--	--	--	--	
Sometimes	--	0 (0)	1 (8)	9 (22)	3 (15)	7 (19)	9 (15)	8 (21)	5 (17)	6 (11)	--	--	--	--	--	--	
Always	--	11 (65)	8 (61)	18 (45)	10 (50)	19 (53)	20 (32)	11 (28)	10 (33)	21 (40)	--	--	--	--	--	--	
Condom use with casual sex partner(s) last month (%)																	
No	--	--	--	17 (38)	7 (32)	9 (23)	28 (47)	19 (51)	13 (50)	20 (43)	--	--	--	--	--	--	
Sometimes	--	--	--	7 (16)	1 (4)	9 (23)	12 (20)	5 (14)	2 (8)	5 (11)	--	--	--	--	--	--	
Always	--	--	--	21 (46)	14 (64)	21 (54)	20 (33)	13 (35)	11 (42)	21 (46)	--	--	--	--	--	--	
Sex work last month (%)																	
No	26 (86)	76 (92)	35 (75)	136 (85)	78 (91)	126 (88)	152 (93)	115 (91)	115 (86)	141 (88)	160 (94)	145 (91)	99 (90)	177 (90)	203 (91)	200 (91)	
Yes	2 (7)	7 (8)	8 (17)	20 (12)	8 (9)	15 (11)	8 (5)	8 (6)	13 (10)	16 (10)	8 (5)	10 (6)	4 (4)	11 (6)	11 (5)	6 (3)	
Not reported	2 (7)	0 (0)	4 (8)	5 (3)	0 (0)	2 (1)	4 (2)	4 (3)	5 (4)	4 (2)	2 (1)	5 (3)	7 (6)	8 (4)	8 (4)	13 (6)	
Condom used at last sex work (%)																	
Yes	1 (50)	5 (71)	7 (88)	17 (89)	7 (88)	12 (92)	6 (86)	6 (75)	11 (85)	13 (81)	4 (50)	7 (88)	4 (100)	9 (82)	8 (73)	5 (83)	

Table 9.6 Number (percentage) of respondents by previous testing for HIV, HBV, HCV infection, HBV vaccination and HCV treatment by year

WESTERN AUSTRALIA N° surveyed	1995 N=30	1996 N=83	1997 N=48	1998 N=161	1999 N=86	2000 N=143	2001 N=164	2002 N=127	2003 N=133	2004 N=161	2005 N=170	2006 N=160	2007 N=110	2008 N=196	2009 N=222	2010 N=219
Previous HIV test (%)																
Yes, last year	13 (43)	62 (75)	35 (73)	107 (66)	62 (72)	104 (73)	100 (61)	75 (59)	90 (68)	100 (62)	96 (56)	83 (52)	58 (53)	99 (51)	111 (50)	113 (52)
> 1 year ago	11 (37)	8 (10)	11 (23)	34 (21)	19 (22)	23 (16)	46 (28)	37 (29)	30 (23)	39 (24)	48 (28)	61 (38)	38 (35)	75 (38)	78 (35)	60 (27)
Never tested	2 (7)	1 (1)	0 (0)	18 (11)	5 (6)	16 (11)	17 (10)	15 (12)	12 (9)	21 (13)	25 (15)	12 (8)	12 (11)	14 (7)	26 (12)	33 (15)
Not reported	4 (13)	12 (14)	2 (4)	2 (1)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	1 (1)	1 (1)	4 (3)	2 (2)	8 (4)	7 (3)	13 (6)
Self report HBV infection (%)																
No	23 (77)	65 (78)	32 (67)	112 (70)	59 (69)	115 (81)	118 (72)	85 (67)	96 (72)	106 (66)	120 (71)	121 (76)	79 (72)	--	--	--
Yes	6 (20)	18 (22)	12 (25)	27 (17)	16 (19)	19 (13)	25 (15)	26 (21)	26 (20)	33 (21)	30 (18)	18 (11)	12 (11)	--	--	--
Don't know	--	--	4 (8)	19 (12)	8 (9)	9 (6)	19 (12)	13 (10)	8 (6)	20 (12)	19 (11)	16 (10)	17 (15)	--	--	--
Not reported	1 (3)	0 (0)	0 (0)	3 (1)	3 (3)	0 (0)	2 (1)	3 (2)	3 (2)	2 (1)	1 (1)	5 (3)	2 (2)	--	--	--
Self report HBV vaccination (%)																
No	15 (50)	46 (55)	29 (60)	63 (39)	33 (38)	62 (43)	61 (37)	49 (39)	51 (38)	57 (35)	72 (42)	49 (31)	37 (34)	--	--	--
Yes	14 (47)	35 (42)	14 (29)	66 (41)	45 (52)	70 (49)	80 (49)	67 (53)	75 (56)	82 (51)	79 (46)	93 (58)	60 (55)	--	--	--
Don't know	--	--	5 (10)	25 (16)	6 (7)	8 (6)	19 (12)	8 (6)	6 (5)	18 (11)	18 (11)	13 (8)	10 (9)	--	--	--
Not reported	1 (3)	2 (2)	0 (0)	7 (4)	2 (2)	3 (2)	4 (2)	3 (2)	1 (<1)	4 (2)	1 (<1)	5 (3)	3 (3)	--	--	--
Previous HCV test (%)																
Yes, ever	25 (83)	63 (76)	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Yes, last year	--	--	34 (71)	117 (73)	61 (71)	112 (78)	115 (70)	81 (70)	94 (71)	106 (66)	103 (61)	94 (59)	62 (56)	108 (55)	128 (58)	124 (57)
> 1 year ago	--	--	10 (21)	23 (14)	20 (23)	16 (11)	34 (21)	29 (21)	29 (22)	30 (19)	45 (27)	52 (33)	34 (31)	65 (33)	71 (32)	63 (29)
Never tested	3 (10)	17 (20)	2 (4)	18 (11)	5 (6)	14 (10)	15 (9)	17 (13)	9 (7)	23 (14)	19 (11)	11 (7)	11 (10)	15 (8)	15 (7)	13 (6)
Not reported	2 (7)	3 (4)	2 (4)	3 (2)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	2 (1)	3 (2)	3 (2)	3 (3)	8 (4)	8 (4)	19 (9)
Any treatment for HCV (%)																
Interferon/+Ribavirin	--	--	--	--	3 (11)	1 (2)	7 (12)	2 (5)	1 (2)	8 (13)	3 (5)	5 (8)	2 (6)	9 (10)	13 (14)	19 (16)
Other	--	--	--	--	0 (0)	3 (6)	2 (3)	1 (3)	1 (2)	0 (0)	1 (2)	2 (3)	1 (3)	4 (4)	1 (1)	2 (2)
No treatment	--	--	--	--	25 (89)	43 (88)	50 (84)	35 (91)	53 (94)	54 (87)	62 (94)	54 (83)	27 (87)	75 (83)	72 (78)	92 (77)
Not reported	--	--	--	--	0 (0)	2 (4)	1 (2)	0 (0)	1 (2)	0 (0)	0 (0)	4 (6)	1 (3)	2 (2)	6 (7)	7 (6)
Current treatment for HCV (%)																
Interferon/ + Ribavirin	--	--	--	--	1	0	2	0	0	3	2	1	1	3	5	4
Other	--	--	--	--	0	2	0	1	1	0	0	1	0	2	0	1

Table 9.7 Number (percentage) of respondents by treatment for drug use and year

WESTERN AUSTRALIA N° surveyed	1995 N=30	1996 N=83	1997 N=48	1998 N=161	1999 N=86	2000 N=143	2001 N=164	2002 N=127	2003 N=133	2004 N=161	2005 N=170	2006 N=160	2007 N=110	2008 N=196	2009 N=222	2010 N=219	
Ever any treatment/therapy for drug use (%)																	
No	13 (43)	37 (45)	13 (27)	57 (35)	26 (30)	48 (34)	53 (32)	39 (31)	47 (35)	39 (24)	40 (24)	41 (26)	31 (28)	54 (28)	57 (26)	50 (23)	
Yes	17 (57)	46 (55)	33 (69)	102 (64)	60 (70)	93 (65)	111 (68)	87 (68)	85 (64)	121 (75)	126 (74)	113 (71)	76 (69)	139 (71)	158 (71)	165 (75)	
Not reported	0 (0)	0 (0)	2 (4)	2 (1)	0 (0)	2 (1)	0 (0)	1 (1)	1 (1)	1 (1)	5 (2)	6 (4)	3 (3)	3 (2)	7 (3)	4 (2)	
History of methadone maintenance treatment (%)																	
Current	11 (37)	20 (24)	20 (42)	35 (22)	36 (30)	28 (20)	37 (22)	22 (17)	27 (20)	28 (17)	50 (30)	30 (19)	21 (19)	39 (20)	53 (24)	53 (25)	
Previous	5 (17)	15 (18)	4 (8)	23 (14)	13 (15)	29 (20)	39 (24)	37 (29)	37 (28)	43 (27)	34 (20)	43 (27)	27 (25)	55 (28)	52 (23)	56 (26)	
Never	14 (47)	48 (58)	22 (46)	101 (63)	47 (55)	84 (59)	88 (54)	67 (53)	68 (51)	89 (55)	83 (49)	84 (53)	60 (55)	99 (51)	112 (50)	97 (44)	
Not reported	0 (0)	0 (0)	2 (4)	2 (1)	0 (0)	2 (1)	0 (0)	1 (1)	1 (1)	1 (1)	4 (2)	3 (2)	2 (2)	3 (2)	5 (2)	11 (5)	
History of other pharmacotherapy treatment (%)																	
Current	--	--	--	--	--	9 (6)	17 (10)	22 (17)	22 (16)	28 (17)	42 (25)	25 (16)	14 (13)	28 (14)	35 (16)	32 (15)	
Previous	--	--	--	--	--	36 (25)	30 (18)	23 (18)	29 (22)	31 (19)	29 (17)	34 (21)	34 (31)	52 (27)	41 (18)	43 (20)	
Never	--	--	--	--	--	93 (65)	116 (71)	80 (63)	81 (61)	101 (63)	95 (56)	96 (60)	58 (53)	114 (58)	144 (65)	144 (66)	
Not reported	--	--	--	--	--	5 (4)	1 (1)	2 (2)	1 (1)	1 (1)	4 (2)	5 (3)	4 (4)	2 (1)	1 (1)	0 (0)	

Table 9.8 Number (percentage) of respondents by source of needle and syringe acquisition in the month prior to survey and year

WESTERN AUSTRALIA N° injected last month	1995 N=29	1996 N=72	1997 N=47	1998 N=143	1999 N=81	2000 N=127	2001 N=151	2002 N=110	2003 N=126	2004 N=143	2005 N=163	2006 N=154	2007 N=103	2008 N=188	2009 N=215	2010 N=208	
Needle/syringe acquisition in the last month (%) [more than one could be selected]																	
Needle Syringe Program	--	--	--	--	70 (86)	109 (86)	133 (88)	98 (89)	113 (90)	128 (90)	148 (91)	142 (92)	52 (50)	159 (85)	102 (47)	175 (84)	
Pharmacy	--	--	--	--	59 (73)	85 (67)	91 (60)	58 (53)	74 (59)	67 (47)	65 (40)	77 (50)	35 (34)	96 (51)	72 (33)	55 (26)	
Personal Sources	--	--	--	--	--	--	--	--	--	--	--	--	35 (34)	--	46 (21)	32 (15)	
Vending Machine	--	--	--	--	--	--	--	--	--	--	--	--	1 (1)	--	0 (0)	1 (1)	
Other sources	--	--	--	--	--	--	--	--	--	--	--	--	2 (2)	--	5 (2)	4 (2)	
Onward supply of syringes in last month (%)																	
Yes, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	48 (47)	--	21 (30)	89 (43)	
No, onward supply	--	--	--	--	--	--	--	--	--	--	--	--	37 (36)	--	39 (56)	119 (57)	
Not reported	--	--	--	--	--	--	--	--	--	--	--	--	18 (17)	--	10 (14)	0 (0)	

HIV ANTIBODY PREVALENCE

Table 9.9 HIV antibody prevalence by gender and year

WESTERN AUSTRALIA	Male		Female			Total		
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	(%)	N ^o tested	N ^o with HIV (%)	(%)
1995	14	2 (14.3)	10	0 (0.0)		24	2 (8.3)	
1996	51	1 (2.0)	30	0 (0.0)		83	1 (1.2)	
1997	12	0 (0.0)	7	0 (0.0)		19	0 (0.0)	
1998	76	1 (1.3)	48	1 (2.1)		126	2 (1.6)	
1999	53	0 (0.0)	32	0 (0.0)		85	0 (0.0)	
2000	56	0 (0.0)	19	0 (0.0)		75	0 (0.0)	
2001	83	0 (0.0)	49	0 (0.0)		134	0 (0.0)	
2002	87	0 (0.0)	36	0 (0.0)		123	0 (0.0)	
2003	75	0 (0.0)	57	0 (0.0)		133	0 (0.0)	
2004	69	0 (0.0)	43	0 (0.0)		113	0 (0.0)	
2005	100	3 (3.0)	55	0 (0.0)		156	3 (1.9)	
2006	82	1 (1.2)	49	0 (0.0)		132	1 (0.8)	
2007	54	1 (1.9)	31	0 (0.0)		85	1 (1.2)	
2008	106	2 (1.9)	62	0 (0.0)		168	2 (1.2)	
2009	126	1 (0.8)	85	1 (1.2)		212	2 (0.9)	
2010	121	0 (0.0)	92	1 (1.1)		213	1 (0.5)	
χ^2 trend p value		0.401		0.616			0.583	

HCV ANTIBODY PREVALENCE

Table 9.10 HCV antibody prevalence by gender and year

WESTERN AUSTRALIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	13	6 (46)	10	5 (50)	23	11 (48)
1996	47	17 (37)	30	13 (42)	78	32 (41)
1997	12	6 (50)	7	3 (43)	19	9 (47)
1998	76	32 (42)	48	19 (40)	126	52 (41)
1999	53	28 (53)	32	15 (47)	85	43 (51)
2000	57	27 (47)	21	5 (24)	78	32 (41)
2001	84	49 (58)	51	24 (47)	137	75 (55)
2002	87	34 (39)	37	19 (51)	124	53 (43)
2003	75	47 (63)	57	29 (51)	133	77 (58)
2004	69	42 (61)	43	22 (51)	113	65 (58)
2005	101	59 (58)	55	31 (56)	156	90 (58)
2006	82	46 (56)	49	30 (61)	132	76 (58)
2007	54	23 (43)	31	14 (45)	85	37 (44)
2008	101	59 (58)	59	32 (54)	160	91 (57)
2009	125	60 (48)	85	42 (49)	211	102 (48)
2010	119	65 (55)	92	54 (59)	211	119 (56)
χ^2 trend p value		0.040		0.016		0.004

Table 9.11 HCV antibody prevalence by sexual identity, gender and year

WESTERN AUSTRALIA	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heterosexual	10	4 (40)	7	4 (57)	17	8 (47)
Bisexual	1	1 (100)	3	1 (33)	4	2 (50)
Homosexual	2	1 (50)	0	0 (0)	2	1 (50)
1996						
Heterosexual	41	17 (41)	23	12 (52)	66	31 (47)
Bisexual	3	1 (33)	6	2 (33)	9	3 (33)
Homosexual	3	2 (67)	1	1 (100)	4	3 (75)
1997						
Heterosexual	11	6 (55)	4	3 (75)	15	9 (60)
Bisexual	1	0 (0)	1	0 (0)	2	0 (0)
Homosexual	12	6 (50)	2	0 (0)	2	0 (0)
1998						
Heterosexual	64	26 (41)	32	13 (41)	96	39 (41)
Bisexual	4	2 (50)	7	3 (43)	12	5 (42)
Homosexual	6	3 (50)	8	3 (38)	14	6 (43)
1999						
Heterosexual	45	25 (56)	20	9 (45)	65	34 (52)
Bisexual	5	2 (40)	5	2 (40)	10	4 (40)
Homosexual	1	1 (100)	5	2 (40)	6	3 (50)
2000						
Heterosexual	49	24 (49)	10	3 (30)	59	27 (46)
Bisexual	3	1 (33)	5	0 (0)	8	1 (13)
Homosexual	3	1 (33)	5	2 (40)	8	3 (38)
2001						
Heterosexual	71	40 (56)	36	19 (53)	108	60 (56)
Bisexual	3	3 (100)	9	1 (11)	12	4 (33)
Homosexual	3	1 (33)	3	2 (67)	7	4 (57)
2002						
Heterosexual	75	31 (41)	23	14 (61)	98	45 (46)
Bisexual	1	0 (0)	10	3 (30)	11	3 (27)
Homosexual	4	1 (25)	2	0 (0)	6	1 (17)
2003						
Heterosexual	66	41 (62)	38	19 (50)	104	60 (58)
Bisexual	1	0 (0)	8	6 (75)	9	6 (67)
Homosexual	2	1 (50)	5	1 (20)	7	2 (29)
2004						
Heterosexual	61	38 (62)	35	17 (49)	96	55 (57)
Bisexual	0	0 (0)	5	3 (60)	5	3 (60)
Homosexual	4	2 (50)	3	2 (67)	7	4 (57)
2005						
Heterosexual	89	56 (63)	37	21 (57)	126	77 (61)
Bisexual	4	0 (0)	10	5 (50)	14	5 (36)
Homosexual	4	1 (25)	3	1 (33)	7	2 (29)
2006						
Heterosexual	73	43 (59)	36	22 (61)	109	65 (60)
Bisexual	4	2 (50)	8	6 (75)	13	8 (62)
Homosexual	1	0 (0)	5	2 (40)	6	2 (33)
2007						
Heterosexual	50	23 (46)	23	11 (48)	73	34 (47)
Bisexual	1	0 (0)	4	1 (25)	5	1 (20)
Homosexual	3	0 (0)	3	1 (33)	6	1 (17)
2008						
Heterosexual	91	53 (58)	39	19 (49)	130	72 (55)
Bisexual	4	2 (50)	14	10 (71)	18	12 (67)
Homosexual	3	1 (33)	4	2 (50)	7	3 (43)
2009						
Heterosexual	109	52 (48)	68	32 (47)	177	84 (47)
Bisexual	3	2 (67)	9	7 (78)	12	9 (75)
Homosexual	4	2 (50)	6	2 (33)	10	4 (40)
2010						
Heterosexual	110	62 (56)	65	40 (62)	175	102 (58)
Bisexual	3	1 (33)	11	5 (45)	14	6 (43)
Homosexual	0	0 (0)	8	3 (38)	8	3 (38)
2010 p value		0.583		0.316		0.316

Table 9.12 HCV antibody prevalence by age group, gender and year

WESTERN AUSTRALIA	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	1	0 (0)	7	3 (43)	8	3 (38)
25-34 years	7	3 (43)	1	0 (0)	8	3 (38)
35+ years	5	3 (60)	2	2 (100)	7	5 (71)
1996						
<25 years	17	1 (6)	15	4 (27)	32	5 (16)
25-34 years	16	8 (50)	10	7 (70)	27	16 (59)
35+ years	13	11 (85)	5	4 (80)	19	16 (84)
1997						
<25 years	5	1 (20)	1	0 (0)	6	1 (17)
25-34 years	2	1 (50)	4	1 (25)	6	2 (33)
35+ years	5	4 (80)	2	2 (100)	7	6 (86)
1998						
<25 years	21	4 (19)	22	5 (23)	43	9 (21)
25-34 years	36	13 (36)	16	7 (44)	52	20 (38)
35+ years	19	15 (79)	10	7 (70)	31	23 (74)
1999						
<25 years	13	5 (38)	13	3 (23)	26	8 (31)
25-34 years	22	9 (41)	14	7 (50)	36	16 (44)
35+ years	18	14 (78)	5	5 (100)	23	19 (83)
2000						
<25 years	14	4 (29)	5	0 (0)	19	4 (21)
25-34 years	26	11 (42)	10	3 (30)	36	14 (39)
35+ years	17	12 (71)	6	2 (33)	23	14 (61)
2001						
<25 years	20	6 (30)	18	3 (17)	38	9 (24)
25-34 years	30	16 (53)	17	11 (65)	48	28 (58)
35+ years	34	27 (79)	16	10 (63)	51	38 (75)
2002						
<25 years	19	5 (26)	8	1 (13)	27	6 (22)
25-34 years	29	9 (31)	11	7 (64)	40	16 (40)
35+ years	39	20 (51)	18	11 (61)	57	31 (54)
2003						
<25 years	6	1 (17)	12	3 (25)	18	4 (22)
25-34 years	26	13 (50)	23	10 (43)	50	24 (48)
35+ years	43	33 (77)	22	16 (73)	65	49 (75)
2004						
<25 years	10	2 (20)	7	1 (14)	17	3 (18)
25-34 years	20	10 (50)	13	5 (38)	33	15 (45)
35+ years	39	30 (77)	23	16 (70)	62	46 (74)
2005						
<25 years	15	5 (33)	11	4 (36)	26	9 (35)
25-34 years	27	14 (52)	18	7 (39)	45	21 (47)
35+ years	59	40 (68)	26	20 (77)	85	60 (71)
2006						
<25 years	8	5 (63)	4	3 (75)	12	8 (67)
25-34 years	33	14 (42)	18	10 (56)	51	24 (47)
35+ years	41	27 (66)	27	17 (63)	69	44 (64)
2007						
<25 years	6	2 (33)	3	0 (0)	9	2 (22)
25-34 years	18	4 (22)	13	6 (46)	31	10 (32)
35+ years	30	17 (57)	15	8 (53)	45	25 (56)
2008						
<25 years	5	1 (20)	5	0 (0)	10	1 (10)
25-34 years	39	21 (54)	25	15 (60)	64	36 (56)
35+ years	56	36 (64)	29	17 (59)	85	53 (62)
2009						
<25 years	8	2 (25)	6	0 (0)	14	2 (14)
25-34 years	36	17 (47)	33	18 (55)	70	35 (50)
35+ years	81	41 (51)	46	24 (52)	127	65 (51)
2010						
<25 years	2	0 (0)	6	3 (50)	8	3 (38)
25-34 years	31	16 (52)	30	14 (47)	61	30 (49)
35+ years	86	49 (57)	56	37 (66)	142	86 (61)
2010 p value		0.296		0.197		0.174

Table 9.13 HCV antibody prevalence by time since first injection, gender and year

WESTERN AUSTRALIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
<3 years	0	0 (0)	5	2 (40)	5	2 (40)
3-10 years	4	1 (25)	2	1 (50)	6	2 (33)
11+ years	9	5 (56)	3	2 (67)	12	7 (58)
1996						
<3 years	10	1 (10)	8	1 (13)	18	2 (11)
3-10 years	22	6 (27)	9	3 (33)	33	11 (33)
11+ years	11	10 (91)	12	10 (83)	23	20 (87)
1997						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3-10 years	8	2 (25)	2	0 (0)	10	2 (20)
11+ years	4	4 (100)	4	3 (75)	8	7 (88)
1998						
<3 years	7	0 (0)	8	2 (25)	16	2 (13)
3-10 years	40	12 (30)	24	7 (29)	64	19 (30)
11+ years	28	20 (71)	14	10 (71)	42	30 (71)
1999						
<3 years	2	0 (0)	6	0 (0)	8	0 (0)
3-10 years	30	10 (33)	16	7 (44)	46	17 (37)
11+ years	20	18 (90)	9	7 (78)	29	25 (86)
2000						
<3 years	6	2 (33)	3	0 (0)	9	2 (22)
3-10 years	24	7 (29)	10	2 (20)	34	9 (26)
11+ years	25	17 (68)	7	3 (43)	32	20 (63)
2001						
<3 years	5	1 (20)	8	2 (25)	13	3 (23)
3-10 years	30	13 (43)	26	10 (38)	56	23 (41)
11+ years	45	35 (78)	16	12 (75)	63	49 (78)
2002						
<3 years	7	1 (14)	2	1 (50)	9	2 (22)
3-10 years	34	10 (29)	14	6 (43)	48	16 (33)
11+ years	44	23 (52)	18	12 (67)	62	35 (56)
2003						
<3 years	3	1 (33)	7	1 (14)	10	2 (20)
3-10 years	18	6 (33)	19	6 (32)	37	12 (32)
11+ years	50	38 (76)	29	22 (76)	79	60 (76)
2004						
<3 years	4	2 (50)	0	0 (0)	4	2 (50)
3-10 years	22	9 (41)	16	4 (25)	38	13 (34)
11+ years	43	31 (72)	26	18 (69)	69	49 (71)
2005						
<3 years	2	0 (0)	1	0 (0)	3	0 (0)
3-10 years	24	11 (46)	19	7 (37)	43	18 (42)
11+ years	75	48 (64)	33	23 (70)	108	71 (66)
2006						
<3 years	1	0 (0)	0	0 (0)	2	0 (0)
3-10 years	23	11 (48)	15	7 (47)	38	18 (47)
11+ years	57	35 (61)	33	22 (67)	90	57 (63)
2007						
<3 years	4	0 (0)	3	0 (0)	7	0 (0)
3-10 years	16	4 (25)	11	2 (18)	27	6 (22)
11+ years	33	18 (55)	17	12 (71)	50	30 (60)
2008						
<3 years	0	0 (0)	2	1 (50)	2	1 (50)
3-10 years	23	8 (35)	17	5 (29)	40	13 (33)
11+ years	74	48 (65)	40	26 (65)	114	74 (65)
2009						
<3 years	4	0 (0)	5	1 (20)	9	1 (11)
3-10 years	20	6 (30)	22	7 (32)	42	13 (31)
11+ years	95	52 (55)	58	34 (59)	154	86 (56)
2010						
<3 years	6	0 (0)	4	2 (50)	10	2 (20)
3-10 years	13	4 (31)	21	11 (52)	34	15 (44)
11+ years	98	60 (61)	66	40 (61)	164	100 (61)
2010 p value		0.001		0.733		0.014

Table 9.14 HCV antibody prevalence by last drug injected, time since first injection and year

WESTERN AUSTRALIA	Male		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heroin	0	0 (0)	8	5 (63)	8	5 (63)
Methamphetamine	4	2 (50)	5	2 (40)	9	4 (44)
Other	1	0 (0)	5	2 (40)	6	2 (33)
1996						
Heroin	11	0 (0)	37	23 (62)	53	27 (51)
Methamphetamine	4	2 (50)	8	1 (13)	12	3 (25)
Other	3	0 (0)	11	7 (64)	14	7 (50)
1997						
Heroin	0	0 (0)	12	8 (67)	12	8 (67)
Methamphetamine	1	0 (0)	4	1 (25)	5	1 (20)
Other	0	0 (0)	2	0 (0)	2	0 (0)
1998						
Heroin	8	1 (13)	75	40 (53)	84	41 (49)
Methamphetamine	5	1 (20)	20	3 (15)	25	4 (16)
Other	3	0 (0)	11	6 (55)	14	6 (43)
1999						
Heroin	6	6 (100)	50	29 (58)	57	30 (53)
Methamphetamine	2	2 (100)	12	5 (42)	15	5 (33)
Other	0	0 (0)	13	8 (62)	13	8 (62)
2000						
Heroin	4	2 (50)	37	19 (51)	42	22 (52)
Methamphetamine	4	0 (0)	14	5 (36)	18	5 (28)
Other	1	0 (0)	15	5 (33)	16	5 (31)
2001						
Heroin	1	1 (100)	19	15 (79)	22	16 (73)
Methamphetamine	9	2 (22)	68	36 (53)	77	38 (49)
Other	3	0 (0)	32	21 (66)	35	21 (60)
2002						
Heroin	2	2 (100)	25	14 (56)	25	14 (56)
Methamphetamine	7	0 (0)	43	17 (40)	47	19 (40)
Other	9	2 (22)	41	19 (46)	48	19 (40)
2003						
Heroin	4	0 (0)	35	27 (77)	39	27 (69)
Methamphetamine	5	2 (40)	50	23 (46)	55	25 (45)
Other	1	0 (0)	30	22 (73)	35	24 (69)
2004						
Heroin	0	0 (0)	28	21 (75)	28	21 (75)
Methamphetamine	3	1 (33)	44	14 (32)	48	15 (31)
Other	1	1 (100)	33	27 (82)	34	28 (82)
2005						
Heroin	0	0 (0)	46	30 (65)	47	31 (66)
Methamphetamine	3	0 (0)	47	22 (47)	50	22 (44)
Other	0	0 (0)	53	33 (62)	53	33 (62)
2006						
Heroin	1	0 (0)	26	20 (77)	27	20 (74)
Methamphetamine	0	0 (0)	59	29 (49)	60	30 (50)
Other	1	0 (0)	42	25 (60)	44	25 (57)
2007						
Heroin	0	0 (0)	22	17 (77)	23	18 (78)
Methamphetamine	4	0 (0)	22	5 (23)	26	5 (19)
Other	3	0 (0)	31	13 (42)	34	13 (38)
2008						
Heroin	1	1 (100)	49	34 (69)	52	37 (71)
Methamphetamine	1	0 (0)	40	13 (33)	42	13 (31)
Other	0	0 (0)	62	38 (61)	63	39 (62)
2009						
Heroin	1	1 (100)	70	38 (54)	71	39 (55)
Methamphetamine	3	0 (0)	36	7 (19)	41	7 (17)
Other	5	0 (0)	87	52 (60)	93	52 (56)
2010						
Heroin	3	1 (33)	61	42 (69)	66	45 (68)
Methamphetamine	2	0 (0)	53	17 (32)	55	17 (31)
Other	5	1 (20)	79	53 (67)	84	54 (64)
2010 p value		1.000		<0.001		<0.001

Table 9.15 HCV antibody prevalence by frequency of injection, time since first injection and year

WESTERN AUSTRALIA	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Less than daily	4	1 (25)	12	4 (33)	16	5 (31)
Daily or more	1	1 (100)	5	4 (80)	6	5 (83)
Not last month	0	0 (0)	1	1 (100)	1	1 (100)
1996						
Less than daily	13	1 (8)	23	13 (57)	38	16 (42)
Daily or more	4	1 (25)	24	14 (58)	30	16 (53)
Not last month	1	0 (0)	8	4 (50)	10	5 (50)
1997						
Less than daily	1	0 (0)	5	3 (60)	6	3 (50)
Daily or more	0	0 (0)	13	6 (46)	13	6 (46)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
1998						
Less than daily	10	1 (10)	37	16 (43)	48	17 (35)
Daily or more	6	1 (17)	57	30 (53)	63	31 (49)
Not last month	0	0 (0)	12	3 (25)	13	3 (23)
1999						
Less than daily	1	0 (0)	25	16 (64)	28	17 (61)
Daily or more	0	0 (0)	45	24 (53)	52	24 (46)
Not last month	0	0 (0)	5	2 (40)	5	2 (40)
2000						
Less than daily	3	0 (0)	24	8 (33)	27	8 (30)
Daily or more	6	2 (33)	39	19 (49)	47	22 (47)
Not last month	0	0 (0)	3	2 (67)	3	2 (67)
2001						
Less than daily	5	1 (20)	46	25 (54)	53	26 (49)
Daily or more	8	2 (25)	65	45 (69)	73	47 (64)
Not last month	0	0 (0)	8	2 (25)	8	2 (25)
2002						
Less than daily	6	2 (33)	46	22 (48)	53	24 (45)
Daily or more	3	0 (0)	51	26 (51)	55	26 (47)
Not last month	0	0 (0)	13	3 (23)	14	3 (21)
2003						
Less than daily	4	1 (25)	47	25 (53)	51	26 (51)
Daily or more	6	1 (17)	67	46 (69)	75	49 (65)
Not last month	0	0 (0)	2	1 (50)	3	1 (33)
2004						
Less than daily	2	1 (50)	39	17 (44)	41	18 (44)
Daily or more	2	1 (50)	58	41 (71)	61	42 (69)
Not last month	0	0 (0)	9	4 (44)	9	4 (44)
2005						
Less than daily	1	0 (0)	50	27 (54)	51	27 (53)
Daily or more	2	0 (0)	96	59 (61)	99	60 (61)
Not last month	0	0 (0)	5	3 (60)	6	3 (50)
2006						
Less than daily	2	0 (0)	48	27 (56)	51	27 (53)
Daily or more	0	0 (0)	74	45 (61)	75	46 (61)
Not last month	0	0 (0)	5	3 (60)	5	3 (60)
2007						
Less than daily	5	0 (0)	20	7 (35)	25	7 (28)
Daily or more	2	0 (0)	51	26 (51)	54	27 (50)
Not last month	0	0 (0)	5	2 (40)	5	2 (40)
2008						
Less than daily	1	0 (0)	50	27 (54)	52	27 (52)
Daily or more	1	1 (100)	100	59 (59)	104	63 (61)
Not last month	0	0 (0)	4	1 (25)	4	1 (25)
2009						
Less than daily	5	0 (0)	56	23 (41)	62	23 (37)
Daily or more	3	1 (33)	138	76 (55)	144	79 (55)
Not last month	1	0 (0)	2	0 (0)	4	0 (0)
2010						
Less than daily	4	1 (25)	80	46 (58)	84	47 (56)
Daily or more	5	1 (20)	110	67 (61)	117	70 (60)
Not last month	1	0 (0)	8	2 (25)	10	2 (20)
2010 p value		1.000		0.147		0.051

Table 9.16 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, time since first injection and year

WESTERN AUSTRALIA	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
No receptive sharing	3	1 (33)	13	6 (46)	16	7 (44)
Receptive sharing	2	1 (50)	4	2 (50)	6	3 (50)
1996						
No receptive sharing	14	2 (14)	36	20 (56)	53	25 (47)
Receptive sharing	3	0 (0)	11	7 (64)	15	7 (47)
1997						
No receptive sharing	1	0 (0)	16	8 (50)	17	8 (47)
Receptive sharing	0	0 (0)	2	1 (50)	2	1 (50)
1998						
No receptive sharing	11	2 (18)	71	33 (46)	82	35 (43)
Receptive sharing	5	0 (0)	20	10 (50)	26	10 (38)
1999						
No receptive sharing	5	0 (0)	48	24 (50)	54	24 (44)
Receptive sharing	2	0 (0)	21	15 (71)	24	16 (67)
2000						
No receptive sharing	5	0 (0)	42	16 (38)	47	16 (34)
Receptive sharing	3	1 (33)	19	9 (47)	24	11 (46)
2001						
No receptive sharing	8	2 (25)	79	51 (65)	89	53 (60)
Receptive sharing	5	1 (20)	27	14 (52)	32	15 (47)
2002						
No receptive sharing	7	2 (29)	80	35 (44)	89	37 (42)
Receptive sharing	2	0 (0)	15	12 (80)	17	12 (71)
2003						
No receptive sharing	7	3 (43)	91	57 (63)	100	61 (61)
Receptive sharing	4	0 (0)	19	12 (63)	23	12 (52)
2004						
No receptive sharing	3	1 (33)	69	41 (59)	75	43 (57)
Receptive sharing	1	1 (100)	24	15 (63)	26	16 (62)
2005						
No receptive sharing	2	0 (0)	112	63 (56)	115	64 (56)
Receptive sharing	1	0 (0)	24	18 (75)	25	18 (72)
2006						
No receptive sharing	1	0 (0)	103	56 (54)	106	57 (54)
Receptive sharing	1	0 (0)	16	13 (81)	17	13 (76)
2007						
No receptive sharing	5	0 (0)	55	26 (47)	61	27 (44)
Receptive sharing	2	0 (0)	13	6 (46)	15	6 (40)
2008						
No receptive sharing	2	1 (50)	121	70 (58)	127	74 (58)
Receptive sharing	0	0 (0)	28	16 (57)	28	16 (57)
2009						
No receptive sharing	7	1 (14)	150	73 (49)	161	75 (47)
Receptive sharing	1	0 (0)	40	24 (60)	42	25 (60)
2010						
No receptive sharing	9	2 (22)	136	78 (57)	147	82 (56)
Receptive sharing	0	0 (0)	28	18 (64)	28	18 (64)
2010 p value		--		0.535		0.533

Table 9.17 HCV antibody prevalence by imprisonment last year, time since first injection and year

WESTERN AUSTRALIA	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
No imprisonment	5	2 (40)	13	6 (46)	18	8 (44)
Imprisonment	0	0 (0)	3	2 (67)	3	2 (67)
1996						
No imprisonment	17	2 (12)	44	22 (50)	66	28 (42)
Imprisonment	1	0 (0)	10	7 (70)	11	7 (64)
1997						
No imprisonment	1	0 (0)	12	5 (42)	13	5 (38)
Imprisonment	0	0 (0)	5	3 (60)	5	3 (60)
1998						
No imprisonment	13	1 (8)	89	42 (47)	105	43 (41)
Imprisonment	3	1 (33)	16	6 (38)	19	7 (37)
1999						
No imprisonment	8	0 (0)	64	34 (53)	74	35 (47)
Imprisonment	0	0 (0)	11	8 (73)	11	8 (73)
2000						
No imprisonment	8	1 (13)	56	24 (43)	67	26 (39)
Imprisonment	1	1 (100)	10	5 (50)	11	6 (55)
2001						
No imprisonment	12	2 (17)	95	53 (56)	111	55 (50)
Imprisonment	1	1 (100)	21	18 (86)	22	19 (86)
2002						
No imprisonment	7	2 (29)	98	45 (46)	110	47 (43)
Imprisonment	2	0 (0)	11	6 (55)	13	6 (46)
2003						
No imprisonment	13	3 (23)	96	60 (63)	110	64 (58)
Imprisonment	2	1 (50)	17	11 (65)	19	12 (63)
2004						
No imprisonment	4	2 (50)	81	41 (51)	91	45 (49)
Imprisonment	0	0 (0)	20	18 (90)	20	18 (90)
2005						
No imprisonment	5	1 (20)	120	67 (56)	133	71 (53)
Imprisonment	0	0 (0)	15	13 (87)	17	15 (88)
2006						
No imprisonment	2	0 (0)	104	55 (53)	107	56 (52)
Imprisonment	0	0 (0)	17	14 (82)	18	14 (78)
2007						
No imprisonment	7	0 (0)	59	27 (46)	66	27 (41)
Imprisonment	0	0 (0)	14	7 (50)	15	8 (53)
2008						
No imprisonment	2	1 (50)	133	74 (56)	139	78 (56)
Imprisonment	0	0 (0)	18	12 (67)	18	12 (67)
2009						
No imprisonment	9	1 (11)	172	82 (48)	185	85 (46)
Imprisonment	0	0 (0)	19	15 (79)	20	15 (75)
2010						
No imprisonment	10	2 (20)	143	77 (54)	156	81 (52)
Imprisonment	0	0 (0)	15	11 (73)	15	11 (73)
2010 p value		--		0.179		0.174

Table 9.18 HCV antibody prevalence by sex work last month, time since first injection and year

WESTERN AUSTRALIA	<3 years IDU		3+ years IDU		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
No sex work	5	2 (40)	15	7 (47)	20	9 (45)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
1996						
No sex work	18	2 (11)	51	27 (53)	74	33 (45)
Sex work	0	0 (0)	5	4 (80)	5	4 (80)
1997						
No sex work	1	0 (0)	12	6 (50)	13	6 (46)
Sex work	0	0 (0)	3	1 (33)	3	1 (33)
1998						
No sex work	14	1 (7)	92	41 (45)	108	42 (39)
Sex work	2	1 (50)	10	7 (70)	13	8 (62)
1999						
No sex work	7	0 (0)	68	37 (54)	77	38 (49)
Sex work	1	0 (0)	7	5 (71)	8	5 (63)
2000						
No sex work	9	2 (22)	53	24 (45)	65	27 (42)
Sex work	0	0 (0)	11	5 (45)	11	5 (45)
2001						
No sex work	13	3 (23)	109	65 (60)	127	68 (54)
Sex work	0	0 (0)	7	5 (71)	7	5 (71)
2002						
No sex work	8	1 (13)	99	45 (45)	112	46 (41)
Sex work	0	0 (0)	8	8 (100)	8	4 (50)
2003						
No sex work	13	4 (31)	100	61 (61)	115	66 (57)
Sex work	1	0 (0)	12	11 (92)	13	11 (85)
2004						
No sex work	3	1 (33)	91	52 (57)	99	55 (56)
Sex work	1	1 (100)	10	7 (70)	11	8 (73)
2005						
No sex work	5	1 (20)	131	78 (60)	146	84 (58)
Sex work	0	0 (0)	8	4 (50)	8	4 (50)
2006						
No sex work	2	0 (0)	117	67 (57)	121	68 (56)
Sex work	0	0 (0)	7	5 (71)	7	5 (71)
2007						
No sex work	5	0 (0)	69	32 (46)	75	33 (44)
Sex work	1	0 (0)	3	1 (33)	4	1 (25)
2008						
No sex work	2	1 (50)	140	79 (56)	146	83 (57)
Sex work	0	0 (0)	9	4 (44)	9	4 (44)
2009						
No sex work	9	1 (11)	178	90 (51)	193	93 (48)
Sex work	0	0 (0)	10	5 (50)	10	5 (50)
2010						
No sex work	9	2 (22)	182	106 (58)	194	110 (57)
Sex work	1	0 (0)	5	3 (60)	6	3 (50)
2010 p value		1.000		1.000		1.000

Table 9.19 HCV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year

WESTERN AUSTRALIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995						
Non-Indigenous	13	6 (46)	10	5 (50)	23	11 (48)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
1996						
Non-Indigenous	47	20 (43)	27	14 (52)	76	36 (47)
Indigenous	0	0 (0)	2	1 (50)	2	1 (50)
1997						
Non-Indigenous	11	6 (55)	7	3 (43)	18	9 (50)
Indigenous	1	0 (0)	0	0 (0)	1	0 (0)
1998						
Non-Indigenous	69	29 (42)	43	18 (42)	114	48 (42)
Indigenous	6	2 (33)	4	1 (25)	10	3 (30)
1999						
Non-Indigenous	49	27 (55)	28	13 (46)	77	40 (52)
Indigenous	3	1 (33)	3	1 (33)	6	2 (33)
2000						
Non-Indigenous	52	25 (48)	18	4 (22)	70	29 (41)
Indigenous	4	1 (25)	2	1 (50)	6	2 (33)
2001						
Non-Indigenous	80	46 (58)	45	20 (44)	127	68 (54)
Indigenous	4	3 (75)	6	4 (67)	10	7 (70)
2002						
Non-Indigenous	83	33 (40)	37	19 (51)	120	52 (43)
Indigenous	1	0 (0)	0	0 (0)	1	0 (0)
2003						
Non-Indigenous	72	45 (63)	49	26 (53)	122	72 (59)
Indigenous	1	0 (0)	6	2 (33)	7	2 (29)
2004						
Non-Indigenous	60	37 (62)	40	20 (50)	101	58 (57)
Indigenous	5	3 (60)	2	1 (50)	7	4 (57)
2005						
Non-Indigenous	93	53 (57)	51	29 (57)	144	82 (57)
Indigenous	6	4 (67)	4	2 (50)	10	6 (60)
2006						
Non-Indigenous	81	45 (56)	46	27 (59)	128	72 (56)
Indigenous	1	1 (100)	1	1 (100)	2	2 (100)
2007						
Non-Indigenous	51	21 (41)	28	12 (43)	79	33 (42)
Indigenous	2	1 (50)	3	2 (67)	5	3 (60)
2008						
Non-Indigenous	93	54 (58)	53	31 (58)	146	85 (58)
Indigenous	4	1 (25)	4	1 (25)	8	2 (25)
2009						
Non-Indigenous	122	57 (47)	78	39 (50)	201	96 (48)
Indigenous	1	1 (100)	7	3 (43)	8	4 (50)
2010						
Non-Indigenous	113	61 (54)	80	46 (58)	193	107 (55)
Indigenous	3	1 (33)	7	6 (86)	10	7 (70)
2010 p value		0.597		0.234		0.518

Table 9.13 HCV antibody prevalence by country of birth, gender and year

WESTERN AUSTRALIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2003						
Australia	58	37 (64)	46	22 (48)	105	60 (57)
Other	16	9 (56)	10	7 (70)	26	16 (62)
2004						
Australia	54	32 (59)	32	17 (53)	87	50 (57)
Other	13	8 (62)	4	1 (25)	24	13 (54)
2005						
Australia	84	48 (57)	43	25 (58)	127	73 (57)
Other	16	10 (63)	12	6 (50)	28	16 (57)
2006						
Australia	68	37 (54)	36	24 (67)	104	61 (59)
Other	13	8 (62)	11	4 (36)	25	12 (48)
2007						
Australia	43	18 (42)	26	13 (50)	69	31 (45)
Other	10	4 (40)	5	1 (20)	15	5 (33)
2008						
Australia	77	44 (57)	43	24 (56)	120	68 (57)
Other	21	13 (62)	14	8 (57)	35	21 (60)
2009						
Australia	102	46 (45)	67	34 (51)	169	80 (47)
Other	20	13 (65)	17	7 (41)	38	20 (53)
2010						
Australia	95	52 (55)	74	43 (58)	169	95 (56)
Other	22	11 (50)	16	9 (56)	38	20 (53)
2010 p value		0.813		1.000		0.720

Table 9.14 HCV antibody prevalence by language spoken at home by parents, gender and year

WESTERN AUSTRALIA	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2003						
English speaking	72	45 (63)	54	29 (54)	127	75 (59)
Non-English speaking	3	2 (67)	0	0 (0)	3	2 (67)
2004						
English speaking	52	32 (62)	29	15 (52)	82	48 (59)
Non-English speaking	4	2 (50)	5	3 (60)	9	5 (56)
2005						
English speaking	84	48 (57)	50	28 (56)	134	76 (57)
Non-English speaking	17	11 (65)	5	3 (60)	22	14 (64)
2006						
English speaking	71	41 (58)	46	28 (61)	118	69 (58)
Non-English speaking	5	3 (60)	1	0 (0)	6	3 (50)
2007						
English speaking	52	22 (42)	30	14 (47)	82	36 (44)
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)
2008						
English speaking	95	55 (58)	58	32 (55)	153	87 (57)
Non-English speaking	6	4 (67)	1	0 (0)	7	4 (57)
2009						
English speaking	120	55 (46)	85	42 (49)	205	97 (47)
Non-English speaking	4	4 (100)	0	0 (0)	5	4 (80)
2010						
English speaking	111	58 (52)	89	51 (57)	200	109 (55)
Non-English speaking	6	5 (83)	1	1 (100)	7	6 (86)
2010 p value		0.215		1.000		0.135

10. REFERENCES

Peer reviewed publications describing ANSPS methodology

1. Topp, L., Iversen, J., Wand, H., Day, C., Kaldor, J. & Maher, L. (2008a). Representativeness of injecting drug users who participate in HIV surveillance: Results from Australia's Needle and Syringe Program Survey. *Journal of Acquired Immune Deficiency Syndromes*, 47(5), 632-638.
2. White, B., Day, C. & Maher, L. (2007). Self reported drug use and risk behaviour among injecting drug users: self versus assisted questionnaire completion. *AIDS Care*, 19, 441-447.
3. MacDonald, M., Wodak, A.D., Ali, R., Crofts, N., Cunningham, P.H., Dolan, K.A., Kelaher, M., Loxley, W.M., van Beek, I. & Kaldor, J.M. (1997). HIV prevalence and risk behaviour in needle exchange attenders: a national study. *Medical Journal of Australia*, 166, 237-240.

Peer reviewed publications describing ANSPS results

4. Topp, L., Day, C.A., Iversen, J., Wand, H. & Maher, L. (2011). Fifteen years of HIV surveillance among people who inject drugs: The Australian Needle and Syringe Program Survey 1995-2009. *AIDS*, 25(6), 835-842.
5. Iversen, J., Wand, H., Gonnermann, A. & Maher, L., on behalf of the collaboration of Australian Needle and Syringe Programs. (2010) Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998-2008. *International Journal of Drug Policy*, 21, 471-476.
6. Maher, L. and J. Iversen (2009). Syringe exchange in the United States: doing the simple things better? *Addiction* 104(9): 1448-1450.
7. Falster, K., Kaldor, J.M. & Maher, L. (2009). Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of Needle and Syringe Program attendees in Australia, 1995-2004. *Journal of Urban Health*, 86, 106-118.
8. Day, C., Topp, L., Iversen, J. & Maher, L. (2008) Blood-borne virus prevalence and risk among steroid injectors: Results from the Australian Needle and Syringe Program Survey. *Drug and Alcohol Review*, 27, 559-561.
9. Topp, L., Iversen, J., Conroy, A., Salmon, A. & Maher, L. (2008b). Prevalence and predictors of injecting-related injury and disease among clients of Australia's Needle and Syringe Programs. *Australian and New Zealand Journal of Public Health*, 32, 34-37.
10. Thein, H-H., Denoe, M., van Beek, I., Dore, G. & MacDonald, M. (2003). Injecting behaviour of injecting drug users at needle and syringe programmes and pharmacies in Australia. *International Journal of Drug Policy*, 14, 425-430.
11. MacDonald, M.A., Wodak, A.D., Dolan, K.A., van Beek, I., Cunningham, P.H. & Kaldor, J.M. (2000). Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. *Medical Journal of Australia*, 172, 57-61.

Other references

12. Topp, L., Day, C., Dore, G., & Maher, L. (2009). Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: a review. *Drug and Alcohol Review*, 28, 669-675
13. Maher, L., Li, J., Jalaludin, B., Wand, H., Jayasuriya, R., Dixon, D., et al. (2007). Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug users in New South Wales, Australia. *Drug Alcohol Dependence*, 89(2-3), 244-250.
14. Degenhardt, L., Day, C., Dietze, P., Pointer, S., Conroy, E., Collins, L., et al. (2005). Effects of a sustained heroin shortage in three Australian States. *Addiction*, 100(7), 908-920.
15. Topp, L., Day, C., & Degenhardt, L. (2003). Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. *Drug & Alcohol Dependence*, 70(3), 275-286.

11. LIST OF TABLES

Demographic characteristics and drug use

1. Number (%) of respondents by demographic characteristic and year
2. Number (%) of respondents by drug last injected and year
3. Number (%) of respondents by places injected in the last month and year
4. Number (%) of respondents by injecting behaviour in the month prior to survey and year
5. Number (%) of respondents by sexual behaviour in the month prior to survey and year
6. Number (%) of respondents by previous testing for HIV, HBV, HCV infection, HBV vaccination and HCV treatment by year
7. Number (%) of respondents by treatment for drug use and year
8. Number (%) of respondents by source of needle and syringe acquisition in the month prior to survey and year

HIV prevalence

9. HIV antibody prevalence by gender and year
10. HIV antibody prevalence by sexual identity, gender and year
11. HIV antibody prevalence by age group, gender and year
12. HIV antibody prevalence by time since first drug injection, gender and year
13. HIV antibody prevalence by drug last injected, gender and year
14. HIV antibody prevalence by frequency of injection last month, gender and year
15. HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year
16. HIV antibody prevalence by imprisonment last year, gender and year
17. HIV antibody prevalence by condom use with regular partner in last month, gender and year
18. HIV antibody prevalence by sex work last month, gender and year
19. HIV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year
20. HIV antibody prevalence by country of birth, gender and year
21. HIV antibody prevalence by language spoken at home by parents, gender and year

HCV prevalence

22. HCV antibody prevalence by gender and year
23. HCV antibody prevalence by sexual identity, gender and year
24. HCV antibody prevalence by age group, gender and year
25. HCV antibody prevalence by time since first drug injection, gender and year
26. HCV antibody prevalence by drug last injected, time since first injection and year
27. HCV antibody prevalence by frequency of injection, time since first injection and year
28. HCV antibody prevalence by re-use of someone else's used needle and syringe last month, time since first injection and year
29. HCV antibody prevalence by imprisonment last year, time since first injection and year
30. HCV antibody prevalence by sex work last month, time since first injection and year
31. HCV antibody prevalence by Aboriginal and Torres Strait Islander status, gender and year
32. HCV antibody prevalence by country of birth, gender and year
33. HCV antibody prevalence by language spoken at home by parents, gender and year

Appendix 1: Participating NSP services

PARTICIPATING NSP SERVICES	'95	'96	'97	'98	'99	'00	'01	'02	'03	'04	'05	'06	'07	'08	'09	'10
AUSTRALIAN CAPITAL TERRITORY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
ACT IV League	✓															
Directions ACT, Canberra			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
NEW SOUTH WALES	4	4	7	11	13	13	14	16	18	18	19	18	21	22	20	22
ACON Hunter								✓		✓	✓	✓	✓	✓	✓	✓
Albury Base Hospital & Community Health Centre								✓	✓	✓	✓		✓	✓	✓	✓
Auburn NSP Service					✓	✓	✓	✓	✓							
Ballina/Byron Harm Reduction Services										✓	✓	✓	✓	✓	✓	✓
Blacktown NSP Service	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Central Access Service, St George & Sutherland	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓		✓	✓	✓	✓	✓
Coffs Harbour/Grafton Harm Reduction Services																
Fairfield Harm Reduction, Cabramatta & Fairfield				✓	✓	✓	✓	✓	✓	✓						
First Step Program Port Kembla and Nowra								✓	✓	✓	✓	✓	✓	✓	✓	✓
Gosford NSP Service													✓	✓	✓	✓
Health Connexions, Liverpool											✓		✓	✓	✓	✓
Indo-Chinese Outreach Network, Bankstown, Cabramatta & Liverpool				✓	✓	✓	✓	✓	✓	✓						
K2 Health Service, Kings Cross			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Kirketon Road Centre, Kings Cross		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Long Jetty NSP Service													✓	✓	✓	✓
Merrylands NSP Service											✓					
Mt Druitt NSP Service					✓		✓	✓	✓	✓	✓		✓	✓	✓	✓
Murwillumbah/Tweed Harm Reduction Services									✓	✓	✓	✓	✓	✓	✓	✓
Newcastle Harm Minimisation Program								✓	✓	✓	✓	✓	✓	✓	✓	✓
Nimbin/Lismore Harm Reduction Services			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
NSW Users and AIDS Association (NUAA)											✓	✓	✓	✓	✓	✓
Parramatta NSP Service	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Resource and Education Program for IDU, Canterbury				✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Resource and Education Program for IUDs (REPIDU), Redfern			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Response User Services in Health (RUSH), Ryde, Manly & St Leonards					✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
South Court Primary Care, Nepean				✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Wagga Wagga NSP Service																✓

PARTICIPATING NSP SERVICES CONTINUED		'95	'96	'97	'98	'99	'00	'01	'02	'03	'04	'05	'06	'07	'08	'09	'10
NORTHERN TERRITORY		2	2	2	2	1	2	2	1	1	2	3	1	3	3	3	3
NT AIDS and Hepatitis C Council, Alice Springs		✓	✓	✓	✓		✓					✓		✓	✓	✓	✓
NT AIDS and Hepatitis C Council, Darwin		✓	✓	✓	✓		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
NT AIDS and Hepatitis C Council, Palmerston											✓	✓		✓	✓	✓	✓
QUEENSLAND		4	5	5	6	6	6	6	9	10	7	7	7	7	8	8	8
Bodyline		✓															
Biala Community Alcohol and Drugs Services, Brisbane		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cairns Needle and Syringe Program			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cairns Youth Link										✓							
Gold Coast Hospital					✓												
Kobi House, Toowoomba			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Logan Youth Health Service									✓	✓							
Mackay Sexual Health Services									✓	✓							
QulHN, Brisbane		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
QulHN, Gold Coast		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
QulHN, Sunshine Coast						✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Townsville ATODS NSP															✓	✓	✓
West Moreton Sexual Health Service, Ipswich									✓	✓	✓	✓	✓	✓	✓	✓	✓
SOUTH AUSTRALIA		2	2	2	5	6	8	6	6	6	6	7	6	7	7	7	7
Hindmarsh Centre CNP							✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Lyell McEwin							✓										
Nunkuarrin Yunti CNP											✓	✓		✓	✓	✓	✓
SAVIVE, Noarlunga				✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
SAVIVE, Norwood		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
SAVIVE, Parks					✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
SAVIVE, Port Adelaide						✓	✓	✓	✓	✓		✓	✓	✓	✓	✓	✓
SAVIVE, Shopfront		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Warinilla Clinic					✓	✓	✓										

PARTICIPATING NSP SERVICES CONTINUED		'95	'96	'97	'98	'99	'00	'01	'02	'03	'04	'05	'06	'07	'08	'09	'10
TASMANIA		1	1	1	2	1	1	1	4	4	4	3	2	4	4	4	4
Clarence Community Health Centre										✓	✓	✓		✓	✓	✓	✓
Salvation Army, Launceston									✓					✓	✓	✓	✓
TasCHARD, Glenorchy									✓	✓	✓	✓	✓	✓	✓	✓	✓
TasCHARD, Hobart		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
The Link- Youth Health Service									✓	✓	✓						
Users Health Support League, Hobart					✓												
VICTORIA		5	3	4	4	3	3	4	4	4	5	5	4	6	6	6	5
Ballarat CHS		✓															
Barwon NSP, Geelong		✓												✓	✓	✓	✓
Health Works, Western Region Health Region				✓	✓	✓	✓	✓	✓	✓	✓	✓					
Innerspace/MINE, Collingwood		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
North Richmond NSP Services														✓	✓	✓	✓
Northcote NSP Services														✓	✓	✓	✓
SHARPS, Frankston		✓	✓	✓	✓				✓	✓	✓	✓	✓	✓	✓	✓	✓
South East Alcohol and Drug Service, Dandenong								✓			✓	✓	✓				
St Kilda NSP Services		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
WESTERN AUSTRALIA		1	1	1	2	2	2	3	3	3	3	3	3	2	2	2	3
Western Australia Substance Users Association (WASUA), Perth		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Western Australia Substance Users Association (WASUA), Bunbury								✓	✓	✓	✓	✓	✓				
WA AIDS Council Mobile Exchange					✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

Note: Sites with a combined total of less than five participants are not listed.

APPENDIX 2. METHODOLOGICAL NOTES

Data presented in this report were analysed using Stata, Version 10 (Stata Corporation, College Station TX). Changes for HIV and HCV antibody prevalence overtime were assessed using the χ^2 test for linear trends. Associations between demographic and behavioural variables and HIV/HCV antibody prevalence were assessed using the χ^2 test or Fisher's exact test where expected frequencies were less than five.

Tables reporting HIV antibody prevalence stratified by demographic and drug use characteristics are not included in this report for states and territories where the number of HIV antibody positive participants was less than 5 in the majority of survey years.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as transgender. Time since first injection was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection.

The symbol "--" shown in some Tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". While the majority of survey questions were consistent over all survey years, this was not always the case. Notably, questions on sexual behaviour were amended in 2005 in a manner which renders comparison over time invalid. The question on receptive sharing of ancillary injecting equipment was modified; with the addition in 2006 of the response option to report "no shared items". Temporal trends for "any shared ancillary item" are reported only for the period 1995 to 2005 to avoid any confounding effects of this questionnaire amendment. Supplementary response options were added to items assessing drug treatment history as new opioid replacement therapies became available. Following a review of the literature which concluded that the accuracy of self-reported hepatitis B status among people who inject drugs is poor (Topp, L., Day, C., Dore, G., & Maher, L., 2009) ANSPS items designed to assess participants' hepatitis B infection and vaccination histories were removed from the questionnaire in 2008.

